

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 365 034 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
26.11.2003 Bulletin 2003/48

(51) Int Cl.7: **C12Q 1/68**, B01L 3/00,
A61K 48/00, G06F 17/00

(21) Application number: **03010447.5**

(22) Date of filing: **09.05.2003**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(71) Applicant: **Bayer Aktiengesellschaft**
51368 Leverkusen (DE)

(72) Inventors:
• **Wirtz, Ralph, Dr.**
50674 Köln (DE)
• **Munnes, Marc, Dr.**
40699 Erkrath (DE)
• **Kallabis, Harald, Dr.**
50161 Köln (DE)

(30) Priority: **21.05.2002 EP 02010291**
13.02.2003 EP 03003112

(54) **Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia**

(57) The invention provides compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and breast cancer in particular. Genes that are differentially

expressed in breast tissue of breast cancer patients versus those of normal people are disclosed.

EP 1 365 034 A2

Description

TECHNICAL FIELD OF THE INVENTION

[0001] The invention relates to methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of neoplastic disease. Neoplastic disease is often caused by chromosomal rearrangements which lead to over- or underexpression of the rearranged genes. The invention discloses genes which are overexpressed in neoplastic tissue and are useful as diagnostic markers and targets for treatment. Methods are disclosed for predicting, diagnosing and prognosing as well as preventing and treating neoplastic disease.

BACKGROUND OF THE INVENTION

[0002] Chromosomal aberrations (amplifications, deletions, inversions, insertions, translocations and/or viral integrations) are of importance for the development of cancer and neoplastic lesions, as they account for deregulations of the respective regions. Amplifications of genomic regions have been described, in which genes of importance for growth characteristics, differentiation, invasiveness or resistance to therapeutic intervention are located. One of those regions with chromosomal aberrations is the region carrying the HER-2/neu gene which is amplified in breast cancer patients. In approximately 25% of breast cancer patients the HER-2/neu gene is overexpressed due to gene amplification. HER-2/neu overexpression correlates with a poor prognosis (relapse, overall survival, sensitivity to therapeutics). The importance of HER-2/neu for the prognosis of the disease progression has been described [Gusterson et al., 1992, (1)]. Gene specific antibodies raised against HER-2/neu (Herceptin™) have been generated to treat the respective cancer patients. However, only about 50% of the patients benefit from the antibody treatment with Herceptin™, which is most often combined with chemotherapeutic regimen. The discrepancy of HER-2/neu positive tumors (overexpressing HER-2/neu to similar extent) with regard to responsiveness to therapeutic intervention suggest, that there might be additional factors or genes being involved in growth and apoptotic characteristics of the respective tumor tissues. There seems to be no monocausal relationship between overexpression of the growth factor receptor HER-2/neu and therapy outcome. In line with this the measurement of commonly used tumor markers such as estrogen receptor, progesterone receptor, p53 and Ki-67 do provide only very limited information on clinical outcome of specific therapeutic decisions. Therefore there is a great need for a more detailed diagnostic and prognostic classification of tumors to enable improved therapy decisions and prediction of survival of the patients. The present invention addresses the need for additional markers by providing genes, which expression is deregulated in tumors and correlates with clinical outcome. One focus is the deregulation of genes present in specific chromosomal regions and their interaction in disease development and drug responsiveness.

[0003] HER-2/neu and other markers for neoplastic disease are commonly assayed with diagnostic methods such as immunohistochemistry (IHC) (e.g. HercepTest™ from DAKO Inc.) and Fluorescence-In-Situ-Hybridization (FISH) (e.g. quantitative measurement of the HER-2/neu and Topoisomerase II alpha with a fluorescence-in-situ-Hybridization kit from VYSIS). Additionally HER-2/neu can be assayed by detecting HER-2/neu fragments in serum with an ELISA test (BAYER Corp.) or a with a quantitative PCR kit which compares the amount of HER-2/neu gene with the amount of a non-amplified control gene in order to detect HER-2/neu gene amplifications (ROCHE). These methods, however, exhibit multiple disadvantages with regard to sensitivity, specificity, technical and personnel efforts, costs, time consumption, inter-lab reproducibility. These methods are also restricted with regard to measurement of multiple parameters within one patient sample ("multiplexing"). Usually only about 3 to 4 parameters (e.g. genes or gene products) can be detected per tissue slide. Therefore, there is a need to develop a fast and simple test to measure simultaneously multiple parameters in one sample. The present invention addresses the need for a fast and simple high-resolution method, that is able to detect multiple diagnostic and prognostic markers simultaneously.

SUMMARY OF THE INVENTION

[0004] The present invention is based on discovery that chromosomal alterations in cancer tissues can lead to changes in the expression of genes that are encoded by the altered chromosomal regions. Exemplary 43 human genes have been identified that are co-amplified in neoplastic lesions from breast cancer tissue resulting in altered expression of several of these genes (Tables 1 to 4). These 43 genes are differentially expressed in breast cancer states, relative to their expression in normal, or non-breast cancer states. The present invention relates to derivatives, fragments, analogues and homologues of these genes and uses or methods of using of the same.

[0005] The present invention further relates to novel preventive, predictive, diagnostic, prognostic and therapeutic compositions and uses for malignant neoplasia and breast cancer in particular. Especially membrane bound marker gene products containing extracellular domains can be a particularly useful target for treatment methods as well as diagnostic and clinical monitoring methods.

[0006] It is a discovery of the present invention that several of these genes are characterized in that their gene products functionally interact in signaling cascades or by directly or indirectly influencing each other. This interaction is important for the normal physiology of certain non-neoplastic tissues (e.g. brain or neurogenic tissue). The deregulation of these genes in neoplastic lesions where they are normally exhibit of different level of activity or are not active, however, results in pathophysiology and affects the characteristics of the disease-associated tissue.

[0007] The present invention further relates to methods for detecting these deregulations in malignant neoplasia on DNA and mRNA level.

[0008] The present invention further relates to a method for the detection of chromosomal alterations characterized in that the relative abundance of individual mRNAs, encoded by genes, located in altered chromosomal regions is detected.

[0009] The present invention further relates to a method for the detection of the flanking breakpoints of named chromosomal alterations by measurement of DNA copy number by quantitative PCR or DNA-Arrays and DNA sequencing.

[0010] A method for the prediction, diagnosis or prognosis of malignant neoplasia by the detection of DNA sequences flanking named genomic breakpoint or are located within such.

[0011] The present invention further relates to a method for the detection of chromosomal alterations characterized in that the copy number of one or more genomic nucleic acid sequences located within an altered chromosomal region (s) is detected by quantitative PCR techniques (e.g. TaqMan™, Lightcycler™ and iCycler™).

[0012] The present invention further relates to a method for the prediction, diagnosis or prognosis of malignant neoplasia by the detection of at least 2 markers whereby the markers are genes and fragments thereof or genomic nucleic acid sequences that are located on one chromosomal region which is altered in malignant neoplasia and breast cancer in particular.

[0013] The present invention also discloses a method for the prediction, diagnosis or prognosis of malignant neoplasia by the detection of at least 2 markers whereby the markers are located on one or more chromosomal region(s) which is/are altered in malignant neoplasia; and the markers interact as (i) receptor and ligand or (ii) members of the same signal transduction pathway or (iii) members of synergistic signal transduction pathways or (iv) members of antagonistic signal transduction pathways or (v) transcription factor and transcription factor binding site.

[0014] Also disclosed is a method for the prediction, diagnosis or prognosis of malignant neoplasia by the detection of at least one marker whereby the marker is a VNTR, SNP, RFLP or STS which is located on one chromosomal region which is altered in malignant neoplasia due to amplification and the marker is detected in (a) a cancerous and (b) a non cancerous tissue or biological sample from the same individual. A preferred embodiment is the detection of at least one VNTR marker of Table 6 or at least on SNP marker of Table 4 or combinations thereof.. Even more preferred can the detection, quantification and sizing of such polymorphic markers be achieved by methods of (a) for the comparative measurement of amount and size by PCR amplification and subsequent capillary electrophoresis, (b) for sequence determination and allelic discrimination by gel electrophoresis (e.g. SSCP, DGGE), real time kinetic PCR, direct DNA sequencing, pyro-sequencing, mass-specific allelic discrimination or resequencing by DNA array technologies, (c) for the dertermination of specific restriction patterns and subsequent electrophoretic separation and (d) for allelic discrimination by allele specific PCR (e.g. ASO). An even more favorable detection of a hetrozygous VNTR, SNP, RFLP or STS is done in a multiplex fashion, utilizing a variety of labeled primers (e.g. fluorescent, radioactive, bioactive) and a suitable capillary electrophoresis (CE) detection system.

[0015] In another embodiment the expression of these genes can be detected with DNA-arrays as described in WO9727317 and US6379895.

[0016] In a further embodiment the expression of these genes can be detected with bead based direct fluorescent readout techniques such as described in WO9714028 and WO9952708.

[0017] In one embodiment, the invention pertains to a method of determining the phenotype of a cell or tissue, comprising detecting the differential expression, relative to a normal or untreated cell, of at least one polynucleotide comprising SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19 or 21 to 26 or 53 to 75, wherein the polynucleotide is differentially expressed by at least about 1.5 fold, at least about 2 fold or at least about 3 fold.

[0018] In a further aspect the invention pertains to a method of determining the phenotype of a cell or tissue, comprising detecting the differential expression, relative to a normal or untreated cell, of at least one polynucleotide which hybridizes under stringent conditions to one of the polynucleotides of SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19 or 21 to 26 or 53 to 75 and encodes a polypeptide exhibiting the same biological function as given in Table 2 or 3 for the respective polynucleotide, wherein the polynucleotide is differentially expressed by at least at least about 1.5 fold, at least about 2 fold or at least about 3 fold.

[0019] In another embodiment of the invention a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19 or 21 to 26 and 53 to 75 or encoding one of the polypeptides with SEQ ID NO: 28 to 32, 34, 35, 37 to 42, 44, 45 or 47 to 52 or 76 to 98 can be used to identify cells or tissue in individuals which exhibit a phenotype predisposed to breast cancer or a diseased phenotype, thereby (a) predicting whether an individual is at risk for the development, or (b) diagnosing whether an individual is having, or (c) prognosing the progression or the

outcome of the treatment malignant neoplasia and breast cancer in particular.

[0020] In yet another embodiment the invention provides a method for identifying genomic regions which are altered on the chromosomal level and encode genes that are linked by function and are differentially expressed in malignant neoplasia and breast cancer in particular.

5 [0021] In yet another embodiment the invention provides the genomic regions 17q12, 3p21 and 12q13 for use in prediction, diagnosis and prognosis as well as prevention and treatment of malignant neoplasia and breast cancer. In particular not only the intragenic regions, but also intergenic regions, pseudogenes or non-transcribed genes of said chromosomal regions can be used for diagnostic, predictive, prognostic and preventive and therapeutic compositions and methods.

10 [0022] In yet another embodiment the invention provides methods of screening for agents which regulate the activity of a polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75. A test compound is contacted with a polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75. Binding of the test compound to the polypeptide is detected. A test compound which binds to the polypeptide is thereby identified as a potential therapeutic agent for the treatment of malignant neoplasia and more particularly breast cancer.

15 [0023] In even another embodiment the invention provides another method of screening for agents which regulate the activity of a polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75. A test compound is contacted with a polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75. A biological activity mediated by the polypeptide is detected. A test compound which decreases the biological activity is thereby identified as a potential therapeutic agent for decreasing the activity of the polypeptide encoded by a polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 in malignant neoplasia and breast cancer in particular. A test compound which increases the biological activity is thereby identified as a potential therapeutic agent for increasing the activity of the polypeptide encoded by a polypeptide selected from one of the polypeptides with SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 in malignant neoplasia and breast cancer in particular.

20 [0024] In another embodiment the invention provides a method of screening for agents which regulate the activity of a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75. A test compound is contacted with a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75. Binding of the test compound to the polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 is detected. A test compound which binds to the polynucleotide is thereby identified as a potential therapeutic agent for regulating the activity of a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 in malignant neoplasia and breast cancer in particular.

25 [0025] The invention thus provides polypeptides selected from one of the polypeptides with SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 which can be used to identify compounds which may act, for example, as regulators or modulators such as agonists and antagonists, partial agonists, inverse agonists, activators, co-activators and inhibitors of the polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75. Accordingly, the invention provides reagents and methods for regulating a polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 in malignant neoplasia and more particularly breast cancer. The regulation can be an up-or down regulation. Reagents that modulate the expression, stability or amount of a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 or the activity of the polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 can be a protein, a peptide, a peptidomimetic, a nucleic acid, a nucleic acid analogue (e.g. peptide nucleic acid, locked nucleic acid) or a small molecule. Methods that modulate the expression, stability or amount of a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 or the activity of the polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 can be gene replacement therapies, antisense, ribozyme and triplex nucleic acid approaches.

30 [0026] In one embodiment of the invention provides antibodies which specifically bind to a full-length or partial polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 or a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 for use in prediction, prevention, diagnosis, prognosis and

treatment of malignant neoplasia and breast cancer in particular.

[0027] Yet another embodiment of the invention is the use of a reagent which specifically binds to a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 or a polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 in the preparation of a medicament for the treatment of malignant neoplasia and breast cancer in particular.

[0028] Still another embodiment is the use of a reagent that modulates the activity or stability of a polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 or the expression, amount or stability of a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 in the preparation of a medicament for the treatment of malignant neoplasia and breast cancer in particular.

[0029] Still another embodiment of the invention is a pharmaceutical composition which includes a reagent which specifically binds to a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 or a polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75, and a pharmaceutically acceptable carrier.

[0030] Yet another embodiment of the invention is a pharmaceutical composition including a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 or encoding a polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98.

[0031] In one embodiment, a reagent which alters the level of expression in a cell of a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 or encoding a polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98, or a sequence complementary thereto, is identified by providing a cell, treating the cell with a test reagent, determining the level of expression in the cell of a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 or encoding a polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or a sequence complementary thereto, and comparing the level of expression of the polynucleotide in the treated cell with the level of expression of the polynucleotide in an untreated cell, wherein a change in the level of expression of the polynucleotide in the treated cell relative to the level of expression of the polynucleotide in the untreated cell is indicative of an agent which alters the level of expression of the polynucleotide in a cell.

[0032] The invention further provides a pharmaceutical composition comprising a reagent identified by this method.

[0033] Another embodiment of the invention is a pharmaceutical composition which includes a polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or which is encoded by a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75.

[0034] A further embodiment of the invention is a pharmaceutical composition comprising a polynucleotide including a sequence which hybridizes under stringent conditions to a polynucleotide comprising a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 and encoding a polypeptide exhibiting the same biological function as given for the respective polynucleotide in Table 2 or 3, or encoding a polypeptide comprising a polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98. Pharmaceutical compositions, useful in the present invention may further include fusion proteins comprising a polypeptide comprising a polynucleotide selected from SEQ ID NO: 27 to 52 and 76 to 98, or a fragment thereof, antibodies, or antibody fragments

BRIEF DESCRIPTION OF THE DRAWINGS

[0035]

Fig. 1 shows a sketch of the chromosome 17 with G-banding pattern and cytogenetic positions. In the blow out at the lower part of the figure a detailed view of the chromosomal area of the long arm of chromosome 17 (17q12-21.1) is provided. Each vertical rectangle depicted in medium gray, represents a gene as labeled below or above the individual position. The order of genes depicted in this graph has been deduced from experiments questioning the amplification an over expression and from public available data (e.g. UCSC, NCBI or Ensemble).

Fig. 2 shows the same region as depicted before in Fig. 1 and a cluster representation of the individual expression values measured by DNA-chip hybridization. The gene representing squares are indicated by a dotted line. In the upper part of the cluster representation 4 tumor cell lines, of which two harbor a known HER-2/neu over expression (SKBR3 and AU565), are depicted with their individual expression profiles. Not only the HER-2/neu gene shows a clear over expression but as provided by this invention several other genes with in the surrounding. In the middle part of the cluster representation expression data obtained from immune histochemically characterized tumor samples are presented. Two of the depicted probes show a significant over

expression of genes marked by the white rectangles. For additional information and comparison expression profiles of several non diseased human tissues (RNAs obtained from Clontech Inc.) are provided. Closest relation to the expression profile of HER-2/neu positive tumors displays human brain and neural tissue.

Fig. 3 provides data from DNA amplification measurements by qPCR (e.g. TaqMan). Data indicates that in several analyzed breast cancer cell lines harbor amplification of genes which were located in the previously described region (ARCHEON). Data were displayed for each gene on the x-axis and 40-Ct at the y-axis. Data were normalized to the expression level of GAPDH as seen in the first group of columns.

Fig. 4 represents a graphical overview on the amplified regions and provides information on the length of the individual amplification and over expression in the analyzed tumor cell lines. The length of the amplification and the composition of genes has a significant impact on the nature of the cancer cell and on the responsiveness on certain drugs, as described elsewhere.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

[0036] "Differential expression", as used herein, refers to both quantitative as well as qualitative differences in the genes' expression patterns depending on differential development and/or tumor growth. Differentially expressed genes may represent "marker genes," and/or "target genes". The expression pattern of a differentially expressed gene disclosed herein may be utilized as part of a prognostic or diagnostic breast cancer evaluation. Alternatively, a differentially expressed gene disclosed herein may be used in methods for identifying reagents and compounds and uses of these reagents and compounds for the treatment of breast cancer as well as methods of treatment.

[0037] "Biological activity" or "bioactivity" or "activity" or "biological function", which are used interchangeably, herein mean an effector or antigenic function that is directly or indirectly performed by a polypeptide (whether in its native or denatured conformation), or by any fragment thereof *in vivo* or *in vitro*. Biological activities include but are not limited to binding to polypeptides, binding to other proteins or molecules, enzymatic activity, signal transduction, activity as a DNA binding protein, as a transcription regulator, ability to bind damaged DNA, etc. A bioactivity can be modulated by directly affecting the subject polypeptide. Alternatively, a bioactivity can be altered by modulating the level of the polypeptide, such as by modulating expression of the corresponding gene.

[0038] The term "marker" or "biomarker" refers a biological molecule, e.g., a nucleic acid, peptide, hormone, etc., whose presence or concentration can be detected and correlated with a known condition, such as a disease state.

[0039] "Marker gene," as used herein, refers to a differentially expressed gene which expression pattern may be utilized as part of predictive, prognostic or diagnostic malignant neoplasia or breast cancer evaluation, or which, alternatively, may be used in methods for identifying compounds useful for the treatment or prevention of malignant neoplasia and breast cancer in particular. A marker gene may also have the characteristics of a target gene.

[0040] "Target gene", as used herein, refers to a differentially expressed gene involved in breast cancer in a manner by which modulation of the level of target gene expression or of target gene product activity may act to ameliorate symptoms of malignant neoplasia and breast cancer in particular. A target gene may also have the characteristics of a marker gene.

[0041] The term "biological sample", as used herein, refers to a sample obtained from an organism or from components (e.g., cells) of an organism. The sample may be of any biological tissue or fluid. Frequently the sample will be a "clinical sample" which is a sample derived from a patient. Such samples include, but are not limited to, sputum, blood, blood cells (e.g., white cells), tissue or fine needle biopsy samples, cell-containing bodyfluids, free floating nucleic acids, urine, peritoneal fluid, and pleural fluid, or cells therefrom. Biological samples may also include sections of tissues such as frozen sections taken for histological purposes.

[0042] By "array" or "matrix" is meant an arrangement of addressable locations or "addresses" on a device. The locations can be arranged in two dimensional arrays, three dimensional arrays, or other matrix formats. The number of locations can range from several to at least hundreds of thousands. Most importantly, each location represents a totally independent reaction site. Arrays include but are not limited to nucleic acid arrays, protein arrays and antibody arrays. A "nucleic acid array" refers to an array containing nucleic acid probes, such as oligonucleotides, polynucleotides or larger portions of genes. The nucleic acid on the array is preferably single stranded. Arrays wherein the probes are oligonucleotides are referred to as "oligonucleotide arrays" or "oligonucleotide chips." A "microarray," herein also refers to a "biochip" or "biological chip", an array of regions having a density of discrete regions of at least about 100/cm², and preferably at least about 1000/cm². The regions in a microarray have typical dimensions, e.g., diameters, in the range of between about 10-250 µm, and are separated from other regions in the array by about the same distance. A "protein array" refers to an array containing polypeptide probes or protein probes which can be in native form or

denatured. An "antibody array" refers to an array containing antibodies which include but are not limited to monoclonal antibodies (e.g. from a mouse), chimeric antibodies, humanized antibodies or phage antibodies and single chain antibodies as well as fragments from antibodies.

[0043] The term "agonist", as used herein, is meant to refer to an agent that mimics or upregulates (e.g., potentiates or supplements) the bioactivity of a protein. An agonist can be a wild-type protein or derivative thereof having at least one bioactivity of the wild-type protein. An agonist can also be a compound that upregulates expression of a gene or which increases at least one bioactivity of a protein. An agonist can also be a compound which increases the interaction of a polypeptide with another molecule, e.g., a target peptide or nucleic acid.

[0044] The term "antagonist" as used herein is meant to refer to an agent that downregulates (e.g., suppresses or inhibits) at least one bioactivity of a protein. An antagonist can be a compound which inhibits or decreases the interaction between a protein and another molecule, e.g., a target peptide, a ligand or an enzyme substrate. An antagonist can also be a compound that downregulates expression of a gene or which reduces the amount of expressed protein present.

[0045] "Small molecule" as used herein, is meant to refer to a composition, which has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic (carbon-containing) or inorganic molecules. Many pharmaceutical companies have extensive libraries of chemical and/or biological mixtures, often fungal, bacterial, or algal extracts, which can be screened with any of the assays of the invention to identify compounds that modulate a bioactivity.

[0046] The terms "modulated" or "modulation" or "regulated" or "regulation" and "differentially regulated" as used herein refer to both upregulation (i.e., activation or stimulation (e.g., by agonizing or potentiating) and down regulation (i.e., inhibition or suppression (e.g., by antagonizing, decreasing or inhibiting)).

[0047] "Transcriptional regulatory unit" refers to DNA sequences, such as initiation signals, enhancers, and promoters, which induce or control transcription of protein coding sequences with which they are operably linked. In preferred embodiments, transcription of one of the genes is under the control of a promoter sequence (or other transcriptional regulatory sequence) which controls the expression of the recombinant gene in a cell-type in which expression is intended. It will also be understood that the recombinant gene can be under the control of transcriptional regulatory sequences which are the same or which are different from those sequences which control transcription of the naturally occurring forms of the polypeptide.

[0048] The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

[0049] The term "nucleotide analog" refers to oligomers or polymers being at least in one feature different from naturally occurring nucleotides, oligonucleotides or polynucleotides, but exhibiting functional features of the respective naturally occurring nucleotides (e.g. base pairing, hybridization, coding information) and that can be used for said compositions. The nucleotide analogs can consist of non-naturally occurring bases or polymer backbones, examples of which are LNAs, PNAs and Morpholinos. The nucleotide analog has at least one molecule different from its naturally occurring counterpart or equivalent.

[0050] "BREAST CANCER GENES" or "BREAST CANCER GENE" as used herein refers to the polynucleotides of SEQ ID NO: 1 to 26 and 53 to 75, as well as derivatives, fragments, analogs and homologues thereof, the polypeptides encoded thereby, the polypeptides of SEQ ID NO: 27 to 52 and 76 to 98 as well as derivatives, fragments, analogs and homologues thereof and the corresponding genomic transcription units which can be derived or identified with standard techniques well known in the art using the information disclosed in Tables 1 to 5 and Figures 1 to 4. The GenBank, Locuslink ID and the UniGene accession numbers of the polynucleotide sequences of the SEQ ID NO: 1 to 26 and 53 to 75 and the polypeptides of the SEQ ID NO: 27 to 52 and 76 to 98 are shown in Table 1, the gene description, gene function and subcellular localization is given in Tables 2 and 3.

[0051] The term "chromosomal region" as used herein refers to a consecutive DNA stretch on a chromosome which can be defined by cytogenetic or other genetic markers such as e.g. restriction length polymorphisms (RFLPs), single nucleotide polymorphisms (SNPs), expressed sequence tags (ESTs), sequence tagged sites (STSs), micro-satellites, variable number of tandem repeats (VNTRs) and genes. Typically a chromosomal region consists of up to 2 Megabases (MB), up to 4 MB, up to 6 MB, up to 8 MB, up to 10 MB, up to 20 MB or even more MB.

[0052] The term "altered chromosomal region" or "abberant chromosomal region" refers to a structural change of the chromosomal composition and DNA sequence, which can occur by the following events: amplifications, deletions, inversions, insertions, translocations and/or viral integrations. A trisomy, where a given cell harbors more than two copies of a chromosome, is within the meaning of the term "amplification" of a chromosome or chromosomal region.

[0053] The present invention provides polynucleotide sequences and proteins encoded thereby, as well as probes

derived from the polynucleotide sequences, antibodies directed to the encoded proteins, and predictive, preventive, diagnostic, prognostic and therapeutic uses for individuals which are at risk for or which have malignant neoplasia and breast cancer in particular. The sequences disclosure herein have been found to be differentially expressed in samples from breast cancer.

[0054] The present invention is based on the identification of 43 genes that are differentially regulated (up- or down-regulated) in tumor biopsies of patients with clinical evidence of breast cancer. The identification of 43 human genes which were not known to be differentially regulated in breast cancer states and their significance for the disease is described in the working examples herein. The characterization of the co-expression of these genes provides newly identified roles in breast cancer. The gene names, the database accession numbers (GenBank and UniGene) as well as the putative or known functions of the encoded proteins and their subcellular localization are given in Tables 1 to 4. The primer sequences used for the gene amplification are shown in Table 5.

[0055] In either situation, detecting expression of these genes in excess or in with lower level as compared to normal expression provides the basis for the diagnosis of malignant neoplasia and breast cancer. Furthermore, in testing the efficacy of compounds during clinical trials, a decrease in the level of the expression of these genes corresponds to a return from a disease condition to a normal state, and thereby indicates a positive effect of the compound.

[0056] Another aspect of the present invention is based on the observation that neighboring genes within defined genomic regions functionally interact and influence each others function directly or indirectly. A genomic region encoding functionally interacting genes that are co-amplified and co-expressed in neoplastic lesions has been defined as an "ARCHEON". (ARCHEON = Altered Region of Changed Chromosomal Expression Observed in Neoplasms). Chromosomal alterations often affect more than one gene. This is true for amplifications, duplications, insertions, integrations, inversions, translocations, and deletions. These changes can have influence on the expression level of single or multiple genes. Most commonly in the field of cancer diagnostics and treatment the changes of expression levels have been investigated for single, putative relevant target genes such as MLV12 (5p14), NRASL3 (6p12), EGFR (7p12), c-myc (8q23), Cyclin D1 (11q13), IGF1R (15q25), HER-2/neu (17q12), PCNA (20q12). However, the altered expression level and interaction of multiple (i.e. more than two) genes within one genomic region with each other has not been addressed. Genes of an ARCHEON form gene clusters with tissue specific expression patterns. The mode of interaction of individual genes within such a gene cluster suspected to represent an ARCHEON can be either protein-protein or protein-nucleic acid interaction, which may be illustrated but not limited by the following examples: ARCHEON gene interaction may be in the same signal transduction pathway, may be receptor to ligand binding, receptor kinase and SH2 or SH3 binding, transcription factor to promoter binding, nuclear hormone receptor to transcription factor binding, phosphogroup donation (e.g. kinases) and acceptance (e.g. phosphoprotein), mRNA stabilizing protein binding and transcriptional processes. The individual activity and specificity of a pair genes and or the proteins encoded thereby or of a group of such in a higher order, may be readily deduced from literature, published or deposited within public databases by the skilled person. However in the context of an ARCHEON the interaction of members being part of an ARCHEON will potentiate, exaggerate or reduce their singular functions. This interaction is of importance in defined normal tissues in which they are normally co-expressed. Therefore, these clusters have been commonly conserved during evolution. The aberrant expression of members of these ARCHEON in neoplastic lesions, however, (especially within tissues in which they are normally not expressed) has influence on tumor characteristics such as growth, invasiveness and drug responsiveness. Due to the interaction of these neighboring genes it is of importance to determine the members of the ARCHEON which are involved in the deregulation events. In this regard amplification and deletion events in neoplastic lesions are of special interest.

[0057] The invention relates to a method for the detection of chromosomal alterations by (a) determining the relative mRNA abundance of individual mRNA species or (b) determining the copy number of one or more chromosomal region (s) by quantitative PCR. In one embodiment information on the genomic organization and spatial regulation of chromosomal regions is assessed by bioinformatic analysis of the sequence information of the human genome (UCSC, NCBI) and then combined with RNA expression data from GeneChip™ DNA-Arrays (Affymetrix) and/or quantitative PCR (TaqMan) from RNA-samples or genomic DNA.

[0058] In a further embodiment the functional relationship of genes located on a chromosomal region which is altered (amplified or deleted) is established. The altered chromosomal region is defined as an ARCHEON if genes located on that region functionally interact.

[0059] The 17q 12 locus was investigated as one model system, harboring the HER-2/neu gene. By establishing a high-resolution assay to detect amplification events in neighboring genes, 43 genes that are commonly co-amplified in breast cancer cell lines and patient samples were identified. By gene array technologies and immunological methods their co-overexpression in tumor samples was demonstrated. Surprisingly, by clustering tissue samples with HER-2/neu positive Tumor samples, it was found that the expression pattern of this larger genomic region (consisting of 43 genes) is very similar to control brain tissue. HER-2/neu negative breast tumor tissue did not show a similar expression pattern. Indeed, some of the genes within these cluster are important for neural development (HER-2/neu, THRA) in mouse model systems or are described to be expressed in neural cells (NeuroD2). Moreover, by searching similar

gene combinations in the human and rodent genome additional homologous chromosomal regions on chromosome 3p21 and 12q13 harboring several isoforms of the respective genes (see below) were found. There was a strong evidence for multiple interactions between the 43 candidate genes, as being part of identical pathways (HER-2, neu, GRB7, CrkRS, CDC6), influencing the expression of each other (HER-2/neu, THRA, RARA), interacting with each other (PPARGBP, THRA, RARA, NR1D1 or HER-2/neu, GRB7) or expressed in defined tissues (CACNB1, PPARGBP, etc.). Interestingly, the genomic regions of the ARCHEONS that were identified are amplified in acquired Tamoxifen resistance of HER-2/neu negative cells (MCF7), which are normally sensitive to Tamoxifen treatment [Achuthan et al., 2001,(2)].

[0060] Moreover, altered responsiveness to treatment due to the alterations of the genes within these ARCHEONS was observed. Surprisingly, genes within the ARCHEONS are of importance even in the absence of HER-2/neu homologues. Some of the genes within the ARCHEONS, do not only serve as marker genes for prognostic purposes, but have already been known as targets for therapeutic intervention. For example TOP2 alpha is a target of anthracyclins. THRA and RARA can be targeted by hormones and hormone analogs (e.g. T3, rT3, RA). Due to their high affinity binding sites and available screening assays (reporter assays based on their transcriptional potential) the hormone receptors which are shown to be linked to neoplastic pathophysiology for the first time herein are ideal targets for drug screening and treatment of malignant neoplasia and breast cancer in particular. In this regard it is essential to know which members of the ARCHEON are altered in the neoplastic lesions. Particularly it is important to know the nature, number and extent to which the ARCHEON genes are amplified or deleted. The ARCHEONS are flanked by similar, endogenous retroviruses (e.g. HERV-K= "human endogenous retrovirus"), some of which are activated in breast cancer. These viruses may have also been involved in the evolutionary duplication of the ARCHEONS.

[0061] The analysis of the 17q12 region proved data obtained by IHC and identified several additional genes being co-amplified with the HER-2/neu gene. Comparative Analysis of RNA-based quantitative RT-PCR (TaqMan) with DNA-based qPCR from tumor cell lines identified the same amplified region. Genes at the 17q11.2 -21. region are offered by way of illustration not by way of limitation. A graphical display of the described chromosomal region is provided in Figure 1.

Biological relevance of the genes which are part of the 17q12 ARCHEON

MLN50

[0062] By differential screening of cDNAs from breast cancer-derived metastatic axillary lymph nodes, TRAF4 and 3 other novel genes (MLN51, MLN62, MLN64) were identified that are overexpressed in breast cancer [Tomasetto et al., 1995, (3)]. One gene, which they designated MLN50, was mapped to 17q11-q21.3 by radioactive in situ hybridization. In breast cancer cell lines, overexpression of the 4 kb MLN50 mRNA was correlated with amplification of the gene and with amplification and overexpression of ERBB2, which maps to the same region. The authors suggested that the 2 genes belong to the same amplicon. Amplification of chromosomal region 17q11-q21 is one of the most common events occurring in human breast cancers. They reported that the predicted 261-amino acid MLN50 protein contains an N-terminal LIM domain and a C-terminal SH3 domain. They renamed the protein LASP1, for 'LIM and SH3 protein.' Northern blot analysis revealed that LASP1 mRNA was expressed at a basal level in all normal tissues examined and overexpressed in 8% of primary breast cancers. In most of these cancers, LASP1 and ERBB2 were simultaneously overexpressed.

MLLT6

[0063] The MLLT6 (AF17) gene encodes a protein of 1,093 amino acids, containing a leucine-zipper dimerization motif located 3-prime of the fusion point and a cysteine-rich domain at the end terminus. AF17 was found to contain stretches of amino acids previously associated with domains involved in transcriptional repression or activation.

[0064] Chromosome translocations involving band 11q23 are associated with approximately 10% of patients with acute lymphoblastic leukemia (ALL) and more than 5% of patients with acute myeloid leukemia (AML). The gene at 11q23 involved in the translocations is variously designated ALL1, HRX, MLL, and TAX1. The partner gene in one of the rarer translocations, t(11;17)(q23;q21), designated MLLT6 on 17q12.

ZNF144 (Mel18)

[0065] Mel18 cDNA encodes a novel cys-rich zinc finger motif. The gene is expressed strongly in most tumor cell lines, but its normal tissue expression was limited to cells of neural origin and was especially abundant in fetal neural cells. It belongs to a RING-finger motif family which includes BMI1. The MEL18/BMI1 gene family represents a mammalian homolog of the Drosophila 'polycomb' gene group, thereby belonging to a memory mechanism involved in

maintaining the the expression pattern of key regulatory factors such as Hox genes. Bmi1, Mel18 and M33 genes, as representative examples of mouse Pc-G genes. Common phenotypes observed in knockout mice mutant for each of these genes indicate an important role for Pc-G genes not only in regulation of Hox gene expression and axial skeleton development but also in control of proliferation and survival of haematopoietic cell lineages. This is in line with the observed proliferative deregulation observed in lymphoblastic leukemia. The MEL18 gene is conserved among vertebrates. Its mRNA is expressed at high levels in placenta, lung, and kidney, and at lower levels in liver, pancreas, and skeletal muscle. Interestingly, cervical and lumbo-sacral-HOX gene expression is altered in several primary breast cancers with respect to normal breast tissue with the HoxB gene cluster being present on 17q distal to the 17q12 locus. Moreover, delay of differentiation with persistent nests of proliferating cells was found in endothelial cells cocultured with HOXB7-transduced SkBr3 cells, which exhibit a 17q12 amplification. Tumorigenicity of these cells has been evaluated in vivo. Xenograft in athymic nude mice showed that SkBr3/HOXB7 cells developed tumors with an increased number of blood vessels, either irradiated or not, whereas parental SkBr3 cells did not show any tumor take unless mice were sublethally irradiated. As part of this invention, we have found MEL18 to be overexpressed specifically in tumors bearing Her-2/neu gene amplification, which can be critical for Hox expression.

PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE, TYPE II, BETA; PIP5K2B

[0066] Phosphoinositide kinases play central roles in signal transduction. Phosphatidylinositol-4-phosphate 5-kinases (PIP5Ks) phosphorylate phosphatidylinositol 4-phosphate, giving rise to phosphatidylinositol 4,5-bisphosphate. The PIP5K enzymes exist as multiple isoforms that have various immunoreactivities, kinetic properties, and molecular masses. They are unique in that they possess almost no homology to the kinase motifs present in other phosphatidylinositol, protein, and lipid kinases. By screening a human fetal brain cDNA library with the PIP5K2B EST the full length gene could be isolated. The deduced 416-amino acid protein is 78% identical to PIP5K2A. Using SDS-PAGE, the authors estimated that bacterially expressed PIP5K2B has a molecular mass of 47 kD. Northern blot analysis detected a 6.3-kb PIP5K2B transcript which was abundantly expressed in several human tissues. PIP5K2B interacts specifically with the juxtamembrane region of the p55 TNF receptor (TNFR1) and PIP5K2B activity is increased in mammalian cells by treatment with TNF-alpha. A modeled complex with membrane-bound substrate and ATP shows how a phosphoinositide kinase can phosphorylate its substrate in situ at the membrane interface. The substrate-binding site is open on 1 side, consistent with dual specificity for phosphatidylinositol 3- and 5-phosphates. Although the amino acid sequence of PIP5K2A does not show homology to known kinases, recombinant PIP5K2A exhibited kinase activity. PIP5K2A contains a putative Src homology 3 (SH3) domain-binding sequence. Overexpression of mouse PIP5K1B in COS7 cells induced an increase in short actin fibers and a decrease in actin stress fibers.

TEM7

[0067] Using serial analysis of gene expression (SAGE) a partial cDNAs corresponding to several tumor endothelial markers (TEMs) that displayed elevated expression during tumor angiogenesis could be identified. Among the genes identified was TEM7. Using database searches and 5-prime RACE the entire TEM7 coding region, which encodes a 500-amino acid type I transmembrane protein, has been described. The extracellular region of TEM7 contains a plexin-like domain and has weak homology to the ECM protein nidogen. The function of these domains, which are usually found in secreted and extracellular matrix molecules, is unknown. Nidogen itself belongs to the entactin protein family and helps to determine pathways of migrating axons by switching from circumferential to longitudinal migration. Entactin is involved in cell migration, as it promotes trophoblast outgrowth through a mechanism mediated by the RGD recognition site, and plays an important role during invasion of the endometrial basement membrane at implantation. As entactin promotes thymocyte adhesion but affects thymocyte migration only marginally, it is suggested that entactin may play a role in thymocyte localization during T cell development.

[0068] In situ hybridization analysis of human colorectal cancer demonstrated that TEM7 was expressed clearly in the endothelial cells of the tumor stroma but not in the endothelial cells of normal colonic tissue. Using in situ hybridization to assay expression in various normal adult mouse tissues, they observed that TEM7 was largely undetectable in mouse tissues or tumors, but was abundantly expressed in mouse brain.

ZNFN1A3

[0069] By screening a B-cell cDNA library with a mouse Aiolos N-terminal cDNA probe, a cDNA encoding human Aiolos, or ZNFN1A3, was obtained. The deduced 509-amino acid protein, which is 86% identical to its mouse counterpart, has 4 DNA-binding zinc fingers in its N terminus and 2 zinc fingers that mediate protein dimerization in its C terminus. These domains are 100% and 96% homologous to the corresponding domains in the mouse protein, respectively. Northern blot analysis revealed strong expression of a major 11.0- and a minor 4.4-kb ZNFN1A3 transcript in

peripheral blood leukocytes, spleen, and thymus, with lower expression in liver, small intestine, and lung.

[0070] Ikaros (ZNFN1A1), a hemopoietic zinc finger DNA-binding protein, is a central regulator of lymphoid differentiation and is implicated in leukemogenesis. The execution of normal function of Ikaros requires sequence-specific DNA binding, transactivation, and dimerization domains. Mice with a mutation in a related zinc finger protein, Aiolos, are prone to B-cell lymphoma. In chemically induced murine lymphomas allelic losses on markers surrounding the Znf1al gene were detected in 27% of the tumors analyzed. Moreover specific Ikaros expression was in primary mouse hormone-producing anterior pituitary cells and substantial for Fibroblast growth factor receptor 4 (FGFR4) expression, which itself is implicated in a multitude of endocrine cell hormonal and proliferative properties with FGFR4 being differentially expressed in normal and neoplastic pituitary. Moreover Ikaros binds to chromatin remodelling complexes containing SWI/SNF proteins, which antagonize Polycomb function. Interestingly at the telomeric end of the disclosed ARCHEON the SWI/SNF complex member SMARCE1 (= SWI/SNF-related, matrix-associated, actin-dependent regulators of chromatin) is located and part of the described amplification. Due to the related binding specificities of Ikaros and Palindrom Binding Protein (PBP) it is suggestive, that ZNFN1A3 is able to regulate the Her-2/neu enhancer.

PPP1R1B

[0071] Midbrain dopaminergic neurons play a critical role in multiple brain functions, and abnormal signaling through dopaminergic pathways has been implicated in several major neurologic and psychiatric disorders. One well-studied target for the actions of dopamine is DARPP32. In the densely dopamine- and glutamate-innervated rat caudate-putamen, DARPP32 is expressed in medium-sized spiny neurons that also express dopamine D1 receptors. The function of DARPP32 seems to be regulated by receptor stimulation. Both dopaminergic and glutamatergic (NMDA) receptor stimulation regulate the extent of DARPP32 phosphorylation, but in opposite directions.

[0072] The human DARPP32 was isolated from a striatal cDNA library. The 204-amino acid DARPP32 protein shares 88% and 85% sequence identity, respectively, with bovine and rat DARPP32 proteins. The DARPP32 sequence is particularly conserved through the N terminus, which represents the active portion of the protein. Northern blot analysis demonstrated that the 2.1-kb DARPP32 mRNA is more highly expressed in human caudate than in cortex. In situ hybridization to postmortem human brain showed a low level of DARPP32 expression in all neocortical layers, with the strongest hybridization in the superficial layers. CDK5 phosphorylated DARPP32 in vitro and in intact brain cells. Phospho-thr75 DARPP32 inhibits PKA in vitro by a competitive mechanism. Decreasing phospho-thr75 DARPP32 in striatal cells either by a CDK5-specific inhibitor or by using genetically altered mice resulted in increased dopamine-induced phosphorylation of PKA substrates and augmented peak voltage-gated calcium currents. Thus, DARPP32 is a bifunctional signal transduction molecule which, by distinct mechanisms, controls a serine/threonine kinase and a serine/threonine phosphatase.

[0073] DARPP32 and t-DARPP are overexpressed in gastric cancers. It's suggested that overexpression of these 2 proteins in gastric cancers may provide an important survival advantage to neoplastic cells. It could be demonstrated that Darpp32 is an obligate intermediate in progesterone-facilitated sexual receptivity in female rats and mice. The facilitative effect of progesterone on sexual receptivity in female rats was blocked by antisense oligonucleotides to Darpp32. Homozygous mice carrying a null mutation for the Darpp32 gene exhibited minimal levels of progesterone-facilitated sexual receptivity when compared to their wildtype littermates, and progesterone significantly increased hypothalamic cAMP levels and cAMP-dependent protein kinase activity.

CACNB1

[0074] In 1991 a cDNA clone encoding a protein with high homology to the beta subunit of the rabbit skeletal muscle dihydropyridine-sensitive calcium channel from a rat brain cDNA library [Pragnell et al., 1991, (4)]. This rat brain beta-subunit cDNA hybridized to a 3.4-kb message that was expressed in high levels in the cerebral hemispheres and hippocampus and much lower levels in cerebellum. The open reading frame encodes 597 amino acids with a predicted mass of 65,679 Da which is 82% homologous with the skeletal muscle beta subunit. The corresponding human beta-subunit gene was localized to chromosome 17 by analysis of somatic cell hybrids. The authors suggested that the encoded brain beta subunit, which has a primary structure highly similar to its isoform in skeletal muscle, may have a comparable role as an integral regulatory component of a neuronal calcium channel.

RPL19

[0075] The ribosome is the only organelle conserved between prokaryotes and eukaryotes. In eukaryotes, this organelle consists of a 60S large subunit and a 40S small subunit. The mammalian ribosome contains 4 species of RNA and approximately 80 different ribosomal proteins, most of which appear to be present in equimolar amounts. In mammalian cells, ribosomal proteins can account for up to 15% of the total cellular protein, and the expression of the different

ribosomal protein genes, which can account for up to 7 to 9% of the total cellular mRNAs, is coordinately regulated to meet the cell's varying requirements for protein synthesis. The mammalian ribosomal protein genes are members of multigene families, most of which are composed of multiple processed pseudogenes and a single functional intron-containing gene. The presence of multiple pseudogenes hampered the isolation and study of the functional ribosomal protein genes. By study of somatic cell hybrids, it has been elucidated that DNA sequences complementary to 6 mammalian ribosomal protein cDNAs could be assigned to chromosomes 5, 8, and 17. Ten fragments mapped to 3 chromosomes [Nakamichi et al., 1986, (5)]. These are probably a mixture of functional (expressed) genes and pseudogenes. One that maps to 5q23-q33 rescues Chinese hamster emetine-resistance mutations in interspecies hybrids and is therefore the transcriptionally active RPS14 gene. In 1989 a PCR-based strategy for the detection of intron-containing genes in the presence of multiple pseudogenes was described. This technique was used to identify the intron-containing PCR products of 7 human ribosomal protein genes and to map their chromosomal locations by hybridization to human/rodent somatic cell hybrids [Feo et al., 1992, (6)]. All 7 ribosomal protein genes were found to be on different chromosomes: RPL19 on 17p12-q11; RPL30 on 8; RPL35A on 18; RPL36A on 14; RPS6 on 9pter-p13; RPS11 on 19cen-qter; and RPS17 on 11pter-p13. These are also different sites from the chromosomal location of previously mapped ribosomal protein genes S14 on chromosome 5, S4 on Xq and Yp, and RP117A on 9q3-q34. By fluorescence in situ hybridization the position of the RPL19 gene was mapped to 17q11 [Davies et al., 1989, (7)].

PPARBP, PBP, CRSP1, CRSP200, TRIP2, TRAP220, RB18A, DRIP230

[0076] The thyroid hormone receptors (TRs) are hormone-dependent transcription factors that regulate expression of a variety of specific target genes. They must specifically interact with a number of proteins as they progress from their initial translation and nuclear translocation to heterodimerization with retinoid X receptors (RXRs), functional interactions with other transcription factors and the basic transcriptional apparatus, and eventually, degradation. To help elucidate the mechanisms that underlie the transcriptional effects and other potential functions of TRs, the yeast interaction trap, a version of the yeast 2-hybrid system, was used to identify proteins that specifically interact with the ligand-binding domain of rat TR-beta-1 (THRB) [Lee et al., 1995, (8)]. The authors isolated HeLa cell cDNAs encoding several different TR-interacting proteins (TRIPs), including TRIP2. TRIP2 interacted with rat Thrb only in the presence of thyroid hormone. It showed a ligand-independent interaction with RXR-alpha, but did not interact with the glucocorticoid receptor (NR3C1) under any condition. By immunoscreening a human B-lymphoma cell cDNA expression library with the 'anti-p53 monoclonal antibody PAb1801, PPARBP was identified, which was called RB18A for 'recognized by PAb1801 monoclonal antibody' [Drane et al., 1997, (9)]. The predicted 1,566-amino acid RB 18A protein contains several potential nuclear localization signals, 13 potential N-glycosylation sites, and a high number of potential phosphorylation sites. Despite sharing common antigenic determinants with p53, RB18A does not show significant nucleotide or amino acid sequence similarity with p53. Whereas the calculated molecular mass of RB18A is 166 kD, the apparent mass of recombinant RB18A was 205 kD by SDS-PAGE analysis. The authors demonstrated that RB18A shares functional properties with p53, including DNA binding, p53 binding, and self-oligomerization. Furthermore, RB18A was able to activate the sequence-specific binding of p53 to DNA, which was induced through an unstable interaction between both proteins. Northern blot analysis of human tissues detected an 8.5-kb RB18A transcript in all tissues examined except kidney, with highest expression in heart. Moreover mouse Pparbp, which was called Pbp for 'Ppar-binding protein,' as a protein that interacts with the Ppar-gamma (PPARG) ligand-binding domain in a yeast 2-hybrid system was identified [Zhu et al., 1997, (10)]. The authors found that Pbp also binds to PPAR-alpha (PPARA), RAR-alpha (RARA), RXR, and TR-beta-1 in vitro. The binding of Pbp to these receptors increased in the presence of specific ligands. Deletion of the last 12 amino acids from the C terminus of PPAR-gamma resulted in the abolition of interaction between Pbp and PPAR-gamma. Pbp modestly increased the transcriptional activity of PPAR-gamma, and a truncated form of Pbp acted as a dominant-negative repressor, suggesting that Pbp is a genuine transcriptional co-activator for PPAR. The predicted 1,560-amino acid Pbp protein contains 2 LXXLL motifs, which are considered necessary and sufficient for the binding of several co-activators to nuclear receptors. Northern blot analysis detected Pbp expression in all mouse tissues examined, with higher levels in liver, kidney, lung, and testis. In situ hybridization showed that Pbp is expressed during mouse ontogeny, suggesting a possible role for Pbp in cellular proliferation and differentiation. In adult mouse, in situ hybridization detected Pbp expression in liver, bronchial epithelium in the lung, intestinal mucosa, kidney cortex, thymic cortex, splenic follicles, and seminiferous epithelium in testis. Lateron PPARBP was identified, which was called TRAP220, from an immunopurified TR-alpha (THRA)-TRAP complex [Yuan et al., 1998, (11)]. The authors cloned Jurkat cell cDNAs encoding TRAP220. The predicted 1,581-amino acid TRAP220 protein contains LXXLL domains, which are found in other nuclear receptor-interacting proteins. TRAP220 is nearly identical to RB18A, with these proteins differing primarily by an extended N terminus on TRAP220. In the absence of TR-alpha, TRAP220 appears to reside in a single complex with other TRAPs. TRAP220 showed a direct ligand-dependent interaction with TR-alpha, which was mediated through the C terminus of TR-alpha and, at least in part, the LXXLL domains of TRAP220. TRAP220 also interacted with other nuclear receptors, including vitamin D receptor,

RARA, RXRA, PPARA, PPARG, and estrogen receptor-alpha (ESR1; 133430), in a ligand-dependent manner. TRAP220 moderately stimulated human TR-alpha-mediated transcription in transfected cells, whereas a fragment containing the LXXLL motifs acted as a dominant-negative inhibitor of nuclear receptor-mediated transcription both in transfected cells and in cell-free transcription systems. Further studies indicated that TRAP220 plays a major role in anchoring other TRAPs to TR-alpha during the function of the TR-alpha-TRAP complex and that TRAP220 may be a global co-activator for the nuclear receptor superfamily. PBP, a nuclear receptor co-activator, interacts with estrogen receptor-alpha (ESR1) in the absence of estrogen. This interaction was enhanced in the presence of estrogen, but was reduced in the presence of the anti-estrogen Tamoxifen. Transfection of PBP into cultured cells resulted in enhancement of estrogen-dependent transcription, indicating that PBP serves as a co-activator in estrogen receptor signaling. To examine whether overexpression of PBP plays a role in breast cancer because of its co-activator function in estrogen receptor signaling, the levels of PBP expression in breast tumors was determined [Zhu et al., 1999, (12)]. High levels of PBP expression were detected in approximately 50% of primary breast cancers and breast cancer-cell lines by ribonuclease protection analysis, in situ hybridization, and immunoperoxidase staining. By using FISH, the authors mapped the PBP gene to 17q12, a region that is amplified in some breast cancers. They found PBP gene amplification in approximately 24% (6 of 25) of breast tumors and approximately 30% (2 of 6) of breast cancer cell lines, implying that PBP gene overexpression can occur independent of gene amplification. They determined that the PBP gene comprises 17 exons that together span more than 37 kb. Their findings, in particular PBP gene amplification, suggested that PBP, by its ability to function as an estrogen receptor-alpha co-activator, may play a role in mammary epithelial differentiation and in breast carcinogenesis.

NEUROD2

[0077] Basic helix-loop-helix (bHLH) proteins are transcription factors involved in determining cell type during development. In 1995 a bHLH protein was described, termed NeuroD (for 'neurogenic differentiation'), that functions during neurogenesis [Lee et al., 1995, (13)]. The human NEUROD gene maps to chromosome 2q32. The cloning and characterization of 2 additional NEUROD genes, NEUROD2 and NEUROD3 was described in 1996 [McCormick et al., 1996, (14)]. Sequences for the mouse and human homologues were presented. NEUROD2 shows a high degree of homology to the bHLH region of NEUROD, whereas NEUROD3 is more distantly related. The authors found that mouse neuroD2 was initially expressed at embryonic day 11, with persistent expression in the adult nervous system. Similar to neuroD, neuroD2 appears to mediate neuronal differentiation. The human NEUROD2 was mapped to 17q12 by fluorescence in situ hybridization and the mouse homologue to chromosome 11 [Tamimi et al., 1997, (15)].

TELETHONIN

[0078] Telethonin is a sarcomeric protein of 19 kD found exclusively in striated and cardiac muscle. It appears to be localized to the Z disc of adult skeletal muscle and cultured myocytes. Telethonin is a substrate of titin, which acts as a molecular 'ruler' for the assembly of the sarcomere by providing spatially defined binding sites for other sarcomeric proteins. After activation by phosphorylation and calcium/calmodulin binding, titin phosphorylates the C-terminal domain of telethonin in early differentiating myocytes. The telethonin gene has been mapped to 17q12, adjacent to the phenylethanolamine N-methyltransferase gene [Valle et al., 1997, (16)].

PENT, PNMT

[0079] Phenylethanolamine N-methyltransferase catalyzes the synthesis of epinephrine from norepinephrine, the last step of catecholamine biosynthesis. The cDNA clone was first isolated in 1998 for bovine adrenal medulla PNMT using mixed oligodeoxynucleotide probes whose synthesis was based on the partial amino acid sequence of tryptic peptides from the bovine enzyme [Kaneda et al., 1988, (17)]. Using a bovine cDNA as a probe, the authors screened a human pheochromocytoma cDNA library and isolated a cDNA clone with an insert of about 1.0 kb, which contained a complete coding region of the enzyme. Northern blot analysis of human pheochromocytoma polyadenylated RNA using this cDNA insert as the probe demonstrated a single RNA species of about 1,000 nucleotides, suggesting that this clone is a full-length cDNA. The nucleotide sequence showed that human PNMT has 282 amino acid residues with a predicted molecular weight of 30,853, including the initial methionine. The amino acid sequence was 88% homologous to that of bovine enzyme. The PNMT gene was found to consist of 3 exons and 2 introns spanning about 2,100 basepairs. It was demonstrated that in transgenic mice the gene is expressed in adrenal medulla and retina. A hybrid gene consisting of 2 kb of the PNMT 5-prime-flanking region fused to the simian virus 40 early region also resulted in tumor antigen mRNA expression in adrenal glands and eyes; furthermore, immunocytochemistry showed that the tumor antigen was localized in nuclei of adrenal medullary cells and cells of the inner nuclear cell layer of the retina, both prominent sites of epinephrine synthesis. The results indicate that the enhancer(s) for appropriate expres-

sion of the gene in these cell types are in the 2-kb 5-prime-flanking region of the gene.

[0080] Kaneda et al., 1988 (17), assigned the human PNMT gene to chromosome 17 by Southern blot analysis of DNA from mouse-human somatic cell hybrids. In 1992 the localization was narrowed down to 17q21-q22 by linkage analysis using RFLPs related to the PNMT gene and several 17q DNA markers [Hoehe et al., 1992, (18)]. The findings are of interest in light of the description of a genetic locus associated with blood pressure regulation in the stroke-prone spontaneously hypertensive rat (SHR-SP) on rat chromosome 10 in a conserved linkage synteny group corresponding to human chromosome 17q22-q24. See essential hypertension.

MGC9753

[0081] This gene maps on chromosome 17, at 17q12 according to RefSeq. It is expressed at very high level. It is defined by cDNA clones and produces, by alternative splicing, 7 different transcripts can be obtained (SEQ ID NO:60 to 66 and 83 to 89, Table 1), altogether encoding 7 different protein isoforms. Of specific interest is the putatively secreted isoform g, encoded by a mRNA of 2.55 kb. It's premessenger covers 16.94 kb on the genome. It has a very long 3' UTR. The protein (226 aa, MW 24.6 kDa, pI 8.5) contains no Pfam motif. The MGC9753 gene produces, by alternative splicing, 7 types of transcripts, predicted to encode 7 distinct proteins. It contains 13 confirmed introns, 10 of which are alternative. Comparison to the genome sequence shows that 11 introns follow the consensual [gt-ag] rule, 1 is atypical with good support [tg_cg]. The six most abundant isoforms are designated by a) to i) and code for proteins as follows:

a) This mRNA is 3.03 kb long, its premessenger covers 16.95 kb on the genome. It has a very long 3' UTR. The protein (190 aa, MW 21.5 kDa, pI 7.2) contains no Pfam motif. It is predicted to localise in the endoplasmic reticulum.

c) This mRNA is 1.17 kb long, its premessenger covers 16.93 kb on the genome. It may be incomplete at the N terminus. The protein (368 aa, MW 41.5 kDa, pI 7.3) contains no Pfam motif.

d) This mRNA is 3.17 kb long, its premessenger covers 16.94 kb on the genome. It has a very long 3' UTR and 5'p UTR. The protein (190 aa, MW 21.5 kDa, pI 7.2) contains no Pfam motif. It is predicted to localise in the endoplasmic reticulum.

g) This mRNA is 2.55 kb long, its premessenger covers 16.94 kb on the genome. It has a very long 3' UTR. The protein (226 aa, MW 24.6 kDa, pI 8.5) contains no Pfam motif. It is predicted to be secreted.

h) This mRNA is 2.68 kb long, its premessenger covers 16.94 kb on the genome. It has a very long 3' UTR. The protein (320 aa, MW 36.5 kDa, pI 6.8) contains no Pfam motif. It is predicted to localise in the endoplasmic reticulum.

i) This mRNA is 2.34 kb long, its premessenger covers 16.94 kb on the genome. It may be incomplete at the N terminus. It has a very long 3' UTR. The protein (217 aa, MW 24.4 kDa, pI 5.9) contains no Pfam motif.

[0082] The MGC9753 gene may be homologue to the CAB2 gene located on chromosome 17q12. The CAB2, a human homologue of the yeast COS16 required for the repair of DNA double-strand breaks was cloned. Autofluorescence analysis of cells transfected with its GFP fusion protein demonstrated that CAB2 translocates into vesicles, suggesting that overexpression of CAB2 may decrease intercellular Mn-(2+) by accumulating it in the vesicles, in the same way as yeast.

Her-2/neu, ERBB2, NGL, TKR1

[0083] The oncogene originally called NEU was derived from rat neuro/glioblastoma cell lines. It encodes a tumor antigen, p185, which is serologically related to EGFR, the epidermal growth factor receptor. EGFR maps to chromosome 7. In 1985 it was found, that the human homologue, which they designated NGL (to avoid confusion with neuraminidase, which is also symbolized NEU), maps to 17q12-q22 by in situ hybridization and to 17q21-qter in somatic cell hybrids [Yang-Feng et al., 1985, (19)]. Thus, the SRO is 17q21-q22. Moreover, in 1985 a potential cell surface receptor of the tyrosine kinase gene family was identified and characterized by cloning the gene [Coussens et al., 1985, (20)]. Its primary sequence is very similar to that of the human epidermal growth factor receptor. Because of the seemingly close relationship to the human EGF receptor, the authors called the gene HER2. By Southern blot analysis of somatic cell hybrid DNA and by in situ hybridization, the gene was assigned to 17q21-q22. This chromosomal location of the gene is coincident with the NEU oncogene, which suggests that the 2 genes may in fact be the same; indeed, sequencing indicates that they are identical. In 1988 a correlation between overexpression of NEU protein and the

large-cell, comedo growth type of ductal carcinoma was found [van de Vijver et al., 1988, (21)]. The authors found no correlation, however, with lymph-node status or tumor recurrence. The role of HER2/NEU in breast and ovarian cancer was described in 1989, which together account for one-third of all cancers in women and approximately one-quarter of cancer-related deaths in females [Slamon et al., 1989, (22)].

[0084] An ERBB-related gene that is distinct from the ERBB gene, called ERBB1 was found in 1985. ERBB2 was not amplified in vulva carcinoma cells with EGFR amplification and did not react with EGF receptor mRNA. About 30-fold amplification of ERBB2 was observed in a human adenocarcinoma of the salivary gland. By chromosome sorting combined with velocity sedimentation and Southern hybridization, the ERBB2 gene was assigned to chromosome 17 [Fukushige et al., 1986, (23)]. By hybridization to sorted chromosomes and to metaphase spreads with a genomic probe, they mapped the ERBB2 locus to 17q21. This is the chromosome 17 breakpoint in acute promyelocytic leukemia (APL). Furthermore, they observed amplification and elevated expression of the ERBB2 gene in a gastric cancer cell line. Antibodies against a synthetic peptide corresponding to 14 amino acid residues at the COOH-terminus of a protein deduced from the ERBB2 nucleotide sequence were raised in 1986. With these antibodies, the ERBB2 gene product from adenocarcinoma cells was precipitated and demonstrated to be a 185-kD glycoprotein with tyrosine kinase activity. A cDNA probe for ERBB2 and by in situ hybridization to APL cells with a 15;17 chromosome translocation located the gene to the proximal side of the breakpoint [Kaneko et al., 1987, (24)]. The authors suggested that both the gene and the breakpoint are located in band 17q21.1 and, further, that the ERBB2 gene is involved in the development of leukemia. In 1987 experiments indicated that NEU and HER2 are both the same as ERBB2 [Di Fiore et al., 1987, (25)]. The authors demonstrated that overexpression alone can convert the gene for a normal growth factor receptor, namely, ERBB2, into an oncogene. The ERBB2 to 17q11-q21 by in situ hybridization [Popescu et al., 1989, (26)]. By in situ hybridization to chromosomes derived from fibroblasts carrying a constitutional translocation between 15 and 17, they showed that the ERBB2 gene was relocated to the derivative chromosome 15; the gene can thus be localized to 17q12-q21.32. By family linkage studies using multiple DNA markers in the 17q12-q21 region the ERBB2 gene was placed on the genetic map of the region.

[0085] Interleukin-6 is a cytokine that was initially recognized as a regulator of immune and inflammatory responses, but also regulates the growth of many tumor cells, including prostate cancer. Overexpression of ERBB2 and ERBB3 has been implicated in the neoplastic transformation of prostate cancer. Treatment of a prostate cancer cell line with IL6 induced tyrosine phosphorylation of ERBB2 and ERBB3, but not ERBB1/EGFR. The ERBB2 forms a complex with the gp130 subunit of the IL6 receptor in an IL6-dependent manner. This association was important, because the inhibition of ERBB2 activity resulted in abrogation of IL6-induced MAPK activation. Thus, ERBB2 is a critical component of IL6 signaling through the MAP kinase pathway [Qiu et al., 1998, (27)]. These findings showed how a cytokine receptor can diversify its signaling pathways by engaging with a growth factor receptor kinase.

[0086] Overexpression of ERBB2 confers Taxol resistance in breast cancers. Overexpression of ERBB2 inhibits Taxol-induced apoptosis [Yu et al., 1998, (28)]. Taxol activates CDC2 kinase in MDA-MB-435 breast cancer cells, leading to cell cycle arrest at the G2/M phase and, subsequently, apoptosis. A chemical inhibitor of CDC2 and a dominant-negative mutant of CDC2 blocked Taxol-induced apoptosis in these cells. Overexpression of ERBB2 in MDA-MB-435 cells by transfection transcriptionally upregulates CDKN1A which associates with CDC2, inhibits Taxol-mediated CDC2 activation, delays cell entrance to G2/M phase, and thereby inhibits Taxol-induced apoptosis. In CDKN1A antisense-transfected MDA-MB-435 cells or in p21^{-/-} MEF cells, ERBB2 was unable to inhibit Taxol-induced apoptosis. Therefore, CDKN1A participates in the regulation of a G2/M checkpoint that contributes to resistance to Taxol-induced apoptosis in ERBB2-overexpressing breast cancer cells.

[0087] A secreted protein of approximately 68 kD was described, designated herstatin, as the product of an alternative ERBB2 transcript that retains intron 8 [Doherty et al., 1999, (29)]. This alternative transcript specifies 340 residues identical to subdomains I and II from the extracellular domain of p185ERBB2, followed by a unique C-terminal sequence of 79 amino acids encoded by intron 8. The recombinant product of the alternative transcript specifically bound to ERBB2-transfected cells and was chemically crosslinked to p185ERBB2, whereas the intron-encoded sequence alone also bound with high affinity to transfected cells and associated with p185 solubilized from cell extracts. The herstatin mRNA was expressed in normal human fetal kidney and liver, but was at reduced levels relative to p185ERBB2 mRNA in carcinoma cells that contained an amplified ERBB2 gene. Herstatin appears to be an inhibitor of p185ERBB2, because it disrupts dimers, reduces tyrosine phosphorylation of p185, and inhibits the anchorage-independent growth of transformed cells that overexpress ERBB2. The HER2 gene is amplified and HER2 is overexpressed in 25 to 30% of breast cancers, increasing the aggressiveness of the tumor. Finally, it was found that a recombinant monoclonal antibody against HER2 increased the clinical benefit of first-line chemotherapy in metastatic breast cancer that overexpresses HER2 [Slamon et al., 2001, (30)].

GRB7

[0088] Growth factor receptor tyrosine kinases (GF-RTKs) are involved in activating the cell cycle. Several substrates

of GF-RTKs contain Src-homology 2 (SH2) and SH3 domains. SH2 domain-containing proteins are a diverse group of molecules important in tyrosine kinase signaling. Using the CORT (cloning of receptor targets) method to screen a high expression mouse library, the gene for murine Grb7, which encodes a protein of 535 amino acids, was isolated [Margolis et al., 1992, (31)]. GRB7 is homologous to ras-GAP (ras-GTPase-activating protein). It contains an SH2 domain and is highly expressed in liver and kidney. This gene defines the GRB7 family, whose members include the mouse gene Grb 10 and the human gene GRB14.

[0089] A putative GRB7 signal transduction molecule and a GRB7V novel splice variant from an invasive human esophageal carcinoma was isolated [Tanaka et al., 1998, (32)]. Although both GRB7 isoforms shared homology with the Mig-10 cell migration gene of *Caenorhabditis elegans*, the GRB7V isoform lacked 88 basepairs in the C terminus; the resultant frameshift led to substitution of an SH2 domain with a short hydrophobic sequence. The wildtype GRB7 protein, but not the GRB7V isoform, was rapidly tyrosyl phosphorylated in response to EGF stimulation in esophageal carcinoma cells. Analysis of human esophageal tumor tissues and regional lymph nodes with metastases revealed that GRB7V was expressed in 40% of GRB7-positive esophageal carcinomas. GRB7V expression was enhanced after metastatic spread to lymph nodes as compared to the original tumor tissues. Transfection of an antisense GRB7 RNA expression construct lowered endogenous GRB7 protein levels and suppressed the invasive phenotype exhibited by esophageal carcinoma cells. These findings suggested that GRB7 isoforms are involved in cell invasion and metastatic progression of human esophageal carcinomas. By sequence analysis, The GRB7 gene was mapped to chromosome 17q21-q22, near the topoisomerase-2 gene [Dong et al., 1997, (33)]. GRB-7 is amplified in concert with HER2 in several breast cancer cell lines and that GRB-7 is overexpressed in both cell lines and breast tumors. GRB-7, through its SH2 domain, binds tightly to HER2 such that a large fraction of the tyrosine phosphorylated HER2 in SKBR-3 cells is bound to GRB-7 [Stein et al., 1994, (34)].

GCSF, CSF3

[0090] Granulocyte colony-stimulating factor (or colony stimulating factor-3) specifically stimulates the proliferation and differentiation of the progenitor cells for granulocytes. The partial amino acid sequence of purified GCSF protein was determined, and by using oligonucleotides as probes, several GCSF cDNA clones were isolated from a human squamous carcinoma cell line cDNA library [Nagata et al., 1986, (35)]. Cloning of human GCSF cDNA shows that a single gene codes for a 177- or 180-amino acid mature protein of molecular weight 19,600. The authors found that the GCSF gene has 4 introns and that 2 different polypeptides are synthesized from the same gene by differential splicing of mRNA. The 2 polypeptides differ by the presence or absence of 3 amino acids. Expression studies indicate that both have authentic GCSF activity. A stimulatory activity from a glioblastoma multiform cell line being biologically and biochemically indistinguishable from GCSF produced by a bladder cell line was found in 1987. By somatic cell hybridization and in situ chromosomal hybridization, the GCSF gene was mapped to 17q11 in the region of the breakpoint in the 15;17 translocation characteristic of acute promyelocytic leukemia [Le Beau et al., 1987, (36)]. Further studies indicated that the gene is proximal to the said breakpoint and that it remains on the rearranged chromosome 17. Southern blot analysis using both conventional and pulsed field gel electrophoresis showed no rearranged restriction fragments. By use of a full-length cDNA clone as a hybridization probe in human-mouse somatic cell hybrids and in flow-sorted human chromosomes, the gene for GCSF was mapped to 17q21-q22 lateron

THRA, THRA1, ERBA, EAR7, ERBA2, ERBA3

[0091] Both human and mouse DNA have been demonstrated to have two distantly related classes of ERBA genes and that in the human genome multiple copies of one of the classes exist [Jansson et al., 1983, (37)]. A cDNA was isolated derived from rat brain messenger RNA on the basis of homology to the human thyroid receptor gene [Thompson et al., 1987, (38)]. Expression of this cDNA produced a high-affinity binding protein for thyroid hormones. Messenger RNA from this gene was expressed in tissue-specific fashion, with highest levels in the central nervous system and no expression in the liver. An increasing body of evidence indicated the presence of multiple thyroid hormone receptors. The authors suggested that there may be as many as 5 different but related loci. Many of the clinical and physiologic studies suggested the existence of multiple receptors. For example, patients had been identified with familial thyroid hormone resistance in which peripheral response to thyroid hormones is lost or diminished while neuronal functions are maintained. Thyroidologists recognize a form of cretinism in which the nervous system is severely affected and another form in which the peripheral functions of thyroid hormone are more dramatically affected.

[0092] The cDNA encoding a specific form of thyroid hormone receptor expressed in human liver, kidney, placenta, and brain was isolated [Nakai et al., 1988, (39)]. Identical clones were found in human placenta. The cDNA encodes a protein of 490 amino acids and molecular mass of 54,824. Designated thyroid hormone receptor type alpha-2 (THRA2), this protein is represented by mRNAs of different size in liver and kidney, which may represent tissue-specific processing of the primary transcript.

[0093] The THRA gene contains 10 exons spanning 27 kb of DNA. The last 2 exons of the gene are alternatively spliced. A 5-kb THRA1 mRNA encodes a predicted 410-amino acid protein; a 2.7-kb THRA2 mRNA encodes a 490-amino acid protein. A third isoform, TR-alpha-3, is derived by alternative splicing. The proximal 39 amino acids of the TH-alpha-2 specific sequences are deleted in TR-alpha-3. A second gene, THRB on chromosome 3, encodes 2 isoforms of TR-beta by alternative splicing. In 1989 the structure and function of the EAR1 and EAR7 genes was elucidated, both located on 17q21 [Miyajima et al., 1989, (40)]. The authors determined that one of the exons in the EAR7 coding sequence overlaps an exon of EAR1, and that the 2 genes are transcribed from opposite DNA strands. In addition, the EAR7 mRNA generates 2 alternatively spliced isoforms, referred to as EAR71 and EAR72, of which the EAR71 protein is the human counterpart of the chicken c-erbA protein.

[0094] The thyroid hormone receptors, beta, alpha-1, and alpha-2 3 mRNAs are expressed in all tissues examined and the relative amounts of the three mRNAs were roughly parallel. None of the 3 mRNAs was abundant in liver, which is the major thyroid hormone-responsive organ. This led to the assumption that another thyroid hormone receptor may be present in liver. It was found that ERBA, which potentiates ERBB, has an amino acid sequence different from that of other known oncogene products and related to those of the carbonic anhydrases [Debuire et al., 1984, (41)]. ERBA potentiates ERBB by blocking differentiation of erythroblasts at an immature stage. Carbonic anhydrases participate in the transport of carbon dioxide in erythrocytes. In 1986 it was shown that the ERBA protein is a high-affinity receptor for thyroid hormone. The cDNA sequence indicates a relationship to steroid-hormone receptors, and binding studies indicate that it is a receptor for thyroid hormones. It is located in the nucleus, where it binds to DNA and activates transcription.

[0095] Maternal thyroid hormone is transferred to the fetus early in pregnancy and is postulated to regulate brain development. The ontogeny of TR isoforms and related splice variants in 9 first-trimester fetal brains by semi-quantitative RT-PCR analysis has been investigated. Expression of the TR-beta-1, TR-alpha-1, and TR-alpha-2 isoforms was detected from 8.1 weeks' gestation. An additional truncated species was detected with the TR-alpha-2 primer set, consistent with the TR-alpha-3 splice variant described in the rat. All TR-alpha-derived transcripts were coordinately expressed and increased approximately 8-fold between 8.1 and 13.9 weeks' gestation. A more complex ontogenic pattern was observed for TR-beta-1, suggestive of a nadir between 8.4 and 12.0 weeks' gestation. The authors concluded that these findings point to an important role for the TR-alpha-1 isoform in mediating maternal thyroid hormone action during first-trimester fetal brain development.

[0096] The identification of the several types of thyroid hormone receptor may explain the normal variation in thyroid hormone responsiveness of various organs and the selective tissue abnormalities found in the thyroid hormone resistance syndromes. Members of sibships, who were resistant to thyroid hormone action, had retarded growth, congenital deafness, and abnormal bones, but had normal intellect and sexual maturation, as well as augmented cardiovascular activity. In this family abnormal T3 nuclear receptors in blood cells and fibroblasts have been demonstrated. The availability of cDNAs encoding the various thyroid hormone receptors was considered useful in determining the underlying genetic defect in this family.

[0097] The ERBA oncogene has been assigned to chromosome 17. The ERBA locus remains on chromosome 17 in the t(15;17) translocation of acute promyelocytic leukemia (APL). The thymidine kinase locus is probably translocated to chromosome 15; study of leukemia with t(17;21) and apparently identical breakpoint showed that TK was on 21q+. By in situ hybridization of a cloned DNA probe of c-erb-A to meiotic pachytene spreads obtained from uncultured spermatocytes it has been concluded that ERBA is situated at 17q21.33-17q22, in the same region as the break that generated the t(15;17) seen in APL. Because most of the grains were seen in 17q22, they suggested that ERBA is probably in the proximal region of 17q22 or at the junction between 17q22 and 17q21.33. By in situ hybridization it has been demonstrated, that that ERBA remains at 17q11-q12 in APL, whereas TP53, at 17q21-q22, is translocated to chromosome 15. Thus, ERBA must be at 17q11.2 just proximal to the breakpoint in the APL translocation and just distal to it in the constitutional translocation.

[0098] The aberrant THRA expression in nonfunctioning pituitary tumors has been hypothesized to reflect mutations in the receptor coding and regulatory sequences. They screened THRA mRNA and THRB response elements and ligand-binding domains for sequence anomalies. Screening THRA mRNA from 23 tumors by RNase mismatch and sequencing candidate fragments identified 1 silent and 3 missense mutations, 2 in the common THRA region and 1 that was specific for the alpha-2 isoform. No THRB response element differences were detected in 14 nonfunctioning tumors, and no THRB ligand-binding domain differences were detected in 23 nonfunctioning tumors. Therefore it has been suggested that the novel thyroid receptor mutations may be of functional significance in terms of thyroid receptor action, and further definition of their functional properties may provide insight into the role of thyroid receptors in growth control in pituitary cells.

RAR-alpha

[0099] A cDNA encoding a protein that binds retinoic acid with high affinity has been cloned [Petkovich et al., 1987,

(42)]. The protein was found to be homologous to the receptors for steroid hormones, thyroid hormones, and vitamin D3, and appeared to be a retinoic acid-inducible transacting enhancer factor. Thus, the molecular mechanisms of the effect of vitamin A on embryonic development, differentiation and tumor cell growth may be similar to those described for other members of this nuclear receptor family. In general, the DNA-binding domain is most highly conserved, both within and between the 2 groups of receptors (steroid and thyroid); Using a cDNA probe, the RAR-alpha gene has been mapped to 17q21 by in situ hybridization [Mattei et al., 1988, (43)]. Evidence has been presented for the existence of 2 retinoic acid receptors, RAR-alpha and RAR-beta, mapping to chromosome 17q21.1 and 3p24, respectively. The alpha and beta forms of RAR were found to be more homologous to the 2 closely related thyroid hormone receptors alpha and beta, located on 17q11.2 and 3p25-p21, respectively, than to any other members of the nuclear receptor family. These observations suggest that the thyroid hormone and retinoic acid receptors evolved by gene, and possibly chromosome, duplications from a common ancestor, which itself diverged rather early in evolution from the common ancestor of the steroid receptor group of the family. They noted that the counterparts of the human RARA and RARB genes are present in both the mouse and chicken. The involvement of RARA at the APL breakpoint may explain why the use of retinoic acid as a therapeutic differentiation agent in the treatment of acute myeloid leukemias is limited to APL. Almost all patients with APL have a chromosomal translocation t(15;17)(q22;q21). Molecular studies reveal that the translocation results in a chimeric gene through fusion between the PML gene on chromosome 15 and the RARA gene on chromosome 17. A hormone-dependent interaction of the nuclear receptors RARA and RXRA with CLOCK and MOP4 has been presented.

CDC18 L, CDC 6

[0100] In yeasts, Cdc6 (*Saccharomyces cerevisiae*) and Cdc18 (*Schizosaccharomyces pombe*) associate with the origin recognition complex (ORC) proteins to render cells competent for DNA replication. Thus, Cdc6 has a critical regulatory role in the initiation of DNA replication in yeast. cDNAs encoding *Xenopus* and human homologues of yeast CDC6 have been isolated [Williams et al., 1997, (44)]. They designated the human and *Xenopus* proteins p62(cdc6). Independently, in a yeast 2-hybrid assay using PCNA as bait, cDNAs encoding the human CDC6/Cdc 18 homologue have been isolated [Saha et al, 1998, (45)]. These authors reported that the predicted 560-amino acid human protein shares approximately 33% sequence identity with the 2 yeast proteins. On Western blots of HeLa cell extracts, human CDC6/Cdc18 migrates as a 66-kD protein. Although Northern blots indicated that CDC6/Cdc18 mRNA levels peak at the onset of S phase and diminish at the onset of mitosis in HeLa cells, the authors found that total CDC6/Cdc18 protein level is unchanged throughout the cell cycle. Immunofluorescent analysis of epitope-tagged protein revealed that human CDC6/Cdc18 is nuclear in G1 and cytoplasmic in S-phase cells, suggesting that DNA replication may be regulated by either the translocation of this protein between the nucleus and cytoplasm or by selective degradation of the protein in the nucleus. Immunoprecipitation studies showed that human CDC6/Cdc18 associates in vivo with cyclin A, CDK2, and ORC1. The association of cyclin-CDK2 with CDC6/Cdc18 was specifically inhibited by a factor present in mitotic cell extracts. Therefore it has been suggested that if the interaction between CDC6/Cdc18 with the S phase-promoting factor cyclin-CDK2 is essential for the initiation of DNA replication, the mitotic inhibitor of this interaction could prevent a premature interaction until the appropriate time in G1 Cdc6 is expressed selectively in proliferating but not quiescent mammalian cells, both in culture and within tissues in intact animals [Yan et al., 1998, (46)]. During the transition from a growth-arrested to a proliferative state, transcription of mammalian Cdc6 is regulated by E2F proteins, as revealed by a functional analysis of the human Cdc6 promoter and by the ability of exogenously expressed E2F proteins to stimulate the endogenous Cdc6 gene. Immunodepletion of Cdc6 by microinjection of anti-Cdc6 antibody blocked initiation of DNA replication in a human tumor cell line. The authors concluded that expression of human Cdc6 is regulated in response to mitogenic signals through transcriptional control mechanisms involving E2F proteins, and that Cdc6 is required for initiation of DNA replication in mammalian cells.

[0101] Using a yeast 2-hybrid system, co-purification of recombinant proteins, and immunoprecipitation, it has been demonstrated lateron that an N-terminal segment of CDC6 binds specifically to PR48, a regulatory subunit of protein phosphatase 2A (PP2A). The authors hypothesized that dephosphorylation of CDC6 by PP2A, mediated by a specific interaction with PR48 or a related B-double prime protein, is a regulatory event controlling initiation of DNA replication in mammalian cells. By analysis of somatic cell hybrids and by fluorescence in situ hybridization the human p62(cdc6) gene has been to 17q21.3.

TOP2A, TOP2

[0102] DNA topoisomerases are enzymes that control and alter the topologic states of DNA in both prokaryotes and eukaryotes. Topoisomerase II from eukaryotic cells catalyzes the relaxation of supercoiled DNA molecules, catenation, decatenation, knotting, and unknotting of circular DNA. It appears likely that the reaction catalyzed by topoisomerase II involves the crossing-over of 2 DNA segments. It has been estimated that there are about 100,000 molecules of

topoisomerase II per HeLa cell nucleus, constituting about 0.1% of the nuclear extract. Since several of the abnormal characteristics of ataxia-telangiectasia appear to be due to defects in DNA processing, screening for these enzyme activities in 5 AT cell lines has been performed [Singh et al., 1988, (47)]. In comparison to controls, the level of DNA topoisomerase II, determined by unknotting of P4 phage DNA, was reduced substantially in 4 of these cell lines and to a lesser extent in the fifth. DNA topoisomerase I, assayed by relaxation of supercoil DNA, was found to be present at normal levels.

[0103] The entire coding sequence of the human TOP2 gene has been determined [Tsai-Pflugfelder et al., 1988, (48)].

[0104] In addition human cDNAs that had been isolated by screening a cDNA library derived from a mechlorethamine-resistant Burkitt lymphoma cell line (Raji-HN2) with a Drosophila Topo II cDNA had been sequenced [Chung et al., 1989, (49)]. The authors identified 2 classes of sequence representing 2 TOP2 isoenzymes, which have been named TOP2A and TOP2B. The sequence of 1 of the TOP2A cDNAs is identical to that of an internal fragment of the TOP2 cDNA isolated by Tsai-Pflugfelder et al., 1988 (48). Southern blot analysis indicated that the TOP2A and TOP2B cDNAs are derived from distinct genes. Northern blot analysis using a TOP2A-specific probe detected a 6.5-kb transcript in the human cell line U937. Antibodies against a TOP2A peptide recognized a 170-kD protein in U937 cell lysates. Therefore it was concluded that their data provide genetic and immunochemical evidence for 2 TOP2 isozymes. The complete structures of the TOP2A and TOP2B genes has been reported [Lang et al., 1998, (50)]. The TOP2A gene spans approximately 30 kb and contains 35 exons.

[0105] Tsai-Pflugfelder et al., 1988 (48) showed that the human enzyme is encoded by a single-copy gene which they mapped to 17q21-q22 by a combination of in situ hybridization of a cloned fragment to metaphase chromosomes and by Southern hybridization analysis with a panel of mouse-human hybrid cell lines. The assignment to chromosome 17 has been confirmed by the study of somatic cell hybrids. Because of co-amplification in an adenocarcinoma cell line, it was concluded that the TOP2A and ERBB2 genes may be closely linked on chromosome 17 [Keith et al., 1992, (51)]. Using probes that detected RFLPs at both the TOP2A and TOP2B loci, the demonstrated heterozygosity at a frequency of 0.17 and 0.37 for the alpha and beta loci, respectively. The mouse homologue was mapped to chromosome 11 [Kingsmore et al., 1993, (52)]. The structure and function of type II DNA topoisomerases has been reviewed [Watt et al., 1994, (53)]. DNA topoisomerase II-alpha is associated with the pol II holoenzyme and is a required component of chromatin-dependent co-activation. Specific inhibitors of topoisomerase II blocked transcription on chromatin templates, but did not affect transcription on naked templates. Addition of purified topoisomerase II-alpha reconstituted chromatin-dependent activation activity in reactions with core pol II. Therefore the transcription on chromatin templates seems to result in the accumulation of superhelical tension, making the relaxation activity of topoisomerase II essential for productive RNA synthesis on nucleosomal DNA.

IGFBP4

[0106] Six structurally distinct insulin-like growth factor binding proteins have been isolated and their cDNAs cloned: IGFBP1, IGFBP2, IGFBP3, IGFBP4, IGFBP5 and IGFBP6. The proteins display strong sequence homologies, suggesting that they are encoded by a closely related family of genes. The IGFBPs contain 3 structurally distinct domains each comprising approximately one-third of the molecule. The N-terminal domain 1 and the C-terminal domain 3 of the 6 human IGFBPs show moderate to high levels of sequence identity including 12 and 6 invariant cysteine residues in domains 1 and 3, respectively (IGFBP6 contains 10 cysteine residues in domain 1), and are thought to be the IGF binding domains. Domain 2 is defined primarily by a lack of sequence identity among the 6 IGFBPs and by a lack of cysteine residues, though it does contain 2 cysteines in IGFBP4. Domain 3 is homologous to the thyroglobulin type I repeat unit. Recombinant human insulin-like growth factor binding proteins 4, 5, and 6 have been characterized by their expression in yeast as fusion proteins with ubiquitin [Kiefer et al., 1992, (54)]. Results of the study suggested to the authors that the primary effect of the 3 proteins is the attenuation of IGF activity and suggested that they contribute to the control of IGF-mediated cell growth and metabolism.

[0107] Based on peptide sequences of a purified insulin-like growth factor-binding protein (IGFBP) rat IGFBP4 has been cloned by using PCR [Shimasaki et al., 1990, (55)]. They used the rat cDNA to clone the human ortholog from a liver cDNA library. Human IGFBP4 encodes a 258-amino acid polypeptide, which includes a 21-amino acid signal sequence. The protein is very hydrophilic, which may facilitate its ability as a carrier protein for the IGFs in blood. Northern blot analysis of rat tissues revealed expression in all tissues examined, with highest expression in liver. It was stated that IGFBP4 acts as an inhibitor of IGF-induced bone cell proliferation. The genomic region containing the IGFBP gene. The gene consists of 4 exons spanning approximately 15 kb of genomic DNA has been examined [Zazzi et al., 1998, (56)]. The upstream region of the gene contains a TATA box and a cAMP-responsive promoter.

[0108] By in situ hybridization, the IGFBP4 gene was mapped to 17q12-q21 [Bajalica et al., 1992, (57)]. Because the hereditary breast-ovarian cancer gene BRCA1 had been mapped to the same region, it has been investigated whether IGFBP4 is a candidate gene by linkage analysis of 22 BRCA1 families; the finding of genetic recombination suggested that it is not the BRCA1 gene [Tonin et al., 1993, (58)].

EBI 1, CCR7, CMKBR7

[0109] Using PCR with degenerate oligonucleotides, a lymphoid-specific member of the G protein-coupled receptor family has been identified and mapped to 17q12-q21.2 by analysis of human/mouse somatic cell hybrid DNAs and fluorescence in situ hybridization. It has been shown that this receptor had been independently identified as the Epstein-Barr-induced cDNA (symbol EBI1) [Birkenbach et al., 1993, (59)]. EBI1 is expressed in normal lymphoid tissues and in several B- and T-lymphocyte cell lines. While the function and the ligand for EBI1 remains unknown, its sequence and gene structure suggest that it is related to receptors that recognize chemoattractants, such as interleukin-8, RANTES, C5a, and fMet-Leu-Phe. Like the chemoattractant receptors, EBI1 contains intervening sequences near its 5-prime end; however, EBI1 is unique in that both of its introns interrupt the coding region of the first extracellular domain. Mouse Ebi1 cDNA has been isolated and found to encode a protein with 86% identity to the human homologue.

[0110] Subsets of murine CD4⁺ T cells localize to different areas of the spleen after adoptive transfer. Naïve and T helper-1 (TH1) cells, which express CCR7, home to the periaarteriolar lymphoid sheath, whereas activated TH2 cells, which lack CCR7, form rings at the periphery of the T-cell zones near B-cell follicles. It has been found that retroviral transduction of TH2 cells with CCR7 forced them to localize in a TH1-like pattern and inhibited their participation in B-cell help in vivo but not in vitro. Apparently differential expression of chemokine receptors results in unique cellular migration patterns that are important for effective immune responses.

[0111] CCR7 expression divides human memory T cells into 2 functionally distinct subsets. CCR7-memory cells express receptors for migration to inflamed tissues and display immediate effector function. In contrast, CCR7⁺ memory cells express lymph node homing receptors and lack immediate effector function, but efficiently stimulate dendritic cells and differentiate into CCR7⁺ effector cells upon secondary stimulation. The CCR7⁺ and CCR7⁻ T cells, named central memory (T-CM) and effector memory (T-EM), differentiate in a step-wise fashion from naïve T cells, persist for years after immunization, and allow a division of labor in the memory response.

[0112] CCR7 expression in memory CD8⁺ T lymphocyte responses to HIV and to cytomegalovirus (CMV) tetramers has been evaluated. Most memory T lymphocytes express CD45RO, but a fraction express instead the CD45RA marker. Flow cytometric analyses of marker expression and cell division identified 4 subsets of HIV- and CMV-specific CD8⁺ T cells, representing a lineage differentiation pattern: CD45RA⁺CCR7⁺ (double-positive); CD45RA⁺CCR7⁻; CD45RA⁻CCR7⁻ (double-negative); CD45RA⁻CCR7⁺. The capacity for cell division, as measured by 5-(and 6)-carboxyl-fluorescein diacetate, succinimidyl ester, and intracellular staining for the Ki67 nuclear antigen, is largely confined to the CCR7⁺ subsets and occurred more rapidly in cells that are also CD45RA⁺. Although the double-negative cells did not divide or expand after stimulation, they did revert to positivity for either CD45RA or CCR7 or both. The CD45RA⁺CCR7⁻ cells, considered to be terminally differentiated, fail to divide, but do produce interferon-gamma and express high levels of perforin. The representation of subsets specific for CMV and for HIV is distinct. Approximately 70% of HIV-specific CD8⁺ memory T cells are double-negative or preterminally differentiated compared to 40% of CMV-specific cells. Approximately 50% of the CMV-specific CD8⁺ memory T cells are terminally differentiated compared to fewer than 10% of the HIV-specific cells. It has been proposed that terminally differentiated CMV-specific cells are poised to rapidly intervene, while double-positive precursor cells remain for expansion and replenishment of the effector cell pool. Furthermore, high-dose antigen tolerance and the depletion of HIV-specific CD4⁺ helper T-cell activity may keep the HIV-specific memory CD8⁺ T cells at the double-negative stage, unable to differentiate to the terminal effector state. B lymphocytes recirculate between B cell-rich compartments (follicles or B zones) in secondary lymphoid organs, surveying for antigen. After antigen binding, B cells move to the boundary of B and T zones to interact with T-helper cells. Furthermore it has been demonstrated that antigen-engaged B cells have increased expression of CCR7, the receptor for the T-zone chemokines CCL19 (also known as ELC) and CCL21, and that they exhibit increased responsiveness to both chemoattractants. In mice lacking lymphoid CCL19 and CCL21 chemokines, or with B cells that lack CCR7, antigen engagement fails to cause movement to the T zone. Using retroviral-mediated gene transfer, the authors demonstrated that increased expression of CCR7 is sufficient to direct B cells to the T zone. Reciprocally, overexpression of CXCR5, the receptor for the B-zone chemokine CXCL13, is sufficient to overcome antigen-induced B-cell movement to the T zone. This points toward a mechanism of B-cell relocalization in response to antigen, and established that cell position in vivo can be determined by the balance of responsiveness to chemoattractants made in separate but adjacent zones.

BAF57, SMARCE 1

[0113] The SWI/SNF complex in *S. cerevisiae* and *Drosophila* is thought to facilitate transcriptional activation of specific genes by antagonizing chromatin-mediated transcriptional repression. The complex contains an ATP-dependent nucleosome disruption activity that can lead to enhanced binding of transcription factors. The BRG1/brm-associated factors, or BAF, complex in mammals is functionally related to SWI/SNF and consists of 9 to 12 subunits, some of which are homologous to SWI/SNF subunits. A 57-kD BAF subunit, BAF57, is present in higher eukaryotes, but not in

yeast. Partial coding sequence has been obtained from purified BAF57 from extracts of a human cell line [Wang et al., 1998, (60)]. Based on the peptide sequences, they identified cDNAs encoding BAF57. The predicted 411-amino acid protein contains an HMG domain adjacent to a kinesin-like region. Both recombinant BAF57 and the whole BAF complex bind 4-way junction (4WJ) DNA, which is thought to mimic the topology of DNA as it enters or exits the nucleosome. The BAF57 DNA-binding activity has characteristics similar to those of other HMG proteins. It was found that complexes with mutations in the BAF57 HMG domain retain their DNA-binding and nucleosome-disruption activities. They suggested that the mechanism by which mammalian SWI/SNF-like complexes interact with chromatin may involve recognition of higher-order chromatin structure by 2 or more DNA-binding domains. RNase protection studies and Western blot analysis revealed that BAF57 is expressed ubiquitously. Several lines of evidence point toward the involvement of SWI/SNF factors in cancer development [Klochendler-Yeivin et al., 2002, (61)]. Moreover, SWI/SNF related genes are assigned to chromosomal regions that are frequently involved in somatic rearrangements in human cancers [Ring et al., 1998, (62)]. In this respect it is interesting that some of the SWI/SNF family members (i.e. SMARCC1, SMARCC2, SMARCD1 and SMARCD22 are neighboring 3 of the eucaryotic ARCHEONS we have identified (i.e. 3p21-p24, 12q13-q14 and 17q respectively) and which are part of the present invention. In this invention we could also map SMARCE1/BAF57 to the 17q12 region by PCR karyotyping.

KRT 10, K10

[0114] Keratin 10 is an intermediate filament (IF) chain which belongs to the acidic type I family and is expressed in terminally differentiated epidermal cells. Epithelial cells almost always co-express pairs of type I and type II keratins, and the pairs that are co-expressed are highly characteristic of a given epithelial tissue. For example, in human epidermis, 3 different pairs of keratins are expressed: keratins 5 (type II) and 14 (type I), characteristic of basal or proliferative cells; keratins 1 (type II) and 10 (type I), characteristic of suprabasal terminally differentiating cells; and keratins 6 (type II) and 16 (type I) (and keratin 17 [type I]), characteristic of cells induced to hyper-proliferate by disease or injury, and epithelial cells grown in cell culture. The nucleotide sequence of a 1,700 bp cDNA encoding human epidermal keratin 10 (56.5 kD) [Darmon et al., 1987, (63)] has been published as well as the complete amino acid sequence of human keratin 10 [Zhou et al., 1988, (64)]. Polymorphism of the KRT10 gene, restricted to insertions and deletions of the glycine-richquasipeptide repeats that form the glycine-loop motif in the C-terminal domain, have been extensively described [Korge et al., 1992, (65)].

[0115] By use of specific cDNA clones in conjunction with somatic cell hybrid analysis and in situ hybridization, KRT10 gene has been mapped to 17q12-q21 in a region proximal to the breakpoint at 17q21 that is involved in a t(17;21)(q21;q22) translocation associated with a form of acute leukemia. KRT10 appeared to be telomeric to 3 other loci that map in the same region: CSF3, ERBA1, and HER2 [Lessin et al., 1988, (66)]. NGFR and HOX2 are distal to K9. It has been demonstrated that the KRT10, KRT13, and KRT15 genes are located in the same large pulsed field gel electrophoresis fragment [Romano et al., 1991, (67)]. A correlation of assignments of the 3 genes makes 17q21-q22 the likely location of the cluster. Transgenic mice expressing a mutant keratin 10 gene have the phenotype of epidermolytic hyperkeratosis, thus suggesting that a genetic basis for the human disorder resides in mutations in genes encoding suprabasal keratins KRT1 or KRT10 [Fuchs et al 1992, (68)]. The authors also showed that stimulation of basal cell proliferation can result from a defect in suprabasal cells and that distortion of nuclear shape or alterations in cytokinesis can occur when an intermediate filament network is perturbed. In a family with keratosis palmaris et plantaris without blistering either spontaneously or in response to mild mechanical or thermal stress and with no involvement of the skin and parts of the body other than the palms and soles, a tight linkage to an insertion-deletion polymorphism in the C-terminal coding region of the KRT10 gene (maximum lod score = 8.36 at theta = 0.00) was found [Rogaev et al., 1993, (69)]. It is noteworthy that it was a rare, high molecular weight allele of the KRT10 polymorphism that segregated with the disorder. The allele was observed once in 96 independent chromosomes from unaffected Caucasians. The KRT10 polymorphism arose from the insertion/deletion of imperfect (CCG)_n repeats within the coding region and gave rise to a variable glycine loop motif in the C-terminal tail of the keratin 10 protein. It is possible that there was a pathogenic role for the expansion of the imperfect trinucleotide repeat.

KRT12,K12

[0116] Keratins are a group of water-insoluble proteins that form 10 nm intermediate filaments in epithelial cells. Approximately 30 different keratin molecules have been identified. They can be divided into acidic and basic-neutral subfamilies according to their relative charges, immunoreactivity, and sequence homologies to types I and II wool keratins, respectively. In vivo, a basic keratin usually is co-expressed and 'paired' with a particular acidic keratin to form a heterodimer. The expression of various keratin pairs is tissue specific, differentiation dependent, and developmentally regulated. The presence of specific keratin pairs is essential for the maintenance of the integrity of epithelium. For example, mutations in human K14/K5 pair and the K10/K1 pair underlie the skin diseases, epidermolysis bullosa

simplex and epidermolytic hyperkeratosis, respectively. Expression of the K3 and K12 keratin pair have been found in the cornea of a wide number of species, including human, mouse, and chicken, and is regarded as a marker for corneal-type epithelial differentiation. The murine Krt12 (Krt1.12) gene and demonstrated that its expression is corneal epithelial cell specific, differentiation dependent, and developmentally regulated [Liu et al., 1993, (70)]. The corneal-specific nature of keratin 12 gene expression signifies keratin 12 plays a unique role in maintaining normal corneal epithelial function. Nevertheless, the exact function of keratin 12 remains unknown and no hereditary human corneal epithelial disorder has been linked directly to the mutation in the keratin 12 gene. As part of a study of the expression profile of human corneal epithelial cells, a cDNA with an open reading frame highly homologous to the cornea-specific mouse keratin 12 gene has been isolated [Nishida et al., 1996, (71)]. To elucidate the function of keratin 12 knockout mice lacking the Krt1.12 gene have been created by gene targeting techniques. The heterozygous mice appeared normal. Homozygous mice developed normally and suffered mild corneal epithelial erosion. The corneal epithelia were fragile and could be removed by gentle rubbing of the eyes or brushing. The corneal epithelium of the homozygotes did not express keratin 12 as judged by immunohistochemistry, Western immunoblot analysis with epitope-specific anti-keratin 12 antibodies, Northern hybridization, and in situ hybridization with an antisense keratin 12 riboprobe. The KRT12 gene has been mapped to 17q by study of radiation hybrids and localized it to the type I keratin cluster in the interval between D17S800 and D17S930 (17q12-q21) [Nishida et al., 1997, (72)]. The authors presented the exon-intron boundary structure of the KRT12 gene and mapped the gene to 17q12 by fluorescence in situ hybridization. The gene contains 7 introns, defining 8 exons that cover the coding sequence. Together the exons and introns span approximately 6 kb of genomic DNA.

[0117] Meesmann corneal dystrophy is an autosomal dominant disorder causing fragility of the anterior corneal epithelium, where the cornea-specific keratins K3 and K12 are expressed. Dominant-negative mutations in these keratins might be the cause of Meesmann corneal dystrophy. Indeed, linkage of the disorder to the K12 locus in Meesmann's original German kindred [Meesmann and Wilke, 1939, (73)] with $Z(\text{max}) = 7.53$ at $\theta = 0.0$ has been found. In 2 pedigrees from Northern Ireland, they found that the disorder co-segregated with K12 in one pedigree and K3 in the other. Heterozygous missense mutations in K3 or in K12 (R135T, V143L,) in each family have been identified. All these mutations occurred in highly conserved keratin helix boundary motifs, where dominant mutations in other keratins have been found to compromise cytoskeletal function severely, leading to keratinocyte fragility.

[0118] The regions of the human KRT12 gene have been sequenced to enable mutation detection for all exons using genomic DNA as a template [Corden et al., 2000, (74)]. The authors found that the human genomic sequence spans 5,919 bp and consists of 8 exons. A microsatellite dinucleotide repeat was identified within intron 3, which was highly polymorphic and which they developed for use in genotype analysis. In addition, 2 mutations in the helix initiation motif of K12 were found in families with Meesmann corneal dystrophy. In an American kindred, a missense M129T mutation was found in the KRT12 gene. They stated that a total of 8 mutations in the KRT12 gene had been reported.

Genetic interactions within ARCHEONs

[0119] Genes involved in genomic alterations (amplifications, insertions, translocations, deletions, etc.) exhibit changes in their expression pattern. Of particular interest are gene amplifications, which account for gene copy numbers >2 per cell or deletions accounting for gene copy numbers <2 per cell. Gene copy number and gene expression of the respective genes do not necessarily correlate. Transcriptional overexpression needs an intact transcriptional context, as determined by regulatory regions at the chromosomal locus (promotor, enhancer and silencer), and sufficient amounts of transcriptional regulators being present in effective combinations. This is especially true for genomic regions, which expression is tightly regulated in specific tissues or during specific developmental stages. ARCHEONs are specified by gene clusters of more than two genes being directly neighboured or in chromosomal order, interspersed by a maximum of 10, preferably 7, more preferably 5 or at least 1 gene. The interspersed genes are also co-amplified but do not directly interact with the ARCHEON. Such an ARCHEON may spread over a chromosomal region of a maximum of 20, more preferably 10 or at least 6 Megabases. The nature of an ARCHEON is characterized by the simultaneous amplification and/or deletion and the correlating expression (i.e. upregulation or downregulation respectively) of the encompassed genes in a specific tissue, cell type, cellular or developmental state or time point. Such ARCHEONs are commonly conserved during evolution, as they play critical roles during cellular development. In case of these ARCHEONs whole gene clusters are overexpressed upon amplification as they harbor self-regulatory feedback loops, which stabilize gene expression and/or biological effector function even in abnormal biological settings, or are regulated by very similar transcription factor combinations, reflecting their simultaneous function in specific tissues at certain developmental stages. Therefore, the gene copy numbers correlates with the expression level especially for genes in gene clusters functioning as ARCHEONs. In case of abnormal gene expressions in neoplastic lesions it is of great importance to know whether the self-regulatory feedback loops have been conserved as they determine the biological activity of the ARCHEON gene members.

[0120] The intensive interaction between genes in ARCHEONs is described for the 17q12 ARCHEON (Fig. 1) by

way of illustration not by limitation. In one embodiment the presence or absence of alterations of genes within distinct genomic regions are correlated with each other, as exemplified for breast cancer cell lines (Fig.3 and Fig. 4). This confers to the discovery of the present invention, that multiple interactions of said gene products of defined chromosomal localizations happen, that according to their respective alterations in abnormal tissue have predictive, diagnostic, prognostic and/or preventive and therapeutic value. These interactions are mediated directly or indirectly, due to the fact that the respective genes are part of interconnected or independent signaling networks or regulate cellular behavior (differentiation status, proliferative and /or apoptotic capacity, invasiveness, drug responsiveness, immune modulatory activities) in a synergistic, antagonistic or independent fashion. The order of functionally important genes within the ARCHEONs has been conserved during evolution (e.g. the ARCHEON on human chromosom 17q12 is present on mouse chromosome 11). Moreover, it has been found that the 17q12 ARCHEON is also present on human chromosome 3p21 and 12q13, both of which are also involved in amplification events and in tumor development. Most probably these homologous ARCHEONs were formed by duplications and rearrangements during vertebrate evolution. Homologous ARCHEONs consist of homologous genes and/or isoforms of specific gene families (e.g. RARA or RARB or RARG, THRA or THRB, TOP2A or TOP2B, RABSA or RABSB, BAF170 or BAF 155, BAF60A or BAF60B, WNT5A or WNT5B, IGFBP4 or IGFBP6). Moreover these regions are flanked by homologous chromosomal gene clusters (e.g. CACN, SCYA, HOX, Keratins). These ARCHEONs have diverged during evolution to fulfill their respective functions in distinct tissues (e.g. the 17q12 ARCHEON has one of its main functions in the central nervous system). Due to their tissue specific function extensive regulatory loops control the expression of the members of each ARCHEON. During tumor development these regulations become critical for the characteristics of the abnormal tissues with respect to differentiation, proliferation, drug responsiveness, invasiveness. It has been found that the co-amplification of genes within ARCHEONs can lead to co-expression of the respective gene products. Some of said genes also exhibit additional mutations or specific patterns of polymorphisms, which are substantial for the oncogenic capacities of these ARCHEONs. It is one of the critical features of such amplicons, which members of the ARCHEON have been conserved during tumor formation (e.g. during amplification and deletion events), thereby defining these genes as diagnostic marker genes. Moreover, the expression of the certain genes within the ARCHEON can be influenced by other members of the ARCHEON, thereby defining the regulatory and regulated genes as target genes for therapeutic intervention. It was also observed, that the expression of certain members of the ARCHEON is sensitive to drug treatment (e.g. TOPO2 alpha, RARA, THRA, HER-2) which defines these genes as "marker genes". Moreover several other genes are suitable for therapeutic intervention by antibodies (CACNB1, EBI1), ligands (CACNB1) or drugs like e.g. kinase inhibitors (CrkRS, CDC6). The following examples of interactions between members of ARCHEONs are offered by way of illustration, not by way of limitation.

[0121] EBI1/CCR7 is lymphoid-specific member of the G protein-coupled receptor family. EBI1 recognizes chemotactants, such as interleukin-8, SCYAs, Rantes, C5a, and fMet-Leu-Phe. The capacity for cell division is largely confined to the CCR7⁺ subsets in lymphocytes. Double-negative cells did not divide or expand after stimulation. CCR7⁺ cells, considered to be terminally differentiated, fail to divide, but do produce interferon-gamma and express high levels of perforin. EBI1 is induced by viral activities such as the Epstein-Barr-Virus. Therefore, EBI1 is associated with transformation events in lymphocytes. A functional role of EBI1 during tumor formation in non-lymphoid tissues has been investigated in this invention. Interestingly, also ERBA and ERBB, located in the same genomic region, are associated with lymphocyte transformation. Moreover, ligands of the receptor (i.e. SCYA5/Rantes) are in genomic proximity on 17q. Abnormal expression of both of these factors in lymphoid and non-lymphoid tissues establishes an autotregulatory feedback loop, inducing signaling events within the respective cells. Expression of lymphoid factors has effect on immune cells and modulates cellular behavior. This is of particular interest with regard to abnormal breast tissue being infiltrated by lymphocytes. In line with this, another immunomodulatory and proliferation factor is located nearby on 17q12. Granulocyte colony-stimulating factor (GCSF3) specifically stimulates the proliferation and differentiation of the progenitor cells for granulocytes. A stimulatory activity from a glioblastoma multiforme cell line being biologically and biochemically indistinguishable from GCSF produced by a bladder cell line has also been found. Colony-stimulating factors not only affects immune cells, but also induce cellular responses of non-immune cells, indicating possible involvement in tumor development upon abnormal expression. In addition several other genes of the 17q12 ARCHEON are involved in proliferation, survival, differentiation of immune cells and/or lymphoblastic leukemia, such as MLLT6, ZNF144 and ZNFN1A3, again demonstrating the related functions of the gene products in interconnected key processes within specific cell types. Aberrant expression of more than one of these genes in non-immune cells constitutes signalling activities, that contribute to the oncogenic activities that derive solely from overexpression of the Her-2/neu gene.

[0122] PPARBP has been found in complex with the tumorsuppressor gene of the p53 family. Moreover, PPARBP also binds to PPAR-alpha (PPARA), RAR-alpha (RARA), RXR, THRA and TR-beta-1. Due to it's ability to bind to thyroid hormone receptors it has been named TRIP2 and TRAP220. In this complexes PPARBP affects gene regulatory activities. Interestingly, PPARBP is located in genomic proximity to its interaction partners THRA and RARA. We have found PPARBP to be co-amplified with THRA and RARA in tumor tissue. THRA has been isolated from avian eryth-

roblastosis virus in conjunction with ERBB and therefore was named ERBA. ERBA potentiates ERBB by blocking differentiation of erythroblasts at an immature stage. ERBA has been shown to influence ERBB expression. In this setting deletions of C-terminal portions of the THRA gene product are of influence. Aberrant THRA expression has also been found in nonfunctioning pituitary tumors, which has been hypothesized to reflect mutations in the receptor coding and regulatory sequences. THRA function promotes tumor cell development by regulating gene expression of regulatory genes and by influencing metabolic activities (e.g. of key enzymes of alternative metabolic pathways in tumors such as malic enzyme and genes responsible for lipogenesis). The observed activities of nuclear receptors not only reflect their transactivating potential, but are also due to posttranscriptional activities in the absence or presence of ligands. Co-amplification of THRA /ERBA and ERBB has been shown, but its influence on tumor development has been doubted as no overexpression could be demonstrated in breast tumors [van de Vijver et al., 1987, (75)]. THRA and RARA are part of nuclear receptor family whose function can be mediated as monomers, homodimers or heterodimers. RARA regulates differentiation of a broad spectrum of cells. Interactions of hormones with ERBB expression has been investigated. Ligands of RARA can inhibit the expression of amplified ERBB genes in breast tumors [Offertinger et al., 1998, (76)]. As being part of this invention co-amplification and co-expression of THRA and RARA could be shown. It was also found that multiple genes, which are regulated by members of the thyroid hormone receptor - and retinoic acid receptor family, are differentially expressed in tumor samples, corresponding to their genomic alterations (amplification, mutation, deletion). These hormone receptor genes and respective target genes are useful to discriminate patient samples with respect to clinical features.

[0123] By expression analysis of multiple normal tissues, tumor samples and tumor cell lines and subsequent clustering of the 17q12 region, it was found that the expression profile of Her-2/neu positive tumor cells and tumor samples exhibits similarities with the expression pattern of tissue from the central nervous system (Fig. 2). This is in line with the observed malformations in the central nervous system of Her-2/neu and THRA knock-out mice. Moreover, it was found that NEUROD2, a nuclear factor involved specifically in neurogenesis, is commonly expressed in the respective samples. This led to the definition of the 17q12 Locus as being an "ARCHEON", whose primary function in normal organ development is defined to the central nervous system. Surprisingly, the expression of NEUROD2 was affected by therapeutic intervention. Strikingly, also ZNF144, TEM7, PIP5K and PPP1R1B are expressed in neuronal cells, where they display diverse tissue specific functions.

[0124] In addition Her-2/neu is often co-amplified with GRB7, a downstream member of the signaling cascade being involved in invasive properties of tumors. Surprisingly, we have found another member of the Her-2/neu signaling cascade being overexpressed in primary breast tumors TOB1 (= "Transducer of ERBB signaling"). Strong overexpression of TOB1 correlated with weaker overexpression of Her-2/neu, already indicating its involvement in oncogenic signaling activities. Amplification of Her-2/neu has been assigned to enhanced proliferative capacity, due to the identified downstream components of the signaling cascade (e.g. Ras-Raf-MAPK). In this respect it was surprising that some cdc genes, which are cell cycle dependent kinases, are part of the amplicons, which upon altered expression have great impact on cell cycle progression.

[0125] According to the observations described above the following examples of genes at 3q21-26 are offered by way of illustration, not by way of limitation.

→ WNT5A, CACNA1D, THRB, RARB, TOP2B, RAB5B, SMARCC1 (BAF155), RAF, WNT7A

[0126] The following examples of genes at 12q13 are offered by way of illustration, not by way of limitation.

→ CACNB3, Keratins, NR4A1, RAB5/13, RARGamma, STAT6, WNT10B, (GCN5), (SAS: Sarcoma Amplified Sequence), SMARCC2 (BAF170), SMARCD1 (BAF60A), (GAS41: Glioma Amplified Sequence), (CHOP), Her3, KRTHB, HOX C, IGFBP6, WNT5B

[0127] There is cross-talk between the amplified ARCHEONS described above and some other highly amplified genomic regions locate approximately at 1p13, 1q32, 2p16, 2q21, 3p12, 5p13, 6p12, 7p12, 7q21, 8q23, 11q13, 13q12, 19q13, 20q13 and 21q11. The above mentioned chromosomal regions are described by way of illustration not by way of limitation, as the amplified regions often span larger and/or overlapping positions at these chromosomal positions.

[0128] Additional alterations of non-transcribed genes, pseudogenes or intergenic regions of said chromosomal locations can be measured for prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and breast cancer in particular. Some of the genes or genomic regions have no direct influence on the members of the ARCHEONS or the genes within distinct chromosomal regions but still retain marker gene function due to their chromosomal positioning in the neighborhood of functionally critical genes (e.g. Telethonin neighboring the Her-2/neu gene).

[0129] The invention further relates to the use of:

a) a polynucleotide comprising at least one of the sequences of SEQ ID NO: 1 to 26 or 53 to 75;

b) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

c) a polynucleotide the sequence of which deviates from the polynucleotide specified in (a) and (b) due to the generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

d) a polynucleotide which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (c)

e) an antisense molecule targeting specifically one of the polynucleotide sequences specified in (a) to (d);

f) a purified polypeptide encoded by a polynucleotide sequence specified in (a) to (d)

g) a purified polypeptide comprising at least one of the sequences of SEQ ID NO: 27 to 52 or 76 to 98;

h) an antibody capable of binding to one of the polynucleotide specified in (a) to (d) or a polypeptide specified in (f) and (g)

i) a reagent identified by any of the methods of claim 14 to 16 that modulates the amount or activity of a polynucleotide sequence specified in (a) to (d) or a polypeptide specified in (f) and (g).

in the preparation of a composition for the prevention, prediction, diagnosis, prognosis or a medicament for the treatment of malignant neoplasia and breast cancer in particular.

Polynucleotides

[0130] A "BREAST CANCER GENE" polynucleotide can be single- or double-stranded and comprises a coding sequence or the complement of a coding sequence for a "BREAST CANCER GENE" polypeptide. Degenerate nucleotide sequences encoding human "BREAST CANCER GENE" polypeptides, as well as homologous nucleotide sequences which are at least about 50, 55, 60, 65, 70, preferably about 75, 90, 96, or 98% identical to the nucleotide sequences of SEQ ID NO: 1 to 26 or 53 to 75 also are "BREAST CANCER GENE" polynucleotides. Percent sequence identity between the sequences of two polynucleotides is determined using computer programs such as ALIGN which employ the FASTA algorithm, using an affine gap search with a gap open penalty of -12 and a gap extension penalty of -2. Complementary DNA (cDNA) molecules, species homologues, and variants of "BREAST CANCER GENE" polynucleotides which encode biologically active "BREAST CANCER GENE" polypeptides also are "BREAST CANCER GENE" polynucleotides.

Preparation of Polynucleotides

[0131] A naturally occurring "BREAST CANCER GENE" polynucleotide can be isolated free of other cellular components such as membrane components, proteins, and lipids. Polynucleotides can be made by a cell and isolated using standard nucleic acid purification techniques, or synthesized using an amplification technique, such as the polymerase chain reaction (PCR), or by using an automatic synthesizer. Methods for isolating polynucleotides are routine and are known in the art. Any such technique for obtaining a polynucleotide can be used to obtain isolated "BREAST CANCER GENE" polynucleotides. For example, restriction enzymes and probes can be used to isolate polynucleotide fragments which comprises "BREAST CANCER GENE" nucleotide sequences. Isolated polynucleotides are in preparations which are free or at least 70, 80, or 90% free of other molecules.

[0132] "BREAST CANCER GENE" cDNA molecules can be made with standard molecular biology techniques, using "BREAST CANCER GENE" mRNA as a template. Any RNA isolation technique which does not select against the isolation of mRNA may be utilized for the purification of such RNA samples. See, for example, Sambrook et al., 1989, (77); and Ausubel, F. M. et al., 1989, (78), both of which are incorporated herein by reference in their entirety. Additionally, large numbers of tissue samples may readily be processed using techniques well known to those of skill in the art, such as, for example, the single-step RNA isolation process of Chomczynski, P. (1989, U.S. Pat. No. 4,843,155), which is incorporated herein by reference in its entirety.

[0133] "BREAST CANCER GENE" cDNA molecules can thereafter be replicated using molecular biology techniques known in the art and disclosed in manuals such as Sambrook et al., 1989, (77). An amplification technique, such as PCR, can be used to obtain additional copies of polynucleotides of the invention, using either human genomic DNA or

cDNA as a template.

[0134] Alternatively, synthetic chemistry techniques can be used to synthesize "BREAST CANCER GENE" polynucleotides. The degeneracy of the genetic code allows alternate nucleotide sequences to be synthesized which will encode a "BREAST CANCER GENE" polypeptide or a biologically active variant thereof.

Identification of differential expression

[0135] Transcripts within the collected RNA samples which represent RNA produced by differentially expressed genes may be identified by utilizing a variety of methods which are well known to those of skill in the art. For example, differential screening [Tedder, T. F. et al., 1988, (79)], subtractive hybridization [Hedrick, S. M. et al., 1984, (80); Lee, S. W. et al., 1984, (81)], and, preferably, differential display [Liang, P., and Pardee, A. B., 1993, U.S. Pat. No. 5,262,311, which is incorporated herein by reference in its entirety], may be utilized to identify polynucleotide sequences derived from genes that are differentially expressed.

[0136] Differential screening involves the duplicate screening of a cDNA library in which one copy of the library is screened with a total cell cDNA probe corresponding to the mRNA population of one cell type while a duplicate copy of the cDNA library is screened with a total cDNA probe corresponding to the mRNA population of a second cell type. For example, one cDNA probe may correspond to a total cell cDNA probe of a cell type derived from a control subject, while the second cDNA probe may correspond to a total cell cDNA probe of the same cell type derived from an experimental subject. Those clones which hybridize to one probe but not to the other potentially represent clones derived from genes differentially expressed in the cell type of interest in control versus experimental subjects.

[0137] Subtractive hybridization techniques generally involve the isolation of mRNA taken from two different sources, e.g., control and experimental tissue, the hybridization of the mRNA or single-stranded cDNA reverse-transcribed from the isolated mRNA, and the removal of all hybridized, and therefore double-stranded, sequences. The remaining non-hybridized, single-stranded cDNAs, potentially represent clones derived from genes that are differentially expressed in the two mRNA sources. Such single-stranded cDNAs are then used as the starting material for the construction of a library comprising clones derived from differentially expressed genes.

[0138] The differential display technique describes a procedure, utilizing the well known polymerase chain reaction (PCR; the experimental embodiment set forth in Mullis, K. B., 1987, U.S. Pat. No. 4,683,202) which allows for the identification of sequences derived from genes which are differentially expressed. First, isolated RNA is reverse-transcribed into single-stranded cDNA, utilizing standard techniques which are well known to those of skill in the art. Primers for the reverse transcriptase reaction may include, but are not limited to, oligo dT-containing primers, preferably of the reverse primer type of oligonucleotide described below. Next, this technique uses pairs of PCR primers, as described below, which allow for the amplification of clones representing a random subset of the RNA transcripts present within any given cell. Utilizing different pairs of primers allows each of the mRNA transcripts present in a cell to be amplified. Among such amplified transcripts may be identified those which have been produced from differentially expressed genes.

[0139] The reverse oligonucleotide primer of the primer pairs may contain an oligo dT stretch of nucleotides, preferably eleven nucleotides long, at its 5' end, which hybridizes to the poly(A) tail of mRNA or to the complement of a cDNA reverse transcribed from an mRNA poly(A) tail. Second, in order to increase the specificity of the reverse primer, the primer may contain one or more, preferably two, additional nucleotides at its 3' end. Because, statistically, only a subset of the mRNA derived sequences present in the sample of interest will hybridize to such primers, the additional nucleotides allow the primers to amplify only a subset of the mRNA derived sequences present in the sample of interest. This is preferred in that it allows more accurate and complete visualization and characterization of each of the bands representing amplified sequences.

[0140] The forward primer may contain a nucleotide sequence expected, statistically, to have the ability to hybridize to cDNA sequences derived from the tissues of interest. The nucleotide sequence may be an arbitrary one, and the length of the forward oligonucleotide primer may range from about 9 to about 13 nucleotides, with about 10 nucleotides being preferred. Arbitrary primer sequences cause the lengths of the amplified partial cDNAs produced to be variable, thus allowing different clones to be separated by using standard denaturing sequencing gel electrophoresis. PCR reaction conditions should be chosen which optimize amplified product yield and specificity, and, additionally, produce amplified products of lengths which may be resolved utilizing standard gel electrophoresis techniques. Such reaction conditions are well known to those of skill in the art, and important reaction parameters include, for example, length and nucleotide sequence of oligonucleotide primers as discussed above, and annealing and elongation step temperatures and reaction times. The pattern of clones resulting from the reverse transcription and amplification of the mRNA of two different cell types is displayed via sequencing gel electrophoresis and compared. Differences in the two banding patterns indicate potentially differentially expressed genes.

[0141] When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Randomly-primed libraries are preferable, in that they will contain more sequences which contain the

5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d (T) library does not yield a full-length cDNA. Genomic libraries can be useful for extension of sequence into 5' non-transcribed regulatory regions.

[0142] Commercially available capillary electrophoresis systems can be used to analyze the size or confirm the nucleotide sequence of PCR or sequencing products. For example, capillary sequencing can employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity can be converted to electrical signal using appropriate software (e.g. GENOTYPER and Sequence NAVIGATOR, Perkin Elmer; ABI), and the entire process from loading of samples to computer analysis and electronic data display can be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

[0143] Once potentially differentially expressed gene sequences have been identified via bulk techniques such as, for example, those described above, the differential expression of such putatively differentially expressed genes should be corroborated. Corroboration may be accomplished via, for example, such well known techniques as Northern analysis and/or RT-PCR. Upon corroboration, the differentially expressed genes may be further characterized, and may be identified as target and/or marker genes, as discussed, below.

[0144] Also, amplified sequences of differentially expressed genes obtained through, for example, differential display may be used to isolate full length clones of the corresponding gene. The full length coding portion of the gene may readily be isolated, without undue experimentation, by molecular biological techniques well known in the art. For example, the isolated differentially expressed amplified fragment may be labeled and used to screen a cDNA library. Alternatively, the labeled fragment may be used to screen a genomic library.

[0145] An analysis of the tissue distribution of the mRNA produced by the identified genes may be conducted, utilizing standard techniques well known to those of skill in the art. Such techniques may include, for example, Northern analyses and RT-PCR. Such analyses provide information as to whether the identified genes are expressed in tissues expected to contribute to breast cancer. Such analyses may also provide quantitative information regarding steady state mRNA regulation, yielding data concerning which of the identified genes exhibits a high level of regulation in, preferably, tissues which may be expected to contribute to breast cancer.

[0146] Such analyses may also be performed on an isolated cell population of a particular cell type derived from a given tissue. Additionally, standard in situ hybridization techniques may be utilized to provide information regarding which cells within a given tissue express the identified gene. Such analyses may provide information regarding the biological function of an identified gene relative to breast cancer in instances wherein only a subset of the cells within the tissue is thought to be relevant to breast cancer.

Identification of co-amplified genes

[0147] Genes involved in genomic alterations (amplifications, insertions, translocations, deletions, etc.) are identified by PCR-based karyotyping in combination with database analysis. Of particular interest are gene amplifications, which account for gene copy numbers >2 per cell. Gene copy number and gene expression of the respective genes often correlates. Therefore clusters of genes being simultaneously overexpressed due to gene amplifications can be identified by expression analysis via DNA-chip technologies or quantitative RTPCR. For example, the altered expression of genes due to increased or decreased gene copy numbers can be determined by GeneArray™ technologies from Affymetrix or qRT-PCR with the TaqMan or iCycler Systems. Moreover combination of RNA with DNA analytic enables highly parallel and automated characterization of multiple genomic regions of variable length with high resolution in tissue or single cell samples. Furthermore these assays enable the correlation of gene transcription relative to gene copy number of target genes. As there is not necessarily a linear correlation of expression level and gene copy number and as there are synergistic or antagonistic effects in certain gene clusters, the identification on the RNA-level is easier and probably more relevant for the biological outcome of the alterations especially in tumor tissue.

Detection of co-amplified genes in malignant neoplasia

[0148] Chromosomal changes are commonly detected by FISH (=Fluorescence-In-Situ-Hybridization) and CGH (=Comparative Genomic Hybridization). For quantification of genomic regions genes or intergenic regions can be used. Such quantification measures the relative abundance of multiple genes with respect to each other (e.g. target gene vs. centromeric region or housekeeping genes). Changes in relative abundance can be detected in paraffin-embedded material even after extraction of RNA or genomic DNA. Measurement of genomic DNA has advantages compared to RNA-analysis due to the stability of DNA, which accounts for the possibility to perform also retrospective studies and offers multiple internal controls (genes not being altered, amplified or deleted) for standardization and exact calculations. Moreover, PCR-analysis of genomic DNA offers the advantage to investigate intergenic, highly variable regions

or combinations of SNP's (=Single Nucleotide Polymorphisms), RFLPs, VNTRs and STRs (in general polymorphic markers). Determination of SNPs or polymorphic markers within defined genomic regions (e.g. SNP analysis by "Pyrosequencing™") has impact on the phenotype of the genomic alterations. For example it is of advantage to determine combinations of polymorphisms or haplotypes in order to characterize the biological potential of genes being part of amplified alleles. Of particular interest are polymorphic markers in breakpoint regions, coding regions or regulatory regions of genes or intergenic regions. By determining predictive haplotypes with defined biological or clinical outcome it is possible to establish diagnostic and prognostic assays with non-tumor samples from patients. Depending on whether preferably one allele or both alleles to same extent are amplified (= linear or non-linear amplifications) haplotypes can be determined. Overrepresentation of specific polymorphic markers combinations in cells or tissues with gene amplifications facilitates haplotype determination, as e.g. combinations of heterozygous polymorphic markers in nucleic acids isolated from normal tissues, body fluids or biological samples of one patient become almost homozygous in neoplastic tissue of the very same patient. This "gain of homozygosity" corresponds to the measurement of altered genomic region due to amplification events and is suitable for identification of "gain of function"- alterations in tumors, which result in e.g. oncogenic or growth promoting activities. In contrast, the detection of "losses of heterozygosity" is used for identification of anti-oncogenes, gate keeper genes or checkpoint genes, that suppress oncogenic activities and negatively regulate cellular growth processes. This intrinsic difference clearly opposes the impact of the respective genomic regions for tumor development and emphasizes the significance of "gain of homozygosity" measurements disclosed in this invention. In addition to the analyses on SNPs, a comparative approach of blood leucocyte DNA and tumor DNA based on VNTR detection can reveal the existence of a formerly described ARCHEON. SNP and VNTR sequences and primer sets most suitable for detection of the ARCHEON at 17q11-21 are disclosed in Table 4 and Table 6. Detection, quantification and sizing of such polymorphic markers can be achieved by methods known to those with skill in the art. In one embodiment of this invention we disclose the comparative measurement of amount and size of any of the disclosed VNTRs (Table 6) by PCR amplification and capillary electrophoresis. PCR can be carried out by standard protocols favorably in a linear amplification range (low cycle number) and detection by CE should be carried out by suppliers protocols (e.g. Agilent). More favorably the detection of the VNTRs disclosed in Table 6 can be carried out in a multiplex fashion, utilizing a variety of labeled primers (e.g. fluorescent, radioactive, bioactive) and a suitable CE detection system (e.g. ABI 310). However the detection can also be performed on slab gels consisting of highly concentrated agarose or polyacrylamide with a monochromal DNA stain. Enhancement of resolution can be achieved by appropriate primer design and length variation to give best results in multiplex PCR.

[0149] It is also of interest to determine covalent modifications of DNA (e.g. methylation) or the associated chromatin (e.g. acetylation or methylation of associated proteins) within the altered genomic regions, that have impact on transcriptional activity of the genes. In general, by measuring multiple, short sequences (60-300 bp) these techniques enable high-resolution analysis of target regions, which cannot be obtained by conventional methods such as FISH analytic (2-100 kb). Moreover the PCR-based DNA analysis techniques offer advantages with regard to sensitivity, specificity, multiplexing, time consumption and low amount of patient material required. These techniques can be optimized by combination with microdissection or macrodissection to obtain purer starting material for analysis.

Extending Polynucleotides

[0150] In one embodiment of such a procedure for the identification and cloning of full length gene sequences, RNA may be isolated, following standard procedures, from an appropriate tissue or cellular source. A reverse transcription reaction may then be performed on the RNA using an oligonucleotide primer complementary to the mRNA that corresponds to the amplified fragment, for the priming of first strand synthesis. Because the primer is anti-parallel to the mRNA, extension will proceed toward the 5' end of the mRNA. The resulting RNA hybrid may then be "tailed" with guanines using a standard terminal transferase reaction, the hybrid may be digested with RNase H, and second strand synthesis may then be primed with a poly-C primer. Using the two primers, the 5' portion of the gene is amplified using PCR. Sequences obtained may then be isolated and recombined with previously isolated sequences to generate a full-length cDNA of the differentially expressed genes of the invention. For a review of cloning strategies and recombinant DNA techniques, see e.g., Sambrook et al., (77); and Ausubel et al., (78).

[0151] Various PCR-based methods can be used to extend the polynucleotide sequences disclosed herein to detect upstream sequences such as promoters and regulatory elements. For example, restriction site PCR uses universal primers to retrieve unknown sequence adjacent to a known locus [Sarkar, 1993, (82)]. Genomic DNA is first amplified in the presence of a primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

[0152] Inverse PCR also can be used to amplify or extend sequences using divergent primers based on a known region [Triglia et al., 1988, (83)]. Primers can be designed using commercially available software, such as OLIGO 4.06

Primer Analysis software (National Biosciences Inc., Plymouth, Minn.), to be e.g. 2230 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68-72°C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

[0153] Another method which can be used is capture PCR, which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA [Lagerstrom et al., 1991, (84)]. In this method, multiple restriction enzyme digestions and ligations also can be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

[0154] Additionally, PCR, nested primers, and PROMOTERFINDER libraries (CLONTECH, Palo Alto, Calif.) can be used to walk genomic DNA (CLONTECH, Palo Alto, Calif.). This process avoids the need to screen libraries and is useful in finding intron/exon junctions.

[0155] The sequences of the identified genes may be used, utilizing standard techniques, to place the genes onto genetic maps, e.g., mouse [Copeland & Jenkins, 1991, (85)] and human genetic maps [Cohen, et al., 1993, (86)]. Such mapping information may yield information regarding the genes' importance to human disease by, for example, identifying genes which map near genetic regions to which known genetic breast cancer tendencies map.

Identification of polynucleotide variants and homologues or splice variants

[0156] Variants and homologues of the "BREAST CANCER GENE" polynucleotides described above also are "BREAST CANCER GENE" polynucleotides. Typically, homologous "BREAST CANCER GENE" polynucleotide sequences can be identified by hybridization of candidate polynucleotides to known "BREAST CANCER GENE" polynucleotides under stringent conditions, as is known in the art. For example, using the following wash conditions: 2 X SSC (0.3 M NaCl, 0.03 M sodium citrate, pH 7.0), 0.1% SDS, room temperature twice, 30 minutes each; then 2 X SSC, 0.1% SDS, 50 EC once, 30 minutes; then 2 X SSC, room temperature twice, 10 minutes each homologous sequences can be identified which contain at most about 25-30% basepair mismatches. More preferably, homologous polynucleotide strands contain 15-25% basepair mismatches, even more preferably 5-15% basepair mismatches.

[0157] Species homologues of the "BREAST CANCER GENE" polynucleotides disclosed herein also can be identified by making suitable probes or primers and screening cDNA expression libraries from other species, such as mice, monkeys, or yeast. Human variants of "BREAST CANCER GENE" polynucleotides can be identified, for example, by screening human cDNA expression libraries. It is well known that the T_m of a double-stranded DNA decreases by 1-1.5°C with every 1% decrease in homology [Bonner et al., 1973, (87)]. Variants of human "BREAST CANCER GENE" polynucleotides or "BREAST CANCER GENE" polynucleotides of other species can therefore be identified by hybridizing a putative homologous "BREAST CANCER GENE" polynucleotide with a polynucleotide having a nucleotide sequence of one of the sequences of the SEQ ID NO: 1 to 26 or 53 to 75 or the complement thereof to form a test hybrid. The melting temperature of the test hybrid is compared with the melting temperature of a hybrid comprising polynucleotides having perfectly complementary nucleotide sequences, and the number or percent of basepair mismatches within the test hybrid is calculated.

[0158] Nucleotide sequences which hybridize to "BREAST CANCER GENE" polynucleotides or their complements following stringent hybridization and/or wash conditions also are "BREAST CANCER GENE" polynucleotides. Stringent wash conditions are well known and understood in the art and are disclosed, for example, in Sambrook et al., (77). Typically, for stringent hybridization conditions a combination of temperature and salt concentration should be chosen that is approximately 12-20°C below the calculated T_m of the hybrid under study. The T_m of a hybrid between a "BREAST CANCER GENE" polynucleotide having a nucleotide sequence of one of the sequences of the SEQ ID NO: 1 to 26 or 53 to 75 or the complement thereof and a polynucleotide sequence which is at least about 50, preferably about 75, 90, 96, or 98% identical to one of those nucleotide sequences can be calculated, for example, using the equation below [Bolton and McCarthy, 1962, (88)]:

$$T_m = 81.5^\circ\text{C} - 16.6(\log_{10}[\text{Na}^+]) + 0.41(\%G + C) - 0.63(\%\text{formamide}) - 600/l,$$

where l = the length of the hybrid in basepairs.

[0159] Stringent wash conditions include, for example, 4 X SSC at 65°C, or 50% formamide, 4 X SSC at 28°C, or 0.5 X SSC, 0.1% SDS at 65°C. Highly stringent wash conditions include, for example, 0.2 X SSC at 65°C.

[0160] The biological function of the identified genes may be more directly assessed by utilizing relevant in vivo and in vitro systems. In vivo systems may include, but are not limited to, animal systems which naturally exhibit breast cancer predisposition, or ones which have been engineered to exhibit such symptoms, including but not limited to the apoE-deficient malignant neoplasia mouse model [Plump et al., 1992, (89)].

[0161] Splice variants derived from the same genomic region, encoded by the same pre mRNA can be identified by

hybridization conditions described above for homology search. The specific characteristics of variant proteins encoded by splice variants of the same pre transcript may differ and can also be assayed as disclosed. A "BREAST CANCER GENE" polynucleotide having a nucleotide sequence of one of the sequences of the SEQ ID NO: 1 to 26 or 53 to 75 or the complement thereof may therefor differ in parts of the entire sequence as presented for SEQ ID NO: 60 and the encoded splice variants SEQ ID NO: 61 to 66. These refer to individual proteins SEQ ID NO: 83 to 89. The prediction of splicing events and the identification of the utilized acceptor and donor sites within the pre mRNA can be computed (e.g. Software Package GRAIL or GenomeSCAN) and verified by PCR method by those with skill in the art.

Antisense oligonucleotides

[0162] Antisense oligonucleotides are nucleotide sequences which are complementary to a specific DNA or RNA sequence. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form complexes and block either transcription or translation. Preferably, an antisense oligonucleotide is at least 6 nucleotides in length, but can be at least 7, 8, 10, 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences also can be used. Antisense oligonucleotide molecules can be provided in a DNA construct and introduced into a cell as described above to decrease the level of "BREAST CANCER GENE" gene products in the cell.

[0163] Antisense oligonucleotides can be deoxyribonucleotides, ribonucleotides, peptide nucleic acids (PNAs; described in U.S. Pat. No. 5,714,331), locked nucleic acids (LNAs; described in WO 99/12826), or a combination of them. Oligonucleotides can be synthesized manually or by an automated synthesizer, by covalently linking the 5' end of one nucleotide with the 3' end of another nucleotide with non-phosphodiester internucleotide linkages such as alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, alkylphosphonates, phosphoramidates, phosphate esters, carbamates, acetamides, carboxymethyl esters, carbonates, and phosphate triesters [Brown, 1994, (126); Sonveaux, 1994, (127) and Uhlmann et al., 1990, (128)].

[0164] Modifications of "BREAST CANCER GENE" expression can be obtained by designing antisense oligonucleotides which will form duplexes to the control, 5', or regulatory regions of the "BREAST CANCER GENE". Oligonucleotides derived from the transcription initiation site, e.g., between positions 10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or chaperons. Therapeutic advances using triplex DNA have been described in the literature [Gee et al., 1994, (129)]. An antisense oligonucleotide also can be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

[0165] Precise complementarity is not required for successful complex formation between an antisense oligonucleotide and the complementary sequence of a "BREAST CANCER GENE" polynucleotide. Antisense oligonucleotides which comprise, for example, 2, 3, 4, or 5 or more stretches of contiguous nucleotides which are precisely complementary to a "BREAST CANCER GENE" polynucleotide, each separated by a stretch of contiguous nucleotides which are not complementary to adjacent "BREAST CANCER GENE" nucleotides, can provide sufficient targeting specificity for "BREAST CANCER GENE" mRNA. Preferably, each stretch of complementary contiguous nucleotides is at least 4, 5, 6, 7, or 8 or more nucleotides in length. Non-complementary intervening sequences are preferably 1, 2, 3, or 4 nucleotides in length. One skilled in the art can easily use the calculated melting point of an antisense-sense pair to determine the degree of mismatching which will be tolerated between a particular antisense oligonucleotide and a particular "BREAST CANCER GENE" polynucleotide sequence.

[0166] Antisense oligonucleotides can be modified without affecting their ability to hybridize to a "BREAST CANCER GENE" polynucleotide. These modifications can be internal or at one or both ends of the antisense molecule. For example, inter-nucleoside phosphate linkages can be modified by adding cholesteryl or diamine moieties with varying numbers of carbon residues between the amino groups and terminal ribose. Modified bases and/or sugars, such as arabinose instead of ribose, or a 3', 5' substituted oligonucleotide in which the 3' hydroxyl group or the 5' phosphate group are substituted, also can be employed in a modified antisense oligonucleotide. These modified oligonucleotides can be prepared by methods well known in the art [Agrawal et al., 1992, (130); Uhlmann et al., 1987, (131) and Uhlmann et al., (128)].

Ribozymes

[0167] Ribozymes are RNA molecules with catalytic activity [Cech, 1987, (132); Cech, 1990, (133) and Couture & Stinchcomb, 1996, (134)]. Ribozymes can be used to inhibit gene function by cleaving an RNA sequence, as is known in the art (e.g., Haseloff et al., U.S. Patent 5,641,673). The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of specific nucleotide sequences.

[0168] The transcribed sequence of a "BREAST CANCER GENE" can be used to generate ribozymes which will specifically bind to mRNA transcribed from a "BREAST CANCER GENE" genomic locus. Methods of designing and constructing ribozymes which can cleave other RNA molecules in trans in a highly sequence specific manner have been developed and described in the art [Haseloff et al., 1988, (135)]. For example, the cleavage activity of ribozymes can be targeted to specific RNAs by engineering a discrete "hybridization" region into the ribozyme. The hybridization region contains a sequence complementary to the target RNA and thus specifically hybridizes with the target [see, for example, Gertach et al., EP 0 321201].

[0169] Specific ribozyme cleavage sites within a "BREAST CANCER GENE" RNA target can be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target RNA containing the cleavage site can be evaluated for secondary structural features which may render the target inoperable. Suitability of candidate "BREAST CANCER GENE" RNA targets also can be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays. Longer complementary sequences can be used to increase the affinity of the hybridization sequence for the target. The hybridizing and cleavage regions of the ribozyme can be integrally related such that upon hybridizing to the target RNA through the complementary regions, the catalytic region of the ribozyme can cleave the target.

[0170] Ribozymes can be introduced into cells as part of a DNA construct. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce a ribozyme-containing DNA construct into cells in which it is desired to decrease "BREAST CANCER GENE" expression. Alternatively, if it is desired that the cells stably retain the DNA construct, the construct can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art. A ribozyme-encoding DNA construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of ribozymes in the cells.

[0171] As taught in Haseloff et al., U.S. Pat. No. 5,641,673, ribozymes can be engineered so that ribozyme expression will occur in response to factors which induce expression of a target gene. Ribozymes also can be engineered to provide an additional level of regulation, so that destruction of mRNA occurs only when both a ribozyme and a target gene are induced in the cells.

Polypeptides

[0172] "BREAST CANCER GENE" polypeptides according to the invention comprise an polypeptide selected from SEQ ID NO: 27 to 52 and 76 to 98 or encoded by any of the polynucleotide sequences of the SEQ ID NO: 1 to 26 and 53 to 75 or derivatives, fragments, analogues and homologues thereof. A "BREAST CANCER GENE" polypeptide of the invention therefore can be a portion, a full-length, or a fusion protein comprising all or a portion of a "BREAST CANCER GENE" polypeptide.

Protein Purification

[0173] "BREAST CANCER GENE" polypeptides can be purified from any cell which expresses the enzyme, including host cells which have been transfected with "BREAST CANCER GENE" expression constructs. Breast tissue is an especially useful source of "BREAST CANCER GENE" polypeptides. A purified "BREAST CANCER GENE" polypeptide is separated from other compounds which normally associate with the "BREAST CANCER GENE" polypeptide in the cell, such as certain proteins, carbohydrates, or lipids, using methods well-known in the art. Such methods include, but are not limited to, size exclusion chromatography, ammonium sulfate fractionation, ion exchange chromatography, affinity chromatography, and preparative gel electrophoresis. A preparation of purified "BREAST CANCER GENE" polypeptides is at least 80% pure; preferably, the preparations are 90%, 95%, or 99% pure. Purity of the preparations can be assessed by any means known in the art, such as SDS-polyacrylamide gel electrophoresis.

Obtaining Polypeptides

[0174] "BREAST CANCER GENE" polypeptides can be obtained, for example, by purification from human cells, by expression of "BREAST CANCER GENE" polynucleotides, or by direct chemical synthesis.

Biologically Active Variants

[0175] "BREAST CANCER GENE" polypeptide variants which are biologically active, i.e., retain an "BREAST CANCER GENE" activity, also are "BREAST CANCER GENE" polypeptides. Preferably, naturally or non-naturally occurring "BREAST CANCER GENE" polypeptide variants have amino acid sequences which are at least about 60, 65, or 70,

preferably about 75, 80, 85, 90, 92, 94, 96, or 98% identical to the any of the amino acid sequences of the polypeptides of SEQ ID NO: 27 to 52 or 76 to 98 or the polypeptides encoded by any of the polynucleotides of SEQ ID NO: 1 to 26 or 53 to 75 or a fragment thereof. Percent identity between a putative "BREAST CANCER GENE" polypeptide variant and of the polypeptides of SEQ ID NO: 27 to 52 or 76 to 98 or the polypeptides encoded by any of the polynucleotides of SEQ ID NO: 1 to 26 or 53 to 75 or a fragment thereof is determined by conventional methods. [See, for example, Altschul *et al.*, 1986, (90 and Henikoff & Henikoff, 1992, (91)]. Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "BLOSUM62" scoring matrix of Henikoff & Henikoff, (91).

[0176] Those skilled in the art appreciate that there are many established algorithms available to align two amino acid sequences. The "FASTA" similarity search algorithm of Pearson & Lipman is a suitable protein alignment method for examining the level of identity shared by an amino acid sequence disclosed herein and the amino acid sequence of a putative variant [Pearson & Lipman, 1988, (92), and Pearson, 1990, (93)]. Briefly, FASTA first characterizes sequence similarity by identifying regions shared by the query sequence (e.g., SEQ ID NO: 1 to 26 or 53 to 75) and a test sequence that have either the highest density of identities (if the ktup variable is 1) or pairs of identities (if ktup=2), without considering conservative amino acid substitutions, insertions, or deletions. The ten regions with the highest density of identities are then rescored by comparing the similarity of all paired amino acids using an amino acid substitution matrix, and the ends of the regions are "trimmed" to include only those residues that contribute to the highest score. If there are several regions with scores greater than the "cutoff" value (calculated by a predetermined formula based upon the length of the sequence the ktup value), then the trimmed initial regions are examined to determine whether the regions can be joined to form an approximate alignment with gaps. Finally, the highest scoring regions of the two amino acid sequences are aligned using a modification of the Needleman-Wunsch-Sellers algorithm [Needleman & Wunsch, 1970, (94), and Sellers, 1974, (95)], which allows for amino acid insertions and deletions. Preferred parameters for FASTA analysis are: ktup=1, gap opening penalty=10, gap extension penalty=1, and substitution matrix=BLOSUM62. These parameters can be introduced into a FASTA program by modifying the scoring matrix file ("SMATRIX"), as explained in Appendix 2 of Pearson, (93).

[0177] FASTA can also be used to determine the sequence identity of nucleic acid molecules using a ratio as disclosed above. For nucleotide sequence comparisons, the ktup value can range between one to six, preferably from three to six, most preferably three, with other parameters set as default.

[0178] Variations in percent identity can be due, for example, to amino acid substitutions, insertions, or deletions. Amino acid substitutions are defined as one for one amino acid replacements. They are conservative in nature when the substituted amino acid has similar structural and/or chemical properties. Examples of conservative replacements are substitution of a leucine with an isoleucine or valine, an aspartate with a glutamate, or a threonine with a serine.

[0179] Amino acid insertions or deletions are changes to or within an amino acid sequence. They typically fall in the range of about 1 to 5 amino acids. Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological or immunological activity of a "BREAST CANCER GENE" polypeptide can be found using computer programs well known in the art, such as DNASTAR software. Whether an amino acid change results in a biologically active "BREAST CANCER GENE" polypeptide can readily be determined by assaying for "BREAST CANCER GENE" activity, as described for example, in the specific Examples, below. Larger insertions or deletions can also be caused by alternative splicing. Protein domains can be inserted or deleted without altering the main activity of the protein.

Fusion Proteins

[0180] Fusion proteins are useful for generating antibodies against "BREAST CANCER GENE" polypeptide amino acid sequences and for use in various assay systems. For example, fusion proteins can be used to identify proteins which interact with portions of a "BREAST CANCER GENE" polypeptide. Protein affinity chromatography or library-based assays for protein-protein interactions, such as the yeast two-hybrid or phage display systems, can be used for this purpose. Such methods are well known in the art and also can be used as drug screens.

[0181] A "BREAST CANCER GENE" polypeptide fusion protein comprises two polypeptide segments fused together by means of a peptide bond. The first polypeptide segment comprises at least 25, 50, 75, 100, 150, 200, 300, 400, 500, 600, 700 or 750 contiguous amino acids of an amino acid sequence encoded by any polynucleotide sequences of the SEQ ID NO: 1 to 26 or 53 to 75 or of a biologically active variant, such as those described above. The first polypeptide segment also can comprise full-length "BREAST CANCER GENE".

[0182] The second polypeptide segment can be a full-length protein or a protein fragment. Proteins commonly used in fusion protein construction include β -galactosidase, β -glucuronidase, green fluorescent protein (GFP), autofluorescent proteins, including blue fluorescent protein (BFP), glutathione-S-transferase (GST), luciferase, horseradish peroxidase (HRP), and chloramphenicol acetyltransferase (CAT). Additionally, epitope tags are used in fusion protein constructions, including histidine (His) tags, FLAG tags, influenza hemagglutinin (HA) tags, Myc tags, VSV-G tags,

and thioredoxin (Trx) tags. Other fusion constructions can include maltose binding protein (MBP), S-tag, Lex a DNA binding domain (DBD) fusions, GAL4 DNA binding domain fusions, and herpes simplex virus (HSV) BP16 protein fusions. A fusion protein also can be engineered to contain a cleavage site located between the "BREAST CANCER GENE" polypeptide-encoding sequence and the heterologous protein sequence, so that the "BREAST CANCER GENE" polypeptide can be cleaved and purified away from the heterologous moiety.

[0183] A fusion protein can be synthesized chemically, as is known in the art. Preferably, a fusion protein is produced by covalently linking two polypeptide segments or by standard procedures in the art of molecular biology. Recombinant DNA methods can be used to prepare fusion proteins, for example, by making a DNA construct which comprises coding sequences selected from any of the polynucleotide sequences of the SEQ ID NO: 1 to 26 and 53 to 75 in proper reading frame with nucleotides encoding the second polypeptide segment and expressing the DNA construct in a host cell, as is known in the art. Many kits for constructing fusion proteins are available from companies such as Promega Corporation (Madison, WI), Stratagene (La Jolla, CA), CLONTECH (Mountain View, CA), Santa Cruz Biotechnology (Santa Cruz, CA), MBL International Corporation (MIC; Watertown, MA), and Quantum Biotechnologies (Montreal, Canada; 1-888-DNA-KITS).

Identification of Species Homologues

[0184] Species homologues of human a "BREAST CANCER GENE" polypeptide can be obtained using "BREAST CANCER GENE" polypeptide polynucleotides (described below) to make suitable probes or primers for screening cDNA expression libraries from other species, such as mice, monkeys, or yeast, identifying cDNAs which encode homologues of a "BREAST CANCER GENE" polypeptide, and expressing the cDNAs as is known in the art.

Expression of Polynucleotides

[0185] To express a "BREAST CANCER GENE" polynucleotide, the polynucleotide can be inserted into an expression vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods which are well known to those skilled in the art can be used to construct expression vectors containing sequences encoding "BREAST CANCER GENE" polypeptides and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described, for example, in Sambrook et al., (77) and in Ausubel et al., (78).

[0186] A variety of expression vector/host systems can be utilized to contain and express sequences encoding a "BREAST CANCER GENE" polypeptide. These include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors, insect cell systems infected with virus expression vectors (e.g., baculovirus), plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids), or animal cell systems.

[0187] The control elements or regulatory sequences are those regions of the vector enhancers, promoters, 5' and 3' untranslated regions which interact with host cellular proteins to carry out transcription and translation. Such elements can vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, can be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the BLUESCRIPT phagemid (Stratagene, LaJolla, Calif.) or pSPORT1 plasmid (Life Technologies) and the like can be used. The baculovirus polyhedrin promoter can be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO, and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) can be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of a nucleotide sequence encoding a "BREAST CANCER GENE" polypeptide, vectors based on SV40 or EBV can be used with an appropriate selectable marker.

Bacterial and Yeast Expression Systems

[0188] In bacterial systems, a number of expression vectors can be selected depending upon the use intended for the "BREAST CANCER GENE" polypeptide. For example, when a large quantity of the "BREAST CANCER GENE" polypeptide is needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified can be used. Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene). In a BLUESCRIPT vector, a sequence encoding the "BREAST CANCER GENE" polypeptide can be ligated into the vector in frame with sequences for the amino terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced. pIN vectors [Van Heeke & Schuster,

(17)] or pGEX vectors (Promega, Madison, Wis.) also can be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST).

[0189] In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems can be designed to include heparin, thrombin, or factor Xa protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

[0190] In the yeast *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH can be used. For reviews, see Ausubel et al., (4) and Grant et al., (18).

Plant and Insect Expression Systems

[0191] If plant expression vectors are used, the expression of sequences encoding "BREAST CANCER GENE" polypeptides can be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV can be used alone or in combination with the omega leader sequence from TMV [Takamatsu, 1987, (96)]. Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters can be used [Coruzzi et al., 1984, (97); Broglie et al., 1984, (98); Winter et al., 1991, (99)]. These constructs can be introduced into plant cells by direct DNA transformation or by pathogen-mediated transfection. Such techniques are described in a number of generally available reviews.

[0192] An insect system also can be used to express a "BREAST CANCER GENE" polypeptide. For example, in one such system *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia* larvae. Sequences encoding "BREAST CANCER GENE" polypeptides can be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of "BREAST CANCER GENE" polypeptides will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses can then be used to infect *S. frugiperda* cells or *Trichoplusia* larvae in which "BREAST CANCER GENE" polypeptides can be expressed [Engelhard et al., 1994, (100)].

Mammalian Expression Systems

[0193] A number of viral-based expression systems can be used to express "BREAST CANCER GENE" polypeptides in mammalian host cells. For example, if an adenovirus is used as an expression vector, sequences encoding "BREAST CANCER GENE" polypeptides can be ligated into an adenovirus transcription/translation complex comprising the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome can be used to obtain a viable virus which is capable of expressing a "BREAST CANCER GENE" polypeptide in infected host cells [Logan & Shenk, 1984, (101)]. If desired, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, can be used to increase expression in mammalian host cells.

[0194] Human artificial chromosomes (HACs) also can be used to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6M to 10M are constructed and delivered to cells via conventional delivery methods (e.g., liposomes, polycationic amino polymers, or vesicles).

[0195] Specific initiation signals also can be used to achieve more efficient translation of sequences encoding "BREAST CANCER GENE" polypeptides. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding a "BREAST CANCER GENE" polypeptide, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals (including the ATG initiation codon) should be provided. The initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used [Scharf et al., 1994, (102)].

Host Cells

[0196] A host cell strain can be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed "BREAST CANCER GENE" polypeptide in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Posttranslational processing which cleaves a "prepro" form of the polypeptide also can be used to facilitate correct insertion, folding and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for Post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; 10801 University Boulevard, Manassas, VA 20110-2209) and can be chosen

to ensure the correct modification and processing of the foreign protein.

[0197] Stable expression is preferred for long-term, high-yield production of recombinant proteins. For example, cell lines which stably express "BREAST CANCER GENE" polypeptides can be transformed using expression vectors which can contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells can be allowed to grow for 12 days in an enriched medium before they are switched to a selective medium. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced "BREAST CANCER GENE" sequences. Resistant clones of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type [Freshney et al., 1986, (103)].

[0198] Any number of selection systems can be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase [Wigler et al., 1977, (104)] and adenine phosphoribosyltransferase [Lowy et al., 1980, (105)] genes which can be employed in tk- or aprt- cells, respectively. Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dhfr confers resistance to methotrexate [Wigler et al., 1980, (106)], npt confers resistance to the aminoglycosides, neomycin and G418 [Colbere-Garapin et al., 1981, (107)], and als and pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. Additional selectable genes have been described. For example, trpB allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine [Hartman & Mulligan, 1988, (108)]. Visible markers such as anthocyanins, β -glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, can be used to identify transformants and to quantify the amount of transient or stable protein expression attributable to a specific vector system [Rhodes et al., 1995, (109)].

Detecting Expression and gene product

[0199] Although the presence of marker gene expression suggests that the "BREAST CANCER GENE" polynucleotide is also present, its presence and expression may need to be confirmed. For example, if a sequence encoding a "BREAST CANCER GENE" polypeptide is inserted within a marker gene sequence, transformed cells containing sequences which encode a "BREAST CANCER GENE" polypeptide can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding a "BREAST CANCER GENE" polypeptide under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the "BREAST CANCER GENE" polynucleotide.

[0200] Alternatively, host cells which contain a "BREAST CANCER GENE" polynucleotide and which express a "BREAST CANCER GENE" polypeptide can be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include membrane, solution, or chip-based technologies for the detection and/or quantification of polynucleotide or protein. For example, the presence of a polynucleotide sequence encoding a "BREAST CANCER GENE" polypeptide can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding a "BREAST CANCER GENE" polypeptide. Nucleic acid amplification-based assays involve the use of oligonucleotides selected from sequences encoding a "BREAST CANCER GENE" polypeptide to detect transformants which contain a "BREAST CANCER GENE" polynucleotide.

[0201] A variety of protocols for detecting and measuring the expression of a "BREAST CANCER GENE" polypeptide, using either polyclonal or monoclonal antibodies specific for the polypeptide, are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay using monoclonal antibodies reactive to two non-interfering epitopes on a "BREAST CANCER GENE" polypeptide can be used, or a competitive binding assay can be employed. These and other assays are described in Hampton et al., (110) and Maddox et al., (111).

[0202] A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding "BREAST CANCER GENE" polypeptides include oligo labeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, sequences encoding a "BREAST CANCER GENE" polypeptide can be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and can be used to synthesize RNA probes in vitro by addition of labeled nucleotides and an appropriate RNA polymerase such as T7, T3, or SP6. These procedures can be conducted using a variety of commercially available kits (Amersham Pharmacia Biotech, Promega, and US Biochemical). Suitable reporter molecules or labels which can be used for ease of detection include radionuclides, enzymes, and fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Expression and Purification of Polypeptides

[0203] Host cells transformed with nucleotide sequences encoding a "BREAST CANCER GENE" polypeptide can be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The polypeptide produced by a transformed cell can be secreted or stored intracellular depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode "BREAST CANCER GENE" polypeptides can be designed to contain signal sequences which direct secretion of soluble "BREAST CANCER GENE" polypeptides through a prokaryotic or eukaryotic cell membrane or which direct the membrane insertion of membrane-bound "BREAST CANCER GENE" polypeptide.

[0204] As discussed above, other constructions can be used to join a sequence encoding a "BREAST CANCER GENE" polypeptide to a nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, Wash.). Inclusion of cleavable linker sequences such as those specific for Factor Xa or enterokinase (Invitrogen, San Diego, CA) between the purification domain and the "BREAST CANCER GENE" polypeptide also can be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing a "BREAST CANCER GENE" polypeptide and 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification by IMAC (immobilized metal ion affinity chromatography [Porath et al., 1992, (112)]), while the enterokinase cleavage site provides a means for purifying the "BREAST CANCER GENE" polypeptide from the fusion protein. Vectors which contain fusion proteins are disclosed in Kroll et al., (113).

Chemical Synthesis

[0205] Sequences encoding a "BREAST CANCER GENE" polypeptide can be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers et al., (114) and Horn et al., (115). Alternatively, a "BREAST CANCER GENE" polypeptide itself can be produced using chemical methods to synthesize its amino acid sequence, such as by direct peptide synthesis using solid-phase techniques [Merrifield, 1963, (116) and Roberge et al., 1995, (117)]. Protein synthesis can be performed using manual techniques or by automation. Automated synthesis can be achieved, for example, using Applied Biosystems 431 A Peptide Synthesizer (Perkin Elmer). Optionally, fragments of "BREAST CANCER GENE" polypeptides can be separately synthesized and combined using chemical methods to produce a full-length molecule.

[0206] The newly synthesized peptide can be substantially purified by preparative high performance liquid chromatography [Creighton, 1983, (118)]. The composition of a synthetic "BREAST CANCER GENE" polypeptide can be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; see Creighton, (118). Additionally, any portion of the amino acid sequence of the "BREAST CANCER GENE" polypeptide can be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins to produce a variant polypeptide or a fusion protein.

Production of Altered Polypeptides

[0207] As will be understood by those of skill in the art, it may be advantageous to produce "BREAST CANCER GENE" polypeptide-encoding nucleotide sequences possessing non-natural occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

[0208] The nucleotide sequences disclosed herein can be engineered using methods generally known in the art to alter "BREAST CANCER GENE" polypeptide-encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the polypeptide or mRNA product. DNA shuffling by random fragmentation and PCR re-assembly of gene fragments and synthetic oligonucleotides can be used to engineer the nucleotide sequences. For example, site-directed mutagenesis can be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

Predictive, Diagnostic and Prognostic Assays

[0209] The present invention provides method for determining whether a subject is at risk for developing malignant neoplasia and breast cancer in particular by detecting one of the disclosed polynucleotide markers comprising any of

the polynucleotides sequences of the SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19 or 21 to 26 or 53 to 75 and/or the polypeptide markers encoded thereby or polypeptide markers comprising any of the polypeptide sequences of the SEQ ID NO: 28 to 32, 34, 35, 37 to 42, 44, 45 or 47 to 52 or 76 to 98 or at least 2 of the disclosed polynucleotides selected from SEQ ID NO: 1 to 26 and 53 to 75 or the at least 2 of the disclosed polypeptides selected from SEQ ID NO: 28 to 32 and 76 to 98 for malignant neoplasia and breast cancer in particular.

[0210] In clinical applications, biological samples can be screened for the presence and/or absence of the biomarkers identified herein. Such samples are for example needle biopsy cores, surgical resection samples, or body fluids like serum, thin needle nipple aspirates and urine. For example, these methods include obtaining a biopsy, which is optionally fractionated by cryostat sectioning to enrich diseased cells to about 80% of the total cell population. In certain embodiments, polynucleotides extracted from these samples may be amplified using techniques well known in the art. The expression levels of selected markers detected would be compared with statistically valid groups of diseased and healthy samples.

[0211] In one embodiment the diagnostic method comprises determining whether a subject has an abnormal mRNA and/or protein level of the disclosed markers, such as by Northern blot analysis, reverse transcription-polymerase chain reaction (RT-PCR), in situ hybridization, immunoprecipitation, Western blot hybridization, or immunohistochemistry. According to the method, cells are obtained from a subject and the levels of the disclosed biomarkers, protein or mRNA level, is determined and compared to the level of these markers in a healthy subject. An abnormal level of the biomarker polypeptide or mRNA levels is likely to be indicative of malignant neoplasia such as breast cancer.

[0212] In another embodiment the diagnostic method comprises determining whether a subject has an abnormal DNA content of said genes or said genomic loci, such as by Southern blot analysis, dot blot analysis, fluorescence or colorimetric In Situ hybridization, comparative genomic hybridization, genotyping by VNTR, STS-PCR or quantitative PCR. In general these assays comprise the usage of probes from representative genomic regions. The probes contain at least parts of said genomic regions or sequences complementary or analogous to said regions. In particular intra- or intergenic regions of said genes or genomic regions. The probes can consist of nucleotide sequences or sequences of analogous functions (e.g. PNAs, Morpholino oligomers) being able to bind to target regions by hybridization. In general genomic regions being altered in said patient samples are compared with unaffected control samples (normal tissue from the same or different patients, surrounding unaffected tissue, peripheral blood) or with genomic regions of the same sample that don't have said alterations and can therefore serve as internal controls. In a preferred embodiment regions located on the same chromosome are used. Alternatively, gonosomal regions and /or regions with defined varying amount in the sample are used. In one favored embodiment the DNA content, structure, composition or modification is compared that lie within distinct genomic regions. Especially favored are methods that detect the DNA content of said samples, where the amount of target regions are altered by amplification and or deletions. In another embodiment the target regions are analyzed for the presence of polymorphisms (e.g. Single Nucleotide Polymorphisms or mutations) that affect or predispose the cells in said samples with regard to clinical aspects, being of diagnostic, prognostic or therapeutic value. Preferably, the identification of sequence variations is used to define haplotypes that result in characteristic behavior of said samples with said clinical aspects.

[0213] The following examples of genes in 17q12-21.2 are offered by way of illustration, not by way of limitation.

[0214] One embodiment of the invention is a method for the prediction, diagnosis or prognosis of malignant neoplasia by the detection of at least 10, at least 5, or at least 4, or at least 3 and more preferably at least 2 markers whereby the markers are genes and fragments thereof and/or genomic nucleic acid sequences that are located on one chromosomal region which is altered in malignant neoplasia.

[0215] One further embodiment of the invention is method for the prediction, diagnosis or prognosis of malignant neoplasia by the detection of at least 10, at least 5, or at least 4, or at least 3 and more preferably at least 2 markers whereby the markers (a) are genes and fragments thereof and/or genomic nucleic acid sequences that are located on one or more chromosomal region(s) which is/are altered in malignant neoplasia and (b) functionally interact as (i) receptor and ligand or (ii) members of the same signal transduction pathway or (iii) members of synergistic signal transduction pathways or (iv) members of antagonistic signal transduction pathways or (v) transcription factor and transcription factor binding site.

[0216] In one embodiment, the method for the prediction, diagnosis or prognosis of malignant neoplasia and breast cancer in particular is done by the detection of:

(a) polynucleotide selected from the polynucleotides of the SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19, 21 to 26 or 53 to 75;

(b) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3;

(c) a polynucleotide the sequence of which deviates from the polynucleotide specified in (a) and (b) due to the

generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3;

(d) a polynucleotide which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (c);

in a biological sample comprising the following steps: hybridizing any polynucleotide or analogous oligomer specified in (a) to (d) to a polynucleotide material of a biological sample, thereby forming a hybridization complex; and detecting said hybridization complex.

[0217] In another embodiment the method for the prediction, diagnosis or prognosis of malignant neoplasia is done as just described but, wherein before hybridization, the polynucleotide material of the biological sample is amplified.

[0218] In another embodiment the method for the diagnosis or prognosis of malignant neoplasia and breast cancer in particular is done by the detection of:

(a) a polynucleotide selected from the polynucleotides of the SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19, 21 to 26 or 53 to 75;

(b) a polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3;

(c) a polynucleotide the sequence of which deviates from the polynucleotide specified in (a) and (b) due to the generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3;

(d) a polynucleotide which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (c);

(e) a polypeptide encoded by a polynucleotide sequence specified in (a) to (d)

(f) a polypeptide comprising any polypeptide of SEQ ID NO: 28 to 32, 34, 35, 37 to 42, 44, 45, 47 to 52 or 76 to 98;

comprising the steps of contacting a biological sample with a reagent which specifically interacts with the polynucleotide specified in (a) to (d) or the polypeptide specified in (e).

DNA array technology

[0219] In one embodiment, the present invention also provides a method wherein polynucleotide probes are immobilized on a DNA chip in an organized array. Oligonucleotides can be bound to a solid support by a variety of processes, including lithography. For example a chip can hold up to 4100,00 oligonucleotides (GeneChip, Affymetrix). The present invention provides significant advantages over the available tests for malignant neoplasia, such as breast cancer, because it increases the reliability of the test by providing an array of polynucleotide markers on a single chip.

[0220] The method includes obtaining a biopsy of an affected person, which is optionally fractionated by cryostat sectioning to enrich diseased cells to about 80% of the total cell population and the use of body fluids such as serum or urine, serum or cell containing liquids (e.g. derived from fine needle aspirates). The DNA or RNA is then extracted, amplified, and analyzed with a DNA chip to determine the presence or absence of the marker polynucleotide sequences. In one embodiment, the polynucleotide probes are spotted onto a substrate in a two-dimensional matrix or array. Samples of polynucleotides can be labeled and then hybridized to the probes. Double-stranded polynucleotides, comprising the labeled sample polynucleotides bound to probe polynucleotides, can be detected once the unbound portion of the sample is washed away.

[0221] The probe polynucleotides can be spotted on substrates including glass, nitrocellulose, etc. The probes can be bound to the substrate by either covalent bonds or by non-specific interactions, such as hydrophobic interactions. The sample polynucleotides can be labeled using radioactive labels, fluorophores, chromophores, etc. Techniques for constructing arrays and methods of using these arrays are described in EP 0 799 897; WO 97/29212; WO 97/27317; EP 0 785 280; WO 97/02357; U.S. Pat. No. 5,593,839; U.S. Pat. No. 5,578,832; EP 0 728 520; U.S. Pat. No. 5,599,695; EP 0 721 016; U.S. Pat. No. 5,556,752; WO 95/22058; and U.S. Pat. No. 5,631,734.

[0222] Further, arrays can be used to examine differential expression of genes and can be used to determine gene function. For example, arrays of the instant polynucleotide sequences can be used to determine if any of the polynucleotide sequences are differentially expressed between normal cells and diseased cells, for example. High expression

of a particular message in a diseased sample, which is not observed in a corresponding normal sample, can indicate a breast cancer specific protein.

[0223] Accordingly, in one aspect, the invention provides probes and primers that are specific to the unique polynucleotide markers disclosed herein.

[0224] In one embodiment, the method comprises using a polynucleotide probe to determine the presence of malignant or breast cancer cells in particular in a tissue from a patient. Specifically, the method comprises:

1) providing a polynucleotide probe comprising a nucleotide sequence at least 12 nucleotides in length, preferably at least 15 nucleotides, more preferably, 25 nucleotides, and most preferably at least 40 nucleotides, and up to all or nearly all of the coding sequence which is complementary to a portion of the coding sequence of a polynucleotide selected from the polynucleotides of SEQ ID NO: 1 to 26 and 53 to 75 or a sequence complementary thereto and is

2) differentially expressed in malignant neoplasia, such as breast cancer;

3) obtaining a tissue sample from a patient with malignant neoplasia;

4) providing a second tissue sample from a patient with no malignant neoplasia;

5) contacting the polynucleotide probe under stringent conditions with RNA of each of said first and second tissue samples (e.g., in a Northern blot or in situ hybridization assay); and

6) comparing (a) the amount of hybridization of the probe with RNA of the first tissue sample, with (b) the amount of hybridization of the probe with RNA of the second tissue sample;

wherein a statistically significant difference in the amount of hybridization with the RNA of the first tissue sample as compared to the amount of hybridization with the RNA of the second tissue sample is indicative of malignant neoplasia and breast cancer in particular in the first tissue sample.

Data analysis methods

[0225] Comparison of the expression levels of one or more "BREAST CANCER GENES" with reference expression levels, e.g., expression levels in diseased cells of breast cancer or in normal counterpart cells, is preferably conducted using computer systems. In one embodiment, expression levels are obtained in two cells and these two sets of expression levels are introduced into a computer system for comparison. In a preferred embodiment, one set of expression levels is entered into a computer system for comparison with values that are already present in the computer system, or in computer-readable form that is then entered into the computer system.

[0226] In one embodiment, the invention provides a computer readable form of the gene expression profile data of the invention, or of values corresponding to the level of expression of at least one "BREAST CANCER GENE" in a diseased cell. The values can be mRNA expression levels obtained from experiments, e.g., microarray analysis. The values can also be mRNA levels normalised relative to a reference gene whose expression is constant in numerous cells under numerous conditions, e.g., GAPDH. In other embodiments, the values in the computer are ratios of, or differences between, normalized or non-normalized mRNA levels in different samples.

[0227] The gene expression profile data can be in the form of a table, such as an Excel table. The data can be alone, or it can be part of a larger database, e.g., comprising other expression profiles. For example, the expression profile data of the invention can be part of a public database. The computer readable form can be in a computer. In another embodiment, the invention provides a computer displaying the gene expression profile data.

[0228] In one embodiment, the invention provides a method for determining the similarity between the level of expression of one or more "BREAST CANCER GENES" in a first cell, e.g., a cell of a subject, and that in a second cell, comprising obtaining the level of expression of one or more "BREAST CANCER GENES" in a first cell and entering these values into a computer comprising a database including records comprising values corresponding to levels of expression of one or more "BREAST CANCER GENES" in a second cell, and processor instructions, e.g., a user interface, capable of receiving a selection of one or more values for comparison purposes with data that is stored in the computer. The computer may further comprise a means for converting the comparison data into a diagram or chart or other type of output.

[0229] In another embodiment, values representing expression levels of "BREAST CANCER GENES" are entered into a computer system, comprising one or more databases with reference expression levels obtained from more than one cell. For example, the computer comprises expression data of diseased and normal cells. Instructions are provided to the computer, and the computer is capable of comparing the data entered with the data in the computer to determine

whether the data entered is more similar to that of a normal cell or of a diseased cell.

[0230] In another embodiment, the computer comprises values of expression levels in cells of subjects at different stages of breast cancer, and the computer is capable of comparing expression data entered into the computer with the data stored, and produce results indicating to which of the expression profiles in the computer, the one entered is most similar, such as to determine the stage of breast cancer in the subject.

[0231] In yet another embodiment, the reference expression profiles in the computer are expression profiles from cells of breast cancer of one or more subjects, which cells are treated *in vivo* or *in vitro* with a drug used for therapy of breast cancer. Upon entering of expression data of a cell of a subject treated *in vitro* or *in vivo* with the drug, the computer is instructed to compare the data entered to the data in the computer, and to provide results indicating whether the expression data input into the computer are more similar to those of a cell of a subject that is responsive to the drug or more similar to those of a cell of a subject that is not responsive to the drug. Thus, the results indicate whether the subject is likely to respond to the treatment with the drug or unlikely to respond to it.

[0232] In one embodiment, the invention provides a system that comprises a means for receiving gene expression data for one or a plurality of genes; a means for comparing the gene expression data from each of said one or plurality of genes to a common reference frame; and a means for presenting the results of the comparison. This system may further comprise a means for clustering the data.

[0233] In another embodiment, the invention provides a computer program for analyzing gene expression data comprising (i) a computer code that receives as input gene expression data for a plurality of genes and (ii) a computer code that compares said gene expression data from each of said plurality of genes to a common reference frame.

[0234] The invention also provides a machine-readable or computer-readable medium including program instructions for performing the following steps: (i) comparing a plurality of values corresponding to expression levels of one or more genes characteristic of breast cancer in a query cell with a database including records comprising reference expression or expression profile data of one or more reference cells and an annotation of the type of cell; and (ii) indicating to which cell the query cell is most similar based on similarities of expression profiles. The reference cells can be cells from subjects at different stages of breast cancer. The reference cells can also be cells from subjects responding or not responding to a particular drug treatment and optionally incubated *in vitro* or *in vivo* with the drug.

[0235] The reference cells may also be cells from subjects responding or not responding to several different treatments, and the computer system indicates a preferred treatment for the subject. Accordingly, the invention provides a method for selecting a therapy for a patient having breast cancer, the method comprising: (i) providing the level of expression of one or more genes characteristic of breast cancer in a diseased cell of the patient; (ii) providing a plurality of reference profiles, each associated with a therapy, wherein the subject expression profile and each reference profile has a plurality of values, each value representing the level of expression of a gene characteristic of breast cancer; and (iii) selecting the reference profile most similar to the subject expression profile, to thereby select a therapy for said patient. In a preferred embodiment step (iii) is performed by a computer. The most similar reference profile may be selected by weighing a comparison value of the plurality using a weight value associated with the corresponding expression data.

[0236] The relative abundance of an mRNA in two biological samples can be scored as a perturbation and its magnitude determined (i.e., the abundance is different in the two sources of mRNA tested), or as not perturbed (i.e., the relative abundance is the same). In various embodiments, a difference between the two sources of RNA of at least a factor of about 25% (RNA from one source is 25% more abundant in one source than the other source), more usually about 50%, even more often by a factor of about 2 (twice as abundant), 3 (three times as abundant) or 5 (five times as abundant) is scored as a perturbation. Perturbations can be used by a computer for calculating and expression comparisons.

[0237] Preferably, in addition to identifying a perturbation as positive or negative, it is advantageous to determine the magnitude of the perturbation. This can be carried out, as noted above, by calculating the ratio of the emission of the two fluorophores used for differential labeling, or by analogous methods that will be readily apparent to those of skill in the art.

[0238] The computer readable medium may further comprise a pointer to a descriptor of a stage of breast cancer or to a treatment for breast cancer.

[0239] In operation, the means for receiving gene expression data, the means for comparing the gene expression data, the means for presenting, the means for normalizing, and the means for clustering within the context of the systems of the present invention can involve a programmed computer with the respective functionalities described herein, implemented in hardware or hardware and software; a logic circuit or other component of a programmed computer that performs the operations specifically identified herein, dictated by a computer program; or a computer memory encoded with executable instructions representing a computer program that can cause a computer to function in the particular fashion described herein.

[0240] Those skilled in the art will understand that the systems and methods of the present invention may be applied to a variety of systems, including IBM-compatible personal computers running MS-DOS or Microsoft Windows.

[0241] The computer may have internal components linked to external components. The internal components may include a processor element interconnected with a main memory. The computer system can be an Intel Pentium®-based processor of 200 MHz or greater clock rate and with 32 MB or more of main memory. The external component may comprise a mass storage, which can be one or more hard disks (which are typically packaged together with the processor and memory). Such hard disks are typically of 1 GB or greater storage capacity. Other external components include a user interface device, which can be a monitor, together with an inputting device, which can be a "mouse", or other graphic input devices, and/or a keyboard. A printing device can also be attached to the computer.

[0242] Typically, the computer system is also linked to a network link, which can be part of an Ethernet link to other local computer systems, remote computer systems, or wide area communication networks, such as the Internet. This network link allows the computer system to share data and processing tasks with other computer systems.

[0243] Loaded into memory during operation of this system are several software components, which are both standard in the art and special to the instant invention. These software components collectively cause the computer system to function according to the methods of this invention. These software components are typically stored on a mass storage. A software component represents the operating system, which is responsible for managing the computer system and its network interconnections. This operating system can be, for example, of the Microsoft Windows' family, such as Windows 95, Windows 98, or Windows NT. A software component represents common languages and functions conveniently present on this system to assist programs implementing the methods specific to this invention. Many high or low level computer languages can be used to program the analytic methods of this invention. Instructions can be interpreted during run-time or compiled. Preferred languages include C/C++, and JAVA®. Most preferably, the methods of this invention are programmed in mathematical software packages which allow symbolic entry of equations and high-level specification of processing, including algorithms to be used, thereby freeing a user of the need to procedurally program individual equations or algorithms. Such packages include Matlab from Mathworks (Natick, Mass.), Mathematica from Wolfram Research (Champaign, Ill.), or S-Plus from Math Soft (Cambridge, Mass.). Accordingly, a software component represents the analytic methods of this invention as programmed in a procedural language or symbolic package. In a preferred embodiment, the computer system also contains a database comprising values representing levels of expression of one or more genes characteristic of breast cancer. The database may contain one or more expression profiles of genes characteristic of breast cancer in different cells.

[0244] In an exemplary implementation, to practice the methods of the present invention, a user first loads expression profile data into the computer system. These data can be directly entered by the user from a monitor and keyboard, or from other computer systems linked by a network connection, or on removable storage media such as a CD-ROM or floppy disk or through the network. Next the user causes execution of expression profile analysis software which performs the steps of comparing and, e.g., clustering co-varying genes into groups of genes.

[0245] In another exemplary implementation, expression profiles are compared using a method described in U.S. Patent No. 6,203,987. A user first loads expression profile data into the computer system. Geneset profile definitions are loaded into the memory from the storage media or from a remote computer, preferably from a dynamic geneset database system, through the network. Next the user causes execution of projection software which performs the steps of converting expression profile to projected expression profiles. The projected expression profiles are then displayed.

[0246] In yet another exemplary implementation, a user first loads a projected profile into the memory. The user then causes the loading of a reference profile into the memory. Next, the user causes the execution of comparison software which performs the steps of objectively comparing the profiles.

Detection of variant polynucleotide sequence

[0247] In yet another embodiment, the invention provides methods for determining whether a subject is at risk for developing a disease, such as a predisposition to develop malignant neoplasia, for example breast cancer, associated with an aberrant activity of any one of the polypeptides encoded by any of the polynucleotides of the SEQ ID NO: 1 to 26 or 53 to 75, wherein the aberrant activity of the polypeptide is characterized by detecting the presence or absence of a genetic lesion characterized by at least one of these:

- (i) an alteration affecting the integrity of a gene encoding a marker polypeptides, or
- (ii) the misexpression of the encoding polynucleotide.

[0248] To illustrate, such genetic lesions can be detected by ascertaining the existence of at least one of these:

- I. a deletion of one or more nucleotides from the polynucleotide sequence
- II. an addition of one or more nucleotides to the polynucleotide sequence

III. a substitution of one or more nucleotides of the polynucleotide sequence

IV. a gross chromosomal rearrangement of the polynucleotide sequence

V. a gross alteration in the level of a messenger RNA transcript of the polynucleotide sequence

VI. aberrant modification of the polynucleotide sequence, such as of the methylation pattern of the genomic DNA

VII. the presence of a non-wild type splicing pattern of a messenger RNA transcript of the gene

VIII. a non-wild type level of the marker polypeptide

IX. allelic loss of the gene

X. allelic gain of the gene

XI. inappropriate post-translational modification of the marker polypeptide

[0249] The present invention provides assay techniques for detecting mutations in the encoding polynucleotide sequence. These methods include, but are not limited to, methods involving sequence analysis, Southern blot hybridization, restriction enzyme site mapping, and methods involving detection of absence of nucleotide pairing between the polynucleotide to be analyzed and a probe.

[0250] Specific diseases or disorders, e.g., genetic diseases or disorders, are associated with specific allelic variants of polymorphic regions of certain genes, which do not necessarily encode a mutated protein. Thus, the presence of a specific allelic variant of a polymorphic region of a gene in a subject can render the subject susceptible to developing a specific disease or disorder. Polymorphic regions in genes, can be identified, by determining the nucleotide sequence of genes in populations of individuals. If a polymorphic region is identified, then the link with a specific disease can be determined by studying specific populations of individuals, e.g. individuals which developed a specific disease, such as breast cancer. A polymorphic region can be located in any region of a gene, e.g., exons, in coding or non coding regions of exons, introns, and promoter region.

[0251] In an exemplary embodiment, there is provided a polynucleotide composition comprising a polynucleotide probe including a region of nucleotide sequence which is capable of hybridising to a sense or antisense sequence of a gene or naturally occurring mutants thereof, or 5' or 3' flanking sequences or intronic sequences naturally associated with the subject genes or naturally occurring mutants thereof. The polynucleotide of a cell is rendered accessible for hybridization, the probe is contacted with the polynucleotide of the sample, and the hybridization of the probe to the sample polynucleotide is detected. Such techniques can be used to detect lesions or allelic variants at either the genomic or mRNA level, including deletions, substitutions, etc., as well as to determine mRNA transcript levels.

[0252] A preferred detection method is allele specific hybridization using probes overlapping the mutation or polymorphic site and having about 5, 10, 20, 25, or 30 nucleotides around the mutation or polymorphic region. In a preferred embodiment of the invention, several probes capable of hybridising specifically to allelic variants are attached to a solid phase support, e.g., a "chip". Mutation detection analysis using these chips comprising oligonucleotides, also termed "DNA probe arrays" is described e.g., in Cronin et al. (119). In one embodiment, a chip comprises all the allelic variants of at least one polymorphic region of a gene. The solid phase support is then contacted with a test polynucleotide and hybridization to the specific probes is detected. Accordingly, the identity of numerous allelic variants of one or more genes can be identified in a simple hybridization experiment.

[0253] In certain embodiments, detection of the lesion comprises utilizing the probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligase chain reaction (LCR) [Landegran et al., 1988, (120) and Nakazawa et al., 1994 (121)], the latter of which can be particularly useful for detecting point mutations in the gene; Abravaya et al., 1995, (122)]. In a merely illustrative embodiment, the method includes the steps of (i) collecting a sample of cells from a patient, (ii) isolating polynucleotide (e.g., genomic, mRNA or both) from the cells of the sample, (iii) contacting the polynucleotide sample with one or more primers which specifically hybridize to a polynucleotide sequence under conditions such that hybridization and amplification of the polynucleotide (if present) occurs, and (iv) detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

[0254] Alternative amplification methods include: self sustained sequence replication [Guatelli, J.C. et al., 1990, (123)], transcriptional amplification system [Kwoh, D.Y. et al., 1989, (124)], Q-Beta replicase [Lizardi, P.M. et al., 1988,

(125)], or any other polynucleotide amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of polynucleotide molecules if such molecules are present in very low numbers.

[0255] In a preferred embodiment of the subject assay, mutations in, or allelic variants, of a gene from a sample cell are identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis. Moreover, the use of sequence specific ribozymes (see, for example, U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In situ hybridization

[0256] In one aspect, the method comprises *in situ* hybridization with a probe derived from a given marker polynucleotide, which sequence is selected from any of the polynucleotide sequences of the SEQ ID NO: 1 to 9, or 11 to 19 or 21 to 26 and 53 to 75 or a sequence complementary thereto. The method comprises contacting the labeled hybridization probe with a sample of a given type of tissue from a patient potentially having malignant neoplasia and breast cancer in particular as well as normal tissue from a person with no malignant neoplasia, and determining whether the probe labels tissue of the patient to a degree significantly different (e.g., by at least a factor of two, or at least a factor of five, or at least a factor of twenty, or at least a factor of fifty) than the degree to which normal tissue is labelled.

Polypeptide detection

[0257] The subject invention further provides a method of determining whether a cell sample obtained from a subject possesses an abnormal amount of marker polypeptide which comprises (a) obtaining a cell sample from the subject, (b) quantitatively determining the amount of the marker polypeptide in the sample so obtained, and (c) comparing the amount of the marker polypeptide so determined with a known standard, so as to thereby determine whether the cell sample obtained from the subject possesses an abnormal amount of the marker polypeptide. Such marker polypeptides may be detected by immunohistochemical assays, dot-blot assays, ELISA and the like.

Antibodies

[0258] Any type of antibody known in the art can be generated to bind specifically to an epitope of a "BREAST CANCER GENE" polypeptide. An antibody as used herein includes intact immunoglobulin molecules, as well as fragments thereof, such as Fab, F(ab)₂, and Fv, which are capable of binding an epitope of a "BREAST CANCER GENE" polypeptide. Typically, at least 6, 8, 10, or 12 contiguous amino acids are required to form an epitope. However, epitopes which involve non-contiguous amino acids may require more, e.g., at least 15, 25, or 50 amino acids.

[0259] An antibody which specifically binds to an epitope of a "BREAST CANCER GENE" polypeptide can be used therapeutically, as well as in immunochemical assays, such as Western blots, ELISAs, radioimmunoassays, immunohistochemical assays, immunoprecipitations, or other immunochemical assays known in the art. Various immunoassays can be used to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays are well known in the art. Such immunoassays typically involve the measurement of complex formation between an immunogen and an antibody which specifically binds to the immunogen.

[0260] Typically, an antibody which specifically binds to a "BREAST CANCER GENE" polypeptide provides a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in an immunochemical assay. Preferably, antibodies which specifically bind to "BREAST CANCER GENE" polypeptides do not detect other proteins in immunochemical assays and can immunoprecipitate a "BREAST CANCER GENE" polypeptide from solution.

[0261] "BREAST CANCER GENE" polypeptides can be used to immunize a mammal, such as a mouse, rat, rabbit, guinea pig, monkey, or human, to produce polyclonal antibodies. If desired, a "BREAST CANCER GENE" polypeptide can be conjugated to a carrier protein, such as bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin. Depending on the host species, various adjuvants can be used to increase the immunological response. Such adjuvants include, but are not limited to, Freund's adjuvant, mineral gels (e.g., aluminum hydroxide), and surface active substances (e.g. lysolécithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol). Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and *Corynebacterium parvum* are especially useful.

[0262] Monoclonal antibodies which specifically bind to a "BREAST CANCER GENE" polypeptide can be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These techniques include, but are not limited to, the hybridoma technique, the human B cell hybridoma technique, and the EBV hybridoma technique [Kohler et al., 1985, (136); Kozbor et al., 1985, (137); Cote et al., 1983, (138) and Cole et

al., 1984, (139)].

[0263] In addition, techniques developed for the production of chimeric antibodies, the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used [Morrison et al., 1984, (140); Neuberger et al., 1984, (141); Takeda et al., 1985, (142)]. Monoclonal and other antibodies also can be humanized to prevent a patient from mounting an immune response against the antibody when it is used therapeutically. Such antibodies may be sufficiently similar in sequence to human antibodies to be used directly in therapy or may require alteration of a few key residues. Sequence differences between rodent antibodies and human sequences can be minimized by replacing residues which differ from those in the human sequences by site directed mutagenesis of individual residues or by grating of entire complementarity determining regions. Alternatively, humanized antibodies can be produced using recombinant methods, as described in GB2188638B. Antibodies which specifically bind to a "BREAST CANCER GENE" polypeptide can contain antigen binding sites which are either partially or fully humanized, as disclosed in U.S. Patent 5,565,332.

[0264] Alternatively, techniques described for the production of single chain antibodies can be adapted using methods known in the art to produce single chain antibodies which specifically bind to "BREAST CANCER GENE" polypeptides. Antibodies with related specificity, but of distinct idiotypic composition, can be generated by chain shuffling from random combinatorial immunoglobulin libraries [Burton, 1991, (143)].

[0265] Single-chain antibodies also can be constructed using a DNA amplification method, such as PCR, using hybridoma cDNA as a template [Thirion et al., 1996, (144)]. Single-chain antibodies can be mono- or bispecific, and can be bivalent or tetravalent. Construction of tetravalent, bispecific single-chain antibodies is taught, for example, in Coloma & Morrison, (145). Construction of bivalent, bispecific single-chain antibodies is taught in Mallender & Voss, (146).

[0266] A nucleotide sequence encoding a single-chain antibody can be constructed using manual or automated nucleotide synthesis, cloned into an expression construct using standard recombinant DNA methods, and introduced into a cell to express the coding sequence, as described below. Alternatively, single-chain antibodies can be produced directly using, for example, filamentous phage technology [Verhaar et al., 1995, (147); Nicholls et al., 1993, (148)].

[0267] Antibodies which specifically bind to "BREAST CANCER GENE" polypeptides also can be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature [Orlandi et al., 1989, (149) and Winter et al., 1991, (150)].

[0268] Other types of antibodies can be constructed and used therapeutically in methods of the invention. For example, chimeric antibodies can be constructed as disclosed in WO 93/03151. Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the antibodies described in WO 94/13804, also can be prepared.

[0269] Antibodies according to the invention can be purified by methods well known in the art. For example, antibodies can be affinity purified by passage over a column to which a "BREAST CANCER GENE" polypeptide is bound. The bound antibodies can then be eluted from the column using a buffer with a high salt concentration.

[0270] Immunoassays are commonly used to quantify the levels of proteins in cell samples, and many other immunoassay techniques are known in the art. The invention is not limited to a particular assay procedure, and therefore is intended to include both homogeneous and heterogeneous procedures. Exemplary immunoassays which can be conducted according to the invention include fluorescence polarisation immunoassay (FPIA), fluorescence immunoassay (FIA), enzyme immunoassay (EIA), nephelometric inhibition immunoassay (NIA), enzyme linked immunosorbent assay (ELISA), and radioimmunoassay (RIA). An indicator moiety, or label group, can be attached to the subject antibodies and is selected so as to meet the needs of various uses of the method which are often dictated by the availability of assay equipment and compatible immunoassay procedures. General techniques to be used in performing the various immunoassays noted above are known to those of ordinary skill in the art.

[0271] In another embodiment, the level of at least one product encoded by any of the polynucleotide sequences of the SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19 or 21 to 26 or 53 to 75 or of at least 2 products encoded by a polynucleotide selected from SEQ ID NO: 1 to 26 and 53 to 75 or a sequence complementary thereto, in a biological fluid (e.g., blood or urine) of a patient may be determined as a way of monitoring the level of expression of the marker polynucleotide sequence in cells of that patient. Such a method would include the steps of obtaining a sample of a biological fluid from the patient, contacting the sample (or proteins from the sample) with an antibody specific for a encoded marker polypeptide, and determining the amount of immune complex formation by the antibody, with the amount of immune complex formation being indicative of the level of the marker encoded product in the sample. This determination is particularly instructive when compared to the amount of immune complex formation by the same antibody in a control sample taken from a normal individual or in one or more samples previously or subsequently obtained from the same person.

[0272] In another embodiment, the method can be used to determine the amount of marker polypeptide present in a cell, which in turn can be correlated with progression of the disorder, e.g., plaque formation. The level of the marker polypeptide can be used predictively to evaluate whether a sample of cells contains cells which are, or are predisposed

towards becoming, plaque associated cells. The observation of marker polypeptide level can be utilized in decisions regarding, e.g., the use of more stringent therapies.

[0273] As set out above, one aspect of the present invention relates to diagnostic assays for determining, in the context of cells isolated from a patient, if the level of a marker polypeptide is significantly reduced in the sample cells. The term "significantly reduced" refers to a cell phenotype wherein the cell possesses a reduced cellular amount of the marker polypeptide relative to a normal cell of similar tissue origin. For example, a cell may have less than about 50%, 25%, 10%, or 5% of the marker polypeptide that a normal control cell. In particular, the assay evaluates the level of marker polypeptide in the test cells, and, preferably, compares the measured level with marker polypeptide detected in at least one control cell, e.g., a normal cell and/or a transformed cell of known phenotype.

[0274] Of particular importance to the subject invention is the ability to quantify the level of marker polypeptide as determined by the number of cells associated with a normal or abnormal marker polypeptide level. The number of cells with a particular marker polypeptide phenotype may then be correlated with patient prognosis. In one embodiment of the invention, the marker polypeptide phenotype of the lesion is determined as a percentage of cells in a biopsy which are found to have abnormally high/low levels of the marker polypeptide. Such expression may be detected by immunohistochemical assays, dot-blot assays, ELISA and the like.

Immunohistochemistry

[0275] Where tissue samples are employed, immunohistochemical staining may be used to determine the number of cells having the marker polypeptide phenotype. For such staining, a multiblock of tissue is taken from the biopsy or other tissue sample and subjected to proteolytic hydrolysis, employing such agents as protease K or pepsin. In certain embodiments, it may be desirable to isolate a nuclear fraction from the sample cells and detect the level of the marker polypeptide in the nuclear fraction.

[0276] The tissues samples are fixed by treatment with a reagent such as formalin, glutaraldehyde, methanol, or the like. The samples are then incubated with an antibody, preferably a monoclonal antibody, with binding specificity for the marker polypeptides. This antibody may be conjugated to a Label for subsequent detection of binding. samples are incubated for a time sufficient for formation of the immuno-complexes. Binding of the antibody is then detected by virtue of a Label conjugated to this antibody. Where the antibody is unlabelled, a second labeled antibody may be employed, e.g., which is specific for the isotype of the anti-marker polypeptide antibody. Examples of labels which may be employed include radionuclides, fluorescence, chemiluminescence, and enzymes.

[0277] Where enzymes are employed, the Substrate for the enzyme may be added to the samples to provide a colored or fluorescent product. Examples of suitable enzymes for use in conjugates include horseradish peroxidase, alkaline phosphatase, malate dehydrogenase and the like. Where not commercially available, such antibody-enzyme conjugates are readily produced by techniques known to those skilled in the art.

[0278] In one embodiment, the assay is performed as a dot blot assay. The dot blot assay finds particular application where tissue samples are employed as it allows determination of the average amount of the marker polypeptide associated with a Single cell by correlating the amount of marker polypeptide in a cell-free extract produced from a predetermined number of cells.

[0279] In yet another embodiment, the invention contemplates using one or more antibodies which are generated against one or more of the marker polypeptides of this invention, which polypeptides are encoded by any of the polynucleotide sequences of the SEQ ID NO: 1 to 26 or 53 to 75. Such a panel of antibodies may be used as a reliable diagnostic probe for breast cancer. The assay of the present invention comprises contacting a biopsy sample containing cells, e.g., macrophages, with a panel of antibodies to one or more of the encoded products to determine the presence or absence of the marker polypeptides.

[0280] The diagnostic methods of the subject invention may also be employed as follow-up to treatment, e.g., quantification of the level of marker polypeptides may be indicative of the effectiveness of current or previously employed therapies for malignant neoplasia and breast cancer in particular as well as the effect of these therapies upon patient prognosis.

[0281] The diagnostic assays described above can be adapted to be used as prognostic assays, as well. Such an application takes advantage of the sensitivity of the assays of the invention to events which take place at characteristic stages in the progression of plaque generation in case of malignant neoplasia. For example, a given marker gene may be up- or down-regulated at a very early stage, perhaps before the cell is developing into a foam cell, while another marker gene may be characteristically up or down regulated only at a much later stage. Such a method could involve the steps of contacting the mRNA of a test cell with a polynucleotide probe derived from a given marker polynucleotide which is expressed at different characteristic levels in breast cancer tissue cells at different stages of malignant neoplasia progression, and determining the approximate amount of hybridization of the probe to the mRNA of the cell, such amount being an indication of the level of expression of the gene in the cell, and thus an indication of the stage of disease progression of the cell; alternatively, the assay can be carried out with an antibody specific for the gene

product of the given marker polynucleotide, contacted with the proteins of the test cell. A battery of such tests will disclose not only the existence of a certain arteriosclerotic plaque, but also will allow the clinician to select the mode of treatment most appropriate for the disease, and to predict the likelihood of success of that treatment.

[0282] The methods of the invention can also be used to follow the clinical course of a given breast cancer predisposition. For example, the assay of the invention can be applied to a blood sample from a patient; following treatment of the patient for BREAST CANCER, another blood sample is taken and the test repeated. Successful treatment will result in removal of demonstrate differential expression, characteristic of the breast cancer tissue cells, perhaps approaching or even surpassing normal levels.

Polypeptide activity

[0283] In one embodiment the present invention provides a method for screening potentially therapeutic agents which modulate the activity of one or more "BREAST CANCER GENE" polypeptides, such that if the activity of the polypeptide is increased as a result of the upregulation of the "BREAST CANCER GENE" in a subject having or at risk for malignant neoplasia and breast cancer in particular, the therapeutic substance will decrease the activity of the polypeptide relative to the activity of the same polypeptide in a subject not having or not at risk for malignant neoplasia or breast cancer in particular but not treated with the therapeutic agent. Likewise, if the activity of the polypeptide as a result of the downregulation of the "BREAST CANCER GENE" is decreased in a subject having or at risk for malignant neoplasia or breast cancer in particular, the therapeutic agent will increase the activity of the polypeptide relative to the activity of the same polypeptide in a subject not having or not at risk for malignant neoplasia or breast cancer in particular, but not treated with the therapeutic agent.

[0284] The activity of the "BREAST CANCER GENE" polypeptides indicated in Table 2 or 3 may be measured by any means known to those of skill in the art, and which are particular for the type of activity performed by the particular polypeptide. Examples of specific assays which may be used to measure the activity of particular polynucleotides are shown below.

a) G protein coupled receptors

[0285] In one embodiment, the "BREAST CANCER GENE" polynucleotide may encode a G protein coupled receptor. In one embodiment, the present invention provides a method of screening potential modulators (inhibitors or activators) of the G protein coupled receptor by measuring changes in the activity of the receptor in the presence of a candidate modulator.

1. G_i-coupled receptors

[0286] Cells (such as CHO cells or primary cells) are stably transfected with the relevant receptor and with an inducible CRE-luciferase construct. Cells are grown in 50% Dulbecco's modified Eagle medium / 50% F12 (DMEM/F12) supplemented with 10% FBS, at 37°C in a humidified atmosphere with 10% CO₂ and are routinely split at a ratio of 1:10 every 2 or 3 days. Test cultures are seeded into 384 - well plates at an appropriate density (e.g. 2000 cells / well in 35 µl cell culture medium) in DMEM/F12 with FBS, and are grown for 48 hours (range: ~ 24 - 60 hours, depending on cell line). Growth medium is then exchanged against serum free medium (SFM; e.g. Ultra-CHO), containing 0,1% BSA. Test compounds dissolved in DMSO are diluted in SFM and transferred to the test cultures (maximal final concentration 10 µmolar), followed by addition of forskolin (~ 1 µmolar, final conc.) in SFM + 0,1% BSA 10 minutes later. In case of antagonist screening both, an appropriate concentration of agonist, and forskolin are added. The plates are incubated at 37°C in 10% CO₂ for 3 hours. Then the supernatant is removed, cells are lysed with lysis reagent (25 mmolar phosphate-buffer, pH 7,8, containing 2 mmolar DDT, 10% glycerol and 3% Triton X100). The luciferase reaction is started by addition of substrate-buffer (e.g. luciferase assay reagent, Promega) and luminescence is immediately determined (e.g. Berthold luminometer or Hamamatsu camera system).

2. G_s-coupled receptors

[0287] Cells (such as CHO cells or primary cells) are stably transfected with the relevant receptor and with an inducible CRE-luciferase construct. Cells are grown in 50% Dulbecco's modified Eagle medium / 50% F12 (DMEM/F12) supplemented with 10% FBS, at 37°C in a humidified atmosphere with 10% CO₂ and are routinely split at a ratio of 1:10 every 2 or 3 days. Test cultures are seeded into 384 - well plates at an appropriate density (e.g. 1000 or 2000 cells / well in 35 µl cell culture medium) in DMEM/F12 with FBS, and are grown for 48 hours (range: ~ 24 - 60 hours, depending on cell line). The assay is started by addition of test-compounds in serum free medium (SFM; e.g. Ultra-CHO) containing 0,1% BSA: Test compounds are dissolved in DMSO, diluted in SFM and transferred to the test cultures (maximal final

concentration 10 μ molar, DMSO conc. < 0,6 %). In case of antagonist screening an appropriate concentration of agonist is added 5 - 10 minutes later. The plates are incubated at 37°C in 10% CO₂ for 3 hours. Then the cells are lysed with 10 μ l lysis reagent per well (25 mmolar phosphate-buffer, pH 7,8, containing 2 mmolar DDT, 10% glycerol and 3% Triton X100) and the luciferase reaction is started by addition of 20 μ l substrate-buffer per well (e.g. luciferase assay reagent, Promega). Measurement of luminescence is started immediately (e.g. Berthold luminometer or Hamamatsu camera system).

3. G_q-coupled receptors

[0288] Cells (such as CHO cells or primary cells) are stably transfected with the relevant receptor. Cells expressing functional receptor protein are grown in 50% Dulbecco's modified Eagle medium / 50% F12 (DMEM/F12) supplemented with 10% FBS, at 37°C in a humidified atmosphere with 5% CO₂ and are routinely split at a cell line dependent ratio every 3 or 4 days. Test cultures are seeded into 384 - well plates at an appropriate density (e.g. 2000 cells / well in 35 μ l cell culture medium) in DMEM/F12 with FBS, and are grown for 48 hours (range: ~ 24 - 60 hours, depending on cell line). Growth medium is then exchanged against physiological salt solution (e.g. Tyrode solution). Test compounds dissolved in DMSO are diluted in Tyrode solution containing 0.1% BSA and transferred to the test cultures (maximal final concentration 10 molar). After addition of the receptor specific agonist the resulting G_q-mediated intracellular calcium increase is measured using appropriate read-out systems (e.g. calcium-sensitive dyes).

b) Ion channels

[0289] Ion channels are integral membrane proteins involved in electrical signaling, transmembrane signal transduction, and electrolyte and solute transport. By forming macromolecular pores through the membrane lipid bilayer, ion channels account for the flow of specific ion species driven by the electrochemical potential gradient for the permeating ion. At the single molecule level, individual channels undergo conformational transitions ("gating") between the 'open' (ion conducting) and 'closed' (non conducting) state. Typical single channel openings last for a few milliseconds and result in elementary transmembrane currents in the range of 10⁻⁹ - 10⁻¹² Ampere. Channel gating is controlled by various chemical and/or biophysical parameters, such as neurotransmitters and intracellular second messengers ('ligand-gated' channels) or membrane potential ('voltage-gated' channels). Ion channels are functionally characterized by their ion selectivity, gating properties, and regulation by hormones and pharmacological agents. Because of their central role in signaling and transport processes, ion channels present ideal targets for pharmacological therapeutics in various pathophysiological settings.

[0290] In one embodiment, the "BREAST CANCER GENE" may encode an ion channel. In one embodiment, the present invention provides a method of screening potential activators or inhibitors of channels activity of the "BREAST CANCER GENE" polypeptide. Screening for compounds interaction with ion channels to either inhibit or promote their activity can be based on (1.) binding and (2.) functional assays in living cells [Hille (1983)].

1. For ligand-gated channels, e.g. ionotropic neurotransmitter/hormone receptors, assays can be designed detecting binding to the target by competition between the compound and a labeled ligand.

2. Ion channel function can be tested functionally in living cells. Target proteins are either expressed endogenously in appropriate reporter cells or are introduced recombinantly. Channel activity can be monitored by (2.1) concentration changes of the permeating ion (most prominently Ca²⁺ ions), (2.2) by changes in the transmembrane electrical potential gradient, and (2.3) by measuring a cellular response (e.g. expression of a reporter gene, secretion of a neurotransmitter) triggered or modulated by the target activity.

2.1 Channel activity results in transmembrane ion fluxes. Thus activation of ionic channels can be monitored by the resulting changes in intracellular ion concentrations using luminescent or fluorescent indicators. Because of its wide dynamic range and availability of suitable indicators this applies particularly to changes in intracellular Ca²⁺ ion concentration ([Ca²⁺]_i). [Ca²⁺]_i can be measured, for example, by aequorin luminescence or fluorescence dye technology (e.g. using Fluo-3, Indo-1, Fura-2). Cellular assays can be designed where either the Ca²⁺ flux through the target channel itself is measured directly or where modulation of the target channel affects membrane potential and thereby the activity of co-expressed voltage-gated Ca²⁺ channels.

2.2 Ion channel currents result in changes of electrical membrane potential (V_m) which can be monitored directly using potentiometric fluorescent probes. These electrically charged indicators (e.g. the anionic oxonol dye DiBAC₄(3)) redistribute between extra- and intracellular compartment in response to voltage changes. The equilibrium distribution is governed by the Nernst-equation. Thus changes in membrane potential results

in concomitant changes in cellular fluorescence. Again, changes in V_m might be caused directly by the activity of the target ion channel or through amplification and/or prolongation of the signal by channels co-expressed in the same cell.

2.3 Target channel activity can cause cellular Ca^{2+} entry either directly or through activation of additional Ca^{2+} channel (see 2.1). The resulting intracellular Ca^{2+} signals regulate a variety of cellular responses, e.g. secretion or gene transcription. Therefore modulation of the target channel can be detected by monitoring secretion of a known hormone/transmitter from the target-expressing cell or through expression of a reporter gene (e.g. luciferase) controlled by an Ca^{2+} -responsive promoter element (e.g. cyclic AMP/ Ca^{2+} -responsive elements; CRE).

c) DNA-binding proteins and transcription factors

[0291] In one embodiment, the "BREAST CANCER GENE" may encode a DNA-binding protein or a transcription factor. The activity of such a DNA-binding protein or a transcription factor may be measured, for example, by a promoter assay which measures the ability of the DNA-binding protein or the transcription factor to initiate transcription of a test sequence linked to a particular promoter. In one embodiment, the present invention provides a method of screening test compounds for its ability to modulate the activity of such a DNA-binding protein or a transcription factor by measuring the changes in the expression of a test gene which is regulated by a promoter which is responsive to the transcription factor.

d) Promotor assays

[0292] A promoter assay was set up with a human hepatocellular carcinoma cell HepG2 that was stably transfected with a luciferase gene under the control of a gene of interest (e.g. thyroid hormone) regulated promoter. The vector 2xIOLuc, which was used for transfection, carries a thyroid hormone responsive element (TRE) of two 12 bp inverted palindromes separated by an 8 bp spacer in front of a tk minimal promoter and the luciferase gene. Test cultures were seeded in 96 well plates in serum - free Eagle's Minimal Essential Medium supplemented with glutamine, tricine, sodium pyruvate, non - essential amino acids, insulin, selen, transferrin, and were cultivated in a humidified atmosphere at 10 % CO_2 at 37°C. After 48 hours of incubation serial dilutions of test compounds or reference compounds (L-T3, L-T4 e.g.) and co-stimulator if appropriate (final concentration 1 nM) were added to the cell cultures and incubation was continued for the optimal time (e.g. another 4-72 hours). The cells were then lysed by addition of buffer containing Triton X100 and luciferin and the luminescence of luciferase induced by T3 or other compounds was measured in a luminometer. For each concentration of a test compound replicates of 4 were tested. EC_{50} values for each test compound were calculated by use of the Graph Pad Prism Scientific software.

Screening Methods

[0293] The invention provides assays for screening test compounds which bind to or modulate the activity of a "BREAST CANCER GENE" polypeptide or a "BREAST CANCER GENE" polynucleotide. A test compound preferably binds to a "BREAST CANCER GENE" polypeptide or polynucleotide. More preferably, a test compound decreases or increases "BREAST CANCER GENE" activity by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the test compound.

Test Compounds

[0294] Test compounds can be pharmacological agents already known in the art or can be compounds previously unknown to have any pharmacological activity. The compounds can be naturally occurring or designed in the laboratory. They can be isolated from microorganisms, animals, or plants, and can be produced recombinant, or synthesised by chemical methods known in the art. If desired, test compounds can be obtained using any of the numerous combinatorial library methods known in the art, including but not limited to, biological libraries, spatially addressable parallel solid phase or solution phase libraries, synthetic library methods requiring de-convolution, the one-bead one-compound library method, and synthetic library methods using affinity chromatography selection. The biological library approach is limited to polypeptide libraries, while the other four approaches are applicable to polypeptide, non-peptide oligomer, or small molecule libraries of compounds. [For review see Lam, 1997, (151)].

[0295] Methods for the synthesis of molecular libraries are well known in the art [see, for example, DeWitt et al., 1993, (152); Erb et al., 1994, (153); Zuckermann et al., 1994, (154); Cho et al., 1993, (155); Carell et al., 1994, (156) and Gallop et al., 1994, (157). Libraries of compounds can be presented in solution [see, e.g., Houghten, 1992, (158)].

or on beads [Lam, 1991, (159)], DNA-chips [Fodor, 1993, (160)], bacteria or spores [Ladner, U.S. Patent 5,223,409], plasmids [Cull et al., 1992, (161)], or phage [Scott & Smith, 1990, (162); Devlin, 1990, (163); Cwirla et al., 1990, (164); Felici, 1991, (165)].

5 High Throughput Screening

[0296] Test compounds can be screened for the ability to bind to "BREAST CANCER GENE" polypeptides or polynucleotides or to affect "BREAST CANCER GENE" activity or "BREAST CANCER GENE" expression using high throughput screening. Using high throughput screening, many discrete compounds can be tested in parallel so that large numbers of test compounds can be quickly screened. The most widely established techniques utilize 96-well, 384-well or 1536-well microtiter plates. The wells of the microtiter plates typically require assay volumes that range from 5 to 500 μ l. In addition to the plates, many instruments, materials, pipettors, robotics, plate washers, and plate readers are commercially available to fit the microwell formats.

[0297] Alternatively, free format assays, or assays that have no physical barrier between samples, can be used. For example, an assay using pigment cells (melanocytes) in a simple homogeneous assay for combinatorial peptide libraries is described by Jayawickreme et al., (166). The cells are placed under agarose in culture dishes, then beads that carry combinatorial compounds are placed on the surface of the agarose. The combinatorial compounds are partially released the compounds from the beads. Active compounds can be visualised as dark pigment areas because, as the compounds diffuse locally into the gel matrix, the active compounds cause the cells to change colors.

[0298] Another example of a free format assay is described by Chelsky, (167). Chelsky placed a simple homogenous enzyme assay for carbonic anhydrase inside an agarose gel such that the enzyme in the gel would cause a color change throughout the gel.

[0299] Thereafter, beads carrying combinatorial compounds via a photolinker were placed inside the gel and the compounds were partially released by UV light. Compounds that inhibited the enzyme were observed as local zones of inhibition having less color change.

[0300] In another example, combinatorial libraries were screened for compounds that had cytotoxic effects on cancer cells growing in agar [Salmon et al., 1996, (168)].

[0301] Another high throughput screening method is described in Beutel et al., U.S. Patent 5,976,813. In this method, test samples are placed in a porous matrix. One or more assay components are then placed within, on top of, or at the bottom of a matrix such as a gel, a plastic sheet, a filter, or other form of easily manipulated solid support. When samples are introduced to the porous matrix they diffuse sufficiently slowly, such that the assays can be performed without the test samples running together.

35 Binding Assays

[0302] For binding assays, the test compound is preferably a small molecule which binds to and occupies, for example, the ATP/GTP binding site of the enzyme or the active site of a "BREAST CANCER GENE" polypeptide, such that normal biological activity is prevented. Examples of such small molecules include, but are not limited to, small peptides or peptide-like molecules.

[0303] In binding assays, either the test compound or a "BREAST CANCER GENE" polypeptide can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase. Detection of a test compound which is bound to a "BREAST CANCER GENE" polypeptide can then be accomplished, for example, by direct counting of radioemission, by scintillation counting, or by determining conversion of an appropriate substrate to a detectable product.

[0304] Alternatively, binding of a test compound to a "BREAST CANCER GENE" polypeptide can be determined without labeling either of the interactants. For example, a microphysiometer can be used to detect binding of a test compound with a "BREAST CANCER GENE" polypeptide. A microphysiometer (e.g., CytosensorJ) is an analytical instrument that measures the rate at which a cell acidifies its environment using a light-addressable potentiometric sensor (LAPS). Changes in this acidification rate can be used as an indicator of the interaction between a test compound and a "BREAST CANCER GENE" polypeptide [McConnell et al., 1992, (169)].

[0305] Determining the ability of a test compound to bind to a "BREAST CANCER GENE" polypeptide also can be accomplished using a technology such as real-time Bimolecular Interaction Analysis (BIA) [Sjolander & Urbaniczky, 1991, (170), and Szabo et al., 1995, (171)]. BIA is a technology for studying biospecific interactions in real time, without labeling any of the interactants (e.g., BIAcore™). Changes in the optical phenomenon surface plasmon resonance (SPR) can be used as an indication of real-time reactions between biological molecules.

[0306] In yet another aspect of the invention, a "BREAST CANCER GENE" polypeptide can be used as a "bait protein" in a two-hybrid assay or three-hybrid assay [see, e.g., U.S. Patent 5,283,317; Zervos et al., 1993, (172); Madura et al., 1993, (173); Bartel et al., 1993, (174); Iwabuchi et al., 1993, (175) and Brent WO 94/10300], to identify

other proteins which bind to or interact with the "BREAST CANCER GENE" polypeptide and modulate its activity.

[0307] The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. For example, in one construct, polynucleotide encoding a "BREAST CANCER GENE" polypeptide can be fused to a polynucleotide encoding the DNA binding domain of a known transcription factor (e.g., GAL4). In the other construct a DNA sequence that encodes an unidentified protein ("prey" or "sample") can be fused to a polynucleotide that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact in vivo to form an protein-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ), which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected, and cell colonies containing the functional transcription factor can be isolated and used to obtain the DNA sequence encoding the protein which interacts with the "BREAST CANCER GENE" polypeptide.

[0308] It may be desirable to immobilize either a "BREAST CANCER GENE" polypeptide (or polynucleotide) or the test compound to facilitate separation of bound from unbound forms of one or both of the interactants, as well as to accommodate automation of the assay. Thus, either a "BREAST CANCER GENE" polypeptide (or polynucleotide) or the test compound can be bound to a solid support. Suitable solid supports include, but are not limited to, glass or plastic slides, tissue culture plates, microtiter wells, tubes, silicon chips, or particles such as beads (including, but not limited to, latex, polystyrene, or glass beads). Any method known in the art can be used to attach a "BREAST CANCER GENE" polypeptide (or polynucleotide) or test compound to a solid support, including use of covalent and non-covalent linkages, passive absorption, or pairs of binding moieties attached respectively to the polypeptide (or polynucleotide) or test compound and the solid support. Test compounds are preferably bound to the solid support in an array, so that the location of individual test compounds can be tracked. Binding of a test compound to a "BREAST CANCER GENE" polypeptide (or polynucleotide) can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and microcentrifuge tubes.

[0309] In one embodiment, a "BREAST CANCER GENE" polypeptide is a fusion protein comprising a domain that allows the "BREAST CANCER GENE" polypeptide to be bound to a solid support. For example, glutathione S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, which are then combined with the test compound or the test compound and the nonadsorbed "BREAST CANCER GENE" polypeptide; the mixture is then incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components. Binding of the interactants can be determined either directly or indirectly, as described above. Alternatively, the complexes can be dissociated from the solid support before binding is determined.

[0310] Other techniques for immobilising proteins or polynucleotides on a solid support also can be used in the screening assays of the invention. For example, either a "BREAST CANCER GENE" polypeptide (or polynucleotide) or a test compound can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated "BREAST CANCER GENE" polypeptides (or polynucleotides) or test compounds can be prepared from biotin NHS (N-hydroxysuccinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.) and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies which specifically bind to a "BREAST CANCER GENE" polypeptide, polynucleotide, or a test compound, but which do not interfere with a desired binding site, such as the ATP/GTP binding site or the active site of the "BREAST CANCER GENE" polypeptide, can be derivatised to the wells of the plate. Unbound target or protein can be trapped in the wells by antibody conjugation.

[0311] Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies which specifically bind to a "BREAST CANCER GENE" polypeptide or test compound, enzyme-linked assays which rely on detecting an activity of a "BREAST CANCER GENE" polypeptide, and SDS gel electrophoresis under non-reducing conditions.

[0312] Screening for test compounds which bind to a "BREAST CANCER GENE" polypeptide or polynucleotide also can be carried out in an intact cell. Any cell which comprises a "BREAST CANCER GENE" polypeptide or polynucleotide can be used in a cell-based assay system. A "BREAST CANCER GENE" polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Binding of the test compound to a "BREAST CANCER GENE" polypeptide or polynucleotide is determined as described above.

Modulation of Gene Expression

[0313] In another embodiment, test compounds which increase or decrease "BREAST CANCER GENE" expression are identified. A "BREAST CANCER GENE" polynucleotide is contacted with a test compound, and the expression of an RNA or polypeptide product of the "BREAST CANCER GENE" polynucleotide is determined. The level of expression of appropriate mRNA or polypeptide in the presence of the test compound is compared to the level of expression of

mRNA or polypeptide in the absence of the test compound. The test compound can then be identified as a modulator of expression based on this comparison. For example, when expression of mRNA or polypeptide is greater in the presence of the test compound than in its absence, the test compound is identified as a stimulator or enhancer of the mRNA or polypeptide expression. Alternatively, when expression of the mRNA or polypeptide is less in the presence of the test compound than in its absence, the test compound is identified as an inhibitor of the mRNA or polypeptide expression.

[0314] The level of "BREAST CANCER GENE" mRNA or polypeptide expression in the cells can be determined by methods well known in the art for detecting mRNA or polypeptide. Either qualitative or quantitative methods can be used. The presence of polypeptide products of a "BREAST CANCER GENE" polynucleotide can be determined, for example, using a variety of techniques known in the art, including immunochemical methods such as radioimmunoassay, Western blotting, and immunohistochemistry. Alternatively, polypeptide synthesis can be determined in vivo, in a cell culture, or in an in vitro translation system by detecting incorporation of labeled amino acids into a "BREAST CANCER GENE" polypeptide.

[0315] Such screening can be carried out either in a cell-free assay system or in an intact cell. Any cell which expresses a "BREAST CANCER GENE" polynucleotide can be used in a cell-based assay system. A "BREAST CANCER GENE" polynucleotide can be naturally occurring in the cell or can be introduced using techniques such as those described above. Either a primary culture or an established cell line, such as CHO or human embryonic kidney 293 cells, can be used.

Therapeutic Indications and Methods

[0316] Therapies for treatment of breast cancer primarily relied upon effective chemotherapeutic drugs for intervention on the cell proliferation, cell growth or angiogenesis. The advent of genomics-driven molecular target identification has opened up the possibility of identifying new breast cancer-specific targets for therapeutic intervention that will provide safer, more effective treatments for malignant neoplasia patients and breast cancer patients in particular. Thus, newly discovered breast cancer-associated genes and their products can be used as tools to develop innovative therapies. The identification of the Her2/neu receptor kinase presents exciting new opportunities for treatment of a certain subset of tumor patients as described before. Genes playing important roles in any of the physiological processes outlined above can be characterized as breast cancer targets. Genes or gene fragments identified through genomics can readily be expressed in one or more heterologous expression systems to produce functional recombinant proteins. These proteins are characterized in vitro for their biochemical properties and then used as tools in high-throughput molecular screening programs to identify chemical modulators of their biochemical activities. Modulators of target gene expression or protein activity can be identified in this manner and subsequently tested in cellular and in vivo disease models for therapeutic activity. Optimization of lead compounds with iterative testing in biological models and detailed pharmacokinetic and toxicological analyses form the basis for drug development and subsequent testing in humans.

[0317] This invention further pertains to the use of novel agents identified by the screening assays described above. Accordingly, it is within the scope of this invention to use a test compound identified as described herein in an appropriate animal model. For example, an agent identified as described herein (e.g., a modulating agent, an antisense polynucleotide molecule, a specific antibody, ribozyme, or a human "BREAST CANCER GENE" polypeptide binding molecule) can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described herein can be used in an animal model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above described screening assays for treatments as described herein.

[0318] A reagent which affects human "BREAST CANCER GENE" activity can be administered to a human cell, either in vitro or in vivo, to reduce or increase human "BREAST CANCER GENE" activity. The reagent preferably binds to an expression product of a human "BREAST CANCER GENE". If the expression product is a protein, the reagent is preferably an antibody. For treatment of human cells ex vivo, an antibody can be added to a preparation of stem cells which have been removed from the body. The cells can then be replaced in the same or another human body, with or without clonal propagation, as is known in the art.

[0319] In one embodiment, the reagent is delivered using a liposome. Preferably, the liposome is stable in the animal into which it has been administered for at least about 30 minutes, more preferably for at least about 1 hour, and even more preferably for at least about 24 hours. A liposome comprises a lipid composition that is capable of targeting a reagent, particularly a polynucleotide, to a particular site in an animal, such as a human. Preferably, the lipid composition of the liposome is capable of targeting to a specific organ of an animal, such as the lung, liver, spleen, heart brain, lymph nodes, and skin.

[0320] A liposome useful in the present invention comprises a lipid composition that is capable of fusing with the plasma membrane of the targeted cell to deliver its contents to the cell. Preferably, the transfection efficiency of a liposome is about 0.5 µg of DNA per 16 nmol of liposome delivered to about 10⁶ cells, more preferably about 1.0 µg

of DNA per 16 nmol of liposome delivered to about 10^6 cells, and even more preferably about 2.0 μg of DNA per 16 nmol of liposome delivered to about 10^6 cells. Preferably, a liposome is between about 100 and 500 nm, more preferably between about 150 and 450 nm, and even more preferably between about 200 and 400 nm in diameter.

[0321] Suitable liposomes for use in the present invention include those liposomes usually used in, for example, gene delivery methods known to those of skill in the art. More preferred liposomes include liposomes having a polycationic lipid composition and/or liposomes having a cholesterol backbone conjugated to polyethylene glycol. Optionally, a liposome comprises a compound capable of targeting the liposome to a particular cell type, such as a cell-specific ligand exposed on the outer surface of the liposome.

[0322] Complexing a liposome with a reagent such as an antisense oligonucleotide or ribozyme can be achieved using methods which are standard in the art (see, for example, U.S. Patent 5,705,151). Preferably, from about 0.1 μg to about 10 μg of polynucleotide is combined with about 8 nmol of liposomes, more preferably from about 0.5 μg to about 5 μg of polynucleotides are combined with about 8 nmol liposomes, and even more preferably about 1.0 μg of polynucleotides is combined with about 8 nmol liposomes.

[0323] In another embodiment, antibodies can be delivered to specific tissues in vivo using receptor-mediated targeted delivery. Receptor-mediated DNA delivery techniques are taught in, for example, Findeis et al., 1993, (176); Chiou et al., 1994, (177); Wu & Wu, 1988, (178); Wu et al., 1994, (179); Zenke et al., 1990, (180); Wu et al., 1991, (181).

Determination of a Therapeutically Effective Dose

[0324] The determination of a therapeutically effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient which increases or decreases human "BREAST CANCER GENE" activity relative to the human "BREAST CANCER GENE" activity which occurs in the absence of the therapeutically effective dose.

[0325] For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The animal model also can be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

[0326] Therapeutic efficacy and toxicity, e.g., ED_{50} (the dose therapeutically effective in 50% of the population) and LD_{50} (the dose lethal to 50% of the population), can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, $\text{LD}_{50}/\text{ED}_{50}$.

[0327] Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

[0328] The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active ingredient or to maintain the desired effect. Factors which can be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on the half-life and clearance rate of the particular formulation.

[0329] Normal dosage amounts can vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

[0330] If the reagent is a single-chain antibody, polynucleotides encoding the antibody can be constructed and introduced into a cell either ex vivo or in vivo using well-established techniques including, but not limited to, transfection-mediated DNA transfer, transfection with naked or encapsulated nucleic acids, liposome-mediated cellular fusion, intracellular transportation of DNA-coated latex beads, protoplast fusion, viral infection, electroporation, a gene gun, and DEAE- or calcium phosphate-mediated transfection.

[0331] Effective in vivo dosages of an antibody are in the range of about 5 μg to about 50 $\mu\text{g}/\text{kg}$, about 50 μg to about 5 mg/kg, about 100 μg to about 500 $\mu\text{g}/\text{kg}$ of patient body weight, and about 200 to about 250 $\mu\text{g}/\text{kg}$ of patient body weight. For administration of polynucleotides encoding single-chain antibodies, effective in vivo dosages are in the range of about 100 ng to about 200 ng, 500 ng to about 50 mg, about 1 μg to about 2 mg, about 5 μg to about 500 μg , and about 20 μg to about 100 μg of DNA.

[0332] If the expression product is mRNA, the reagent is preferably an antisense oligonucleotide or a ribozyme. Polynucleotides which express antisense oligonucleotides or ribozymes can be introduced into cells by a variety of methods, as described above.

[0333] Preferably, a reagent reduces expression of a "BREAST CANCER GENE" gene or the activity of a "BREAST CANCER GENE" polypeptide by at least about 10, preferably about 50, more preferably about 75, 90, or 100% relative to the absence of the reagent. The effectiveness of the mechanism chosen to decrease the level of expression of a "BREAST CANCER GENE" gene or the activity of a "BREAST CANCER GENE" polypeptide can be assessed using methods well known in the art, such as hybridization of nucleotide probes to "BREAST CANCER GENE"-specific mRNA, quantitative RT-PCR, immunologic detection of a "BREAST CANCER GENE" polypeptide, or measurement of "BREAST CANCER GENE" activity.

[0334] In any of the embodiments described above, any of the pharmaceutical compositions of the invention can be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy can be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents can act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

[0335] Any of the therapeutic methods described above can be applied to any subject in need of such therapy, including, for example, birds and mammals such as dogs, cats, cows, pigs, sheep, goats, horses, rabbits, monkeys, and most preferably, humans.

[0336] All patents and patent applications cited in this disclosure are expressly incorporated herein by reference. The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided for purposes of illustration only and are not intended to limit the scope of the invention.

Pharmaceutical Compositions

[0337] The invention also provides pharmaceutical compositions which can be administered to a patient to achieve a therapeutic effect. Pharmaceutical compositions of the invention can comprise, for example, a "BREAST CANCER GENE" polypeptide, "BREAST CANCER GENE" polynucleotide, ribozymes or antisense oligonucleotides, antibodies which specifically bind to a "BREAST CANCER GENE" polypeptide, or mimetics, agonists, antagonists, or inhibitors of a "BREAST CANCER GENE" polypeptide activity. The compositions can be administered alone or in combination with at least one other agent, such as stabilizing compound, which can be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions can be administered to a patient alone, or in combination with other agents, drugs or hormones.

[0338] In addition to the active ingredients, these pharmaceutical compositions can contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Pharmaceutical compositions of the invention can be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, parenteral, topical, sublingual, or rectal means. Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

[0339] Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethylcellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

[0340] Dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which also can contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

[0341] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids,

such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

[0342] Pharmaceutical formulations suitable for parenteral administration can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds can be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Non-lipid polycationic amino polymers also can be used for delivery. Optionally, the suspension also can contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0343] The pharmaceutical compositions of the present invention can be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. The pharmaceutical composition can be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation can be a lyophilized powder which can contain any or all of the following: 150 mM histidine, 0.1 % sucrose, and 27% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

[0344] Further details on techniques for formulation and administration can be found in the latest edition of REMINGTON'S PHARMACEUTICAL SCIENCES (182). After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. Such labeling would include amount, frequency, and method of administration.

Material and Methods

[0345] One strategy for identifying genes that are involved in breast cancer is to detect genes that are expressed differentially under conditions associated with the disease versus non-disease conditions. The sub-sections below describe a number of experimental systems which may be used to detect such differentially expressed genes. In general, these experimental systems include at least one experimental condition in which subjects or samples are treated in a manner associated with breast cancer, in addition to at least one experimental control condition lacking such disease associated treatment. Differentially expressed genes are detected, as described below, by comparing the pattern of gene expression between the experimental and control conditions.

[0346] Once a particular gene has been identified through the use of one such experiment, its expression pattern may be further characterized by studying its expression in a different experiment and the findings may be validated by an independent technique. Such use of multiple experiments may be useful in distinguishing the roles and relative importance of particular genes in breast cancer. A combined approach, comparing gene expression pattern in cells derived from breast cancer patients to those of *in vitro* cell culture models can give substantial hints on the pathways involved in development and/or progression of breast cancer.

[0347] Among the experiments which may be utilized for the identification of differentially expressed genes involved in malignant neoplasia and breast cancer, for example, are experiments designed to analyze those genes which are involved in signal transduction. Such experiments may serve to identify genes involved in the proliferation of cells.

[0348] Below are methods described for the identification of genes which are involved in breast cancer. Such represent genes which are differentially expressed in breast cancer conditions relative to their expression in normal, or non-breast cancer conditions or upon experimental manipulation based on clinical observations. Such differentially expressed genes represent "target" and/or "marker" genes. Methods for the further characterization of such differentially expressed genes, and for their identification as target and/or marker genes, are presented below.

[0349] Alternatively, a differentially expressed gene may have its expression modulated, i.e., quantitatively increased or decreased, in normal versus breast cancer states, or under control versus experimental conditions. The degree to which expression differs in normal versus breast cancer or control versus experimental states need only be large enough to be visualized via standard characterization techniques, such as, for example, the differential display technique described below. Other such standard characterization techniques by which expression differences may be visualized include but are not limited to quantitative RT-PCR and Northern analyses, which are well known to those of skill in the art.

EXAMPLE 1*Expression profiling**a) Expression profiling utilizing quantitative RT-PCR*

[0350] For a detailed analysis of gene expression by quantitative PCR methods, one will utilize primers flanking the genomic region of interest and a fluorescent labeled probe hybridizing in-between. Using the PRISM 7700 Sequence Detection System of PE Applied Biosystems (Perkin Elmer, Foster City, CA, USA) with the technique of a fluorogenic probe, consisting of an oligonucleotide labeled with both a fluorescent reporter dye and a quencher dye, one can perform such a expression measurement. Amplification of the probe-specific product causes cleavage of the probe, generating an increase in reporter fluorescence. Primers and probes were selected using the Primer Express software and localized mostly in the 3' region of the coding sequence or in the 3' untranslated region (see Table 5 for primer- and probe- sequences) according to the relative positions of the probe sequence used for the construction of the Affymetrix HG_U95A-E or HG-U133A-B DNA-chips. All primer pairs were checked for specificity by conventional PCR reactions. To standardize the amount of sample RNA, GAPDH was selected as a reference, since it was not differentially regulated in the samples analyzed. TaqMan validation experiments were performed showing that the efficiencies of the target and the control amplifications are approximately equal which is a prerequisite for the relative quantification of gene expression by the comparative $\Delta\Delta C_T$ method, known to those with skills in the art.

[0351] As well as the technology provided by Perkin Elmer one may use other technique implementations like Lightcycler™ from Roche Inc. or iCycler from Stratagene Inc..

b) Expression profiling utilizing DNA microarrays

[0352] Expression profiling can be carried out using the Affymetrix Array Technology. By hybridization of mRNA to such a DNA-array or DNA-Chip, it is possible to identify the expression value of each transcripts due to signal intensity at certain position of the array. Usually these DNA-arrays are produced by spotting of cDNA, oligonucleotides or sub-cloned DNA fragments. In case of Affymetrix technology app. 400.000 individual oligonucleotide sequences were synthesized on the surface of a silicon wafer at distinct positions. The minimal length of oligomers is 12 nucleotides, preferable 25 nucleotides or full length of the questioned transcript. Expression profiling may also be carried out by hybridization to nylon or nitrocellulose membrane bound DNA or oligonucleotides. Detection of signals derived from hybridization may be obtained by either colorimetric, fluorescent, electrochemical, electronic, optic or by radioactive readout. Detailed description of array construction have been mentioned above and in other patents cited. To determine the quantitative and qualitative changes in the chromosomal region to analyze, RNA from tumor tissue which is suspected to contain such genomic alterations has to be compared to RNA extracted from benign tissue (e.g. epithelial breast tissue, or micro dissected ductal tissue) on the basis of expression profiles for the whole transcriptome. With minor modifications, the sample preparation protocol followed the Affymetrix GeneChip Expression Analysis Manual (Santa Clara, CA). Total RNA extraction and isolation from tumor or benign tissues, biopsies, cell isolates or cell containing body fluids can be performed by using TRIzol (Life Technologies, Rockville, MD) and Oligotex mRNA Midi kit (Qiagen, Hilden, Germany), and an ethanol precipitation step should be carried out to bring the concentration to 1 mg/ml. Using 5-10 mg of mRNA to create double stranded cDNA by the Superscript system (Life Technologies). First strand cDNA synthesis was primed with a T7-(dT24) oligonucleotide. The cDNA can be extracted with phenol/chloroform and precipitated with ethanol to a final concentration of 1 mg/ml. From the generated cDNA, cRNA can be synthesized using Enzo's (Enzo Diagnostics Inc., Farmingdale, NY) *in vitro* Transcription Kit. Within the same step the cRNA can be labeled with biotin nucleotides Bio-11-CTP and Bio-16-UTP (Enzo Diagnostics Inc., Farmingdale, NY). After labeling and cleanup (Qiagen, Hilden (Germany) the cRNA then should be fragmented in an appropriated fragmentation buffer (e.g., 40 mM Tris-Acetate, pH 8.1, 100 mM KOAc, 30 mM MgOAc, for 35 minutes at 94°C). As per the Affymetrix protocol, fragmented cRNA should be hybridized on the HG_U133 arrays A and B, comprising app. 40.000 probed transcripts each, for 24 hours at 60 rpm in a 45°C hybridization oven. After Hybridization step the chip surfaces have to be washed and stained with streptavidin phycoerythrin (SAPE; Molecular Probes, Eugene, OR) in Affymetrix fluidics stations. To amplify staining, a second labeling step can be introduced, which is recommended but not compulsive. Here one should add SAPE solution twice with an antistreptavidin biotinylated antibody. Hybridization to the probe arrays may be detected by fluorometric scanning (Hewlett Packard Gene Array Scanner; Hewlett Packard Corporation, Palo Alto, CA).

[0353] After hybridization and scanning, the microarray images can be analyzed for quality control, looking for major chip defects or abnormalities in hybridization signal. Therefor either Affymetrix GeneChip MAS 5.0 Software or other microarray image analysis software can be utilized. Primary data analysis should be carried out by software provided by the manufacturer..

[0354] In case of the genes analyses in one embodiment of this invention the primary data have been analyzed by further bioinformatic tools and additional filter criteria. The bioinformatic analysis is described in detail below.

c) Data analysis

[0355] According to Affymetrix measurement technique (Affymetrix GeneChip Expression Analysis Manual, Santa Clara, CA) a single gene expression measurement on one chip yields the average difference value and the absolute call. Each chip contains 16-20 oligonucleotide probe pairs per gene or cDNA clone. These probe pairs include perfectly matched sets and mismatched sets, both of which are necessary for the calculation of the average difference, or expression value, a measure of the intensity difference for each probe pair, calculated by subtracting the intensity of the mismatch from the intensity of the perfect match. This takes into consideration variability in hybridization among probe pairs and other hybridization artifacts that could affect the fluorescence intensities. The average difference is a numeric value supposed to represent the expression value of that gene. The absolute call can take the values 'A' (absent), 'M' (marginal), or 'P' (present) and denotes the quality of a single hybridization. We used both the quantitative information given by the average difference and the qualitative information given by the absolute call to identify the genes which are differentially expressed in biological samples from individuals with breast cancer versus biological samples from the normal population. With other algorithms than the Affymetrix one we have obtained different numerical values representing the same expression values and expression differences upon comparison.

[0356] The differential expression E in one of the breast cancer groups compared to the normal population is calculated as follows. Given n average difference values d_1, d_2, \dots, d_n in the breast cancer population and m average difference values c_1, c_2, \dots, c_m in the population of normal individuals, it is computed by the equation:

$$E \equiv \exp \left(\frac{1}{m} \sum_{i=1}^m \ln(c_i) - \frac{1}{n} \sum_{i=1}^n \ln(d_i) \right)$$

If $d_j < 50$ or $c_i < 50$ for one or more values of i and j , these particular values c_i and/or d_j are set to an "artificial" expression value of 50. These particular computation of E allows for a correct comparison to TaqMan results.

[0357] A gene is called up-regulated in breast cancer versus normal if $E \geq 1.5$ and if the number of absolute calls equal to 'P' in the breast cancer population is greater than $n/2$.

[0358] A gene is called down-regulated in breast cancer versus normal if $E \leq 1.5$ and if the number of absolute calls equal to 'P' in the normal population is greater than $m/2$.

[0359] The final list of differentially regulated genes consists of all up-regulated and all down-regulated genes in biological samples from individuals with breast cancer versus biological samples from the normal population. Those genes on this list which are interesting for a pharmaceutical application were finally validated by TaqMan. If a good correlation between the expression values/behavior of a transcript could be observed with both techniques, such a gene is listed in Tables 1 to 3.

[0360] Since not only the information on differential expression of a single gene within an identified ARCHEON, but also the information on the co-regulation of several members is important for predictive, diagnostic, preventive and therapeutic purposes we have combined expression data with information on the chromosomal position (e.g. golden path) taken from public available databases to develop a picture of the overall transcriptom of a given tumor sample. By this technique not only known or suspected regions of genomes can be inspected but even more valuable, new regions of dysregulation with chromosomal linkage can be identified. This is of value in other types of neoplasia or viral integration and chromosomal rearrangements. By SQL based database searches one can retrieve information on expression, qualitative value of a measurement (denoted by Affymetrix MAS 5.0 Software), expression values derived from other techniques than DNA-chip hybridization and chromosomal linkage.

EXAMPLE 2

Identification of the ARCHEON

a) Identification and localization of genes or gene probes (represented by the so called probe sets on Affymetrix arrays HG-U95A-E or HG-U133A-B) in their chromosomal context and order on the human genome.

[0361] For identification of larger chromosomal changes or aberrations, as they have been described in detail above,

a sufficient number of genes, transcripts or DNA-fragments is needed. The density of probes covering a chromosomal region is not necessarily limited to the transcribed genes, in case of the use of array based CGH but by utilizing RNA as probe material the density is given by the distance of genes on a chromosome. The DNA-microarrays provided by Affymetrix Inc. Do contain hitherto all transcripts from the known humane genome, which are be represented by 40.000 - 60.000 probe sets. By BLAST mapping and sorting the sequences of these short DNA-oligomers to the public available sequence of the human genome represented by the so called "golden path", available at the university of California in Santa Cruz or from the NCBI, a chromosomal display of the whole Transcriptome of a tissue specimen evolves. By graphical display of the individual chromosomal regions and color coding of over or under represented transcripts, compared to a reference transcriptome regions with DNA gains and losses can be identified.

b) Quantification of gene copy numbers by combined IHC and quantitative PCR (PCR karyotyping) or directly by quantitative PCR

[0362] Usually one to three paraffin-embedded tissue sections that are 5 µm thick are used to obtain genomic DNA from the samples. Tissue section are stained by colorimetric IHC after deparaffinization to identify regions containing disease associated cells. Stained regions are macrodissected with a scalpel and transferred into a microcentrifuge tube. The genomic DNA of these isolated tissue sections is extracted using appropriate buffers. The isolated DNA is then used for quantitative PCR with appropriate primers and probes. Optionally the IHC staining can be omitted and the genomic DNA can be directly isolated with or without prior deparaffinization, with appropriate buffers. Those who are skilled in the art may vary the conditions and buffers described below to obtain equivalent results.

[0363] Reagents from DAKO (HercepTest Code No. K 5204) and TaKaRa were used (Biomedicals Cat.: 9091) according to the manufactures protocol.

[0364] It is convenient to prepare the following reagents prior to staining:

Solution No. 7

[0365] Epitope Retrieval Solution (Citrate buffer + antimicrobial agent) (10xconc.) 20 ml ad 200 ml aqua dest. (stable for 1 month at 2-8°C)

Solution No. 8

[0366] Washing-buffer (Tris-HCl + antimicrobial agent) (10 x conc.) 30 ml ad 300 ml distilled water (stable for 1 month at 2-8°C)

Staining solution: DAB

[0367] 1 ml solution is sufficient for 10 slides. The solution were prepared immediately before usage.:

[0368] 1 ml DAB buffer (Substrate Buffer solution, pH 7.5, containing H₂O₂, stabilizer, enhancers and an antimicrobial agent) + 1 drop (25-3 µl) DAB-Chromogen (3,3'-diaminobenzidine chromogen solution). This solution is stable for up to 5 days at 2-8°C. Precipitated substances do not influence the staining result. Additionally required are: 2x approx. 100 ml Xylol, 2x approx. 100 ml Ethanol 100%, 2x Ethanol 95%, aqua dest. These solution can be used for up to 40 stainings. A water bath is required for the epitope retrieval step.

Staining procedure:

[0369] All reagents are pre-warmed to room temperature (20-25°C) prior to immuno-staining. Likewise all incubations were performed at room temperature. Except the epitope retrieval which is performed in at 95°C water bath. Between the steps excess of liquid is tapped off from the slides with lintless tissue (Kim Wipe).

Deparaffinization

[0370] Slides are placed in a xylene bath and incubated for 5 minutes. The bath is changed and the step repeated once. Excess of liquid is tapped off and the slides are placed in absolute ethanol for 3 minutes. The bath is changed and the step repeated once. Excess of liquid is tapped off and the slides are placed in 95% ethanol for 3 minutes. The bath is changed and the step repeated once. Excess of liquid is tapped off and the slides are placed in distilled water for a minimum of 30 seconds.

Epitope Retrieval

[0371] Staining jars are filled with diluted epitope retrieval solution and preheated in a water bath at 95°C. The deparaffinized sections are immersed into the preheated solution in the staining jars and incubated for 40 minutes at 95°C. The entire jar is removed from the water bath and allowed to cool down at room temperature for 20 minutes. The epitope retrieval solution is decanted, the sections are rinsed in distilled water and finally soaked in wash buffer for 5 minutes.

Peroxidase Blocking:

[0372] Excess of buffer is tapped off and the tissue section encircled with a DAKO pen. The specimen is covered with 3 drops (100 µl) Peroxidase-Blocking solution and incubated for 5 minutes. The slides are rinsed in distilled water and placed into a fresh washing buffer bath.

Antibody Incubation

[0373] Excess of liquid is tapped off and the specimen are covered with 3 drops (100 µl) of Anti-Her-2/neu reagent (Rabbit Anti-Human Her2 Protein in 0.05 mol/L Tris/HCl, 0.1 mol/L NaCl, 15 mmol/L pH7.2 NaN₃ containing stabilizing protein) or negative control reagent (= IGG fraction of normal rabbit serum at an equivalent protein concentration as the Her2 Ab). After 30 minutes of incubation the slide is rinsed in water and placed into a fresh water bath.

Visualization

[0374] Excess of liquid is tapped off and the specimen are covered with 3 drops (100 µl) of visualization reagent. After 30 minutes of incubation the slide is rinsed in water and placed into a fresh water bath. Excess of liquid is tapped off and the specimen are covered with 3 drops (100 µl) of Substrate-Chromogen solution (DAB) for 10 minutes. After rinsing the specimen with distilled water, photographs are taken with a conventional Olympus microscope to document the staining intensity and tumor regions within the specimen. Optionally a counterstain with hematoxylin was performed.

DNA extraction

[0375] The whole specimens or dissected subregions are transferred into a microcentrifuge tubes. Optionally a small amount (10 µl) of preheated TaKaRa solution (DEXPAT™) is preheated and placed onto the specimen to facilitate sample transfer with a scalpel. 50 to 150 µl of TaKaRa solution were added to the samples depending on the size of the tissue sample selected. The sample are incubated at 100°C for 10 minutes in a block heater, followed by centrifugation at 12.000 rpm in a microcentrifuge. The supernatant is collected using a micropet and placed in a separate microcentrifuge tube. If no deparaffinization step has been undertaken one has to be sure not to withdraw tissue debris and resin. Genomic DNA left in the pellet can be collected by adding resin-free TaKaRa buffer and an additional heating and centrifugation step. Samples are stored at -20°C.

[0376] Genomic DNA from different tumor cell lines (MCF-7, BT-20, BT-474, SKBR-3, AU-565, UACC-812, UACC-893, HCC-1008, HCC-2157, HCC-1954, HCC-2218, HCC-1937, HCC1599, SW480), or from lymphocytes is prepared with the QIAamp® DNA Mini Kits or the QIAamp® DNA Blood Mini Kits according to the manufacturers protocol. Usually between 1 ng up to 1 µg DNA is used per reaction.

Quantitative PCR

[0377] To measure the gene copy number of the genes within the patient samples the respective primer/probes (see table below) are prepared by mixing 25 µl of the 100 µM stock solution "Upper Primer", 25 µl of the 100 µM stock solution "Lower Primer" with 12,5 µl of the 100 µM stock solution Taq Man Probe (Quencher Tamra) and adjusted to 500 µl with aqua dest. For each reaction 1,25 µl DNA-Extract of the patient samples or 1,25 µl DNA from the cell lines were mixed with 8,75 µl nuclease-free water and added to one well of a 96 Well-Optical Reaction Plate (Applied Biosystems Part No. 4306737). 1,5 µl Primer/Probe mix, 12, µl Taq Man Universal-PCR Mix (2x) (Applied Biosystems Part No. 4318157) and 1 µl Water are then added. The 96 well plates are closed with 8 Caps/Strips (Applied Biosystems Part Number 4323032) and centrifuged for 3 minutes. Measurements of the PCR reaction are done according to the instructions of the manufacturer with a TaqMan 7900 HT from Applied Biosystems (No. 20114) under appropriate conditions (2 min. 50°C, 10 min. 95°C, 0.15 min. 95°C, 1 min. 60°C; 40 cycles). Software SDS 2.0 from Applied Biosystems is used according to the respective instructions. CT-values are then further analyzed with appropriate software (Microsoft Excel™).

REFERENCES**[0378]**

5
10
15
20
25
30
35
40

<u>Patents cited</u>	
U.S. Pat. No. 4,843,155	Chomczynski, P.
U.S. Pat. No. 5,262,31	Liang, P., and Pardee, A. B., 1993
U.S. Pat. No. 4,683,202	Mullis, K. B., 1987
U.S. Pat. No. 5,593,839	
U.S. Pat. No. 5,578,832	
U.S. Pat. No. 5,556,752	
U.S. Pat. No. 5,631,734	
U.S. Pat. No. 5,599,695	
U.S. Pat. No. 4,683,195	
U.S. Pat. No. 5,498,531	
U.S. Pat. No. 5,714,331	
U.S. Pat. No. 5,641,673	Haseloff et al.,
U.S. Pat. No. 5,223,409	Lander, E.,
U.S. Pat. No. 5,976,813	Beutel et al.
U.S. Pat. No. 5,283,317	
U.S. Pat. No. 6,203,987	
U.S. Pat. No. 6,379,895	
WO 97/29212	
WO 97/27317	
WO 95/22058	
WO 99/12826	
WO 97/02357	
WO 94/13804	
WO 94/10300	
WO 97/14028	
WO 99/52708	
EP 0 785 280	
EP 0 799 897	
EP 0 728 520	
EP 0 721 016	
EP 0 321 201	

GB2188638B

Publications cited

45
50
55

[0379]

- (1) Gusterson et al., Journal of Clinical Oncology 10, 1049-1056, 1992
- (2) Achuthan et al., Cancer Genet Cytogenet. 130:166-72, 2001
- (3) Tomasetto et al., FEBS Lett. 373: 245-249, 1995
- (4) Pragnell et al., FEBS Lett. 291: 253-258, 1991
- (5) Nakamichi et al. 1986
- (6) Feo et al., Proc. Nat. Acad. Sci. 86: 6691-6695, 1989
- (7) Davies et al., Proc. Nat. Acad. Sci. 86: 6691-6695, 1989
- (8) Lee et al., Molec. Endocr. 9: 243-254, 1995
- (9) Drane et al., Oncogene 15: 3013-3024, 1997
- (10) Zhu et al., J. Biol. Chem. 272: 25500-25506, 1997
- (11) Yuan et al., Proc. Nat. Acad. Sci. 95: 7939-7944, 1998

- (12) Zhu et al., Proc. Nat. Acad. Sci. 96: 10848-10853, 1999
- (13) Lee et al., Science 268: 836-844, 1995
- (14) McCormick et al., Molec. Cell. Biol. 16: 5792-5800, 1996
- (15) Tamimi et al., Genomics 40: 355-357, 1997
- 5 (16) Valle et al., *FEBS Lett.* 415: 163-168, 1997
- (17) Kaneda et al., J. Biol. Chem. 263: 7672-7677, 1988
- (18) Hoehe et al., Hum. Molec. Genet. 1:175-178, 1992
- (19) Yang-Feng et al., Abstract Cytogenet. Cell Genet. 40: 784, 1985
- (20) Coussens et al., Science 230: 1132-1139, 1985
- 10 (21) van de Vijver et al., New Eng. J. Med. 319: 1239-1245, 1988
- (22) Slamon et al., Science 244: 707-712, 1989
- (23) Fukushige et al., Res. Commun. 134: 477-483, 1986
- (24) Kaneko et al., Jpn. J. Cancer Res. 78: 16-19, 1987
- (25) Di Fiore et al., Science 237: 178-182, 1987
- 15 (26) Popescu et al., Genomics 4: 362-366, 1989
- (27) Qiu et al., Nature 393: 83-85, 1998
- (28) Yu et al., Molec. Cell 2: 581-591, 1998
- (29) Doherty et al., Proc. Nat. Acad. Sci. 96: 10869-10874, 1999
- (30) Slamon et al., New Eng. J. Med. 344: 783-792, 2001
- 20 (31) Margolis et al., J. Clin. Invest. 102: 821-827, 1998
- (32) Tanaka et al., J. Clin. Invest. 102: 821-827, 1998
- (33) Dong et al., J. Biol. Chem. 272: 29104-29112, 1997
- (34) Stein et al., EMBO J.13:1331-40, 1994
- (35) Nagata et al., Nature 319: 415-418, 1986
- 25 (36) Le Beau et al., Leukemia 1: 795-799, 1987,
- (37) Jansson et al., EMBO J. 2: 561-565, 1983
- (38) Thompson et al., Science 237:1610-1614, 1987
- (39) Nakai et al., Proc. Nat. Acad. Sci. 85: 2781-2785, 1988
- (40) Miyajima et al., Cell 57: 31-39, 1989
- 30 (41) Debuire et al., Science 224: 1456-1459, 1984
- (42) Petkovich et al., Nature 330: 444-450, 1987
- (43) Mattei et al., Hum. Genet. 80: 186-188, 1988.
- (44) Williams et al., Molec. Cell. Biol. 18: 2758-2767, 1998
- (45) Saha et al, Molec. Cell. Biol. 18: 2758-2767, 1998
- 35 (46) Yan et al., Proc. Nat. Acad. Sci. 95: 3603-3608, 1998
- (47) Singh et al., Nucleic Acids Res. 16: 3919-3929, 1988
- (48) Tsai-Pflugfelder et al., Proc. Nat. Acad. Sci. 85: 7177-7181, 1988
- (49) Chung et al., Proc. Nat. Acad. Sci. 86: 9431-9435, 1989
- (50) Lang et al., Gene 221: 255-266, 1998
- 40 (51) Keith et al., Genes Chromosomes Cancer 4: 169-175, 1992
- (52) Kingsmore et al., Mammalian Genome 4: 288-289, 1993
- (53) Watt et al., Biochem. J. 303: 681-695, 1994.
- (54) Kiefer et al., J. Biol. Chem. 267: 12692-12699, 1992
- (55) Shimasaki et al., Molec. Endocr. 4: 1451-1458, 1990
- 45 (56) Zazzi et al., Genomics 49: 401-410, 1998
- (57) Bajalica et al., Hum. Genet. 89: 234-236, 1992
- (58) Tonin et al., Genomics 18: 414-417, 1993
- (59) Birkenbach et al., J. Virol. 67: 2209-2220, 1993
- (60) Wang et al., Proc. Nat. Acad. Sci. 95: 492-498, 1998
- 50 (61) Klochendler-Yeivin et al., Curr Opin Genet Dev 12:73-9,2002
- (62) Ring et al., Genomics 51:140-3, 1998
- (63) Darmon et al., Molec. Biol. Rep. 12: 277-283, 1987
- (64) Zhou et al., J. Biol. Chem. 263: 15584-15589, 1988
- (65) Korge et al., Proc. Nat. Acad. Sci. 89: 910-914, 1992
- 55 (66) Lessin et al., J. Invest. Derm. 91: 572-578, 1988
- (67) Romano et al., Cytogenet. Cell Genet. 58: 2009-2010, 1991.
- (68) Fuchs et al., Proc. Nat. Acad. Sci. 89: 6906-6910, 1992
- (69) Rogaev et al., Nature Genet. 5: 158-162, 1993

- (70) Liu et al., *Curr. Eye Res.* 12: 963-974, 1993
- (71) Nishida et al., *Invest. Ophthalm. Vis. Sci.* 37: 1800-1809, 1996
- (72) Nishida et al., *Am. J. Hum. Genet.* 61: 1268-1275, 1997
- (73) Meesmann and Wilke, 1939
- 5 (74) Corden et al., *Exp. Eye Res.* 70: 41-49, 2000
- (75) van de Vijver et al., *Mol Cell Biol* 7, 2091-23, 1987
- (76) Offerdinger et al., *Biochem Biophys Res Comm* 251, 907-13, 1988
- (77) Sambrook et al., *MOLECULAR CLONING: A LABORATORY MANUAL*, 2d ed., 1989
- (78) Ausubel et al., *CURRENT PROTOCOLS IN MOLECULAR BIOLOGY*, John Wiley & Sons, New York, N.Y., 1989.
- 10 (79) Tedder, T. F. et al., *Proc. Natl. Acad. Sci. U.S.A.* 85:208-212, 1988
- (80) Hedrick, S. M. et al., *Nature* 308:149-153, 1984
- (81) Lee, S. W. et al., *Proc. Natl. Acad. Sci. U.S.A.* 88:4225, 1984
- (82) Sarkar, *PCR Methods Applic.* 2, 318-322, 1993
- 15 (83) Triglia et al., *Nucleic Acids Res.* 16, 81-86, 1988
- (84) Lagerstrom et al., *PCR Methods Applic.* 1, 111-119, 1991
- (85) Copeland & Jenkins, *Trends in Genetics* 7: 113-118, 1991
- (86) Cohen, et al., *Nature* 366: 698-701, 1993
- (87) Bonner et al., *J. Mol. Biol.* 81, 123 1973
- 20 (88) Bolton and McCarthy, *Proc. Natl. Acad. Sci. U.S.A.* 48, 1390 1962
- (89) Plump et al., *Cell* 71: 343-353, 1992
- (90) Altschul et al., *Bull. Math. Bio.* 48:603, 1986,
- (91) Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915, 1992
- (92) Pearson & Lipman, *Proc. Nat'l Acad. Sci. USA* 85:2444, 1988
- 25 (93) Pearson et al., *Meth. Enzymol.* 183:63, 1990
- (94) Needleman & Wunsch, *J. Mol. Biol.* 48:444, 1970
- (95) Sellers, *SIAM J. Appl. Math.* 26:787, 1974
- (96) Takamatsu, *EMBO J.* 6, 307-311, 1987
- (97) Coruzzi et al., *EMBO J.* 3, 1671-1680, 1984
- 30 (98) Broglie et al., *Science* 224, 838-843, 1984
- (99) Winter et al., *Results Probl. Cell Differ.* 17, 85-105, 1991
- (100) Engelhard et al., *Proc. Nat. Acad. Sci.* 91, 3224-3227, 1994
- (101) Logan & Shenk, *Proc. Natl. Acad. Sci.* 81, 3655-3659, 1984
- (102) Scharf et al., *Results Probl. Cell Differ.* 20, 125-162, 1994
- 35 (103) Freshney R.I., ed., *ANIMAL CELL CULTURE*, 1986
- (104) Wigler et al., *Cell* 11, 223-232, 1977
- (105) Lowy et al., *Cell* 22, 817-823, 1980
- (106) Wigler et al., *Proc. Natl. Acad. Sci.* 77, 3567-3570, 1980
- (107) Colbere-Garapin et al., *J. Mol. Biol.* 150, 114, 1981
- 40 (108) Hartman & Mulligan, *Proc. Natl. Acad. Sci.* 85, 8047-8051, 1988
- (109) Rhodes et al., *Methods Mol. Biol.* 55, 121-131, 1995
- (110) Hampton et al., *SEROLOGICAL METHODS: A LABORATORY MANUAL*, APS Press, St. Paul, Minn., 1990
- (111) Maddox et al., *J. Exp. Med.* 158, 1211-1216, 1983
- (112) Porath et al., *Prot. Exp. Purif.* 3, 263-281, 1992
- 45 (113) Kroll et al., *DNA Cell Biol.* 12, 441-453, 1993
- (114) Caruthers et al., *Nucl. Acids Res. Symp. Ser.* 215-223, 1980
- (115) Horn et al. *Nucl. Acids Res. Symp. Ser.* 225-232, 1980
- (116) Merrifield, *J. Am. Chem. Soc.* 85, 2149-2154, 1963
- (117) Roberge et al., *Science* 269, 202-204, 1995
- 50 (118) Creighton, *PROTEINS: STRUCTURES AND MOLECULAR PRINCIPLES*, WH and Co., New York, N.Y., 1983
- (119) Cronin et al., *Human Mutation* 7:244, 1996
- (120) Landegran et al., *Science* 241:1077-1080, 1988
- (121) Nakazawa et al., *PNAS* 91:360-364, 1994
- (122) Abravaya et al., *Nuc Acid Res* 23:675-682, 1995
- 55 (123) Guatelli, J.C. et al., *Proc. Natl. Acad. Sci. USA* 87:1874-1878, 1990
- (124) Kwok, D.Y. et al., *Proc. Natl. Acad. Sci. USA* 86:1173-1177, 1989
- (125) Lizardi, P.M. et al., *Bio/Technology* 6:1197, 1988
- (126) Brown, *Meth. Mol. Biol.* 20, 18, 1994

- (127) Sonveaux, Meth. Mol. Biol. 26, 1-72, 1994
- (128) Uhlmann et al., Chem. Rev. 90, 543-583, 1990
- (129) Gee et al., in Huber & Carr, MOLECULAR AND IMMUNOLOGIC APPROACHES, Publishing Co., Mt. Kisco, N.Y., 1994
- 5 (130) Agrawal et al., Trends Biotechnol. 10, 152-158, 1992
- (131) Uhlmann et al., Tetrahedron. Lett. 215, 3539-3542, 1987
- (132) Cech, Science 236, 1532-1539, 1987
- (133) Cech, Ann. Rev. Biochem. 59, 543-568, 1990
- (134) Couture & Stinchcomb, Trends Genet. 12, 510-515, 1996
- 10 (135) Haseloff et al. Nature 334, 585-591, 1988
- (136) Kohler et al., Nature 256, 495-497, 1985
- (137) Kozbor et al., J. Immunol. Methods 81, 3142, 1985
- (138) Cote et al., Proc. Natl. Acad. Sci. 80, 2026-2030, 1983
- (139) Cole et al., Mol. Cell Biol. 62, 109-120, 1984
- 15 (140) Morrison et al., Proc. Natl. Acad. Sci. 81, 6851-6855, 1984
- (141) Neuberger et al., Nature 312, 604-608, 1984
- (142) Takeda et al., Nature 314, 452-454, 1985
- (143) Burton, Proc. Natl. Acad. Sci. 88, 11120-11123, 1991
- (144) Thirion et al., Eur. J. Cancer Prev. 5, 507-11, 1996
- 20 (145) Coloma & Morrison, Nat. Biotechnol. 15, 159-63, 1997
- (146) Mallender & Voss, J. Biol. Chem. 269, 199-206, 1994
- (147) Verhaar et al., Int. J. Cancer 61, 497-501, 1995
- (148) Nicholls et al., J. Immunol. Meth. 165, 81-91, 1993
- (149) Orlandi et al., Proc. Natl. Acad. Sci. 86, 3833-3837, 1989
- 25 (150) Winter et al., Nature 349, 293-299, 1991
- (151) Lam, Anticancer Drug Des. 12, 145, 1997
- (152) DeWitt et al., Proc. Natl. Acad. Sci. U.S.A. 90, 6909, 1993
- (153) Erb et al. Proc. Natl. Acad. Sci. U.S.A. 91, 11422, 1994
- (154) Zuckermann et al., J. Med. Chem. 37, 2678, 1994
- 30 (155) Cho et al., Science 261, 1303, 1993
- (156) Carell et al., Angew. Chem. Int. Ed. Engl. 33, 2059 & 2061, 1994
- (157) Gallop et al., J. Med. Chem. 37, 1233, 1994
- (158) Houghten, BioTechniques 13, 412-421, 1992
- (159) Lam, Nature 354, 8284, 1991
- 35 (160) Fodor, Nature 364, 555-556, 1993
- (161) Cull et al., Proc. Natl. Acad. Sci. U.S.A. 89, 1865-1869, 1992
- (162) Scott & Smith, Science 249, 386-390, 1990
- (163) Devlin, Science 249, 404-406, 1990
- (164) Cwirla et al., Proc. Natl. Acad. Sci. 97, 6378-6382, 1990
- 40 (165) Felici, J. Mol. Biol. 222, 301-310, 1991
- (166) Jayawickreme et al., Proc. Natl. Acad. Sci. U.S.A. 19, 1614-1618, 1994
- (167) Chelsky, Strategies for Screening Combinatorial Libraries 1995
- (168) Salmon et al., Molecular Diversity 2, 57-63, 1996
- (169) McConnell et al., Science 257, 1906-1912, 1992
- 45 (170) Sjolander & Urbaniczky, Anal. Chem. 63, 2338-2345, 1991
- (171) Szabo et al., Curr. Opin. Struct. Biol. 5, 699-705, 1995
- (172) Zervos et al., Cell 72, 223-232, 1993
- (173) Madura et al., J. Biol. Chem. 268, 12046-12054, 1993
- (174) Bartel et al., BioTechniques 14, 920-924, 1993
- 50 (175) Iwabuchi et al., Oncogene 8, 1693-1696, 1993
- (176) Findeis et al. Trends in Biotechnol. 11, 202-205, 1993
- (177) Chiou et al., GENE THERAPEUTICS: METHODS AND APPLICATIONS OF DIRECT GENE TRANSFER J. A. Wolf ed., 1994
- (178) Wu & Wu, J. Biol. Chem. 263, 621-24, 1988
- 55 (179) Wu et al., J. Biol. Chem. 269, 542-46, 1994
- (180) Zenke et al., Proc. Natl. Acad. Sci. U.S.A. 87, 3655-59, 1990
- (181) Wu et al., J. Biol. Chem. 266, 338-42, 1991
- (182) REMINGTON'S PHARMACEUTICAL SCIENCES Maack Publishing Co., Easton, Pa.

EP 1 365 034 A2

(183) Hille, Excitable Membranes, Sunderland, MA, Sinauer Associates, Inc.

Table 1

DNA SEQ ID NO:	Protein SEQ ID NO:	Genbank ID	Unigene_v133_ID	Locus Link ID	Gene Name
1	27	NM_006148.1	75080	3927	LASP1
2	28	NM_000723.1	635	782	CACNB1
3	29	NM_000981.1	252723	6143	RPL19RPL19
4	30	Y13467	15589	5469	PPARGBP
5	31	NM_016507.1	123073		CrkRS
6	32	AB021742.1	322431	4761	NEUROD2
7	33	NM_006804.1	77628	10948	MLN64
8	34	NM_003673.1	111110	8557	TELETHONIN
9	35	NM_002686.1	1892	5409	PNMT
10	36	X03363.1	323910	2064	ERBB2
11	37	AB008790.1	86859	2886	GRB7
12	38	NM_002809.1	9736	5709	PSMD3
13	39	NM_000759.1	2233	1440	GCSFG
14	40	A1023317	23106	9862	KIAA0130
15	41	X55005		7067	c-erbA-1
16	42	X72631	211606	9572	NRID1
17	43	NM_007359.1	83422	22794	MLN51
18	44	U77949.1	69563	990	CDC6
19	45	U41742.1		5914	RARA
20	46	NM_001067.1	156346	7153	TOP2A
21	47	NM_001552.1	1516		IGFBP4
22	48	NM_001838.1	1652		CCR7 EBI1
23	49	NM_003079.1	332848	6605	SMARCE1 BAF57
24	50	X14487	99936	3858	KRT10
25	51	NM_000223.1	66739		KRT12
26	52	NM_002279.2	32950	3884	hHKa3-II
53	76	NM_005937	349196	4302	MLLT6
54	77	XM_008147	184669	7703	ZNF144
55	78	NM_138687	432736	8396	PIP5K2B
56	79	NM_020405	125036	57125	TEM7
57	80	XM_012694	258579	22806	ZNFN1A3
58	81	XM_085731	13996	147179	WIRE
59	82	NM_002795	82793	5691	PSMB3
60	83	NM_033419	91668	93210	MGC9753 Variant a

Table 1 (continued)

DNA SEQ ID NO:	Protein SEQ ID NO:	Genbank ID	Unigene_v133_ID	Locus Link ID	Gene Name
61	84				MGC9753 Variant c
62	85				MGC9753 Variant d
63	86				MGC9753 Variant e
64	87				MGC9753 Variant g
65	88				MGC9753 Variant h
66	89				MGC9753 Variant i
67	90	AF395708	374824	94103	ORMDL3
68	91	NM_032875	194498	84961	MGC15482
69	92	NM_032192	286192	84152	PPP1R1B
70	93	NM_032339	333526	84299	MGC14832
71	94	NM_057555	12101	51242	LOC51242
72	95	NM_017748	8928	54883	FLJ20291
73	96	NM_018530	19054	55876	Pro2521
74	97	NM_016339	118562	51195	Link-GEFII
75	98	NM_032865	294022	84951	CTEN

Table 2

DNA SEQ ID NO:	Gene description
1	Member of a subfamily of LIM proteins that contains a LIM domain and an SH3 (Src homology region 3) domain
2	Beta 1 subunit of a voltage-dependent calcium channel (dihydropyridine receptor), involved in coupling of excitation and contraction in muscle, also acts as a calcium channel in various other tissues
3	Ribosomal protein L19, component of the large 60S ribosomal subunit
4	Protein with similarity to nuclear receptor-interacting proteins; binds and co-activates the nuclear receptors PPARalpha (PPARA), RARalpha (RARA), RXR, TRbeta1, and VDR
5	we26e0 CDC2-related protein kinase 7
6	Neurogenic differentiation, a basic-helix-loop-helix transcription factor that mediates neuronal differentiation
7	Protein that is overexpressed in malignant tissues, contains a putative trans-membrane region and a STAR Homology Domain (SHD), may function in steroidogenesis and contribute to tumor progression
8	Telethonin, a sarcomeric protein specifically expressed in skeletal and heart muscle, caps titin (TTN) and is important for structural integrity of the sarcomere

Table 2 (continued)

DNA SEQ ID NO:	Gene description
9	Phenylethanolamine N-methyltransferase, acts in catecholamine biosynthesis to convert norepinephrine to epinephrine
10	Tyrosine kinase receptor that has similarity to the EGF receptor, a critical component of IL-6 signaling through the MAP kinase pathway, overexpression associated with prostate, ovary and breast cancer
11	Growth factor receptor-bound protein, an SH2 domain-containing protein that has isoforms which may have a role in cell invasion and metastatic progression of esophageal carcinomas
12	Non-ATPase subunit of the 26S proteasome (prosome, macropain)
13	Granulocyte colony stimulating factor, a glycoprotein that regulates growth, differentiation, and survival of neutrophilic granulocytes
14	Member of the Vitamin D Receptor Interacting Protein co-activator complex, has strong similarity to thyroid hormone receptor-associated protein (murine Trap 100) which function as a transcriptional coregulator
15	Thyroid hormone receptor alpha, a high affinity receptor for thyroid hormone that activates transcription; homologous to avian erythroblastic leukemia virus oncogene
16	encoding Rev-Erbaap nuclear receptor subfamily 1, group D, member 1
17	Protein that is overexpressed in breast carcinomas
18	Protein which interacts with the DNA replication proteins PCNA and Orc1, translocates from the nucleus following onset of S phase; S. cerevisiae homolog Cdc6p is required for initiation of S phase
19	Retinoic acid receptor alpha, binds retinoic acid and stimulates transcription in a ligand-dependent manner
20	DNA topoisomerase II alpha, member of a family of proteins that relieves torsional stress created by DNA replication, transcription, and cell division;
21	Insulin-like growth factor binding protein, the major IGFBP of osteoblast-like cells, binds IGF1 and IGF2 and inhibits their effects on promoting DNA and glycogen synthesis in osteoblastic cells
22	HUMEB103 G protein-coupled receptor (EBI 1) gene exon 3 chemokine (C-C motif) receptor 7 G protein-coupled receptor
23	Protein with an HMG 1/2 DNA-binding domain that is subunit of the SNF/SWI complex associated with the nuclear matrix and implicated in regulation of transcription by affecting chromatin structure
24	Keratin 10, a type I keratin that is a component of intermediate filaments and is expressed in terminally differentiated epidermal cells; mutation of the corresponding gene causes epidermolytic hyperkeratosis
25	Keratin 12, a component of intermediate filaments in corneal epithelial cells; mutation of the corresponding gene causes Meesmann corneal dystrophy
26	Hair keratin 3B, a type I keratin that is a member of a family of structural proteins that form intermediate filaments
53	MLLT6 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 6
54	zinc finger protein 144 (Mel-18)
55	phosphatidylinositol-4-phosphate 5-kinase type II beta isoform a
56	tumor endothelial marker 7 precursor

EP 1 365 034 A2

Table 2 (continued)

DNA SEQ ID NO:	Gene description
57	zinc finger protein, subfamily 1A, 3
58	WASP-binding protein putative cr16 and wip like protein similar to Wiskott-Aldrich syndrome protein
59	proteasome (prosome, macropain) subunit, beta type, 3
60	Predicted
67	ORM1-like 3 (<i>S. cerevisiae</i>)
68	F-box domain A Receptor for Ubiquitination Targets
69	protein phosphatase 1, regulatory (inhibitor) subunit 1B (dopamine and cAMP regulated phosphoprotein, DARPP-32)
70	Predicted Protein
71	Predicted Protein
72	Predicted Protein
73	Predicted Protein
74	Link-GEFII: Link guanine nucleotide exchange factor II
75	C-terminal tensin-like

Table 3

DNA SEQ ID NO:	Gene function	Subcellular localization
1	SH3/SH2 adapter protein	-
3	voltage-gated calcium channel membrane fraction Channel [passive transporter]	Plasma membrane
4	RNA binding structural protein of ribosome protein biosynthesis	Cytoplasm
5	transcription co-activator nucleus Pol II transcription	Nucleus
6	-	-
7	transcription factor transcription regulation from Pol II promoter neurogenesis	-
8	mitochondrial transport steroid and lipid metabolism	Cytoplasm
9	structural protein of muscle sarcomere alignment	Cytoplasm
10	phenylethanolamine N-methyltransferase Transferase	-
11	Neu/ErbB-2 receptor receptor signaling protein tyrosine kinase	Plasma membrane
12	SH3/SH2 adapter protein EGF receptor signaling pathway	Cytoplasm
13	26S proteasome Protein degradation Proteasome subunit	Cytoplasm
14	developmental processes positive control of cell proliferation	Extracellular space
15	fatty acid omega-hydroxylase fatty acid omega-hydroxylase	-
16	DNA-binding protein Transcription factor	Nucleus
17	steroid hormone receptor transcription co-repressor	Nucleus
18	-	-
19	nucleotide binding cell cycle regulator DNA replication checkpoint regulation of CDK activity	nucleus
20	retinoic acid receptor transcription co-activator transcription factor	nucleus
21	DNA binding DNA topoisomerase (ATP-hydrolyzing)	nucleus
22	skeletal development DNA metabolism signal transduction cell proliferation	plasma membrane
23	chromatin binding transcription co-activator nucleosome disassembly transcription	nucleus nuclear chromosome
24	Cell structure Cytoskeletal Epidermal Development and Maintenance	cytoplasm
25	structural protein vision cell shape and cell size control intermediate filament	cytoplasm
26	cell shape and cell size control Cell structure	cytoplasm
53	leucine-zipper containing fusion	-

Table 3 (continued)

DNA SEQ ID NO:	Gene function	Subcellular localization
54		-
55	Tumor endothelial marker 7 precursor; may be involved in angiogenesis	-
56	Aiolos; DNA binding protein that may be a transcription factor; has strong similarity to murine Znf1a3, contains zinc finger domain	-
57	The WASP-binding protein WIRE has a role in the regulation of the actin filament system downstream of the platelet-derived growth factor receptor	-
58		-
59		-
60		-
67		-
68		-
69	Midbrain dopaminergic neurons play a critical role in multiple brain functions, and abnormal signaling through dopaminergic pathways has been implicated in several major neurologic and psychiatric disorders. One well-studied target for the actions of dopamine is DARPP32.	-
70		-
71		-
72		-
73		-
74	Brain-specific guanine nucleotide exchange factor; activates the ERK/MAP kinase cascade plus R-Ras and H-ras; activates targets through a Ca2+- and diacylglycerol-sensitive mechanism; active protein associates with membranes	-
75	C-terminal tensin-like <u>Phosphotyrosine-binding domain, phosphotyrosine-interaction (PTI) domain</u>	-

Table 4

DNA SEQ ID NO:	Protein SEQ ID NO:	Gene Name	DBSNPID	Type	Codon	AA-Seq
9	34	ERBB2	rs2230698	coding-synon	TCA TCG	S S
9	34	ERBB2	rs2230700	noncoding		
9	34	ERBB2	rs1058808	coding-nonsynon	CCC GCC	P A
9	34	ERBB2	rs1801200	noncoding		
9	34	ERBB2	rs903506	noncoding		
9	34	ERBB2	rs2313170	noncoding		
9	34	ERBB2	rs1136201	coding-nonsynon	ATC GTC	I V
9	34	ERBB2	rs2934968	noncoding		
9	34	ERBB2	rs2172826	noncoding		
9	34	ERBB2	rs1810132	coding-nonsynon	ATC GTC	I V
9	34	ERBB2	rs1801201	noncoding		
14	39	c-erbA-1	rs2230702	coding-synon	TCC TCT	S S
14	39	c-erbA-1	rs2230701	coding-synon	GCC GCT	A A
14	39	c-erbA-1	rs1126503	coding-nonsynon	ACC AGC	T S
14	39	c-erbA-1	rs3471	noncoding		
19	44	TOP2A	rs13695	noncoding		
19	44	TOP2A	rs471692	noncoding		
19	44	TOP2A	rs558068	noncoding		
19	44	TOP2A	rs1064288	noncoding		
19	44	TOP2A	rs1061692	coding-synon	GGA GGG	G G
19	44	TOP2A	rs520630	noncoding		
19	44	TOP2A	rs782774	coding-nonsynon	AAT ATT ATT TTT	N I I F
19	44	TOP2A	rs565121	noncoding		
19	44	TOP2A	rs2586112	noncoding		
19	44	TOP2A	rs532299	coding-nonsynon	TTT GTT	F V
19	44	TOP2A	rs2732786	noncoding		
19	44	TOP2A	rs1804539	noncoding		
19	44	TOP2A	rs1804538	noncoding		
19	44	TOP2A	rs1804537	noncoding		
19	44	TOP2A	rs1141364	coding-synon	AAA AAG	K K
23	48	KRT10	rs12231	noncoding		
23	48	KRT10	rs1132259	coding-nonsynon	CAT CGT	H R
23	48	KRT10	rs1132257	coding-synon	CTG TTG	L L
23	48	KRT10	rs1132256	coding-synon	GCC GCT	A A
23	48	KRT10	rs1132255	coding-synon	CTG TTG	L L
23	48	KRT10	rs1132254	coding-synon	GGC GGT	G G
23	48	KRT10	rs1132252	coding-synon	TTC TTT	F F

Table 4 (continued)

DNA SEQ ID NO:	Protein SEQ ID NO:	Gene Name	DBSNPID	Type	Codon	AA-Seq
23	48	KRT10	rs1132268	coding-nonsynon	CAG GAG	Q E
23	48	KRT10	rs1132258	coding-nonsynon	CGG TGG	R W

Table 5

PRIMER	SEQUENCE
CACNB1	FAM 5' CCATATATAAAACCACTGTCCTTTGTGGCT 3'TAMRA
CACNB1FOR	5' CCCCCATCTGTCTGTCTATATTGTC 3'
CACNB1REV	5' TGCCTACGCTGACGACTATGTG 3'
CDC6	FAM 5' TTTGGTTTCTACAACTGTTGCTAT 3'TAMRA
CDC6FOR	5' GGGCTCCACACACCAGATG 3'
CDC6REV	5' ACGCTCTGAGCACCCCTCTACA 3'
EBI1-1	FAM 5' TGTACAGGGACTGAAAACCTCTCCTCATGT 3'TAMRA
EBI1-1 FOR	5' CCCAAGGCCACGAGCTT 3'
EBI1-1 REV	5' TGTGCTCTCTTAACGAATCGAAA 3'
EBI1-2	FAM 5' CTGGTCAACAAACTCTCTGAACCCCTCC 3'TAMRA
EBI1-2 FOR	5' TGGTGAGGAAAGCGGACAT 3'
EBI1-2 REV	5' CTGGCTTGGAGGACAGTGAAG 3'
GCSF	FAM 5' CCAAGCCCTCCCCATCCCATGTAT 3'TAMRA
GCSF FOR	5' GAGGTGTCGTACCGGTTCTA 3'
GCSF REV	5' CCGTTCTGCTCTTCCCTGTCT 3'
GRB7	FAM 5' CCAGACCCGCTTCACTGACCTGC 3'TAMRA
GRB7 FOR	5' CGCCTGTACTTCAGCATGGA 3'
GRB7 REV	5' GCGGTTCAAGTGGTGA 3'
HKA3	FAM 5' ACCCCGAGGCATCACCACAAATCAT 3'TAMRA
HKA3 FOR	5' AGTTCTGCCTCTCTGACAAACCAT 3'
HKA3 REV	5' TAGGCTCAGAGTCAGACCCAAAC 3'
MLN50	FAM 5' CCCTCGTGGGCTTGTGCTCGG 3'TAMRA
MLN50 FOR	5' AAGCCGCCAGTTCACTCTTTT 3'
MLN50 REV	5' CTGTGTGTTCAAGTCAATGTTTCAG 3'
MLN64-1	FAM 5' TCTGCCTGCGCTCTCGTCGGT 3'TAMRA
MLN64-1 FOR	5' GGGCTGGGACCTGACTT 3'

Table 5 (continued)

PRIMER	SEQUENCE
MLN64-1REV	5' CCCAACAAAGGTCCCAGACT 3'
MLN64-2	FAM 5' CGGCGCATTGAGCGGCG 3'TAMRA
MLN64-2 FOR	5' CCCAAGGGACTTCGTGAATG 3'
MLN64-2REV	5' GGGGATCCCTGATGACAAAGTA 3'
PPARBP	FAM 5' AGCACCAACTGTGAACCAAGGTACAATGGC 3'TAMRA
PPARBP FOR	5' GAGGGAGGCTCTGCTTTGG 3'
PPARBP REV	5' TCACAACTAGCGGGTGAGGAG 3'
PSMD3	FAM 5' TGCAGAGGAACGGCGTGAGCG 3'TAMRA
PSMD3 FOR	5' TGAGGTTTCTCTCCAAATCGTA 3'
PSMD3 REV	5' CAGCTCAAGGGAAGCTGTCATC 3'
RAR	FAM 5' CCCCCACATGTTCCCAAGATGCT 3'TAMRA
RAR FOR	5' GGAGGGCGCTAAAGGTCTACGT 3'
RAR REV	5' TGATGCTTCGCAGGTCAGTAA 3'
RPL23A	FAM 5' CTCCTGCCCTCTCTAAAGCTGAAGCC 3'TAMRA
RPL23A FOR	5' GGACGCGTGGGCTTTTC 3'
RPL23A REV	5' TGTGGCTGTGGACACCTTTC 3'
RPL19	FAM 5' CCACAAGCTGAAGGCAGACAAGGCC 3'TAMRA
RPL19 FOR	5' GCGGATTCTCATGGAAACACA 3'
RPL19 REV	5' GGTCAGCCAGGAGCTTCTTG 3'
NEUROD2	FAM 5' ACCACCTTGGCAGGTTGTCCAG 3'TAMRA
NEUROD2 FOR	5' CGCATGCCAGCCTGAAC 3'
NEUROD2 REV	5' GTCTCGATCTTGGACAGCTTCTG 3'
TELE TELETHONIN	FAM 5' AACTGTCCACACGCCCCGAGG 3'TAMRA
TELE TELETHONIN FOR	5' CTGGGCAGAAATGGAAGGATCT 3'
TELE TELETHONIN REV	5' GGGACTCTAGCAGACCCACACT 3'
PENT PNMT	FAM 5' CACCCACCTGGATTCCCTGTTTC 3'TAMRA
PENT PNMT FOR	5' CCTTCAGACAGGCGTAGATGATG 3'
PENT PNMT REV	5' GGGTATTATTCTTTATTAGGTGCCACTT 3'

Table 5 (continued)

PRIMER	SEQUENCE
HER2/NEU;ERBB2	FAM 5' TTCCCTAAGGCTTTCAGTACCCAGGATCTG 3'TAMRA
HER2/NEU;ERBB FOR	5' CCAGCTTGGCCCTTTTCCT 3'
HER2/NEU;ERBB REV	5' GAATGGGTGCTTTTGTCTTAG 3'
KIA0130	FAM 5' TCACGGACCTCAGCCCTGCCCT 3'TAMRA
KIA0130 FOR	5' TGGTGAAGGTGTCAGCCATGT 3'
KIA0130 REV	5' TCAGAGTGCAGCAATGGCTTT 3'
THRA	FAM 5' ACCTCCTTCCCCAGCTCCCC 3'TAMRA
THRA FOR	5' GGCAACATCTTACTTGTCTTTGA 3'
THRA REV	5' CCAAGGAAGCACAGACAATATTTC 3'
MLN51	FAM 5' TCCTCCCTATCCATGGCACTAAACCACTTC 3'TAMRA
MLN51 FOR	5' TGGGCAAGGGCTCCTATCT 3'
MLN51 REV	5' GTTACCCCTGGCAGACGTATG 3'
TOP2A	FAM 5' TGCCTCTGAGTCTGAATCTCCCAAAGAGAGA 3'TAMRA
TOP2A FOR	5' GAGTAGTTATGTGATTATTTTCAGCTCTTGAC 3'
TOP2A REV	5' TCAAAATGTTGTCCCCGAGTCT 3'
KRT10	FAM 5' CAGAAATTCGGAAGACAGAACTATTGTCATGCCT 3'TAMRA
KRT10 FOR	5' GATTAGTAACCCATAGCAGTTGAAGGT 3'
KRT10 REV	5' ATTTACTGACGGTGGTCTGAACATAC 3'
K12 KRT12	FAM 5' TGACAGACTCCAAATCACAAGCACAGTCAAC 3'TAMRA
K12 KRT12 FOR	5' TGATGGTTTGGAGGAAAGTTTATT 3'
K12 KRT12 REV	5' TTTGGTTGGTCTTTAGAGGAATC 3'
NR1D1	FAM 5' TGCCCAACCATGCATCAGGTAGCCC 3'TAMRA
NR1D1 FOR	5' CAGCTCACCTGGCAACTTCA 3'
NR1D1 REV	5' CCTGATTTTCCCAGCGATGT 3'
HSERBT1	FAM 5' CGCCGCTCCGGTCTGCT 3'TAMRA
HSERBT FOR	5' TGGCCAAGCGTAAGCTGATT 3'
HSERBT REV	5' GCTGCAGTGATCGGATCATCT 3'
MLLT6	FAM 5' CACCATGGAGCCCATCGTGTG 3'TAMRA
MLLT6 FOR	5' ATCCCCGAGGTGCAATTG 3'

Table 5 (continued)

PRIMER	SEQUENCE
MLLT6 REV	5' AGCGATCATGAGGCACGTACT 3'
ZNF144	FAM 5' CCTGCCAGATAGGAGACCCAGACAGCT 3'TAMRA
ZNF144 FOR	5' ATCCCCCTGAGCCTTTTCA 3'
ZNF144 REV	5' CAGCCTCTGGTCCCAACAT 3'
PIP5K2B	FAM 5' TGATCATCAATTCCAAACCTCTCCCGAA 3'TAMRA
PIP5K2B FOR	5' CCCCATGGTGTCCGAAAC 3'
PIP5K2B REV	5' TGCCAGGAGCCTCCATACC 3'
TEM7	FAM 5' CAGCCTTCTAAACACAATGTATTCAATG 3'TAMRA
TEM7 FOR	5' CCTGAACCTTAATGGTAGAATTCAGATC 3'
TEM7 REV	5' TATTAACACTGAGAATCCATGCAGAGA 3'
ZNFN1A3	FAM 5' TATCTGGTCTCAGGGATTGCTCCTATGTATTTCAGC 3'TAMRA
ZNFN1A3 FOR	5' CACAGAGCCCTGCTGAAGTG 3'
ZNFN1A3 REV	5' GCGAGGTCATTGGTTTITAGAAA 3'
WIRE	FAM 5' CTGTGATCCGAAATGGTGCCAG 3'TAMRA
WIRE FOR	5' CCGTCTCCACATCCAAACCT 3'
WIRE REV	5' ACCCATGCATTCGGTATGGT 3'
PSMB3	FAM 5' AGTGGCACCTGCGCCGAACAA 3'TAMRA
PSMB3 FOR	5' CCCCATGGTGACTGATGACTT 3'
PSMB3 REV	5' CCAGAGGGGACTCACACATTCC 3'
MGC9753	FAM 5' CCAGAAACTTCCATCCCAAGGCAGTCT 3'TAMRA
MGC9753 FOR	5' CTGCCCCACAGGAATAGATG 3'
MGC9753 REV	5' AAAAATCCAGTCTGCTTCAACCA 3'
ORMDL3	FAM 5' AGTGCCCCCAGCTCCACGGA 3'TAMRA
ORMDL3 FOR	5' TCCCTGATGAGCGTGCTTATC 3'
ORMDL3 REV	5' TCTCAGTACTTATTGATTCCAAAAATCC 3'
MGC15482	FAM 5' TCCAGTGAAGCAACCCAGTGTTTC 3'TAMRA
MGC15482 FOR	5' CACTTCTAGAGCTACCGTGGAGTCT 3'
MGC15482 REV	5' CCCTCACTTTGTAAACCTTGCT 3'
PPP1R1B	FAM 5' CAGCGTGGCGCAACAACCCA 3'TAMRA

Table 5 (continued)

PRIMER	SEQUENCE
PPP1R1B FOR	5' GGGATTGTTTCGCCACACATA 3'
PPP1R1B REV	5' CCGATGTTAAGGCCCATAGC 3'
MGC14832	FAM 5' TAAATGTCCGGCCAAACATGAGTTCCC 3'TAMRA
MGC14832 FOR	5' CGCAGTGCCTGGCACAT 3'
MGC14832 REV	5' GACACCCCTGACCTATGGA 3'
LOC51242	FAM 5' CAGTGACCTCTCCCGTTCCTTGGA 3'TAMRA
LOC51242 FOR	5' TGGTCCCTGTGTCTCTTC 3'
LOC51242 REV	5' AGGGTCAGGAGGGAGAAAC 3'
FLJ20291	FAM 5' CCAGTGCCCAACCCGTTAAAGAGTCAA 3'TAMRA
FLJ20291 FOR	5' TTGTGGGACACTCAGTAACCTTTGG 3'
FLJ20291 REV	5' ACAAGCACTCCCAACCGAGAT 3'
PRO2521	FAM 5' AGTCTGTCTCCTCACTGCCATCGCCA 3'TAMRA
PRO2521 FOR	5' AAGCCTCTGGGTTTCCCTTT 3'
PRO2521 REV	5' CCCACTGGTGACAGGATGGT 3'
Link-GEFII	FAM 5' CATCTGACATCTTCCCGTGGAG 3'TAMRA
Link-GEFII FOR	5' CTTTGCACGATGTCTCAACCA 3'
Link-GEFII REV	5' TTTCCCGTGGAGCAGGAA 3'
CTEN	FAM 5' CCGCCGCCTAATATGCAACATTAGGG 3'TAMRA
CTEN FOR	5' CGAGTATTCCAAAGCTGGTATCG 3'
CTEN REV	5' ATCACAGAGAGATGGCCCTATCT 3'

Table 6

No.	ID	forward	reverse	PCR size (bp)	GB ID
1	D17S946	ACAGTCTATCAAGCAGAAAAATCCT	TGCCGTGCCAGAGAGA	128-142	Z24029
2	D17S1181	GACAAACAGAGCAGACTCCC	GCCAGCCTGTCACTTATTC	122	-
3	D17S2026	TGGTCATTCCGACAAACGAA	CAGCATTGGATGCAATCC	171-318	G05498 X53777
4	D17S838	CTCCAGAATCCAGACCATGA	AGGACAGTGTAGCCCTTC	71-103	Z51080
5	D17S250	GGAGAATCAAAATAGACAAT	GCTGGCCATATATATTTAAACC	151	-
6	D17S1818	CATAGGTATGTTCAAAATGTGA	TGCCTACTGGAAACCAGA	119-151	Z52895
7	D17S614	AAGGGGAAGGGCTTTCAAAGCT	NGGAGGTGCAGTGAGCCAAGAT	136	L29873
8	D17S2019	CAAAAGCTTATGATGCTCAAACC	TTGTTCCCTTTGACTTCTGA	151-152	G07286 Z39013
9	D17S608	TAGGTTACCTCTCATTTCTTCAG	GTCTGGGTCTTTATGNGCTTGTG	136	L29870
10	D17S1655	CGGACCAGAGTGTCCATGG	GCATACAGCACCCCTCTACCT	240	-
11	D17S2147	AGGGGAGAAATAAAATCTGTGG	CAGGAGTGAGACACTCTCCATG	138	G15195
12	D17S754	TGGATTCACTGACTCAGCCTGC	GCGTGTCTCTCCATGTGTGC	145	-
13	D17S1814	TCCCCAATGACGGTGATG	CTGGAGGTGGCTTGTGGAT	150-166	Z52854
14	D17S2007	GGTCCCACGAATTTGCTG	CCACCCAGAAAAACAGGAGA	102-103	G07073 X03438
15	D17S1246	TCGATCTCCTGACCTTGTA	TTGTCACCCCATTGCCTTTC	115	-
16	D17S1979	CCTTGGATAGATTCACTCCC	CTGTCCCTTCTCAATCCTCC	199	G11172 X55068
17	D17S1984	TTAAGCAAGGTTTAAATTAAGCTGC	GATTACAGTGCTCCCTCTCCC	134	G14779 T50487
18	D17S1984	GGTTTAAATTAAGCTGCATGGC	GATTACAGTGCTCCCTCTCCC	126	G11580 T50487
19	D17S1867	AGTTTGACACTGAGGCTTTG	TTTAGACTTGGTAACITGCCG	94	Z51301
20	D17S1788	TGCAGATGCCCTAAGAACTTTTCAG	GCCATGATCTCCCAAAGCC	156-168	Z52160
21	D17S1836	TCGAGGTTATGGTGAGCC	AAACTGTGTGTGTCAAAGGATACT	167-173	Z53182
22	D17S1787	GCTGATCTGAAGCCAATGA	TACATGAAGGCATGGTCTG	239-251	Z52130
23	D17S1660	CTAATATAATCCTGGGCACATGG	GCTGCGGACCAGACAGAT	201	G06069
24	D17S2154	GATAAAAACAAGCACTGGCTCC	CCCACGGCTTCTTGTATCTA	137	G15440
25	D17S1955	TGTAATGTAAGCCCCCATGAGG	CACTCAACTCAACAGTCTAAAGGTG	180	G11900
26	D17S2098	GTGAGTTCAAGCATAGTAATTATCC	ATTCAGCCTCAGTTCACTGCTTC	181	G13994
27	D17S518	GATCCAGTGGAGACTCAGAG	TAGTCTCTGGGACACCCAGA	88 - 100	X60690
28	D17S1851	ATTCTTGAGTGTCTACCCCTGTTGAG	ACTGACTGCGCCACTGC	237 - 253	Z53675
29	D11S4358	TCGAGAAAGGACAAAATCACC	GAACAGGGTTAGTCCATTCCG	58	-

Table 6 (continued)

No.	ID	forward	reverse	PCR size (bp)	GB ID
30	D17S964	GTTCTTTCCCTCTTGTTGGG	AGTCAGCTGAGATTGTGCC	224	L36695
31	D19S1091	CAAGCCAAAGACATCCCAGTT	CCCCACACAGCTCATATG	238	G14589
32	D17S1179	TTTTCTCTCATTCATTGGG	GCAACAGAGGGAGACTCCAA	113 - 125	-
33	D10S2160	TCCCATCCCGTAAGACCTC	TATGGAGTACCTACTCTATGCCAGG	349	G06592
34	D17S1230	ATTCAAAGCTGGATCCCTTT	AGCTGTGACAAATGCCTGTA	108	L32949
35	D17S1338	TCACCTGAGATTGGGAGACC	AAGATGGGGCAGGAATGG	178 - 200	-
36	D17S2011	TCACTGTCTCCAAAGCCAG	AAACACCACACTCTCCCTG	115	G07143
37	D17S1237	TTCTTGGGCTTCCCGTAGCC	GGGGCAGACGACTTCTCCTT	186	L32947
38	D17S2038	GGGATACAACTTTAAAGTTCC	ATTCACCTAATGAGGATTCTTCTTT	228	G6219
39	D17S2091	GCTGAAATAGCCATCTTGAGCTAC	TCCGCATCCTTTTAAAGAGGCAC	157	G13941
40	D17S649	CTTTCACCTCTTTCAGCTGAAGAGG	TGACGTGCTATTTCTGTTTTGTCT	146	L36685
41	D17S1190	GTTTGTGCTATGCCTGC	CAACACACTACCCACGGA	122	L18197
42	M87506	ACTCCTCATCTGTAGGGTCT	GAGTCCGCTACCTGAGTGCT	102 - 120	m87506

SEQUENCE LISTING

<110> Bayer AG

<120> METHODS AND COMPOSITIONS FOR THE PREDICTION, DIAGNOSIS, PROGNOSIS,
PREVENTION AND TREATMENT OF MALIGNANT NEOPLASIA

<130> LaA 36108.1 EP

<150> EP02010291.9

<151> 2002-05-21

<160> 314

<170> PatentIn version 3.1

<210> 1

<211> 3846

<212> DNA

<213> Homo sapiens

<400> 1

gcctcccgcc	agctcgccctc	ggggaacagg	acgcgcgtga	gctcaggcgt	ccccgcccc	60
gcttttctcg	gaaccatgaa	ccccaactgc	gcccgggtcg	gcaagatcgt	gtatcccacg	120
gagaagggtga	actgtctgga	taagttctgg	cataaagcat	gottccattg	cgagacotgc	180
aagatgacac	tgaacatgaa	gaactacaag	ggctacgaga	agaagcccta	ctgcaacgca	240
cactacccca	agcagtcctt	caccatggtg	gcggacaccc	cgaaaaacct	tcgcctcaag	300
caacagagtg	agctccagag	tcaggtgcgc	tacaaggagg	agtttgagaa	gaacaagggc	360
aaaggtttca	gcgtagtggc	agacacgccc	gagctccaga	gaatcaagaa	gacccaggac	420
cagatcagta	atataaaata	ccatgaggag	tttgagaaga	gccgcatggg	ccctagcggg	480
ggcgagggca	tggagccaga	gcgtcgggat	tcacaggacg	gcagcagcta	ccggcgggcc	540
ctggagcagc	agcagcctca	ccacatcccc	accagtgcgc	cggtttacca	gcagcccag	600
cagcagccgg	tggcccagtc	ctatggtggc	tacaaggagc	ctgcagcccc	agtctccata	660
cagcgcagcg	ccccagggtg	tggcgggaag	cggtagcgcg	cgggtgatga	ctacagcgcc	720
gccgacgagg	acgaggtctc	cttcacggac	ggggacacca	togtcaacgt	gcagcagatc	780
gaacgagcgt	ggatgtacgg	gaagggtggg	cgcaccggcg	acacggggat	gctgcggggc	840
aactacgtgg	aggccatctg	aacccggagc	gcccccatct	gtcttcagca	cattccacgg	900
catcgcatcc	gtcctggggc	tgagccgtcc	attcttcagt	gtctctgttt	tttaaacct	960

5 ggcacagctt gtgattccta cccctcttcc agcttctttt gccaaactgaa gccttcttct 1020
 gccacttctg cgggctccct cctctggcag gcttcccccg tgatcgactt cttggttttc 1080
 tctctggatg gaacgggtat gggcctctct gggggaggca gggctggaat gggagacctg 1140
 ttggcctgtg ggcctcacct gccctctgt tctctcccct cacatcctcc tgcccagctc 1200
 ctcacatacc cacacattcc agggctgggg tgagcctgac tgccaggacc ccaggtcagg 1260
 ggctccotac attccccaga gtgggatcca cttcttggtt cctgggatgg cgatggggac 1320
 totgccctg tgtagggacc agtgggatgg gctctacctc tctttctcaa agagggggct 1380
 ctgcccacct ggggtctctc tccctacctc cctcctcagg ggcaacaaca ggagaatggg 1440
 10 gttcctgtgt tggggcgaat tcatccctc cccgcgcgtt ccttcgcaca ctgtgatttt 1500
 gccctcctgc ccacgcagac ctgcagcggg caaagagctc ccgaggaagc acagcttggg 1560
 tcaggttctt gcctttctta attttaggga cagctaccgg aaggagggga acaaggagt 1620
 ctcttcogca gcccctttcc ccacgcccac cccagctc cagggaccct tgccctgcctc 1680
 ctaggctgga agccatggtc ccgaagtgtg gggcaagggt gcctcaggac cttttggtct 1740
 tcagcctccc tcagcccca ggatctgggt taggtggccg ctcctccctg ctcctcatgg 1800
 15 gaagatgtct cagagccttc catgaacctc cctcccagc ccaatgocaa gtggacttgg 1860
 agotgcacaa agtcagcagg gaccactaaa totccaagac ctggtgtgag gaggcaggag 1920
 catgtatgtc tgcagggtgc tgacacgcaa gtgtgtgagt gtgagtgtga gagaatgggg 1980
 gggggtgtgt ctgtagggtg ctctgggctt gtgtgtgggt ggggttatgt gagggatgga 2040
 agagctgtct tcccctgaga gtttctctag aaccacagt gagaggggag ggctcctggg 2100
 20 gcagagaagt tccctagggt ttctttggaa tggtgtcagg tggaaggtaa gaggttgggtg 2160
 ggaggaagcc caccatcttg ccttttgag tgtgtcaggg taagcgggtg aggaaggcto 2220
 tggagtgggg gctgccatag ggtctgcagc ctgctggggc taagcgggtg aggaaggcto 2280
 tgtcactcca ggcatagttt tcccctctc tgtctggggc tacagaatag ggtggcagaa 2340
 gtgtcaccct gtgggtgtct cctctggggg ctcttcccct agacctcccc ctcacttaca 2400
 25 taaagctccc ttgaagcaag aaagaggggc ccagggtgc aaaactggaa gcacagcctc 2460
 ggggatgggg agggaaagac ggtgctatat ctagttctct ctctctgctc atgggtggct 2520
 gtgacaaccc tggcctcact tgattcatct ctggttttct tgccaccctc tgggagtccc 2580
 catoccatth tcatcctgag cccaaccagg cctgccatt ggctcttctt ccttggcac 2640
 acttgtaccc acagggtgagg ggcaggacct gaaggtattg gcctgttcaa caatcagta 2700
 30 tcatgggtgt ttttgtcaac tgcttgttaa ttgatttggg gatgtttgac ccgaatgaga 2760
 gggttaggaa aagactgtgg gtggggaggc cctgcctgac ccacccctt tctttctgg 2820
 cccagccta ggtggaggca agtggaatat cttatattgg gcgatttggg ggctcgggga 2880
 ggcagagaat ctcttgggag tottgggtgg cgctgggtga ttctgtttcc tcttgatctc 2940
 aaagcacaat gtggatttgg ggaccaaagg tcagggacac atccccttag aggacctgag 3000
 tttgggagag tgggtgagtgg aaggaggagg cagcaagaag cagcctgttt tcaotcagct 3060
 35 taattctcct tcccagataa ggcaagccag tcatggaatc ttgtgtcagg ccctccctct 3120
 actcttctct tccataaaat aggggcccgt ttottacaca ccccagaga gaggagggac 3180
 tgtcacactg gtgctgagtg accgggggct gctgggctc tgttctttac caaaaccatc 3240
 catccctaga agagcacaga gccctgaggg gctgggctga gccctgggtc 3300
 ttctotacag ttcacagagg totttcagct catttaatcc caggaaagag gcatacaagc 3360
 40 tagaatgtga atataacttt tgtgggcoaa tactaagaat aacaagaagc ccagtgggtga 3420
 ggaaagtgcg ttctoccagc actgcctcct gttttctccc tctcatgtcc ctccagggaa 3480
 aatgacttta ttgcttaatt totgcotttc cccctcaca catgcacttt tgggcctttt 3540
 tttatagctg gaaaaaacia aataccacco tacaacctg tatttaaaaa gaaacagaaa 3600
 tgaccacgtg aaatttgct ctgtccaaac atttcatcgg tgtgtatgtg tatgtgtgtg 3660
 45 agtgtgtgaa gccgccagt catottttta tatggggttg ttgtctcatt ttggtctgtt 3720
 ttggctccct cctcgtggg cttgtgctcg ggatcaaac tttctggcct gttatgattc 3780
 tgaacatttg acttgaacca caagtgaatc tttctcctgg tgactcaaat aaaagtataa 3840
 ttttta

<210> 2

<211> 1711

<212> DNA

<213> Homo sapiens

<400> 2

5	gaggggaagggc	aggaaggagg	cagccgaagg	cagagctggg	tggtgggacc	gggtgctggc	60
	tgccgcgcgt	gcttttcggct	cccacggcct	ctcccatgcg	ctgagggagc	ccggctgcgg	120
	gccggcgggc	ggagggggagg	ctcctctcca	tggtccagaa	gaccagcatg	tcccggggcc	180
	ottacocacc	ctcccaggag	atcccatg	aggctctcga	ccccagcccg	cagggcaaat	240
10	acagcaagag	gaaagggcga	ttcaaacggt	cagatgggag	caogtctcgc	gataccacat	300
	ccaacagctt	tgctccgccag	ggctcagcgg	agtcctacac	cagccgtcca	tcagactctg	360
	atgtatctct	ggaggaggac	cgggaagcct	taaggaagga	agcagagcgc	caggcattag	420
	cgagctcga	gaaggccaag	accaagccag	tgccatttgc	tggtcggaca	aatgttggct	480
	acaatccgtc	tccaggggat	gaggtgcctg	tgccaggagt	ggccatcacc	ttcgagccca	540
	aagaottcct	gcacatcaag	gagaaataca	ataatgactg	gtggatcggg	cggtgggtga	600
15	aggagggctg	tgaggttggc	ttcattccca	gcccgtcaa	actggacagc	cttogcctgc	660
	tgccaggaaca	gaagctgcgc	cagaacggcc	tcggctccag	caaatacaggc	gataactcca	720
	gttcagctct	gggagatgtg	gtgactggca	cccgccggcc	cacacccct	gccagtgcga	780
	aacagaagca	gaagtgcaca	gagcatgtgc	ccccctatga	cgtgggtgcct	tccatgaggc	840
	ccatcatcct	ggtgggacog	tcgctcaagg	gctacgaggt	tacagacatg	atgcagaaag	900
20	ctttatttga	cttcttgaag	oatcggtttg	atggcaggat	ctccatcact	cgtgtgacgg	960
	cagatatttc	cctggctaag	cgctcagttc	tcaacaaccc	cagcaaacac	atcatcattg	1020
	agcgtccaa	cacacgctcc	agcctggctg	agggtgcagag	tgaaatcgag	cgaatottcg	1080
	agctggcccg	gaoccttcag	ttggctcgctc	tggtatgctga	caccatcaat	caccagcccg	1140
	agctgtccaa	gacctcgctg	gcccccatca	ttgtttacat	caagatcacc	tctcccaagg	1200
25	tacttcaag	gctcatcaag	tcccaggagaa	agtctcagtc	caaacacctc	aatgtccaaa	1260
	tagcggcctc	ggaaaagctg	gcacagtgc	cccctgaaat	gtttgacatc	atcctggatg	1320
	agaaccaatt	ggaggatgcc	tgccagcatc	tgccggagta	cttgggaagcc	tattggaagg	1380
	ccacacaccc	gcccagcagc	acgccaccca	atccgctgct	gaaccgcacc	atggctaccg	1440
	cagccctgog	ccgtagccct	gcccctgtct	ccaacctcca	ggtacagggt	ctcacctcgc	1500
	tcaggagaaa	cctcggtctc	tgggggcggc	tgagtgctc	acagcggggc	agtgtgggtg	1560
30	cccaggagca	ggaacatgcc	atgtagtggg	cgccctggcc	gtcttccctc	ctgctotggg	1620
	gtcggaactg	gagtgacggg	aacatggagg	aggaagggaa	gagctttatt	ttgtaaaaaa	1680
	ataagatgag	cggcaaaaaa	aaaaaaaaaa	a			1711

<210> 3

<211> 698

<212> DNA

<213> Homo sapiens

<400> 3

45	ttttcctttc	gctgctgcgg	ccgcagccat	gagtatgctc	aggcttcaga	agaggctcgc	60
	ctctagtgtc	ctccgctgtg	gcaagaagaa	ggctctggtta	gaccccaatg	agaccaatga	120
	aatogccaat	gccaaactccc	gtcagcagat	ccggaagctc	atcaaagatg	ggctgatcat	180
	ccgcaagcct	gtgacgggtc	attcccgggc	tcgatgcggg	aaaaacacct	tgcccccgcg	240
	gaagggcagg	cacatgggca	taggtaagcg	gaaggggtaca	gccaatgccc	gaatgccaga	300
	gaaggtcaca	tggtatgagga	gaatgaggat	tttgccggcg	ctgctcagaa	gataccgtga	360
50	atctaagaag	atcgatcgcc	acatgtatca	cagcctgtac	ctgaagggtga	aggggaatgt	420
	gttcaaaaac	aagcggattc	tcatggaaca	catccacaag	ctgaaggcag	acaaggcccg	480
	caagaagctc	ctggctgacc	aggctgaggc	ccgcaggtct	aagaccaagg	aagcacgcaa	540
	gcgccgtgaa	gagcgcctcc	aggccaagaa	ggaggagatc	atcaagactt	tatccaagga	600
	ggaagagacc	aagaaataaa	acctcccact	ttgtctgtac	atactggcct	ctgtgattac	660
55	atagatcagc	cattaaaata	aaacaagcct	taactctgc			698

<210> 4

<211> 5810

<212> DNA

<213> Homo sapiens

<400> 4

gggaagatgg	cggcggcctc	gagcaccctc	ctcttcttgc	cgccggggac	ttcagattga	60
tccttcccg	gaagagtagg	gactgctggt	gocctgcgtc	ccgggatccc	gagccaactt	120
gtttcctccg	ttagtgttgg	ggaagggctt	atccttttgt	ggcggtata	gcttctcctc	180
gcottcagga	tgaaagctca	ggggggaaac	cgaggagtoa	gaaaagctga	gtaagatgag	240
ttctctcctg	gaacggctcc	atgcaaaatt	taaccaaaat	agaccctgga	gtgaaaccat	300
taagcttgtg	cgtoaagtca	tggagaagag	ggttgtgatg	agttctggag	ggcatcaaca	360
tttggtcagc	tgtttgagag	cattgcagaa	ggctctcaaa	gtaacatctt	taccagcaat	420
gactgatcgt	ttggagtcca	tagcaggaca	gaatggaotg	ggctctcctc	tcagtgccag	480
tggcactgaa	tgttacatca	cgtcagatat	gttctatgtg	gaagtgcagt	tagatcctgc	540
aggacagcct	tgtgatgtaa	aagtggctca	ccatggggag	aatcctgtga	gctgtccgga	600
gcttgtacag	cagctaaggg	aaaaaaattc	tgatgaattt	tctaagcacc	ttaaggggct	660
tgtaaatctg	tataaccttc	caggggacaa	caaactgaag	actaaaatgt	acttggctct	720
ccaatcctta	gaacaagatc	tttctaaaat	ggcaattatg	tactggaaag	caactaatgc	780
tgttcccttg	gataagattc	ttcatggaag	tggtggctat	ctcacacca	ggagtggggg	840
tcatttaaatg	aacctgaagt	actatgtctc	tcottctgac	ctactggatg	acaagactgc	900
atctccatc	attttgcatg	agaataatgt	ttctcgatct	ttggcatga	atgcatcagt	960
gacaattgaa	ggaacatctg	ctgtgtacaa	actcccaatt	gcaccattaa	ttatggggtc	1020
acatccagtt	gacaataaat	ggaccccttc	cttctcctca	atcaccagt	ccaacagtgt	1080
tgatcttctc	gcotgtttct	tottgaaatt	tccccagcca	atcccagtat	ctagagcatt	1140
tgttcagaaa	ctgcagaact	gcacaggaa	tccattgttt	gaaactcaac	caacttatgc	1200
accctgttat	gaactgatca	ctcagtttga	gctatcaaag	gacctgacc	ccataccttt	1260
gaatocacaac	atgagatttt	atgctgctct	tctgggtcag	cagcactgct	atttctcaa	1320
caaggatgct	cctgttccag	atggccgaag	tctacagggg	acccttggtt	gcaaaatcac	1380
ctttcagcac	octggccgag	ttctctttat	octaaaatgt	atcagacacc	aagtggccta	1440
taacaccctc	attggaagct	gtgtcaaaag	aactattotg	aaagaagatt	ctcctgggct	1500
tctccaattt	gaagtgtgtc	ctctctcaga	gtctcgtttc	agcgtatctt	ttcagcacc	1560
tggtgaatgac	tcctgtgtgt	gtgtggtaat	ggatgtgcag	ggcttaacac	atgtgagctg	1620
taaactctac	aaagggctgt	cggtgtgact	gatctgcaca	gatgaattca	ttgccaaagt	1680
tgttcaaaga	tgatatgtcca	ttcotgtgac	gatgagggct	attcggagga	aagctgaaac	1740
cattcaagcc	gacacccag	caactgtccot	cattgcagag	acagttgaag	acatggtgaa	1800
aaagaacctg	ccccgggcta	gcagcccagg	gtatggcatg	accacaggca	acaacccaat	1860
gagtgggtacc	actacatcaa	ccaacacott	tccggggggg	cccattgcca	ccttgtttta	1920
tatgagcatg	agcatcaaag	atoggcata	gtoggtgggc	catggggagg	acttcagcaa	1980
ggtgtctcag	aacccaattc	ttaccagtgt	gttgcaaatc	acagggaaac	gggggtctac	2040
cattggctcg	agtcgcgccc	ctcotcatca	caogccgcca	cctgtctctt	cgatggccgg	2100
caacaccaag	aaccacccga	tgctcatgaa	cottctcaaa	gataatcttg	cccaggattt	2160
ctcaaccttt	tatggaagca	gcccttttaga	aaggcagaac	tcctcttccg	gctcaccocg	2220
catggaaata	tgctcgggga	gcaacaagac	caagaaaaag	aagtcatcaa	gattaccacc	2280
tgagaaacca	aagcaccaga	ctgaagatga	ctttcagagg	gagctatttt	caatggatgt	2340
tgactcacag	aacctatatc	ttgatgtcaa	catgacagct	gacacgctgg	atacgccaca	2400
catcaactcca	gtctcaagcc	agtgtagcac	tcccccaaca	acttaccac	aaccagtacc	2460
tcacccccaa	cccagtattc	aaaggatggt	ccgactatcc	agttcagaca	gcattggccc	2520
agatgtaaact	gacatccttt	cagacattgc	agaagaagct	tctaaaactc	ccagcactag	2580
tgatgattgc	ccagccattg	gcacccctct	tcagattctc	tcaagctctg	ggcattctca	2640
gagtaccctg	tttgaacttg	atgtctttca	aactaacaat	aatgaaaaatc	cataacttga	2700
tccagctgat	cttattgcag	atgctgtctg	aagcccccag	agtgactctc	ctaccaatca	2760
tttttttcat	gatggagtag	atttcaatcc	tgattttattg	aacagccaga	gccaaagtgg	2820
ttttggagaa	gaatatattt	atgaaagcag	ccaaagtggg	gataatgatg	atttcaaagg	2880

atttgcattct caggcaactaa atacttttggg ggtgccaatg cttggagggtg ataatgggga 2940
 gaccaagttt aagggaata accaagccga cacagttgat ttcagtatta tttcagtagc 3000
 cggcaagct ttagctcttg cagatcttat ggagcatcac agtggttagtc agggtccttt 3060
 actgaccact ggggacttag ggaagaaaa gactcaaaag agggtaaagg aaggcaatgg 3120
 caccagtaat agtactctct cggggcccggt attagacagc aaaccaggga agcgagtcg 3180
 gacccttct aatgatggga aaagcaaaaga taagcctcca aagcggaaga aggcagacac 3240
 tgagggaag tctcatctc atagttotc taacagacct tttacccac ctaccagtac 3300
 aggtggatct aaatcgccag gcagtgcagg aagatctcag actccccag gtgttgccac 3360
 accaccatt cccaaaatca ctattcagat tctaaggga acagtgatgg tgggcaagcc 3420
 ttctctcac agtcagtata ccagcagtggt ttctgtgtct tctcaggga gcaaaagcca 3480
 ccatagccat tcttctctc cttctctcacc tgcttccacc tcagggaaga tgaaaagcag 3540
 taaatcagaa ggttcacaa gttccaagtt aagtagcagt atgtattcta gccagggggtc 3600
 ttctggatct agocagtcga aaaattcacc coagttctgg ggaagccag gctcctctcc 3660
 cataaccaag catggaotga gcagtggctc tagcagcacc aagatgaaac ctcaaggaaa 3720
 gocatcatca ctatgaato cttctttaag taaaccaaac atatccctt ctcatccaag 3780
 gccacctgga ggtctgaca agcttgctc tccaatgaag cctgttctct gaactcctcc 3840
 atctctaaa gccaaagtcc ctatcagttc aggttctggt gggtctcata tgtotggaac 3900
 tagttcaagc tctggcatga agtcatcttc agggtagga tctcagggt cgttgtcca 3960
 gaaaactccc ccatcatota attctgttac ggcattctcc tctcctttt cctcaagtgg 4020
 ctcttccatg tcatctctc agaaccagca tgggagttct aaaggaaaat cctccagcag 4080
 aaacaagaag cgtccttga cagotgtcat agataaactg aagcatgggg ttgtcaccag 4140
 tggccctggg ggtgaagacc cactggacgg ccagatgggg gtgagcaca attcttccag 4200
 ccatctatg tcttccaaac ataactgtc agggaggag tttcagggca agcgtgagaa 4260
 aagtataaa gacaaatcaa aggtttccac ctccgggagt tcagtggatt cttotaagaa 4320
 gacctcagag tcaaaaaatg tggggagcac aggtgtggca aaaattatca tcagtaagca 4380
 tgatggaggc tccctagca ttaaagccaa agtgactttg cagaaacctg gggaaagtag 4440
 tggagaaggg cttaggctc aaatggctc tcttaaaaac tatggctctc caotcatcag 4500
 tggttccact ccaaagcatg agcgtggctc tccagccat agtaagtcac cagcatatac 4560
 cccccagaat ctggacagt aaagtgagtc aggotcctcc atagcagaga aatottatca 4620
 gaatagtcoc agctcagac atggtatccg accaactcca gaatacagca cagagaaaca 4680
 taagaagcac aaaaaggaaa agaagaaagt aaaagacaaa gatagggacc gagaccggga 4740
 caaagaccga gacaagaaa aatctcatag catcaagcca gagagttggt ccaaatcacc 4800
 catctcttca gaccagtcct tgtctatgac aagtaacaca atottatctg cagacagacc 4860
 ctcaaggctc agccagact ttatgattgg ggaggaagat gatgatctta tggatgtggo 4920
 octgattggg aattaggaac cttatttctc aaaagaaaca gggccagagg aaaaaaact 4980
 attgataagt ttataggcaa accaccataa ggggtgagtc agacaggtct gatttggtta 5040
 agaatcctaa atggcatggc tttgacatca agctgggtga attagaaagg cataccaga 5100
 ccotattaaa gaaccacag ggttgattc tggttaccag gaagtctctt ttgttctgt 5160
 gccagaaaga aagttaaaat acttgcttaa gaaaggagg ggggtgggag ggggtgtagg 5220
 agagggaagg gagggaaaca gttttgtggg aaatattcat atatatctt tctcctctt 5280
 ttocattttt aggccatgtt ttaaactcat tttagtgc atatatgaag ggctgggag 5340
 aaaatgaaaa agcaatcat tcttgatgc atttgcata aggttgttca actttgtttg 5400
 aggtagttgt cgtttgagt catgggcaaa tgaaggactt tggctatttt ggacacttaa 5460
 gtaatgtttg gtgtctgtt cttaggagt actggggag ggaagattat tttagctatt 5520
 tatttgaat attttaaccc tttatctgtt tgttttata cagtgtttcg ttctaaatct 5580
 atgaggttta gggttcaaaa tgatggaagg ccgaagagca aggttatat ggtggtaggg 5640
 agcttatagc ttgtgcta atctagcat caagcccaag caaattagtc agagcccgcc 5700
 ttttaggtta aatataatag aaaaaccaa atgatatttt tattttagga gggtttaaat 5760
 aggttcaga gatcatagga atattaggag ttacctctc gtggagggtat 5810

<210> 5

<211> 5515

<212> DNA

<213> Homo sapiens

[illegible]

	cagotgaatc	aaagtgaatt	ggcagtgtta	ttaaacctgc	tgcagagcca	aaccgacctg	3420
	agcatccctc	aaatggcaca	gctgcttaac	atccactcca	accagagat	gcagcagcag	3480
	ctggaagccc	tgaaccaatc	catcagtgcc	ctgaoggaag	ctacttccca	gcagcaggac	3540
5	tcagagacca	tggccccaga	ggagtotttg	aaggaagcac	cctctgcccc	agtgatcctg	3600
	cottcagcag	aacagatgac	ccttgaagct	tcaagcacac	cagctgacat	gcagaatata	3660
	ttggcagttc	tcttgagtca	gctgatgaaa	acccaagagc	cagcaggcag	tctggaggaa	3720
	aacaacagtg	acaagaacag	tggggccacag	ggggcccgaa	gaactccac	aatgccacag	3780
	gaggaggcag	cagcatgtcc	tcctcacatt	cttccaccag	agaagaggcc	ccctgagccc	3840
	ccoggacctc	caccgcccgc	acctccaccc	cctctgggtg	aaggcgatct	ttccagcgcc	3900
10	ccccaggagt	tgaaccacgc	ogtgacagcc	gccttgctgc	aaottttato	ccagcctgaa	3960
	gcagagcctc	ctggccacct	gccacatgag	caccaggcct	tgagaccaat	ggagtactcc	4020
	acccgacccc	gtccaacacg	gacttatgga	aacactgatg	ggcctgaaac	aggggttcagt	4080
	gccattgaca	ctgatgaacg	aaactctggt	ccagccttga	cagaatcott	ggtccagacc	4140
	ctgggtgaaga	acaggacctt	ctcaggctct	ctgagccacc	ttggggagtc	cagcagttac	4200
15	cagggcacag	ggtcagtgoa	gtttccaggg	gaccaggacc	tcogttttgc	caggggtccc	4260
	ttagcgttac	acccggtggt	cgggcaacca	ttcotgaagg	ctgagggaa	cagcaattct	4320
	gtgggtacatg	cagagaccaa	attgcaaaac	ttggggagc	tgaggccagg	aaocactggg	4380
	gccagcagct	caggagcagg	ccttcaactg	gggggcccac	ctcagttctc	tgcttatgga	4440
	aaactotato	gggggcctac	aagagtccca	ccaagagggg	gaagaggggg	aggagttcct	4500
	tactaaccoc	gagacttcag	tgctcotgaa	gattcctttc	ctatccatcc	ttccatccag	4560
20	ttctctgaat	ctttaatgaa	atcatttgcc	agagcgaggt	aatcatctgc	atttggctac	4620
	tgcaaaagctg	tcogttgtat	tcottgctca	cttgctacta	gcaggcgact	taggaaataa	4680
	tgatgttgcc	accagttccc	cotggatggg	ctatagccag	aacatttact	tcaactctac	4740
	cttagtagat	acaagtagag	aatatggaga	ggatcattac	attgaaaagt	aaatgtttta	4800
	ttagttcatt	gcctgcactt	actggtcgga	agagagaaag	aacagtttoa	gtattgagat	4860
25	ggctcaggag	aggctctttg	atttttaaag	ttttgggggtg	gggggttggtg	tggtggttct	4920
	ttcttttgaa	ttttaattta	ggtgttttgg	gtttttttcc	tttaaagaga	atagtgttca	4980
	caaaaatttga	gctgctcttt	ggcttttgc	ataagggaaa	cagagtggcc	tggtgatttt	5040
	gaataaatgt	ttcttttoct	tccaccatct	cacattttgc	ttttaagtga	acactttttc	5100
	occattgagc	atcttgaaca	tacttttttt	ccaaataaat	tactcatcot	taaagtttac	5160
30	tccactttga	caaaagatac	gcccttctcc	ctgcacataa	agcaggttgt	agaacgtggc	5220
	attcttgggc	aagtaggtag	actttaccca	gtctctttcc	ttttttgctg	atgtgtgctc	5280
	ttctctctct	ttctctctct	ttctctctct	ttctctctct	ttctctctct	ttctctctct	5340
	gotctctctg	ttctctctct	tttgaggcat	ttgtttggaa	aaaatcgttg	agatgcccac	5400
	gaacctggga	taattcttta	ctttttttga	aataaaggaa	aggaaattca	aaaaaaaaaa	5460
	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaa	5515
35	<210> 6						
	<211> 6131						
40	<212> DNA						
	<213> Homo sapiens						
45	<400> 6						
	gaattotagg	cccagttctg	tgtttccct	gtgtgttct	aggcaggtca	gtttccctcc	60
	atgggctctc	gtaagatgag	gagttggaga	ggtacattct	caggctactt	tcaactccca	120
	gccaaagtgc	tcaagagtcc	caggcagcac	cagcaccctc	atctccaagg	cctcctgatg	180
	tggtgtctota	tttagaactt	aatccaacct	acccaacatc	agatcagtgt	cttaccagcc	240
50	caaggctccct	ggggagcctc	ctagagggag	agagccctgc	ccaccagat	tgagggtaaa	300
	ggcctccccc	tgctcatttt	tgtaccacca	cagtgttgg	cacatggtag	acatcaaaat	360
	gtgtgtgtgt	aaagtataat	tgaagttgtg	tatatatgtc	agctagagtg	tctggagggg	420
	cagaaatgtg	ggtctaaaaa	atacaaatgc	tccaaatggg	gtgtgggcaa	gggtotgtct	480
	acaccaggct	gtgattacct	gotcacatac	atgtgtctat	ctgagtaggg	gtatgttatc	540
	tatttttcta	caccacaggg	tgagggaacag	gtatatgtgt	gcattgtgtat	gcattcgtgt	600
55	gtgtgtgtat	gtgtgtgtgc	atgagtggtg	gtgtgtgtgt	ccaaagccac	ctcttcaacc	660

	tgtgccattt	gtatctgtgt	ctggcccaat	gagagtgttg	aaaggtgagc	cacaagataa	720
	aacagcaact	tcctacctcc	cttatcaaga	cagctgtctg	acctacctcc	cottggccac	780
	tcttgggatt	actgggggtt	gcttoagtat	tttcagattt	ttcagaaggg	gaggagaatg	840
5	cttgagtctc	atccagggaac	ttaggcagtt	ctcagcactg	cctgctcctc	ctccctcaaa	900
	taaccaagtc	tgaagaccag	gagagaaagc	cgctggtgga	ctggtcacot	gtctggcagt	960
	gggaggagga	gagttagagg	tttctaggtg	ggaatccaga	cttagaccot	ccccccacc	1020
	occagatggg	tggtgcacag	gotcatctcg	cggccctcc	ccactccacc	ctaactgga	1080
	tacgccccca	acaaccaagg	aaagatctcc	catcggtgga	ctccacagat	acacacatgt	1140
	ccccacagac	acacacaogc	coatgcagag	gcacagacat	coaggcacat	ctttcccttt	1200
10	ctctgtcttt	cccttgggtt	gaattctcgt	tagccacata	tggtgtgtgt	gcgtgagggt	1260
	gggtggggga	ggggcagaca	gggatgaggg	atggcatggg	gccaacatct	acctatgggg	1320
	ctcggggccag	ggagccocot	tacagccatc	ctgggagggg	gtctcagctg	tccctttgtg	1380
	gccaaggggga	ccctcctggg	gagtgggggc	aagcacagag	gtcctttctc	cccaaccggg	1440
	gggtctggtc	ctgaccaccc	ttgggggoc	gcaggggagg	aaatggacag	agcgggaccc	1500
15	tgaggggagca	tagaattggc	caccacgagc	ccccagtgct	cagccttgcc	accccatgtg	1560
	tccogtgagg	gggtctctat	atacaggggg	caactcctcc	caccttctc	tcaatccctg	1620
	ctttccctgc	gttggggcgg	gaggggaggg	cggcagaaat	atttatttat	ttcctttatt	1680
	tatttaattt	tttttttttt	tttttggagt	agagagtgac	agatggoggc	gggtcccggg	1740
	ggagccggct	ctccccagt	gcagacgcac	gccaatcacc	gtctotcatg	tgatagctgc	1800
20	tgccogtgac	gtgccaagcc	catatggcct	ggcatagagg	ctggtacccc	gcctggtaga	1860
	gatgccacac	tcgtctccgc	gttcgcatgg	cgctctgaag	acgcogggcg	ccgcgcctt	1920
	gaggagccgc	tgcccccgct	coctgaagat	gggggaacaa	tgaaataagc	gagaagatcc	1980
	ctottctccc	ccctctctct	cttgccctcc	ccccccctcc	cccttgaact	gggagggagg	2040
	ccctctccgag	gtaaagtgtc	cgaaaggag	cgagatctga	cccgccggtt	gggagggagg	2100
	gcggcagctt	cgcccgacag	gagggctctc	aaatacctcc	ttcctgggat	gatgcccccc	2160
25	tcattgggtg	ggcatcggag	gggccccagg	ttctctctcc	cttaggggct	gcagccocag	2220
	gggctgcaga	ggaggtgtot	ctgcctgcga	tgggtctcgt	ggggggggaa	ggcaggatca	2280
	cggagggggga	tatgcgaaga	ggccgagacg	gaggaccctc	ccatggttgt	cccaaaaagc	2340
	ctgccaccct	tcctccaccac	cgaaaaaagg	gaagcaaaac	aacaattttg	gatttttccc	2400
	ccatcaatcc	caaaatacaa	cgagatctga	agagccttgt	gggagggagt	cagcttgaa	2460
30	ggggaaaggg	gtccctgacc	gcagagggga	cggactgggc	tcgcttctct	cagtctcctc	2520
	cccacgcccc	gctgcttcag	tcctcgccgc	ccagagccgg	ctccgggagc	tggggacgca	2580
	tcggctagag	gagacgatcc	tcocgcctct	ggaattgggg	gtgcgggggt	ggggggccag	2640
	caagggggcg	cgcgcagcca	agtgtcaaat	tggattaggg	agcgtggggg	tgagagccac	2700
	gggaggggtg	agggagctgg	gccggggggc	ccgggcccgc	agagcgcgga	gcggggcagc	2760
	tgtccccacc	ggcgcccgac	cagcctctct	ccaccgccag	gagagaacgg	gctttcaggg	2820
35	cgagcgcgcc	gcctccctcg	gcaaagatat	ctggtcccta	aaaacccccc	ccggtccctg	2880
	ccctgaccct	gagaagaagc	aggcgccggg	agcagccccc	cattcaagcg	aggggcgagg	2940
	cggggggccc	gcgcggggga	gagggcctgg	gccagatcc	caggccggca	gccgggtagg	3000
	ggtcccgccg	ctctggggcg	ggcaggccgg	ggaggtgggc	atccagggta	gcctaggcag	3060
	gagcccgcac	gagactcggg	ggtggaggag	ggttgtgggg	gggctcgggt	accccagcgc	3120
40	gcccctcact	ttgtgtgtgc	tgtctccctc	tcocgcccgc	ggggcgccct	caggccaccat	3180
	gctgaccggc	ctgttcagcg	agcccgccct	tcctctcgac	gtgcccaggt	tggccagctg	3240
	gggcgacggc	gaagacgacg	agccgaggag	cgacaagggc	gacgcggccg	caocgccacc	3300
	gcotgcgccc	gggcccaggg	ctccggggcc	agcccgggcg	gccaagccag	tcctctcccg	3360
	tggagaagag	gggacggagg	ccacgttggc	cgaggtcaag	gaggaaggcg	agctgggggg	3420
	agaggaggag	gaggaagagg	aggaggaaga	aggactggac	gagggcgagg	gcgagcgggc	3480
45	caagaagcgc	gggcccaga	agcgcaagat	gaccaaggcg	cgcttggagc	gctccaagct	3540
	tcggcgccag	aaggcggaacg	cgcgggagcg	caacogcatg	cacgacctga	acgcagccct	3600
	ggacaacctg	cgcaaggtgg	tgccctgcta	ctccaagacg	cagaagctgt	ccaagatcga	3660
	gacgctgcgc	ctagccaaga	actatatctg	ggcgctctcg	gagatcctgc	gctccggcaa	3720
	gcggccagac	ctagtgtcct	acgtgcagac	tctgtgcaag	ggtctgtcgc	agcccaccac	3780
50	caatctggtg	gccggctgtc	tgacgtcaca	ctctcgcaac	ttcctcacgg	agcaaggcgc	3840
	cgacgggtgc	ggccgcttcc	acggctcggg	cggcccggtc	gccaatgcacc	cctaccgcta	3900
	cccgctgctc	cgccctggcg	gcgcacagtg	ccaggcgggc	ggcgccctgg	gcggcgccgc	3960
	ggcgcacggc	ctgcggaccc	acggctactg	cgcgcctac	gagacgctgt	atgcggcgcc	4020
	aggcggtggc	ggcgcgagcc	cggactacaa	cagctccgag	tacgagggcc	cgctcagccc	4080
	cccgctctgt	ctcaatggca	acttctcact	caagcaggac	tcctcgcccg	accacgagaa	4140
55	aagctaccac	tactctatgc	actactcggc	gctgcccggg	tcgcgcacag	gccacgggct	4200

5 agtcttcggc tcgtcggctg tgcgcggggg cgtccactcg gagaatctct tgtcttaaga 4260
 tatgcacctt caccacgacc ggggccccat gtacgaggag ctcaatgogt tttttcataa 4320
 ctgagacttc ggcgcggctc ccttcttttt cttttgcctt tgcccggccc cctgtcccca 4380
 gccccagca ggcgagggtg cccccccatc ctaccccggc gccggggcgg gggagcgggc 4440
 caccggctct gccgctctcc tggggcagcg cagtctgtt acctgtgggt ggctgttccc 4500
 aggggctcgc cttcccccag gggactcgcg ttctctctcc ccaaggggtt ccctcctcct 4560
 ctctcccaag gagtgcctct ccagggaact ctctcgggg gctccctgga ggcacccctc 4620
 ccccatctcc aatatcttcg ctgaggtttc ctctccccc tctccctgc aggcccaagg 4680
 cgttggttaag ggggcagctg agcaatggaa cgcgtttccc cctctcatta ttattttaaa 4740
 10 aacagacacc cagctgccga ggcaaaaaag agccaggcgc tccctctttc ttgaagaggg 4800
 tagtattttg ggcgcgggag cccgggctcg gaacgccctc acccgcaacc tccagtctcc 4860
 gcgtttttcg attttaattt tggcgggagg ggaagtggat tgagaggaaa gagagaggcc 4920
 aagacaattt gtaactagaa tocgtttttc cttttcctt tttttaaaca acaaaacata 4980
 caaaaaaaaa aaaaaaaaaa aaaaaaaaaa aagctaagag gcgacggaag ccgaacgcag 5040
 15 agtcoogata ggagagaaaa cgcagtaagg acttttagaa gcaataaaag gcaaaaaaaa 5100
 caaaaaacaa aaaaacaaac aaaaaaaaac cactactacc aataatcaaa gacacaaata 5160
 tctatgcaag gaggctccac tgagcctcgc ggcgcggccc ggcccggga tgcccggccc 5220
 ggccctgogg ccgcccggcc cgcgcgggga tctgtgcact ttggtgaagt gggggccggc 5280
 gccgccccct ccccctcccc aggttcttac aatcagtgac tcggagattt ggggccccag 5340
 20 tgccactgcc ctccccggcc ccgtcccggt tgtgogtoat gctgtttttt aaaaaacctgt 5400
 ttccaaattt gtatggatg gcaaatgtt ggggggtcgg tttggggagg gaggggtttg 5460
 atgaaagaca caogcacacc acaccgcacg cacaagcagg cccggcgccg gcgtccgggg 5520
 ggcagaagga ggtgagctcg ccggtcctc ctcocgggg ccattctgtc ccctcctggg 5580
 gtgaggggtg gggatggaga cctgggggca gcccacccc tgcccggaact gtgcctcggg 5640
 ggggtgccacc tggcgatttc cgggtgtctg agagagtatt ttttggcca aggagtcctc 5700
 25 ttggcttttag ctggtgggtg ggcggggaga ggtctgagg ctctaactg aggttccccc 5760
 aaaaaggggc aaaaggagac cctctgcccc ccggaggcag gggatcaggc atccaaatac 5820
 accgatgcaa aatgcaatcc cacaggcgac acaccacac actcaccoac acacacgcaa 5880
 ttttaccttc ctctgttagc gaagatgaaa ctcccgctcg acacccgaag tgcattgcgt 5940
 gtttctgttc agtttaataa cgattaataa atatttatgt aaatgagatg caaagccgga 6000
 30 ccggtttctc acggtggcct catttcattg aggggggaga gaaggtttga gctggggctg 6060
 ggggtgatgaa ggcagagtgt caagtgactg tgcagaggcc aaacagaggg acttcccagg 6120
 aaaaagcact g 6131

<210> 7

35 <211> 2020

<212> DNA

<213> Homo sapiens

40

<400> 7

45 gctactgagg ccgcggagcc ggactgcggg tggggcggga agagccgggg ccgtgggtga 60
 catggagcag ccctgctgct gaggccggcg cctccccggc ctgaggtggg ggcccaccag 120
 gatgagcaag ctgcccaggg agctgaoccg agacttgagg cgcagcctgc ctgcccgtggc 180
 ctccctgggc tctcactgt cccacagcca gagcctctcc tgcacctcc ttcggcggcc 240
 tgagaagcga agggocact ctgatgtccg cgcaccttc tgtctottcg tcaccttcga 300
 cctgctcttc atctocctgc tctggatcat cgaactgaat accaacacag gcatccgtaa 360
 gaacttgagg caggagatca tccagtacaa ctttaaaact tctttottcg acatotttgt 420
 50 cctggccttc ttcogcttct ctggactgct cctaggctat gccgtgotgc agctccggca 480
 ctggtgggtg attgcggtca cgcgctgggt gtccagtga tctctcattg tcaaggatcat 540
 cctctctgag ctgctcagca aaggggcatt tggctacctg ctccccatcg tctcttttgt 600
 cctgcctcgg ttggagacct ggttccttga cttcaaagtc ctaccccagg aagctgaaga 660
 ggagcgatgg tatcttgccg ccaggttgcg tgttgccggt ggacccctgc tgtttctcgg 720
 55 tgcctgttcc gagggacagt tctattcacc ccagaaatcc tttgcagggt ctgacaatga 780
 atcagatgaa gaagtgtctg ggaagaaaag tttctctgct caggagcggg agtacatccg 840

	ccaggggaag	gaggccacgg	cagtgggtgga	ccagatcttg	gccaggaag	agaactggaa	900
	gtttgagaag	aataatgaat	atggggacac	cgtgtacacc	attgaagtgc	cctttcacgg	960
	caagacgttt	atcctgaaga	ccttcctgcc	ctgtcctgcg	gagctcgtgt	accaggaggt	1020
5	gatcctgcag	cccagagagga	tgtgtcgtgtg	gaacaagaca	gtgactgcct	gccagatcct	1080
	gcagcagtg	gaagacaaca	ccctcatctc	ctatgacgtg	tctgcagggg	ctgcgggcgg	1140
	cgtggtctcc	ccaagggact	togtgaatgt	ccggcgcat	gagcggcgca	gggaccgata	1200
	cttgtcatca	gggatcgcca	cctcacacag	tgccaagccc	ccgacgcaca	aatatgtccg	1260
	gggagagaat	ggccctgggg	gcttcatcgt	gctcaagtcg	gccagtaacc	cccgtgtttg	1320
	ccactttgtc	tggattotta	atacagatct	caagggcgcg	ctgccccggg	acctcatcca	1380
10	ccagagcctc	gcggccacca	tggttgaaat	tgcccttcac	ctgcgacagc	gcacacagca	1440
	gctggggggc	cgggcgtagc	tgtgccccct	cccaccctgc	gggcccagggt	cctgtcgcca	1500
	ccacttcag	agocagaaag	ggtgccagtt	gggctcgcac	tgcccacatg	ggacctggcc	1560
	ccaggctgtc	accctccacc	gagccacgca	gtgcctggag	ttgactgact	gagcaggctg	1620
	tggggtggag	cactggactc	cggggccccca	ctggctggag	gaagtggggg	ctggcctgtt	1680
15	gatgtttaca	tgggccctcg	cctcctggag	gaccagattg	ctctgccccca	ccttgccagg	1740
	gcagggtctg	ggctggggcac	ctgacttggc	tggggaggac	caggggccctg	ggcagggcag	1800
	ggcagcctgt	caccctgtgtg	aagatgaagg	ggctcttcat	ctgcctgcgc	tctcgtoggt	1860
	tttttttagga	ttattgaaag	agtctgggac	ccttgttggg	gagtgggtgg	cagggtggggg	1920
20	tgggctgctg	gccatgaatc	tctgctctc	ccaggctgtc	ccccctctcc	caggggcctcc	1980
	tgggggacct	ttgtattaa	ccaattaaaa	acatgaattt			2020

<210> 8

<211> 1730

<212> DNA

<213> Homo sapiens

<400> 8

	gtggtgaggg	tgactgggga	ctaggcacta	ggcctttggg	gcaggcgcct	gaggacktg	60
	ttgcactctc	ccttctgggg	atatgccctt	gagcccaggc	agaggagagc	acagcccagg	120
	gcaggacctg	gcagccctgg	tacagagccc	agagggggca	tcagttcctg	ctgggtcctg	180
35	tctgtttaca	gacaactg	tgctctccct	gcaaagggga	gtgggtgggg	cagagggcaa	240
	ktgccagggg	ggcacaaggg	tgggcatgtg	gctggcatga	gacgggtgtc	gagtaatgtc	300
	aggcacctgg	aggcattgac	cccaggacct	tggaccccag	acctctgacc	gtggggcagc	360
	cagcgtccag	gtaccoccaa	ccctgcccctg	ggtccggcgt	ccccccatta	gtgagtcttg	420
	gctctactta	tagcatctga	caccagaggg	gccgaaaata	gcccctggag	aagggggagg	480
40	agggggctat	ttaaagggcc	tgggagggga	gagagaatga	ggagtgatca	tggctacctc	540
	agagctgagc	tgcgaggtgt	cggaggagaa	ctgtgagcgc	cgggaggcct	tctgggcaga	600
	atggaaggat	ctgacactgt	ccacacggcc	cgaggagggg	tgagtgtggg	totgctagag	660
	tccctgcctc	tgctccccc	gagcaccctc	actgagccat	gaggccagag	catgaagccc	720
	tggagaaatt	tctgggggtg	ggggcaggaa	gaatgcccc	tggggagagc	aaaggggaac	780
	cacccttcct	gccccaggt	cccagcagcc	caggggagcc	ccccaccag	cctgtgcccc	840
45	gagagcaaca	gctcccagga	gctcactgcc	cctccctct	ccccagctgc	tccttgcctg	900
	aggaggacac	ccagagacat	gagacctacc	accagcaggg	gcagtgccag	gtgctgggtg	960
	agcgtctgcc	ctggctgatg	atgoggatgg	gcactcctcg	ccgtgggctg	caggagtacc	1020
	agctgcccta	ctagcgggta	ctgccctgc	ccatcttcac	ccctgccaag	atgggcgcca	1080
	ccaaggagga	gcgtgaggac	acccccatcc	agcttcagga	gctgctggcg	ctggagacag	1140
50	ccctgggtgg	ccagtgtgtg	gaccgccagg	aggtggctga	gatcacaag	cagctgcccc	1200
	ctgtgggtgcc	tgctcagcaag	cccggtgcmc	ttcgtcgtct	cctgtcccg	tccatgtccc	1260
	aggaagcaca	gagaggctga	gagggactgt	gacttgggct	ccgctgtgce	cgccccctgg	1320
	gctggggcct	tccctggctag	gacctgtgga	ggggcagctc	gctggcccat	ggctgctttg	1380
	tagtttgccc	agagttgggg	gctaggggag	gggggagcca	gaggccagga	tgctgagccc	1440
	ccctgagttc	ccaaagggag	ggtggcagag	acagtgggca	ctaagggtgg	agagttgggg	1500
55	gccagcacag	ctgaggaccc	tcagccccag	gagaaggagc	aaaagggtact	ggtgagggca	1560

agagggtgcct	gggaggagtg	gccctgatcc	aggaaaatgt	gaggggaatc	tggaacgctc	1620
taggcagaag	aagctgggag	ggagggggag	gtgaaaaggg	cagaggcaag	gatggtgggg	1680
ccccagcac	cctctgttag	tgccgcaata	aatgctcaat	catgtgccag		1730

<210> 9

<211> 3799

<212> DNA

<213> Homo sapiens

<400> 9

ctggcactgg	gtggtaacca	gcaagccagc	tggcatccgc	atccagggtt	tgtttcaatg	60
atgtctctgt	gagaatatgg	aggggctggt	gccaggactg	tccttggctt	tgctctgggg	120
tgtgaacggg	gtcagtgacc	totaaaacta	acctgcctot	cagttctgaa	tccagacaga	180
atcaatcctc	agctgtgtct	ogctccacac	cccccgccct	ggaagccagg	gaaggttggg	240
gggtgctagg	ggtcaggctc	ccctctgtga	ccccgcagc	tgttgtgggt	actcatgtcc	300
caacctagct	gcctctccca	aggagacttt	ccccctgggac	aagggggagg	gaatggcatg	360
gaggaggccc	acatcaagcg	gggccaggaa	cccacgggtg	caggagctgg	gctggtgacc	420
taccaggggc	agaaggggcc	gggactcatc	cagaggggaa	ggaaggggtc	ttcaggaaga	480
ccacggagat	gccacaggca	gaattggctt	cccatctggg	agataggtgg	ggagaccotg	540
gcattttgac	agccagaacc	tggggtgctg	agcagaatct	tcatgctctg	cctggccgcc	600
ttoggaggga	agctggaggg	ttgggtgctg	gaggagtggg	gtcagagccc	ctacatccgc	660
aggaccccaa	atcggctggg	ccccaaaggc	cggactgogc	tccccgggtg	ccccggcggo	720
cctccgcgaa	tgcgtcctgc	ccctcccttg	cccaagccct	ctgocctcac	ccgggtcccg	780
cgccgcccc	gaagtggcgg	gaacaacccg	aaccggaacc	ttctgtcctc	gggagccccc	840
agataagcgg	ctgggaaccc	gcggggcccg	caggggaggc	ccggctgttc	cgcccgctaa	900
gtgcattagc	acagctcac	tcccctatcg	cgctgtccat	cgacgggca	gtgccgcgcc	960
ctgctctctg	gcccccgagg	cgaccacagc	ggaggccgga	acggactgtc	ctttctgggg	1020
cggggtgggg	agggggtgtc	gctggagggc	ccggtggcat	agcaacggac	gagagaggcc	1080
tggaggaggg	gcggggaggg	ggagtgtgtg	ggcagttcta	agggaaaggt	gggtgctggg	1140
acgggtgtcc	gggaggaggg	ggagcctggc	gggtctggg	gcctctgtgc	ggagggcgct	1200
gcgaggggga	aactggggaa	agggccta	tcccagctct	ccacctcgaa	tcaggaaaga	1260
gaaggggcgg	gotgctgggc	aaaagaggtg	aatgctgtcg	gggggctgga	gaagagagat	1320
gggaggggcc	ggccggcggg	ggtagggggg	tctaagatt	gtgggggtga	ggaactgagg	1380
gtggggggcg	cccagaggcg	ggactcgggg	cggggcaggc	gagggcgagg	gcgagggctg	1440
cgggagcaag	taaggagccg	ggggtgtggg	ggacgattgc	cgctgcagcc	gccgccccac	1500
tcacctccgg	tgtgtctgca	gcccggacac	taaggagat	ggatgaatgg	gtggggagga	1560
tgoggcgcac	atggccccgg	gcggctcggc	ggtcagctgc	cgccccaca	gcggaccggg	1620
cggggcgggg	gtcgggcggg	agaaaaaagg	gccgcgaggc	gagcggggca	ctgggcggac	1680
cgcggcggga	gcattgagcg	cgagacccgt	agccccaatg	cgggcgagc	ccctgactcg	1740
gccccggggc	aggcggcggg	ggcttcggcc	taccagcgct	tcgagccggc	cgctacctc	1800
cgcaacaact	acgcgcccc	tcgcggggac	ctgtgcaacc	cgaaacggct	cgggccgtgg	1860
aagctgcgct	gcttggcgca	gaccttcgcc	accggtgagc	gggggaaact	gaggcaogag	1920
ggacaagagg	togtcgggga	gtgaaagcag	gcgcagggaa	ataaaaagaa	ggaaagggag	1980
acagaccagg	cgccaaacag	atggggacca	agaaacaaga	gatagctgag	aggtgcaaac	2040
agaagagaaa	aaggagcaac	atcccttagg	agaggggcag	aggagagaga	ggtggagaga	2100
gggggcggag	agtgtctaga	attgagagct	aaggtggggg	atgcaggaca	gactgagggtg	2160
gagatgcata	ggaggaaatg	gaggcagatg	tgggacaggg	gtgagaaact	ccaggatttc	2220
ctcgctgagc	ctggctggta	ggtatagtgt	ttttctttct	ttttctttat	tttattttca	2280
tttattttact	tatttttatt	ttttatttgt	tttgagacgg	agtttcgctc	ttgttgccca	2340
ggctggagta	caatggcgcc	atctcggtct	actgcaacct	ccgcctcccc	gggttcaagc	2400
gattctcttg	cctcagcttc	octagtagct	gggattacag	gcattgcgcc	ccatgcctgg	2460
ctaattttatt	tgtattttta	gtagagacgg	gacttctcca	tggtggtcag	gctggtctcg	2520
aactcccaac	cttaggatcc	acccaccccg	gcctcccaaa	gtgctgggat	tacagggtgtg	2580
agccactgcg	cccgccaggt	aggtatagtc	ttctagatgt	gaaacctgag	tctcagagcg	2640

	gtgaagttcc	cttccgaagg	gcagcccatg	ttggagctgg	gttcagtcta	actctggggc	2700
	caatgctttt	tccagatgga	gacacatttg	cagaggagaa	ggaagaacta	gagagaggca	2760
	gggagatgca	ggggagggaa	gggtaaggag	gcaggggctg	cctgggctgg	ctggcaccag	2820
5	gaccctcttc	ctctgccctg	cccaggtgaa	gtgtccggac	gcaccctcat	cgacattggt	2880
	tcaggcccca	ccgtgtacca	gctgctcagt	gcctgcagcc	actttgagga	catcaocatg	2940
	acagatttcc	tggagggtcaa	ccgcoaggag	ctggggcgct	ggctgcagga	ggagccgggg	3000
	gcottcaact	ggagcatgta	cagccaacat	gcctgcctca	ttgagggcaa	ggggtaagga	3060
	ctgggggggtg	agggttgggg	aggaggcttc	ccatagagtg	gctggttggg	gcaacagagg	3120
	cctgagcgta	gaacagcctt	gagccctgcc	ttgtgcctcc	tgacagggga	atgctggcag	3180
10	gataaggagc	gccagctcgg	agccaggggtg	aaacgggtcc	tgcccatcga	cgctgaccag	3240
	ccccagcccc	tgggtgctgg	gagcccgagt	ccctgcctg	ctgacgccct	ggtctctgcc	3300
	ttctgcttgg	aggctgtgag	cccagatctt	gccagcttcc	agcggggccct	ggaccacatc	3360
	accacgctgc	tgaggcctgg	ggggcacctc	ctcctcatcg	gggccttgga	ggagtctgtg	3420
	tacctggctg	gggaggccag	gctgacgggtg	gtgccagtgt	ctgaggagga	ggtgagggag	3480
15	gccotgggtg	gtagtggcta	caaggtccgg	gacctccgca	cctatatcat	gctgcccac	3540
	cttcagacag	gcgtagatga	tgtcaagggc	gtcttcttcg	cctgggtcca	gaaggttggg	3600
	ctgtgagggc	tgtacctggg	gcctgtggc	ccccaccac	ctggattccc	tgctctttga	3660
	agtggcacct	aataaagaaa	taataccctg	ccgtgcgggt	cagtgtctgt	tgtggctctc	3720
	ctgggaagca	gcaaggcccc	agagatctga	gtgtccgggt	aggggagaca	ttcacccatg	3780
20	gctttttttc	cagaagctt					3799
	<210>	10					
	<211>	4530					
25	<212>	DNA					
	<213>	Homo sapiens					
30	<400>	10					
	aattotcgag	ctcgtcgacc	ggtcgacgag	ctcgagggtc	gacgagctcg	agggcgcgcg	60
	cccgcccccc	accctctgca	gcaccccgcg	cccccgcccc	tcccagccgg	gtccagccgg	120
	agccatgggg	ccggagccgc	agtgagcacc	atggagotgg	cgcccttgtg	ccgtgggggg	180
	ctcctctctg	ccctcttgcc	ccccggagcc	gcgagcacc	aagtgtgcac	cgccacagac	240
35	atgaagetgc	ggctccctgc	cagtcccggag	acccacctgg	acatgtctcg	ccacctctac	300
	cagggctgcc	aggtgtgtca	gggaaacctg	gaactcacct	acctgcccac	caatgccagc	360
	ctgtccttcc	tgcaggatat	ccaggagggtg	cagggctacg	tgctcatcgc	tcacaaccaa	420
	gtgaggcagg	tcccactgca	gaggctgcgg	attgtgcgag	gcacccagct	ctttgaggac	480
	aactatgccc	tggcogtgct	agacaatgga	gaaccgctga	acaataccac	ccctgtcaca	540
40	ggggcctccc	caggaggcct	gcgggagctg	cagcttcgaa	gcctcacaga	gatottgaaa	600
	ggaggggtct	tgatccagcg	gaacccccag	ctctgtctacc	aggacaogat	tttgtggaag	660
	gacatcttcc	acaagaacaa	ccagctggct	ctcacactga	tagacaccaa	ccgtctctgg	720
	gcctgccacc	cctgttctcc	gatgtgtaag	ggctcccgtc	gctggggaga	gagttctgag	780
	gattgtcaga	gcctgacgcg	cactgtctgt	gcgggtggct	gtgcccgtg	caaggggcca	840
	ctgcccactg	actgctgcc	tgagcagtg	gctgcccgtc	gcacggggcc	caagcactct	900
45	gaotgcctgg	cctgcctcca	cttcaaccac	agtgcatct	gtgagctgca	ctgcccagcc	960
	ctggtcacct	acaacacaga	cacgtttgag	tccatgcccc	atcccagagg	ccgtataaca	1020
	ttcggcgcca	gotgtgtgac	tgctgttccc	tacaactacc	ttttacgga	cgtgggatcc	1080
	tgcacccctg	tctgccccct	gcacaaccaa	gaggtgacag	cagaggatgg	aacacagcgg	1140
	tgtgagaagt	gcagcaagcc	ctgtgcccga	gtgtgctatg	gtctgggcat	ggagcacttg	1200
50	cgagaggtga	gggcagttac	cagtgccaat	atccaggagt	ttgtgtgctg	caagaagatc	1260
	tttgggagcc	tggcatttct	gccggagagc	tttgatgggg	acccagcctc	caacactgcc	1320
	ccgtctccagc	cagagcagct	ccaagtgttt	gagactctgg	aagagatcac	aggttaccta	1380
	tacatctcag	catggccgga	cagcctgcct	gacctcagcg	tcttccagaa	cctgcaagta	1440
	atccggggag	gaattctgca	caatggcgcc	tactcgctga	ccctgcaagg	gctgggcato	1500
	agctggctgg	ggctgcgctc	actgagggaa	ctgggcagtg	gactggccct	catccaccat	1560
55	aacacccacc	tctgcttctg	gcacacgggtg	ccctgggacc	agctctttcg	gaacccgcac	1620

	caagctctgo	tccacactgc	caaccggcca	gaggacgagt	gtgtgggcca	gggcctggcc	1680
	tgccaccagc	tgtgcgcccg	agggcactgc	tggggtccag	ggcccaccca	gtgtgtcaac	1740
	tgacagcoagt	tccttcgggg	ccaggagtgc	gtggaggaat	gocgagtact	gcaggggctc	1800
5	cccagggagt	atgtgaatgc	caggcactgt	ttgccgtgcc	accctgagt	tcagccccag	1860
	aatggctcag	tgacctgttt	tggaccggag	gctgaccagt	gtgtggcctg	tgcccaactat	1920
	aaggaccctc	ccttctgcgt	ggcccgcctc	cccagcgggtg	tgaacctga	cctctcctac	1980
	atgcccatct	ggaagtttcc	agatgaggag	ggcgcatgcc	agccttgccc	catcaactgc	2040
	accactcct	gtgtggacot	ggatgacaag	ggctgccccg	ccgagcagag	agccagccct	2100
10	ctgacgtcca	togtctctgc	gggtggttggc	attctgctgg	tcgtggtott	gggggtggtc	2160
	tttgggatcc	tcatcaagcg	acggcagcag	aagatccgga	agtacacgat	gcggagactg	2220
	ctgcaggaaa	cggagctggt	ggagccgctg	acacctagcg	gagcgatgco	caaccaggcg	2280
	cagatgcgga	tcctgaaaga	gacggagctg	aggaaggtga	aggtgcttgg	atctggcgct	2340
	tttggcacag	tcataaagg	catctggatc	octgatgggg	agaatgtgaa	aattccagt	2400
	gccatcaaag	tggtgagga	aaacacatcc	cccaaagcca	acaaagaaat	cttagacgaa	2460
15	gcatacgtga	tggtggtgt	gggtctccca	tatgtctccc	gccttctggg	catctgcctg	2520
	acatccacgg	tgacgtggt	gacacagctt	atgccctatg	gctgcctott	agaccatgtc	2580
	cgggaaaacc	gcgagcgcct	gggtctccag	gacctgctga	actggtgtat	gcagattgco	2640
	aaggggatga	gctaacctgga	ggatgtgcgg	ctcgtacaca	gggacttggc	cgctcggaac	2700
	gtgctggtca	agagtcccaa	ccatgtcaaa	attacagact	tcgggctggc	tcggctgctg	2760
20	gacattgacg	agacagagta	ccatgcagat	gggggcaagg	tgcccatcaa	gtggatggcg	2820
	ctggagtcca	ttctccggcg	gcggttcacc	caccagagtg	atgtgtggag	ttatggtgtg	2880
	actgtgtggg	agctgatgac	ttttggggcc	aaaccttacg	atgggatccc	agcccgggag	2940
	atccctgacc	tgctggaaaa	gggggagcgg	ctgcccagc	cccccatotg	caccattgat	3000
	gtctacatga	tcattgtcaa	atgttggatg	attgactctg	aatgtoggcc	aagattccgg	3060
	gagttggtgt	ctgaattctc	cgcgatggcc	agggaccccc	agcgtttgt	ggtcatccag	3120
25	aatgaggact	tgggccacgc	cagtcacctg	gacagcacct	tcaccgcctc	actgctggag	3180
	gacgatgaca	tgggggacot	gggtgatgct	gaggagtatc	tggtacccca	gcagggcttc	3240
	ttctgtccag	accctgcccc	gggcgctggg	ggcatggtcc	accacaggca	ccgcagctca	3300
	totaccagga	gtggcggtgg	ggacctgaca	ctagggtgg	agccctctga	agaggaggcc	3360
	cccaggtctc	cactggcacc	ctccgaaggg	gctggctccg	atgtatttga	tggtgacotg	3420
30	ggaatggggg	cagccaaggg	gctgcaaagc	ctccccacac	atgacccccag	ccctctacag	3480
	cgttacagt	aggacccccac	agtacccctg	ccctctgaga	ctgatggcta	cgttgccccc	3540
	ctgacctgca	gccccacagc	tgaatatgtg	aaccagccag	atgttcggcc	ccagccccc	3600
	tcgcccggag	aggccctctc	gocctgtgcc	cgacctgctg	gtgccactot	ggaaagggcc	3660
	aagactctct	ccccaggga	gaatggggct	gtcaaagacg	tttttgctt	tgggggtgcc	3720
35	gtggagaacc	ccgagtaott	gacacccccag	ggaggagctg	cccctcagcc	ccacccctct	3780
	cctgccttca	gcccagcctt	cgacaaacctc	tattactggg	accaggaccc	accagagcgg	3840
	ggggctccac	ccagcacctt	caaagggaca	cctacggcag	agaacccaga	gtacotgggt	3900
	ctggacgtgc	cagtgtgaac	cagaaggcca	agtcgcgaga	agccctgatg	tgtctcagg	3960
	gagcagggaa	ggcctgactt	ctgctggcat	caagagggtg	gagggccctc	cgaccacttc	4020
	caggggaacc	tgccatgcca	ggaacctgtc	ctaagggaac	ttccttctctg	cttgagttcc	4080
40	cagatggctg	gaaggggtcc	agcctcgttg	gaagagggaac	agcactgggg	agtctttgtg	4140
	gattctgagg	ccctgccccaa	tgagactcta	gggtccagtg	gatgccacag	cccagotttg	4200
	ccctttcctt	ccagatcctg	ggtactgaaa	gccttaggga	agctggcctg	agaggggaag	4260
	ogggccctaag	ggagtgtcta	agaacaaaag	cgaccctatc	agagactgtc	cctgaaacct	4320
	agtactgccc	cccatgagga	aggaacagca	atggtgtcag	tatccaggct	ttgtacagag	4380
	tgcttttctg	tttagttttt	actttttttg	ttttgttttt	ttaaagacga	aataaagacc	4440
45	caggggagaa	tggtgtgtgt	atggggaggc	aagtgtgggg	ggtccttctc	cacacccact	4500
	ttgtccattt	gcaaatatat	tttgaaaaac				4530

<210> 11

50 <211> 2205

<212> DNA

<213> Homo sapiens

55

<400> 11

5	cacaggggtc	ccccccgct	ctgacttttc	tgccgaagt	cgggacacco	tcctaccacc	60
	tgtagagaag	cgggagtggg	tctgaaataa	aatccaggaa	tctgggggtt	cctagacgga	120
	gccagacttc	ggaacgggtg	tcctgctact	cotgctgggg	ctcctocagg	acaagggcac	180
	acaactgggt	ccgttaagcc	cctctctcgc	tcagacgcca	tggagctgga	totgtctcca	240
10	cctcatctta	gcagctctcc	ggaagacctt	tggccagccc	ctgggacccc	tcctgggact	300
	ccccggcccc	ctgatacccc	tctgcctgag	gaggtaaaga	ggtcccagcc	tctctctatc	360
	ccaaccaocg	gcaggaaact	tcgagaggag	gagaggcggt	ccacctccct	ccccctatc	420
	cccaacccct	tccttgagct	ctgcagtcct	ccctcacaga	gccaattct	cgggggcccc	480
	tcagtgcaa	gggggtgct	cccccgcat	gccagccgcc	cccatgtagt	aaaggtgtac	540
	agttaggatg	gggctgcag	gtctgtggag	gtggcagcag	gtgccacagc	tcgccacgtg	600
15	tgtagaatgc	tggtgcagcg	agctcacgcc	ttgagcgacg	agacctgggg	gctgggtggg	660
	tgccaccccc	acctagcaat	ggagcggggt	ttggaggacc	acgagtcogt	ggtggaagtg	720
	caggctgcct	ggcccggtgg	cggagatagc	cgcttctgtc	tcgggaaaaa	cttcgccaag	780
	tacgaactgt	tcaagagctc	cccacactcc	ctgttccag	aaaaaatggt	ctccagctgt	840
	ctcgatgcac	acactgggtat	atcccatgaa	gacotcatcc	agaacttcc	gaatgctggc	900
	agctttctctg	agatccaggg	ctttctgcag	ctggggggtt	caggacggaa	gctttgaaa	960
20	cgctttttct	gtttcttgcg	ccgatctggc	ctctattact	ccaccaaggg	cacctotaag	1020
	gatccgaggc	acctgcagta	cgtggcagat	gtgaacagat	ccaacgtgta	cgtggtgacg	1080
	cagggcgcga	agctotaocg	gatgccaact	gacttcggtt	totgtgtcaa	gccaacaag	1140
	cttcgaaatg	gacacaaggg	gcttcggatc	ttctgcagtg	aagatgagca	gagccgcacc	1200
	tgctggctgg	ctgecttcog	cctcttcaag	tacgggggtc	agctgtacaa	gaattaccag	1260
25	caggcacagt	ctcgccatct	gcattccatct	tgcttgggct	ccccaccctt	gagaagtgcc	1320
	tcagataata	ccctggtggo	catggacttc	tctggccatg	ctgggctgtg	cattgagaac	1380
	ccccgggagg	ctctgagtg	ggccctggag	gaggccacag	cctggaggaa	gaagacaaac	1440
	caccgcctca	gcctgcccct	gccagccctc	ggcacgagcc	tcagtgcagc	catccaccgc	1500
	acccaactct	ggttccaocg	gcgcatttcc	cgtgaggaga	gccagcggct	tattggacag	1560
30	cagggtcttg	tagacggcct	gttctctggt	cgggagagtc	agcgggaaccc	ccagggtctt	1620
	gtcctctctt	tgtagcaact	gcagaaagtg	aagcattatc	tcctcctgcc	gagcggaggag	1680
	gagggtcgcc	tgtaactcag	catggatgat	ggccagaccc	gcttactga	cctgctgcag	1740
	ctcgtggagt	tcacacagct	gaaccgcggc	atcctgcogt	gcttgcctgc	ccattgctgc	1800
	acgcgggtgg	ccctctgacc	aggccgtgga	ctggctcatg	cctcagcccg	ccttoaggct	1860
	gcccgcgcgc	cctccaccca	tcagtggtac	tcggggcgcc	ggccacaggg	gacgggatga	1920
35	ggagcgggag	ggttcgcgca	ctocagtttt	ctcctctgt	tctttgctc	cctcagatag	1980
	aaaacagccc	ccactccagt	ccactcctga	cccctctcct	caagggaagg	ccttgggtgg	2040
	ccccctctoc	ttctcctagc	tctggaggtg	ctgctctagg	gcagggaatt	atggggagaag	2100
	tgggggcagc	ccaggcgggt	tcacgcccc	cactttgtac	agaccgagag	gccagttgat	2160
	ctgctctgtt	ttatactagt	gacaataaag	attatttttt	gatac		2205

<210> 12

<211> 2177

<212> DNA

<213> Homo sapiens

<400> 12

50	gaattcgogg	ccgctggttt	gcagctgtct	cgctcatcgt	cgccccgacg	ctatctogcg	60
	ctcgtgtgca	ggccccgtct	ggctcctggt	ccccgggtgc	aggggttaacg	cgaggccccg	120
	gcctcgggtc	ccggactagg	ccgtgacccc	gggtgccatg	aagcaggagg	gctcggcgcg	180
	gcgcgcggcg	gcggacaagg	cgaaaccgcc	gcccggcgga	ggagaacaag	aacccccacc	240
	gccgcgggcc	ccccaggatg	tggagatgaa	agaggaggca	gcgacgggtg	gcgggtcaac	300
55	gggggaggca	gacggcaaga	cgccggcgcc	agcgggttag	cactcccagc	gagagctgga	360

cacagtcacc ttggaggaca tcaaggagca cgtgaaacag ctagagaaaag cggtttcagg 420
 caaggagccg agattcgtgc tgcgggccct gcggatgctg ccttccacat cagccgcct 480
 caaccactat gttctgtata aggcctgtgca gggcttcttc acttcaaata atgccactcg 540
 5 agactttttg ctccctctoc tggaaagagcc catggacaca gaggttgatt tacagttccg 600
 tccccgcacg ggaaaaagctg cgtcgacacc cctcctgcct gaagtggag cctatctcca 660
 actcctcgtg gtcactctca tgatgaacag caagcgctac aaagaggcac agaagatctc 720
 tgatgatctg atgcagaaga tcagtactca gaaccgcccg gccctagacc ttgtagccgc 780
 aaagtgttac tattatcacg cccgggtota tgagttcctg gacaagctgg atgtggtgcg 840
 cagcttcttg catgctcggc tccggacagc tacgcttogg catgacgcag acgggcaggc 900
 10 caccctgttg aacctcctgc tgcggaatta cctacactac agcttgtag accaggctga 960
 gaagctggtg tccaagtctg tggtcccaga gcaggccaac aacaatgagt gggccaggta 1020
 cctctactac acagggcgaa tcaaaagccat ccagctggag tactcagagg cccggagaac 1080
 gatgaccaac gcccttgca aggccctca gcacacagct gtcggttca aacagacggt 1140
 gcacaagctt ctcatcgtgg tggagctggt gctgggggag atccctgacc ggctgcagtt 1200
 15 ccgccagccc tccctcaagc gctcactcat gccctatttc cttctgactc aagctgtcag 1260
 gacaggaaac ctagccaagt tcaaccaggc cctggatcag tttggggaga agtttcaagc 1320
 agatgggacc tacaccctaa ttatccggct gcggcacaac gtgattaaga caggtgtacg 1380
 catgatcagc ctctcctatt ccogaatoto cttggctgac atcgcccaga agotgcagtt 1440
 ggatagcccc gaagatgcag agttcattgt tgccaaggcc atccgggatg gtgtcattga 1500
 20 ggccagcacc aaccacgaga agggctatgt ccaatccaag gagatgattg acatctatto 1560
 cccccgagag ccccagctag ccttccacca gcgcatctoc ttctgcotag atatcccaa 1620
 catgtctgtc aaggccatga gggttctctc caaatcgtac aacaaggact tggagtctgc 1680
 agaggaaacg cgtgagcgag aacagcagga cttggagttt gccaaaggaga tggcagaaga 1740
 tgatgatgac agcttccctt gagctggggg gctggggagg ggtaggggga atggggacag 1800
 25 gctctttccc ccttgggggt cccctgcccga gggcactgtc ccatttttcc cacacacagc 1860
 tcatatgctg cattctgtca ggggttgggg gtgtgtgggg ccagccaccc tgacctcccc 1920
 cagggctcct cccagccggg tgacttactg tacagcaggo aggggggtgg gcaggcaacc 1980
 tccccgggca gggctcctggc cagcagtggt ggagcaggag ggaaggata gttotgtgta 2040
 30 ctcttttagg gagtggggga ctagaactgg gatgtcttgg cttgtatgtt ttttgaagct 2100
 tcgattatga tttttaaaca ataaaaagtt ctcccaaaaa aaaaaaaaaa aaaaaaaaaa 2160
 aaagcgcccg ogaattc 2177

<210> 13

<211> 2960

<212> DNA

<213> Homo sapiens

<400> 13

ctgcccgttc caggcgtcta tcagcggctc agcctttgtt cagctgtttot gttcaaacac 60
 tctggggcca ttcaggcctg ggtggggcag cgggaggaag ggagtttgag gggggcaagg 120
 cgacgtcaaa ggaggatcag agattccaca atttcacaaa actttcgcaa acagcttttt 180
 45 gttccaaccc ccttgcatg tcttgacac caaatttgca taaatcctgg gaagttatta 240
 ctaagcetta gtctgtggcc caggtaatct cctcccaggc ctccatgggg ttatgtataa 300
 agggccccct agagctgggc cccaaaacag cccggagcct gcagcccagc cccaccaga 360
 cccatggctg gacctgccac ccagagcccc atgaagctga tgggtgagtg tcttggccca 420
 ggatgggaga gccgcctgcc ctggcatggg agggaggctg gtgtgacaga ggggctgggg 480
 atccccgttc tgggaatggg gattaaaggc acccagtgct cccgagaggg cctcaggtgg 540
 50 tagggaacag catgtctcct gagcccgtc tgctcccagc cctgcagctg ctgctgtggc 600
 acagtgcact ctggacagtg caggaagcca cccctctggg ccctgccagc tccctgcccc 660
 agagcttctt gctcaagtgc ttagagcaag tgagggaagt ggagggaagc ccggtgggga 720
 tccaggagaa gctggtgagt gaggtgggtg agaggctgt ggagggaagc ccggtgggga 780
 55 gagctaaggg ggtatggaact gcagggccaa catcctctgg aaggagacat ggagaatatt 840
 aggagcagtg gagctgggga aggctgggaa gggacttggg gaggaggacc ttggtgggga 900
 cagtgcctcg gagggctggc tgggatggga gtggaggcat cacattcagg agaaagggca 960

```

aggggccctg tgagatcaga gagtgggggt gcagggcaga gaggaactga acagocctggc 1020
aggacatgga gggaggggaa agaccagaga gtcggggagg acccggaag gagcggcgac 1080
ccggccacgg cgagtctcac tcagcatcct tccatcocca gtgtgccacc tacaagctgt 1140
5 ggcaccccgga ggagctggtg ctgctggac actctctggg catcccctgg gctcccctga 1200
gcagctgccc gagccaggcc ctgcagctgg tgagtgtcag gaaaggataa ggotaatgag 1260
gagggggaag gagaggagga acacccatgg gctcccccct gtctccagggt tocaagctgg 1320
gggcctgaag tatctcaggc agcaccctct aactcttccg ctctgtctca caggcaggct 1380
gottgagcca actccatagc ggcottttcc tctaccaggg gctcctgcag gccctggaag 1440
10 ggatctcccc cgagttgggt cccaccttgg acacactgca gctggacgtc gccgactttg 1500
ccaccaocat ctggcagcag gtgagccttg ttgggcaggg tggccaagggt cgtgctggca 1560
ttctgggcac cacagccggg cctgtgtatg ggccctgtcc atgtgtcag cccccagcat 1620
ttctcattt gtaataacgc ccaactcagaa gggcccaacc actgatcaca gctttcccc 1680
acagatggaa gaactgggaa tggcccctgc cctgcagccc acccagggtg ccatgccggc 1740
15 ctctgcctct gctttccagc gccgggcagg aggggtcctg gttgcctccc atctgcagag 1800
cttctggag gtgtctgacc gcgttttacg ccaccttggc cagccctgag ccaagccctc 1860
ccatcccat gtatttatct ctatttaata tttatgtcta tttaagcctc atattttaaag 1920
acagggaaga gcagaacgga gcccaggcc tctgtgtcct tccctgcatt tctgagtttc 1980
attctctgc ctgtagcagt gagaaaaagc tctgtctctc ccatccctg gactgggagg 2040
tagataggta aataccaagt atttattact atgactgtc cccagccctg gctctgcaat 2100
20 gggcactggg atgagccgct gtgagccctt ggtcctgagg gtcccccact gggacccttg 2160
agagtatcag gtctccacg tgggagacaa gaaatccctg tttaatat t aaacagcagt 2220
gttcccatc tgggtccttg caccctcac tctggcctca gccgaactgca cagcgggccc 2280
tgcacccct tggctgtgag gccctggac aagcagaggt ggccagagct gggaggcatg 2340
gccctggggt cccacgaatt tgctgggaa tctgtttttt cttcttaaga cttttgggac 2400
25 atggtttgac tcccgaaat caccgacgtg tctcctgttt ttctgggtg cctcgggaca 2460
cctgccctgc cccacagagg gtcaggactg tgactctttt tagggccagg cagggtgcctg 2520
gacatttgcc ttgctggatg gggactggg atgtgggagg gagcagacag gaggaatcat 2580
gtcaggcctg tgtgtgaaag gaagctccac tgtaaccctc cacctcttca cccccactc 2640
accagtgtoc cctccactgt cacattgtaa ctgaacttca ggataataaa gtgtttgcct 2700
30 ccagtcacgt ccttctcct tcttgagtcc agctgggtgc tggccagggg ctggggagggt 2760
ggctgaaggg tgggagaggc cagagggagg toggggagga ggtotgggga ggagggtccag 2820
ggaggaggag gaaagtctc aagttcgtct gacattcatt ccgttagcac atatttatct 2880
gagcacctac tctgtgcaga cgotgggcta agtgtgggg acacagcagg gaacaaggca 2940
gacatggaat ctgcactcga 2960

```

<210> 14

<211> 850

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (3) .. (4)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (9) .. (9)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (11) .. (11)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (18) .. (18)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (202) .. (202)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (205) .. (205)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (273) .. (273)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (327) .. (327)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (367) .. (367)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (581) .. (581)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (599) .. (599)

<223> n=a, c, g or t

<220>

<221> misc_feature.

<222> (628) .. (628)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (673) .. (673)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (675)..(675)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (682)..(682)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (693)..(693)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (698)..(698)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (700)..(700)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (720)..(720)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (730)..(730)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (734)..(734)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (742)..(743)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (746)..(746)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (748)..(748)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (752)..(752)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (762)..(762)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (767)..(767)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (777)..(777)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (783)..(784)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (789)..(789)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (794)..(794)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (797)..(798)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (803)..(805)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (810)..(810)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (817)..(817)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (826)..(827)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (831)..(832)

<223> n=a, c, g or t

<220>

<221> misc_feature

5 <222> (834)..(834)

<223> n=a, c, g or t

10 <220>

<221> misc_feature

<222> (837)..(838)

15 <223> n=a, c, g or t

<220>

20 <221> misc_feature

<222> (840)..(840)

25 <223> n=a, c, g or t

<220>

<221> misc_feature

30 <222> (844)..(844)

<223> n=a, c, g or t

35 <220>

<221> misc_feature

<222> (846)..(848)

40 <223> n=a, c, g or t

<400> 14

45	ttnnotttnt	ngccatgncc	agttcaactc	agcctctcag	ttccacacgg	acaacatgcg	60
	ggaccctctg	aaccgagtc	tggccaacct	gttctgtctc	atctcctcca	tcctggggtc	120
	tcgcaccgct	ggccccaca	cccagttcgt	gcagtggttc	atggaggagt	gtgtggactg	180
	cctggagcag	ggtggccgtg	gnagngtcct	gcagttcatg	cccttcacca	cogtgtcggg	240
	actggtgaag	gtgtcagcca	tgtctagccc	canggtggtt	ctggccatca	cggacctcag	300
	cctgccccctg	ggccgccagg	tggctgntaa	agccattgct	gcactctgag	gggcttgcca	360
50	tggccognagt	gggggctggg	gactggcgca	gccccaggcg	cctccaaggg	aagcagttag	420
	gaaagatgag	gcatcgctgc	tcacatccgt	tccacatggt	gcaagagcct	ctagcggcct	480
	ccagttcccc	gctcctgact	cctgactcca	ggatgtctcc	cggtttcttc	ttttcaaaat	540
	tttctctccc	atcttgctgg	caactgaggc	gagtgagcag	nctggaccac	aagcccagng	600
	gttcacccct	gtgttgcgcc	cggccagnc	aggagtagtc	ttacctcttg	aggaactttc	660
	ttggatggaa	agngngtttt	tntgtgttgt	gtntgtgnan	gtgtttttcg	gggttttttn	720
55	gggcaatatn	ttanggggaat	cnnccntncc	cncatttttt	cnttagagct	ccccggngga	780

aanntettna tccnctnnct ttnnnctecn tcacctnct tctttntct nntntnnn 840
tccnennnc 850

<210> 15

<211> 2309

<212> DNA

<213> Homo sapiens

<400> 15

ccccggcg	aggaggcg	cgccccgg	ccaccggccc	cccatggacg	ccccagcac	60
ggggcgctga	gacccccg	tcgctgcccc	gccccggtccg	gcgcgccacg	ccagggatct	120
ctggacagga	caagactccg	aagctactcc	cccagcacac	agccccgggac	ccacaaaccc	180
agcttgcccc	cagccctccc	acctgccact	ccctggcccc	tcccaccgcc	cgccccccctt	240
ggggcgcgag	gcatgggtgtg	aaaggccaag	tgctgaggcg	ggtatcatgg	gtgctgtgoc	300
ctagggcctg	ggtggcgagg	ggtgggtggc	ctgtgggtgt	gccggggggg	ccagtgtgoc	360
caccccagtc	tcttggogtg	ctggagggca	tcctggatgg	aattgaagtg	aatggaacag	420
aagccaagca	aggtggagtg	tggttcagac	ccagaggaga	acagtggcag	gtcaccagat	480
ggaaagcgaa	aaagaaagaa	cggccaatgt	tcctgaaaa	ccagcatgtc	agggatatatc	540
cctagttacc	tggaacaaga	cgagcagtg	gtcgtgtgtg	gggacaaggc	aactggttat	600
cactaccgct	gtatcacttg	tgagggtgc	aagggtctct	ttcgccgcac	aatccagaag	660
aacctccatc	ccacctatct	ctgcaaatat	gacagotgct	gtgtcattga	caagatcacc	720
cgcaatcagt	gccagctgtg	ccgttccaag	aagtgcacgc	ccgtgggcac	ggccatggac	780
ttggttctag	atgactogaa	gcgggtggcc	aagcgtaagc	tgattgagca	gaaccgggag	840
cggcgcgga	aggaggagat	gatccgatca	ctgcagcagc	gaccagagcc	cactcctgaa	900
gagtgggata	tgatccacat	tgccacagag	gccccatcgca	gcaccaatgc	ccagggcagc	960
catttgaaac	agaggcgga	attcctgccc	gatgacattg	gccagtcacc	cattgtctcc	1020
atgccggacg	gagacaaggt	ggacctggaa	gccttcagcg	agtttaccaa	gatcatcacc	1080
ccggccatca	ccogtgtggt	ggactttgcc	aaaaaactgc	ccatgttctc	cgagctgcct	1140
tgcaagacc	agatcatcct	cctgaagggg	tgctgcatgg	agatcatgtc	cctgcggggc	1200
gctgtccgct	acgacctga	gagcgacacc	ctgacgtga	gtggggagat	ggctgtcaag	1260
cgggagcagc	tcaagaatgg	cggcctgggc	gtagtctccg	acgccatctt	tgaactgggc	1320
aagtcaactct	ctgcctttta	cctggatgac	acggaagtgg	ctctgctgca	ggctgtgctg	1380
ctaattgcaa	cagaccgctc	gggcctgctg	tgtgtggaca	agatcgagaa	gagtcaggag	1440
gcgtacctgc	tggcgttcga	gcaactacgc	aaccaccgca	aacacaacat	tccgcacttc	1500
tgccccaagc	tgctgatgaa	ggagagagaa	gtgcagagtt	cgattctgta	caagggggca	1560
gcggcagaag	gccggcgagg	cgggtcaactg	ggcgtccaac	cggaaggaca	gcagcttctc	1620
ggaatgcatg	ttgttcaggg	tcgcaggtgc	cggcagcttg	agcagcagct	tggtgaagcg	1680
ggaagtctcc	aagggcgggt	tcttcagcac	cagagccoga	agagcccgca	gcagcgtctc	1740
ctggagctgc	tccaccgaag	cgggaattctc	catgcccag	cggctctgtg	ggaagacgac	1800
agcagtgagg	cggactcccc	gagctcctct	gaggaggaa	cggaggtctg	cgaggacctg	1860
gcaggcaatg	cagcctctcc	ctgaagcccc	ccagaaggcc	gatggggaag	gagaaggagt	1920
gccatacctt	ctcccaggcc	tctgccccaa	gagcaggagg	tgccatgaa	ctgggagcgt	1980
gggtcagca	gggtgggtca	cctcccatcc	cgtaaagaca	ccttcccttc	ctcagcaggc	2040
caaacatggc	cagactccct	tgctttttgc	tgtgtagtgc	cctctgcctg	ggatgcctct	2100
ccccctttct	ctgcctggca	acatcttact	tgtcctttga	ggccccaa	caagtgtcac	2160
ctccttcccc	agctccccc	ggcagaaata	gtgtgtgtg	cttccctgg	tcagtctct	2220
actgtgacac	ttatctcact	gtttataat	tagtcgggca	tgagtctgtt	tcccaagcta	2280
gactgtgtct	gaatcatgtc	tgtatcccg				2309

<210> 16

<211> 2355

<212> DNA

<213> Homo sapiens

<400> 16

ccgttgccctc	aacgtccaac	ccttctgcag	ggctgcagtc	cggccacccc	aagacottgc	60
tgcagggtgc	tteggatcct	gatcgtgagt	cgcggggtcc	actccccgcc	cttagccagt	120
gcccaggggg	caacagcggc	gatcgcaacc	tctagtttga	gtcaagggtcc	agtttgaatg	180
accgctctca	gctggtgaag	acatgaccac	cctggactcc	aaacaaca	caggtggcgt	240
catcacctac	attggtcca	gtggctcttc	cccaagcgc	accagccctg	aatccctcta	300
tagtgacaac	tccaatggca	gcttccagtc	cctgacccaa	ggctgtccca	cctacttccc	360
accatccccc	actggtcccc	tcacccaaga	cccggtcgc	tcotttgga	gcattccacc	420
cagcctgagt	gatgacggct	ccccttcttc	ctcatcttcc	togtctcat	cctcctcttc	480
cttctataat	gggagcccc	ctgggagtct	acaagtggcc	atggaggaca	gcagcogagt	540
gtcccccagc	aagagcacca	gcaacatcac	caagctgaat	ggcatggtgt	tactgtgtaa	600
agtgtgtggg	gacgttgctt	cgggcttcca	ctacggtgtg	ctcgcctgog	agggctgcaa	660
gggctttttc	cgtcggagca	tccagcagaa	catccagtac	aaaaggtgtc	tgaagaatga	720
gaattgtctc	atcgtccgca	tcaatcgcaa	ccgctgccag	caatgtcgtc	tcaagaagtg	780
tctctctgtg	ggcatgtctc	gagaogctgt	gcgttttggg	cgcaccccca	aacgagagaa	840
gcagcggatg	cttgtgtgaga	tgagagtgc	catgaacctg	gccacaaccc	agttgagcag	900
ccagtgcocg	ctggagactt	cacccacca	gcacccacc	ccaggcccca	tgggcccctc	960
gccacccoot	gctccggtcc	cctcaccctt	ggtgggcttc	tccagtttc	cacaacagct	1020
gacgcctccc	agatcccca	gccctgagcc	cacagtggag	gatgtgat	cccaggtggc	1080
cogggcccac	cgagagatct	tcacctaagc	ccatgacaag	ctgggcagct	cacotggcaa	1140
cttcaatgcc	aacctgcat	caggtagccc	tccagccacc	acccacatc	gctgggaaaa	1200
tcagggtgc	ccactggccc	ccaatgacaa	caacaccttg	gctgccagc	gtcataacga	1260
ggccctaaat	ggtctgcgcc	aggctccctc	ctcctaccct	cccacctggc	ctcctggccc	1320
tgacacccac	agctgccacc	agtccaacag	caacgggcac	ogtctatgcc	ccaccacagt	1380
gtatgcagcc	ccagaaggca	aggcacctgc	caacagtccc	cggcagggca	actcaaagaa	1440
tgttctgctg	gcatgtccta	tgaacatgta	cccgcattga	cgcagtgggc	gaacggtgca	1500
ggagatatgg	gaggatttct	ccatgagctt	cacgcccgt	gtgcgggagg	tggtagagtt	1560
tgccaaacac	atcccgggct	tccgtgacct	ttctcagcat	gaccaagtca	ccctgcttaa	1620
ggctggcacc	tttgagggtc	tgatggtgcg	ctttgcttcg	ttgttcaacg	tgaaggacca	1680
gacagtgatg	ttcctaagcc	ggaccaccta	cagcctgcag	gagcttggtg	ccatgggcac	1740
gggagacctg	ctcagtgcga	tgttcgactt	cagcgagaag	ctcaactccc	tggcgcttac	1800
cgaggaggag	ctgggcctct	tcaccgcggt	ggtgcttgtc	tctgcagacc	gctcgggcat	1860
ggagaattcc	gcttgggtgg	agcagotcca	ggagacgctg	ctgcgggctc	ttcgggctct	1920
ggtgctgaag	aaccggccct	tggagacttc	ccgcttcacc	aagctgctgc	tcaagctgcc	1980
ggacctgcgg	accctgaaca	acatgcatte	cgagaagctg	ctgtccttcc	gggtggacgc	2040
ccagtgaacc	gcccgccggg	ccttctgcgc	ctgccccott	gtacagaatc	gaaototgca	2100
cttctctctc	ctttacgaga	cgaaaaggaa	aagcaaacca	gaatcttatt	tatattgtta	2160
taaaatattc	caagatgagc	ctctggcccc	ctgagccttc	ttgtaaatac	ctgcctccct	2220
ccccatcac	cgaacttccc	ctcctccctt	atttaaacca	ctctgtctcc	cccacaaccc	2280
tcccctggcc	ctctgatttg	ttctgttctt	gtctcaaatc	caatagtcca	cagctaaaaa	2340
aaaaaaaaaa	aaaaag					2355

<210> 17

<211> 4119

<212> DNA

<213> Homo sapiens

<400> 17

gaattccggt	gctgtcgac	acacacacac	acacacacac	acacacacac	acacacacac	60
acaccccaac	acacacacac	acacacacac	acacacacac	acacacacac	acacacacac	120
atggccgagc	gccgcacgog	tagcacgcog	ggactagcta	tccagcctcc	cagcagcctc	180
tgccgacggc	gcgggtcgta	agtacotcgc	cgggtggtggc	cgttctccgt	aagatggcgg	240
acogggcgcg	gcagcgcgct	tcgcaagaca	ccgaggacga	ggatctcgg	gottcgggct	300
ccgacagcgg	cggctccccg	ttgcggggag	gcgggagctg	cagcggtagc	gccggaggcg	360
ggggcagcgg	ctctctgcct	tcacagcgcg	gaggccgaac	cggggccott	catctgcggc	420
gggtggagag	cggggcgccg	aagagtgcgt	aggagtogga	gtgtgagagt	gaagatggca	480
ttgaagggtga	tgctgttoto	tcggattatg	aaagtgcaga	agactcggaa	ggtgaagaag	540
gtgaatacag	tgaagaggaa	aactccaaag	tggagotgaa	atcagaagct	aatgatgctg	600
ttaattcttc	aacaaaagaa	gagaaggag	aagaaaagcc	tgacaccaa	agcaactgtga	660
otggagagag	gcaaagtggg	gacggacagg	agagcacaga	gcctgtggag	aacaaagtgg	720
gtaaaaaggg	ccctaagcat	ttggatgatg	atgaagatcg	gaagaatcca	gcatacatat	780
ctcggaagg	gctcttcttt	gagcatgatc	ttcgagggca	aactcaggag	gaggaagtca	840
gacccaaggg	gcgtcagcga	aagctatgga	aggatgaggg	tcgctgggag	catgacaagt	900
tcoggggaaga	tgagcaggcc	ccaaagtccc	gacaggagct	cattgctctt	tatggttatg	960
acattcgttc	agctcataat	cctgatgaca	tcaaacotcg	aagaatccgg	aaaccccgat	1020
atgggagtcc	tccacaaaga	gatcoaaact	ggaacgggtga	gggctaaac	aagtctcatc	1080
gccaccaggg	tcttgggggc	accctaccac	caaggacatt	tattaacagg	aatgctgcag	1140
gtaccggccg	tatgtctgca	cccaggaatt	attctcgatc	tgggggcttc	aaggaaggtc	1200
gtgctggttt	taggcctgtg	gaagctggtg	ggcagcatgg	tggccgggtct	ggtgagactg	1260
ttaagcatga	gattagtta	cggtcacggc	gcctagagca	gacttctgtg	agggatccat	1320
ctccagaagc	agatgctcca	gtgcttgcca	gtcctgagaa	ggaagaggca	gcctcagagc	1380
caccctctgc	tgctctctgat	gtgcaccac	caccccttga	taggcccatt	gagaagaaat	1440
cctattcccg	ggcaagaaga	actogaacca	aagttggaga	tcagtcgaag	cttgcagagg	1500
agggtgcccc	tcctcctgaa	ggactgattc	cagcacctcc	agtcccagaa	accaccccaa	1560
ctccacctac	taagactggg	acctgggaag	ctccgggtgga	ttctagtaca	agtggacttg	1620
agcaagatgt	ggcacaaacta	aatatagcag	aacagaattg	gagtcggggg	cagcctctct	1680
tcctgcaacc	acgggaaoct	cgaggtatgc	ccaaoccatat	acacatggga	gcaggacotc	1740
cacctcagtt	taaccggatg	gaagaaatgg	gtgtccaggg	tggctgagcc	aaacgctatt	1800
catcccagcg	gcaaagacct	gtgccagagc	cccccgcccc	tccagtgcac	atcagtatca	1860
tgaggggaca	ttactatgat	ccactgcagt	tcaggggacc	aatctatacc	catggtgaca	1920
gccctgcccc	gotgcctcca	cagggcagtc	ttgtgcagcc	aggaatgaac	cttcccacc	1980
caggtttaca	tcaccaccag	acaccagctc	ctctgcccac	tccaggcctc	tatccccac	2040
cagtgtccat	gtctccagga	cagccaccac	ctcagcagtt	gcttgcctct	acttactttt	2100
ctgctccagg	cgctcatgaa	tttggtaatc	ccagttaccc	ttatgctcca	ggggcactgc	2160
ctccccacc	accgcctcat	ctgtatccta	atacacaggc	ccatcacag	gtatatggag	2220
gagtgaacct	ctataacccc	gccagcgagc	aggtgcagcc	aaagccctcc	ccaccccgga	2280
ggactcccca	gccagtcacc	atcaagcccc	ctccacctga	ggttgtaagc	aggggttcca	2340
gttaatacaa	gtttctgaat	attttaaatc	ttaacatcat	ataaaaagca	gcagaggtga	2400
gaactcagaa	gagaaataca	gctggctatc	tactaccaga	agggcttcaa	agataaggg	2460
tgtggtcct	accagcaaac	agctgaaaga	ggaggaoccc	tgcttctctc	tgaggacagg	2520
ctctagagag	agggagaaac	aagtggacct	cgctccatct	tcactottca	cttgagttgg	2580
ctgtgttcgg	gggagcagag	agagccagac	agccccaagc	ttctgagttc	agatacagaa	2640
gcccattgtc	tctgctgttc	ttcactttct	ggaaattgaa	gtgtctctct	ttcccaagga	2700
agctccttcc	tgtttatttt	gttttctaat	atgttctatt	ttaaagcctg	gcttcttctc	2760
cttaatatata	tttttaattt	ttctctttgt	ttctgtttct	tgctctctct	ccctgccttt	2820
aaatgaaaca	agtctagtct	tctggttttc	tagccctctc	ggattccctt	ttgactcttc	2880

5 cgtgcatccc agataatgga gaatgtatca gccagccttc cccaccaagt ctaaaaagac 2940
 ctggcctttc acttttagtt ggcatttgtt atcctcttgt tcccttaact 3000
 ctaaccctgt ggaagcatgg ctgtctgcac agaggggtccc attgtgcaga aaagctcaga 3060
 gtaggtgggt aggagccctt ctctttgact taggttttta ggagtctgag catocatcaa 3120
 tacctgtact atgatgggct totgttctot gctgagggcc aataccctac tgtggggaga 3180
 gatggcacac cagatgcttt tgtgagaaag ggatgggtgga gtgagagcct ttgccttttag 3240
 ggggtgtgat tcacatagtc ctcagggtct agtcttttga ggtaagtgga attagagggc 3300
 cttgcttctc ttctttccat tcttcttgct acaccccttt tccagttgct gtggaccaat 3360
 10 gcatctcttt aaaggcaaatt attatccagc aagcagtcta ccctgtcctt tgcaattgct 3420
 cttctccacg tctttcctgc tacaagtgtt ttagatgtta ctaccttatt ttccccgaat 3480
 totatttttg tccttgacaga cagaatataa aaactcctgg gcttaaggcc taagggaagcc 3540
 agtoaccttc tgggcaaggc ctcctatctt tctctccctat ccatggcact aaaccacttc 3600
 tctgctgcct ctgtggaaga gattcctatt actgcagtac atacgtctgc caggggtaac 3660
 ctggccactg tccctgtcct tctacagaac ctgagggcaa agatgggtggc tgtgtctctc 3720
 15 ccoggtaatg tcaactgtttt tattccttcc atctagoagc tggcctaate actctgagtc 3780
 acaggtgtgg gatggagagt ggggagaggc acttaatotg taacccccaa ggaggaaata 3840
 actaagagat tottctaggg gtagctggtg gttgtgcctt ttgtaggctg ttccctttgc 3900
 cttaaaccctg aagatgtctc ctcaagcctg tgggcagcat gccagattc ccagacctta 3960
 agacactgtg agagttgtct ctgttggtcc actgtgttta gttgcaagga tttttccatg 4020
 20 tgtggtggtg tttttgttta ctgttttaa ggggtgccat ttgtgatcag cattgtgact 4080
 tggagataat aaaatttaga ctataaactt gaaaaaaaa 4119

<210> 18

<211> 2653

<212> DNA

<213> Homo sapiens

<400> 18

35 gagcgcggtt ggagtttgtt gctgccgtg tgcagtttgt tcaggggctt gtggcggtga 60
 gtccgagagg ctgctgttga gagacgtgag aaggatcctg cactgaggag gtggaaagaa 120
 gaggattgtt cgaggaggcc tgggtgtgtt gagacagcgg agctgggtga aggctgcggg 180
 ttccggcgag gcctgagotg tgcgtctgtc atgcctcaaa cccgatccca ggcaacaggct 240
 acaatcagtt ttccaaaaag gaagctgtct cgggcattga acaaagctaa aaactccagt 300
 gatgccaaac tagaaccaac aaatgtccaa accgtaacct gttctctctg tgtaaaagcc 360
 ctgcctctca gcccaggaa acgtctgggc atgacaacac tatgcaacac tccccattta 420
 40 cctccttggt cttccaccaa gcaaggcaag aaagagaatg gtccctctca ctacataca 480
 cttaaggggac gaagattggt atttgacaat cagctgacaa ttaagtctcc tagcaaaaga 540
 gaactagoca aagttcacca aaacaaaata ctttcttcag ttagaaaaag tcaagagatc 600
 acaacaaatt ctgagcagag atgtccactg aagaaagaat ctgcatgtgt gagactatc 660
 aagcaagaag gcacttgota ccagcaagca aagctgggtc tgaacacagc tgtcccagat 720
 cggctgcctg ccagggaag ggagatggat gtcacagga atttcttgag ggaacacatc 780
 45 tgtgggaaaa aagctggaag cctttacctt tctggtgtct ctggaactgg aaaaactgcc 840
 tgottaagcc ggattctgca agacctcaag aaggaactga aaggctttaa aactatcatg 900
 ctgaattgca tgtccttgag gactgccag gctgtattcc cagctattgc tcaggagatt 960
 tgtcaggaag aggtatccag gccagctggg aaggacatga tgaggaaatt ggaaaaacat 1020
 atgactgcag agaaggccc catgattgtg ttggtattgg acgagatgga tcaactggac 1080
 agcaaaggcc aggatgtatt gtacacgcta tttgaatggc catggctaag caattctcac 1140
 50 ttggtgtgta ttggtattgc taataccctg gatctcacag atagaattct acctaggctt 1200
 caagctagag aaaaatgtaa gccacagctg ttgaacttcc caccttatac cagaaatcag 1260
 atagtcacta ttttgcaaga tgcactaat caggatatcta gagatcaggt totggacaa 1320
 gctgcagttc aattctgtgc ccgcaaagtc tctgctgttt caggagatgt tcgcaaaagc 1380
 ctggatgttt gcaggagagc tattgaaatt atgtcaaaag ccagactatt 1440
 55 ctcaaacac tgtctgaatg taaatcacct tctgagcctc tgattcccaa gaggggttgt 1500
 cttattcaca tatcccaagt catctcagaa gttgatggta acaggatgac cttgagccaa 1560

	gagggagcac	aagattcctt	ccctcttcag	cagaagatct	tggtttgctc	tttgatgctc	1620
	ttgatcaggc	agttgaaaat	caaagaggtc	actctgggga	agttatatga	agcctacagt	1680
	aaagtctgtc	gcaaacagca	ggtggcggct	gtggaccagt	cagagtgttt	gtcactttca	1740
5	gggctcttgg	aagccagggg	catttttagga	ttaaagagaa	acaaggaaac	ccgtttgaca	1800
	aaggtgtttt	tcaagattga	agagaaagaa	atagaacatg	ctctgaaaga	taaagcttta	1860
	attggaata	totttagctac	tggtttgcct	taaattotct	tcttacaccc	caccgaaag	1920
	tattcagctg	gcatttagag	agctacagtc	ttcatttttag	tgctttacac	attcgggcct	1980
	gaaaacaaat	atgacctttt	ttacttgaag	ccaatgaatt	ttaatctata	gattotttaa	2040
10	tattagcaca	gaataatctc	tttgggtctt	actattttta	cccataaaaag	tgaccaggta	2100
	gacctttttt	aattacattc	actacttcta	ccacttgtgt	atctctagcc	aatgtgcttg	2160
	caagtgtaca	gatctgtgta	gaggaatgtg	tgtatattta	cctcttcgtt	tgctcaaaca	2220
	tgagtgggta	tttttttggg	tggtttgttg	tttttgaggc	gcgtctcacc		2280
	ctgttgccca	ggctggagtg	caatggcgcg	ttctctgctc	actacagcac	ccgcttccca	2340
	ggttgaagtg	attctcttgc	ctcagcctcc	cgagtagctg	ggattacagg	tgcccaccac	2400
15	cgcgcccgag	taatttttta	attttttagta	gagacagggg	tttaacctgt	tgcccgaggc	2460
	ggtcttgaac	tcttgacctc	caagtgtatc	gcccacottg	gcctccctaa	gtgtgggatg	2520
	tataggogtg	agccaccatg	ctcagccatt	aaggtatttt	gttaagaact	ttaagttag	2580
	ggttaagaaga	atgaaaatga	tccagaaaaa	tgcaagcaag	tccacatgga	gatttgagg	2640
	acactggtta	aag					2653
20	<210> 19						
	<211> 2907						
	<212> DNA						
25	<213> Homo sapiens						
30	<400> 19						
	gocatctggg	cccaggcccc	atgccccgag	gaggggtggt	ctgaagccca	ccagagcccc	60
	ctgccagact	gtctgcctcc	cttctgactg	tgcccgcttg	gcattggccag	caacagcagc	120
	tctgcccga	cacctggggg	cgggcacctc	aatgggtacc	cggtgcctcc	ctacgccttc	180
	ttcttccccc	ctatgctggg	tggtactctc	ccgccaggcg	ctctgaccac	tctccagcac	240
	cagcttccag	ttagtggata	tagcacacca	tcccagccca	ccattgagac	ccagagcagc	300
35	agttctgaag	agatagtgcc	cagccctccc	tcgccacccc	ctctaccccg	catctacaag	360
	ccttgctttg	tctgtcagga	caagtcctca	ggctaccact	atgggggtcag	cgctgtgag	420
	ggctgcaagg	gcttcttccg	cgcagcatc	cagaagaaca	tggtgtacac	gtgtcacccg	480
	gacaagaact	gcacatcaaa	caaggtgacc	cggaaaccgt	gccagtactg	ccgactgcag	540
	aagtgccttg	aagtgggcat	gtccaaggag	tctgtgagaa	acgaccgaaa	caagaagaag	600
40	aaggaggtgc	ccaagccoga	gtgctctgag	agctacacgc	tgacgcggga	ggtgggggag	660
	ctcattgaga	aggtgcgcaa	agcgcaccag	gaaaccttcc	ctgcctcttg	ccagctgggc	720
	aaatacacta	cgaacaacag	ctcagaacaa	cgtgtctctc	tggaattga	cctctgggac	780
	aagttoagtg	aactctccac	caagtgcac	attaagactg	tggtgttcgc	caagcagctg	840
	cccggttca	ccacctcac	catcgccgac	cagatcacc	tcctcaaggc	tgctgcctg	900
	gacatcctga	tctgcgggat	ctgcacggg	tacaogccc	agcaggacac	catgaccttc	960
45	tcggacgggc	tgacctgaa	ccggacccag	atgcacaacg	ctggcttcgg	ccccctcac	1020
	gacctggtct	ttgcttctgc	caaccagctg	ctgcccctgg	agatggatga	tgccggagacg	1080
	gggtgctca	gcccctctg	cctcatctgc	ggagaccgca	aggacctgga	gcagccggac	1140
	cggttgagca	tgctgcagga	gcgctgctg	gagggcgtaa	aggtctacgt	gcggaagcgg	1200
	agggccagcc	gccccacat	gttccccaag	atgctaatga	agattactga	cctgcgaagc	1260
50	atcagcgcca	agggggctga	gcgggtgatc	acgtgaaga	tgagatccc	gggtccatg	1320
	ccgctctca	tccaggaaat	gttgagagaa	tcagagggcc	tggaactct	gagcggacag	1380
	ccgggggggtg	ggggggcgga	cggggggtgc	ctggccccc	cgccaggcag	ctgtagcccc	1440
	agcctcagcc	ccagctccaa	cagaagcagc	ctggccccc	actcccctg	accgcccacg	1500
	ccacatggac	acagccctcg	ccctccgccc	cggcttttct	ctgcctttct	accgaccatg	1560
	tgaccccgca	ccagccctgc	ccccacctgc	cctccggggc	agtactgggg	accttccctg	1620
55	ggggacgggg	agggaggag	cagcgactcc	ttggacagag	gcctgggccc	tcagtggact	1680

gcctgctccc acagcctggg ctgacgtcag aggccgagge caggaactga gtgaggcccc 1740
 tggtcctggg totcaggatg ggtcctgggg goctcgtgtt catcaagaca cccctctgcc 1800
 cagotcacca catottcato accagcaaac gccaggactt ggctcccca tcctcagaac 1860
 5 tcacaagcca ttgotcccca gctggggaac ctoaacctcc cccctgcctc ggttggtgac 1920
 agaggggggtg ggacaggggc ggggggttcc ccctgtacat accctgccat accaaccoca 1980
 ggtattaatt ctcgotggtt ttgtttttat tttaattttt ttgttttgat ttttttaata 2040
 agaattttca ttttaagcac atttatactg aaggaatttg tgotgtgtat tggggggagc 2100
 tggatccaga gctggagggg gtgggtccgg gggaggaggt ggctoggaag gggcccccac 2160
 10 totcctttca tgtccctgtg ccccccagtt ctctctctca gccttttcct cctoagtttt 2220
 ctcttttaaaa ctgtgaagta ctaactttcc aaggcctgcc ttccctccc tcccactgga 2280
 gaagcccgcca gccctttct cctctgcct gaccactggg tgtggacggt gtggggcagc 2340
 cotgaaagga caggctcctg gccttggcac ttgcctgcac ccaccatgag gcatggagca 2400
 gggcagagca agggcccccgg gacagagttt tcccagacct ggctcctcgg cagagctgcc 2460
 toccgtcagg gccacatca tctaggctcc ccagcccca ctgtgaaggg gctggccagg 2520
 15 ggccogagct gcccacccc ccggcctoag ccaccagcac ccccataggg cccocagaca 2580
 ccacacacat gcgcgtgcgc acacacacaa acacacacac actggacagt agatgggccc 2640
 acacacactt ggcccagatt cctccatttc cctggcctgc cccccacccc caactgtcc 2700
 cacccccgtg cccctcctt accccgcagg acgggcctac aggggggtct cccctcacco 2760
 ctgcaccccc agctggggga gctggctctg ccccgacctc cttcaccagg ggttggggcc 2820
 20 ccttcccctg gagcccggtg gtgcacctgt tactgttggg ctttccactg agatctactg 2880
 gataaagaat aaagttctat ttattct 2907

<210> 20

<211> 2096

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (23) .. (23)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (27) .. (27)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (80) .. (80)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (120)..(120)

<223> n=a, c, g or t

<400> 20

agatgtttta	aaatactttg	atnctcngtt	tccacctctc	ttaaattgtc	tttccctatg	60
ttaaatatat	agtcatac	ttgttgaaaa	aagttcgcaa	tgagaacaat	catctaaaa	120
tggtgttaac	taggtcaggc	gcggttgctc	atgcctgtaa	tcccaccact	ttgggaggcc	180
gaggcaattg	gatcacctga	ggtcaggatt	ttgagaccag	cttgaccaac	atgggtggaat	240
cccatctcta	ctaaaaatac	aaaaaattag	ccgggtgtgg	tggcacaccc	ctgtaatccc	300
acctactcag	gaggtctgag	caggaataac	ccttgaaacc	aggaggcaaa	ggttgcattg	360
agccgaaata	acacoactgc	actccagcct	ggacgataga	gtgagacccc	atctcaaaaa	420
aagagcagct	gtgacaaaat	cctgtattga	attgcagggtc	agtcttcac	ctccactacc	480
ggtgccaaaa	aaagggctgc	cccaaaagga	actaaaaggg	atccagcttt	gaattctggg	540
gtctotcaaa	agcctgatcc	tgccaaaacc	aagaatogcc	gcaaaaggaa	gccatccact	600
tctgatgatt	ctgactctaa	ttttgagaaa	attgtttcga	aagcagtcac	aagcaagggtg	660
agtgttgatc	ctagtccagtc	cttttgctgt	agatgttctg	aaacacgtaa	ctaagccatt	720
gttcttaaaa	atttggcata	tctttaagaa	aattaaactct	catattctgt	tagcttttac	780
gttacatatt	tagttttaac	aaagttaaat	atgccactta	tttgccaat	ggaagagttg	840
gccttagatc	tgcttattat	tacttggtag	aaaatagaaa	actccttgaa	tatagtgtct	900
tgatacattt	ttttacatta	caattatggt	gtcagattta	caatgtgcaa	gttacctggg	960
cttttctctt	ttagaaatcc	aagggggaga	gtgatgactt	ccatatggac	tttgactcag	1020
ctgtggctcc	tggggcaaaa	tctgtacggg	caaagaaacc	tataaagtac	ctggaagagt	1080
cagatgaaga	tgatctgttt	taaaatgtga	ggcgattatt	ttaagtaatt	atcttaccac	1140
gccaagact	ggtttttaag	ttacctgaag	ctcttaactt	cctccctctc	gaatttagtt	1200
tggggaaggt	gttttttagta	caagacatca	aagtgaagta	aagcccaagt	gttcttttagc	1260
tttttataat	aotgtataaa	tagtgaccat	ctcatgggca	ttgttttctt	ctctgctttg	1320
tctgtgtttt	gagtctgctt	cttttgtctt	taaaacctga	tttttaagtt	cttctgaact	1380
gtagaaatag	ctatctgata	acttcagcgt	aaagcagtg	gtttattaac	catccactaa	1440
gctaaaacta	gagcagtttg	attttaaagt	gtcactcttc	ctccttttct	actttcagta	1500
gatatgagat	agagcataat	tatctgtttt	atcttagttt	tatacataat	ttaccatcag	1560
atagaacttt	atggttctag	tacagatact	ctactacact	cagcctctta	tgtgcccaagt	1620
ttttotttta	gcaatgagaa	attgctcatg	ttcttcatct	tctcaaatca	tcagagggcg	1680
aagaaaaaca	ctttggctgt	gtctataact	tgacacagtc	aatagaatga	agaaaattag	1740
agtagttatg	tgattatttc	agctcttgac	ctgtcccttc	tggtgcctc	tgagtctgaa	1800
tctoccaaag	agagaaacca	atttctaaga	ggactggatt	gcagaagact	cggggacaa	1860
atttgcataa	agatcttaaa	tggttatattg	ataaccatgc	tcagcaatga	gctattagat	1920
tcattttggg	aaatctccat	aatttcaatt	tgtaaaacttt	gttaagacct	gtctacattg	1980
ttatatgtgt	gtgacttgag	taatgttata	aacgtttttg	tatatattta	ctatgttttt	2040
ctattagcta	aattccaaca	attttgtact	ttaataaaat	gttctaaaca	ttgaaa	2096

<210> 21

<211> 2160

<212> DNA

<213> Homo sapiens

<400> 21

	agccccotgc	ccctcgccgc	cccccgccgc	ctgcctgggc	cgggccgagg	atgcggcgca	60
	gogcctcggc	ggccagggtt	gtccccctcc	ggcagcgctg	ctaacttccc	ccgctacgtc	120
5	cccgttccgc	cgccggggcg	ccccgtctcc	ccgcggcctc	cggggtccggg	tcctccagga	180
	cgggcaggcc	gtgcgcgcgt	gtgcccctccg	ccgctcgccc	gcgcgcgcgcg	cgctccccgc	240
	ctgcgcccag	cgccccgcgc	ccgcgcceca	gtcctcgggc	ggtcctatgt	gccccctctgc	300
	ctcgtggccg	ccctgctgct	ggccgcgcgg	ccggggccga	gcctggggcg	cgaagccatc	360
	cactgcccgc	cctgctccga	ggagaagctg	gogcgctgce	gcccccccg	gggctgcgag	420
10	gagctgggtg	gagaggcggg	ctgcggctgt	tgccccaact	gcgccctggg	cttggggatg	480
	ccctgcgggg	tgtacacccc	ccgttgccgc	tcgggcctgc	gctgctaccc	gccccgaggg	540
	gtggagaagc	ccctgoacac	actgatgcac	gggcaaggcg	tgtgcatgga	gctggcgagg	600
	atcgaggcca	tcaggaaag	cctgcagccc	tctgacaagg	acgagggtga	ccaccccaac	660
	aacagcttca	gccccgttag	cgcccatgac	cgcagggtgc	tcgagaagca	cttcgccaaa	720
	attcgagacc	ggagcaccag	tgggggcaag	atgaaggcca	atggggcgcc	ccgggaggat	780
15	gccccggcctg	tgccccagg	cctcctgccc	agcgagctgc	accgggcgct	ggagcggtcg	840
	gocgcttcac	agagccgcac	ccacgaggac	ctctacttca	tccccatccc	caactgcgac	900
	cgcaacggca	acttccaccc	caagcagtgt	caaccagctc	tggatgggca	gcgtggcaag	960
	tgctggtgtg	tggaccggaa	gacgggggtg	aagcttccgg	ggggcctgga	gccaaagggg	1020
	gagctggact	gccaccagct	ggctgacagc	tttcgagagt	gaggcctgcc	agcaggccag	1080
20	ggactcagcg	tcacctgcta	ctcctgtgtc	ctggaggctg	cagagctgac	ccagagtggg	1140
	gtctgagttc	gagtcctgtc	totgcttgcg	gcccagaagt	ttccctcaaa	tgcgcggtgtg	1200
	cacgtgtgct	tgtgcgtgct	tgtgtgtgtg	tttgtgagca	tgggtgtgct	cttggggtaa	1260
	gccagagcct	ggggtgttct	ctttggtgtt	acacagccca	agaggactga	gactggcact	1320
	tagcccaaga	ggtctgagcc	ctggtgtgtt	tcagatcga	tcctggattc	actcactcac	1380
	tcattccttc	actcatccag	ccacctaaaa	acatttactg	accatgtact	acgtgccagc	1440
25	totagttttc	agccttgagg	ggtttttatt	tgacttcctc	tgattttggc	atgtggagac	1500
	actcctataa	ggagagttca	agcctgtggg	agtagaaaaa	tctcattccc	agagtccagag	1560
	gagaagagac	atgtaccttg	accatcgtcc	ttcctctcaa	gctagcccag	aggggtgggag	1620
	cctaaggaag	cgtggggtag	cagatggagt	aatgggtcacg	aggtccagac	ccactcccaa	1680
	agctcagact	tgccaggctc	cctttctctt	ctccccagg	tccttctttt	aggtctggtt	1740
30	ggtgaccat	ctgcttggtt	ggctggcagc	tgagagccct	gctgtgggag	agcgaagggg	1800
	gtcaaaggaa	gacttgaagc	acagagggtc	agggaggtgg	ggtacatttc	tctgagcagt	1860
	caggggtggg	agaaagaatg	caagagtggg	ctgaatgtgc	ctaattggaga	agaccacagt	1920
	gotaggggat	gaggggcttc	ctgggtcctg	ttcccttacc	ccatttgtgg	tcacagccat	1980
	gaagtcaccg	ggatgaacct	atccttccag	tggtctgctc	cctgtagctc	tgccctccctc	2040
	tcctatatct	cttcccttac	acctccctcc	ccacacctcc	ctactccctc	gggcatcttc	2100
35	tggtctgact	ggatggaagg	agaottagga	acctaccagt	tggccatgat	gtctttttct	2160

<210> 22

<211> 2215

<212> DNA

<213> Homo sapiens

<400> 22

	ctgcaggag	ccatgattgc	accactgcac	tcagcctgg	gcaacagagt	gagaccatgt	60
	ctcaagaaaa	aaaaaaaaaga	aagaaaccac	tgctctaggc	taaatcccag	ccagagttag	120
	agccacccag	ctaaactggc	ctgttttccc	tcatttctct	ccccgaagg	atgcctgtgt	180
50	caagatgagg	tcacggacga	ttacatcgga	gacaacacca	cagtggacta	cactttgttc	240
	gagtccttgt	gctccaagaa	ggacgtgcgg	aactttaaag	cctggttctc	ccctatcatg	300
	tactccatca	tttgtttcgt	gggcctactg	ggcaatgggc	tggtcgtgtt	gacctatac	360
	tatttcaaga	ggctcaagac	catgaccgat	acctaactgc	tcaacctggc	ggtggcagac	420
	atcctcttcc	tcctgacctc	tccttcttgg	gcctacagcg	cgcccaagtc	ctgggtcttc	480
	gggtgtccact	tttgcaagct	catctttgcc	atctacaaga	tgagcttctt	cagtggcatg	540
55	ctcctacttc	tttgcatcag	cattgaccgc	tacgtggcca	togtccaggc	tgtctcagct	600

	caocgccacc	gtgcccgcgt	ccttotcadc	agcaagctgt	cctgtgtggg	catctggata	660
	ctagccacag	tgtcttccat	cccagagctc	ctgtacagtg	acctccagag	gagcagcagt	720
5	gagcaagcga	tgcgatgctc	tctcatcaca	gagcatgtgg	aggcctttat	caccatccag	780
	gtggcccaga	tgggtgatcg	ctttctggtc	cccctgctgg	ccatgagctt	ctgttacctt	840
	gtcatcatcc	gcaccctgct	ccaggcacgc	aactttgagc	gcaacaaggc	catcaagggtg	900
	atcatcgctg	tggctgtggt	cttcatagtc	ttocagctgc	cctacaatgg	ggtggtcctg	960
	goccagacgg	tggccaactt	caacatcacc	agtagcacct	gtgagctcag	taagcaactc	1020
10	aacatcgctt	acgacgtcac	ctacagcctg	gcctgcgtcc	gctgctgctg	caaccctttc	1080
	ttgtacgcct	tcatcggcgt	caagttccgc	aacgatctct	tcaagctctt	caaggacctg	1140
	ggctgectca	gccaggagca	gctccggcag	tggctcttct	gtcggcacat	ccggcgctcc	1200
	tccatgagtg	tggaggccga	gaccaccacc	accttctccc	cataggcgac	tcttctgcct	1260
	ggagtagagg	gacctctccc	agggctccctg	gggtggggat	agggagcaga	tgcaatgact	1320
	caggacatcc	ccccgccaaa	agctgctcag	ggaaaagcag	ctctccctcc	agagtgcagg	1380
15	ccctgctcca	gaagttagct	tcaocccaat	cccagctacc	tcaaccaatg	ccgaaaaaga	1440
	cagggtctgat	aagctaacac	cagacagaca	acactgggaa	acagaggcta	ttgtccccta	1500
	aacaaaaaac	tgaagtgaa	agtccagaaa	ctgttcccac	ctgctggagt	gaaggggcca	1560
	aggaggggtga	gtgcaagggg	cgtgggagtg	gcctgaagag	tcctctgaat	gaaccttctg	1620
	gcctcccaca	gactcaaatg	ctcagaccag	ctottccgaa	aaccaggcct	tatctccaag	1680
20	accagagata	gtggggagac	ttottggctt	ggtagggaaa	agcggacatc	agctggtcaa	1740
	acaaactctc	tgaacccctc	cctccatcgt	tttcttccat	gtactocaag	ccagcgggaa	1800
	tggcagctgc	cacgccgccc	taaaagcaca	ctcatccctt	cacttgccgc	gtcgcctcc	1860
	caggctctca	acaggggaga	gtgtggtgtt	tcctgcaggc	caggccagct	gcctccgcgt	1920
	gatcaaaagg	acactctggg	ctccagagtg	gggatgacat	gcactcagct	cttggctcca	1980
	ctgggatggg	aggagaggac	aagggaatg	tcaggggcgg	ggaggggtgac	agtggccgcc	2040
25	caaggccacg	agcttgttct	ttgttctttg	tcacagggac	tgaaaacctc	tcctcatgtt	2100
	ctgcttttga	ttcgttaaga	gagcaacatt	ttaccacac	acagataaag	tttcccttg	2160
	aggaaacaac	agctttaaaa	gaaaaaagaa	aaaaaaagct	tggtaagtca	agtag	2215
	<210> 23						
30	<211> 958						
	<212> DNA						
35	<213> Homo sapiens						
	<400> 23						
40	ggggccggac	gcgagggggc	gggagagcgc	gggacaaaag	gaagcgaagc	cggagctgcg	60
	ggcgcttttt	ctgcccgogg	tgtctcagat	tcattcttaa	ggaactgaga	acttaatttt	120
	ccaaaatgtc	aaaaagacca	tcttatgccc	cacctccac	cccagctcct	gcaacacaaa	180
	tgcccagcac	accagggttt	gtgggataca	atccatacag	tcatctcgcc	tacaacaact	240
	acaggctggg	agggaaaccc	agcaccaca	gccgggtcac	ggcatcctct	ggtatcacga	300
	ttccaaaacc	cccaaagcca	ccagataaag	cgctgatgcc	ctacatgagg	tacagcagaa	360
45	aggtctggga	ccaagtaaa	gcttccaacc	ctgacctaaa	gttgtgggag	attggcaaga	420
	ttattggtgg	catgtggcga	gatctcactg	atgaagaaaa	acaagaatat	ttaaacgaat	480
	acgaagcaga	aaagatagag	tacaatgaat	ctatgaaggc	ctatcataat	tcccccgct	540
	acctgtctta	cataaatgca	aaaagtctgt	cagaagctgc	tttagaggaa	gaaagtgcac	600
	agagacaatc	tcgcatggag	aaaggagaac	cgtacatgag	cattcagcct	gctgaagatc	660
50	cagatgatta	tgatgatggc	ttttcaatga	agcatacagc	caccgcccgt	ttccagagaa	720
	accaccgcct	catcagtcaa	attcttagtg	agagtgtggt	gccagacgtt	cggtcagttg	780
	tcacaacagc	tagaatgcag	gtcctcaaac	ggcaggtcca	gtccttaatg	gttcatcagc	840
	gaaaactaga	agctgaactt	cttcaaatag	aggaaacgac	ccaggagaag	aagaggaaat	900
55	tcctggaaaag	cacagattca	tttaacaatg	aacttaaaag	gttgtgcggt	ctgaaagt	958

<210> 24

<211> 6483

<212> DNA

<213> Homo sapiens

<400> 24

aagcttctaa	ttgcagttca	accacctgtt	acatatctto	aggaaaaaat	cacaacctct	60
caacttcaac	ttcctcttct	ataaattaga	aataacaata	accacacctg	taaccccagc	120
actttgggag	gccaaggcag	gcagatcaag	aggtgaggag	attgagacca	tcctggctaa	180
catgatgaaa	ccctgtctct	acaaaaaaga	caaaaaatta	gccaggtagt	gtggcacaca	240
cctgtagtcc	cagctactcg	ggaggctgag	gcaggagaat	ggcgtgaacc	cgggagggtg	300
agcttgcagt	gagccgagat	ggcgccactg	cactccagcc	tggcgacag	agcaagcctc	360
cgtctaaaaa	aaaaaaaaaga	aagaaagaaa	gaaagaaaga	aaagaaataa	taataaccac	420
cattcctatc	tcaacagott	gttctagaaa	tttttaaago	acagtatcac	aaacagcact	480
acataattgt	aaaacatgta	tgaatatata	catccaaaca	acagcaatgt	catagcctat	540
gggtagatat	aatottatac	aatgtaccaa	aatcccaatt	tacttacta	gacaaaactgt	600
tataccaaat	totgtacaca	gtatatccaa	gaaaaatgtg	tgtttttatt	gagaaaactga	660
acctagottg	ggaacacatg	tgcacagctc	agttcataat	atttggtgca	agtatcatto	720
totaatatag	attttacattt	ttgcaagcaa	atttttactt	gcaatcgtaa	catatocaaa	780
ttttcccttt	ttactcaatc	agaaottagt	gtaaagtact	acaagttagt	tcttcggatt	840
tcattgctaag	aaaataatgc	agattttctg	cattattatg	gtcttcacag	aaaccttaac	900
tatgatgaat	ttaaaagtgc	aaaataatoc	aggataaact	tatgatttca	cattttttta	960
tgttaaaaat	aatgccatca	ttaattagaa	aatttctaaa	tcattactto	cacttttotta	1020
ggcaaaatat	caatatactc	tcatttgcca	aataaattaa	aagatctcct	acaaacacaa	1080
tctcctaaat	tggtggtttta	tggttttaatt	gttttatgtg	tggcaactat	tgatgctagt	1140
taaaattttta	gaaactcttt	ctttttgatt	ccctacagtt	gtctacaaga	acottattgt	1200
agcatgatcc	tgccagaactt	tatactattt	gttgctccaa	ttaaaactgt	ttaaaacatg	1260
aatttgaaaa	atottattttt	aactataatt	ttgtagctga	aacttttttt	tctaaacttt	1320
gcaaacattc	tatgcaacct	gaatttagtg	tgagaaaatt	ggatcttaatt	ggttgctcaa	1380
tggtottcaa	caggtgaaaa	gcataataaa	acatgctcat	ctgaactcca	cccattttca	1440
atttcaacat	agcatacctc	gtgttttatt	ttagggcaaa	ttcaaaattg	tacatattag	1500
gattgggttat	tactgaagat	aatttatgca	atcataagcc	aaagatgcta	agtgggcaaa	1560
aagaaaacaa	tgtaagtaag	caaaotctaa	cacatgtgga	cacacctctc	cagtatataa	1620
aggcttgtoa	ctgtcccttg	tagcaggcac	tccttgggct	aaacagcatc	accatgtctg	1680
ttcgatacag	ctcaagcaag	cactactctt	octcccgcag	tggaggagga	ggaggaggag	1740
gaggatgtgg	aggaggagga	ggagtgtcat	coctaagaat	ttctagcagc	aaaggctccc	1800
ttggtggagg	atttagctca	gggggggttca	gtggtggctc	ttttagccgt	gggagctctg	1860
gtgggggatg	ctttgggggc	tcacaggtg	gctatggagg	attaggagggt	tttgggtggag	1920
gtagctttca	tggaagctat	ggaagtagca	gctttggtgg	gagttatgga	ggcagctttg	1980
gagggggcaa	tttcggagggt	ggcagctttg	gtgggggcag	ctttggtgga	ggcggctttg	2040
gtggaggcgg	ctttggagga	ggctttgtgt	gtggatttgg	aggagatggt	ggccttctct	2100
ctggaaatga	aaaagtaacc	atgcagaatc	tgaatgaccg	cctggcttcc	tacttggaac	2160
aagtctgggc	tctggaagaa	tcaaaactatg	agctggaagg	caaaatcaag	gagtgggtatg	2220
aaaagcatgg	caactcacat	caggggggagc	ctcgtgacta	cagcaaatac	tacaaaacca	2280
tcgatgacct	taaaaatcag	gtaagaggtta	tttttaaato	cagctttaag	tatcttgctc	2340
atgtaatcca	gacagatgaa	tottaaatta	agcacaatgt	ggctgttcac	tatgcttacc	2400
catgttactt	tcttcccttca	aaaataaccc	agctctcatca	aagataaaca	tctgtgaaac	2460
tatggtcatg	gcaatottca	tcacagcaagt	gtgctacttg	tcttaagagg	atgggagatt	2520
tactaagcac	ttttgagggt	ttaatgagca	tacaatgagt	ccacagttaa	aatatgctag	2580
gctattttaca	aatgtagaaa	ctgaaaaaaa	aaatcatgat	atgaatcaga	acaaaatggt	2640
attcagactg	ataacaagcc	atatttcagta	ccaacatggc	aagaaaaata	aattttccag	2700
tatgaaaatg	ggacactgct	tgcttctga	gaatttctga	attgtacctta	ttgtgtacca	2760
gttcagagtg	tatttattta	ttagtattta	tcattgagtta	aacaaatgca	ggtgtgagtc	2820
agccaaagca	tggttgaaat	acatggaaat	cacatagtct	aaaagaggag	ggcacactta	2880

	caggaataca	tctatataat	tccagttagt	tttcagaaa	gaataattcg	tgtacagaaa	2940
	tacaagactg	gagaaattcc	aagagaacaa	ataattcaaa	gttaagtata	tgggtaagcc	3000
	tgcaatat	catattttaa	ataaaaaatt	ttcccaagat	tttgaagag	aacaacataa	3060
5	aagtgcagag	tgcatctatg	tcactacaaa	agccatatct	gcactcgacc	tcttctcaaa	3120
	taactgtgcc	tctccctoca	gattctcaac	ctaacaactg	ataatgccaa	catcctgctt	3180
	cagatcgaca	atgccaggct	ggcagctgat	gacttcaggc	tgaagtaagt	taagtgatcg	3240
	ttgtataata	ctatcacaa	gaatacatca	gtgggtttta	acaatgactt	gggatgccct	3300
	caataacatt	tacatttttc	tgaattcacc	caaagttaaa	tagtattgga	gttatctgag	3360
10	aaatttttoca	tgtcagtggt	acctttttgg	caatatataa	ggaagaaaat	gcataattaa	3420
	gtaactgcta	aggttttttc	cattaaacca	ctattacttc	taagagaact	gtacatgaca	3480
	aatattgcc	ttacatgaga	tcaactatgt	agttgctttt	taaatagtct	ctgcccagat	3540
	acatctcccc	tataaagtt	ataaccagta	ttgatcat	gcttgtttca	ggtagagaa	3600
	tgaggtagct	ctgcccaga	gctggaggc	tgacatcaac	ggcctgcta	gggtgctgga	3660
	tgagctgacc	ctgaccamgg	ctgacctgga	gatgcaaat	gagagcctga	ctgaagagct	3720
15	ggcctatctg	agaagaacc	acgaggaggt	gacacaaaag	ttatactttt	cccagccaaa	3780
	agagagttca	ttatggctct	cgtgtagcca	ataaactctt	ctgttccctca	aacaggaaat	3840
	gaaagacctt	cgaaatgtgt	ccactggtga	tgtgaatgtg	gaaatgaatg	ctgccccggg	3900
	tggtgatctg	actcaacttc	tgaataacat	gagaagccaa	atgaacaac	ttgctgaaca	3960
	aaaccgcaaa	gagtctgaag	cctggttcaa	tgaaaaggta	aagtaactct	octtatagt	4020
20	aaactcatgg	aggtttttatc	atttocaagt	ttctcacc	tttctctgt	ttttaatact	4080
	ctagagcaag	gaactgacta	cagaaattga	taataacatt	gaacagatat	ccagctataa	4140
	atctcgagatt	actgaattga	gacgtaatgt	acaagctctg	gagatagaac	tacagtccca	4200
	actggccttg	gtatgttaac	totcatgaaa	tgacttcaac	tttatcatac	aaagtttcat	4260
	gctcacctaa	gaataatgcaa	tgcaacaaa	aaatgcagag	ttggaggtaa	gaaagagaaa	4320
	acaaagtga	gctcatgtta	atggaggaaa	agtactacta	gtgttgatct	aaaagtgtct	4380
25	aaactgaaat	ggtgccatta	aacatacaac	aaattctgtt	cattttctta	ttcttctata	4440
	taatgcctta	ctaaataatc	aaataagcgt	caccatactc	aaotgaacaa	ggaagtcact	4500
	aagccacaaa	aaaatccgtt	tcagaacaaa	tccttggaag	cctccttggc	agaaacagaa	4560
	ggtcgctact	gtgtgcagct	ctcacagatt	cacgccagag	tatccgctct	ggaagaacag	4620
	ttgcaacaga	ttcgagctga	aaccgagctg	cagaatactg	aataccaaca	actcotggat	4680
30	attaagatcc	gactggagaa	tgaaattcaa	acctaccgca	gctgctaga	aggagaggga	4740
	aggtaaat	taacatgaaa	agttatocca	gtttctttta	ttcaatatc	cagatagcaa	4800
	ggcttatcta	aaccccaaga	agatgccaga	gaatgagagg	aaggaggagg	agagggtaga	4860
	gtacagaaaa	aggagtagcg	aaccgcaatc	tcactttctc	atgaatttgg	cccaaatga	4920
	ttcttaagag	ttctgtgaa	ttaacattgt	tttcaaggga	tggtttttta	aatataacc	4980
	tggcagggtt	ttattttttc	aacacgtttt	gcttattttc	taaattaacg	gcaactggaa	5040
35	agctaccac	cgtttttcaa	cgtagagat	aaccggaatg	gacctcacc	cgtttagttc	5100
	cggaggcggc	ggacggcgcg	gcggaagttt	cggcgcggcg	tacggcggcg	gaagctccgg	5160
	cggcggaagc	tccggcggcg	gctacggcgg	cggcaccggc	ggcagttccg	gcggcggtta	5220
	cggaggcgga	agctccggcg	gcgggaagtc	cggcgcggcg	tacgggggcg	gaagctccag	5280
	cggcgggcac	ggcgggcgga	gctccagcgg	cggccacggc	ggcagttcca	gcggcggtta	5340
40	cgggtggtggc	agttccggcg	gcggcgcgcg	cggctacggg	ggcggcagct	ccggcgcgcg	5400
	cagcagctcc	ggcgggcgat	acggcgcgcg	cagctccagc	ggaggccaca	agtctctctc	5460
	ttccgggtcc	gtgggagagt	cttcatctaa	gggaccaagg	tcagcagaaa	ctagctgggg	5520
	taactctagaa	ttagttttta	cttctgtgta	tggttttttt	gcgttttaag	ctctagagtt	5580
	gttttaaaaa	attaaaaatc	ttagagacgg	ttccgttttg	attgtttcac	aaactactct	5640
	taacaccagc	cgtgaaaaat	ggcatgatca	aaatgtcata	ccttaagcat	ttttttgggc	5700
45	ttaaacaatgt	aaagttagaa	tttccctctt	tttacaatat	ttgcttggtta	attactaagg	5760
	atccctacag	actgttttaa	attttttttc	catcattcac	acagatacta	acaaaaccag	5820
	agtaatcaag	acaattattg	aagaggtggc	gcccagcggg	agagttcttt	catctatggg	5880
	tgcaatcagaa	accaagaaac	actactatta	aactgcatac	agaggaaaga	gtctcccttc	5940
	acacagacca	ttattttacag	atgcatggaa	aacaaagtct	ccaagaaaac	acttctgtct	6000
50	tgatggtcta	tggaatatga	ccttgaaaat	aaggtgtcta	caaggtgttt	tggtggtttct	6060
	gtatttcttc	ttttcaacttt	accacaaagt	gttctttta	ggaaagaaaa	acaactttgt	6120
	gttctcattt	actaatgaat	ttcaataaac	ttctttaotg	atgcaaaacta	tcccaatttg	6180
	tcagaattta	cttttactta	agtacataat	actctttaa	attaaagatt	agtaaccocat	6240
	agcagttgaa	ggttgatgta	tccagaaatt	cggagagacag	aactattgtc	atgccttttc	6300
	taagtttttt	aatcatgtat	gttcagacca	ccgtcagtaa	attcactgag	taaagtctgt	6360
55	aaatccccaa	tattactctt	taagatacac	aatatgtgga	aggctcccag	ctctctggct	6420

ttaaattatt tcaatcctgg aaattctgga atatctcaa tataaccccc aaaataataa 6480
taa 6483

<210> 25

<211> 1871

<212> DNA

<213> Homo sapiens

<400> 25

agttgtggcc	accttccc	ggocatggat	ctctccaaca	acaccatgtc	actctcagt	60
cgcacccccc	gactgtcccg	gcggctctcc	tcgcagagt	tgataggcag	acccaggggc	120
atgtctgctt	ccagtgttgg	aagtgggttat	gggggaagt	ccttttgctt	tggagccagc	180
tggtggggag	gcttttctgc	tgottccatg	tttggttota	gttccggott	tgggggtggc	240
tccggaagtt	ccatggcagg	aggactgggt	gctggttatg	ggagagccct	gggtggaggt	300
agctttggag	ggctggggat	gggatttggg	ggcagccag	gaggtggctc	tctaggtatt	360
ctctcgggca	atgatggagg	ccttctttct	ggatcagaaa	aagaaaactat	gcaaaatctt	420
aatgatagat	tagcttcccta	cctggataag	gtgcagctc	tagaagaggc	taatactag	480
ctagaaaata	aaattcgaga	atggtatgaa	acacgaggaa	ctgggaactgc	agatgottca	540
cagagcgatt	acagcaaata	ttatccactg	attgaagacc	tcaggaataa	gatcatttca	600
gccagcattg	gaaatgccc	gctcctcttg	cagattgaca	atgcgagact	agotgctgag	660
gacttcagga	tgaagtatga	gaatgaactg	gccctgogcc	agggcgtaga	ggccgacatc	720
aatggcctgc	gccgggtgct	ggacgagctg	accctgacca	ggaccgacct	ggagatgcag	780
atcgagagcc	tgaacgagga	gctggcctac	atgaagaaga	accacgagga	tgagctccaa	840
agcttccggg	tgggcggccc	aggcgaggctc	agcgtagaaa	tggacgctgc	ccccggagtg	900
gacctcacca	ggctcctcaa	tgatatgogg	gcgcagtatg	aaaccatcgc	tgagcagaat	960
cggaaggacg	ctgaagcctg	gttcattgaa	aagagcgggg	agctccgtaa	ggagattagc	1020
accaacacog	agcagcttca	gtccagcaag	agcgaggcca	ccgacctgcg	tcgcgccttt	1080
cagaacctgg	agatcgagct	acagtccag	ctcggcatga	agaaatccct	ggaggactoc	1140
ttggccgaag	ccgagggcga	ttactgcgcg	cagctgtccc	aggtgcagca	gctcatcagc	1200
aacctggagg	cacagctgct	ccagggtgctc	gcggacgcag	agcgccagaa	cgtggaccac	1260
cagcggctgc	tgaatgtcaa	ggcccgcctg	gagctggaga	ttgagacct	ccgcgccttg	1320
ctggacgggg	aggcccaagg	tgatggtttg	gaggaaagt	tatttgtgac	agaotccaaa	1380
tcacaagcac	agtcaactga	ttcctctaaa	gacccaacca	aaaccogaaa	aatcaagaca	1440
gttgtgcagg	agatgggtgaa	tggtgaggtg	gtctcatctc	aagttcagga	aattgaagaa	1500
ctaattgtaa	atttcacaag	atctgcccc	tgattggcto	cttaggaaca	agaaatttac	1560
aagtagaaat	tattcctttc	agagtaacat	gctgtattac	ttcaatccct	atTTTTgtct	1620
gttcattttt	ctttggattc	cctattcaca	ttgaatoott	tttgoccttc	tgaacaata	1680
ttcagtcaca	agtcattttg	gtcatgttgg	tctttgtaac	aaatcaaaat	taccttatat	1740
ccttctggac	aactggagta	gtcttttaac	gaactttott	ctggtaaccc	ggaatatatt	1800
cttaatoata	gagctttact	caagtagtat	tgttttaata	gagttaattg	taataaaaga	1860
tgaatggtaa	a					1871

<210> 26

<211> 1447

<212> DNA

<213> Homo sapiens

<400> 26
 ctgcaactgg ttctgcgagg gotccttcaa tggcagcgag aaggagacta tgcagttcct 60
 gaacgaccgc ctggccagct acctggagaa ggtgcgtcac gtggagcggg acaacgcgga 120
 5 gctggagaac etcatccggg agoggtctca gcagcaggag cccttgcgtg gccccagcta 180
 ccagtcctac ttcaagacca ttgaggagct ccagcagaag atcctgtgca gcaagtctga 240
 gaatgccagg ctggtggtgc agatcgacaa tgccaagctg gctgcagatg acttcagaac 300
 caagtaccag acggagcagt ccctgcggca gctggtggag tccgacatca acagcctgcg 360
 caggattctg gatgagctga ccctgtgcag gtctgacctg gaggcccaga tggagtccct 420
 10 gaaggaggag ctgctgtccc tcaagcagaa ccattgagcag gaagtcaaca ccttgcgctg 480
 ccagcttggg gaccgcctca acgtggaggt ggacgctgct cccgctgtgg acctgaacca 540
 ggtcctgaac gagaccagga atcagtatga ggccctggtg gaaaccaacc gcagggaagt 600
 ggagcaatgg ttgccacgc agaccgagga gctgaacaag cagggtggtat ccagctcgga 660
 gcagctgcag tctaccagg oggagatcat ogagctgaga cgcacagtca atgccctgga 720
 15 gatcgagctg caggcccagc acaacctgcg atactctctg gaaaacacgc tgacagagag 780
 cgaggccogc tacagctccc agctgtccc ggtgcagagc ctgatcacca acgtggagtc 840
 ccagctggcg gagatccgca gtgacctgga gcggcagaac caggagtatc aggtgctgct 900
 ggacgtgcgg ggcgggctgg agtgtgagat caacacatac oggagcctgc tggagagcga 960
 ggactgcaag ctgccctcca acccctgcgc caccaccaat gcatgtgaaa agcccattgg 1020
 atcctgtgtc accaatcctt gtggtcctcg ttcccgctgt gggccttgca acaccttgg 1080
 20 gtactagata ccctggggcc agcagaagta tagcatgaag acagaactac catcggtggg 1140
 ccagttctgc ctctctgaca accatcagcc accggacccc accccgaggc atcaccacaa 1200
 atcatggtct ggaaggagaa caaatgccca gcgtttgggt ctgactctga gcctagggct 1260
 actgatctc ctcaccccag gtccctctcc tgtagtcagt ctgagttctg atggtcagag 1320
 gttggagctg tgacagtggc atacgaggtg tttgttctc tctgctgctt ctacctttat 1380
 25 tgcagttccc caaatgcct aataaacttt cctcttgcaa agcagacaaa aaaaaaaaaa 1440
 aaaaaaa 1447

<210> 27

<211> 261

<212> PRT

<213> Homo sapiens

<400> 27
 Met Asn Pro Asn Cys Ala Arg Cys Gly Lys Ile Val Tyr Pro Thr Glu
 1 5 10 15
 40 Lys Val Asn Cys Leu Asp Lys Phe Trp His Lys Ala Cys Phe His Cys
 20 25 30
 Glu Thr Cys Lys Met Thr Leu Asn Met Lys Asn Tyr Lys Gly Tyr Glu
 35 40 45
 Lys Lys Pro Tyr Cys Asn Ala His Tyr Pro Lys Gln Ser Phe Thr Met
 50 55 60
 45 Val Ala Asp Thr Pro Glu Asn Leu Arg Leu Lys Gln Gln Ser Glu Leu
 65 70 75 80
 Gln Ser Gln Val Arg Tyr Lys Glu Glu Phe Glu Lys Asn Lys Gly Lys
 85 90 95
 Gly Phe Ser Val Val Ala Asp Thr Pro Glu Leu Gln Arg Ile Lys Lys
 100 105 110
 50 Thr Gln Asp Gln Ile Ser Asn Ile Lys Tyr His Glu Glu Phe Glu Lys
 115 120 125
 Ser Arg Met Gly Pro Ser Gly Glu Gly Met Glu Pro Glu Arg Arg
 130 135 140
 55 Asp Ser Gln Asp Gly Ser Ser Tyr Arg Arg Pro Leu Glu Gln Gln Gln
 145 150 155 160

Pro His His Ile Pro Thr Ser Ala Pro Val Tyr Gln Gln Pro Gln Gln
 165 170 175
 Gln Pro Val Ala Gln Ser Tyr Gly Gly Tyr Lys Glu Pro Ala Ala Pro
 180 185 190
 Val Ser Ile Gln Arg Ser Ala Pro Gly Gly Gly Lys Arg Tyr Arg
 195 200 205
 Ala Val Tyr Asp Tyr Ser Ala Ala Asp Glu Asp Glu Val Ser Phe Gln
 210 215 220
 Asp Gly Asp Thr Ile Val Asn Val Gln Gln Ile Asp Asp Gly Trp Met
 225 230 235 240
 Tyr Gly Thr Val Glu Arg Thr Gly Asp Thr Gly Met Leu Pro Ala Asn
 245 250 255
 Tyr Val Glu Ala Ile
 260

<210> 28

<211> 478

<212> PRT

<213> Homo sapiens

<400> 28

Met Val Gln Lys Thr Ser Met Ser Arg Gly Pro Tyr Pro Pro Ser Gln
 1 5 10 15
 Glu Ile Pro Met Glu Val Phe Asp Pro Ser Pro Gln Gly Lys Tyr Ser
 20 25 30
 Lys Arg Lys Gly Arg Phe Lys Arg Ser Asp Gly Ser Thr Ser Ser Asp
 35 40 45
 Thr Thr Ser Asn Ser Phe Val Arg Gln Gly Ser Ala Glu Ser Tyr Thr
 50 55 60
 Ser Arg Pro Ser Asp Ser Asp Val Ser Leu Glu Glu Asp Arg Glu Ala
 65 70 75 80
 Leu Arg Lys Glu Ala Glu Arg Gln Ala Leu Ala Gln Leu Glu Lys Ala
 85 90 95
 Lys Thr Lys Pro Val Ala Phe Ala Val Arg Thr Asn Val Gly Tyr Asn
 100 105 110
 Pro Ser Pro Gly Asp Glu Val Pro Val Gln Gly Val Ala Ile Thr Phe
 115 120 125
 Glu Pro Lys Asp Phe Leu His Ile Lys Glu Lys Tyr Asn Asn Asp Trp
 130 135 140
 Trp Ile Gly Arg Leu Val Lys Glu Gly Cys Glu Val Gly Phe Ile Pro
 145 150 155 160
 Ser Pro Val Lys Leu Asp Ser Leu Arg Leu Leu Gln Glu Gln Lys Leu
 165 170 175
 Arg Gln Asn Arg Leu Gly Ser Ser Lys Ser Gly Asp Asn Ser Ser Ser
 180 185 190
 Ser Leu Gly Asp Val Val Thr Gly Thr Arg Arg Pro Thr Pro Pro Ala
 195 200 205
 Ser Ala Lys Gln Lys Gln Lys Ser Thr Glu His Val Pro Pro Tyr Asp
 210 215 220
 Val Val Pro Ser Met Arg Pro Ile Ile Leu Val Gly Pro Ser Leu Lys
 225 230 235 240
 Gly Tyr Glu Val Thr Asp Met Met Gln Lys Ala Leu Phe Asp Phe Leu
 245 250 255

Lys His Arg Phe Asp Gly Arg Ile Ser Ile Thr Arg Val Thr Ala Asp
 260 265 270
 Ile Ser Leu Ala Lys Arg Ser Val Leu Asn Asn Pro Ser Lys His Ile
 275 280 285
 Ile Ile Glu Arg Ser Asn Thr Arg Ser Ser Leu Ala Glu Val Gln Ser
 290 295 300
 Glu Ile Glu Arg Ile Phe Glu Leu Ala Arg Thr Leu Gln Leu Val Ala
 305 310 315 320
 Leu Asp Ala Asp Thr Ile Asn His Pro Ala Gln Leu Ser Lys Thr Ser
 325 330 335
 Leu Ala Pro Ile Ile Val Tyr Ile Lys Ile Thr Ser Pro Lys Val Leu
 340 345 350
 Gln Arg Leu Ile Lys Ser Arg Gly Lys Ser Gln Ser Lys His Leu Asn
 355 360 365
 Val Gln Ile Ala Ala Ser Glu Lys Leu Ala Gln Cys Pro Pro Glu Met
 370 375 380
 Phe Asp Ile Ile Leu Asp Glu Asn Gln Leu Glu Asp Ala Cys Glu His
 385 390 395 400
 Leu Ala Glu Tyr Leu Glu Ala Tyr Trp Lys Ala Thr His Pro Pro Ser
 405 410 415
 Ser Thr Pro Pro Asn Pro Leu Leu Asn Arg Thr Met Ala Thr Ala Ala
 420 425 430
 Leu Arg Arg Ser Pro Ala Pro Val Ser Asn Leu Gln Val Gln Val Leu
 435 440 445
 Thr Ser Leu Arg Arg Asn Leu Gly Phe Trp Gly Gly Leu Glu Ser Ser
 450 455 460
 Gln Arg Gly Ser Val Val Pro Gln Glu Gln Glu His Ala Met
 465 470 475

<210> 29

<211> 196

<212> PRT

<213> Homo sapiens

<400> 29

Met Ser Met Leu Arg Leu Gln Lys Arg Leu Ala Ser Ser Val Leu Arg
 1 5 10 15
 Cys Gly Lys Lys Lys Val Trp Leu Asp Pro Asn Glu Thr Asn Glu Ile
 20 25 30
 Ala Asn Ala Asn Ser Arg Gln Gln Ile Arg Lys Leu Ile Lys Asp Gly
 35 40 45
 Leu Ile Ile Arg Lys Pro Val Thr Val His Ser Arg Ala Arg Cys Arg
 50 55 60
 Lys Asn Thr Leu Ala Arg Arg Lys Gly Arg His Met Gly Ile Gly Lys
 65 70 75 80
 Arg Lys Gly Thr Ala Asn Ala Arg Met Pro Glu Lys Val Thr Trp Met
 85 90 95
 Arg Arg Met Arg Ile Leu Arg Arg Leu Leu Arg Arg Tyr Arg Glu Ser
 100 105 110
 Lys Lys Ile Asp Arg His Met Tyr His Ser Leu Tyr Leu Lys Val Lys
 115 120 125
 Gly Asn Val Phe Lys Asn Lys Arg Ile Leu Met Glu His Ile His Lys
 130 135 140

Leu Lys Ala Asp Lys Ala Arg Lys Lys Leu Leu Ala Asp Gln Ala Glu
 145 150 155 160
 Ala Arg Arg Ser Lys Thr Lys Glu Ala Arg Lys Arg Arg Glu Glu Arg
 165 170 175
 Leu Gln Ala Lys Lys Glu Glu Ile Ile Lys Thr Leu Ser Lys Glu Glu
 180 185 190
 Glu Thr Lys Lys
 195

<210> 30

<211> 1566

<212> PRT

<213> Homo sapiens

<400> 30

Met Ser Ser Leu Leu Glu Arg Leu His Ala Lys Phe Asn Gln Asn Arg
 1 5 10 15
 Pro Trp Ser Glu Thr Ile Lys Leu Val Arg Gln Val Met Glu Lys Arg
 20 25 30
 Val Val Met Ser Ser Gly Gly His Gln His Leu Val Ser Cys Leu Glu
 35 40 45
 Thr Leu Gln Lys Ala Leu Lys Val Thr Ser Leu Pro Ala Met Thr Asp
 50 55 60
 Arg Leu Glu Ser Ile Ala Gly Gln Asn Gly Leu Gly Ser His Leu Ser
 65 70 75 80
 Ala Ser Gly Thr Glu Cys Tyr Ile Thr Ser Asp Met Phe Tyr Val Glu
 85 90 95
 Val Gln Leu Asp Pro Ala Gly Gln Leu Cys Asp Val Lys Val Ala His
 100 105 110
 His Gly Glu Asn Pro Val Ser Cys Pro Glu Leu Val Gln Gln Leu Arg
 115 120 125
 Glu Lys Asn Ser Asp Glu Phe Ser Lys His Leu Lys Gly Leu Val Asn
 130 135 140
 Leu Tyr Asn Leu Pro Gly Asp Asn Lys Leu Lys Thr Lys Met Tyr Leu
 145 150 155 160
 Ala Leu Gln Ser Leu Glu Gln Asp Leu Ser Lys Met Ala Ile Met Tyr
 165 170 175
 Trp Lys Ala Thr Asn Ala Gly Pro Leu Asp Lys Ile Leu His Gly Ser
 180 185 190
 Val Gly Tyr Leu Thr Pro Arg Ser Gly Gly His Leu Met Asn Leu Lys
 195 200 205
 Tyr Tyr Val Ser Pro Ser Asp Leu Leu Asp Asp Lys Thr Ala Ser Pro
 210 215 220
 Ile Ile Leu His Glu Asn Asn Val Ser Arg Ser Leu Gly Met Asn Ala
 225 230 235 240
 Ser Val Thr Ile Glu Gly Thr Ser Ala Val Tyr Lys Leu Pro Ile Ala
 245 250 255
 Pro Leu Ile Met Gly Ser His Pro Val Asp Asn Lys Trp Thr Pro Ser
 260 265 270
 Phe Ser Ser Ile Thr Ser Ala Asn Ser Val Asp Leu Pro Ala Cys Phe
 275 280 285
 Phe Leu Lys Phe Pro Gln Pro Ile Pro Val Ser Arg Ala Phe Val Gln
 290 295 300

5 Lys Leu Gln Asn Cys Thr Gly Ile Pro Leu Phe Glu Thr Gln Pro Thr
 305 310 315 320
 Tyr Ala Pro Leu Tyr Glu Leu Ile Thr Gln Phe Glu Leu Ser Lys Asp
 325 330 335
 Pro Asp Pro Ile Pro Leu Asn His Asn Met Arg Phe Tyr Ala Ala Leu
 340 345 350
 Pro Gly Gln Gln His Cys Tyr Phe Leu Asn Lys Asp Ala Pro Leu Pro
 355 360 365
 10 Asp Gly Arg Ser Leu Gln Gly Thr Leu Val Ser Lys Ile Thr Phe Gln
 370 375 380
 His Pro Gly Arg Val Pro Leu Ile Leu Asn Leu Ile Arg His Gln Val
 385 390 395 400
 Ala Tyr Asn Thr Leu Ile Gly Ser Cys Val Lys Arg Thr Ile Leu Lys
 405 410 415
 15 Glu Asp Ser Pro Gly Leu Leu Gln Phe Glu Val Cys Pro Leu Ser Glu
 420 425 430
 Ser Arg Phe Ser Val Ser Phe Gln His Pro Val Asn Asp Ser Leu Val
 435 440 445
 20 Cys Val Val Met Asp Val Gln Gly Leu Thr His Val Ser Cys Lys Leu
 450 455 460
 Tyr Lys Gly Leu Ser Asp Ala Leu Ile Cys Thr Asp Asp Phe Ile Ala
 465 470 475 480
 Lys Val Val Gln Arg Cys Met Ser Ile Pro Val Thr Met Arg Ala Ile
 485 490 495
 25 Arg Arg Lys Ala Glu Thr Ile Gln Ala Asp Thr Pro Ala Leu Ser Leu
 500 505 510
 Ile Ala Glu Thr Val Glu Asp Met Val Lys Lys Asn Leu Pro Pro Ala
 515 520 525
 Ser Ser Pro Gly Tyr Gly Met Thr Thr Gly Asn Asn Pro Met Ser Gly
 530 535 540
 30 Thr Thr Thr Ser Thr Asn Thr Phe Pro Gly Gly Pro Ile Ala Thr Leu
 545 550 555 560
 Phe Asn Met Ser Met Ser Ile Lys Asp Arg His Glu Ser Val Gly His
 565 570 575
 35 Gly Glu Asp Phe Ser Lys Val Ser Gln Asn Pro Ile Leu Thr Ser Leu
 580 585 590
 Leu Gln Ile Thr Gly Asn Gly Gly Ser Thr Ile Gly Ser Ser Pro Thr
 595 600 605
 Pro Pro His His Thr Pro Pro Val Ser Ser Met Ala Gly Asn Thr
 610 615 620
 40 Lys Asn His Pro Met Leu Met Asn Leu Leu Lys Asp Asn Pro Ala Gln
 625 630 635 640
 Asp Phe Ser Thr Leu Tyr Gly Ser Ser Pro Leu Glu Arg Gln Asn Ser
 645 650 655
 Ser Ser Gly Ser Pro Arg Met Glu Ile Cys Ser Gly Ser Asn Lys Thr
 660 665 670
 45 Lys Lys Lys Lys Ser Ser Arg Leu Pro Pro Glu Lys Pro Lys His Gln
 675 680 685
 Thr Glu Asp Asp Phe Gln Arg Glu Leu Phe Ser Met Asp Val Asp Ser
 690 695 700
 50 Gln Asn Pro Ile Phe Asp Val Asn Met Thr Ala Asp Thr Leu Asp Thr
 705 710 715 720
 Pro His Ile Thr Pro Ala Pro Ser Gln Cys Ser Thr Pro Pro Thr Thr
 725 730 735
 Tyr Pro Gln Pro Val Pro His Pro Gln Pro Ser Ile Gln Arg Met Val
 740 745 750
 55 Arg Leu Ser Ser Ser Asp Ser Ile Gly Pro Asp Val Thr Asp Ile Leu
 755 760 765

Ser Asp Ile Ala Glu Glu Ala Ser Lys Leu Pro Ser Thr Ser Asp Asp
 770 775 780
 Cys Pro Ala Ile Gly Thr Pro Leu Arg Asp Ser Ser Ser Ser Gly His
 5 785 790 795 800
 Ser Gln Ser Thr Leu Phe Asp Ser Asp Val Phe Gln Thr Asn Asn Asn
 805 810 815
 Glu Asn Pro Tyr Thr Asp Pro Ala Asp Leu Ile Ala Asp Ala Ala Gly
 820 825 830
 10 Ser Pro Ser Ser Asp Ser Pro Thr Asn His Phe Phe His Asp Gly Val
 835 840 845
 Asp Phe Asn Pro Asp Leu Leu Asn Ser Gln Ser Gln Ser Gly Phe Gly
 850 855 860
 Glu Glu Tyr Phe Asp Glu Ser Ser Gln Ser Gly Asp Asn Asp Asp Phe
 865 870 875 880
 15 Lys Gly Phe Ala Ser Gln Ala Leu Asn Thr Leu Gly Val Pro Met Leu
 885 890 895
 Gly Gly Asp Asn Gly Glu Thr Lys Phe Lys Gly Asn Asn Gln Ala Asp
 900 905 910
 Thr Val Asp Phe Ser Ile Ile Ser Val Ala Gly Lys Ala Leu Ala Pro
 915 920 925
 20
 Ala Asp Leu Met Glu His His Ser Gly Ser Gln Gly Pro Leu Leu Thr
 930 935 940
 Thr Gly Asp Leu Gly Lys Glu Lys Thr Gln Lys Arg Val Lys Glu Gly
 945 950 955 960
 25 Asn Gly Thr Ser Asn Ser Thr Leu Ser Gly Pro Gly Leu Asp Ser Lys
 965 970 975
 Pro Gly Lys Arg Ser Arg Thr Pro Ser Asn Asp Gly Lys Ser Lys Asp
 980 985 990
 Lys Pro Pro Lys Arg Lys Lys Ala Asp Thr Glu Gly Lys Ser Pro Ser
 995 1000 1005
 30 His Ser Ser Ser Asn Arg Pro Phe Thr Pro Pro Thr Ser Thr Gly
 1010 1015 1020
 Gly Ser Lys Ser Pro Gly Ser Ala Gly Arg Ser Gln Thr Pro Pro
 1025 1030 1035
 35 Gly Val Ala Thr Pro Pro Ile Pro Lys Ile Thr Ile Gln Ile Pro
 1040 1045 1050
 Lys Gly Thr Val Met Val Gly Lys Pro Ser Ser His Ser Gln Tyr
 1055 1060 1065
 Thr Ser Ser Gly Ser Val Ser Ser Ser Gly Ser Lys Ser His His
 1070 1075 1080
 40 Ser His Ser Ser Ser Ser Ser Ser Ser Ala Ser Thr Ser Gly Lys
 1085 1090 1095
 Met Lys Ser Ser Lys Ser Glu Gly Ser Ser Ser Lys Leu Ser
 1100 1105 1110
 Ser Ser Met Tyr Ser Ser Gln Gly Ser Ser Gly Ser Ser Gln Ser
 1115 1120 1125
 45 Lys Asn Ser Ser Gln Ser Gly Gly Lys Pro Gly Ser Ser Pro Ile
 1130 1135 1140
 Thr Lys His Gly Leu Ser Ser Gly Ser Ser Ser Thr Lys Met Lys
 1145 1150 1155
 Pro Gln Gly Lys Pro Ser Ser Leu Met Asn Pro Ser Leu Ser Lys
 1160 1165 1170
 50 Pro Asn Ile Ser Pro Ser His Ser Arg Pro Pro Gly Gly Ser Asp
 1175 1180 1185
 Lys Leu Ala Ser Pro Met Lys Pro Val Pro Gly Thr Pro Pro Ser
 1190 1195 1200
 55 Ser Lys Ala Lys Ser Pro Ile Ser Ser Gly Ser Gly Gly Ser His
 1205 1210 1215

	Met	Ser	Gly	Thr	Ser	Ser	Ser	Ser	Gly	Met	Lys	Ser	Ser	Ser	Gly
	1220						1225					1230			
5	Leu	Gly	Ser	Ser	Gly	Ser	Leu	Ser	Gln	Lys	Thr	Pro	Pro	Ser	Ser
	1235						1240					1245			
	Asn	Ser	Cys	Thr	Ala	Ser	Ser	Ser	Ser	Phe	Ser	Ser	Ser	Gly	Ser
	1250						1255					1260			
	Ser	Met	Ser	Ser	Ser	Gln	Asn	Gln	His	Gly	Ser	Ser	Lys	Gly	Lys
	1265						1270					1275			
10	Ser	Pro	Ser	Arg	Asn	Lys	Lys	Pro	Ser	Leu	Thr	Ala	Val	Ile	Asp
	1280						1285					1290			
	Lys	Leu	Lys	His	Gly	Val	Val	Thr	Ser	Gly	Pro	Gly	Gly	Glu	Asp
	1295						1300					1305			
	Pro	Leu	Asp	Gly	Gln	Met	Gly	Val	Ser	Thr	Asn	Ser	Ser	Ser	His
	1310						1315					1320			
15	Pro	Met	Ser	Ser	Lys	His	Asn	Met	Ser	Gly	Gly	Glu	Phe	Gln	Gly
	1325						1330					1335			
	Lys	Arg	Glu	Lys	Ser	Asp	Lys	Asp	Lys	Ser	Lys	Val	Ser	Thr	Ser
	1340						1345					1350			
	Gly	Ser	Ser	Val	Asp	Ser	Ser	Lys	Lys	Thr	Ser	Glu	Ser	Lys	Asn
	1355						1360					1365			
20	Val	Gly	Ser	Thr	Gly	Val	Ala	Lys	Ile	Ile	Ile	Ser	Lys	His	Asp
	1370						1375					1380			
	Gly	Gly	Ser	Pro	Ser	Ile	Lys	Ala	Lys	Val	Thr	Leu	Gln	Lys	Pro
	1385						1390					1395			
	Gly	Glu	Ser	Ser	Gly	Glu	Gly	Leu	Arg	Pro	Gln	Met	Ala	Ser	Ser
25	1400						1405					1410			
	Lys	Asn	Tyr	Gly	Ser	Pro	Leu	Ile	Ser	Gly	Ser	Thr	Pro	Lys	His
	1415						1420					1425			
	Glu	Arg	Gly	Ser	Pro	Ser	His	Ser	Lys	Ser	Pro	Ala	Tyr	Thr	Pro
	1430						1435					1440			
30	Gln	Asn	Leu	Asp	Ser	Glu	Ser	Glu	Ser	Gly	Ser	Ser	Ile	Ala	Glu
	1445						1450					1455			
	Lys	Ser	Tyr	Gln	Asn	Ser	Pro	Ser	Ser	Asp	Asp	Gly	Ile	Arg	Pro
	1460						1465					1470			
	Leu	Pro	Glu	Tyr	Ser	Thr	Glu	Lys	His	Lys	Lys	His	Lys	Lys	Glu
	1475						1480					1485			
35	Lys	Lys	Lys	Val	Lys	Asp	Lys	Asp	Arg	Asp	Arg	Asp	Arg	Asp	Lys
	1490						1495					1500			
	Asp	Arg	Asp	Lys	Lys	Lys	Ser	His	Ser	Ile	Lys	Pro	Glu	Ser	Trp
	1505						1510					1515			
	Ser	Lys	Ser	Pro	Ile	Ser	Ser	Asp	Gln	Ser	Leu	Ser	Met	Thr	Ser
	1520						1525					1530			
40	Asn	Thr	Ile	Leu	Ser	Ala	Asp	Arg	Pro	Ser	Arg	Leu	Ser	Pro	Asp
	1535						1540					1545			
	Phe	Met	Ile	Gly	Glu	Glu	Asp	Asp	Asp	Leu	Met	Asp	Val	Ala	Leu
	1550						1555					1560			
45	Ile	Gly	Asn												
	1565														

<210> 31

<211> 1490

<212> PRT

<213> Homo sapiens

<400> 31
 Met Pro Asn Ser Glu Arg His Gly Gly Lys Lys Asp Gly Ser Gly Gly
 1 5 10 15
 5 Ala Ser Gly Thr Leu Gln Pro Ser Ser Gly Gly Gly Ser Ser Asn Ser
 20 25 30
 Arg Glu Arg His Arg Leu Val Ser Lys His Lys Arg His Lys Ser Lys
 35 40 45
 His Ser Lys Asp Met Gly Leu Val Thr Pro Glu Ala Ala Ser Leu Gly
 50 55 60
 10 Thr Val Ile Lys Pro Leu Val Glu Tyr Asp Asp Ile Ser Ser Asp Ser
 65 70 75 80
 Asp Thr Phe Ser Asp Asp Met Ala Phe Lys Leu Asp Arg Arg Glu Asn
 85 90 95
 15 Asp Glu Arg Arg Gly Ser Asp Arg Ser Asp Arg Leu His Lys His Arg
 100 105 110
 His His Gln His Arg Arg Ser Arg Asp Leu Leu Lys Ala Lys Gln Thr
 115 120 125
 Glu Lys Glu Lys Ser Gln Glu Val Ser Ser Lys Ser Gly Ser Met Lys
 130 135 140
 20 Asp Arg Ile Ser Gly Ser Ser Lys Arg Ser Asn Glu Glu Thr Asp Asp
 145 150 155 160
 Tyr Gly Lys Ala Gln Val Ala Lys Ser Ser Lys Glu Ser Arg Ser
 165 170 175
 Ser Lys Leu His Lys Glu Lys Thr Arg Lys Glu Arg Glu Leu Lys Ser
 180 185 190
 25 Gly His Lys Asp Arg Ser Lys Ser His Arg Lys Arg Glu Thr Pro Lys
 195 200 205
 Ser Tyr Lys Thr Val Asp Ser Pro Lys Arg Arg Ser Arg Ser Pro His
 210 215 220
 Arg Lys Trp Ser Asp Ser Ser Lys Gln Asp Asp Ser Pro Ser Gly Ala
 225 230 235 240
 30 Ser Tyr Gly Gln Asp Tyr Asp Leu Ser Pro Ser Arg Ser His Thr Ser
 245 250 255
 Ser Asn Tyr Asp Ser Tyr Lys Lys Ser Pro Gly Ser Thr Ser Arg Arg
 260 265 270
 35 Gln Ser Val Ser Pro Pro Tyr Lys Glu Pro Ser Ala Tyr Gln Ser Ser
 275 280 285
 Thr Arg Ser Pro Ser Pro Tyr Ser Arg Arg Gln Arg Ser Val Ser Pro
 290 295 300
 Tyr Ser Arg Arg Arg Ser Ser Ser Tyr Glu Arg Ser Gly Ser Tyr Ser
 305 310 315 320
 40 Gly Arg Ser Pro Ser Pro Tyr Gly Arg Arg Arg Ser Ser Ser Pro Phe
 325 330 335
 Leu Ser Lys Arg Ser Leu Ser Arg Ser Pro Leu Pro Ser Arg Lys Ser
 340 345 350
 Met Lys Ser Arg Ser Arg Ser Pro Ala Tyr Ser Arg His Ser Ser Ser
 355 360 365
 45 His Ser Lys Lys Lys Arg Ser Ser Ser Arg Ser Arg His Ser Ser Ile
 370 375 380
 Ser Pro Val Arg Leu Pro Leu Asn Ser Ser Leu Gly Ala Glu Leu Ser
 385 390 395 400
 Arg Lys Lys Lys Glu Arg Ala Ala Ala Ala Ala Ala Lys Met Asp
 405 410 415
 50 Gly Lys Glu Ser Lys Gly Ser Pro Val Phe Leu Pro Arg Lys Glu Asn
 420 425 430
 Ser Ser Val Glu Ala Lys Asp Ser Gly Leu Glu Ser Lys Lys Leu Pro
 435 440 445
 55 Arg Ser Val Lys Leu Glu Lys Ser Ala Pro Asp Thr Glu Leu Val Asn
 450 455 460

Val Thr His Leu Asn Thr Glu Val Lys Asn Ser Ser Asp Thr Gly Lys
 465 470 475 480
 Val Lys Leu Asp Glu Asn Ser Glu Lys His Leu Val Lys Asp Leu Lys
 485 490 495
 Ala Gln Gly Thr Arg Asp Ser Lys Pro Ile Ala Leu Lys Glu Glu Ile
 500 505 510
 Val Thr Pro Lys Glu Thr Glu Thr Ser Glu Lys Glu Thr Pro Pro Pro
 515 520 525
 Leu Pro Thr Ile Ala Ser Pro Pro Pro Pro Leu Pro Thr Thr Thr Pro
 530 535 540
 Pro Pro Gln Thr Pro Pro Leu Pro Pro Leu Pro Pro Ile Pro Ala Leu
 545 550 555 560
 Pro Gln Gln Pro Pro Leu Pro Pro Ser Gln Pro Ala Phe Ser Gln Val
 565 570 575
 Pro Ala Ser Ser Thr Ser Thr Leu Pro Pro Ser Thr His Ser Lys Thr
 580 585 590
 Ser Ala Val Ser Ser Gln Ala Asn Ser Gln Pro Pro Val Gln Val Ser
 595 600 605
 Val Lys Thr Gln Val Ser Val Thr Ala Ala Ile Pro His Leu Lys Thr
 610 615 620
 Ser Thr Leu Pro Pro Leu Pro Leu Pro Pro Leu Leu Pro Gly Gly Asp
 625 630 635 640
 Asp Met Asp Ser Pro Lys Glu Thr Leu Pro Ser Lys Pro Val Lys Lys
 645 650 655
 Glu Lys Glu Gln Arg Thr Arg His Leu Leu Thr Asp Leu Pro Leu Pro
 660 665 670
 Pro Glu Leu Pro Gly Gly Asp Leu Ser Pro Pro Asp Ser Pro Glu Pro
 675 680 685
 Lys Ala Ile Thr Pro Pro Gln Gln Pro Tyr Lys Lys Arg Pro Lys Ile
 690 695 700
 Cys Cys Pro Arg Tyr Gly Glu Arg Arg Gln Thr Glu Ser Asp Trp Gly
 705 710 715 720
 Lys Arg Cys Val Asp Lys Phe Asp Ile Ile Gly Ile Ile Gly Glu Gly
 725 730 735
 Thr Tyr Gly Gln Val Tyr Lys Ala Arg Asp Lys Asp Thr Gly Glu Leu
 740 745 750
 Val Ala Leu Lys Lys Val Arg Leu Asp Asn Glu Lys Glu Gly Phe Pro
 755 760 765
 Ile Thr Ala Ile Arg Glu Ile Lys Ile Leu Arg Gln Leu Ile His Arg
 770 775 780
 Ser Val Val Asn Met Lys Glu Ile Val Thr Asp Lys Gln Asp Ala Leu
 785 790 795 800
 Asp Phe Lys Lys Asp Lys Gly Ala Phe Tyr Leu Val Phe Glu Tyr Met
 805 810 815
 Asp His Asp Leu Met Gly Leu Leu Glu Ser Gly Leu Val His Phe Ser
 820 825 830
 Glu Asp His Ile Lys Ser Phe Met Lys Gln Leu Met Glu Gly Leu Glu
 835 840 845
 Tyr Cys His Lys Lys Asn Phe Leu His Arg Asp Ile Lys Cys Ser Asn
 850 855 860
 Ile Leu Leu Asn Asn Ser Gly Gln Ile Lys Leu Ala Asp Phe Gly Leu
 865 870 875 880
 Ala Arg Leu Tyr Asn Ser Glu Glu Ser Arg Pro Tyr Thr Asn Lys Val
 885 890 895
 Ile Thr Leu Trp Tyr Arg Pro Pro Glu Leu Leu Leu Gly Glu Glu Arg
 900 905 910
 Tyr Thr Pro Ala Ile Asp Val Trp Ser Cys Gly Cys Ile Leu Gly Glu
 915 920 925

Leu Phe Thr Lys Lys Pro Ile Phe Gln Ala Asn Leu Glu Leu Ala Gln
 930 935 940
 Leu Glu Leu Ile Ser Arg Leu Cys Gly Ser Pro Cys Pro Ala Val Trp
 945 950 955 960
 Pro Asp Val Ile Lys Leu Pro Tyr Phe Asn Thr Met Lys Pro Lys Lys
 965 970 975
 Gln Tyr Arg Arg Arg Leu Arg Glu Glu Phe Ser Phe Ile Pro Ser Ala
 980 985 990
 Ala Leu Asp Leu Leu Asp His Met Leu Thr Leu Asp Pro Ser Lys Arg
 995 1000 1005
 Cys Thr Ala Glu Gln Thr Leu Gln Ser Asp Phe Leu Lys Asp Val
 1010 1015 1020
 Glu Leu Ser Lys Met Ala Pro Pro Asp Leu Pro His Trp Gln Asp
 1025 1030 1035
 Cys His Glu Leu Trp Ser Lys Lys Arg Arg Arg Gln Arg Gln Ser
 1040 1045 1050
 Gly Val Val Val Glu Glu Pro Pro Pro Ser Lys Thr Ser Arg Lys
 1055 1060 1065
 Glu Thr Thr Ser Gly Thr Ser Thr Glu Pro Val Lys Asn Ser Ser
 1070 1075 1080
 Pro Ala Pro Pro Gln Pro Ala Pro Gly Lys Val Glu Ser Gly Ala
 1085 1090 1095
 Gly Asp Ala Ile Gly Leu Ala Asp Ile Thr Gln Gln Leu Asn Gln
 1100 1105 1110
 Ser Glu Leu Ala Val Leu Leu Asn Leu Leu Gln Ser Gln Thr Asp
 1115 1120 1125
 Leu Ser Ile Pro Gln Met Ala Gln Leu Leu Asn Ile His Ser Asn
 1130 1135 1140
 Pro Glu Met Gln Gln Gln Leu Glu Ala Leu Asn Gln Ser Ile Ser
 1145 1150 1155
 Ala Leu Thr Glu Ala Thr Ser Gln Gln Gln Asp Ser Glu Thr Met
 1160 1165 1170
 Ala Pro Glu Glu Ser Leu Lys Glu Ala Pro Ser Ala Pro Val Ile
 1175 1180 1185
 Leu Pro Ser Ala Glu Gln Met Thr Leu Glu Ala Ser Ser Thr Pro
 1190 1195 1200
 Ala Asp Met Gln Asn Ile Leu Ala Val Leu Leu Ser Gln Leu Met
 1205 1210 1215
 Lys Thr Gln Glu Pro Ala Ser Leu Glu Glu Asn Asn Ser Asp
 1220 1225 1230
 Lys Asn Ser Gly Pro Gln Gly Pro Arg Arg Thr Pro Thr Met Pro
 1235 1240 1245
 Gln Glu Glu Ala Ala Ala Cys Pro Pro His Ile Leu Pro Pro Glu
 1250 1255 1260
 Lys Arg Pro Pro Glu Pro Pro Gly Pro Pro Pro Pro Pro Pro Pro
 1265 1270 1275
 Pro Pro Leu Val Glu Gly Asp Leu Ser Ser Ala Pro Gln Glu Leu
 1280 1285 1290
 Asn Pro Ala Val Thr Ala Ala Leu Leu Gln Leu Leu Ser Gln Pro
 1295 1300 1305
 Glu Ala Glu Pro Pro Gly His Leu Pro His Glu His Gln Ala Leu
 1310 1315 1320
 Arg Pro Met Glu Tyr Ser Thr Arg Pro Arg Pro Asn Arg Thr Tyr
 1325 1330 1335
 Gly Asn Thr Asp Gly Pro Glu Thr Gly Phe Ser Ala Ile Asp Thr
 1340 1345 1350
 Asp Glu Arg Asn Ser Gly Pro Ala Leu Thr Glu Ser Leu Val Gln
 1355 1360 1365

Thr Leu Val Lys Asn Arg Thr Phe Ser Gly Ser Leu Ser His Leu
 1370 1375 1380
 Gly Glu Ser Ser Ser Tyr Gln Gly Thr Gly Ser Val Gln Phe Pro
 1385 1390 1395
 Gly Asp Gln Asp Leu Arg Phe Ala Arg Val Pro Leu Ala Leu His
 1400 1405 1410
 Pro Val Val Gly Gln Pro Phe Leu Lys Ala Glu Gly Ser Ser Asn
 1415 1420 1425
 Ser Val Val His Ala Glu Thr Lys Leu Gln Asn Tyr Gly Glu Leu
 1430 1435 1440
 Gly Pro Gly Thr Thr Gly Ala Ser Ser Ser Gly Ala Gly Leu His
 1445 1450 1455
 Trp Gly Gly Pro Thr Gln Ser Ser Ala Tyr Gly Lys Leu Tyr Arg
 1460 1465 1470
 Gly Pro Thr Arg Val Pro Pro Arg Gly Gly Arg Gly Arg Gly Val
 1475 1480 1485
 Pro Tyr
 1490

<210> 32

<211> 381

<212> PRT

<213> Homo sapiens

<400> 32

Met Leu Thr Arg Leu Phe Ser Glu Pro Gly Leu Leu Ser Asp Val Pro
 1 5 10 15
 Lys Phe Ala Ser Trp Gly Asp Gly Glu Asp Asp Glu Pro Arg Ser Asp
 20 25 30
 Lys Gly Asp Ala Pro Pro Pro Pro Pro Ala Pro Gly Pro Gly Ala
 35 40 45
 Pro Gly Pro Ala Arg Ala Ala Lys Pro Val Pro Leu Arg Gly Glu Glu
 50 55 60
 Gly Thr Glu Ala Thr Leu Ala Glu Val Lys Glu Glu Gly Glu Leu Gly
 65 70 75 80
 Gly Glu Glu Glu Glu Glu Glu Glu Glu Glu Gly Leu Asp Glu Ala
 85 90 95
 Glu Gly Glu Arg Pro Lys Lys Arg Gly Pro Lys Lys Arg Lys Met Thr
 100 105 110
 Lys Ala Arg Leu Glu Arg Ser Lys Leu Arg Arg Gln Lys Ala Asn Ala
 115 120 125
 Arg Glu Arg Asn Arg Met His Asp Leu Asn Ala Ala Leu Asp Asn Leu
 130 135 140
 Arg Lys Val Val Pro Cys Tyr Ser Lys Thr Gln Lys Leu Ser Lys Ile
 145 150 155 160
 Glu Thr Leu Arg Leu Ala Lys Asn Tyr Ile Trp Ala Leu Ser Glu Ile
 165 170 175
 Leu Arg Ser Gly Lys Arg Pro Asp Leu Val Ser Tyr Val Gln Thr Leu
 180 185 190
 Cys Lys Gly Leu Ser Gln Pro Thr Thr Asn Leu Val Ala Gly Cys Leu
 195 200 205
 Gln Leu Asn Ser Arg Asn Phe Leu Thr Glu Gln Gly Ala Asp Gly Ala
 210 215 220

Gly Arg Phe His Gly Ser Gly Gly Pro Phe Ala Met His Pro Tyr Pro
 225 230 235 240
 Tyr Pro Cys Ser Arg Leu Ala Gly Ala Gln Cys Gln Ala Ala Gly Gly
 245 250 255
 Leu Gly Gly Gly Ala Ala His Ala Leu Arg Thr His Gly Tyr Cys Ala
 260 265 270
 Ala Tyr Glu Thr Leu Tyr Ala Ala Gly Gly Gly Gly Ala Ser Pro
 275 280 285
 Asp Tyr Asn Ser Ser Glu Tyr Glu Gly Pro Leu Ser Pro Pro Leu Cys
 290 295 300
 Leu Asn Gly Asn Phe Ser Leu Lys Gln Asp Ser Ser Pro Asp His Glu
 305 310 315 320
 Lys Ser Tyr His Tyr Ser Met His Tyr Ser Ala Leu Pro Gly Ser Arg
 325 330 335
 His Gly His Gly Leu Val Phe Gly Ser Ser Ala Val Arg Gly Gly Val
 340 345 350
 His Ser Glu Asn Leu Leu Ser Tyr Asp Met His Leu His His Asp Arg
 355 360 365
 Gly Pro Met Tyr Glu Glu Leu Asn Ala Phe Phe His Asn
 370 375 380

<210> 33

<211> 445

<212> PRT

<213> Homo sapiens

<400> 33

Met Ser Lys Leu Pro Arg Glu Leu Thr Arg Asp Leu Glu Arg Ser Leu
 1 5 10 15
 Pro Ala Val Ala Ser Leu Gly Ser Ser Leu Ser His Ser Gln Ser Leu
 20 25 30
 Ser Ser His Leu Leu Pro Pro Pro Glu Lys Arg Arg Ala Ile Ser Asp
 35 40 45
 Val Arg Arg Thr Phe Cys Leu Phe Val Thr Phe Asp Leu Leu Phe Ile
 50 55 60
 Ser Leu Leu Trp Ile Ile Glu Leu Asn Thr Asn Thr Gly Ile Arg Lys
 65 70 75 80
 Asn Leu Glu Gln Glu Ile Ile Gln Tyr Asn Phe Lys Thr Ser Phe Phe
 85 90 95
 Asp Ile Phe Val Leu Ala Phe Phe Arg Phe Ser Gly Leu Leu Leu Gly
 100 105 110
 Tyr Ala Val Leu Gln Leu Arg His Trp Trp Val Ile Ala Val Thr Thr
 115 120 125
 Leu Val Ser Ser Ala Phe Leu Ile Val Lys Val Ile Leu Ser Glu Leu
 130 135 140
 Leu Ser Lys Gly Ala Phe Gly Tyr Leu Leu Pro Ile Val Ser Phe Val
 145 150 155 160
 Leu Ala Trp Leu Glu Thr Trp Phe Leu Asp Phe Lys Val Leu Pro Gln
 165 170 175
 Glu Ala Glu Glu Glu Arg Trp Tyr Leu Ala Ala Gln Val Ala Val Ala
 180 185 190
 Arg Gly Pro Leu Leu Phe Ser Gly Ala Leu Ser Glu Gly Gln Phe Tyr
 195 200 205

Ser Pro Pro Glu Ser Phe Ala Gly Ser Asp Asn Glu Ser Asp Glu Glu
 210 215 220
 Val Ala Gly Lys Lys Ser Phe Ser Ala Gln Glu Arg Glu Tyr Ile Arg
 225 230 235 240
 Gln Gly Lys Glu Ala Thr Ala Val Val Asp Gln Ile Leu Ala Gln Glu
 245 250 255
 Glu Asn Trp Lys Phe Glu Lys Asn Asn Glu Tyr Gly Asp Thr Val Tyr
 260 265 270
 Thr Ile Glu Val Pro Phe His Gly Lys Thr Phe Ile Leu Lys Thr Phe
 275 280 285
 Leu Pro Cys Pro Ala Glu Leu Val Tyr Gln Glu Val Ile Leu Gln Pro
 290 295 300
 Glu Arg Met Val Leu Trp Asn Lys Thr Val Thr Ala Cys Gln Ile Leu
 305 310 315 320
 Gln Arg Val Glu Asp Asn Thr Leu Ile Ser Tyr Asp Val Ser Ala Gly
 325 330 335
 Ala Ala Gly Gly Val Val Ser Pro Arg Asp Phe Val Asn Val Arg Arg
 340 345 350
 Ile Glu Arg Arg Arg Asp Arg Tyr Leu Ser Ser Gly Ile Ala Thr Ser
 355 360 365
 His Ser Ala Lys Pro Pro Thr His Lys Tyr Val Arg Gly Glu Asn Gly
 370 375 380
 Pro Gly Gly Phe Ile Val Leu Lys Ser Ala Ser Asn Pro Arg Val Cys
 385 390 395 400
 Thr Phe Val Trp Ile Leu Asn Thr Asp Leu Lys Gly Arg Leu Pro Arg
 405 410 415
 Tyr Leu Ile His Gln Ser Leu Ala Ala Thr Met Phe Glu Phe Ala Phe
 420 425 430
 His Leu Arg Gln Arg Ile Ser Glu Leu Gly Ala Arg Ala
 435 440 445

<210> 34

<211> 167

<212> PRT

<213> Homo sapiens

<400> 34

Met Ala Thr Ser Glu Leu Ser Cys Glu Val Ser Glu Glu Asn Cys Glu
 1 5 10 15
 Arg Arg Glu Ala Phe Trp Ala Glu Trp Lys Asp Leu Thr Leu Ser Thr
 20 25 30
 Arg Pro Glu Glu Gly Cys Ser Leu His Glu Glu Asp Thr Gln Arg His
 35 40 45
 Glu Thr Tyr His Gln Gln Gly Gln Cys Gln Val Leu Val Gln Arg Ser
 50 55 60
 Pro Trp Leu Met Met Arg Met Gly Ile Leu Gly Arg Gly Leu Gln Glu
 65 70 75 80
 Tyr Gln Leu Pro Tyr Gln Arg Val Leu Pro Leu Pro Ile Phe Thr Pro
 85 90 95
 Ala Lys Met Gly Ala Thr Lys Glu Glu Arg Glu Asp Thr Pro Ile Gln
 100 105 110
 Leu Gln Glu Leu Leu Ala Leu Glu Thr Ala Leu Gly Gly Gln Cys Val
 115 120 125

Asp Arg Gln Glu Val Ala Glu Ile Thr Lys Gln Leu Pro Pro Val Val
 130 135 140
 Pro Val Ser Lys Pro Gly Ala Leu Arg Arg Ser Leu Ser Arg Ser Met
 145 150 155 160
 Ser Gln Glu Ala Gln Arg Gly
 165

<210> 35

<211> 282

<212> PRT

<213> Homo sapiens

<400> 35

Met Ser Gly Ala Asp Arg Ser Pro Asn Ala Gly Ala Ala Pro Asp Ser
 1 5 10 15
 Ala Pro Gly Gln Ala Ala Val Ala Ser Ala Tyr Gln Arg Phe Glu Pro
 20 25 30
 Arg Ala Tyr Leu Arg Asn Asn Tyr Ala Pro Pro Arg Gly Asp Leu Cys
 35 40 45
 Asn Pro Asn Gly Val Gly Pro Trp Lys Leu Arg Cys Leu Ala Gln Thr
 50 55 60
 Phe Ala Thr Gly Glu Val Ser Gly Arg Thr Leu Ile Asp Ile Gly Ser
 65 70 75 80
 Gly Pro Thr Val Tyr Gln Leu Leu Ser Ala Cys Ser His Phe Glu Asp
 85 90 95
 Ile Thr Met Thr Asp Phe Leu Glu Val Asn Arg Gln Glu Leu Gly Arg
 100 105 110
 Trp Leu Gln Glu Glu Pro Gly Ala Phe Asn Trp Ser Met Tyr Ser Gln
 115 120 125
 His Ala Cys Leu Ile Glu Gly Lys Gly Glu Cys Trp Gln Asp Lys Glu
 130 135 140
 Arg Gln Leu Arg Ala Arg Val Lys Arg Val Leu Pro Ile Asp Val His
 145 150 155 160
 Gln Pro Gln Pro Leu Gly Ala Gly Ser Pro Ala Pro Leu Pro Ala Asp
 165 170 175
 Ala Leu Val Ser Ala Phe Cys Leu Glu Ala Val Ser Pro Asp Leu Ala
 180 185 190
 Ser Phe Gln Arg Ala Leu Asp His Ile Thr Thr Leu Leu Arg Pro Gly
 195 200 205
 Gly His Leu Leu Leu Ile Gly Ala Leu Glu Glu Ser Trp Tyr Leu Ala
 210 215 220
 Gly Glu Ala Arg Leu Thr Val Val Pro Val Ser Glu Glu Glu Val Arg
 225 230 235 240
 Glu Ala Leu Val Arg Ser Gly Tyr Lys Val Arg Asp Leu Arg Thr Tyr
 245 250 255
 Ile Met Pro Ala His Leu Gln Thr Gly Val Asp Asp Val Lys Gly Val
 260 265 270
 Phe Phe Ala Trp Ala Gln Lys Val Gly Leu
 275 280

<210> 36

<211> 1255

<212> PRT

<213> Homo sapiens

<400> 36

Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu
 1 5 10 15
 Pro Pro Gly Ala Ala Ser Thr Gln Val Cys Thr Gly Thr Asp Met Lys
 20 25 30
 Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His
 35 40 45
 Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr
 50 55 60
 Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val
 65 70 75 80
 Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu
 85 90 95
 Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr
 100 105 110
 Ala Leu Ala Val Leu Asp Asn Gly Asp Pro Leu Asn Asn Thr Thr Pro
 115 120 125
 Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser
 130 135 140
 Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln
 145 150 155 160
 Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn
 165 170 175
 Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys
 180 185 190
 His Pro Cys Ser Pro Met Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser
 195 200 205
 Ser Glu Asp Cys Gln Ser Leu Thr Arg Thr Val Cys Ala Gly Gly Cys
 210 215 220
 Ala Arg Cys Lys Gly Pro Leu Pro Thr Asp Cys Cys His Glu Gln Cys
 225 230 235 240
 Ala Ala Gly Cys Thr Gly Pro Lys His Ser Asp Cys Leu Ala Cys Leu
 245 250 255
 His Phe Asn His Ser Gly Ile Cys Glu Leu His Cys Pro Ala Leu Val
 260 265 270
 Thr Tyr Asn Thr Asp Thr Phe Glu Ser Met Pro Asn Pro Glu Gly Arg
 275 280 285
 Tyr Thr Phe Gly Ala Ser Cys Val Thr Ala Cys Pro Tyr Asn Tyr Leu
 290 295 300
 Ser Thr Asp Val Gly Ser Cys Thr Leu Val Cys Pro Leu His Asn Gln
 305 310 315 320
 Glu Val Thr Ala Glu Asp Gly Thr Gln Arg Cys Glu Lys Cys Ser Lys
 325 330 335
 Pro Cys Ala Arg Val Cys Tyr Gly Leu Gly Met Glu His Leu Arg Glu
 340 345 350
 Val Arg Ala Val Thr Ser Ala Asn Ile Gln Glu Phe Ala Gly Cys Lys
 355 360 365
 Lys Ile Phe Gly Ser Leu Ala Phe Leu Pro Glu Ser Phe Asp Gly Asp
 370 375 380

Pro Ala Ser Asn Thr Ala Pro Leu Gln Pro Glu Gln Leu Gln Val Phe
 385 390 395 400
 Glu Thr Leu Glu Glu Ile Thr Gly Tyr Leu Tyr Ile Ser Ala Trp Pro
 405 410 415
 Asp Ser Leu Pro Asp Leu Ser Val Phe Gln Asn Leu Gln Val Ile Arg
 420 425 430

 Gly Arg Ile Leu His Asn Gly Ala Tyr Ser Leu Thr Leu Gln Gly Leu
 435 440 445
 Gly Ile Ser Trp Leu Gly Leu Arg Ser Leu Arg Glu Leu Gly Ser Gly
 450 455 460
 Leu Ala Leu Ile His His Asn Thr His Leu Cys Phe Val His Thr Val
 465 470 475 480
 Pro Trp Asp Gln Leu Phe Arg Asn Pro His Gln Ala Leu Leu His Thr
 485 490 495
 Ala Asn Arg Pro Glu Asp Glu Cys Val Gly Glu Gly Leu Ala Cys His
 500 505 510
 Gln Leu Cys Ala Arg Gly His Cys Trp Gly Pro Gly Pro Thr Gln Cys
 515 520 525
 Val Asn Cys Ser Gln Phe Leu Arg Gly Gln Glu Cys Val Glu Glu Cys
 530 535 540
 Arg Val Leu Gln Gly Leu Pro Arg Glu Tyr Val Asn Ala Arg His Cys
 545 550 555 560
 Leu Pro Cys His Pro Glu Cys Gln Pro Gln Asn Gly Ser Val Thr Cys
 565 570 575
 Phe Gly Pro Glu Ala Asp Gln Cys Val Ala Cys Ala His Tyr Lys Asp
 580 585 590
 Pro Pro Phe Cys Val Ala Arg Cys Pro Ser Gly Val Lys Pro Asp Leu
 595 600 605
 Ser Tyr Met Pro Ile Trp Lys Phe Pro Asp Glu Glu Gly Ala Cys Gln
 610 615 620
 Pro Cys Pro Ile Asn Cys Thr His Ser Cys Val Asp Leu Asp Asp Lys
 625 630 635 640
 Gly Cys Pro Ala Glu Gln Arg Ala Ser Pro Leu Thr Ser Ile Val Ser
 645 650 655
 Ala Val Val Gly Ile Leu Leu Val Val Val Leu Gly Val Val Phe Gly
 660 665 670
 Ile Leu Ile Lys Arg Arg Gln Gln Lys Ile Arg Lys Tyr Thr Met Arg
 675 680 685
 Arg Leu Leu Gln Glu Thr Glu Leu Val Glu Pro Leu Thr Pro Ser Gly
 690 695 700
 Ala Met Pro Asn Gln Ala Gln Met Arg Ile Leu Lys Glu Thr Glu Leu
 705 710 715 720
 Arg Lys Val Lys Val Leu Gly Ser Gly Ala Phe Gly Thr Val Tyr Lys
 725 730 735
 Gly Ile Trp Ile Pro Asp Gly Glu Asn Val Lys Ile Pro Val Ala Ile
 740 745 750
 Lys Val Leu Arg Glu Asn Thr Ser Pro Lys Ala Asn Lys Glu Ile Leu
 755 760 765
 Asp Glu Ala Tyr Val Met Ala Gly Val Gly Ser Pro Tyr Val Ser Arg
 770 775 780
 Leu Leu Gly Ile Cys Leu Thr Ser Thr Val Gln Leu Val Thr Gln Leu
 785 790 795 800
 Met Pro Tyr Gly Cys Leu Leu Asp His Val Arg Glu Asn Arg Gly Arg
 805 810 815
 Leu Gly Ser Gln Asp Leu Leu Asn Trp Cys Met Gln Ile Ala Lys Gly
 820 825 830
 Met Ser Tyr Leu Glu Asp Val Arg Leu Val His Arg Asp Leu Ala Ala
 835 840 845

Arg Asn Val Leu Val Lys Ser Pro Asn His Val Lys Ile Thr Asp Phe
 850 855 860
 Gly Leu Ala Arg Leu Leu Asp Ile Asp Glu Thr Glu Tyr His Ala Asp
 865 870 875 880
 Gly Gly Lys Val Pro Ile Lys Trp Met Ala Leu Glu Ser Ile Leu Arg
 885 890 895
 Arg Arg Phe Thr His Gln Ser Asp Val Trp Ser Tyr Gly Val Thr Val
 900 905 910
 Trp Glu Leu Met Thr Phe Gly Ala Lys Pro Tyr Asp Gly Ile Pro Ala
 915 920 925
 Arg Glu Ile Pro Asp Leu Leu Glu Lys Gly Glu Arg Leu Pro Gln Pro
 930 935 940
 Pro Ile Cys Thr Ile Asp Val Tyr Met Ile Met Val Lys Cys Trp Met
 945 950 955 960
 Ile Asp Ser Glu Cys Arg Pro Arg Phe Arg Glu Leu Val Ser Glu Phe
 965 970 975
 Ser Arg Met Ala Arg Asp Pro Gln Arg Phe Val Val Ile Gln Asn Glu
 980 985 990
 Asp Leu Gly Pro Ala Ser Pro Leu Asp Ser Thr Phe Tyr Arg Ser Leu
 995 1000 1005
 Leu Glu Asp Asp Asp Met Gly Asp Leu Val Asp Ala Glu Glu Tyr
 1010 1015 1020
 Leu Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly
 1025 1030 1035
 Ala Gly Gly Met Val His His Arg His Arg Ser Ser Ser Thr Arg
 1040 1045 1050
 Ser Gly Gly Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu
 1055 1060 1065
 Glu Ala Pro Arg Ser Pro Leu Ala Pro Ser Glu Gly Ala Gly Ser
 1070 1075 1080
 Asp Val Phe Asp Gly Asp Leu Gly Met Gly Ala Ala Lys Gly Leu
 1085 1090 1095
 Gln Ser Leu Pro Thr His Asp Pro Ser Pro Leu Gln Arg Tyr Ser
 1100 1105 1110
 Glu Asp Pro Thr Val Pro Leu Pro Ser Glu Thr Asp Gly Tyr Val
 1115 1120 1125
 Ala Pro Leu Thr Cys Ser Pro Gln Pro Glu Tyr Val Asn Gln Pro
 1130 1135 1140
 Asp Val Arg Pro Gln Pro Pro Ser Pro Arg Glu Gly Pro Leu Pro
 1145 1150 1155
 Ala Ala Arg Pro Ala Gly Ala Thr Leu Glu Arg Ala Lys Thr Leu
 1160 1165 1170
 Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val Phe Ala Phe Gly
 1175 1180 1185
 Gly Ala Val Glu Asn Pro Glu Tyr Leu Thr Pro Gln Gly Gly Ala
 1190 1195 1200
 Ala Pro Gln Pro His Pro Pro Pro Ala Phe Ser Pro Ala Phe Asp
 1205 1210 1215
 Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Pro Glu Arg Gly Ala Pro
 1220 1225 1230
 Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr
 1235 1240 1245
 Leu Gly Leu Asp Val Pro Val
 1250 1255

<210> 37

<211> 532

<212> PRT

<213> Homo sapiens

<400> 37

Met Glu Leu Asp Leu Ser Pro Pro His Leu Ser Ser Ser Pro Glu Asp
 1 5 10 15
 Leu Trp Pro Ala Pro Gly Thr Pro Pro Gly Thr Pro Arg Pro Pro Asp
 20 25 30
 Thr Pro Leu Pro Glu Glu Val Lys Arg Ser Gln Pro Leu Leu Ile Pro
 35 40 45
 Thr Thr Gly Arg Lys Leu Arg Glu Glu Glu Arg Arg Ala Thr Ser Leu
 50 55 60
 Pro Ser Ile Pro Asn Pro Phe Pro Glu Leu Cys Ser Pro Pro Ser Gln
 65 70 75 80
 Ser Pro Ile Leu Gly Gly Pro Ser Ser Ala Arg Gly Leu Leu Pro Arg
 85 90 95
 Asp Ala Ser Arg Pro His Val Val Lys Val Tyr Ser Glu Asp Gly Ala
 100 105 110
 Cys Arg Ser Val Glu Val Ala Ala Gly Ala Thr Ala Arg His Val Cys
 115 120 125
 Glu Met Leu Val Gln Arg Ala His Ala Leu Ser Asp Glu Thr Trp Gly
 130 135 140
 Leu Val Glu Cys His Pro His Leu Ala Leu Glu Arg Gly Leu Glu Asp
 145 150 155 160
 His Glu Ser Val Val Glu Val Gln Ala Ala Trp Pro Val Gly Gly Asp
 165 170 175
 Ser Arg Phe Val Phe Arg Lys Asn Phe Ala Lys Tyr Glu Leu Phe Lys
 180 185 190
 Ser Ser Pro His Ser Leu Phe Pro Glu Lys Met Val Ser Ser Cys Leu
 195 200 205
 Asp Ala His Thr Gly Ile Ser His Glu Asp Leu Ile Gln Asn Phe Leu
 210 215 220
 Asn Ala Gly Ser Phe Pro Glu Ile Gln Gly Phe Leu Gln Leu Arg Gly
 225 230 235 240
 Ser Gly Arg Lys Leu Trp Lys Arg Phe Phe Cys Phe Leu Arg Arg Ser
 245 250 255
 Gly Leu Tyr Tyr Ser Thr Lys Gly Thr Ser Lys Asp Pro Arg His Leu
 260 265 270
 Gln Tyr Val Ala Asp Val Asn Glu Ser Asn Val Tyr Val Val Thr Gln
 275 280 285
 Gly Arg Lys Leu Tyr Gly Met Pro Thr Asp Phe Gly Phe Cys Val Lys
 290 295 300
 Pro Asn Lys Leu Arg Asn Gly His Lys Gly Leu Arg Ile Phe Cys Ser
 305 310 315 320
 Glu Asp Glu Gln Ser Arg Thr Cys Trp Leu Ala Ala Phe Arg Leu Phe
 325 330 335
 Lys Tyr Gly Val Gln Leu Tyr Lys Asn Tyr Gln Gln Ala Gln Ser Arg
 340 345 350
 His Leu His Pro Ser Cys Leu Gly Ser Pro Pro Leu Arg Ser Ala Ser
 355 360 365
 Asp Asn Thr Leu Val Ala Met Asp Phe Ser Gly His Ala Gly Arg Val
 370 375 380

Ile Glu Asn Pro Arg Glu Ala Leu Ser Val Ala Leu Glu Glu Ala Gln
 385 390 395 400
 Ala Trp Arg Lys Lys Thr Asn His Arg Leu Ser Leu Pro Met Pro Ala
 405 410 415
 Ser Gly Thr Ser Leu Ser Ala Ala Ile His Arg Thr Gln Leu Trp Phe
 420 425 430
 His Gly Arg Ile Ser Arg Glu Glu Ser Gln Arg Leu Ile Gly Gln Gln
 435 440 445
 Gly Leu Val Asp Gly Leu Phe Leu Val Arg Glu Ser Gln Arg Asn Pro
 450 455 460
 Gln Gly Phe Val Leu Ser Leu Cys His Leu Gln Lys Val Lys His Tyr
 465 470 475 480
 Leu Ile Leu Pro Ser Glu Glu Glu Gly Arg Leu Tyr Phe Ser Met Asp
 485 490 495
 Asp Gly Gln Thr Arg Phe Thr Asp Leu Leu Gln Leu Val Glu Phe His
 500 505 510
 Gln Leu Asn Arg Gly Ile Leu Pro Cys Leu Leu Arg His Cys Cys Thr
 515 520 525
 Arg Val Ala Leu
 530

<210> 38

<211> 534

<212> PRT

<213> Homo sapiens

<400> 38

Met Lys Gln Glu Gly Ser Ala Arg Arg Arg Gly Ala Asp Lys Ala Lys
 1 5 10 15
 Pro Pro Pro Gly Gly Gly Glu Gln Glu Pro Pro Pro Pro Pro Ala Pro
 20 25 30
 Gln Asp Val Glu Met Lys Glu Glu Ala Ala Thr Gly Gly Gly Ser Thr
 35 40 45
 Gly Glu Ala Asp Gly Lys Thr Ala Ala Ala Ala Val Glu His Ser Gln
 50 55 60
 Arg Glu Leu Asp Thr Val Thr Leu Glu Asp Ile Lys Glu His Val Lys
 65 70 75 80
 Gln Leu Glu Lys Ala Val Ser Gly Lys Glu Pro Arg Phe Val Leu Arg
 85 90 95
 Ala Leu Arg Met Leu Pro Ser Thr Ser Arg Arg Leu Asn His Tyr Val
 100 105 110
 Leu Tyr Lys Ala Val Gln Gly Phe Phe Thr Ser Asn Asn Ala Thr Arg
 115 120 125
 Asp Phe Leu Leu Pro Phe Leu Glu Glu Pro Met Asp Thr Glu Ala Asp
 130 135 140
 Leu Gln Phe Arg Pro Arg Thr Gly Lys Ala Ala Ser Thr Pro Leu Leu
 145 150 155 160
 Pro Glu Val Glu Ala Tyr Leu Gln Leu Leu Val Val Ile Phe Met Met
 165 170 175
 Asn Ser Lys Arg Tyr Lys Glu Ala Gln Lys Ile Ser Asp Asp Leu Met
 180 185 190
 Gln Lys Ile Ser Thr Gln Asn Arg Arg Ala Leu Asp Leu Val Ala Ala
 195 200 205

Lys Cys Tyr Tyr Tyr His Ala Arg Val Tyr Glu Phe Leu Asp Lys Leu
 210 215 220
 Asp Val Val Arg Ser Phe Leu His Ala Arg Leu Arg Thr Ala Thr Leu
 225 230 235 240
 Arg His Asp Ala Asp Gly Gln Ala Thr Leu Leu Asn Leu Leu Leu Arg
 245 250 255
 Asn Tyr Leu His Tyr Ser Leu Tyr Asp Gln Ala Glu Lys Leu Val Ser
 260 265 270
 Lys Ser Val Phe Pro Glu Gln Ala Asn Asn Asn Glu Trp Ala Arg Tyr
 275 280 285
 Leu Tyr Tyr Thr Gly Arg Ile Lys Ala Ile Gln Leu Glu Tyr Ser Glu
 290 295 300
 Ala Arg Arg Thr Met Thr Asn Ala Leu Arg Lys Ala Pro Gln His Thr
 305 310 315 320
 Ala Val Gly Phe Lys Gln Thr Val His Lys Leu Leu Ile Val Val Glu
 325 330 335
 Leu Leu Leu Gly Glu Ile Pro Asp Arg Leu Gln Phe Arg Gln Pro Ser
 340 345 350
 Leu Lys Arg Ser Leu Met Pro Tyr Phe Leu Leu Thr Gln Ala Val Arg
 355 360 365
 Thr Gly Asn Leu Ala Lys Phe Asn Gln Val Leu Asp Gln Phe Gly Glu
 370 375 380
 Lys Phe Gln Ala Asp Gly Thr Tyr Thr Leu Ile Ile Arg Leu Arg His
 385 390 395 400
 Asn Val Ile Lys Thr Gly Val Arg Met Ile Ser Leu Ser Tyr Ser Arg
 405 410 415
 Ile Ser Leu Ala Asp Ile Ala Gln Lys Leu Gln Leu Asp Ser Pro Glu
 420 425 430
 Asp Ala Glu Phe Ile Val Ala Lys Ala Ile Arg Asp Gly Val Ile Glu
 435 440 445
 Ala Ser Ile Asn His Glu Lys Gly Tyr Val Gln Ser Lys Glu Met Ile
 450 455 460
 Asp Ile Tyr Ser Thr Arg Glu Pro Gln Leu Ala Phe His Gln Arg Ile
 465 470 475 480
 Ser Phe Cys Leu Asp Ile His Asn Met Ser Val Lys Ala Met Arg Phe
 485 490 495
 Pro Pro Lys Ser Tyr Asn Lys Asp Leu Glu Ser Ala Glu Glu Arg Arg
 500 505 510
 Glu Arg Glu Gln Gln Asp Leu Glu Phe Ala Lys Glu Met Ala Glu Asp
 515 520 525
 Asp Asp Asp Ser Phe Pro
 530

<210> 39

<211> 207

<212> PRT

<213> Homo sapiens

<400> 39

Met Ala Gly Pro Ala Thr Gln Ser Pro Met Lys Leu Met Ala Leu Gln
 1 5 10 15
 Leu Leu Leu Trp His Ser Ala Leu Trp Thr Val Gln Glu Ala Thr Pro
 20 25 30

5 Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys Leu
 35 40 45
 Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys
 50 55 60
 Leu Val Ser Glu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu Leu
 65 70 75 80
 Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser Ser
 85 90 95
 10 Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu His
 100 105 110
 Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile
 115 120 125
 Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala
 130 135 140
 15 Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met Ala
 145 150 155 160
 Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser Ala
 165 170 175
 Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln Ser
 180 185 190
 20 Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro
 195 200 205

25 <210> 40

<211> 989

<212> PRT

30 <213> Homo sapiens

<400> 40

35 Met Lys Val Val Asn Leu Lys Gln Ala Ile Leu Gln Ala Trp Lys Glu
 1 5 10 15
 Arg Trp Ser Tyr Tyr Gln Trp Ala Ile Asn Met Lys Lys Phe Pro
 20 25 30
 Lys Gly Ala Thr Trp Asp Ile Leu Asn Leu Ala Asp Ala Leu Leu Glu
 35 40 45
 40 Gln Ala Met Ile Gly Pro Ser Pro Asn Pro Leu Ile Leu Ser Tyr Leu
 50 55 60
 Lys Tyr Ala Ile Ser Ser Gln Met Val Ser Tyr Ser Ser Val Leu Thr
 65 70 75 80
 Ala Ile Ser Lys Phe Asp Asp Phe Ser Arg Asp Leu Cys Val Gln Ala
 85 90 95
 45 Leu Leu Asp Ile Met Asp Met Phe Cys Asp Arg Leu Ser Cys His Gly
 100 105 110
 Lys Ala Glu Glu Cys Ile Gly Leu Cys Arg Ala Leu Leu Ser Ala Leu
 115 120 125
 His Trp Leu Leu Arg Cys Thr Ala Ala Ser Ala Glu Arg Leu Arg Glu
 130 135 140
 50 Gly Leu Glu Ala Gly Thr Pro Ala Ala Gly Glu Lys Gln Leu Ala Met
 145 150 155 160
 Cys Leu Gln Arg Leu Glu Lys Thr Leu Ser Ser Thr Lys Asn Arg Ala
 165 170 175
 55 Leu Leu His Ile Ala Lys Leu Glu Glu Ala Ser Ser Trp Thr Ala Ile
 180 185 190

	Glu	His	Ser	Leu	Leu	Lys	Leu	Gly	Glu	Ile	Leu	Thr	Asn	Leu	Ser	Asn
			195					200					205			
5	Pro	Gln	Leu	Arg	Ser	Gln	Ala	Glu	Gln	Cys	Gly	Thr	Leu	Ile	Arg	Ser
		210				215						220				
	Ile	Pro	Thr	Met	Leu	Ser	Val	His	Ala	Glu	Gln	Met	His	Lys	Thr	Gly
	225					230						235				240
	Phe	Pro	Thr	Val	His	Ala	Val	Ile	Leu	Leu	Glu	Gly	Thr	Met	Asn	Leu
					245					250					255	
10	Thr	Gly	Glu	Thr	Gln	Ser	Leu	Val	Glu	Gln	Leu	Thr	Met	Val	Lys	Arg
					260					265				270		
	Met	Gln	His	Ile	Pro	Thr	Pro	Leu	Phe	Val	Leu	Glu	Ile	Trp	Lys	Ala
			275					280					285			
	Cys	Phe	Val	Gly	Leu	Ile	Glu	Ser	Pro	Glu	Gly	Thr	Glu	Glu	Leu	Lys
		290					295					300				
15	Trp	Thr	Ala	Phe	Thr	Phe	Leu	Lys	Ile	Pro	Gln	Val	Leu	Val	Lys	Leu
	305					310					315					320
	Lys	Lys	Tyr	Ser	His	Gly	Asp	Lys	Asp	Phe	Thr	Glu	Asp	Val	Asn	Cys
					325					330					335	
	Ala	Phe	Glu	Phe	Leu	Leu	Lys	Leu	Thr	Pro	Leu	Leu	Asp	Lys	Ala	Asp
					340					345				350		
20	Gln	Arg	Cys	Asn	Cys	Asp	Cys	Thr	Asn	Phe	Leu	Leu	Gln	Glu	Cys	Gly
			355					360					365			
	Lys	Gln	Gly	Leu	Leu	Ser	Glu	Ala	Ser	Val	Asn	Asn	Leu	Met	Ala	Lys
		370					375					380				
25	Arg	Lys	Ala	Asp	Arg	Glu	His	Ala	Pro	Gln	Gln	Lys	Ser	Gly	Glu	Asn
	385					390					395					400
	Ala	Asn	Ile	Gln	Pro	Asn	Ile	Gln	Leu	Ile	Leu	Arg	Ala	Glu	Pro	Thr
					405					410					415	
	Val	Thr	Asn	Ile	Leu	Lys	Thr	Met	Asp	Ala	Asp	His	Ser	Lys	Ser	Pro
					420				425					430		
30	Glu	Gly	Leu	Leu	Gly	Val	Leu	Gly	His	Met	Leu	Ser	Gly	Lys	Ser	Leu
			435					440					445			
	Asp	Leu	Leu	Leu	Ala	Ala	Ala	Ala	Ala	Thr	Gly	Lys	Leu	Lys	Ser	Phe
		450					455					460				
	Ala	Arg	Lys	Phe	Ile	Asn	Leu	Asn	Glu	Phe	Thr	Thr	Tyr	Gly	Ser	Glu
						470					475					480
35	Glu	Ser	Thr	Lys	Pro	Ala	Ser	Val	Arg	Ala	Leu	Leu	Phe	Asp	Ile	Ser
					485					490					495	
	Phe	Leu	Met	Leu	Cys	His	Val	Ala	Gln	Thr	Tyr	Gly	Ser	Glu	Val	Ile
					500				505					510		
	Leu	Ser	Glu	Ser	Arg	Thr	Gly	Ala	Glu	Val	Pro	Phe	Phe	Glu	Thr	Trp
					515				520					525		
40	Met	Gln	Thr	Cys	Met	Pro	Glu	Gly	Lys	Ile	Leu	Asn	Pro	Asp	His	
		530					535					540				
	Pro	Cys	Phe	Arg	Pro	Asp	Ser	Thr	Lys	Val	Glu	Ser	Leu	Val	Ala	Leu
						550					555					560
45	Leu	Asn	Asn	Ser	Ser	Glu	Met	Lys	Leu	Val	Gln	Met	Lys	Trp	His	Glu
					565					570					575	
	Ala	Cys	Leu	Ser	Ile	Ser	Ala	Ala	Ile	Leu	Glu	Ile	Leu	Asn	Ala	Trp
					580					585				590		
	Glu	Asn	Gly	Val	Leu	Ala	Phe	Glu	Ser	Ile	Gln	Lys	Ile	Thr	Asp	Asn
					595				600				605			
50	Ile	Lys	Gly	Lys	Val	Cys	Ser	Leu	Ala	Val	Cys	Ala	Val	Ala	Trp	Leu
		610					615					620				
	Val	Ala	His	Val	Arg	Met	Leu	Gly	Leu	Asp	Glu	Arg	Glu	Lys	Ser	Leu
						630					635					640
	Gln	Met	Ile	Arg	Gln	Leu	Ala	Gly	Pro	Leu	Phe	Ser	Glu	Asn	Thr	Leu
					645					650						655

5 Gln Phe Tyr Asn Glu Arg Val Val Ile Met Asn Ser Ile Leu Glu Arg
 660 665 670
 Met Cys Ala Asp Val Leu Gln Gln Thr Ala Thr Gln Ile Lys Phe Pro
 675 680 685
 Ser Thr Gly Val Asp Thr Met Pro Tyr Trp Asn Leu Leu Pro Pro Lys
 690 695 700
 Arg Pro Ile Lys Glu Val Leu Thr Asp Ile Phe Ala Lys Val Leu Glu
 705 710 715 720
 10 Lys Gly Trp Val Asp Ser Arg Ser Ile His Ile Phe Asp Thr Leu Leu
 725 730 735
 His Met Gly Gly Val Tyr Trp Phe Cys Asn Asn Leu Ile Lys Glu Leu
 740 745 750
 Leu Lys Glu Thr Arg Lys Glu His Thr Leu Arg Ala Val Glu Leu Leu
 755 760 765
 15 Tyr Ser Ile Phe Cys Leu Asp Met Gln Gln Val Thr Leu Val Leu Leu
 770 775 780
 Gly His Ile Leu Pro Gly Leu Leu Thr Asp Ser Ser Lys Trp His Ser
 785 790 795 800
 Leu Met Asp Pro Pro Gly Thr Ala Leu Ala Lys Leu Ala Val Trp Cys
 805 810 815
 20 Ala Leu Ser Ser Tyr Ser Ser His Lys Gly Gln Ala Ser Thr Arg Gln
 820 825 830
 Lys Lys Arg His Arg Glu Asp Ile Glu Asp Tyr Ile Ser Leu Phe Pro
 835 840 845
 Leu Asp Asp Val Gln Pro Ser Lys Leu Met Arg Leu Leu Ser Ser Asn
 850 855 860
 25 Glu Asp Asp Ala Asn Ile Leu Ser Ser Pro Thr Asp Arg Ser Met Ser
 865 870 875 880
 Ser Ser Leu Ser Ala Ser Gln Leu His Thr Val Asn Met Arg Asp Pro
 885 890 895
 30 Leu Asn Arg Val Leu Ala Asn Leu Phe Leu Leu Ile Ser Ser Ile Leu
 900 905 910
 Gly Ser Arg Thr Ala Gly Pro His Thr Gln Phe Val Gln Trp Phe Met
 915 920 925
 Glu Glu Cys Val Asp Cys Leu Glu Gln Gly Gly Arg Gly Ser Val Leu
 930 935 940
 35 Gln Phe Met Pro Phe Thr Thr Val Ser Glu Leu Val Lys Val Ser Ala
 945 950 955 960
 Met Ser Ser Pro Lys Val Val Leu Ala Ile Thr Asp Leu Ser Leu Pro
 965 970 975
 Leu Gly Arg Gln Val Ala Ala Lys Ala Ile Ala Ala Leu
 980 985

<210> 41

<211> 490

<212> PRT

<213> Homo sapiens

<400> 41

Met Glu Gln Lys Pro Ser Lys Val Glu Cys Gly Ser Asp Pro Glu Glu
 1 5 10 15
 Asn Ser Ala Arg Ser Pro Asp Gly Lys Arg Lys Arg Lys Asn Gly Gln
 20 25 30

	Cys	Ser	Leu	Lys	Thr	Ser	Met	Ser	Gly	Tyr	Ile	Pro	Ser	Tyr	Leu	Asp
			35					40					45			
5	Lys	Asp	Glu	Gln	Cys	Val	Val	Cys	Gly	Asp	Lys	Ala	Thr	Gly	Tyr	His
	50						55					60				
	Tyr	Arg	Cys	Ile	Thr	Cys	Glu	Gly	Cys	Lys	Gly	Phe	Phe	Arg	Arg	Thr
	65					70					75					80
	Ile	Gln	Lys	Asn	Leu	His	Pro	Thr	Tyr	Ser	Cys	Lys	Tyr	Asp	Ser	Cys
				85						90					95	
10	Cys	Val	Ile	Asp	Lys	Ile	Thr	Arg	Asn	Gln	Cys	Gln	Leu	Cys	Arg	Phe
				100					105						110	
	Lys	Lys	Cys	Ile	Ala	Val	Gly	Met	Ala	Met	Asp	Leu	Val	Leu	Asp	Asp
			115					120					125			
	Ser	Lys	Arg	Val	Ala	Lys	Arg	Lys	Leu	Ile	Glu	Gln	Asn	Arg	Glu	Arg
	130						135					140				
15	Arg	Arg	Lys	Glu	Glu	Met	Ile	Arg	Ser	Leu	Gln	Gln	Arg	Pro	Glu	Pro
	145					150					155					160
	Thr	Pro	Glu	Glu	Trp	Asp	Leu	Ile	His	Ile	Ala	Thr	Glu	Ala	His	Arg
					165					170					175	
	Ser	Thr	Asn	Ala	Gln	Gly	Ser	His	Trp	Lys	Gln	Arg	Arg	Lys	Phe	Leu
20				180					185						190	
	Pro	Asp	Asp	Ile	Gly	Gln	Ser	Pro	Ile	Val	Ser	Met	Pro	Asp	Gly	Asp
			195					200					205			
	Lys	Val	Asp	Leu	Glu	Ala	Phe	Ser	Glu	Phe	Thr	Lys	Ile	Ile	Thr	Pro
	210						215					220				
25	Ala	Ile	Thr	Arg	Val	Val	Asp	Phe	Ala	Lys	Lys	Leu	Pro	Met	Phe	Ser
	225					230					235					240
	Glu	Leu	Pro	Cys	Glu	Asp	Gln	Ile	Ile	Leu	Leu	Lys	Gly	Cys	Cys	Met
					245					250					255	
	Glu	Ile	Met	Ser	Leu	Arg	Ala	Ala	Val	Arg	Tyr	Asp	Pro	Glu	Ser	Asp
				260					265					270		
30	Thr	Leu	Thr	Leu	Ser	Gly	Glu	Met	Ala	Val	Lys	Arg	Glu	Gln	Leu	Lys
				275				280					285			
	Asn	Gly	Gly	Leu	Gly	Val	Val	Ser	Asp	Ala	Ile	Phe	Glu	Leu	Gly	Lys
	290					295						300				
	Ser	Leu	Ser	Ala	Phe	Asn	Leu	Asp	Asp	Thr	Glu	Val	Ala	Leu	Leu	Gln
	305					310					315					320
35	Ala	Val	Leu	Leu	Met	Ser	Thr	Asp	Arg	Ser	Gly	Leu	Leu	Cys	Val	Asp
					325					330					335	
	Lys	Ile	Glu	Lys	Ser	Gln	Glu	Ala	Tyr	Leu	Leu	Ala	Phe	Glu	His	Tyr
				340					345					350		
	Val	Asn	His	Arg	Lys	His	Asn	Ile	Pro	His	Phe	Trp	Pro	Lys	Leu	Leu
40				355				360					365			
	Met	Lys	Glu	Arg	Glu	Val	Gln	Ser	Ser	Ile	Leu	Tyr	Lys	Gly	Ala	Ala
	370						375					380				
	Ala	Glu	Gly	Arg	Pro	Gly	Gly	Ser	Leu	Gly	Val	His	Pro	Glu	Gly	Gln
	385					390					395					400
45	Gln	Leu	Leu	Gly	Met	His	Val	Val	Gln	Gly	Pro	Gln	Val	Arg	Gln	Leu
					405					410					415	
	Glu	Gln	Gln	Leu	Gly	Glu	Ala	Gly	Ser	Leu	Gln	Gly	Pro	Val	Leu	Gln
				420					425					430		
	His	Gln	Ser	Pro	Lys	Ser	Pro	Gln	Gln	Arg	Leu	Leu	Glu	Leu	Leu	His
				435				440					445			
50	Arg	Ser	Gly	Ile	Leu	His	Ala	Arg	Ala	Val	Cys	Gly	Glu	Asp	Asp	Ser
	450						455					460				
	Ser	Glu	Ala	Asp	Ser	Pro	Ser	Ser	Ser	Glu	Glu	Pro	Glu	Val	Cys	
	465					470					475				480	
	Glu	Asp	Leu	Ala	Gly	Asn	Ala	Ala	Ser	Pro						
55					485					490						

<210> 42

<211> 614

<212> PRT

<213> Homo sapiens

<400> 42

Met Thr Thr Leu Asp Ser Asn Asn Asn Thr Gly Gly Val Ile Thr Tyr
 1 5 10 15
 Ile Gly Ser Ser Gly Ser Ser Pro Ser Arg Thr Ser Pro Glu Ser Leu
 20 25 30
 Tyr Ser Asp Asn Ser Asn Gly Ser Phe Gln Ser Leu Thr Gln Gly Cys
 35 40 45
 Pro Thr Tyr Phe Pro Pro Ser Pro Thr Gly Ser Leu Thr Gln Asp Pro
 50 55 60
 Ala Arg Ser Phe Gly Ser Ile Pro Pro Ser Leu Ser Asp Asp Gly Ser
 65 70 75 80
 Pro Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Ser Phe Tyr Asn
 85 90 95
 Gly Ser Pro Pro Gly Ser Leu Gln Val Ala Met Glu Asp Ser Ser Arg
 100 105 110
 Val Ser Pro Ser Lys Ser Thr Ser Asn Ile Thr Lys Leu Asn Gly Met
 115 120 125
 Val Leu Leu Cys Lys Val Cys Gly Asp Val Ala Ser Gly Phe His Tyr
 130 135 140
 Gly Val Leu Ala Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg Ser Ile
 145 150 155 160
 Gln Gln Asn Ile Gln Tyr Lys Arg Cys Leu Lys Asn Glu Asn Cys Ser
 165 170 175
 Ile Val Arg Ile Asn Arg Asn Arg Cys Gln Gln Cys Arg Phe Lys Lys
 180 185 190
 Cys Leu Ser Val Gly Met Ser Arg Asp Ala Val Arg Phe Gly Arg Ile
 195 200 205
 Pro Lys Arg Glu Lys Gln Arg Met Leu Ala Glu Met Gln Ser Ala Met
 210 215 220
 Asn Leu Ala Asn Asn Gln Leu Ser Ser Gln Cys Pro Leu Glu Thr Ser
 225 230 235 240
 Pro Thr Gln His Pro Thr Pro Gly Pro Met Gly Pro Ser Pro Pro Pro
 245 250 255
 Ala Pro Val Pro Ser Pro Leu Val Gly Phe Ser Gln Phe Pro Gln Gln
 260 265 270
 Leu Thr Pro Pro Arg Ser Pro Ser Pro Glu Pro Thr Val Glu Asp Val
 275 280 285
 Ile Ser Gln Val Ala Arg Ala His Arg Glu Ile Phe Thr Tyr Ala His
 290 295 300
 Asp Lys Leu Gly Ser Ser Pro Gly Asn Phe Asn Ala Asn His Ala Ser
 305 310 315 320
 Gly Ser Pro Pro Ala Thr Thr Pro His Arg Trp Glu Asn Gln Gly Cys
 325 330 335
 Pro Pro Ala Pro Asn Asp Asn Asn Thr Leu Ala Ala Gln Arg His Asn
 340 345 350
 Glu Ala Leu Asn Gly Leu Arg Gln Ala Pro Ser Ser Tyr Pro Pro Thr
 355 360 365

Trp Pro Pro Gly Pro Ala His His Ser Cys His Gln Ser Asn Ser Asn
 370 375 380
 Gly His Arg Leu Cys Pro Thr His Val Tyr Ala Ala Pro Glu Gly Lys
 385 390 395 400
 Ala Pro Ala Asn Ser Pro Arg Gln Gly Asn Ser Lys Asn Val Leu Leu
 405 410 415
 Ala Cys Pro Met Asn Met Tyr Pro His Gly Arg Ser Gly Arg Thr Val
 420 425 430
 Gln Glu Ile Trp Glu Asp Phe Ser Met Ser Phe Thr Pro Ala Val Arg
 435 440 445
 Glu Val Val Glu Phe Ala Lys His Ile Pro Gly Phe Arg Asp Leu Ser
 450 455 460
 Gln His Asp Gln Val Thr Leu Leu Lys Ala Gly Thr Phe Glu Val Leu
 465 470 475 480
 Met Val Arg Phe Ala Ser Leu Phe Asn Val Lys Asp Gln Thr Val Met
 485 490 495
 Phe Leu Ser Arg Thr Thr Tyr Ser Leu Gln Glu Leu Gly Ala Met Gly
 500 505 510
 Met Gly Asp Leu Leu Ser Ala Met Phe Asp Phe Ser Glu Lys Leu Asn
 515 520 525
 Ser Leu Ala Leu Thr Glu Glu Glu Leu Gly Leu Phe Thr Ala Val Val
 530 535 540
 Leu Val Ser Ala Asp Arg Ser Gly Met Glu Asn Ser Ala Ser Val Glu
 545 550 555 560
 Gln Leu Gln Glu Thr Leu Leu Arg Ala Leu Arg Ala Leu Val Leu Lys
 565 570 575
 Asn Arg Pro Leu Glu Thr Ser Arg Phe Thr Lys Leu Leu Leu Lys Leu
 580 585 590
 Pro Asp Leu Arg Thr Leu Asn Asn Met His Ser Glu Lys Leu Leu Ser
 595 600 605
 Phe Arg Val Asp Ala Gln
 610

<210> 43

<211> 703

<212> PRT

<213> Homo sapiens

<400> 43

Met Ala Asp Arg Arg Arg Gln Arg Ala Ser Gln Asp Thr Glu Asp Glu
 1 5 10 15
 Glu Ser Gly Ala Ser Gly Ser Asp Ser Gly Gly Ser Pro Leu Arg Gly
 20 25 30
 Gly Gly Ser Cys Ser Gly Ser Ala Gly Gly Gly Ser Gly Ser Leu
 35 40 45
 Pro Ser Gln Arg Gly Gly Arg Thr Gly Ala Leu His Leu Arg Arg Val
 50 55 60
 Glu Ser Gly Gly Ala Lys Ser Ala Glu Glu Ser Glu Cys Glu Ser Glu
 65 70 75 80
 Asp Gly Ile Glu Gly Asp Ala Val Leu Ser Asp Tyr Glu Ser Ala Glu
 85 90 95
 Asp Ser Glu Gly Glu Glu Gly Glu Tyr Ser Glu Glu Glu Asn Ser Lys
 100 105 110

	Val	Glu	Leu	Lys	Ser	Glu	Ala	Asn	Asp	Ala	Val	Asn	Ser	Ser	Thr	Lys
			115					120					125			
5	Glu	Glu	Lys	Gly	Glu	Glu	Lys	Pro	Asp	Thr	Lys	Ser	Thr	Val	Thr	Gly
		130					135					140				
	Glu	Arg	Gln	Ser	Gly	Asp	Gly	Gln	Glu	Ser	Thr	Glu	Pro	Val	Glu	Asn
	145					150					155				160	
	Lys	Val	Gly	Lys	Lys	Gly	Pro	Lys	His	Leu	Asp	Asp	Asp	Glu	Asp	Arg
					165					170					175	
10	Lys	Asn	Pro	Ala	Tyr	Ile	Pro	Arg	Lys	Gly	Leu	Phe	Phe	Glu	His	Asp
			180						185					190		
	Leu	Arg	Gly	Gln	Thr	Gln	Glu	Glu	Val	Arg	Pro	Lys	Gly	Arg	Gln	
		195					200					205				
	Arg	Lys	Leu	Trp	Lys	Asp	Glu	Gly	Arg	Trp	Glu	His	Asp	Lys	Phe	Arg
	210						215				220					
15	Glu	Asp	Glu	Gln	Ala	Pro	Lys	Ser	Arg	Gln	Glu	Leu	Ile	Ala	Leu	Tyr
	225					230					235				240	
	Gly	Tyr	Asp	Ile	Arg	Ser	Ala	His	Asn	Pro	Asp	Asp	Ile	Lys	Pro	Arg
				245					250					255		
	Arg	Ile	Arg	Lys	Pro	Arg	Tyr	Gly	Ser	Pro	Pro	Gln	Arg	Asp	Pro	Asn
			260					265						270		
20	Trp	Asn	Gly	Glu	Arg	Leu	Asn	Lys	Ser	His	Arg	His	Gln	Gly	Leu	Gly
		275					280					285				
	Gly	Thr	Leu	Pro	Pro	Arg	Thr	Phe	Ile	Asn	Arg	Asn	Ala	Ala	Gly	Thr
	290						295					300				
25	Gly	Arg	Met	Ser	Ala	Pro	Arg	Asn	Tyr	Ser	Arg	Ser	Gly	Gly	Phe	Lys
	305					310					315				320	
	Glu	Gly	Arg	Ala	Gly	Phe	Arg	Pro	Val	Glu	Ala	Gly	Gly	Gln	His	Gly
					325					330				335		
	Gly	Arg	Ser	Gly	Glu	Thr	Val	Lys	His	Glu	Ile	Ser	Tyr	Arg	Ser	Arg
			340					345					350			
30	Arg	Leu	Glu	Gln	Thr	Ser	Val	Arg	Asp	Pro	Ser	Pro	Glu	Ala	Asp	Ala
		355						360					365			
	Pro	Val	Leu	Gly	Ser	Pro	Glu	Lys	Glu	Glu	Ala	Ala	Ser	Glu	Pro	Pro
		370					375					380				
	Ala	Ala	Ala	Pro	Asp	Ala	Ala	Pro	Pro	Pro	Pro	Asp	Arg	Pro	Ile	Glu
	385					390					395				400	
35	Lys	Lys	Ser	Tyr	Ser	Arg	Ala	Arg	Arg	Thr	Arg	Thr	Lys	Val	Gly	Asp
				405						410					415	
	Ala	Val	Lys	Leu	Ala	Glu	Glu	Val	Pro	Pro	Pro	Pro	Glu	Gly	Leu	Ile
			420					425					430			
	Pro	Ala	Pro	Pro	Val	Pro	Glu	Thr	Thr	Pro	Thr	Pro	Pro	Thr	Lys	Thr
		435					440					445				
40	Gly	Thr	Trp	Glu	Ala	Pro	Val	Asp	Ser	Ser	Thr	Ser	Gly	Leu	Glu	Gln
	450						455					460				
	Asp	Val	Ala	Gln	Leu	Asn	Ile	Ala	Glu	Gln	Asn	Trp	Ser	Pro	Gly	Gln
	465					470				475					480	
	Pro	Ser	Phe	Leu	Gln	Pro	Arg	Glu	Leu	Arg	Gly	Met	Pro	Asn	His	Ile
45					485					490					495	
	His	Met	Gly	Ala	Gly	Pro	Pro	Pro	Gln	Phe	Asn	Arg	Met	Glu	Glu	Met
			500						505					510		
	Gly	Val	Gln	Gly	Gly	Arg	Ala	Lys	Arg	Tyr	Ser	Ser	Gln	Arg	Gln	Arg
			515					520					525			
50	Pro	Val	Pro	Glu	Pro	Pro	Ala	Pro	Pro	Val	His	Ile	Ser	Ile	Met	Glu
		530					535					540				
	Gly	His	Tyr	Tyr	Asp	Pro	Leu	Gln	Phe	Gln	Gly	Pro	Ile	Tyr	Thr	His
	545					550					555				560	
	Gly	Asp	Ser	Pro	Ala	Pro	Leu	Pro	Pro	Gln	Gly	Met	Leu	Val	Gln	Pro
55					565					570					575	

Gly Met Asn Leu Pro His Pro Gly Leu His Pro His Gln Thr Pro Ala
 580 585 590
 Pro Leu Pro Asn Pro Gly Leu Tyr Pro Pro Pro Val Ser Met Ser Pro
 595 600 605
 Gly Gln Pro Pro Pro Gln Gln Leu Leu Ala Pro Thr Tyr Phe Ser Ala
 610 615 620
 Pro Gly Val Met Asn Phe Gly Asn Pro Ser Tyr Pro Tyr Ala Pro Gly
 625 630 635 640
 Ala Leu Pro Pro Pro Pro Pro Pro His Leu Tyr Pro Asn Thr Gln Ala
 645 650 655
 Pro Ser Gln Val Tyr Gly Gly Val Thr Tyr Tyr Asn Pro Ala Gln Gln
 660 665 670
 Gln Val Gln Pro Lys Pro Ser Pro Pro Arg Arg Thr Pro Gln Pro Val
 675 680 685
 Thr Ile Lys Pro Pro Pro Pro Glu Val Val Ser Arg Gly Ser Ser
 690 695 700

<210> 44

<211> 560

<212> PRT

<213> Homo sapiens

<400> 44

Met Pro Gln Thr Arg Ser Gln Ala Gln Ala Thr Ile Ser Phe Pro Lys
 1 5 10 15
 Arg Lys Leu Ser Arg Ala Leu Asn Lys Ala Lys Asn Ser Ser Asp Ala
 20 25 30
 Lys Leu Glu Pro Thr Asn Val Gln Thr Val Thr Cys Ser Pro Arg Val
 35 40 45
 Lys Ala Leu Pro Leu Ser Pro Arg Lys Arg Leu Gly Asp Asp Asn Leu
 50 55 60
 Cys Asn Thr Pro His Leu Pro Pro Cys Ser Pro Lys Gln Gly Lys
 65 70 75 80
 Lys Glu Asn Gly Pro Pro His Ser His Thr Leu Lys Gly Arg Arg Leu
 85 90 95
 Val Phe Asp Asn Gln Leu Thr Ile Lys Ser Pro Ser Lys Arg Glu Leu
 100 105 110
 Ala Lys Val His Gln Asn Lys Ile Leu Ser Ser Val Arg Lys Ser Gln
 115 120 125
 Glu Ile Thr Thr Asn Ser Glu Gln Arg Cys Pro Leu Lys Lys Glu Ser
 130 135 140
 Ala Cys Val Arg Leu Phe Lys Gln Glu Gly Thr Cys Tyr Gln Gln Ala
 145 150 155 160
 Lys Leu Val Leu Asn Thr Ala Val Pro Asp Arg Leu Pro Ala Arg Glu
 165 170 175
 Arg Glu Met Asp Val Ile Arg Asn Phe Leu Arg Glu His Ile Cys Gly
 180 185 190
 Lys Lys Ala Gly Ser Leu Tyr Leu Ser Gly Ala Pro Gly Thr Gly Lys
 195 200 205
 Thr Ala Cys Leu Ser Arg Ile Leu Gln Asp Leu Lys Lys Glu Leu Lys
 210 215 220
 Gly Phe Lys Thr Ile Met Leu Asn Cys Met Ser Leu Arg Thr Ala Gln
 225 230 235 240

	Ala	Val	Phe	Pro	Ala	Ile	Ala	Gln	Glu	Ile	Cys	Gln	Glu	Glu	Val	Ser
					245					250					255	
5	Arg	Pro	Ala	Gly	Lys	Asp	Met	Met	Arg	Lys	Leu	Glu	Lys	His	Met	Thr
				260					265					270		
	Ala	Glu	Lys	Gly	Pro	Met	Ile	Val	Leu	Val	Leu	Asp	Glu	Met	Asp	Gln
			275					280					285			
	Leu	Asp	Ser	Lys	Gly	Gln	Asp	Val	Leu	Tyr	Thr	Leu	Phe	Glu	Trp	Pro
		290				295					300					
10	Trp	Leu	Ser	Asn	Ser	His	Leu	Val	Leu	Ile	Gly	Ile	Ala	Asn	Thr	Leu
	305					310					315					320
	Asp	Leu	Thr	Asp	Arg	Ile	Leu	Pro	Arg	Leu	Gln	Ala	Arg	Glu	Lys	Cys
				325						330					335	
	Lys	Pro	Gln	Leu	Leu	Asn	Phe	Pro	Pro	Tyr	Thr	Arg	Asn	Gln	Ile	Val
				340					345					350		
15	Thr	Ile	Leu	Gln	Asp	Arg	Leu	Asn	Gln	Val	Ser	Arg	Asp	Gln	Val	Leu
		355					360						365			
	Asp	Asn	Ala	Ala	Val	Gln	Phe	Cys	Ala	Arg	Lys	Val	Ser	Ala	Val	Ser
		370					375					380				
	Gly	Asp	Val	Arg	Lys	Ala	Leu	Asp	Val	Cys	Arg	Arg	Ala	Ile	Glu	Ile
20	385					390					395				400	
	Val	Glu	Ser	Asp	Val	Lys	Ser	Gln	Thr	Ile	Leu	Lys	Pro	Leu	Ser	Glu
				405						410					415	
	Cys	Lys	Ser	Pro	Ser	Glu	Pro	Leu	Ile	Pro	Lys	Arg	Val	Gly	Leu	Ile
				420					425					430		
25	His	Ile	Ser	Gln	Val	Ile	Ser	Glu	Val	Asp	Gly	Asn	Arg	Met	Thr	Leu
		435						440					445			
	Ser	Gln	Glu	Gly	Ala	Gln	Asp	Ser	Phe	Pro	Leu	Gln	Gln	Lys	Ile	Leu
		450					455					460				
	Val	Cys	Ser	Leu	Met	Leu	Leu	Ile	Arg	Gln	Leu	Lys	Ile	Lys	Glu	Val
	465					470					475				480	
30	Thr	Leu	Gly	Lys	Leu	Tyr	Glu	Ala	Tyr	Ser	Lys	Val	Cys	Arg	Lys	Gln
				485						490					495	
	Gln	Val	Ala	Ala	Val	Asp	Gln	Ser	Glu	Cys	Leu	Ser	Leu	Ser	Gly	Leu
			500						505					510		
	Leu	Glu	Ala	Arg	Gly	Ile	Leu	Gly	Leu	Lys	Arg	Asn	Lys	Glu	Thr	Arg
		515						520					525			
35	Leu	Thr	Lys	Val	Phe	Phe	Lys	Ile	Glu	Glu	Lys	Glu	Ile	Glu	His	Ala
		530					535					540				
	Leu	Lys	Asp	Lys	Ala	Leu	Ile	Gly	Asn	Ile	Leu	Ala	Thr	Gly	Leu	Pro
	545					550					555					560

40 <210> 45

<211> 462

<212> PRT

45 <213> Homo sapiens

<400> 45

50	Met	Ala	Ser	Asn	Ser	Ser	Ser	Cys	Pro	Thr	Pro	Gly	Gly	Gly	His	Leu
	1				5					10					15	
	Asn	Gly	Tyr	Pro	Val	Pro	Pro	Tyr	Ala	Phe	Phe	Phe	Pro	Pro	Mat	Leu
				20					25					30		
	Gly	Gly	Leu	Ser	Pro	Pro	Gly	Ala	Leu	Thr	Thr	Leu	Gln	His	Gln	Leu
			35					40					45			

	Pro	Val	Ser	Gly	Tyr	Ser	Thr	Pro	Ser	Pro	Ala	Thr	Ile	Glu	Thr	Gln
	50						55					60				
5	Ser	Ser	Ser	Ser	Glu	Glu	Ile	Val	Pro	Ser	Pro	Pro	Ser	Pro	Pro	Pro
	65				70						75					80
	Leu	Pro	Arg	Ile	Tyr	Lys	Pro	Cys	Phe	Val	Cys	Gln	Asp	Lys	Ser	Ser
					85					90					95	
	Gly	Tyr	His	Tyr	Gly	Val	Ser	Ala	Cys	Glu	Gly	Cys	Lys	Gly	Phe	Phe
				100					105					110		
10	Arg	Arg	Ser	Ile	Gln	Lys	Asn	Met	Val	Tyr	Thr	Cys	His	Arg	Asp	Lys
			115					120					125			
	Asn	Cys	Ile	Ile	Asn	Lys	Val	Thr	Arg	Asn	Arg	Cys	Gln	Tyr	Cys	Arg
		130					135					140				
	Leu	Gln	Lys	Cys	Phe	Glu	Val	Gly	Met	Ser	Lys	Glu	Ser	Val	Arg	Asn
15		145				150					155					160
	Asp	Arg	Asn	Lys	Lys	Lys	Lys	Glu	Val	Pro	Lys	Pro	Glu	Cys	Ser	Glu
					165					170					175	
	Ser	Tyr	Thr	Leu	Thr	Pro	Glu	Val	Gly	Glu	Leu	Ile	Glu	Lys	Val	Arg
				180					185					190		
20	Lys	Ala	His	Gln	Glu	Thr	Phe	Pro	Ala	Leu	Cys	Gln	Leu	Gly	Lys	Tyr
		195						200					205			
	Thr	Thr	Asn	Asn	Ser	Ser	Glu	Gln	Arg	Val	Ser	Leu	Asp	Ile	Asp	Leu
		210					215					220				
	Trp	Asp	Lys	Phe	Ser	Glu	Leu	Ser	Thr	Lys	Cys	Ile	Ile	Lys	Thr	Val
		225				230					235					240
25	Glu	Phe	Ala	Lys	Gln	Leu	Pro	Gly	Phe	Thr	Thr	Leu	Thr	Ile	Ala	Asp
					245					250					255	
	Gln	Ile	Thr	Leu	Leu	Lys	Ala	Ala	Cys	Leu	Asp	Ile	Leu	Ile	Leu	Arg
				260					265					270		
	Ile	Cys	Thr	Arg	Tyr	Thr	Pro	Glu	Gln	Asp	Thr	Met	Thr	Phe	Ser	Asp
30			275					280					285			
	Gly	Leu	Thr	Leu	Asn	Arg	Thr	Gln	Met	His	Asn	Ala	Gly	Phe	Gly	Pro
		290					295					300				
	Leu	Thr	Asp	Leu	Val	Phe	Ala	Phe	Ala	Asn	Gln	Leu	Leu	Pro	Leu	Glu
		305				310					315					320
35	Met	Asp	Asp	Ala	Glu	Thr	Gly	Leu	Leu	Ser	Ala	Ile	Cys	Leu	Ile	Cys
					325					330					335	
	Gly	Asp	Arg	Gln	Asp	Leu	Glu	Gln	Pro	Asp	Arg	Val	Asp	Met	Leu	Gln
				340					345					350		
	Glu	Pro	Leu	Leu	Glu	Ala	Leu	Lys	Val	Tyr	Val	Arg	Lys	Arg	Arg	Pro
		355						360					365			
40	Ser	Arg	Pro	His	Met	Phe	Pro	Lys	Met	Leu	Met	Lys	Ile	Thr	Asp	Leu
		370					375					380				
	Arg	Ser	Ile	Ser	Ala	Lys	Gly	Ala	Glu	Arg	Val	Ile	Thr	Leu	Lys	Met
		385				390					395					400
	Glu	Ile	Pro	Gly	Ser	Met	Pro	Pro	Leu	Ile	Gln	Glu	Met	Leu	Glu	Asn
45					405					410					415	
	Ser	Glu	Gly	Leu	Asp	Thr	Leu	Ser	Gly	Gln	Pro	Gly	Gly	Gly	Gly	Arg
				420					425					430		
	Asp	Gly	Gly	Gly	Leu	Ala	Pro	Pro	Pro	Gly	Ser	Cys	Ser	Pro	Ser	Leu
		435					440					445				
50	Ser	Pro	Ser	Ser	Asn	Arg	Ser	Ser	Pro	Ala	Thr	His	Ser	Pro		
		450					455					460				

<210> 46

<211> 1531

<212> PRT

<213> Homo sapiens

<400> 46

Met	Glu	Val	Ser	Pro	Leu	Gln	Pro	Val	Asn	Glu	Asn	Met	Gln	Val	Asn
1				5					10					15	
Lys	Ile	Lys	Lys	Asn	Glu	Asp	Ala	Lys	Lys	Arg	Leu	Ser	Val	Glu	Arg
			20					25					30		
Ile	Tyr	Gln	Lys	Lys	Thr	Gln	Leu	Glu	His	Ile	Leu	Leu	Arg	Pro	Asp
		35					40					45			
Thr	Tyr	Ile	Gly	Ser	Val	Glu	Leu	Val	Thr	Gln	Gln	Met	Trp	Val	Tyr
	50					55					60				
Asp	Glu	Asp	Val	Gly	Ile	Asn	Tyr	Arg	Glu	Val	Thr	Phe	Val	Pro	Gly
65					70				75						80
Leu	Tyr	Lys	Ile	Phe	Asp	Glu	Ile	Leu	Val	Asn	Ala	Ala	Asp	Asn	Lys
				85					90					95	
Gln	Arg	Asp	Pro	Lys	Met	Ser	Cys	Ile	Arg	Val	Thr	Ile	Asp	Pro	Glu
			100					105					110		
Asn	Asn	Leu	Ile	Ser	Ile	Trp	Asn	Asn	Gly	Lys	Gly	Ile	Pro	Val	Val
		115					120					125			
Glu	His	Lys	Val	Glu	Lys	Met	Tyr	Val	Pro	Ala	Leu	Ile	Phe	Gly	Gln
	130					135					140				
Leu	Leu	Thr	Ser	Ser	Asn	Tyr	Asp	Asp	Asp	Glu	Lys	Lys	Val	Thr	Gly
145					150					155					160
Gly	Arg	Asn	Gly	Tyr	Gly	Ala	Lys	Leu	Cys	Asn	Ile	Phe	Ser	Thr	Lys
				165					170					175	
Phe	Thr	Val	Glu	Thr	Ala	Ser	Arg	Glu	Tyr	Lys	Lys	Met	Phe	Lys	Gln
		180						185					190		
Thr	Trp	Met	Asp	Asn	Met	Gly	Arg	Ala	Gly	Glu	Met	Glu	Leu	Lys	Pro
	195					200						205			
Phe	Asn	Gly	Glu	Asp	Tyr	Thr	Cys	Ile	Thr	Phe	Gln	Pro	Asp	Leu	Ser
	210					215					220				
Lys	Phe	Lys	Met	Gln	Ser	Leu	Asp	Lys	Asp	Ile	Val	Ala	Leu	Met	Val
225					230					235					240
Arg	Arg	Ala	Tyr	Asp	Ile	Ala	Gly	Ser	Thr	Lys	Asp	Val	Lys	Val	Phe
				245					250					255	
Leu	Asn	Gly	Asn	Lys	Leu	Pro	Val	Lys	Gly	Phe	Arg	Ser	Tyr	Val	Asp
		260						265					270		
Met	Tyr	Leu	Lys	Asp	Lys	Leu	Asp	Glu	Thr	Gly	Asn	Ser	Leu	Lys	Val
	275					280						285			
Ile	His	Glu	Gln	Val	Asn	His	Arg	Trp	Glu	Val	Cys	Leu	Thr	Met	Ser
	290					295					300				
Glu	Lys	Gly	Phe	Gln	Gln	Ile	Ser	Phe	Val	Asn	Ser	Ile	Ala	Thr	Ser
305					310					315					320
Lys	Gly	Gly	Arg	His	Val	Asp	Tyr	Val	Ala	Asp	Gln	Ile	Val	Thr	Lys
				325					330					335	
Leu	Val	Asp	Val	Val	Lys	Lys	Lys	Asn	Lys	Gly	Gly	Val	Ala	Val	Lys
		340						345					350		
Ala	His	Gln	Val	Lys	Asn	His	Met	Trp	Ile	Phe	Val	Asn	Ala	Leu	Ile
	355						360					365			
Glu	Asn	Pro	Thr	Phe	Asp	Ser	Gln	Thr	Lys	Glu	Asn	Met	Thr	Leu	Gln
		370					375					380			

Pro Lys Ser Phe Gly Ser Thr Cys Gln Leu Ser Glu Lys Phe Ile Lys
 385 390 395 400
 Ala Ala Ile Gly Cys Gly Ile Val Glu Ser Ile Leu Asn Trp Val Lys
 405 410 415
 Phe Lys Ala Gln Val Gln Leu Asn Lys Lys Cys Ser Ala Val Lys His
 420 425 430
 Asn Arg Ile Lys Gly Ile Pro Lys Leu Asp Asp Ala Asn Asp Ala Gly
 435 440 445
 Gly Arg Asn Ser Thr Glu Cys Thr Leu Ile Leu Thr Glu Gly Asp Ser
 450 455 460
 Ala Lys Thr Leu Ala Val Ser Gly Leu Gly Val Val Gly Arg Asp Lys
 465 470 475 480
 Tyr Gly Val Phe Pro Leu Arg Gly Lys Ile Leu Asn Val Arg Glu Ala
 485 490 495
 Ser His Lys Gln Ile Met Glu Asn Ala Glu Ile Asn Asn Ile Ile Lys
 500 505 510
 Ile Val Gly Leu Gln Tyr Lys Lys Asn Tyr Glu Asp Glu Asp Ser Leu
 515 520 525
 Lys Thr Leu Arg Tyr Gly Lys Ile Met Ile Met Thr Asp Gln Asp Gln
 530 535 540
 Asp Gly Ser His Ile Lys Gly Leu Leu Ile Asn Phe Ile His His Asn
 545 550 555 560
 Trp Pro Ser Leu Leu Arg His Arg Phe Leu Glu Glu Phe Ile Thr Pro
 565 570 575
 Ile Val Lys Val Ser Lys Asn Lys Gln Glu Met Ala Phe Tyr Ser Leu
 580 585 590
 Pro Glu Phe Glu Glu Trp Lys Ser Ser Thr Pro Asn His Lys Lys Trp
 595 600 605
 Lys Val Lys Tyr Tyr Lys Gly Leu Gly Thr Ser Thr Ser Lys Glu Ala
 610 615 620
 Lys Gln Tyr Phe Ala Asp Met Lys Arg His Arg Ile Gln Phe Lys Tyr
 625 630 635 640
 Ser Gly Pro Glu Asp Asp Ala Ala Ile Ser Leu Ala Phe Ser Lys Lys
 645 650 655
 Gln Ile Asp Asp Arg Lys Glu Trp Leu Thr Asn Phe Met Glu Asp Arg
 660 665 670
 Arg Gln Arg Lys Leu Leu Gly Leu Pro Glu Asp Tyr Leu Tyr Gly Gln
 675 680 685
 Thr Thr Thr Tyr Leu Thr Tyr Asn Asp Phe Ile Asn Lys Glu Leu Ile
 690 695 700
 Leu Phe Ser Asn Ser Asp Asn Glu Arg Ser Ile Pro Ser Met Val Asp
 705 710 715 720
 Gly Leu Lys Pro Gly Gln Arg Lys Val Leu Phe Thr Cys Phe Lys Arg
 725 730 735
 Asn Asp Lys Arg Glu Val Lys Val Ala Gln Leu Ala Gly Ser Val Ala
 740 745 750
 Glu Met Ser Ser Tyr His His Gly Glu Met Ser Leu Met Met Thr Ile
 755 760 765
 Ile Asn Leu Ala Gln Asn Phe Val Gly Ser Asn Asn Leu Asn Leu Leu
 770 775 780
 Gln Pro Ile Gly Gln Phe Gly Thr Arg Leu His Gly Gly Lys Asp Ser
 785 790 795 800
 Ala Ser Pro Arg Tyr Ile Phe Thr Met Leu Ser Ser Leu Ala Arg Leu
 805 810 815
 Leu Phe Pro Pro Lys Asp Asp His Thr Leu Lys Phe Leu Tyr Asp Asp
 820 825 830
 Asn Gln Arg Val Glu Pro Glu Trp Tyr Ile Pro Ile Ile Pro Met Val
 835 840 845

Leu Ile Asn Gly Ala Glu Gly Ile Gly Thr Gly Trp Ser Cys Lys Ile
 850 855 860
 Pro Asn Phe Asp Val Arg Glu Ile Val Asn Asn Ile Arg Arg Leu Met
 865 870 875 880
 5 Asp Gly Glu Glu Pro Leu Pro Met Leu Pro Ser Tyr Lys Asn Phe Lys
 885 890 895
 Gly Thr Ile Glu Glu Leu Ala Pro Asn Gln Tyr Val Ile Ser Gly Glu
 900 905 910
 Val Ala Ile Leu Asn Ser Thr Thr Ile Glu Ile Ser Glu Leu Pro Val
 915 920 925
 10 Arg Thr Trp Thr Gln Thr Tyr Lys Glu Gln Val Leu Glu Pro Met Leu
 930 935 940
 Asn Gly Thr Glu Lys Thr Pro Pro Leu Ile Thr Asp Tyr Arg Glu Tyr
 945 950 955 960
 15 His Thr Asp Thr Thr Val Lys Phe Val Val Lys Met Thr Glu Glu Lys
 965 970 975
 Leu Ala Glu Ala Glu Arg Val Gly Leu His Lys Val Phe Lys Leu Gln
 980 985 990
 Thr Ser Leu Thr Cys Asn Ser Met Val Leu Phe Asp His Val Gly Cys
 995 1000 1005
 20 Leu Lys Lys Tyr Asp Thr Val Leu Asp Ile Leu Arg Asp Phe Phe
 1010 1015 1020
 Glu Leu Arg Leu Lys Tyr Tyr Gly Leu Arg Lys Glu Trp Leu Leu
 1025 1030 1035
 Gly Met Leu Gly Ala Glu Ser Ala Lys Leu Asn Asn Gln Ala Arg
 1040 1045 1050
 25 Phe Ile Leu Glu Lys Ile Asp Gly Lys Ile Ile Ile Glu Asn Lys
 1055 1060 1065
 Pro Lys Lys Glu Leu Ile Lys Val Leu Ile Gln Arg Gly Tyr Asp
 1070 1075 1080
 Ser Asp Pro Val Lys Ala Trp Lys Glu Ala Gln Gln Lys Val Pro
 1085 1090 1095
 30 Asp Glu Glu Glu Asn Glu Glu Ser Asp Asn Glu Lys Glu Thr Glu
 1100 1105 1110
 Lys Ser Asp Ser Val Thr Asp Ser Gly Pro Thr Phe Asn Tyr Leu
 1115 1120 1125
 35 Leu Asp Met Pro Leu Trp Tyr Leu Thr Lys Glu Lys Lys Asp Glu
 1130 1135 1140
 Leu Cys Arg Leu Arg Asn Glu Lys Glu Gln Glu Leu Asp Thr Leu
 1145 1150 1155
 Lys Arg Lys Ser Pro Ser Asp Leu Trp Lys Glu Asp Leu Ala Thr
 1160 1165 1170
 40 Phe Ile Glu Glu Leu Glu Ala Val Glu Ala Lys Glu Lys Gln Asp
 1175 1180 1185
 Glu Gln Val Gly Leu Pro Gly Lys Gly Gly Lys Ala Lys Gly Lys
 1190 1195 1200
 Lys Thr Gln Met Ala Glu Val Leu Pro Ser Pro Arg Gly Gln Arg
 1205 1210 1215
 45 Val Ile Pro Arg Ile Thr Ile Glu Met Lys Ala Glu Ala Glu Lys
 1220 1225 1230
 Lys Asn Lys Lys Lys Ile Lys Asn Glu Asn Thr Glu Gly Ser Pro
 1235 1240 1245
 50 Gln Glu Asp Gly Val Glu Leu Glu Gly Leu Lys Gln Arg Leu Glu
 1250 1255 1260
 Lys Lys Gln Lys Arg Glu Pro Gly Thr Lys Thr Lys Lys Gln Thr
 1265 1270 1275
 Thr Leu Ala Phe Lys Pro Ile Lys Lys Gly Lys Lys Arg Asn Pro
 1280 1285 1290

Trp Ser Asp Ser Glu Ser Asp Arg Ser Ser Asp Glu Ser Asn Phe
 1295 1300 1305
 Asp Val Pro Pro Arg Glu Thr Glu Pro Arg Arg Ala Ala Thr Lys
 1310 1315 1320
 5 Thr Lys Phe Thr Met Asp Leu Asp Ser Asp Glu Asp Phe Ser Asp
 1325 1330 1335
 Phe Asp Glu Lys Thr Asp Asp Glu Asp Phe Val Pro Ser Asp Ala
 1340 1345 1350
 10 Ser Pro Pro Lys Thr Lys Thr Ser Pro Lys Leu Ser Asn Lys Glu
 1355 1360 1365
 Leu Lys Pro Gln Lys Ser Val Val Ser Asp Leu Glu Ala Asp Asp
 1370 1375 1380
 Val Lys Gly Ser Val Pro Leu Ser Ser Ser Pro Pro Ala Thr His
 1385 1390 1395
 15 Phe Pro Asp Glu Thr Glu Ile Thr Asn Pro Val Pro Lys Lys Asn
 1400 1405 1410
 Val Thr Val Lys Lys Thr Ala Ala Lys Ser Gln Ser Ser Thr Ser
 1415 1420 1425
 Thr Thr Gly Ala Lys Lys Arg Ala Ala Pro Lys Gly Thr Lys Arg
 1430 1435 1440
 20 Asp Pro Ala Leu Asn Ser Gly Val Ser Gln Lys Pro Asp Pro Ala
 1445 1450 1455
 Lys Thr Lys Asn Arg Arg Lys Arg Lys Pro Ser Thr Ser Asp Asp
 1460 1465 1470
 Ser Asp Ser Asn Phe Glu Lys Ile Val Ser Lys Ala Val Thr Ser
 1475 1480 1485
 25 Lys Lys Ser Lys Gly Glu Ser Asp Asp Phe His Met Asp Phe Asp
 1490 1495 1500
 Ser Ala Val Ala Pro Arg Ala Lys Ser Val Arg Ala Lys Lys Pro
 1505 1510 1515
 30 Ile Lys Tyr Leu Glu Glu Ser Asp Glu Asp Asp Leu Phe
 1520 1525 1530

<210> 47

<211> 258

<212> PRT

<213> Homo sapiens

<400> 47

Met Leu Pro Leu Cys Leu Val Ala Ala Leu Leu Leu Ala Ala Gly Pro
 1 5 10 15
 45 Gly Pro Ser Leu Gly Asp Glu Ala Ile His Cys Pro Pro Cys Ser Glu
 20 25 30
 Glu Lys Leu Ala Arg Cys Arg Pro Pro Val Gly Cys Glu Glu Leu Val
 35 40 45
 Arg Glu Pro Gly Cys Gly Cys Cys Ala Thr Cys Ala Leu Gly Leu Gly
 50 55 60
 50 Met Pro Cys Gly Val Tyr Thr Pro Arg Cys Gly Ser Gly Leu Arg Cys
 65 70 75 80
 Tyr Pro Pro Arg Gly Val Glu Lys Pro Leu His Thr Leu Met His Gly
 85 90 95
 Gln Gly Val Cys Met Glu Leu Ala Glu Ile Glu Ala Ile Gln Glu Ser
 100 105 110

Leu Gln Pro Ser Asp Lys Asp Glu Gly Asp His Pro Asn Asn Ser Phe
 115 120 125
 Ser Pro Cys Ser Ala His Asp Arg Arg Cys Leu Gln Lys His Phe Ala
 130 135 140
 Lys Ile Arg Asp Arg Ser Thr Ser Gly Gly Lys Met Lys Val Asn Gly
 145 150 155 160
 Ala Pro Arg Glu Asp Ala Arg Pro Val Pro Gln Gly Ser Cys Gln Ser
 165 170 175
 Glu Leu His Arg Ala Leu Glu Arg Leu Ala Ala Ser Gln Ser Arg Thr
 180 185 190
 His Glu Asp Leu Tyr Ile Ile Pro Ile Pro Asn Cys Asp Arg Asn Gly
 195 200 205
 Asn Phe His Pro Lys Gln Cys His Pro Ala Leu Asp Gly Gln Arg Gly
 210 215 220
 Lys Cys Trp Cys Val Asp Arg Lys Thr Gly Val Lys Leu Pro Gly Gly
 225 230 235 240
 Leu Glu Pro Lys Gly Glu Leu Asp Cys His Gln Leu Ala Asp Ser Phe
 245 250 255
 Arg Glu

<210> 48

<211> 378

<212> PRT

<213> Homo sapiens

<400> 48

Met Asp Leu Gly Lys Pro Met Lys Ser Val Leu Val Val Ala Leu Leu
 1 5 10 15
 Val Ile Phe Gln Val Cys Leu Cys Gln Asp Glu Val Thr Asp Asp Tyr
 20 25 30
 Ile Gly Asp Asn Thr Thr Val Asp Tyr Thr Leu Phe Glu Ser Leu Cys
 35 40 45
 Ser Lys Lys Asp Val Arg Asn Phe Lys Ala Trp Phe Leu Pro Ile Met
 50 55 60
 Tyr Ser Ile Ile Cys Phe Val Gly Leu Leu Gly Asn Gly Leu Val Val
 65 70 75 80
 Leu Thr Tyr Ile Tyr Phe Lys Arg Leu Lys Thr Met Thr Asp Thr Tyr
 85 90 95
 Leu Leu Asn Leu Ala Val Ala Asp Ile Leu Phe Leu Leu Thr Leu Pro
 100 105 110
 Phe Trp Ala Tyr Ser Ala Ala Lys Ser Trp Val Phe Gly Val His Phe
 115 120 125
 Cys Lys Leu Ile Phe Ala Ile Tyr Lys Met Ser Phe Phe Ser Gly Met
 130 135 140
 Leu Leu Leu Leu Cys Ile Ser Ile Asp Arg Tyr Val Ala Ile Val Gln
 145 150 155 160
 Ala Val Ser Ala His Arg His Arg Ala Arg Val Leu Leu Ile Ser Lys
 165 170 175
 Leu Ser Cys Val Gly Ile Trp Ile Leu Ala Thr Val Leu Ser Ile Pro
 180 185 190
 Glu Leu Leu Tyr Ser Asp Leu Gln Arg Ser Ser Ser Glu Gln Ala Met
 195 200 205

Arg Cys Ser Leu Ile Thr Glu His Val Glu Ala Phe Ile Thr Ile Gln
 210 215 220
 Val Ala Gln Met Val Ile Gly Phe Leu Val Pro Leu Leu Ala Met Ser
 225 230 235 240
 Phe Cys Tyr Leu Val Ile Ile Arg Thr Leu Leu Gln Ala Arg Asn Phe
 245 250 255
 Glu Arg Asn Lys Ala Ile Lys Val Ile Ile Ala Val Val Val Val Phe
 260 265 270
 Ile Val Phe Gln Leu Pro Tyr Asn Gly Val Val Leu Ala Gln Thr Val
 275 280 285
 Ala Asn Phe Asn Ile Thr Ser Ser Thr Cys Glu Leu Ser Lys Gln Leu
 290 295 300
 Asn Ile Ala Tyr Asp Val Thr Tyr Ser Leu Ala Cys Val Arg Cys Cys
 305 310 315 320
 Val Asn Pro Phe Leu Tyr Ala Phe Ile Gly Val Lys Phe Arg Asn Asp
 325 330 335
 Leu Phe Lys Leu Phe Lys Asp Leu Gly Cys Leu Ser Gln Glu Gln Leu
 340 345 350
 Arg Gln Trp Ser Ser Cys Arg His Ile Arg Arg Ser Ser Met Ser Val
 355 360 365
 Glu Ala Glu Thr Thr Thr Thr Phe Ser Pro
 370 375

<210> 49

<211> 411

<212> PRT

<213> Homo sapiens

<400> 49

Met Ser Lys Arg Pro Ser Tyr Ala Pro Pro Pro Thr Pro Ala Pro Ala
 1 5 10 15
 Thr Gln Met Pro Ser Thr Pro Gly Phe Val Gly Tyr Asn Pro Tyr Ser
 20 25 30
 His Leu Ala Tyr Asn Asn Tyr Arg Leu Gly Gly Asn Pro Ser Thr Asn
 35 40 45
 Ser Arg Val Thr Ala Ser Ser Gly Ile Thr Ile Pro Lys Pro Pro Lys
 50 55 60
 Pro Pro Asp Lys Pro Leu Met Pro Tyr Met Arg Tyr Ser Arg Lys Val
 65 70 75 80
 Trp Asp Gln Val Lys Ala Ser Asn Pro Asp Leu Lys Leu Trp Glu Ile
 85 90 95
 Gly Lys Ile Ile Gly Gly Met Trp Arg Asp Leu Thr Asp Glu Glu Lys
 100 105 110
 Gln Glu Tyr Leu Asn Glu Tyr Glu Ala Glu Lys Ile Glu Tyr Asn Glu
 115 120 125
 Ser Met Lys Ala Tyr His Asn Ser Pro Ala Tyr Leu Ala Tyr Ile Asn
 130 135 140
 Ala Lys Ser Arg Ala Glu Ala Ala Leu Glu Glu Glu Ser Arg Gln Arg
 145 150 155 160
 Gln Ser Arg Met Glu Lys Gly Glu Pro Tyr Met Ser Ile Gln Pro Ala
 165 170 175
 Glu Asp Pro Asp Tyr Asp Asp Gly Phe Ser Met Lys His Thr Ala
 180 185 190

Thr Ala Arg Phe Gln Arg Asn His Arg Leu Ile Ser Glu Ile Leu Ser
 195 200 205
 Glu Ser Val Val Pro Asp Val Arg Ser Val Val Thr Thr Ala Arg Met
 210 215 220
 Gln Val Leu Lys Arg Gln Val Gln Ser Leu Met Val His Gln Arg Lys
 225 230 235 240
 Leu Glu Ala Glu Leu Leu Gln Ile Glu Glu Arg His Gln Glu Lys Lys
 245 250 255
 Arg Lys Phe Leu Glu Ser Thr Asp Ser Phe Asn Asn Glu Leu Lys Arg
 260 265 270
 Leu Cys Gly Leu Lys Val Glu Val Asp Met Glu Lys Ile Ala Ala Glu
 275 280 285
 Ile Ala Gln Ala Glu Glu Gln Ala Arg Lys Arg Gln Glu Glu Arg Glu
 290 295 300
 Lys Glu Ala Ala Glu Gln Ala Glu Arg Ser Gln Ser Ser Ile Val Pro
 305 310 315 320
 Glu Glu Glu Gln Ala Ala Asn Lys Gly Glu Glu Lys Lys Asp Asp Glu
 325 330 335
 Asn Ile Pro Met Glu Thr Glu Glu Thr His Leu Glu Glu Thr Thr Glu
 340 345 350
 Ser Gln Gln Asn Gly Glu Glu Gly Thr Ser Thr Pro Glu Asp Lys Glu
 355 360 365
 Ser Gly Gln Glu Gly Val Asp Ser Met Ala Glu Glu Gly Thr Ser Asp
 370 375 380
 Ser Asn Thr Gly Ser Glu Ser Asn Ser Ala Thr Val Glu Glu Pro Pro
 385 390 395 400
 Thr Asp Pro Ile Pro Glu Asp Glu Lys Lys Glu
 405 410

<210> 50

<211> 593

<212> PRT

<213> Homo sapiens

<400> 50

Met Ser Val Arg Tyr Ser Ser Ser Lys His Tyr Ser Ser Ser Arg Ser
 1 5 10 15
 Gly Gly Gly Gly Gly Gly Gly Gly Cys Gly Gly Gly Gly Gly Val Ser
 20 25 30
 Ser Leu Arg Ile Ser Ser Ser Lys Gly Ser Leu Gly Gly Gly Phe Ser
 35 40 45
 Ser Gly Gly Phe Ser Gly Gly Ser Phe Ser Arg Gly Ser Ser Gly Gly
 50 55 60
 Gly Cys Phe Gly Gly Ser Ser Gly Gly Tyr Gly Gly Leu Gly Gly Phe
 65 70 75 80
 Gly Gly Gly Ser Phe His Gly Ser Tyr Gly Ser Ser Ser Phe Gly Gly
 85 90 95
 Ser Tyr Gly Gly Ser Phe Gly Gly Gly Asn Phe Gly Gly Gly Ser Phe
 100 105 110
 Gly Gly Gly Ser Phe Gly Gly Gly Gly Phe Gly Gly Gly Phe Gly
 115 120 125
 Gly Gly Phe Gly Gly Gly Phe Gly Gly Asp Gly Gly Leu Leu Ser Gly
 130 135 140

Asn Glu Lys Val Thr Met Gln Asn Leu Asn Asp Arg Leu Ala Ser Tyr
 145 150 155 160
 Leu Asp Lys Val Arg Ala Leu Glu Glu Ser Asn Tyr Glu Leu Glu Gly
 165 170 175
 5 Lys Ile Lys Glu Trp Tyr Glu Lys His Gly Asn Ser His Gln Gly Glu
 180 185 190
 Pro Arg Asp Tyr Ser Lys Tyr Tyr Lys Thr Ile Asp Asp Leu Lys Asn
 195 200 205
 10 Gln Ile Leu Asn Leu Thr Thr Asp Asn Ala Asn Ile Leu Leu Gln Ile
 210 215 220
 Asp Asn Ala Arg Leu Ala Ala Asp Asp Phe Arg Leu Lys Tyr Glu Asn
 225 230 235 240
 Glu Val Ala Leu Arg Gln Ser Val Glu Ala Asp Ile Asn Gly Leu Arg
 245 250 255
 15 Arg Val Leu Asp Glu Leu Thr Leu Thr Lys Ala Asp Leu Glu Met Gln
 260 265 270
 Ile Glu Ser Leu Thr Glu Glu Leu Ala Tyr Leu Lys Lys Asn His Glu
 275 280 285
 Glu Glu Met Lys Asp Leu Arg Asn Val Ser Thr Gly Asp Val Asn Val
 290 295 300
 20 Glu Met Asn Ala Ala Pro Gly Val Asp Leu Thr Gln Leu Leu Asn Asn
 305 310 315 320
 Met Arg Ser Gln Tyr Glu Gln Leu Ala Glu Gln Asn Arg Lys Asp Ala
 325 330 335
 Glu Ala Trp Phe Asn Glu Lys Ser Lys Glu Leu Thr Thr Glu Ile Asp
 340 345 350
 25 Asn Asn Ile Glu Gln Ile Ser Ser Tyr Lys Ser Glu Ile Thr Glu Leu
 355 360 365
 Arg Arg Asn Val Gln Ala Leu Glu Ile Glu Leu Gln Ser Gln Leu Ala
 370 375 380
 30 Leu Lys Gln Ser Leu Glu Ala Ser Leu Ala Glu Thr Glu Gly Arg Tyr
 385 390 395 400
 Cys Val Gln Leu Ser Gln Ile His Ala Gln Ile Ser Ala Leu Glu Glu
 405 410 415
 Gln Leu Gln Gln Ile Arg Ala Glu Thr Glu Cys Gln Asn Thr Glu Tyr
 420 425 430
 35 Gln Gln Leu Leu Asp Ile Lys Ile Arg Leu Glu Asn Glu Ile Gln Thr
 435 440 445
 Tyr Arg Ser Leu Leu Glu Gly Glu Gly Ser Ser Gly Gly Gly Arg
 450 455 460
 40 Gly Gly Gly Ser Phe Gly Gly Gly Tyr Gly Gly Gly Ser Ser Gly Gly
 465 470 475 480
 Gly Ser Ser Gly Gly Gly Tyr Gly Gly Gly His Gly Gly Ser Ser Gly
 485 490 495
 Gly Gly Tyr Gly Gly Gly Ser Ser Gly Gly Gly Ser Ser Gly Gly
 500 505 510
 45 Tyr Gly Gly Gly Ser Ser Ser Gly Gly His Gly Gly Gly Ser Ser Ser
 515 520 525
 Gly Gly His Gly Gly Ser Ser Ser Gly Gly Tyr Gly Gly Gly Ser Ser
 530 535 540
 Gly Gly Gly Gly Gly Gly Tyr Gly Gly Gly Ser Ser Gly Gly Gly Ser
 545 550 555 560
 50 Ser Ser Gly Gly Gly Tyr Gly Gly Gly Ser Ser Ser Gly Gly His Lys
 565 570 575
 Ser Ser Ser Ser Gly Ser Val Gly Glu Ser Ser Ser Lys Gly Pro Arg
 580 585 590
 Tyr

<210> 51

<211> 494

<212> PRT

<213> Homo sapiens

<400> 51

Met Asp Leu Ser Asn Asn Thr Met Ser Leu Ser Val Arg Thr Pro Gly
 1 5 10 15
 Leu Ser Arg Arg Leu Ser Ser Gln Ser Val Ile Gly Arg Pro Arg Gly
 20 25 30
 Met Ser Ala Ser Ser Val Gly Ser Gly Tyr Gly Gly Ser Ala Phe Gly
 35 40 45
 Phe Gly Ala Ser Cys Gly Gly Gly Phe Ser Ala Ala Ser Met Phe Gly
 50 55 60
 Ser Ser Ser Gly Phe Gly Gly Gly Ser Gly Ser Ser Met Ala Gly Gly
 65 70 75 80
 Leu Gly Ala Gly Tyr Gly Arg Ala Leu Gly Gly Gly Ser Phe Gly Gly
 85 90 95
 Leu Gly Met Gly Phe Gly Gly Ser Pro Gly Gly Gly Ser Leu Gly Ile
 100 105 110
 Leu Ser Gly Asn Asp Gly Gly Leu Leu Ser Gly Ser Glu Lys Glu Thr
 115 120 125
 Met Gln Asn Leu Asn Asp Arg Leu Ala Ser Tyr Leu Asp Lys Val Arg
 130 135 140
 Ala Leu Glu Glu Ala Asn Thr Glu Leu Glu Asn Lys Ile Arg Glu Trp
 145 150 155 160
 Tyr Glu Thr Arg Gly Thr Gly Thr Ala Asp Ala Ser Gln Ser Asp Tyr
 165 170 175
 Ser Lys Tyr Tyr Pro Leu Ile Glu Asp Leu Arg Asn Lys Ile Ile Ser
 180 185 190
 Ala Ser Ile Gly Asn Ala Gln Leu Leu Leu Gln Ile Asp Asn Ala Arg
 195 200 205
 Leu Ala Ala Glu Asp Phe Arg Met Lys Tyr Glu Asn Glu Leu Ala Leu
 210 215 220
 Arg Gln Gly Val Glu Ala Asp Ile Asn Gly Leu Arg Arg Val Leu Asp
 225 230 235 240
 Glu Leu Thr Leu Thr Arg Thr Asp Leu Glu Met Gln Ile Glu Ser Leu
 245 250 255
 Asn Glu Glu Leu Ala Tyr Met Lys Lys Asn His Glu Asp Glu Leu Gln
 260 265 270
 Ser Phe Arg Val Gly Gly Pro Gly Glu Val Ser Val Glu Met Asp Ala
 275 280 285
 Ala Pro Gly Val Asp Leu Thr Arg Leu Leu Asn Asp Met Arg Ala Gln
 290 295 300
 Tyr Glu Thr Ile Ala Glu Gln Asn Arg Lys Asp Ala Glu Ala Trp Phe
 305 310 315 320
 Ile Glu Lys Ser Gly Glu Leu Arg Lys Glu Ile Ser Thr Asn Thr Glu
 325 330 335
 Gln Leu Gln Ser Ser Lys Ser Glu Val Thr Asp Leu Arg Arg Ala Phe
 340 345 350
 Gln Asn Leu Glu Ile Glu Leu Gln Ser Gln Leu Ala Met Lys Lys Ser
 355 360 365
 Leu Glu Asp Ser Leu Ala Glu Ala Glu Gly Asp Tyr Cys Ala Gln Leu
 370 375 380

Ser Gln Val Gln Gln Leu Ile Ser Asn Leu Glu Ala Gln Leu Leu Gln
 385 390 395 400
 Val Arg Ala Asp Ala Glu Arg Gln Asn Val Asp His Gln Arg Leu Leu
 405 410 415
 Asn Val Lys Ala Arg Leu Glu Leu Glu Ile Glu Thr Tyr Arg Arg Leu
 420 425 430
 Leu Asp Gly Glu Ala Gln Gly Asp Gly Leu Glu Glu Ser Leu Phe Val
 435 440 445
 Thr Asp Ser Lys Ser Gln Ala Gln Ser Thr Asp Ser Ser Lys Asp Pro
 450 455 460
 Thr Lys Thr Arg Lys Ile Lys Thr Val Val Gln Glu Met Val Asn Gly
 465 470 475 480
 Glu Val Val Ser Ser Gln Val Gln Glu Ile Glu Glu Leu Met
 485 490

<210> 52

<211> 361

<212> PRT

<213> Homo sapiens

<400> 52

Cys Asn Trp Phe Cys Glu Gly Ser Phe Asn Gly Ser Glu Lys Glu Thr
 1 5 10 15
 Met Gln Phe Leu Asn Asp Arg Leu Ala Ser Tyr Leu Glu Lys Val Arg
 20 25 30
 His Val Glu Arg Asp Asn Ala Glu Leu Glu Asn Leu Ile Arg Glu Arg
 35 40 45
 Ser Gln Gln Gln Glu Pro Leu Leu Cys Pro Ser Tyr Gln Ser Tyr Phe
 50 55 60
 Lys Thr Ile Glu Glu Leu Gln Gln Lys Ile Leu Cys Ser Lys Ser Glu
 65 70 75 80
 Asn Ala Arg Leu Val Val Gln Ile Asp Asn Ala Lys Leu Ala Ala Asp
 85 90 95
 Asp Phe Arg Thr Lys Tyr Gln Thr Glu Gln Ser Leu Arg Gln Leu Val
 100 105 110
 Glu Ser Asp Ile Asn Ser Leu Arg Arg Ile Leu Asp Glu Leu Thr Leu
 115 120 125
 Cys Arg Ser Asp Leu Glu Ala Gln Met Glu Ser Leu Lys Glu Glu Leu
 130 135 140
 Leu Ser Leu Lys Gln Asn His Glu Gln Glu Val Asn Thr Leu Arg Cys
 145 150 155 160
 Gln Leu Gly Asp Arg Leu Asn Val Glu Val Asp Ala Ala Pro Ala Val
 165 170 175
 Asp Leu Asn Gln Val Leu Asn Glu Thr Arg Asn Gln Tyr Glu Ala Leu
 180 185 190
 Val Glu Thr Asn Arg Arg Glu Val Glu Gln Trp Phe Ala Thr Gln Thr
 195 200 205
 Glu Glu Leu Asn Lys Gln Val Val Ser Ser Ser Glu Gln Leu Gln Ser
 210 215 220
 Tyr Gln Ala Glu Ile Ile Glu Leu Arg Arg Thr Val Asn Ala Leu Glu
 225 230 235 240
 Ile Glu Leu Gln Ala Gln His Asn Leu Arg Tyr Ser Leu Glu Asn Thr
 245 250 255

Leu Thr Glu Ser Glu Ala Arg Tyr Ser Ser Gln Leu Ser Gln Val Gln
 260 265 270
 Ser Leu Ile Thr Asn Val Glu Ser Gln Leu Ala Glu Ile Arg Ser Asp
 275 280 285
 Leu Glu Arg Gln Asn Gln Glu Tyr Gln Val Leu Leu Asp Val Arg Ala
 290 295 300
 Arg Leu Glu Cys Glu Ile Asn Thr Tyr Arg Ser Leu Leu Glu Ser Glu
 305 310 315 320
 Asp Cys Lys Leu Pro Ser Asn Pro Cys Ala Thr Thr Asn Ala Cys Glu
 325 330 335
 Lys Pro Ile Gly Ser Cys Val Thr Asn Pro Cys Gly Pro Arg Ser Arg
 340 345 350
 Cys Gly Pro Cys Asn Thr Phe Gly Tyr
 355 360

<210> 53

<211> 3282

<212> DNA

<213> Homo sapiens

<400> 53

atgaaggaga	tggtaggagg	ctgctgcgta	tgcttcggacg	agaggggctg	ggccgagaaac	60
ccgctgggtct	actgcgatgg	gcaacgcgtgc	agcgtggccg	tccaccaagc	ttgctatggc	120
atcgttcagg	tgccaacggg	accctgggttc	tgccggaaat	gtgaatctca	ggagcgagca	180
gccaggggtga	ggtgtgagct	gtgcccacac	aaagacgggg	cattgaagag	gactgataat	240
ggaggctggg	cacacgtggt	gtgtgccctc	tacatccocg	aggtgcaatt	tgccaacgtg	300
ctcaccatgg	agcccatcgt	gctgcagtac	gtgcctcatg	atcgcttcaa	caagacctgt	360
tacatctgcg	aggagacggg	ccgggagagc	aaggoggcct	cgggagcctg	catgacctgt	420
aaccgcocatg	gatgtcgaca	agctttccac	gtcacctgtg	cccaaatggc	aggcttgctg	480
tgtgaggaag	aagtgtctga	ggtggacaac	gtcaagtact	gcggctactg	caaataccac	540
ttcagcaaga	tgaagacatc	ccggcagcagc	agcgggggag	gcggaggagg	cgctggaggga	600
ggagggtggca	gcattggggg	aggtggcagt	ggtttctcat	ctggggaggag	aagccgggtca	660
gcctcaccat	ccacgcagca	ggagaagcac	cccacccacc	acgagagggg	ccagaagaag	720
agtcgaaagc	acaaagaacg	ccttaagcag	aagcacaaga	agcggcctga	gtcgcccccc	780
agcatcctca	ccccgcctgt	ggtccccact	gtgacaagg	totcctcctc	ggcttctctc	840
tcctccccacc	acgaggccag	cacgcaggag	acctctgaga	gcagcaggga	gtcaaagggg	900
aaaaagtctt	ccagccatag	cctgagtcac	aaagggaaga	aactgagcag	tgggaaaggt	960
gtgagcagtt	ttacctccgc	ctcctctctc	tcctcctcct	cttcctcctc	ctctgggggg	1020
cccttccagc	ctgcagtctc	gtccctgcag	agctccccctg	actctctctg	attccccaag	1080
ctggagcagc	cagaggagga	caagtactcc	aagcccacag	cccccgcccc	ttcagccctc	1140
ccttctccct	cagctcccca	gccccccaag	gctgaccttt	ttgagcagaa	ggtggtcttc	1200
tctggctttg	ggcccatcat	gcgcttctcc	accaccacct	ccagctcagg	ccggggcccg	1260
gcgccctccc	ctggggacta	taagtctccc	cacgtcacgg	ggtctggggc	ctcggcaggc	1320
acccacaaac	ggtgcccgc	actgagtgc	accctgtgc	ctgctgatga	gacctctgag	1380
acaggccctga	aggagaagaa	gcacaaagcc	agcaagagga	gccgccatgg	gccaggccgt	1440
cccgaaggga	gccggaacaa	ggagggcact	gggggcccag	ctgccccatc	cttgcccagt	1500
gccagctgg	ctggctttac	cgccactgct	gcctcaccct	tctctggagg	ttccctggtc	1560
agctccggcc	tgagggtct	gtcctcccca	acctttgggc	cttctgggag	cttgcccagc	1620
ttgagcctgg	agtccccctt	actaggggca	ggcatctaca	ccagtaataa	ggaccccatc	1680
tcccacagt	gcgggatgct	gcgggctgtc	tgacgacccc	ctctctcctc	cagcctcctg	1740
gggccccccag	ggacctcggc	cctgccccgc	ctcagccgct	ccccgttcac	cagcaccctc	1800
ccctcctctt	ctgctcttat	ctocaccact	caggtgtttt	ctctggctgg	ctctaccttt	1860
agcctccctt	ctaccacat	ctttggaacc	cccatgggtg	ccgttaatcc	cctcctctcc	1920
caagctgaga	gcagccacac	agagccagac	ctggaggact	gcagcttccg	gtgtcggggg	1980

5 acctcccctc aggagagtct gtottccatg tcccccatca gcagcctccc cgoactcttc 2040
 gaccagacag cctctgcacc ctgtgggggc ggccagtttag acccgggggc cccagggagc 2100
 actaacatgg agcagcttct ggagaagcag ggagcagggg aggcggcggt caacatcgtg 2160
 gagatgctga aggcgctgca cgcgctgcag aaggagaacc agcggctgca agagcagatc 2220
 ctgagcctga cggccaaaaa ggagcggctg cagattctca acgtgcagct ctctgtgccc 2280
 ttccctgccc tgctgtctgc cctgcctgcc gccaacggcc ctgtccctgg gccctatggc 2340
 ctgctccccc aagcggggag cagcgactcc ttgagcacca gcaagagccc tccgggaaaag 2400
 agcagcctog gcctggacaa ctgcgtgtcc atttcttctg aggaccacaa ctccaggtgc 2460
 ccgagccgca gcagctcgtc gctgtccttc cacagcacgc cccaccgct gccctcctc 2520
 10 cagcagagcc ctgccactct gcccctggcc ctgcctgggg cccctgcccc actcccgccc 2580
 cagccgcaga acgggttggg ccggggcacc ggggcagcgg ggctgggggc catgcccatg 2640
 gctgaggggc tgttgggggg gctggcaggc agtggggggc tgccctcaa tgggctcctt 2700
 ggggggttga atggggccgc tgcccccac cccgcaagct tgagccaggc tggcggggcc 2760
 cccacgctgc agctgccagg ctgtctcaac agccttacag agcagcagag acatctcctt 2820
 15 cagcagcaag agcagcagct ccagcaactc cagcagctcc tggcctcccc gcagctgacc 2880
 ccggaacacc agactgttgt ctaccagata agcagcaga tccagcaga acgggagctg 2940
 cagcgtctgc agatggctgg ggcctccag ctgcccattg ccagcctgct ggcaggaagc 3000
 tccacccgcg tgctgtctgc gggtaacctt ggctgtctgc ccacagcgtc tgctccacco 3060
 ctgctgcccg ctggagccct agtggctccc tcgcttggca acaacacaag tctcatggcc 3120
 20 gcagcagctg cagctgcagc agtagcagca gcaggcggac ctccagtcct cactgcccag 3180
 accaaccctt tctcagcct gtggggagca gagggcagtg gcggtggccc caaaggaggg 3240
 accgctgaca aaggagctc agccaaccag gaaaaaggct aa 3282

<210> 54

25 <211> 2227

<212> DNA

<213> Homo sapiens

30

<400> 54

35 gagagcccga acaggaagag ggtacagctt tgtgcaggtc acatgcccac tgcagccctc 60
 cagcctctgg tccccagagc ggacttttga agctgaactg cttttgttgc tggaagactt 120
 atgttataat ttaccctggg tggaccaggg togtacaaaa gggaacgct cccagtcctc 180
 cccactccog accccggaat catgcacggg actacacgga tcaaaatcac agagctgaac 240
 cccacactca tgtgtgccct ctgcgggggg tacttcatcg acgccaccac tatcgtggag 300
 tgctgtcatt cctcttgcaa aacctgcacg gtgcgtacc tggagaccaa caaatactgc 360
 cccatgtgtg acgtgcaggt ccataaaacc cggccgctgc tgagcatcag gtctgacaaa 420
 40 acacttcaag acattgtcta caaattgggtc cotgggottt taaagatga gatgaaacgg 480
 cggcgggatt tctatgcagc gtaccccttg acggagggtc ccaacggctc caatgaggac 540
 cgcggcgagg tcttgagca ggagaagggg gctctgagtg atgatgagat tgtcagcctc 600
 tocatogaat tctacgaagg tgccagggac cgggatgaga agaagggccc cctggagaat 660
 ggggatgggg acaaagagaa aacaggggtg cgtctcctgc gatgccagc agcoatgacc 720
 gtcatgcac ttgcaagtt tctccgcaac aagatggatg tgcccagcaa gtacaagggtg 780
 45 gaggttotgt acgaggacga gocactgaag gaatactaca cctcatgga catcgcotac 840
 atctaccctt ggcggcgga a cgggcctctc cccctcaagt accgtgtcca gccagcctgc 900
 aagcggtca ccctagccac ggtgcccacc cctccgagg goaccaacac cagcggggcg 960
 tccgagtggt agtcagtcag cgacaaggct cccagccctg ccaccctgcc agccacctcc 1020
 tctccctgc ccagcccagc caccocatcc catggctctc ccagttccca tgggcctcca 1080
 50 gccaccacc ctacctccc cactccccct tcgacagcca gtggggccac cacagctgcc 1140
 aacgggggta gcttgaactg cctgcagaca ccattctcca ccagcagggg gcgcaagatg 1200
 actgtcaacg gcgtccctg gcccccotta acttgaggcc agggaccctc tcccttctc 1260
 cagccaagcc tctccactcc ttcactttt tctgggccc tttttccact tcttctactt 1320
 tcccagctc ttcccactt ggggtggggg ggcggtttt ataaataaat atatatatat 1380
 55 atgtacatag gaaaaaccaa atatacatat ttattttcta tggaccaacc agattaatat 1440
 aaatgccaca ggaaacaaac tttatgtgtg tgtgtatgtg tggaaaatgg tgttcatttt 1500

ttttgggggg ggttctgtgt aatttgctgt ttttgggggt gcctggagat gaactggatg 1560
 ggccactgga gtotcaataa agctctgcac catcctcgct gtttcccaag gcagggtggtg 1620
 tgttgggggc cccttcagac ccaaagcttt aggcattgatt ccaactggct gcata tagga 1680
 gtcagttaga attgtttctt tctctccccg tttctctccc catcttggct gctgtcctgc 1740
 5 ctotgaccag tggcgcggcc cgcggttgtt gaattgtccag aaattgctaa gaacagtgc 1800
 ttttcaaaat gcagtttatc cctggttctg aggcagcaagt gcagggtgga ggtggcacct 1860
 gcatcacctc ctctcttctg agtggaaact ttgtgcaaag aatagatagt tctgcctctt 1920
 tttttttttt ttctgtgtgt tgtggccttt gcatcattta tcttgtggaa aagaagattc 1980
 agggccctgag aggtctcagc tcttgaggga gggctaaggc tttagcattg tgaagcgtg 2040
 10 cacccccacc aaccttacc caccgggga accctacta gcaggactgg tggtaggtc 2100
 tcacctgggg cctagatgg aagtgggggt ggggttaacct cacacaagca cagatccag 2160
 actttgccag aggcaaacag ggaattccgc cgatactgac gggctccagg agtcgtcgcc 2220
 acactcg 2227

<210> 55

<211> 4283

<212> DNA

<213> Homo sapiens

<400> 55

25 ttgcgggaaa gagccaaacc ctggcggttg gggggccggg cggggagccc ctcccgggt 60
 ccacagcgac gcctgcccag cctcctccc ctctcggctc cggcacgggg ccccgaggcg 120
 ttccggaggcc aggcgggttt ctgtcaggcc cggggaggag gggcgggcgg ggogggcgct 180
 gctccccggg gacggggcgt accacgcgga cggggaggac ggggcccagg gactgcaggg 240
 cggctgcacc gcccgggggc ggggtgcgga ggcggccggc gggctcccgg gggcgggggc 300
 ggagggcggg gcgtggggcg gacggaacca cggggcggg gtgggaggta acgggacggg 360
 30 cggagaccatg gcgcgggtgag ggagcggggg tggggatcgg tccgggggag gctgaggcc 420
 gctggcctgt gcgctgtctc cgcgcggccc ctctttcggc gccgcggcg ccgcccggg 480
 catgtctgcc aactgcacca gcaccacggc ggtggcggtg ggcgcgtca gcgccagcaa 540
 gaccaagacc aagaagaagc atttctgtgt ccagaaagt aagctattcc gggccagcga 600
 gccgatcctc agcgtcctga tgtggggggt gaaccacag atcaatgagc tgagcaatgt 660
 35 tctgttctct gtcatgctaa tgccagatga cttcaaagcc tacagcaaga tcaaggtaga 720
 caatcatctc ttcaataaag agaacctgc cagcgccttt aagtttaagg agtattgccc 780
 catggtgttc cgaaaccttc gggagaggtt tggaaattgat gatcaggatt accagaatto 840
 agtgacgcgc agcggcccca tcaacagtga cagccagggt cgggtgtggc cgcgtttcct 900
 caccacctac gacggcgct ttgtcatcaa gactgtgtcc agcgaggacg tggcgaggat 960
 gcacaacatc ttaagaaat accaccagtt tatagtggag tgtcatggca acacgctttt 1020
 40 gccacagttc ctgggcatgt accgcctgac cgtggatggt gtggaaacct acatgggtgt 1080
 taccaggaac gtgttcagcc atcgctcac tgtgcatcgc aagtatgacc tcaagggttc 1140
 tacggttgcc agagaagcga gcgacaagga gaaggccaag gacttgccaa cattcaaaga 1200
 caatgacttc ctcaatgaag ggcagaagct gcatgtggga gaggagagta aaaagaactt 1260
 cctggagaaa ctgaagcggg acgttgagtt cttggoacag ctgaagatca tggactacag 1320
 45 cctgctggtg ggcattccacg acgtggaccg ggcagagcag gaggagatgg aggtggagga 1380
 gcgggcagag gacgaggagt gtgagaatga tgggggtgggt ggcaacctac tctgctcota 1440
 tggcacacct ccggacagcc ctggcaacct cctcagcttt cctcggttct ttggtcctgg 1500
 ggaattcgac cctctgttg acgttatgac catgaaaagc catgaaagt cccccaagaa 1560
 ggaggtgtat ttcatggcca tcattgatat cctcacgcca tacgatacaa agaagaaagc 1620
 50 tgcacatgct gccaaaacgg tgaaacacgg ggcaggggccc gagatctcga ctgtgaaccc 1680
 tgagcagtac tcaaaacgct tcaacgagtt tatgtccaac atcctgacgt agttctcttc 1740
 taccttcagc cagagccaga gagotggata tggggtcggg gatcgggagt tagggagaag 1800
 ggtgtatttg ggttagatgg gaggggtggga gcagagtcgg gtttgggagg gcttttagcaa 1860
 tgagactgca gcctgtgaca ccgaaagaga ctttagctga agaggagggg gatgtgctgt 1920
 gtgtgcacct gctcacagga tgtaacccca cctctgctt acccttgatt tttctcccc 1980
 55 atttgacacc caggttaaaa aggggttccc ttttgggtac cttgtaacct ttaagatac 2040

5 cttggggcta gagatgaactt cgtgggttta tttgggtttt gtttttgaaa tttcattgct 2100
 ccaggtttgc tatttataat catatttcat cagcctaccc accctcccca tctttgctga 2160
 gctctcagtt cccttcaatt aaagagatac ccagtagacc cagcacaagg gtccttccag 2220
 aaccaagtgc tatggatgcc agattggaga ggtcagacac ctgcgcctgc tgcatttgcct 2280
 cttgtctgga ttaactttgt aatttatgga gtattgtgca caacttootc cacotttccc 2340
 ttggattcaa gtgaaaactg ttgcattatt cctccatcct gtctggaata caccaggtca 2400
 acaccagaga tctcagatca gaatcagaga totcagaggg gaataagttc atoctcatgg 2460
 gatggtgagg ggcaggaaag cggotgggct cttggacacc tggttotcag agaaccctgt 2520
 gatgatcacc caagccccag gctgtcttag cccctggagt tcagaagtc tctctgtaaa 2580
 10 gcctgcctcc cactagggtca agaggaaacta gtagtacctt ggatttatca ggaccctcat 2640

gtttaaatgg ttatttccct ttgggaaaac ttcagaaaot gatgtatcaa atgaggccct 2700
 gtgcctcga tctatttccct tcttccctot gacotcctcc caggcactot tacttctagc 2760
 ogaactctta gctctgggca gatctccaag cgctggagt gcttttttagc agagacacct 2820
 15 cgttaagctc cgggatgacc ttgtaggaga tctgtctccc tgtgcctgga gagttacagc 2880
 cagcaagggtg ccccatctt agagtgtggt gtccaaacgt gaggtggctt cctagtatac 2940
 tgaggatgtg atccaggaaa tcoagtttg agctgtgatg tgggttttga cctggcctca 3000
 gccttggggc gtgttttccct tgttgcctcc ccttagactt ttagcagatc tgcagccac 3060
 aggctttttt ggaaggagtg gottcctgca ggtgttccac ctgccttogg agcctgccc 3120
 20 ccaggccctc agaactgagc cacaggtgct totggccagg agagaaacag ctctgttgtt 3180
 ctgcattggg ggaggtacat tccgtcatct tctcaccoco tcaaccagga actggggatt 3240
 tgggatgaga tatggtcaga cttgtagata accocaaaga tgtgaagatc gcttgtgaaa 3300
 ccattttgaa tgaatagatt ggtttcctgt ggctccctcc aaacctggcc aagcccagct 3360
 tccgaagcag gaaccagcac tgtctctgtg cctgactcac agcatatagg tcaggaaaga 3420
 atggagacgg cattcttggga cttcactggg gctgctggat tggatgggaa acctcttgg 3480
 25 agaggcagat gggggtcaaa ccactgcctt ggccocagga aggggccata ggtaggctctg 3540
 aacaactgcc gcaagaccac tacatgactt agggaaactg aaaccaactg gctcatggag 3600
 aaaacaaatt tgacttggga aagggtattat gtaggaataa tgtttggact tgatttccc 3660
 acgtcataat gaagaatgga agtttggatc tgcctctcgt caggcgagc atctctgaag 3720
 cttggaaagc tgtcttccag cctccaaacc tggccaaagg cagcttccga agcaggaacc 3780
 30 agcactgtot ctgtgcctga ctcacagcat ataggtcagg aaagaatgga gacggcatte 3840
 ttggaactca ctggggctgc tggattggat gggaaacctt ctggaagagg cagatggggg 3900
 tcaaacact gccttggccc caggaagggg ccataggtag gctgaacaa ctgccgcaag 3960
 accactacat gacttaggga acttgaaacc aactggctca tggagaaaac aaatttgact 4020
 tgggaaaggg attatgtagg aataatgttt ggaacttgatt tccccagctc ataataaga 4080
 atggaagttt ggtatctgctc ctgcgcaggo gcagcatctc tgaagottgg aaagctgtct 4140
 35 tccagcagcc tccgtggcct cgggttccca cgggttctc tgcatattgg ctgotgatca 4200
 tgttgccata atgtgtatgg aaagtgtaac acattcttac tggttaaaga cgactaccag 4260
 gtatetaact tgtttaacat tga 4283

<210> 56

<211> 6140

<212> DNA

<213> Homo sapiens

<400> 56

50 ggggcccag cctgagccag gggcccccctc ctgcgcagga ccggggcagc aagcaggccg 60
 ggggcaggtc cgggcaccca ccatgcgagg cgagctctgg ctccctggtgc tgggtgctcag 120
 ggaggtgccc cgggcgctga gcccocagcc cggagcaggt caccgatgagg gcccaggctc 180
 tggatgggct gccaaaggga ccgtgcgggg ctggaaccgg agagcccag agagccctgg 240
 gcatgtgtca gagccggaca ggaccagct gagccaggac ctgggtgggg gcaccctggc 300
 catggacacg ctgccagata acaggaccga ggtggtggag gacaaccaca gctattatgt 360
 55 gtcccgctctc tatggcccca gcgagcccca cagccgggaa ctgtgggtag atgtggccga 420
 ggccaaccgg agccaagtga agatccacac aatactctcc aacaccacc ggcaggcttc 480

	gagagtgggtc	ttgtcctttg	atttcccttt	ctacggggcat	cctctgctggc	agatcaccat	540
	agcaactgga	ggcttcatct	tcatggggga	cgtgatccat	cggatgctca	cagctactca	600
	gtatgtggcg	cccctgatgg	ccaacttcaa	ccctggctac	tccgacaaat	ccacagttgt	660
5	ttactttgac	aatgggacag	tctttgtgg	tcagtgggac	cacgtttatc	tccaaggctg	720
	ggaagacaag	ggcagtttca	ccttccaggc	agctctgcac	catgaaggcc	gcattgtctt	780
	tgccotataaa	gagatcccta	tgtctgtccc	ggaaatcagc	tcctcccagc	atcctgtcaa	840
	aaccggccta	tcggatgcct	tcatgattct	caatccatcc	ccggatgtgc	cagaatctcg	900
	gcgaaggagc	atctttgaat	accaccgcac	agagctggac	cccagcaagg	tcaccagcat	960
	gtcggccgtg	gagttcaccc	cattgcccgc	ctgctctgcag	cataggagct	gtgacgcctg	1020
10	catgtctctca	gacctgacct	tcaactgcag	ctggtgcca	gtcctccaga	gatgtctccag	1080
	tggctttgac	cgctatcgcc	aggagtggat	ggactatggc	tgtgcacagg	aggcagaggg	1140
	caggatgtgc	gaggacttcc	aggatgagga	ccacgactca	gcctcccctg	acacttccct	1200
	cagccccctat	gatggagacc	tcaccactac	ctcctcctcc	ctcttcatcg	acagcctcac	1260
	cacagaagat	gacaccaagt	tgaatcccta	tgcaggagga	gacggccttc	agaaacaacct	1320
15	gtcccccag	acaaagggca	ctcctgtgca	cctgggcaco	atcgtgggca	tcgtgctggc	1380
	agtectctctc	gtggcgggcca	tcatcctggc	tggaaatttac	atcaatggcc	acccacatc	1440
	caatgtctgcg	ctcttcttca	tcgagcgtag	gcctcaccac	tggccagcca	tgaagtctcg	1500
	cagccaccct	gaccattcca	cctatgcgga	ggtggagccc	tcgggccatg	agaaggaggg	1560
	cttcatggag	gctgagcagt	gctgagaaca	ccaagtctcc	cotttgaaga	ctttgaggcc	1620
	acagaaaaga	cagttaaagc	aaagaagaga	agtgaacttt	cctggcctct	cccagcatgc	1680
20	cctgggctga	gatgagatgg	tggtttatgg	ctccagagct	gotgttgcct	tcgtcagcac	1740
	accccgaaata	ttgaagaggg	ggccaaaaaa	caaccacatg	gattttttat	aggaacaaca	1800
	acctaatctc	atcctgtttt	gatgcaaggg	ttctctcttg	tgtcttgtaa	ccatgaaaca	1860
	gcagaagaac	taacataact	aaactccatt	ttgtttaagg	ggcctttacc	tattcctgca	1920
	cctaggctag	gataacttta	gagcactgac	ataaaacgca	aaaacaggaa	tcattgctgt	1980
25	tgcanaaacta	actctgggat	taaaggggaa	gcattgaaac	agctaactgt	ttttgttaaa	2040
	gatttatagg	aatgaggagg	tttggctatt	gtcacatgac	agactgttag	coaaggacaa	2100
	agaagtctctg	caaacctccc	ctggaccctt	gctggtgtcc	agatgtctgc	ggtgtgcagc	2160
	cccttccctt	cccccgacct	aaacataaaa	gacaaaggcaa	agcccgcata	attttaagac	2220
	ggttctttag	gacattagtc	caccatcttc	ttggtttgct	ggctctccga	aataaagtcc	2280
30	ctttccttgc	tccaaactcc	tgtctctcaa	cgtattggct	atgacgcagc	aagcagaatg	2340
	aatttggact	cagttacagg	ctgtcaatgg	tctgtctgt	agcagtctca	gagcctcccc	2400
	gacccactac	ctggagatag	ccagatagcc	agatgcccctg	ctcctggcca	cctttaagc	2460
	ccctgcata	gacacaggtt	aaactaaagt	aagattgggg	ctgctgcatt	ccagggtccc	2520
	tagactocaa	agctggtcct	tggccagggtg	cagtggctca	cgctgttaat	cccagcactt	2580
	tgggaggctg	aggcaggcgg	atcacctgaa	gtcagaagtt	tgaagaccagc	ctggccaaca	2640
35	taattaaat	gtctctacta	aaaatacaaa	aaattagctg	ggtgtggtga	cgcttgccctg	2700
	tatcccagct	actcaggag	ctgagacacg	agaatcactt	gaacctggga	ggcagaggtt	2760
	gcagtgaagt	cagatagtgc	cactgcactc	cagcctgggt	gacagagcga	gactccgtct	2820
	caaaaaaa	aaangaaagc	agaacctcat	ggctatagag	ttggcatttt	agccccagct	2880
	tctgtagctc	tgaagoccta	aagaaggat	tctctccatc	tgtaaacaac	agtatagtgg	2940
40	ctctcagccc	ttggggcatg	ttatcatggg	agggaagtca	aataagagga	gagaaaagaa	3000
	ctcaaggggg	aaactgcatt	tttaggcttt	gctctcttac	cttgcccttt	ctactcagaa	3060
	ccaataactt	ctgcatcaaa	acatgtttaca	gcctgcacac	agggtcttac	cccaacctgc	3120
	agccagcct	tccctgggtg	agcttgctat	gcgcagccac	atttaocatg	tggggctccc	3180
	tattctgatg	ccctgttcgg	tgcgggttt	actcactgcc	ctgttctgat	gtcagtgcct	3240
	gtacatacot	ccaaaggcag	gacttgctcg	ataaatattt	ttcctcctct	gaactggatt	3300
45	ttataggcat	taaagacaag	tcgggtggct	agagggtccc	ttgagacata	cctagcaggg	3360
	aactgcagg	ggattctgtt	gagaggcaaa	gcacctgagt	ggttgggaca	caggcagctg	3420
	gcattgggag	gacttttttt	gagacaggg	ctcaotgtgt	cgccagggc	aaggatgccc	3480
	aaagacacca	gggtggagag	gcacctgcca	actacttget	ttccctggag	cctgcatgtg	3540
	cctgtgggg	ggggaggcgt	aggggtctac	ggctgcctga	gatgggtgtg	cacagtgtgt	3600
50	gaagtaccta	cctccttgcc	ttgctggact	gtcagccagt	cgaggggccg	gccacaagac	3660
	ccatgtctcc	atctggtcat	actccatagc	taccaagtta	acctgctcta	aaactttggag	3720
	aactggtct	gtccaaataa	cgcttatttt	gccaaagcctg	atggctogtg	cctgtactcc	3780
	cagcactttg	ggaggctgag	gtgggaggg	tgcttgagcc	cagggttttg	agaccagctt	3840
	gggcaacaac	aacaaaaatg	ccaggtgtgg	tgggtgacac	ctgtagtccc	agctactagg	3900
	gaggctgagc	caggaggatc	acttgagccc	gggaggttga	ggctgcagtg	gggggtcata	3960
55	atcatgccac	tgtactccag	cctgggtgac	agagtggagac	cctgtctccg	aaaaaaaaaa	4020

	aaaaaaaaga	acggaaaaaag	aaatgcttac	attgtcaggg	atcctgtaga	caatcattaa	4080
	ctctatgaga	tgttgggttc	tatttttttg	ggagactttg	tccaagtgtt	ttggcttaag	4140
	aaatccatag	gcctctcttg	gtgacacatc	tctagtactt	tttgtcataa	acaaacaggc	4200
5	catotgccgc	caaatacatc	cactccccat	gccactgaca	tcctatgggt	cagccaggct	4260
	tgtcttgact	gaggccgagg	catctggaac	tttctctgcc	tgcaggggct	agcagcagag	4320
	gcttcaccgc	atcaccaccc	cttctccacc	tcctgacatt	ctttcccttc	agggatccaa	4380
	aatgggtggc	cgagctccca	gtgggaaaac	gtgtgctaga	gttggggagt	gagatgagt	4440
	gtgctgtcca	tggaaatcagg	ccacagcagg	aactgcccga	ctggccattt	gagacacaca	4500
	caggtggtaa	atgctctgct	ggtgggctgt	gcttccctca	ttcagagagc	tctgttacag	4560
10	cccactgtgt	ccttttagaag	cttgaaagga	acccaactct	ttgtgcact	gtcctttttc	4620
	ttcctcaaat	tcagaccctc	cttcaccogg	caccccccta	ctccaccctc	agctcttctc	4680
	tgctgtggtt	atcaagcaga	gctgaggccc	cacgtttcca	actctgattg	tcacttgcat	4740
	cttcacaaag	gataaaccac	ggagcaactg	gaaaaccatc	agccaagcgt	tcggatgagt	4800
	ctgggttattg	gtccaccccc	gaccagattc	ccttacactt	aactcacttc	tttctttggc	4860
15	aatgaccctc	atgacatgta	taaattgggt	tgactaagaa	gaggctgtga	totaacattt	4920
	atttgtctgc	atTTTTtact	ctggggagaa	gcagcccoaa	ctcatcactg	ggaaagaaact	4980
	ccccctgcaa	accagotaaa	tttgataatt	taaaccacct	gccccataaa	cttctcacag	5040
	agctggggag	ttggtggcaa	ctttccaagt	caaggctctg	cttagaaagt	ccttcactac	5100
	atggccagggt	gcagtggctc	acgcctgtag	tcccaggtag	ttgggagcct	gaggcaggag	5160
	gattgcttga	gctcaggagt	tcaaggctgc	agagagctat	gatcatccca	ctgcatttgt	5220
20	ttaaaaataa	atTTTTtaaaa	tttgtgtgtt	ttatcagggg	tctcctgtac	agtgtatctg	5280
	tgtatgtttg	tgtgtgtgtt	tgtatacagc	ottgtttaat	gttttgagca	ataagatatg	5340
	cacacacagg	tattttgttg	ctaaagagat	tggacaagggt	tgtagctgtg	ctcaggcttc	5400
	agcttggttt	gttaaattga	gagataaaca	atgacaagag	ctgccagcca	accacactat	5460
	tcaaaaagca	aagtgttcac	caotaaagct	aaccattcat	ctgggtgcag	gcaaggctaa	5520
25	ggctctctct	cctctagttc	ctggaaacaga	ctcacagatt	ggcatgaagc	actgatcagg	5580
	ggctgcactc	agactccctg	gccaaagcaa	cctacaccag	aagagtcagt	gtcacagata	5640
	tgtatggggc	aatctctgtc	tccaaaaacc	tacctgaact	taatggtaga	attcacaagat	5700
	ctggggagct	aggggcaccca	gccttctaaa	acacaatgta	ttcatgtgtt	tagtgtaaac	5760
	tctctgcatg	gattctcagt	gttaataata	aaaggaagca	ttctttttaca	actcctgctg	5820
30	tgtgcaaaag	aaagtgcata	ggatttgagg	tggcattccg	aagatcacca	cacatacctt	5880
	ggttctgatg	gctgctgaac	tccgacttct	tgcgtgagac	atgactgtgg	gaacagcctc	5940
	cagotatctg	ctcatcagag	gtgctttcct	caacotcttg	tattgtctg	aaagagaaaca	6000
	gcctaaaaag	aaaccccagc	tgtttactta	tattgtctg	taaattccctg	gaagtaaacc	6060
	ccatgcatctt	ttatctactg	tctgaggaca	tacaataaat	ctgagaaagt	ctatgtctgc	6120
	aaaaaaaaaa	aaaaaaaaaa					6140

<210> 57

<211> 2098

<212> DNA

<213> Homo sapiens

<400> 57

	gcaggagcac	gtggagagggc	cgggtagcca	cagcggcagc	tccagcccg	cccggcagcg	60
	acatggaaga	tatacaaaaca	aatgcggaac	tgaaaagcac	tcaggagcag	tctgtgcccg	120
	cagaaagtgc	agcgggttttg	aatgactaca	gtttaaccac	atctcatgaa	atggaaaaatg	180
	tggacagtgg	agaaggccca	gccaatgaag	atgaagacat	aggagatgat	tcaatgaaag	240
50	tgaaagatga	atacagtga	agagatgaga	atgttttaaa	gtcagaaccc	atgggaaatg	300
	cagaagagcc	tgaatccct	tacagctatt	caagagaata	taatgaatat	gaaaacatta	360
	agttggagag	acatgttgct	tcattcgata	gtagcaggcc	aaccagtgga	aagatgaact	420
	gcgatgtgtg	tggattatcc	tgcatcagct	tcaatgtctt	aatggttcat	aagcgaagcc	480
	atactggtga	acgccatttc	cagtgttaato	agtgtggggc	atcttttact	cagaaaggta	540
	acctctccg	ccacatttaa	ctgcacacag	gggaaaaacc	ttttaagtgt	cacctctgca	600
55	actatgcatg	ccaaagaaga	gatgcgctoa	cggggcatct	taggacacat	tctgtggaga	660

	aacctacaa	atgtgagttt	tgtggaagga	gttacaagca	gagaagttcc	cttgaggagc	720
	acaaggagcg	ctgccgtaca	tttcttcaga	gcactgaccc	aggggacact	gcaagtgcgg	780
	aggcaagaca	catcaaagca	gagatgggaa	gtgaaagagc	tctogtactg	gacagattag	840
5	caagcaatgt	ggcaaaacga	aaaagctcaa	tgccctcagaa	attcattggt	gagaagcgcc	900
	actgctttga	tgtcaactat	aattcaagtt	acatgtatga	gaaagagagt	gagctcatac	960
	agaccgcgat	gatggacca	gccatcaata	acgccatcag	ctatcttggc	gccgaagccc	1020
	tgtgccoctt	ggtccagaca	ccgcctgctc	ccacctcgga	gatggttcca	gttatcagca	1080
	gcattgtatcc	catagccctc	acccgggctg	agatgtcaaa	cgggtgccct	caagagctgg	1140
10	aaaggaaaag	catcctcctt	ccagagaaga	gcgtgccttc	tgagagaggg	ctctctccca	1200
	acaatagtgg	ccacgactcc	acggacactg	acagcaacca	tgaagaacgc	cagaatcaca	1260
	tctatcagca	aaatcacatg	gtcctgtctc	gggcccga	tgggatgcca	cttctgaagg	1320
	aggttccccc	ctcttacgaa	ctcctcaagc	ccccgccat	ctgcccaga	gactctgtca	1380
	aagtgtatcg	caaggaaggg	gaggtgatgg	atgtgtatcg	gtgtgaccac	tgccgcgtcc	1440
	tcttctcgga	ctatgtgatg	ttcacgattc	acatgggctg	ccacggcttc	cgtgaccctt	1500
15	tcgagtgtaa	catgtgtgga	gatcgaagcc	atgatcggta	tgaattctcg	totcacaatg	1560
	ccagaggaga	acacagaagc	ctgctgaagt	gaatatctgg	tctcagggat	tgctcctatg	1620
	tattcagcat	ogtttctaaa	aacagttgac	ctcgcctaac	agattgctct	caaaacatac	1680
	tcagttccaa	acttcttttc	ataccatttt	tagctgtggt	cacaggggta	gccagagaaa	1740
	cactgtottc	cttcagaaat	tattcgcagg	totagcatat	tattactttt	gtgaaacctt	1800
20	tggtttccca	tcagggaact	gaattttatg	gaatttaaaa	gccaaaaagg	tatttggtca	1860
	ttatcttcta	cagcagtgga	atgagtggtc	ccggagatgt	gctatatgaa	acattctttc	1920
	tgagatatat	caaccacacg	tggaaaagcc	tttcagtcac	acatgcaaat	ccacaaagag	1980
	gaagagctga	ccagctgacc	ttgctgggaa	gcctcaccct	tctgcccttc	acaggctgaa	2040
	gggttaagat	ctaattctcc	taattctaat	gacagtctaa	gagtaagtaa	aagaacag	2098
25	<210> 58						
	<211> 2947						
	<212> DNA						
30	<213> Homo sapiens						
	<400> 58						
35	atgccaatcc	ctcctccccc	gccaccccga	cctggctctc	ctccacctcc	cacatttcat	60
	caggcaaaaca	cagagcagcc	caagctgagt	agagatgagc	agcggggctg	aggcgccttc	120
	ttacaggaca	tttgcaaagg	gaccaagctg	aagaaggtga	ccaacattaa	tgatcggagt	180
	gtcctccatcc	togagaagcc	gaaaggaagc	agtgggtggc	atgggtctgg	aggagctgcc	240
	ctgcagccca	agggaggtct	cttccaagga	ggagtgtcga	agcttcgacc	tgtgggagcc	300
40	aaggatgggt	cagagaacct	agctggtaag	ccagccctgc	aaatccccag	ttctcgagct	360
	gctgccccaa	ggcctccagt	atctgccgcc	agcggggctc	ctcaggatga	tacagacago	420
	agccgggccc	cactcccaga	actgcccogg	atgcagagac	cctotttacc	ggacctctct	480
	cggcctaata	ccaccagcag	tacgggcatg	aagcacagct	cctctgcccc	tccccacca	540
	cccccagggc	ggcgtgccaa	cgcacccccc	acacctctgc	ctatgcacag	cagcaaagcc	600
	ccgcctaca	acagagagaa	acccttgcca	ccgacgcctg	gacaaaggct	tcaccctggt	660
45	cgagagggac	ctcctgctcc	acccccagtc	aaaccacctc	cttccccctg	gaatatcaga	720
	acaggaccaaa	gtggccagtc	tctggctcct	cctcctccgc	cttacogcca	gcctcctggg	780
	gtccccaatg	gacctcttag	ccccactaat	gagtcagccc	ctgagctgcc	acagagacac	840
	aattcttttg	ataggaagac	accagggcct	gtcagaggcc	tagcacctcc	tcccccacc	900
	tcggcctccc	catcttttact	gagtaatagg	ccacctcccc	cagcccagaga	ccctcccagt	960
50	cggggagcag	ctcctccacc	cccaccacct	gtgatccgaa	atggtgccag	ggatgctccc	1020
	cctccccccac	caccataccg	aatgcatggg	tcagaacccc	cagcccgagg	aaagccccca	1080
	cctccacctt	caaggagccc	agctggggcca	ccccctcctc	ctccaccgcc	cctgaggaat	1140
	ggccacagag	attctatcac	cactgtccgg	tctttcttgg	atgattttga	gtcaaagtat	1200
	tccttccatc	cagtagaaga	cttctctgct	ccagaagaat	ataaacactt	tcagaggata	1260
55	tatcccagca	aaacaaaacc	agctgcccgt	ggagccccac	ctctgccacc	cattctcagg	1320
	tgaagcctgg	cttggtcccg	ttcctcagga	aaaggatgga	cctctctctc	ttctcagatg	1380

gtcccttcca ttccctgaa acotgcatga gagctcotaa catgtttctc caatgcaatc 1440
 aagccotaga ctccaaatgt cctcccagct cactccatc tatgcatotc atctctggat 1500
 ttggtgatca gactctatat tgacagtagg atctcaaacc ctgcatccat ccttctcca 1560
 5 goaagccctg ctagccacat gaggaacaag tttcogtgc ttctgcctc ctcttgggga 1620
 aaggtgcctt gttgtgatga attaactcac tgtagggca gggtagagaa tggtaactct 1680
 tccttotcct gtccactgtg ggggaagcct ggcaggata ttatatttca tcatttagga 1740
 ggctggcatg accaggactt atgggtggga ggggagcatt tttagtgaag caagaaagga 1800
 gtttgocaag aagtgatotg ttttaaaggt catatttggg gaaagggcaa ggaattgggt 1860
 ctgctttatt tttgggggta ttttgtttt gttotcacct gctgcccccc caccaccaca 1920
 10 cccagggat aaattggata taaacactaa atactaatca gttgaactta acatttaata 1980
 aaaagaaagg gtgaaataaa ctgaagacca ttttagaact agtcagttct ctgcagcaaa 2040
 ggaacagga gccatttgaa cctctggga cccctcacc cactgcttca ggggtgctagg 2100
 ctgagggatg tttttctcc ccctacogc ccatgccott gaaagaaaag tcactttttg 2160
 tggagggcat cattcattcc tgattcacia accccaaaaa cctctggtgg gagataggaa 2220
 15 gatagggcgt gggcctgggc cttaacctca atottgtgtc tgccctcagtc ttttctgact 2280
 ggocctgaag ttgtcagtggt ctctttctgt ccttcagccc ctggaagggtg ctccaggata 2340
 acaaagaagg gcagggtgaa gcccctcatg gaaggagctg gctttgtggg gctgcaaagg 2400
 acttttaagt cctgcctgta ctgaagttoa cagccacct gactgagcag actottctg 2460
 ttcctttctc taccaccctt gccttcccag gactgcaogt ttaacacag cagagtacag 2520
 aaggtggaag aagtgagcag aggcctatga agatattcag atactcttct atgccaggaa 2580
 20 gcacaaagac tttgttgaga tttgcctcag ttcagtagat ottoottggc agccagccat 2640
 aggttgtttc tttgtcttcc gggtootaaa gagcacagag aaaatggagg toccagctct 2700
 aggtaggaag ctgattggat gaggacttct ttttttccga cagcaggatg gggctcttgg 2760
 gctccacaca coagatgctt tggttttcta caactgttgc tatgtgtaga ggggtgctcag 2820
 agcgtggcat gagagcaagg agaccatggc tactctttga aatggatggg gaaaattagc 2880
 25 ttaaaaattt aatcacgaga ttgcgccact gcactccagc ctggggcaga gagccagact 2940
 ccgtctc 2947

<210> 59

<211> 784

<212> DNA

<213> Homo sapiens

<400> 59

gagcggttgc gcagtgaagg ctagaccocg tttactggaa ttgctctggc gatcaggggg 60
 tcctagtaca ccgcaatcat gtotattatg tcctataacg gaggggcccgt catggccatg 120
 40 aaggggaaga actgtgtggo catcgtctga gacaggcgtc tcgggatcca ggcccagatg 180
 gtgaccacgg acttccagaa gatctttccc atgggtgacc ggctgtacat cggctctggc 240
 gggctogcca ctgacgtcca gacagttgcc cagcgcctca agttccggct gaacctgtat 300
 gagttgaagg aaggtcggca gatcaaacct tataccctca tgagcatggt ggccaacctc 360
 ttgtatgaga aacggtttgg cccttactac actgagccag tcattgccgg gttggaccgg 420
 aagaccttta agoccttcat ttgctctcta gaocctcatg gctgccccat ggtgactgat 480
 45 gactttgtgg tcagtggcac ctgcgcggaa caaatgtacg gaatgtgtga gtccctctgg 540
 gagcccaaca tggatccgga tcacctgttt gaaaccatct cccaagccat gctgaatgct 600
 gtggaccggg atgcagtgtc aggcattggga gtcattgtcc acatcatcga gaaggacaaa 660
 atcaccacca ggacactgaa ggcccgaaat gactaacctt gttcccagag cccacttttt 720
 50 tttctttttt tgaaataaaa tagcctgtct ttcaaaaaa aaaaaaaaaa aaaaaaaaaa 780
 aaaa 784

<210> 60

<211> 3033

<212> DNA

<213> Homo sapiens

<400> 60

atactoctaa	gctcctcccc	cggcggcgag	ccaggagagaa	aggatggccg	gcctggcggc	60
gcggttggtc	ctgctagotg	gggcagcggc	gctggcgagc	ggctcccagg	gcgacogtga	120
gocggtgtac	cgcgactgcg	tactgcagtg	cgaagagcag	aactgctctg	ggggcgctct	180
gaatcacttc	cgctcccgcc	agccaatcta	catgagtcta	gcaggctgga	cctgtcggga	240
cgactgtaag	tatgagtgtg	tgtgggtcac	cgttgggctc	tacctocagg	aagggtcacia	300
agtgcctcag	ttocatggca	agtggccctt	ctcccggttc	ctgttctttc	aagagccggc	360
atcgcccggtg	gcctcgctt	tcaatggcct	ggccagcctg	gtgatgctct	gccgctaccg	420
caccttcgtg	ccagcctcct	cccccatgta	ccacacotgt	gtggccttog	cctgggtgtc	480
cctcaatgca	tggttotggg	ccacagtott	ccacaccagg	gacactgacc	tcacagagaa	540
aatggactac	ttctgtgctt	ccactgtcat	cctacactca	atctacctgt	gctgcgtcag	600
gtgagcctgc	ctgggtgggt	gcaggggcaa	aatcgaaccc	tgggggcaga	aaggggtcac	660
ccagccttcc	cotggggggc	ttcttcaact	acctcccaac	acctaogccc	cccaaccccc	720
aacacatcag	ctgtcctggg	tgaggactct	ggggtaggac	tgggggcccc	ggctcctgac	780
aaggagctgt	agcacttgct	gcccagctgt	ggcctgtttg	gtggggagag	gggtagtgtg	840
ttcagggggc	atgcaccaat	gttgggggga	ggagatgott	cagggaatgc	tgctctgggg	900
atggggccacc	tgccctctga	gcaacccctg	acggtggggc	aggaccgtgg	ggctgcagca	960
cccagctgtg	gtcagtgcct	tccgggctct	cotgctgtct	atgctgacog	tgcaogtctc	1020
ctacctgagc	ctcatccgct	tcgaatatgg	ctacaacctg	gtggccaacg	tggctatttg	1080
cctgttcaac	gtggtgtggg	ggctggcctg	gtgcctgtgg	aaccagoggc	ggctgcctca	1140
cgtgcgcaag	tgctgtgtgg	tggctctgtc	gctgcagggg	ctgtccctgc	tcgagctgct	1200
tgacttccca	ccgctcttct	gggtcctgga	tgcccatgcc	atctggcaca	tcagcacat	1260
ccctgtccac	gtcctctttt	tcagctttct	ggaagatgac	agcctgtacc	tgctgaagga	1320
atcagaggac	aagttcaagc	tggactgaag	accttgagag	gagtctgccc	cagtggggat	1380
cctgcccccg	ccctgtgtgc	ctcccttctc	ccctcaaccc	ttgagatgat	tttctctttt	1440
caacttcttg	aacttgagca	tgaaggatgt	ggggccagaa	tcatgtggcc	agcccccccc	1500
ctgtttggccc	tcaccagcct	tggagtctgt	tctagggaag	gcctcccagc	atctggggact	1560
cgagagtggg	cagccctctt	aoctcctgga	gctgaactgg	ggtggaactg	agtgtgttct	1620
tagctctacc	gggaggacag	ctgcctgttt	cctccccacc	agcctcctcc	ccacatcccc	1680
agctgcctgg	ctgggtcctg	aagccctctg	ctacctggg	agaccagggg	ccacaggcct	1740
tagggatata	gggggtcccc	ttctgtttacc	acccccccac	ctcctccagg	acaccactag	1800
gtgggtgtgg	atgcttgttc	tttgccagc	caaggttcac	ggcgattctc	cccatgggat	1860
ottgagggac	caagctgctg	ggattgggaa	ggagtctcac	cctgaccgtt	gcctagacca	1920
ggttcccagg	aggcctcacc	atactccctt	tcagggccag	ggctccagca	agcccagggc	1980
aaggatccctg	tgctgctgtc	tggttgagag	cctggccacc	tggttcggga	gtgtgggcca	2040
ggctgagtgc	ataggtgaca	gggcctgag	catgggcctg	ggtgtgtgtg	agctcaggcc	2100
taggtgcgca	gtgtggagac	gggtgtgtgc	ggggaagagg	tggtgcttca	aagtgtgtgt	2160
gtgcaggggg	tgggtgtgtt	agcgtgggtt	aggggaacgt	gtgtgcgcgt	gctgggtggc	2220
atgtgagatg	agtgactgcc	ggtgaatgtg	tccacagttg	agagggttga	gcaggatgag	2280
ggaatccctgt	caccatcaat	aatcacttgt	ggagcgccag	ctctgcccac	gacgocacct	2340
gggcgggacag	ccaggagctc	tccatggcca	ggctgcctgt	gtgcatgttc	cctgtctggt	2400
gcccccttgc	cgccctcctg	caaacctcac	agggtcccca	cacaacagtg	ccctccagaa	2460
gcagcccttc	ggaggcagag	gaaggaaaat	ggggatggct	ggggctctct	ccatcctcct	2520
tttctccttg	cottogcatg	gctggccttc	ccctccaaaa	cctccattcc	cctgctgcca	2580
gcccccttgc	catagcctga	ttttggggag	gaggaaaggg	cgatttgagg	gagaagggga	2640
gaaagcttat	ggctgggtct	ggtttcttcc	cttcccagag	ggtcttactg	ttccagggtg	2700
gccccagggc	aggcaggggc	cacactatgc	ctgcgccctg	gtaaagggtga	cccctgccat	2760
ttaccagcag	ccctggcatg	ttcctgcccc	acagggaatag	aatggaggga	gctccagaaa	2820
ctttccatcc	caaaggcagt	ctccgtgggt	gaagcagact	ggatttttgc	tctgcccctg	2880

accccttgct cctctttgag ggaggggagc tatgctagga ctccaacctc agggactcgg 2940
 gtggcctgcg ctagcttctt ttgatactga aaacttttaa ggtgggaggg tggcaaggga 3000
 tgtgcttaat aaatcaatto caagcctcac ctg 3033

5 <210> 61

<211> 1174

<212> DNA

10 <213> Homo sapiens

15 <400> 61

aagctcctcc	cccgccggcg	agccaggag	aaaggatggc	cggcctggcg	gcgcggttgg	60
tcoctgctagc	tggggcagcg	gcgctggcga	gcggctccca	gggcgaccgt	gagccgggtg	120
accgcgactg	cgtactgcag	tgccaagagc	agaactgctc	tgggggagct	ctgaatcact	180
tccgctcccg	ccagccaatc	tacatgagtc	tagcaggctg	gacctgtcgg	gacgactgta	240
agtatgagtg	tatgtgggtc	accgttgggc	tctacctcca	ggaaggtcac	aaagtgcctc	300
agttccatgg	caagtggccc	ttctcccggt	tcctgttctt	tcaagagccg	gcatcgcccg	360
tggcctcggt	tctcaatggc	ctggccagcc	tgggtatgct	ctgccgctac	cgcaccttcg	420
tgccagcctc	ctcccccatg	taccacacct	gtgtggcctt	cgcctgggtg	tccctcaatg	480
catggttotg	gtccacagtc	ttccacaacca	gggacactga	cctcacagag	aaaatggact	540
acttctgtgc	ctccactgtc	atcctacact	caatotacct	gtgctgcgtc	aggaccgtgg	600
ggctgcagca	cccagctgtg	gtcagtgcct	tcogggctct	cctgctgctc	atgctgacgg	660
tgcacgtctc	ctacctgagc	ctcatccgct	tcgactatgg	ctacaacctg	gtggccaacg	720
tggctattgg	cctggtcaac	gtggtgtggt	ggctggcctg	gtgcctgtgg	aaccagcggc	780
ggctgcctca	cgtgcgcaag	tgctgtgtgg	tggtcttctt	gctgcagggg	ctgtccctgc	840
togagctgct	tgacttccca	cogctcttct	gggtcctgga	tgcccatgcc	atctggcaca	900
tcagcaccat	ccctgtccac	gtcctctttt	tcagctttct	ggaagatgac	agcctgtacc	960
tgctgaagga	atcagaggac	aagttcaagc	tggttgaagc	agactggatt	tttgccttgc	1020
ccctgacccc	ttgtccctct	ttgagggagg	ggagctatgc	taggactoca	acctcaggga	1080
ctcgggtggc	ctgcgctagc	ttcttttgat	actgaaaact	tttaagggtg	gaggggtggca	1140
agggatgtgc	ttaataaato	aattccaagc	ctca			1174

35 <210> 62

<211> 3167

<212> DNA

40 <213> Homo sapiens

45 <400> 62

aagctcctcc	cccgccggcg	agccaggag	aaaggatggc	cggcctggcg	gcgcggttgg	60
tcoctgctagc	tggggcagcg	gcgctggcga	gcggctccca	gggcgaccgt	gagccgggtg	120
accgcgactg	cgtactgcag	tgccaagagc	agaactgctc	tgggggagct	ctgaatcact	180
tccgctcccg	ccagccaatc	tacatgagtc	tagcaggctg	gacctgtcgg	gacgactgta	240
agtatgagtg	tatgtgggtc	accgttgggc	tctacctcca	ggaaggtcac	aaagtgcctc	300
agttccatgg	caagtggccc	ttctcccggt	tcctgttctt	tcaagagccg	gcatcgcccg	360
tggcctcggt	tctcaatggc	ctggccagcc	tgggtatgct	ctgccgctac	cgcaccttcg	420
tgccagcctc	ctcccccatg	taccacacct	gtgtggcctt	cgcctggatg	agaaaactga	480
ggcacagcaa	ggctaaataa	cttgcccaag	gacacacagg	aaatgcagag	ccaggaactg	540
aaccctggca	gtctggctgt	agggcttgca	ttottaatga	taccactacc	tcccaaatct	600
gaggaaaggg	tgtccctcaa	tgcattggtc	tgggtccacag	tcttccacac	cagggacact	660

	gacctcacag	agaaaatgga	ctacttctgt	gcctccactg	tcatectaca	ctcaatctac	720
	ctgtgctgcy	tcaggtagag	ctgcctgggt	ggctgcagg	gcaaaatcga	accctggggg	780
	cagaaagggg	tcacccagcc	ttccctggg	ggccttcttc	actagtctcc	caacacctac	840
5	gcccccaac	ccccaacaca	tcagctgtcc	tggtgtagga	ctctggggta	ggactggggg	900
	ccctggctcc	tgacaaggag	ctgtagcaact	tgctgcccag	ctgtggcctg	tttgggtggg	960
	agaggggtag	tgacttcagg	ggccatgcac	caatgttggg	gggaggagat	gcttcaggga	1020
	atgtctctct	ggggatgggc	cacctgccct	ctgagcaacc	ctggacgggtg	gggcaggacc	1080
	gtgggggtgc	agcaccagc	tgtggtcagt	gccttccggg	ctctcctgct	gctcatgctg	1140
	accgtgcacg	tctcctacct	gagcctcact	cgcttcgact	atggctacaa	cctgggtggc	1200
10	aacgtggcta	ttggcctggt	caacgtgggt	tggtggctgg	cctgggtgct	gtggaaccag	1260
	cgggcggtgc	ctcacgtgcy	caagtgcgtg	gtgggtggtc	tgctgctgca	ggggctgtcc	1320
	ctgctcgagc	tgcttgactt	cccaccgctc	ttctgggtcc	tggtgcccc	tgccatctgg	1380
	cacatcagca	ccatccctgt	ccacgtcctc	tttttcagct	ttctggaaga	tgacagcctg	1440
	tacctgctga	aggaatcaga	ggacaagtcc	aagctggact	gaagaccttg	gagcgagtct	1500
15	gocccagtg	ggatcctgcc	cccgcctgc	tgccctccct	tctccctcca	accottgaga	1560
	tgattttctc	ttttcaactt	cttgaacttg	gacatgaagg	atgtggggcc	agaatcatgt	1620
	ggccagccca	ccccctgttg	gocctoacca	gccttggagt	ctgttctagg	gaaggcctcc	1680
	cagcatctgg	gactcgagag	tgggcagccc	ctctacctcc	tgagagctga	ctgggggtgga	1740
	actagtggtg	ttcttagctc	taccgggagg	acagctgcct	gtttctctcc	caccagcctc	1800
20	ctccccacat	ccccagctgc	ctggctgggt	cctgaagccc	tctgtctacc	tgggagacca	1860
	gggaccacag	gccttaggga	tacagggggg	ccccttctgt	taccaccccc	caccctctct	1920
	caggacacca	ctagggtggt	ctggatgctt	gttctttggc	cagccaaggt	tcacggcgat	1980
	tctcccatg	ggatottgag	ggaccaagct	gctgggattg	ggaaggagtt	tcacctgac	2040
	cgttgcocta	gccaggttcc	caggaggcct	caccatactc	cctttcaggg	ccagggtccc	2100
	agcaagccca	gggcaaggat	cctgtgctgc	tgtctgggtg	agagcctgcc	accgtgtgtc	2160
25	gggagtggtg	gccaggctga	gtgcataggt	gacagggcgg	tgagcatggg	cctgggtgtg	2220
	tgtgagctca	ggcctagggt	cgcagtggtg	agacgggtgt	tgctggggaa	gaggtgtggc	2280
	ttcaaatgtg	gtgtgtgcag	gggggtgggt	tgtagcgctg	ggtaggggga	acgtgtgtgc	2340
	gcgtgctggt	gggcatgtga	gatgagtga	tgccgggtga	tggtgtccaca	gttgagaggt	2400
	tggagcagga	tgagggaatc	ctgtcaccat	caataatcac	ttgtggagcg	ccagctctgc	2460
30	ccaagacgcc	acctggggcg	acagccagga	gctctccatg	gccaggctgc	ctgtgtgcat	2520
	gttccctgtc	tggtgcccc	ttgcccgcct	cctgcaaacc	tcacagggtc	cccacacaac	2580
	agtgcctccc	agaagcagcc	cctcgagggc	agaggaagga	aaatggggat	ggctggggct	2640
	ctctccatcc	tccttttctc	cttgccctcg	catggctggc	cttcccctcc	aaaacctcca	2700
	ttcccctgct	gccagcccc	ttgccaatag	ctgatttttg	ggaggaggaa	ggggcgattt	2760
	gaggggagaag	gggagaaagc	ttatggctgg	gtctgggttc	ttcccttccc	agagggtott	2820
35	aotgttccag	ggtggcccca	gggcaggcag	gggccacact	atgcctgcgo	cctggtaaa	2880
	gtgaccctcg	ccattttacca	gcagccctgg	catgttctct	ccccacagga	atagaatgga	2940
	gggagctcca	gaaaottttc	atcccaaaag	cagtctccgt	ggttgaagca	gactggattt	3000
	ttgctctgcc	cctgaccctc	tgccctctct	tgagggaggg	gagctatgct	aggactccaa	3060
	cctcagggac	tcgggtggcc	tgcgctagct	tcttttgata	ctgaaaactt	ttaagggtgg	3120
40	agggtggcaa	gggatgtgct	taataaatca	attccaagcc	tcacctg		3167

<210> 63

<211> 2733

45 <212> DNA

<213> Homo sapiens

50

55

<220>

<221> misc_feature

<222> (2694)..(2694)

<223> n=a, c, g or t

<220>

<221> misc_feature

<222> (2724)..(2724)

<223> n=a, c, g or t

<400> 63

20	agggagaaag	gatggccggc	ctggcggcgc	ggttggtcct	gctagctggg	gcagcggcgc	60
	tgccgagcgg	ctcccagggc	gaccgtgagc	cggtgtaccg	cgactgcgta	ctgcagtgcg	120
	aagagcagaa	ctgctotggg	ggcgtctetga	atcaottocg	ctcccgcag	ccaatctaca	180
	tgagtctagc	aggctggacc	tgctcgggacg	actgtaagta	tgagtgtatg	tggtgcaccg	240
	ttgggctcta	cctccaggaa	ggtcacaag	tgctcagtt	ccatggcaag	tgccctctct	300
	cccgttctct	gttctttcaa	gagccggcat	cgccgtggc	ctcgtttctc	aatggcctgg	360
25	ccagcctggt	gatgctctgc	cgctaccgca	ccttcgtgcc	agcctcctcc	cccattgacc	420
	acaactgtgt	ggccttcgcc	tggtgtctcc	tcaatgoatg	gttctgggtcc	acagtcttcc	480
	acaccaggga	cactgacctc	cagagaaaat	ggactacttc	tgtgcctcct	gtatcctaca	540
	ctcaatctac	ctgtgctgcg	tcaggaccgt	ggggctgcag	cacccagctg	tggtcaagtg	600
	ccttcggggc	tctcctgctg	ctcatgctga	ccgtgcacgt	ctcctacctg	agcctcatcc	660
30	gcttcgacta	tggtctacaac	ctgggtggcca	acgtggctat	tgccctggtc	aacgtgggtg	720
	ggtggctggc	ctgggtgctg	tggaaccagc	ggcggctgcc	tcacgtgcgc	aagtgcgtgg	780
	tggtggctct	gctgctgcag	gggtgtctcc	tgctcgagct	gcttgacttc	ccaccgctct	840
	ctgggtctcc	ggatggccat	gccatctggc	acatcagcac	catccctgtc	cacgtcctct	900
	ttttcagctt	tctggaagat	gacagcctgt	acctgctgaa	ggaatcagag	gacaagttca	960
	agctggactg	agaacttgga	gcgaagtctg	ccccagtggt	gatcctgccc	ccgcccctgt	1020
35	ggcctccctt	ctcccctcaa	cccttgagat	gattttctct	tttcaacttc	ttgaacttgg	1080
	acatgaagga	tggtggccca	gaatcatgtg	gccagcccac	ccctgtttgg	ccctcaccag	1140
	ccttgagctc	tggtctaggg	aaggcctccc	agcatctggg	actcgagagt	gggcagcccc	1200
	tctacctcct	gggtggaact	gggtgtgtgt	tgagtgtgtt	cttagctcta	ccgggaggac	1260
	agctgcctgt	ttcctcccca	ccagcctcct	ccccacatcc	ccagctgcct	ggctgggtcc	1320
40	tgaagccctc	tgtctacctg	ggagaccagg	gtaccacagg	ccttagggat	acagggggtc	1380
	cccttctgtt	accaccccc	accctcctcc	aggacaccac	taggtgggtc	tggtatgctg	1440
	ttctttggcc	agccaagggt	cacggcgatt	ctcccatggg	gatcttgagg	gaocaaagctg	1500
	ctgggattgg	gaaggagttt	cacctgacc	gttgccctag	ccaggttccc	aggaggcctc	1560
	accatactcc	ctttcagggc	cagggtctca	gcaagccag	ggcaaggatc	ctgtgctgct	1620
	gtctggttga	gagcctgcca	ccgtgtgtcg	ggagtgtggg	ccaggctgag	tgcataggtg	1680
45	acagggccgt	gagcatgggc	ctgggtgtgt	gtgagctcag	gcctaggtgc	gcagtgtgga	1740
	gacgggtgtt	gtcggggaag	aggtgtggct	tcaaagtgtg	tggtgtgcag	gggtgggtgt	1800
	gttagcgtgg	gttaggggaa	cgtgtgtgctg	cgtgctgggt	ggcatgtgag	atgagtgcct	1860
	gcgggtgaat	gtgtccacag	ttgagaggtt	ggagcaggat	gagggaaatcc	tgccaccatc	1920
	aataatcact	tggtgagcgc	cagctctgcc	caagacgcca	cctgggcgga	cagccaggag	1980
50	ctctccatgg	ccaggctgcc	tggtgtgcag	ttccctgtct	ggtgcccctt	tgcccgcctc	2040
	ctgcaaacct	cacagggtcc	ccacacaaca	gtgccctcca	gaagcagccc	ctcggaggca	2100
	gaggaaggaa	aatggggatg	gctggggctc	tctccatcct	ccttttctcc	ttgccttcgc	2160
	atggctggcc	ttccctccca	aaacctccat	tccctgtctg	ccagcccctt	tgccatagcc	2220
	tgatcttggg	gaggaggaag	gggcgatttg	agggagaagg	ggagaaaagct	tatggctggg	2280
	tctgggttct	tccctcccca	gagggctcta	ctgttccagg	gtggccccag	gcagcagggc	2340
55	cacactatgc	ctgcgcctcg	gtaaagggtga	cccctgccat	ttaccagcag	ccctggcatg	2400

	ttcctgcccc	acaggaatag	aatggaggga	gtccagaaa	ctttccatcc	caaaggcagt	2460
	ctccgtggtt	gaagcagaot	ggatttttgc	tctgcccctg	accccttgtc	cctotttgag	2520
	ggagggggagc	tatgctagga	ctccaacctc	agggactcgg	gtggcctgcg	ctagcttctt	2580
5	ttgatactga	aaacttttaa	ggtggggagg	tggcaaggga	tgtgcttaag	ogggccgcga	2640
	ttcaaaaagc	ttctcgagag	tacttctaga	goggccgcgg	gcccctcgat	tttncacccc	2700
	gggtggggta	cccaggttaag	tgtnccccat	atc			2733

<210> 64

<211> 2546

<212> DNA

<213> Homo sapiens

<400> 64

	aagctcctcc	cccggcggcg	agccagggag	aaaggatggc	cggcctggcg	gcgcgggttg	60
	tctctgtagc	tggggcagcg	gcgctggcga	gcggctccca	gggcgaccgt	gagccgggtgt	120
20	accgcgactg	cgtactgcag	tgcgaagagc	agaactgtc	tgggggcgct	ctgaatcact	180
	tccgctcccc	ccagcacaac	tacatgagtc	tagcaggctg	gacctgtcgg	gacgactgta	240
	agtatgagtg	tatgtgggtc	accgttgggc	tctacctcca	ggaaggctac	aaagtgcctc	300
	agttccatgg	caagtggccc	ttctcccggt	tctgtttctt	tcaagagccg	gcctogggccg	360
	tggcctcggt	tctcaatggc	ctggccagcc	tggatgatgt	ctgccgctac	cgcaccttcg	420
25	tggcagcctc	ctcccccatg	taccacacct	gtgtggcctt	cgcctgggtg	tccctcaatg	480
	catggttctg	gtccacagtc	ttccacacca	gggacaactg	cctcacagag	aaaatggact	540
	acttctgtgc	ctccactgtc	atcctacact	caatctacct	gtgctgcgtc	aggcctgggtc	600
	aacgtgggtg	ggtggcgtgg	ctggtgcctg	tggaccagc	ggcggctgcc	tcacgtgcgc	660
	aagtgcgtgg	tgggtgtctt	gctgctgcag	gggctgtccc	tgtctcgagot	gcttgacttc	720
30	ccaccgctct	tctgggtcct	ggatgcccac	gccatctggc	acatcagcac	catccctgtc	780
	cacgtcctct	ttttcagctt	tctggaagat	gacagcctgt	acctgtgtaa	ggaatcagag	840
	gacaagtcca	agctggaactg	aagaccttgg	agcgagctct	ccccagtggg	gatcctgccc	900
	ccgcctctgt	ggcctccctt	ctccctccaa	cccttgagat	gattttctct	tttcaacttc	960
	ttgaacttgg	acatgaagga	tgtgggcccc	gaatcatgtg	gccagcccoac	cccctgttgg	1020
	ccctcaccag	ccttggaagtc	tgtcttaggg	aaggcctccc	agcatctggg	actcgagagt	1080
35	gggcagcccc	tctacctcct	ggagctgaac	tgggttgga	ctgagtgtgt	tcttagctot	1140
	accgggagga	cagctgcctg	tttctcccc	accagcctcc	tccccacatc	cccagctgce	1200
	tggctgggtc	ctgaagccct	ctgtctacot	gggagaccag	ggaccacagg	ccttagggat	1260
	acagggggtc	ccctctctgt	accaccccc	accctcctcc	aggacaccac	taggtgggtg	1320
	tggatgcttg	ttctttggcc	agccaagggt	cacggcgatt	ctccocatgg	gatcttgagg	1380
40	gaccaagctg	ctgggattgg	gaaggagttt	cacctgacc	gttgccctag	ccaggttccc	1440
	aggaggcctc	accatactcc	ctttcagggc	cagggctcca	gcaagcccag	ggcaaggatc	1500
	ctgtgctgct	gtctggttga	gagcctgcca	cctgtgtctg	ggagtgtggg	ccaggctgag	1560
	tgcataagtg	acagggccgt	gagcatgggc	ctgggtgtgt	gtgagctcag	gcctaggtgc	1620
	gcagtgtgga	gacgggtgtt	gtcggggaag	agggtgtggc	tcaaagtgtg	tgtgtgcagg	1680
	gggtgggtgt	gttagcgtgg	gttaggggaa	cgtgtgtgcg	cgtgtgtgtg	ggcatgtgag	1740
45	atgagtgaat	gcccgtgaat	gtgtccacag	ttgagagggt	ggagcaggat	gagggaaatcc	1800
	tgtcaccatc	aataatcact	tgtggagcgc	cagctctgcc	caagacgcca	cctgggcgga	1860
	cagccaggag	ctctccatgg	ccaggctgcc	tgtgtgcatg	ttccctgtct	ggtgcccctt	1920
	tgcgcgcctc	ctgcaaacct	cacagggtcc	ccacacaaca	gtgccctcca	gaagcagccc	1980
	ctcggaggca	gaggaaggaa	aatggggatg	gctggggctc	tctccatcct	ccttttctcc	2040
50	ttgccttcgc	atggctggcc	ttccctcca	aaacctccat	tcccctgctg	ccagccccc	2100
	tgccatagcc	tgattttggg	gaggaggaa	gggcatgttg	aggagaaagg	ggagaaagct	2160
	tatggctggg	tctggtttct	tcccttccca	gaggtcttta	ctgttccagg	gtggcccccag	2220
	ggcaggcagg	ggccacacta	tgcctgcgcc	ctggtaaaag	tgaccctgc	catttaccag	2280
	cagccctggc	atgttctctg	cccacaggaa	tagaatggag	ggagctccag	aaactttcca	2340
	tcccaaggc	agtctccgtg	gttgaagcag	actggatttt	tgtctgtccc	ctgacccctt	2400
55	gtccctcttt	gagggagggg	agctatgcta	ggactccaac	ctcagggaact	cgggtggcct	2460

gcgctagctt cttttgatac tgaaaacttt taaggtagga gggtaggaag ggatgtgctt 2520
aataaatcaa ttccaagcct cacctg 2546

<210> 65

<211> 2683

<212> DNA

<213> Homo sapiens

<400> 65

15	aagctcctcc	cccggcggcg	agccaggag	aaaggatggc	cggcctggcg	gcgcggttgg	60
	tcctgctagc	tggggcagcg	gcgctggcga	gcggctccca	gggcgaccgt	gagccggtgt	120
	accgcgactg	cgtactgcag	tgogaagagc	agaactgctc	tgggggogct	ctgaatcact	180
	tccgctcccg	ccagccaatc	tacatgagtc	tagcaggctg	gacctgtcgg	gacgactgta	240
	agtatgagtg	tatgtgggtc	accgttgggc	tctacctcca	ggaaggtcac	aaagtgcctc	300
	agttccatgg	caagtggccc	ttctcccggt	tcctgttctt	toaagagccg	gcctcggccg	360
20	tggcctcggt	tctcaatggc	ctggccagcc	tggtagtgct	ctgcgcgtac	cgcaccttcg	420
	tggcagcctc	ctcccccatg	taccacacct	gtgtggcctt	cgcttgggtg	tcctcfaatg	480
	catggtcttg	gtocacagtc	ttccacaoca	gggacaactga	cctcacagag	aaaatggaot	540
	aactctgtgc	ctccactgtc	atcctacaot	caatctacct	gtgctgcgtc	aggaccgtgg	600
	ggctgcagca	cccagctgtg	gtcagtgcc	tccgggctct	cctgctgctc	atgctgaccg	660
25	tgcacgtctc	ctacctgagc	ctcatccgct	tcgactatgg	ctacaacctg	gtggccaacg	720
	tggctattgg	cctggtcaac	gtggtgtggt	ggctggcctg	gtgcctgtgg	aaccagcggc	780
	ggctgcotca	cgtgcgcaag	tgogtgggtg	tggctcttgc	gctgcagggg	ctgtccctgc	840
	togagctgct	tgaactccca	ccgctctctt	gggtcctgga	tgcccatgcc	atctggcaca	900
	tcagcaccat	ccctgtccac	gtcctctttt	tcagctttct	ggaagatgac	agcctgtacc	960
	tgctgaagga	atcagaggac	aagtccaagc	tggactgaag	accttggagc	gagcttgccc	1020
30	cagtggggat	cctgcccccg	ccctgctggc	ctcccttctc	ccctcaaccc	ttgagatgat	1080
	tttctctttt	caactctctg	aacttggaac	tgaaggatgt	gggcccagaa	tcattgtggc	1140
	agcccacccc	ctgttggccc	tcaccagcct	tggagtctgt	tcagggaag	gcctcccagc	1200
	atctgggact	cgagagtggg	cagccctctt	acctcctgga	gctgaactgg	ggtggaactg	1260
	agtgtgttct	tagctotacc	gggaggacag	ctgcctgttt	cctccccacc	agcctcctcc	1320
35	ccacatcccc	agctgcctgg	ctgggtcctg	aagccctctg	tctacctggg	agaccaggga	1380
	ccacaggcct	tagggataca	gggggtcccc	ttctgttacc	acccccacc	ctcctccagg	1440
	acaccactag	gtggtgctgg	atgcttgttc	tttggccagc	caagggttoac	ggcattcttc	1500
	cccattggat	cttgaggggc	caagctgctg	ggattgggaa	ggagtttcac	cctgaccgtt	1560
	gcccagccca	ggttcccagg	aggcctcacc	atactccctt	tcagggccag	ggctccagca	1620
40	agcccagggc	aaggatcctg	tgctgctgtc	tggttgagag	cctgccaccg	tgtgtcggga	1680
	gtgtggggca	ggctgagtg	ataggtgaca	gggcccgtgag	catgggcctg	ggtgtgtgtg	1740
	agctcaggcc	taggtgocga	gtgtggagac	gggtgttgtc	ggggaagagg	tgtggcttca	1800
	aagtgtgtgt	gtgcaggggg	tgggtgtgtt	agcgtgggtt	aggggaacgt	gtgtgcgcgt	1860
	gctggtgggc	atgtgagatg	agtgaactgc	ggtgaatgtg	tccacagttg	agaggttgga	1920
	gcaggatgag	ggaatcctgt	caccatcaat	aatcaactgt	ggagcgccag	ctctgcccaa	1980
45	gacgccacct	gggcgggacg	ccaggagctc	tccatggcca	ggctgcctgt	gtgcatgttc	2040
	cctgtctggt	gcccccttgc	ccgcctcctg	caaacctcac	agggtccccca	cacaacagtg	2100
	ccctccagaa	gcagcccctc	ggaggcagag	gaaggaaaaa	gggatgggt	ggggctctct	2160
	ccatcctcct	tttctccttg	ccttcgcagt	gctggccttc	ccctccaaaa	cctccattcc	2220
	cctgtgcca	gcccccttgc	catagcctga	ttttggggag	gaggaagggg	cgatttgagg	2280
50	gagaaggggg	gaaagcttat	ggctgggtct	ggtttcttcc	cttcccagag	ggtcttactg	2340
	ttocagggtg	gccccagggc	aggcaggggc	cacactatgc	ctgcgccttg	gtaaagggtga	2400
	cccctgccat	ttaccagcag	ccctggcatg	ttcctgcccc	acagggaatg	aatggaggga	2460
	gctccagaaa	ctttccatcc	caaaggcagt	ctccgtgggt	gaagcagact	ggatttttgc	2520
	tctgcccttg	accccttgct	cctctttgag	ggaggggagc	tatgctagga	ctccaacctc	2580
	agggactcgg	gtggcctgcg	ctagcttctt	ttgatactga	aaacttttaa	ggtgggaggg	2640
55	tggcaaggga	tgtgcttaat	aaatcaattc	caagcctcac	ctg		2683

<210> 66

<211> 2341

<212> DNA

<213> Homo sapiens

<400> 66

aagctcctcc	cccggcggcg	agccaggag	aaaggatggc	cggcctggcg	gcgcggttgg	60
tcctgctagc	tggggcagcg	gcgctggcga	gcggctccca	gggcgacogt	gagccggtgt	120
accgogactg	cgtactgcag	tgogaagagc	agaactgctc	tgggggcgct	ctgaatcact	180
tccgctcccg	ccagccaatc	tacatgagtc	tagcaggctg	gacctgtcgg	gacgactgta	240
agtatgagtg	tatgtgggtc	accgttgggc	tctaccteca	ggaaggtcac	aaagtgcctc	300
agttccatgg	caagtggccc	ttctcccggt	tcctgttctt	tcaagagccg	gcctcggccg	360
tggcctcggt	tctcaatggc	ctggccagcc	tgggtatgct	ctgcgcgtac	cgcaccttog	420
tgccagcctc	ctcccccatg	taccacacct	gtgtggcctt	cgcctgggtg	tcctcfaatg	480
catgtttctg	gtccacagtc	ttccacacca	gggacactga	cctcacagag	aaaatggact	540
actttctgtc	ctccactgtc	atcctacact	caatctacct	gtgctgogtc	agctttctgg	600
aagatgacag	cctgtacctg	ctgaaggaat	cagaggacaa	gttcaagctg	gactgaagac	660
cttgagcgga	gtctgcccc	gtggggatcc	tgcccccgcc	ctgotggcct	cccttctccc	720
ctcaaccctt	gagatgattt	tctcttttca	acttcttgaa	cttgacatg	aaggatgtgg	780
gcccagaatc	atgtggcoag	cccacccctt	gttggccctc	accagccttg	gagtctgttc	840
tagggaaggc	ctcccagcat	ctgggaotog	agagtgggca	gcccctctac	ctcctggagc	900
tgaactgggg	tggaaactgag	tgtgtttotta	gctctaccgg	gaggacagct	gcctgtttcc	960
tccccaccag	cctcctcccc	acatccccag	ctgcctggct	gggtcctgaa	gccctctgtc	1020
tacctgggag	accagggacc	acaggccctta	gggatacagg	gggtcccctt	ctgttaccac	1080
ccccacccct	cctccaggac	accactaggt	ggtgtctggat	gcttgttctt	tggccagcca	1140
aggttcaogg	cgattctccc	catgggatct	tgagggacca	agctgotggg	attgggaagg	1200
agtttcaccc	tgaccgttgc	cctagccagg	ttcccaggag	gcctcaccat	actccctttc	1260
agggccaggg	ctccagcaag	cccagggcaa	ggatocctgt	ctgctgtctg	gttgagagcc	1320
tgccaccgtg	tgtcgggagt	gtggggccagg	ctgagtgcac	aggtgacagg	gccgtgagca	1380
tgggcctggg	tgtgtgtgag	ctcaggcccta	ggtgcgcagt	gtggagacgg	gtgttgtcgg	1440
ggaagagggt	tggcttcaaa	gtgtgtgtgt	gcaggggggt	ggtgtgttag	cgtgggttag	1500
gggaacgtgt	gtgcgcgtgc	tggtgggcat	gtgagatgag	tgactgccgg	tgaatgtgtc	1560
cacagttagg	aggttggagc	aggatgaggg	aatcctgtca	ccatcaataa	tcacttgttg	1620
agcgcacagt	ctgcccaga	cgccacotgg	gcggacagcc	aggagctctc	catggcoagg	1680
ctgcctgtgt	gcatgttccc	tgtctggtgc	ccctttgccc	gcctcctgca	aacctcacag	1740
ggtccccaca	caacagtgcc	ctccagaagc	agcccctcgg	aggcagagga	aggaaaatgg	1800
ggatggctgg	ggtctctctc	atcctccttt	tctccttgcc	ttcgcattgc	tggccttccc	1860
ctccaaaacc	tccattcccc	tgtgtccagc	ccctttgcca	tagcctgatt	ttggggagga	1920
ggaaggggcg	atttgaggga	gaaggggaga	aagcttatgg	ctgggtctgg	tttcttccct	1980
tcccagaggg	tcttactgtt	ccaggggtgc	cccagggcag	gcagggggcca	cactatgcct	2040
gcgccttggt	aaaggtgacc	cctgccattt	accagcagcc	ctggcatgtt	cctgcccac	2100
aggaatagaa	tggagggagc	tccagaaaact	ttccatccca	aaggcagtct	ccgtgggtga	2160
agcagactgg	atttttgctc	tgcccctgac	cccttgtccc	tctttgaggg	aggggagcta	2220
tgtctaggact	ccaacctcag	ggactcgggt	ggcctgcgct	agcttctttt	gatactgaaa	2280
acttttaagg	tgggaggggtg	gcaagggatg	tgcttaataa	atcaattcca	agcctcacct	2340
g						2341

<210> 67

<211> 2109

<212> DNA

<213> Homo sapiens

<400> 67

gattcgccg	gagctgccag	cggggaggct	gcagccggcg	gttggttacag	ctgctggagc	60
agcagcgcc	cccgtcccc	ggaaccgttc	ccgggcccgtt	gatcttcggc	cccacacgaa	120
cagcagagag	gggcagcagg	atgaatgtgg	gcacagcgca	cagcgagggtg	aaocccaaca	180
cgcggtgat	gaacagccgt	ggcatctggc	tctcctacgt	gctggocac	ggtctoctcc	240
acatcgtgt	gctgagcatc	ccgtttgtga	gtgtccctgt	cgtctggaco	ctcaccaacc	300
tcattcaca	catgggcatg	tatatottcc	tgcacaoggt	gaaggggaca	ccctttgaga	360
ccccggacca	gggcaaggcg	aggctgtctaa	cccactggga	gcagatggat	tatggggtcc	420
agttcacggc	ctctcggaag	ttcttgacca	tcacacccat	cgtcgtgtac	ttcctcacca	480
gottotacac	taagtacgac	cagatccatt	ttgtgctcaa	caccgtgtcc	ctgatgagcg	540
tgcttatccc	caagctgccc	cagctccacg	gagtcgggat	ttttggaatc	aataagtact	600
gagagtgcag	ccccttcccc	tgcccagggt	ggcaggggag	gggtagggtg	aaaggcatgt	660
gotgcaacac	tgaagacaga	aagaagaagc	ctctggacac	tgccagagat	gggggttgag	720
cctctggcct	aatttcccc	ctcgtctccc	ccagtagcca	acttgagta	gcttgtagtg	780
gggttggggt	aggccccctg	ggctctgacc	ttttctgaat	tttttgatct	cttccctttg	840
ctttttgaat	agagactcca	tggagtgtgt	catggaatgg	gctgggctcc	tgggctgaac	900
atggaocacg	cagttgcgac	aggaggccag	gggaaaaacc	cctgctcact	tgtttgccct	960
caggcagcca	aagcaottta	accctgtcat	agggagcaga	ggcggtacg	gcttctggat	1020
tgtttcactg	tgattcctag	gttttttoga	tgccatgcag	tgtgtgcttt	tgtgtatgga	1080
agcaagtgtg	ggatgggtot	ttgcctttct	gggtaggggag	ctgtctaata	caagtccag	1140
gottttggca	gcttctctgc	aaccacccgt	gggtccctgt	tgggagtggg	gagggtcagg	1200
ttggggaaaag	atggggtaga	gtgtagatgg	cttggttcca	gaggtgaggg	ggccagggct	1260
gotgccatcc	tggcctgggt	gaggttgggg	agctgtagga	gagctagtga	gtcgagactt	1320
agaagaatgg	ggccacatag	cagcagagga	ctgtgttaag	ggagggaggg	gtagggacag	1380
aagctagacc	caatotoott	tgggatgtgg	gcagggaggg	aagcaggctt	ggaggggtta	1440
tttaccacaca	gaatgtgata	gtaatagggg	agggaggctg	ctgtgggttt	aactcctggg	1500
ttggctgttg	ggtagacagg	tggggaaaag	gcccgtgagt	cattgtaagc	acaggtccaa	1560
ottggccctg	actcctgcgg	gggtatgggg	aagctgtgac	agaaacgatg	ggtgctgtgg	1620
tcctctgcag	gcctcacc	cttaacttcc	tcatgcagac	tggcactggg	cagggcctct	1680
catgtggcag	coacatgtgg	cgttgtgagg	ccaccccatg	tgggtctgt	ggtgagagtc	1740
ctgtaggatc	cctgctcaag	cagcacagag	gaaggggcaa	gacgtggcct	gtagggcactg	1800
totcagcctg	cagagaagaa	agttagggccg	ggagcctgag	cctgggctgg	agccttctcc	1860
cctccccagt	tggactaggg	gcagtgttaa	ttttgaaaag	gtgtgggtcc	ctgtgtcctt	1920
ttccaggggt	ccaagggaac	aggagaggto	actgggcctg	ttttctccct	cctgaccctg	1980
catctcccac	cctgtgtatc	atagggaaact	ttcaccttaa	aatctttcta	agcaaagtgt	2040
gaataggatt	tttactccct	ttgtacagta	ttctgaggaa	cgcaaataaa	agggcaacat	2100
gtttctgtt						2109

<210> 68

<211> 2423

<212> DNA

<213> Homo sapiens

<400> 68

	gagagccgag	ctagcgacga	gcagtcgttg	cgccgcgcgg	cgccgcggga	ggtggtggag	60
	gcctagccgg	agccgagagg	tctcttgttc	ccgtcccacg	gtcccggcgt	cacccctccg	120
5	gcgcccagtc	cccgtcccgg	aactcccggg	cctgtccttg	gcccccggtc	tgtgcactcc	180
	gctcgcgcga	gcgcccggcc	cgggccgcac	ccgcggggcc	catgaggagg	gacgtgaacg	240
	gagtgaccaa	gagcaggttt	gagatgttct	caaatagtga	tgaagctgta	atcaataaaa	300
	aacttcccaa	agaactcctg	ttacggatat	ttctttttct	agatgttggt	accctgtgcc	360
	gctgtgtcca	ggtctccagg	gcctggaatg	ttctggctct	ggatggcagt	aactggcagc	420
	gaattgacct	atttgatttc	cagagggata	ttgagggccg	agtagtgagg	aatatttcaa	480
10	aacgatgtgg	gggcttttta	cgaaagttaa	gtcttcgttg	atgtcttgga	gtgggagaca	540
	atgcattaag	aacctttgca	caaaactgca	ggaacattga	agtactgaat	ctaaatgggt	600
	gtacaaagac	aacagacgct	acatgtacta	gccttagcaa	gttctgttcc	aaactcaggc	660
	accttgactt	ggcttctgtt	acatcaataa	caaacatgtc	tctaaaagct	ctgagtgagg	720
	gatgtocact	gttgaggcag	ttgaacattt	cctgggtgta	ccaagtaacc	aaggatggca	780
15	ttcaagcact	agtgaggggc	tgtgggggtc	tcaaggcoct	attcttaaaa	ggctgcaogc	840
	agctagaaga	tgaagctctc	aagtacatag	gtgcacactg	ccctgaactg	gtgaacttga	900
	aactgcagac	ttgcttgcaa	atcacagatg	aagggtctcat	tactatatgc	agaggggtgc	960
	ataagttaca	atccctttgt	gcctctggct	gtccaacat	cacagatgcc	atcctgaatg	1020
	ctctaggcca	gaactgcccc	cggttagaaa	tattggaagt	ggcaagatgt	tctcaattaa	1080
20	cagatgtggg	ctttaaccact	ctagccaggga	attgccatga	acttgaaaag	atggacctgg	1140
	aagagtgtgt	tcagataaca	gatagcacat	taatocaaact	ttctatacac	tgtcctcgac	1200
	ttcaagtatt	gagtotgtct	cactgtgagc	tgatocacaga	tgatggaaat	cgtaacctgg	1260
	ggaatggggc	ctgcgcccat	gaccagctgg	aggtgattga	gotggacaac	tgcccactaa	1320
	tcacagatgc	atccctggag	cacttgaaga	gctgtcatag	ccttgagcgg	atagaactct	1380
	atgactgcc	gcaaatcaca	cggtctggaa	tcaagagact	caggacccat	ttacccaata	1440
25	ttaaagtcca	cgctacttc	gcacctgtca	ctccaccccc	atcagtaggg	ggcagcagac	1500
	agcgtctctg	cagatgtctg	atcatcctat	gacaatggag	gtggtcaacc	ttggcgaaat	1560
	gagtatttaa	tgacacttct	agagctaccg	tggagtctct	ccagtgggaag	caacccccagt	1620
	gttctgagca	agggttacaa	agtgagggag	ggcagtgctc	agatccocag	agccacacat	1680
	acatacacat	acacaccctt	acccccatcc	actotagctt	tgtgaccatg	ggactgaagt	1740
30	ttgtgatggc	ttttttatca	agtagattgg	taaaatttaa	ccattcctgt	tgagggtgccc	1800
	ataagaaaat	cataggccaa	gatagggagg	ggcattccag	caaaocccgt	gttaattgcta	1860
	ctgtggtttt	taaatttttg	tctagggggt	tctttgggga	ttttagaaca	gcatotgotg	1920
	tcctccgggg	tcaagaaaag	catggaaaga	caatatatga	tgtaaccagg	gaccagaaag	1980
	aaaatttctt	tgcatottag	aaatggtaga	cattcattgt	gactaaagag	cttctatgct	2040
	tcctgtgttc	catgccaaaca	tgctgagcat	gtccacaaag	aaggctcgtc	cattcctcct	2100
35	gtgttttagt	atttgcccca	gaggtttcct	aaatggttgc	cttgaaatca	ctgtggtcca	2160
	aatgtaatto	ttcacacactc	aaattatcac	tgtotgtagc	acacttgtgc	acctgtctta	2220
	cattctctgt	tgtccccccc	cacactottg	ctcagtcctg	cacotgttca	gtotgcttac	2280
	tcactcaatt	gttacccttt	tgtgtgtgtc	gtgtttacag	tttgcatttt	gaatgattag	2340
	ttgggattac	caaacatttt	ttaaaaagat	attatcaata	aatatttttt	taattotaaa	2400
40	ttttaaaaaa	aaaaaaaaaa	aaa				2423

<210> 69

<211> 1841

<212> DNA

<213> Homo sapiens

<400> 69

	agctgggacc	ggagggtgag	cccggcagag	gcagagacac	acgcgggagag	gaggagaggg	60
	tgaggggagg	agggtggaga	ggacgggaga	ggcagagaga	ggagacacgc	agagacactc	120
	aggaggggag	agacaccgag	acgcagagag	actcaggagg	ggagagacac	cgagacgcag	180
	agacaccag	ccgggggagc	gcgagggagc	gaggcacaga	cctggctcag	cgagcgcggg	240
55	gggcgagccc	cgagtcccca	gagcctgggg	gcgcgcccag	cccgggcgc	gacctcctc	300

5 cccgtcccgc gccctcccct cggcgggcac ggtattttta tccgtgcgcg aacagccctc 360
 ctccctccct cgcgcgcacag cccgcgcgcct gcgcggggga gccagcaca gaccgcgcgc 420
 gggaccccga gtcgcgcacc ccagccccac cgcgccacccc gcgcgcgatg gaccccaagg 480
 accgcaagaa gatccagttc tcgggtgccc cgcgccctag ccagctcgac ccccgccagg 540
 tggagatgat ccggcgcagg agaccaaogc ctgccatgct gttccggctc tcagagcact 600
 cctcaccaga ggaggaagcc tccccccacc agagagcctc aggagagggg caccatctca 660
 agtcgaagag acccaacccc tgtgcctaca caccaccttc gctgaaagct gtgcagcgca 720
 ttgctgagtc tcacctgoag tctatcagca atttgaatga gaaccaggcc tcagaggagg 780
 aggatgagct gggggagctt cgggagctgg gttatccaag agaggaagat gaggaggaag 840
 10 aggaggatga tgaagaagag gaagaagaag aggacagcca ggctgaagtc ctgaagggtca 900
 tcaggcagtc tgctgggcaa aagacaacct gtggccaggg tctggaaggg ccctgggagc 960
 gcccaacccc tctggatgag tccgagagag atggaggctc tgaggacca gtggaagacc 1020
 cagcactaag tgagcctggg gaggaacctc agcgccttc cccctctgag cctggcacat 1080
 agggacccag cctgcctctc ccaggaggaa gtggagggga catogctgtt cccagaaac 1140
 15 ccactctatc ctcacctgt tttgtgctot tccctcgcc tgctagggct gcggttctg 1200
 acttctagaa gactaaggct ggtctgtgtt tgctgtttg cccaccttg gotgataccc 1260
 agagaacctg ggcaactgtc gcctgatgcc caccccctgc agtcattcct ccattcaccc 1320
 acggggaggt gggatgtgag acagcccaca ttggaatac cagaaaaacc ggaacagggg 1380
 tttgcccttc acaattctac tcccagatc ctctccctg gacacaggag acccacaggg 1440
 caggacccta agatctgggg aaaggaggct ctgagaacct tgaggtaacc ttagatcctt 1500
 20 ttctaccac ttctctatgg aggatccaa gtcaccaact ctctcacogg cttctaccag 1560
 ggtccaggac taaggcgttt ttctccatag cctcaacatt ttgggaatct tcccttaac 1620
 acccttgctc ctctgggtg cctggaagat ggactggcag agacotctt gttgogtttt 1680
 gtgctttgat gccaggaatg ccgcctagtt tatgtcccg gtggggocaa cagcgggggg 1740
 cgccagggtt tccttgctcc ccagctgctc tgcccccttc cccttcttcc ctgactccag 1800
 25 gcctgaaccc ctccctgct gtaataaata tttgtaata a 1841

<210> 70

<211> 748

30 <212> DNA

<213> Homo sapiens

35 <400> 70
 ggccgcgatg agcggggagc cggggcagac gtccgtagcg cccctcccg aggaggctga 60
 gccgggcagt ggggtccgca tcgtggtgga gtactgtgaa ccctgcggct tcgaggcgac 120
 ctacctggag ctggccagt ctgtgaagga gcagtatccg ggcctogaga tcgagtcgcg 180
 40 cctcgggggc acaggtgcct ttgagataga gataaatgga cagctggtgt tctccaagct 240
 ggagaatggg ggctttccct atgagaaaga tctcattgag gccatccgaa gagccagtaa 300
 tggagaaaco ctagaaaaga tcaccaacag ccgtcctccc tgcgtcatcc tgtgactgca 360
 caggactctg ggttccctgt ctgttctggg gtccaaacct tggctccct ttggtcctgc 420
 tgggagctcc ccctgcctct ttccctact tagctcotta gcaaagagac cctggcctcc 480
 actttgccct ttgggtacaa agaaggaata gaagattccg tggccttggg ggcaggagag 540
 45 agacactctc catgaacact tctccagcca cctcatccc ccttcccagg gtaagtgcc 600
 acgaaagccc agtccactct tcgcctcggt aatacctgtc tgatgccaca gattttattt 660
 attctccctt aaccaggggc aatgtcagct attggcagta aagtggcgct acaaacacta 720
 aaaaaaaaaa aaaaaaaaaa aaaaaaaa 748

50

55

<210> 71

<211> 795

<212> DNA

<213> Homo sapiens

<400> 71

tacggctg	agaagacgac	agaagctaga	cccaatctcc	tttgggatgt	gggcagggag	60
ggaagcaggc	ttggaggggt	aatttacc	cagaatgtga	tagtaatagg	ggagggaggc	120
tgctgcggt	ttactcctg	ggttggctgt	tgggtagaca	ggtggggaaa	aggcccgtga	180
gtcattgtaa	gcacaggctc	aacttggccc	tgactcctgc	gggggtatgg	ggaagctgtg	240
acagaaacga	tgggtgctgt	ggtcctctgc	aggccctcac	cccttaactt	cctcatacag	300
actggcactg	ggcagggcct	ctcatgtggc	agccacatgt	ggcgttgtga	ggccacccca	360
tgtggggctc	gtggtgagag	tcctgttaga	tcctgtctca	agcagcacag	aggaaggggc	420
aagacgtggc	ctgtaggcac	tgtctcagcc	tgcagagaag	aaagttaggc	cgggagcctg	480
agcctgggct	ggagccttct	ccctcccca	gttggactag	gggcagtgtt	aattttgaaa	540
aggtgtgggt	ccctgtgtcc	tcttccaggg	gtccaaggga	acaggagagg	tcactggggc	600
tgttttctcc	ctcctgaccc	tgcattctcc	acccogtgta	tcatagggaa	ctttcacctt	660
aaaatctttc	taagcaaagt	gtgaatagga	tttttactcc	ctttgtacag	tattctgaga	720
aacgcaata	aaagggaac	atgtttctgt	taaaaaaaaa	aaaaagtacg	caaaaaaaaa	780
aaaaaaaaaa	aaaaa					795

<210> 72

<211> 2356

<212> DNA

<213> Homo sapiens

<400> 72

ggcacgagggc	cggaaagtgc	ctctagagcg	gtggtgaaac	tggcagttga	cggctcctgg	60
gactagatcc	cgcgaggtag	ccccgaact	atttctctac	gtttctctct	gacccctccg	120
aaatcttcca	gatccgcgta	gtgaggaatc	gtotccacog	tcattggggg	cggagacctg	180
aatctgaaga	agagotggca	ccgcgagacc	ctcaggaatg	tggagaaagt	gtggaaggcc	240
gagcagaagc	atgaggctga	gcggaagaag	attgaggagc	ttcagcggga	gctgcgagaa	300
gagagagccc	gggaagagat	gcagcgctat	gcggaggatg	ttggggccgt	caagaaaaaa	360
gaagaaaagt	tggactggat	gtaccagggt	cctggtggga	tgggtgaaccg	tgacgagtac	420
ctgctggggc	gccccattga	caaatatgtt	tttgagaaga	tggaggagaa	ggaggcaggc	480
tgctcttctg	aaacaggact	tctcccaggc	tctatctttg	ccccatcagg	tgccaattcc	540
cttcttgaca	tggccagcaa	gatccgggag	gacccactct	tcattcatcag	gaagaaggag	600
gaggagaaaa	aacgagaggt	attaaataat	ccagtgaata	tgaagaaat	caaagaattg	660
ttgcaaatga	gtctggaaaa	aaaggagaag	aagaaaaaga	aggagaagaa	aaagaagcac	720
aagaaacata	agcacagaag	ctcagagtagt	gatcgttcca	gcagcgagga	tgagcacagt	780
gcagggagat	cacagaagaa	gatggcaaat	tcctccctg	ttttgtccaa	agtccctgga	840
tatggcttac	aggtccggaa	ctctgaccgt	aaccagggtc	ttcagggtcc	tctgacagca	900
gagcaaaaga	gagggcatgg	gatgaagaac	cattccagat	ccagaagctc	ctccactca	960
cccccaagac	atgccagcaa	gaagagcacc	agggaaagcag	ggtcccgga	caggaggtct	1020
cgatccctgg	gcagaaggctc	acggtcccca	agaccagca	aactgcacaa	ctctaagggtg	1080
aacaggagag	agacaggcca	aactaggagc	ccatcaccta	aaaaagaggt	ctaccaagg	1140
cgcattgctc	ccggatacac	cagaaaaactc	tctgcagagg	aattagagcg	aaaacggcaa	1200
gagatgatgg	aaaacgcca	atggaggggag	gaggagagac	tgaacatcct	caagaggcat	1260
gctaaggatg	aggaacggga	gcagaggcta	gagaagctgg	actcccgga	tgggaagttc	1320

	atccaccgca	tgaagctgga	gagtgcacat	acttoctccc	tggaggatcg	ggtgaagcgg	1380
	aatatctact	ctttacagag	aacttcggta	gctctggaga	agaactttat	gaaaagatga	1440
5	aaactgtccc	ctctcttatt	ggttttcctg	cattttccag	ggaagctgct	gacccttaa	1500
	ttctctttat	aagagttcaa	atgacttcct	tcacagatgt	caaaccacca	gtgttcaaag	1560
	tgaccctgct	tcattgagtc	ctgaaacagc	tcacttcctt	tgagagctag	tgtgacttgc	1620
	tttgtgggac	actcagtaac	tttgggtttt	gactctttaa	cgggtgggca	ctggaccatc	1680
	tcgggtgggag	tgcttgtgcc	actotggaag	gctgttcctt	gggttgtgga	tgtttatcat	1740
	gccacttcct	tcttaacctgt	gccaacagac	ctatttcaat	gcctcagcgt	acaccagacc	1800
10	cttcagaaac	ctctctgggtg	tcacccagat	agattgtgct	tactgagaca	aatgaacggt	1860
	tacttgattt	agaagataat	gtgacagaa	gatgtcaggt	taggtcaaag	ccaaggaggt	1920
	gacagaatct	ggaaaatcaa	acaatacaaa	aagccctaaa	tgaactgtta	actatttgat	1980
	otttggatgt	aaaattgtaa	tgcgatatatg	tacaaatgta	caatttttac	atgcttttaa	2040
	aaaaggttag	ctttgtgaaa	ataccttggt	tggtaaatga	ctttactggg	taatagaacc	2100
	acattgaacc	ttgatggcaa	gtaatacaat	aaggcaggcc	agctcgtttt	tctctctgaa	2160
15	tctggctggg	ttaggaggag	cctgggttta	tcgacgagat	ctggagtatc	tattcttttc	2220
	cactgottgc	agtctccaat	gtaggcagtg	taaagggtata	gtaaaatgat	tttagggagtc	2280
	agaacccaaat	tgccaatatg	ctccatggct	cctaaaggaa	aataaaatgg	aagtttttaa	2340
	aaaaaaaaa	aaaaaa					2356
20	<210> 73						
	<211> 1646						
	<212> DNA						
25	<213> Homo sapiens						
	<400> 73						
30	gtggaatgtc	atcagttaag	gotattttca	tttcttttgt	ggatcttcag	ttgcttcagg	60
	ccatctggat	gtatacatgc	aggtoacagg	gaatatgatg	gcttagcttg	ggttcagagg	120
	cctgacacct	caggetgcca	aatgtggaag	atttaaatac	ttgaaccaat	accctctcc	180
	caaaaactga	aattggcttc	tgtttctgag	ttggtccagg	cgcaatgttc	agcgtatttg	240
	aggaaatcac	aagaattgta	gttaaggaga	tggtgctgg	aggggatatg	attgccgtta	300
	gaagccttgt	tgatgctgat	agattccgct	gcttccatct	ggtgggggag	aagagaactt	360
35	tctttggatg	cgggcactac	acaacaggcc	tcacctgat	ggacattctg	gacacacatg	420
	gggacaagtg	gttagatgaa	ctggattctg	ggctccaagg	tcaaaaggct	gagtttcaaa	480
	ttctggataa	tgtagactca	acgggagagt	tgatagttag	attacccaaa	gaaataacaa	540
	tttcaggcag	ttccagggc	ttccaccatc	agaaaaatcaa	gatatcggag	aaccggatat	600
	occagcagta	tctggctacc	cttgaaaaca	ggaagctgaa	gagggaacta	cocttttcat	660
40	tccgatcaat	taatacgaga	gaaaacctgt	atctggtgac	agaaactctg	gagacggtaa	720
	aggaggaaac	cctgaaaagc	gaccggcaat	ataaattttg	gagccagatc	tctcagggcc	780
	atctcagcta	taaacacaag	ggccaaaagg	aagtgaccat	ccccccaaat	cgggtcctga	840
	gctatcgagt	aaagcagctt	gtcttcccca	acaaggagac	gatgagaaag	tctttgggtt	900
	cggaggattc	cagaaacatg	aaggagaagt	tgaggagacat	ggagagtgtc	ctcaaggacc	960
	tgacagagga	gaagagaaaa	gatgtgctaa	actccctcgc	taagtgcctc	ggcaaggagg	1020
45	atattcggca	ggatctagag	caaagagtat	ctgaggctct	gatttccggg	gagctacaca	1080
	tggaggaaoc	agacaagcct	ctcctaagca	gcctttttaa	tgctgctggg	gtcttggtag	1140
	aagcgcgtgc	aaaagccatt	ctggacttcc	tggtgcoct	gctagagctg	tctgaagagc	1200
	agcagtttgt	ggctgaggcc	ctggagaagg	ggacccttcc	tctgttgaag	gaccagggtga	1260
	aatctgtcat	ggagcagaac	tgggatgagc	tggccagcag	tcctcctgac	atggactatg	1320
	accctgagge	acgaattctc	tgtgcgctgt	atgttgttgt	ctctatcctg	ctggagctgg	1380
50	ctgaggggccc	tacctctgtc	tcttcttaac	tacaaaagcc	ctttctcccc	acaagcctct	1440
	gggttttccc	tttaccagtc	tgctctcact	gccatcgcca	ctaccatcct	gtcaccagtg	1500
	ggacctcttt	aaaacaagca	gccaaaccatt	ctttgatgta	tcccatctgc	tccatgttaa	1560
	catccaaaac	cagcctggat	ttcatacatg	gacttctgat	taaaagtggc	aggttgtgca	1620
55	tgttaaaaaa	aaaaaaaaa	aaaaaa				1646

<210> 74

<211> 3340

<212> DNA

<213> Homo sapiens

<400> 74

cgggcgccca	gagacagcgc	cgcctcagat	atcctgctgg	atgacattgt	cottacccat	60
tctctcttcc	tcccgacgga	gaaatttctg	caggagctac	accagtactt	tgttcgggca	120
ggaggcatgg	agggccctga	agggtctggc	cggaagcaag	cctgtctagc	catgcttctc	180
catttcttgg	acacctacca	ggggtctgct	caagaggaag	agggggccgg	ccacatcctc	240
aaggatctat	acctgcta	tatgaaggac	gagtcctttt	accagggcct	ccgagaggac	300
actctgaggc	tgcaccagct	ggtggagacg	gtggaactaa	agattccaga	ggagaaccag	360
ccaccagca	agcaggtgaa	gccactcttc	cgccacttcc	gccgtagata	ctcctgtctg	420
cagaccgggg	tggccttcgg	gggctctgat	gagatcttct	gccgtgtata	catgcttgac	480
cactcttatg	tgaccataog	cagccgcctt	tcagcatctg	tgcaggacat	tctgggctct	540
gtgacggaga	aacttcaata	ttcagaggag	cccggggggc	gtgaggattc	cctcatcctg	600
gtagctgtgt	cctctcttgg	agagaaggtc	cttctccagc	ccactgagga	ctgtgttttc	660
acgcactgg	gcataaacag	ccacctgttt	gctgtacttc	gggacagcta	tgaggctctg	720
gtgcccctcc	ccgaggagat	ccaggctctc	cctggagaca	cagagatcca	ccgagtggag	780
cctgaggacg	ttgccaacca	cctaactgcc	ttccactggg	agctgttccg	atgtgtgcat	840
gagctggagt	tcgtggacta	cgtgttccac	ggggagcgcg	gpcgcccggg	gacggccaac	900
ttggagctgc	tgctgcagcg	ctgcagcgag	gtcagcgact	gggtggccac	cgaagtgtctg	960
ctctgcgagg	cccggggcaa	gcgcgcgcag	ctgtccaaga	agttcatcaa	gatcggggcc	1020
ctctgcaagc	agaaccagga	cctgtctgtc	ttctacgccc	tggtcatggg	gctgggacaac	1080
gccgctgtca	gccgccttcg	actcaactgg	gagaagctgc	cagggaatt	caagaacttg	1140
tttcgcaaat	ttgagaaact	gacggacccc	tgccaggaac	acaaaagcta	ccgagaagtg	1200
atctccaaa	tgaagcccc	tgtgattccc	ttcgtgcctc	tgatcctcaa	agacctgact	1260
ttcctgcaag	aaggagtaga	gacccttgta	gatggtttgg	tgaacatcga	gaagotgcat	1320
tcagtggccg	aaaaagtgag	gacaatccgc	aaataccgga	gccggccct	ttgcctggac	1380
atggaggcat	cccccaatca	cctgcagacc	aaggcctatg	tgccgcaagt	tcaggctcatc	1440
gacaaccaga	acctctctct	cgagctctcc	tacaagctgg	aggcaaacag	tcagtggagag	1500
tgagggtctc	agtcagaccc	gccagatcct	tgggcacctg	gcactcaagc	actttgcacg	1560
atgtctcaac	caacatctga	catctttccc	gtggagcaac	ttcctgtctc	acgggaaaga	1620
ggtcgatgga	tttacccttg	gacccataag	tctgtttcatc	ctgtgtaagt	ccccctccca	1680
ttgtctcttc	aagccaaaac	tacaotttgc	tggttctctg	cccctctgag	aaaggggata	1740
gaaagctcct	tctctatgt	cctcccatcg	agatctgttc	tggggatgga	gcttccaact	1800
tctctcttca	gcaggaaaga	atgctgtctc	cccttctgtc	ttgcagagt	ggattgtggg	1860
agggattggc	agccttcttc	tccaccacct	gtccagcttc	ttcctggtea	gggctgggac	1920
cccaggaat	attatgttgc	cgtgtgtgtg	tggtgtgtgtg	tggtgtgtgtg	tggtgtgtgtg	1980
tggtctctct	tttagggagc	aggagtgcac	ctggtaattg	aggggtggatg	ttgtgtgtgc	2040
tggggagggg	tccttctgtt	tggtgtctac	ctgtcttact	ctgcccctgg	atggtgcggg	2100
gtgctttctc	cacccccaca	ctccctgtct	agctcctcgt	gctgccctgc	atgcccaggc	2160
ttgtgagcca	aggtgctttt	tggggcaggg	agtagcagca	ggtagggagg	gttaccatc	2220
agcccttgca	agtcccccac	tcaggcctct	ggaaggtcca	gggatgggct	ctgatgagag	2280
ggtaaaagat	gttcagggaa	acacaggcct	cagotgccta	gaggaccctc	cccctgcctt	2340
gcagtgggct	cgggtagagc	agtatcagga	gctagggttg	tctgtgccc	acactcctgc	2400
tttttgggat	atctaactgc	taaggaggga	gttgacatcc	cccttctggc	tcattgtgtc	2460
gacaccaaca	acatggtctc	cgtccctctc	tcttagactc	tcccttctgc	ctccccatag	2520
agctgggggtg	gggtggatcc	ctatactggg	gcaggcagcc	ccaaagtggg	ggagggggat	2580
ggcagagact	gtaaaaggcg	cactggactc	tggaaggcc	tttattacct	ttactccctc	2640
cctctcccat	caccagcctc	aaggcctgag	gggtgcaggg	gctcctggca	gctactgggt	2700
gagggttctc	ggcacagact	caccttctct	tctggcacca	ctctttccct	tttgaagaga	2760
cagcaacagc	cgtagcaaaa	gcagctgctg	ctcctgctat	gagggtgtat	atatttttta	2820
cccaaagctc	tgggaattgta	catttatttt	ttaaaactca	aagagggaaa	gagccttgta	2880

	tcatatgtga	acattgtatc	ataggtaatg	ttgtacagac	ccttttatac	agtgatotgt	2940
	cttgttcctg	cagcaaaaat	cctctatgga	cataggaggt	gctgtgtccc	atgccttctt	3000
	gcctgtgacg	tgtcccatgg	gcccccttct	gtccctgcc	ccctccctgc	tactgtctgat	3060
5	gcactgtcct	ctccctgcag	cccctggctt	cccagccttc	ctcctgaccc	cttccaacag	3120
	cottggaact	ccagctgcca	ccaccctctg	ggtcggacac	tgggacccac	tggcccagtc	3180
	ttggtgtctg	cttaccocct	gccttgatgc	ctgcccaggg	acccccagcc	ccctcccggt	3240
	gccctgcagc	tttaacagag	tgaaccatgt	gtattgtaca	ggcgcggttg	tcattgcaga	3300
	aaccgctggg	tggagaagaa	gccgataaag	tctatgaatc			3340
10	<210> 75						
	<211> 4005						
	<212> DNA						
15	<213> Homo sapiens						
	<400> 75						
20	gggcaacagt	ctgcccacot	gtggacacca	gatcctggga	gctcctggtt	agcaagttag	60
	atctctggga	tgtcagttag	gctgggtgaa	gaccagaggt	aaactgcaga	ggtcaccacc	120
	cccacocatg	cccaggtgat	gtccagccca	ctgctggcag	gaggccatgc	tgtcagcttg	180
	ggcctctgtg	atgagccag	gaggaccctg	caccagcac	ccagcccccag	cctgccaccc	240
	cagtgttctt	actacaccac	ggaaggctgg	ggagcccagg	ccctgatggc	ccccgtgccc	300
25	tgcattggggc	cccctggccg	actccagcaa	gccccacagg	tggaggccaa	agccacotgc	360
	ttcctgcctg	cccctgggtga	gaaggccttg	gggaccccag	aggaccttga	ctcctacatt	420
	gacttctcac	tggagagcct	caatcagatg	atcctggaa	tggaccccac	cttccagctg	480
	cttccccccag	ggaactggggg	ctcccaggct	gagctggccc	agagcaccat	gtcaatgaga	540
	aagaaggagg	aatctgaagc	cttggacata	aagtacatcg	aggtagacctc	cgccagatca	600
	aggtgccacg	attggcccca	gcactgctcc	agcccccttg	tcaccccggc	cttcggctcc	660
30	cctcgcagtg	gtggcctcct	cctttccaga	gaggtccccc	gagagacacg	aagcagcagt	720
	gagagccctca	tcttctctgg	gaaccagggc	agggggcacc	agcgccctct	gccccctca	780
	gagggctctct	cccctcgacc	cccaaattcc	cccagcatct	caatcccttg	catggggagc	840
	aaggcctcga	gcccccatgg	tttgggctcc	cogctgggtg	cttctccaag	actggagaa	900
	cggctgggag	gcctggcccc	acagcggggc	agcaggatct	ctgtgtctgtc	agccagccca	960
35	gtgtctgatg	tcagctatat	gtttggaagc	agccagtccc	tcctgcactc	cagcaactcc	1020
	agccatcagt	catcttccag	atccttggaa	agtcacagca	actottctctc	cagcctccac	1080
	agccttggct	cagtgtccct	gtgtacaaga	cccagtgaact	tcaggctcc	cagaaacccc	1140
	accctaacca	tgggccaacc	cagaacaccc	caactctccac	cactggccaa	agaacatgcc	1200
	agcatctgcc	ccccatccat	caccaactcc	atggtggaca	tacccattgt	gtgatcaac	1260
	ggctgcccag	aaccagggtc	ttctccaccc	cagcggaccc	caggacacca	gaactocgtt	1320
40	caacctggag	ctgcttctcc	cagcaacccc	tgtccagcca	ccaggagcaa	cagccagacc	1380
	ctgtcagatg	ccccctttac	cacatgcccc	gaggtcccg	ccaggagcat	gcagcccacc	1440
	atgaagtctg	tgatggacac	atctaaatac	tgggtttaagc	caaacatcac	ccgagagcaa	1500
	gcaatcgagc	tgtcaggaa	ggaggagcca	ggggcttttg	tcataaggga	cagctcttca	1560
	taccgaggct	ccttcggcct	ggccctgaag	gtgcaggagg	ttcccgcgtc	tgtcagaat	1620
45	cgaccagggtg	aggacagcaa	tgacctcctc	cgacaottcc	tcctcgagtc	gtctgccaaa	1680
	ggagtgcctc	tcaaaggagc	agatgaggag	ccctaacttg	ggagcctctc	tgccttcgtg	1740
	tgccagcatt	ccatcatggc	cctggccctg	ccctgcaaac	tcaccatccc	acagagagaa	1800
	ctgggagggtg	cagatggggc	ctcggactct	acagacagcc	cagcctcctg	ccagaagaaa	1860
	tctgcgggct	gccacaccct	gtacctgagc	tcagttagcg	tggagaccct	gactggagcc	1920
	ctggccgtgc	agaaagccat	ctccaccacc	tttgagaggg	acatccctccc	cagccccacc	1980
50	gtggtccact	tccaagtcac	agagcagggc	atcactctga	ctgatgtcca	gaggaagggtg	2040
	tttttccggc	gccattaccc	actcaccacc	ctccgcttct	gtggtatgga	ccctgagcaa	2100
	cggaggtggc	agaagtactg	caaaccctcc	tggatctttg	ggtttgtggc	caagagccag	2160
	acagagcctc	aggagaacgt	atgccacctc	tttgccgagt	atgacatggt	ccagccagcc	2220
	tcgcaggctca	tggcctggt	gactgctctg	ctgcaggacg	cagaaaggat	gtaggggaga	2280
55	gactgcctgt	gcacctaacc	aacacctcca	ggggctcgtc	aaggagcccc	cctccacccc	2340

ctgaatgggt gtggcttgtg gccatattga cagaccaatc tatgggacta gggggattgg 2400
 catcaagttg acaccottga acctgctatg gccttcagca gtcacccatca tccagacccc 2460
 cogggcctca gtttccctcaa tcatagaaga agaccaatag acaagatcag ctgtttcttag 2520
 5 atgctgggtg gcatttgaac atgotcctcc atgattctga agcatgcaca cctctgaaga 2580
 cccctgcatg aaaataacct ccaaggaccc tctgaccoca tccgacctgg cctgccccac 2640
 acaacagtct gagcaagaga cctgcagccc ctgtttcgtg gcagacagca ggtgcctggc 2700
 ggtgacccac ggggctcctg gottgcagct ggtgatggtc aagaactgac tacaaaacag 2760
 gaatggatag actctatttc cttccatata tgttcctctg ttccctttcc cactttctgg 2820
 10 gtggcttttt ggggtccaccc agccaggatg ctgcaggcca agctgggtgt ggtatttagg 2880
 gcagctcagc agggggaact tgtcccatatg gtcagaggag accoagctgt cctgcacccc 2940
 cttgcagatg agtatcacc cactttttct ttccacttgg tttttatttt tatttttttt 3000
 gagacagagt ctcactgtca cccaggctga actgcagtgg tgtgatctag gtcactgca 3060
 acctccacct cccaggttca agoaattatc ctgcctcagg ctcccagta gctgggatta 3120
 caggcatgtg caactcacc agctaatttt gtatttttag tagagacagg gtttcacat 3180
 15 gttggccagg ctggtcttga actcctgacc gcaggtaatc cacctgcttc ggccctccaa 3240
 agtgcctggg ttacaggcgc aagccaccca gccagcttc ttccattcc ttgataggcg 3300
 agtattocaa agctggtatc gtagctgccc taatgttgca tattaggcgg cgggggcaga 3360
 gataagggcc atctctctgt gattctgcct cagctoctgt ottgctgagc cctcccccaa 3420
 cccacgctcc aacacacaca cacacacaca cacacacaca cacacacaca cacacacaca 3480
 20 cagcggcctc tactgctatg tggcttcaac cagcctcaca gccacacggg ggaagcagag 3540
 agtcaagaat gcaaagaggc cgtctcccta agaggcttgg aggagctggg ctctatccca 3600
 caccaccccc caccocaccc ccaccagcc tccagaagct ggaaccattt ctcccgcagg 3660
 cctgagttcc taaggaaacc accctacogg ggtggaagg agggtcaggg aagaaaacca 3720
 ctcttgctct acgaggagca agtgctgcc cctccccagc agccagccct gccaaagttg 3780
 cattatcttt ggccaaggct gggcctgacg gttatgattt cagccctggg cctgcaggag 3840
 25 aggtgagat cagcccaccc agccagtggg ctagcactgc cccgccgcca aagtctgcag 3900
 aatgtgagat gaggttctca aggtcacagg ccccgatccc agcctggggg ctggcagagg 3960
 ccccatata ctctgtcata gctcctatca tgaaaaataa aatgt 4005

<210> 76

<211> 1093

<212> PRT

<213> Homo sapiens

<400> 76

Met Lys Glu Met Val Gly Gly Cys Cys Val Cys Ser Asp Glu Arg Gly
 1 5 10 15
 40 Trp Ala Glu Asn Pro Leu Val Tyr Cys Asp Gly His Ala Cys Ser Val
 20 25 30
 Ala Val His Gln Ala Cys Tyr Gly Ile Val Gln Val Pro Thr Gly Pro
 35 40 45
 Trp Phe Cys Arg Lys Cys Glu Ser Gln Glu Arg Ala Ala Arg Val Arg
 50 55 60
 45 Cys Glu Leu Cys Pro His Lys Asp Gly Ala Leu Lys Arg Thr Asp Asn
 65 70 75 80
 Gly Gly Trp Ala His Val Val Cys Ala Leu Tyr Ile Pro Glu Val Gln
 85 90 95
 50 Phe Ala Asn Val Leu Thr Met Glu Pro Ile Val Leu Gln Tyr Val Pro
 100 105 110
 His Asp Arg Phe Asn Lys Thr Cys Tyr Ile Cys Glu Glu Thr Gly Arg
 115 120 125
 Glu Ser Lys Ala Ala Ser Gly Ala Cys Met Thr Cys Asn Arg His Gly
 130 135 140

	Cys	Arg	Gln	Ala	Phe	His	Val	Thr	Cys	Ala	Gln	Met	Ala	Gly	Leu	Leu
	145					150					155					160
5	Cys	Glu	Glu	Glu	Val	Leu	Glu	Val	Asp	Asn	Val	Lys	Tyr	Cys	Gly	Tyr
					165					170						175
	Cys	Lys	Tyr	His	Phe	Ser	Lys	Met	Lys	Thr	Ser	Arg	His	Ser	Ser	Gly
				180					185					190		
	Gly	Gly	Gly	Gly	Gly	Ala	Gly	Gly	Gly	Gly	Gly	Ser	Met	Gly	Gly	Gly
				195				200					205			
10	Gly	Ser	Gly	Phe	Ile	Ser	Gly	Arg	Arg	Ser	Arg	Ser	Ala	Ser	Pro	Ser
				210			215					220				
	Thr	Gln	Gln	Glu	Lys	His	Pro	Thr	His	His	Glu	Arg	Gly	Gln	Lys	Lys
	225					230					235					240
	Ser	Arg	Lys	Asp	Lys	Glu	Arg	Leu	Lys	Gln	Lys	His	Lys	Lys	Arg	Pro
				245						250					255	
15	Glu	Ser	Pro	Pro	Ser	Ile	Leu	Thr	Pro	Pro	Val	Val	Pro	Thr	Ala	Asp
				260					265					270		
	Lys	Val	Ser	Ser	Ser	Ala	Ser	Ser	Ser	Ser	His	His	Glu	Ala	Ser	Thr
				275				280					285			
	Gln	Glu	Thr	Ser	Glu	Ser	Ser	Arg	Glu	Ser	Lys	Gly	Lys	Lys	Ser	Ser
				290				295				300				
20	Ser	His	Ser	Leu	Ser	His	Lys	Gly	Lys	Lys	Leu	Ser	Ser	Gly	Lys	Gly
	305					310					315					320
	Val	Ser	Ser	Phe	Thr	Ser	Ala	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser	Ser
				325						330						335
	Ser	Ser	Gly	Gly	Pro	Phe	Gln	Pro	Ala	Val	Ser	Ser	Leu	Gln	Ser	Ser
				340					345					350		
25	Pro	Asp	Phe	Ser	Ala	Phe	Pro	Lys	Leu	Glu	Gln	Pro	Glu	Glu	Asp	Lys
				355				360					365			
	Tyr	Ser	Lys	Pro	Thr	Ala	Pro	Ala	Pro	Ser	Ala	Pro	Pro	Ser	Pro	Ser
				370				375				380				
30	Ala	Pro	Glu	Pro	Pro	Lys	Ala	Asp	Leu	Phe	Glu	Gln	Lys	Val	Val	Phe
	385					390					395					400
	Ser	Gly	Phe	Gly	Pro	Ile	Met	Arg	Phe	Ser	Thr	Thr	Thr	Ser	Ser	Ser
				405						410					415	
	Gly	Arg	Ala	Arg	Ala	Pro	Ser	Pro	Gly	Asp	Tyr	Lys	Ser	Pro	His	Val
				420					425					430		
35	Thr	Gly	Ser	Gly	Ala	Ser	Ala	Gly	Thr	His	Lys	Arg	Met	Pro	Ala	Leu
				435				440					445			
	Ser	Ala	Thr	Pro	Val	Pro	Ala	Asp	Glu	Thr	Pro	Glu	Thr	Gly	Leu	Lys
				450				455				460				
	Glu	Lys	Lys	His	Lys	Ala	Ser	Lys	Arg	Ser	Arg	His	Gly	Pro	Gly	Arg
	465					470					475					480
40	Pro	Lys	Gly	Ser	Arg	Asn	Lys	Glu	Gly	Thr	Gly	Gly	Pro	Ala	Ala	Pro
				485						490					495	
	Ser	Leu	Pro	Ser	Ala	Gln	Leu	Ala	Gly	Phe	Thr	Ala	Thr	Ala	Ala	Ser
				500					505					510		
	Pro	Phe	Ser	Gly	Gly	Ser	Leu	Val	Ser	Ser	Gly	Leu	Gly	Gly	Leu	Ser
				515				520					525			
45	Ser	Arg	Thr	Phe	Gly	Pro	Ser	Gly	Ser	Leu	Pro	Ser	Leu	Ser	Leu	Glu
				530				535				540				
	Ser	Pro	Leu	Leu	Gly	Ala	Gly	Ile	Tyr	Thr	Ser	Asn	Lys	Asp	Pro	Ile
	545					550					555					560
	Ser	His	Ser	Gly	Gly	Met	Leu	Arg	Ala	Val	Cys	Ser	Thr	Pro	Leu	Ser
				565						570					575	
50	Ser	Ser	Leu	Leu	Gly	Pro	Pro	Gly	Thr	Ser	Ala	Leu	Pro	Arg	Leu	Ser
				580					585					590		
	Arg	Ser	Pro	Phe	Thr	Ser	Thr	Leu	Pro	Ser	Ser	Ser	Ala	Ser	Ile	Ser
				595				600						605		

Thr Thr Gln Val Phe Ser Leu Ala Gly Ser Thr Phe Ser Leu Pro Ser
 610 615 620
 5 Thr His Ile Phe Gly Thr Pro Met Gly Ala Val Asn Pro Leu Leu Ser
 625 630 635 640
 Gln Ala Glu Ser Ser His Thr Glu Pro Asp Leu Glu Asp Cys Ser Phe
 645 650 655
 Arg Cys Arg Gly Thr Ser Pro Gln Glu Ser Leu Ser Ser Met Ser Pro
 660 665 670
 10 Ile Ser Ser Leu Pro Ala Leu Phe Asp Gln Thr Ala Ser Ala Pro Cys
 675 680 685
 Gly Gly Gly Gln Leu Asp Pro Ala Ala Pro Gly Thr Thr Asn Met Glu
 690 695 700
 Gln Leu Leu Glu Lys Gln Gly Asp Gly Glu Ala Gly Val Asn Ile Val
 705 710 715 720
 15 Glu Met Leu Lys Ala Leu His Ala Leu Gln Lys Glu Asn Gln Arg Leu
 725 730 735
 Gln Glu Gln Ile Leu Ser Leu Thr Ala Lys Lys Glu Arg Leu Gln Ile
 740 745 750
 Leu Asn Val Gln Leu Ser Val Pro Phe Pro Ala Leu Pro Ala Ala Leu
 755 760 765
 20 Pro Ala Ala Asn Gly Pro Val Pro Gly Pro Tyr Gly Leu Pro Pro Gln
 770 775 780
 Ala Gly Ser Ser Asp Ser Leu Ser Thr Ser Lys Ser Pro Pro Gly Lys
 785 790 795 800
 Ser Ser Leu Gly Leu Asp Asn Ser Leu Ser Thr Ser Ser Glu Asp Pro
 805 810 815
 25 His Ser Gly Cys Pro Ser Arg Ser Ser Ser Ser Leu Ser Phe His Ser
 820 825 830
 Thr Pro Pro Pro Leu Pro Leu Leu Gln Gln Ser Pro Ala Thr Leu Pro
 835 840 845
 30 Leu Ala Leu Pro Gly Ala Pro Ala Pro Leu Pro Pro Gln Pro Gln Asn
 850 855 860
 Gly Leu Gly Arg Ala Pro Gly Ala Ala Gly Leu Gly Ala Met Pro Met
 865 870 875 880
 Ala Glu Gly Leu Leu Gly Gly Leu Ala Gly Ser Gly Gly Leu Pro Leu
 885 890 895
 35 Asn Gly Leu Leu Gly Gly Leu Asn Gly Ala Ala Ala Pro Asn Pro Ala
 900 905 910
 Ser Leu Ser Gln Ala Gly Gly Ala Pro Thr Leu Gln Leu Pro Gly Cys
 915 920 925
 Leu Asn Ser Leu Thr Glu Gln Gln Arg His Leu Leu Gln Gln Gln Glu
 930 935 940
 40 Gln Gln Leu Gln Gln Leu Gln Gln Leu Leu Ala Ser Pro Gln Leu Thr
 945 950 955 960
 Pro Glu His Gln Thr Val Val Tyr Gln Met Ile Gln Gln Ile Gln Gln
 965 970 975
 Lys Arg Glu Leu Gln Arg Leu Gln Met Ala Gly Gly Ser Gln Leu Pro
 980 985 990
 45 Met Ala Ser Leu Leu Ala Gly Ser Ser Thr Pro Leu Leu Ser Ala Gly
 995 1000 1005
 Thr Pro Gly Leu Leu Pro Thr Ala Ser Ala Pro Pro Leu Leu Pro
 1010 1015 1020
 50 Ala Gly Ala Leu Val Ala Pro Ser Leu Gly Asn Asn Thr Ser Leu
 1025 1030 1035
 Met Ala Ala Ala Ala Ala Ala Ala Ala Val Ala Ala Ala Gly Gly
 1040 1045 1050
 Pro Pro Val Leu Thr Ala Gln Thr Asn Pro Phe Leu Ser Leu Ser
 1055 1060 1065

Gly Ala Glu Gly Ser Gly Gly Gly Pro Lys Gly Gly Thr Ala Asp
 1070 1075 1080
 Lys Gly Ala Ser Ala Asn Gln Glu Lys Gly
 1085 1090

<210> 77

<211> 344

<212> PRT

<213> Homo sapiens

<400> 77

Met His Arg Thr Thr Arg Ile Lys Ile Thr Glu Leu Asn Pro His Leu
 1 5 10 15
 Met Cys Ala Leu Cys Gly Gly Tyr Phe Ile Asp Ala Thr Thr Ile Val
 20 20 25 30
 Glu Cys Leu His Ser Phe Cys Lys Thr Cys Ile Val Arg Tyr Leu Glu
 35 40 45
 Thr Asn Lys Tyr Cys Pro Met Cys Asp Val Gln Val His Lys Thr Arg
 50 55 60
 Pro Leu Leu Ser Ile Arg Ser Asp Lys Thr Leu Gln Asp Ile Val Tyr
 65 70 75 80
 Lys Leu Val Pro Gly Leu Phe Lys Asp Glu Met Lys Arg Arg Arg Asp
 85 90 95
 Phe Tyr Ala Ala Tyr Pro Leu Thr Glu Val Pro Asn Gly Ser Asn Glu
 100 105 110
 Asp Arg Gly Glu Val Leu Glu Gln Glu Lys Gly Ala Leu Ser Asp Asp
 115 120 125
 Glu Ile Val Ser Leu Ser Ile Glu Phe Tyr Glu Gly Ala Arg Asp Arg
 130 135 140
 Asp Glu Lys Lys Gly Pro Leu Glu Asn Gly Asp Gly Asp Lys Glu Lys
 145 150 155 160
 Thr Gly Val Arg Phe Leu Arg Cys Pro Ala Ala Met Thr Val Met His
 165 170 175
 Leu Ala Lys Phe Leu Arg Asn Lys Met Asp Val Pro Ser Lys Tyr Lys
 180 185 190
 Val Glu Val Leu Tyr Glu Asp Glu Pro Leu Lys Glu Tyr Tyr Thr Leu
 195 200 205
 Met Asp Ile Ala Tyr Ile Tyr Pro Trp Arg Arg Asn Gly Pro Leu Pro
 210 215 220
 Leu Lys Tyr Arg Val Gln Pro Ala Cys Lys Arg Leu Thr Leu Ala Thr
 225 230 235 240
 Val Pro Thr Pro Ser Glu Gly Thr Asn Thr Ser Gly Ala Ser Glu Cys
 245 250 255
 Glu Ser Val Ser Asp Lys Ala Pro Ser Pro Ala Thr Leu Pro Ala Thr
 260 265 270
 Ser Ser Ser Leu Pro Ser Pro Ala Thr Pro Ser His Gly Ser Pro Ser
 275 280 285
 Ser His Gly Pro Pro Ala Thr His Pro Thr Ser Pro Thr Pro Pro Ser
 290 295 300
 Thr Ala Ser Gly Ala Thr Thr Ala Ala Asn Gly Gly Ser Leu Asn Cys
 305 310 315 320
 Leu Gln Thr Pro Ser Ser Thr Ser Arg Gly Arg Lys Met Thr Val Asn
 325 330 335

Gly Ala Pro Val Pro Pro Leu Thr
340

<210> 78

<211> 416

<212> PRT

<213> Homo sapiens

<400> 78

Met Ser Ser Asn Cys Thr Ser Thr Thr Ala Val Ala Val Ala Pro Leu
1 5 10 15
Ser Ala Ser Lys Thr Lys Thr Lys Lys Lys His Phe Val Cys Gln Lys
20 25 30
Val Lys Leu Phe Arg Ala Ser Glu Pro Ile Leu Ser Val Leu Met Trp
35 40 45
Gly Val Asn His Thr Ile Asn Glu Leu Ser Asn Val Pro Val Pro Val
50 55 60
Met Leu Met Pro Asp Asp Phe Lys Ala Tyr Ser Lys Ile Lys Val Asp
65 70 75 80
Asn His Leu Phe Asn Lys Glu Asn Leu Pro Ser Arg Phe Lys Phe Lys
85 90 95
Glu Tyr Cys Pro Met Val Phe Arg Asn Leu Arg Glu Arg Phe Gly Ile
100 105 110
Asp Asp Gln Asp Tyr Gln Asn Ser Val Thr Arg Ser Ala Pro Ile Asn
115 120 125
Ser Asp Ser Gln Gly Arg Cys Gly Thr Arg Phe Leu Thr Thr Tyr Asp
130 135 140
Arg Arg Phe Val Ile Lys Thr Val Ser Ser Glu Asp Val Ala Glu Met
145 150 155 160
His Asn Ile Leu Lys Lys Tyr His Gln Phe Ile Val Glu Cys His Gly
165 170 175
Asn Thr Leu Leu Pro Gln Phe Leu Gly Met Tyr Arg Leu Thr Val Asp
180 185 190
Gly Val Glu Thr Tyr Met Val Val Thr Arg Asn Val Phe Ser His Arg
195 200 205
Leu Thr Val His Arg Lys Tyr Asp Leu Lys Gly Ser Thr Val Ala Arg
210 215 220
Glu Ala Ser Asp Lys Glu Lys Ala Lys Asp Leu Pro Thr Phe Lys Asp
225 230 235 240
Asn Asp Phe Leu Asn Glu Gly Gln Lys Leu His Val Gly Glu Glu Ser
245 250 255
Lys Lys Asn Phe Leu Glu Lys Leu Lys Arg Asp Val Glu Phe Leu Ala
260 265 270
Gln Leu Lys Ile Met Asp Tyr Ser Leu Leu Val Gly Ile His Asp Val
275 280 285
Asp Arg Ala Glu Gln Glu Glu Met Glu Val Glu Glu Arg Ala Glu Asp
290 295 300
Glu Glu Cys Glu Asn Asp Gly Val Gly Gly Asn Leu Leu Cys Ser Tyr
305 310 315 320
Gly Thr Pro Pro Asp Ser Pro Gly Asn Leu Leu Ser Phe Pro Arg Phe
325 330 335
Phe Gly Pro Gly Glu Phe Asp Pro Ser Val Asp Val Tyr Ala Met Lys
340 345 350

Ser His Glu Ser Ser Pro Lys Lys Glu Val Tyr Phe Met Ala Ile Ile
 355 360 365
 Asp Ile Leu Thr Pro Tyr Asp Thr Lys Lys Lys Ala Ala His Ala Ala
 370 375 380
 Lys Thr Val Lys His Gly Ala Gly Ala Glu Ile Ser Thr Val Asn Pro
 385 390 395 400
 Glu Gln Tyr Ser Lys Arg Phe Asn Glu Phe Met Ser Asn Ile Leu Thr
 405 410 415

<210> 79

<211> 500

<212> PRT

<213> Homo sapiens

<400> 79

Met Arg Gly Glu Leu Trp Leu Leu Val Leu Val Leu Arg Glu Ala Ala
 1 5 10 15
 Arg Ala Leu Ser Pro Gln Pro Gly Ala Gly His Asp Glu Gly Pro Gly
 20 25 30
 Ser Gly Trp Ala Ala Lys Gly Thr Val Arg Gly Trp Asn Arg Arg Ala
 35 40 45
 Arg Glu Ser Pro Gly His Val Ser Glu Pro Asp Arg Thr Gln Leu Ser
 50 55 60
 Gln Asp Leu Gly Gly Gly Thr Leu Ala Met Asp Thr Leu Pro Asp Asn
 65 70 75 80
 Arg Thr Arg Val Val Glu Asp Asn His Ser Tyr Tyr Val Ser Arg Leu
 85 90 95
 Tyr Gly Pro Ser Glu Pro His Ser Arg Glu Leu Trp Val Asp Val Ala
 100 105 110
 Glu Ala Asn Arg Ser Gln Val Lys Ile His Thr Ile Leu Ser Asn Thr
 115 120 125
 His Arg Gln Ala Ser Arg Val Val Leu Ser Phe Asp Phe Pro Phe Tyr
 130 135 140
 Gly His Pro Leu Arg Gln Ile Thr Ile Ala Thr Gly Gly Phe Ile Phe
 145 150 155 160
 Met Gly Asp Val Ile His Arg Met Leu Thr Ala Thr Gln Tyr Val Ala
 165 170 175
 Pro Leu Met Ala Asn Phe Asn Pro Gly Tyr Ser Asp Asn Ser Thr Val
 180 185 190
 Val Tyr Phe Asp Asn Gly Thr Val Phe Val Val Gln Trp Asp His Val
 195 200 205
 Tyr Leu Gln Gly Trp Glu Asp Lys Gly Ser Phe Thr Phe Gln Ala Ala
 210 215 220
 Leu His His Asp Gly Arg Ile Val Phe Ala Tyr Lys Glu Ile Pro Met
 225 230 235 240
 Ser Val Pro Glu Ile Ser Ser Ser Gln His Pro Val Lys Thr Gly Leu
 245 250 255
 Ser Asp Ala Phe Met Ile Leu Asn Pro Ser Pro Asp Val Pro Glu Ser
 260 265 270
 Arg Arg Arg Ser Ile Phe Glu Tyr His Arg Ile Glu Leu Asp Pro Ser
 275 280 285
 Lys Val Thr Ser Met Ser Ala Val Glu Phe Thr Pro Leu Pro Thr Cys
 290 295 300

Leu Gln His Arg Ser Cys Asp Ala Cys Met Ser Ser Asp Leu Thr Phe
 305 310 315 320
 Asn Cys Ser Trp Cys His Val Leu Gln Arg Cys Ser Ser Gly Phe Asp
 325 330 335
 Arg Tyr Arg Gln Glu Trp Met Asp Tyr Gly Cys Ala Gln Glu Ala Glu
 340 345 350
 Gly Arg Met Cys Glu Asp Phe Gln Asp Glu Asp His Asp Ser Ala Ser
 355 360 365
 Pro Asp Thr Ser Phe Ser Pro Tyr Asp Gly Asp Leu Thr Thr Thr Ser
 370 375 380
 Ser Ser Leu Phe Ile Asp Ser Leu Thr Thr Glu Asp Asp Thr Lys Leu
 385 390 395 400
 Asn Pro Tyr Ala Gly Gly Asp Gly Leu Gln Asn Asn Leu Ser Pro Lys
 405 410 415
 Thr Lys Gly Thr Pro Val His Leu Gly Thr Ile Val Gly Ile Val Leu
 420 425 430
 Ala Val Leu Leu Val Ala Ala Ile Ile Leu Ala Gly Ile Tyr Ile Asn
 435 440 445
 Gly His Pro Thr Ser Asn Ala Ala Leu Phe Phe Ile Glu Arg Arg Pro
 450 455 460
 His His Trp Pro Ala Met Lys Phe Arg Ser His Pro Asp His Ser Thr
 465 470 475 480
 Tyr Ala Glu Val Glu Pro Ser Gly His Glu Lys Glu Gly Phe Met Glu
 485 490 495
 Ala Glu Gln Cys
 500

<210> 80

<211> 509

<212> PRT

<213> Homo sapiens

<400> 80

Met Glu Asp Ile Gln Thr Asn Ala Glu Leu Lys Ser Thr Gln Glu Gln
 1 5 10 15
 Ser Val Pro Ala Glu Ser Ala Ala Val Leu Asn Asp Tyr Ser Leu Thr
 20 25 30
 Lys Ser His Glu Met Glu Asn Val Asp Ser Gly Glu Gly Pro Ala Asn
 35 40 45
 Glu Asp Glu Asp Ile Gly Asp Asp Ser Met Lys Val Lys Asp Glu Tyr
 50 55 60
 Ser Glu Arg Asp Glu Asn Val Leu Lys Ser Glu Pro Met Gly Asn Ala
 65 70 75 80
 Glu Glu Pro Glu Ile Pro Tyr Ser Tyr Ser Arg Glu Tyr Asn Glu Tyr
 85 90 95
 Glu Asn Ile Lys Leu Glu Arg His Val Val Ser Phe Asp Ser Ser Arg
 100 105 110
 Pro Thr Ser Gly Lys Met Asn Cys Asp Val Cys Gly Leu Ser Cys Ile
 115 120 125
 Ser Phe Asn Val Leu Met Val His Lys Arg Ser His Thr Gly Glu Arg
 130 135 140
 Pro Phe Gln Cys Asn Gln Cys Gly Ala Ser Phe Thr Gln Lys Gly Asn
 145 150 155 160

5 Leu Leu Arg His Ile Lys Leu His Thr Gly Glu Lys Pro Phe Lys Cys
 165 170 175
 His Leu Cys Asn Tyr Ala Cys Gln Arg Arg Asp Ala Leu Thr Gly His
 180 185 190
 10 Leu Arg Thr His Ser Val Glu Lys Pro Tyr Lys Cys Glu Phe Cys Gly
 195 200 205
 Arg Ser Tyr Lys Gln Arg Ser Ser Leu Glu Glu His Lys Glu Arg Cys
 210 215 220
 Arg Thr Phe Leu Gln Ser Thr Asp Pro Gly Asp Thr Ala Ser Ala Glu
 225 230 235 240
 Ala Arg His Ile Lys Ala Glu Met Gly Ser Glu Arg Ala Leu Val Leu
 245 250 255
 Asp Arg Leu Ala Ser Asn Val Ala Lys Arg Lys Ser Ser Met Pro Gln
 260 265 270
 15 Lys Phe Ile Gly Glu Lys Arg His Cys Phe Asp Val Asn Tyr Asn Ser
 275 280 285
 Ser Tyr Met Tyr Glu Lys Glu Ser Glu Leu Ile Gln Thr Arg Met Met
 290 295 300
 Asp Gln Ala Ile Asn Asn Ala Ile Ser Tyr Leu Gly Ala Glu Ala Leu
 305 310 315 320
 20 Cys Pro Leu Val Gln Thr Pro Pro Ala Pro Thr Ser Glu Met Val Pro
 325 330 335
 Val Ile Ser Ser Met Tyr Pro Ile Ala Leu Thr Arg Ala Glu Met Ser
 340 345 350
 Asn Gly Ala Pro Gln Glu Leu Glu Arg Lys Ser Ile Leu Leu Pro Glu
 355 360 365
 25 Lys Ser Val Pro Ser Glu Arg Gly Leu Ser Pro Asn Asn Ser Gly His
 370 375 380
 Asp Ser Thr Asp Thr Asp Ser Asn His Glu Glu Arg Gln Asn His Ile
 385 390 395 400
 30 Tyr Gln Gln Asn His Met Val Leu Ser Arg Ala Arg Asn Gly Met Pro
 405 410 415
 Leu Leu Lys Glu Val Pro Arg Ser Tyr Glu Leu Leu Lys Pro Pro Pro
 420 425 430
 Ile Cys Pro Arg Asp Ser Val Lys Val Ile Asp Lys Glu Gly Glu Val
 435 440 445
 35 Met Asp Val Tyr Arg Cys Asp His Cys Arg Val Leu Phe Leu Asp Tyr
 450 455 460
 Val Met Phe Thr Ile His Met Gly Cys His Gly Phe Arg Asp Pro Phe
 465 470 475 480
 Glu Cys Asn Met Cys Gly Asp Arg Ser His Asp Arg Tyr Glu Phe Ser
 485 490 495
 40 Ser His Ile Ala Arg Gly Glu His Arg Ser Leu Leu Lys
 500 505

<210> 81

<211> 440

<212> PRT

<213> Homo sapiens

<400> 81

Met Pro Ile Pro Pro Pro Pro Pro Pro Gly Pro Pro Pro Pro
 1 5 10 15
 Pro Thr Phe His Gln Ala Asn Thr Glu Gln Pro Lys Leu Ser Arg Asp
 20 25 30
 Glu Gln Arg Gly Arg Gly Ala Leu Leu Gln Asp Ile Cys Lys Gly Thr
 35 40 45
 Lys Leu Lys Lys Val Thr Asn Ile Asn Asp Arg Ser Ala Pro Ile Leu
 50 55 60
 Glu Lys Pro Lys Gly Ser Ser Gly Gly Tyr Gly Ser Gly Gly Ala Ala
 65 70 75 80
 Leu Gln Pro Lys Gly Gly Leu Phe Gln Gly Gly Val Leu Lys Leu Arg
 85 90 95
 Pro Val Gly Ala Lys Asp Gly Ser Glu Asn Leu Ala Gly Lys Pro Ala
 100 105 110
 Leu Gln Ile Pro Ser Ser Arg Ala Ala Ala Pro Arg Pro Pro Val Ser
 115 120 125
 Ala Ala Ser Gly Arg Pro Gln Asp Asp Thr Asp Ser Ser Arg Ala Ser
 130 135 140
 Leu Pro Glu Leu Pro Arg Met Gln Arg Pro Ser Leu Pro Asp Leu Ser
 145 150 155 160
 Arg Pro Asn Thr Thr Ser Ser Thr Gly Met Lys His Ser Ser Ser Ala
 165 170 175
 Pro Pro Pro Pro Pro Pro Gly Arg Arg Ala Asn Ala Pro Pro Thr Pro
 180 185 190
 Leu Pro Met His Ser Ser Lys Ala Pro Ala Tyr Asn Arg Glu Lys Pro
 195 200 205
 Leu Pro Pro Thr Pro Gly Gln Arg Leu His Pro Gly Arg Glu Gly Pro
 210 215 220
 Pro Ala Pro Pro Pro Val Lys Pro Pro Pro Ser Pro Val Asn Ile Arg
 225 230 235 240
 Thr Gly Pro Ser Gly Gln Ser Leu Ala Pro Pro Pro Pro Tyr Arg
 245 250 255
 Gln Pro Pro Gly Val Pro Asn Gly Pro Ser Ser Pro Thr Asn Glu Ser
 260 265 270
 Ala Pro Glu Leu Pro Gln Arg His Asn Ser Leu His Arg Lys Thr Pro
 275 280 285
 Gly Pro Val Arg Gly Leu Ala Pro Pro Pro Thr Ser Ala Ser Pro
 290 295 300
 Ser Leu Leu Ser Asn Arg Pro Pro Pro Pro Ala Arg Asp Pro Pro Ser
 305 310 315 320
 Arg Gly Ala Ala Pro Pro Pro Pro Pro Val Ile Arg Asn Gly Ala
 325 330 335
 Arg Asp Ala Pro Pro Pro Pro Pro Tyr Arg Met His Gly Ser Glu
 340 345 350
 Pro Pro Ser Arg Gly Lys Pro Pro Pro Pro Pro Ser Arg Thr Pro Ala
 355 360 365
 Gly Pro Pro Pro Pro Pro Pro Pro Leu Arg Asn Gly His Arg Asp
 370 375 380
 Ser Ile Thr Thr Val Arg Ser Phe Leu Asp Asp Phe Glu Ser Lys Tyr
 385 390 395 400
 Ser Phe His Pro Val Glu Asp Phe Pro Ala Pro Glu Glu Tyr Lys His
 405 410 415
 Phe Gln Arg Ile Tyr Pro Ser Lys Thr Asn Arg Ala Ala Arg Gly Ala
 420 425 430
 Pro Pro Leu Pro Pro Ile Leu Arg
 435 440

<210> 82

<211> 205

<212> PRT

<213> Homo sapiens

<400> 82

Met Ser Ile Met Ser Tyr Asn Gly Gly Ala Val Met Ala Met Lys Gly
 1 5 10 15
 Lys Asn Cys Val Ala Ile Ala Ala Asp Arg Arg Phe Gly Ile Gln Ala
 20 25 30
 Gln Met Val Thr Thr Asp Phe Gln Lys Ile Phe Pro Met Gly Asp Arg
 35 40 45
 Leu Tyr Ile Gly Leu Ala Gly Leu Ala Thr Asp Val Gln Thr Val Ala
 50 55 60
 Gln Arg Leu Lys Phe Arg Leu Asn Leu Tyr Glu Leu Lys Glu Gly Arg
 65 70 75 80
 Gln Ile Lys Pro Tyr Thr Leu Met Ser Met Val Ala Asn Leu Leu Tyr
 85 90 95
 Glu Lys Arg Phe Gly Pro Tyr Tyr Thr Glu Pro Val Ile Ala Gly Leu
 100 105 110
 Asp Pro Lys Thr Phe Lys Pro Phe Ile Cys Ser Leu Asp Leu Ile Gly
 115 120 125
 Cys Pro Met Val Thr Asp Asp Phe Val Val Ser Gly Thr Cys Ala Glu
 130 135 140
 Gln Met Tyr Gly Met Cys Glu Ser Leu Trp Glu Pro Asn Met Asp Pro
 145 150 155 160
 Asp His Leu Phe Glu Thr Ile Ser Gln Ala Met Leu Asn Ala Val Asp
 165 170 175
 Arg Asp Ala Val Ser Gly Met Gly Val Ile Val His Ile Ile Glu Lys
 180 185 190
 Asp Lys Ile Thr Thr Arg Thr Leu Lys Ala Arg Met Asp
 195 200 205

<210> 83

<211> 190

<212> PRT

<213> Homo sapiens

<400> 83

Leu Thr Arg Ser Cys Ser Thr Cys Cys Pro Ala Val Ala Cys Leu Val
 1 5 10 15
 Gly Arg Gly Val Val Thr Ser Gly Ala Met His Gln Cys Trp Gly Glu
 20 25 30
 Glu Met Leu Gln Gly Met Leu Leu Trp Gly Trp Ala Thr Cys Pro Leu
 35 40 45
 Ser Asn Pro Gly Arg Trp Gly Arg Thr Val Gly Leu Gln His Pro Ala
 50 55 60
 Val Val Ser Ala Phe Arg Ala Leu Leu Leu Leu Met Leu Thr Val His
 65 70 75 80

Val Ser Tyr Leu Ser Leu Ile Arg Phe Asp Tyr Gly Tyr Asn Leu Val
 85 90 95
 Ala Asn Val Ala Ile Gly Leu Val Asn Val Val Trp Trp Leu Ala Trp
 100 105 110
 Cys Leu Trp Asn Gln Arg Arg Leu Pro His Val Arg Lys Cys Val Val
 115 120 125
 Val Val Leu Leu Leu Gln Gly Leu Ser Leu Leu Glu Leu Leu Asp Phe
 130 135 140
 Pro Pro Leu Phe Trp Val Leu Asp Ala His Ala Ile Trp His Ile Ser
 145 150 155 160
 Thr Ile Pro Val His Val Leu Phe Phe Ser Phe Leu Glu Asp Asp Ser
 165 170 175
 Leu Tyr Leu Leu Lys Glu Ser Glu Asp Lys Phe Lys Leu Asp
 180 185 190

<210> 84

<211> 368

<212> PRT

<213> Homo sapiens

<400> 84

Ala Pro Pro Pro Ala Ala Ser Gln Gly Glu Arg Met Ala Gly Leu Ala
 1 5 10 15
 Ala Arg Leu Val Leu Leu Ala Gly Ala Ala Leu Ala Ser Gly Ser
 20 25 30
 Gln Gly Asp Arg Glu Pro Val Tyr Arg Asp Cys Val Leu Gln Cys Glu
 35 40 45
 Glu Gln Asn Cys Ser Gly Gly Ala Leu Asn His Phe Arg Ser Arg Gln
 50 55 60
 Pro Ile Tyr Met Ser Leu Ala Gly Trp Thr Cys Arg Asp Asp Cys Lys
 65 70 75 80
 Tyr Glu Cys Met Trp Val Thr Val Gly Leu Tyr Leu Gln Glu Gly His
 85 90 95
 Lys Val Pro Gln Phe His Gly Lys Trp Pro Phe Ser Arg Phe Leu Phe
 100 105 110
 Phe Gln Glu Pro Ala Ser Ala Val Ala Ser Phe Leu Asn Gly Leu Ala
 115 120 125
 Ser Leu Val Met Leu Cys Arg Tyr Arg Thr Phe Val Pro Ala Ser Ser
 130 135 140
 Pro Met Tyr His Thr Cys Val Ala Phe Ala Trp Val Ser Leu Asn Ala
 145 150 155 160
 Trp Phe Trp Ser Thr Val Phe His Thr Arg Asp Thr Asp Leu Thr Glu
 165 170 175
 Lys Met Asp Tyr Phe Cys Ala Ser Thr Val Ile Leu His Ser Ile Tyr
 180 185 190
 Leu Cys Cys Val Arg Thr Val Gly Leu Gln His Pro Ala Val Val Ser
 195 200 205
 Ala Phe Arg Ala Leu Leu Leu Leu Met Leu Thr Val His Val Ser Tyr
 210 215 220
 Leu Ser Leu Ile Arg Phe Asp Tyr Gly Tyr Asn Leu Val Ala Asn Val
 225 230 235 240
 Ala Ile Gly Leu Val Asn Val Val Trp Trp Leu Ala Trp Cys Leu Trp
 245 250 255

Asn Gln Arg Arg Leu Pro His Val Arg Lys Cys Val Val Val Val Leu
 260 265 270
 Leu Leu Gln Gly Leu Ser Leu Leu Glu Leu Leu Asp Phe Pro Pro Leu
 275 280 285
 Phe Trp Val Leu Asp Ala His Ala Ile Trp His Ile Ser Thr Ile Pro
 290 295 300
 Val His Val Leu Phe Phe Ser Phe Leu Glu Asp Asp Ser Leu Tyr Leu
 305 310 315 320
 Leu Lys Glu Ser Glu Asp Lys Phe Lys Leu Val Glu Ala Asp Trp Ile
 325 330 335
 Phe Ala Leu Pro Leu Thr Pro Cys Pro Ser Leu Arg Glu Gly Ser Tyr
 340 345 350
 Ala Arg Thr Pro Thr Ser Gly Thr Arg Val Ala Cys Ala Ser Phe Phe
 355 360 365

<210> 85

<211> 190

<212> PRT

<213> Homo sapiens

<400> 85

Leu Thr Arg Ser Cys Ser Thr Cys Cys Pro Ala Val Ala Cys Leu Val
 1 5 10 15
 Gly Arg Gly Val Val Thr Ser Gly Ala Met His Gln Cys Trp Gly Glu
 20 25 30
 Glu Met Leu Gln Gly Met Leu Leu Trp Gly Trp Ala Thr Cys Pro Leu
 35 40 45
 Ser Asn Pro Gly Arg Trp Gly Arg Thr Val Gly Leu Gln His Pro Ala
 50 55 60
 Val Val Ser Ala Phe Arg Ala Leu Leu Leu Leu Met Leu Thr Val His
 65 70 75 80
 Val Ser Tyr Leu Ser Leu Ile Arg Phe Asp Tyr Gly Tyr Asn Leu Val
 85 90 95
 Ala Asn Val Ala Ile Gly Leu Val Asn Val Val Trp Trp Leu Ala Trp
 100 105 110
 Cys Leu Trp Asn Gln Arg Arg Leu Pro His Val Arg Lys Cys Val Val
 115 120 125
 Val Val Leu Leu Leu Gln Gly Leu Ser Leu Leu Glu Leu Leu Asp Phe
 130 135 140
 Pro Pro Leu Phe Trp Val Leu Asp Ala His Ala Ile Trp His Ile Ser
 145 150 155 160
 Thr Ile Pro Val His Val Leu Phe Phe Ser Phe Leu Glu Asp Asp Ser
 165 170 175
 Leu Tyr Leu Leu Lys Glu Ser Glu Asp Lys Phe Lys Leu Asp
 180 185 190

<210> 86

<211> 318

<212> PRT

<213> Homo sapiens

<400> 86

Met Ala Gly Leu Ala Ala Arg Leu Val Leu Leu Ala Gly Ala Ala Ala
 1 5 10 15
 Leu Ala Ser Gly Ser Gln Gly Asp Arg Glu Pro Val Tyr Arg Asp Cys
 20 25 30
 Val Leu Gln Cys Glu Glu Gln Asn Cys Ser Gly Gly Ala Leu Asn His
 35 40 45
 Phe Arg Ser Arg Gln Pro Ile Tyr Met Ser Leu Ala Gly Trp Thr Cys
 50 55 60
 Arg Asp Asp Cys Lys Tyr Glu Cys Met Trp Val Thr Val Gly Leu Tyr
 65 70 75 80
 Leu Gln Glu Gly His Lys Val Pro Gln Phe His Gly Lys Trp Pro Phe
 85 90 95
 Ser Arg Phe Leu Phe Phe Gln Glu Pro Ala Ser Ala Val Ala Ser Phe
 100 105 110
 Leu Asn Gly Leu Ala Ser Leu Val Met Leu Cys Arg Tyr Arg Thr Phe
 115 120 125
 Val Pro Ala Ser Ser Pro Met Tyr His Thr Cys Val Ala Phe Ala Trp
 130 135 140
 Val Ser Leu Asn Ala Trp Phe Trp Ser Thr Val Phe His Thr Arg Asp
 145 150 155 160
 Thr Asp Leu Gln Arg Lys Trp Thr Thr Ser Val Pro Pro Val Ser Tyr
 165 170 175
 Thr Gln Ser Thr Cys Ala Ala Ser Gly Pro Trp Gly Cys Ser Thr Gln
 180 185 190
 Leu Trp Ser Ser Ala Phe Arg Ala Leu Leu Leu Leu Met Leu Thr Val
 195 200 205
 His Val Ser Tyr Leu Ser Leu Ile Arg Phe Asp Tyr Gly Tyr Asn Leu
 210 215 220
 Val Ala Asn Val Ala Ile Gly Leu Val Asn Val Val Trp Trp Leu Ala
 225 230 235 240
 Trp Cys Leu Trp Asn Gln Arg Arg Leu Pro His Val Arg Lys Cys Val
 245 250 255
 Val Val Val Leu Leu Leu Gln Gly Leu Ser Leu Leu Glu Leu Leu Asp
 260 265 270
 Phe Pro Pro Leu Phe Trp Val Leu Asp Ala His Ala Ile Trp His Ile
 275 280 285
 Ser Thr Ile Pro Val His Val Leu Phe Phe Ser Phe Leu Glu Asp Asp
 290 295 300
 Ser Leu Tyr Leu Leu Lys Glu Ser Glu Asp Lys Phe Lys Leu
 305 310 315

<210> 87

<211> 226

<212> PRT

<213> Homo sapiens

<400> 87

1 Met Ala Gly Leu Ala Ala Arg Leu Val Leu Leu Ala Gly Ala Ala Ala
 5 Leu Ala Ser Gly Ser Gln Gly Asp Arg Glu Pro Val Tyr Arg Asp Cys
 Val Leu Gln Cys Glu Glu Gln Asn Cys Ser Gly Gly Ala Leu Asn His
 10 Phe Arg Ser Arg Gln Pro Ile Tyr Met Ser Leu Ala Gly Trp Thr Cys
 Arg Asp Asp Cys Lys Tyr Glu Cys Met Trp Val Thr Val Gly Leu Tyr
 15 Leu Gln Glu Gly His Lys Val Pro Gln Phe His Gly Lys Trp Pro Phe
 Ser Arg Phe Leu Phe Phe Gln Glu Pro Ala Ser Ala Val Ala Ser Phe
 Leu Asn Gly Leu Ala Ser Leu Val Met Leu Cys Arg Tyr Arg Thr Phe
 Val Pro Ala Ser Ser Pro Met Tyr His Thr Cys Val Ala Phe Ala Trp
 20 Val Ser Leu Asn Ala Trp Phe Trp Ser Thr Val Phe His Thr Arg Asp
 Thr Asp Leu Thr Glu Lys Met Asp Tyr Phe Cys Ala Ser Thr Val Ile
 Leu His Ser Ile Tyr Leu Cys Cys Val Arg Pro Gly Gln Arg Gly Val
 25 Val Ala Gly Leu Val Pro Val Glu Pro Ala Ala Ala Ser Arg Ala
 Gln Val Arg Gly Gly Gly Leu Ala Ala Ala Gly Ala Val Pro Ala Arg
 Ala Ala
 30 225

<210> 88

<211> 320

<212> PRT

<213> Homo sapiens

<400> 88

1 Met Ala Gly Leu Ala Ala Arg Leu Val Leu Leu Ala Gly Ala Ala Ala
 45 Leu Ala Ser Gly Ser Gln Gly Asp Arg Glu Pro Val Tyr Arg Asp Cys
 Val Leu Gln Cys Glu Glu Gln Asn Cys Ser Gly Gly Ala Leu Asn His
 Phe Arg Ser Arg Gln Pro Ile Tyr Met Ser Leu Ala Gly Trp Thr Cys
 Arg Asp Asp Cys Lys Tyr Glu Cys Met Trp Val Thr Val Gly Leu Tyr
 50 Leu Gln Glu Gly His Lys Val Pro Gln Phe His Gly Lys Trp Pro Phe
 Ser Arg Phe Leu Phe Phe Gln Glu Pro Ala Ser Ala Val Ala Ser Phe
 Leu Asn Gly Leu Ala Ser Leu Val Met Leu Cys Arg Tyr Arg Thr Phe
 55 115 120 125

Val Pro Ala Ser Ser Pro Met Tyr His Thr Cys Val Ala Phe Ala Trp
 130 135 140
 Val Ser Leu Asn Ala Trp Phe Trp Ser Thr Val Phe His Thr Arg Asp
 145 150 155 160
 Thr Asp Leu Thr Glu Lys Met Asp Tyr Phe Cys Ala Ser Thr Val Ile
 165 170 175
 Leu His Ser Ile Tyr Leu Cys Cys Val Arg Thr Val Gly Leu Gln His
 180 185 190
 Pro Ala Val Val Ser Ala Phe Arg Ala Leu Leu Leu Leu Met Leu Thr
 195 200 205
 Val His Val Ser Tyr Leu Ser Leu Ile Arg Phe Asp Tyr Gly Tyr Asn
 210 215 220
 Leu Val Ala Asn Val Ala Ile Gly Leu Val Asn Val Val Trp Trp Leu
 225 230 235 240
 Ala Trp Cys Leu Trp Asn Gln Arg Arg Leu Pro His Val Arg Lys Cys
 245 250 255
 Val Val Val Val Leu Leu Leu Gln Gly Leu Ser Leu Leu Glu Leu Leu
 260 265 270
 Asp Phe Pro Pro Leu Phe Trp Val Leu Asp Ala His Ala Ile Trp His
 275 280 285
 Ile Ser Thr Ile Pro Val His Val Leu Phe Phe Ser Phe Leu Glu Asp
 290 295 300
 Asp Ser Leu Tyr Leu Leu Lys Glu Ser Glu Asp Lys Phe Lys Leu Asp
 305 310 315 320

<210> 89

<211> 217

<212> PRT

<213> Homo sapiens

<400> 89

Ala Pro Pro Pro Ala Ala Ser Gln Gly Glu Arg Met Ala Gly Leu Ala
 1 5 10 15
 Ala Arg Leu Val Leu Leu Ala Gly Ala Ala Ala Leu Ala Ser Gly Ser
 20 25 30
 Gln Gly Asp Arg Glu Pro Val Tyr Arg Asp Cys Val Leu Gln Cys Glu
 35 40 45
 Glu Gln Asn Cys Ser Gly Gly Ala Leu Asn His Phe Arg Ser Arg Gln
 50 55 60
 Pro Ile Tyr Met Ser Leu Ala Gly Trp Thr Cys Arg Asp Asp Cys Lys
 65 70 75 80
 Tyr Glu Cys Met Trp Val Thr Val Gly Leu Tyr Leu Gln Glu Gly His
 85 90 95
 Lys Val Pro Gln Phe His Gly Lys Trp Pro Phe Ser Arg Phe Leu Phe
 100 105 110
 Phe Gln Glu Pro Ala Ser Ala Val Ala Ser Phe Leu Asn Gly Leu Ala
 115 120 125
 Ser Leu Val Met Leu Cys Arg Tyr Arg Thr Phe Val Pro Ala Ser Ser
 130 135 140
 Pro Met Tyr His Thr Cys Val Ala Phe Ala Trp Val Ser Leu Asn Ala
 145 150 155 160
 Trp Phe Trp Ser Thr Val Phe His Thr Arg Asp Thr Asp Leu Thr Glu
 165 170 175

Lys Met Asp Tyr Phe Cys Ala Ser Thr Val Ile Leu His Ser Ile Tyr
 180 185 190
 Leu Cys Cys Val Ser Phe Leu Glu Asp Asp Ser Leu Tyr Leu Leu Lys
 195 200 205
 Glu Ser Glu Asp Lys Phe Lys Leu Asp
 210 215

<210> 90

<211> 153

<212> PRT

<213> Homo sapiens

<400> 90

Met Asn Val Gly Thr Ala His Ser Glu Val Asn Pro Asn Thr Arg Val
 1 5 10 15
 Met Asn Ser Arg Gly Ile Trp Leu Ser Tyr Val Leu Ala Ile Gly Leu
 20 25 30
 Leu His Ile Val Leu Leu Ser Ile Pro Phe Val Ser Val Pro Val Val
 35 40 45
 Trp Thr Leu Thr Asn Leu Ile His Asn Met Gly Met Tyr Ile Phe Leu
 50 55 60
 His Thr Val Lys Gly Thr Pro Phe Glu Thr Pro Asp Gln Gly Lys Ala
 65 70 75 80
 Arg Leu Leu Thr His Trp Glu Gln Met Asp Tyr Gly Val Gln Phe Thr
 85 90 95
 Ala Ser Arg Lys Phe Leu Thr Ile Thr Pro Ile Val Leu Tyr Phe Leu
 100 105 110
 Thr Ser Phe Tyr Thr Lys Tyr Asp Gln Ile His Phe Val Leu Asn Thr
 115 120 125
 Val Ser Leu Met Ser Val Leu Ile Pro Lys Leu Pro Gln Leu His Gly
 130 135 140
 Val Arg Ile Phe Gly Ile Asn Lys Tyr
 145 150

<210> 91

<211> 436

<212> PRT

<213> Homo sapiens

<400> 91

Met Arg Arg Asp Val Asn Gly Val Thr Lys Ser Arg Phe Glu Met Phe
 1 5 10 15
 Ser Asn Ser Asp Glu Ala Val Ile Asn Lys Lys Leu Pro Lys Glu Leu
 20 25 30
 Leu Leu Arg Ile Phe Ser Phe Leu Asp Val Val Thr Leu Cys Arg Cys
 35 40 45
 Ala Gln Val Ser Arg Ala Trp Asn Val Leu Ala Leu Asp Gly Ser Asn
 50 55 60

Trp Gln Arg Ile Asp Leu Phe Asp Phe Gln Arg Asp Ile Glu Gly Arg
 65 70 75 80
 Val Val Glu Asn Ile Ser Lys Arg Cys Gly Phe Leu Arg Lys Leu
 85 90 95
 Ser Leu Arg Gly Cys Leu Gly Val Gly Asp Asn Ala Leu Arg Thr Phe
 100 105 110
 Ala Gln Asn Cys Arg Asn Ile Glu Val Leu Asn Leu Asn Gly Cys Thr
 115 120 125
 Lys Thr Thr Asp Ala Thr Cys Thr Ser Leu Ser Lys Phe Cys Ser Lys
 130 135 140
 Leu Arg His Leu Asp Leu Ala Ser Cys Thr Ser Ile Thr Asn Met Ser
 145 150 155 160
 Leu Lys Ala Leu Ser Glu Gly Cys Pro Leu Leu Glu Gln Leu Asn Ile
 165 170 175
 Ser Trp Cys Asp Gln Val Thr Lys Asp Gly Ile Gln Ala Leu Val Arg
 180 185 190
 Gly Cys Gly Gly Leu Lys Ala Leu Phe Leu Lys Gly Cys Thr Gln Leu
 195 200 205
 Glu Asp Glu Ala Leu Lys Tyr Ile Gly Ala His Cys Pro Glu Leu Val
 210 215 220
 Thr Leu Asn Leu Gln Thr Cys Leu Gln Ile Thr Asp Glu Gly Leu Ile
 225 230 235 240
 Thr Ile Cys Arg Gly Cys His Lys Leu Gln Ser Leu Cys Ala Ser Gly
 245 250 255
 Cys Ser Asn Ile Thr Asp Ala Ile Leu Asn Ala Leu Gly Gln Asn Cys
 260 265 270
 Pro Arg Leu Arg Ile Leu Glu Val Ala Arg Cys Ser Gln Leu Thr Asp
 275 280 285
 Val Gly Phe Thr Thr Leu Ala Arg Asn Cys His Glu Leu Glu Lys Met
 290 295 300
 Asp Leu Glu Glu Cys Val Gln Ile Thr Asp Ser Thr Leu Ile Gln Leu
 305 310 315 320
 Ser Ile His Cys Pro Arg Leu Gln Val Leu Ser Leu Ser His Cys Glu
 325 330 335
 Leu Ile Thr Asp Asp Gly Ile Arg His Leu Gly Asn Gly Ala Cys Ala
 340 345 350
 His Asp Gln Leu Glu Val Ile Glu Leu Asp Asn Cys Pro Leu Ile Thr
 355 360 365
 Asp Ala Ser Leu Glu His Leu Lys Ser Cys His Ser Leu Glu Arg Ile
 370 375 380
 Glu Leu Tyr Asp Cys Gln Gln Ile Thr Arg Ala Gly Ile Lys Arg Leu
 385 390 395 400
 Arg Thr His Leu Pro Asn Ile Lys Val His Ala Tyr Phe Ala Pro Val
 405 410 415
 Thr Pro Pro Pro Ser Val Gly Gly Ser Arg Gln Arg Phe Cys Arg Cys
 420 425 430
 Cys Ile Ile Leu
 435

<210> 92

<211> 204

<212> PRT

<213> Homo sapiens

<400> 92

Mat Asp Pro Lys Asp Arg Lys Lys Ile Gln Phe Ser Val Pro Ala Pro
 1 5 10 15
 Pro Ser Gln Leu Asp Pro Arg Gln Val Glu Met Ile Arg Arg Arg Arg
 20 25 30
 Pro Thr Pro Ala Met Leu Phe Arg Leu Ser Glu His Ser Ser Pro Glu
 35 40 45
 Glu Glu Ala Ser Pro His Gln Arg Ala Ser Gly Glu Gly His His Leu
 50 55 60
 Lys Ser Lys Arg Pro Asn Pro Cys Ala Tyr Thr Pro Pro Ser Leu Lys
 65 70 75 80
 Ala Val Gln Arg Ile Ala Glu Ser His Leu Gln Ser Ile Ser Asn Leu
 85 90 95
 Asn Glu Asn Gln Ala Ser Glu Glu Glu Asp Glu Leu Gly Glu Leu Arg
 100 105 110
 Glu Leu Gly Tyr Pro Arg Glu Glu Asp Glu Glu Glu Glu Asp Asp
 115 120 125
 Glu Glu Glu Glu Glu Glu Glu Asp Ser Gln Ala Glu Val Leu Lys Val
 130 135 140
 Ile Arg Gln Ser Ala Gly Gln Lys Thr Thr Cys Gly Gln Gly Leu Glu
 145 150 155 160
 Gly Pro Trp Glu Arg Pro Pro Pro Leu Asp Glu Ser Glu Arg Asp Gly
 165 170 175
 Gly Ser Glu Asp Gln Val Glu Asp Pro Ala Leu Ser Glu Pro Gly Glu
 180 185 190
 Glu Pro Gln Arg Pro Ser Pro Ser Glu Pro Gly Thr
 195 200

<210> 93

<211> 115

<212> PRT

<213> Homo sapiens

<400> 93

Met Ser Gly Glu Pro Gly Gln Thr Ser Val Ala Pro Pro Pro Glu Glu
 1 5 10 15
 Val Glu Pro Gly Ser Gly Val Arg Ile Val Val Glu Tyr Cys Glu Pro
 20 25 30
 Cys Gly Phe Glu Ala Thr Tyr Leu Glu Leu Ala Ser Ala Val Lys Glu
 35 40 45
 Gln Tyr Pro Gly Ile Glu Ile Glu Ser Arg Leu Gly Gly Thr Gly Ala
 50 55 60
 Phe Glu Ile Glu Ile Asn Gly Gln Leu Val Phe Ser Lys Leu Glu Asn
 65 70 75 80
 Gly Gly Phe Pro Tyr Glu Lys Asp Leu Ile Glu Ala Ile Arg Arg Ala
 85 90 95
 Ser Asn Gly Glu Thr Leu Glu Lys Ile Thr Asn Ser Arg Pro Pro Cys
 100 105 110
 Val Ile Leu
 115

<210> 94

<211> 144

<212> PRT

<213> Homo sapiens

<400> 94

Met Gly Ala Val Val Leu Cys Arg Pro Ser Pro Leu Asn Phe Leu Ile
1 5 10 15
Gln Thr Gly Thr Gly Gln Gly Leu Ser Cys Gly Ser His Met Trp Arg
20 25 30
Cys Glu Ala Thr Pro Cys Gly Val Cys Gly Glu Ser Pro Val Gly Ser
35 40 45
Leu Leu Lys Gln His Arg Gly Arg Gly Lys Thr Trp Pro Val Gly Thr
50 55 60
Val Ser Ala Cys Arg Glu Glu Ser Glu Ala Gly Ser Leu Ser Leu Gly
65 70 75 80
Trp Ser Leu Leu Pro Ser Pro Val Gly Leu Gly Ala Val Leu Ile Leu
85 90 95
Lys Arg Cys Gly Ser Leu Cys Pro Leu Pro Gly Val Gln Gly Asn Arg
100 105 110
Arg Gly His Trp Ala Cys Phe Leu Pro Pro Asp Pro Ala Ser Pro Thr
115 120 125
Pro Cys Ile Ile Gly Asn Phe His Leu Lys Ile Phe Leu Ser Lys Val
130 135 140

<210> 95

<211> 425

<212> PRT

<213> Homo sapiens

<400> 95

Met Gly Gly Gly Asp Leu Asn Leu Lys Lys Ser Trp His Pro Gln Thr
1 5 10 15
Leu Arg Asn Val Glu Lys Val Trp Lys Ala Glu Gln Lys His Glu Ala
20 25 30
Glu Arg Lys Lys Ile Glu Glu Leu Gln Arg Glu Leu Arg Glu Glu Arg
35 40 45
Ala Arg Glu Glu Met Gln Arg Tyr Ala Glu Asp Val Gly Ala Val Lys
50 55 60
Lys Lys Glu Glu Lys Leu Asp Trp Met Tyr Gln Gly Pro Gly Gly Met
65 70 75 80
Val Asn Arg Asp Glu Tyr Leu Leu Gly Arg Pro Ile Asp Lys Tyr Val
85 90 95
Phe Glu Lys Met Glu Glu Lys Glu Ala Gly Cys Ser Ser Glu Thr Gly
100 105 110
Leu Leu Pro Gly Ser Ile Phe Ala Pro Ser Gly Ala Asn Ser Leu Leu
115 120 125
Asp Met Ala Ser Lys Ile Arg Glu Asp Pro Leu Phe Ile Ile Arg Lys
130 135 140
Lys Glu Glu Glu Lys Lys Arg Glu Val Leu Asn Asn Pro Val Lys Met
145 150 155 160

Lys Lys Ile Lys Glu Leu Leu Gln Met Ser Leu Glu Lys Lys Glu Lys
 165 170 175
 Lys Lys Lys Lys Glu Lys Lys Lys Lys His Lys Lys His Lys His Arg
 180 185 190
 Ser Ser Ser Ser Asp Arg Ser Ser Ser Glu Asp Glu His Ser Ala Gly
 195 200 205
 Arg Ser Gln Lys Lys Met Ala Asn Ser Ser Pro Val Leu Ser Lys Val
 210 215 220
 Pro Gly Tyr Gly Leu Gln Val Arg Asn Ser Asp Arg Asn Gln Gly Leu
 225 230 235 240
 Gln Gly Pro Leu Thr Ala Glu Gln Lys Arg Gly His Gly Met Lys Asn
 245 250 255
 His Ser Arg Ser Arg Ser Ser Ser His Ser Pro Pro Arg His Ala Ser
 260 265 270
 Lys Lys Ser Thr Arg Glu Ala Gly Ser Arg Asp Arg Arg Ser Arg Ser
 275 280 285
 Leu Gly Arg Arg Ser Arg Ser Pro Arg Pro Ser Lys Leu His Asn Ser
 290 295 300
 Lys Val Asn Arg Arg Glu Thr Gly Gln Thr Arg Ser Pro Ser Pro Lys
 305 310 315 320
 Lys Glu Val Tyr Gln Arg Arg His Ala Pro Gly Tyr Thr Arg Lys Leu
 325 330 335
 Ser Ala Glu Glu Leu Glu Arg Lys Arg Gln Glu Met Met Glu Asn Ala
 340 345 350
 Lys Trp Arg Glu Glu Glu Arg Leu Asn Ile Leu Lys Arg His Ala Lys
 355 360 365
 Asp Glu Glu Arg Glu Gln Arg Leu Glu Lys Leu Asp Ser Arg Asp Gly
 370 375 380
 Lys Phe Ile His Arg Met Lys Leu Glu Ser Ala Ser Thr Ser Ser Leu
 385 390 395 400
 Glu Asp Arg Val Lys Arg Asn Ile Tyr Ser Leu Gln Arg Thr Ser Val
 405 410 415
 Ala Leu Glu Lys Asn Phe Met Lys Arg
 420 425

<210> 96

<211> 394

<212> PRT

<213> Homo sapiens

<400> 96

Met Phe Ser Val Phe Glu Glu Ile Thr Arg Ile Val Val Lys Glu Met
 1 5 10 15
 Asp Ala Gly Gly Asp Met Ile Ala Val Arg Ser Leu Val Asp Ala Asp
 20 25 30
 Arg Phe Arg Cys Phe His Leu Val Gly Glu Lys Arg Thr Phe Phe Gly
 35 40 45
 Cys Arg His Tyr Thr Thr Gly Leu Thr Leu Met Asp Ile Leu Asp Thr
 50 55 60
 His Gly Asp Lys Trp Leu Asp Glu Leu Asp Ser Gly Leu Gln Gly Gln
 65 70 75 80
 Lys Ala Glu Phe Gln Ile Leu Asp Asn Val Asp Ser Thr Gly Glu Leu
 85 90 95

Ile Val Arg Leu Pro Lys Glu Ile Thr Ile Ser Gly Ser Phe Gln Gly
 100 105 110
 Phe His His Gln Lys Ile Lys Ile Ser Glu Asn Arg Ile Ser Gln Gln
 115 120 125
 Tyr Leu Ala Thr Leu Glu Asn Arg Lys Leu Lys Arg Glu Leu Pro Phe
 130 135 140
 Ser Phe Arg Ser Ile Asn Thr Arg Glu Asn Leu Tyr Leu Val Thr Glu
 145 150 155 160
 Thr Leu Glu Thr Val Lys Glu Glu Thr Leu Lys Ser Asp Arg Gln Tyr
 165 170 175
 Lys Phe Trp Ser Gln Ile Ser Gln Gly His Leu Ser Tyr Lys His Lys
 180 185 190
 Gly Gln Arg Glu Val Thr Ile Pro Asn Arg Val Leu Ser Tyr Arg
 195 200 205
 Val Lys Gln Leu Val Phe Pro Asn Lys Glu Thr Met Arg Lys Ser Leu
 210 215 220
 Gly Ser Glu Asp Ser Arg Asn Met Lys Glu Lys Leu Glu Asp Met Glu
 225 230 235 240
 Ser Val Leu Lys Asp Leu Thr Glu Glu Lys Arg Lys Asp Val Leu Asn
 245 250 255
 Ser Leu Ala Lys Cys Leu Gly Lys Glu Asp Ile Arg Gln Asp Leu Glu
 260 265 270
 Gln Arg Val Ser Glu Val Leu Ile Ser Gly Glu Leu His Met Glu Asp
 275 280 285
 Pro Asp Lys Pro Leu Leu Ser Ser Leu Phe Asn Ala Ala Gly Val Leu
 290 295 300
 Val Glu Ala Arg Ala Lys Ala Ile Leu Asp Phe Leu Asp Ala Leu Leu
 305 310 315 320
 Glu Leu Ser Glu Glu Gln Gln Phe Val Ala Glu Ala Leu Glu Lys Gly
 325 330 335
 Thr Leu Pro Leu Leu Lys Asp Gln Val Lys Ser Val Met Glu Gln Asn
 340 345 350
 Trp Asp Glu Leu Ala Ser Ser Pro Pro Asp Met Asp Tyr Asp Pro Glu
 355 360 365
 Ala Arg Ile Leu Cys Ala Leu Tyr Val Val Val Ser Ile Leu Leu Glu
 370 375 380
 Leu Ala Glu Gly Pro Thr Ser Val Ser Ser
 385 390

<210> 97

<211> 456

<212> PRT

<213> Homo sapiens

<400> 97

Met Glu Gly Pro Glu Gly Leu Gly Arg Lys Gln Ala Cys Leu Ala Met
 1 5 10 15
 Leu Leu His Phe Leu Asp Thr Tyr Gln Gly Leu Leu Gln Glu Glu
 20 25 30
 Gly Ala Gly His Ile Ile Lys Asp Leu Tyr Leu Leu Ile Met Lys Asp
 35 40 45
 Glu Ser Leu Tyr Gln Gly Leu Arg Glu Asp Thr Leu Arg Leu His Gln
 50 55 60

Leu Val Glu Thr Val Glu Leu Lys Ile Pro Glu Glu Asn Gln Pro Pro
 65 70 75 80
 Ser Lys Gln Val Lys Pro Leu Phe Arg His Phe Arg Arg Ile Asp Ser
 85 90 95
 Cys Leu Gln Thr Arg Val Ala Phe Arg Gly Ser Asp Glu Ile Phe Cys
 100 105 110
 Arg Val Tyr Met Pro Asp His Ser Tyr Val Thr Ile Arg Ser Arg Leu
 115 120 125
 Ser Ala Ser Val Gln Asp Ile Leu Gly Ser Val Thr Glu Lys Leu Gln
 130 135 140
 Tyr Ser Glu Glu Pro Ala Gly Arg Glu Asp Ser Leu Ile Leu Val Ala
 145 150 155 160
 Val Ser Ser Ser Gly Glu Lys Val Leu Leu Gln Pro Thr Glu Asp Cys
 165 170 175
 Val Phe Thr Ala Leu Gly Ile Asn Ser His Leu Phe Ala Cys Thr Arg
 180 185 190
 Asp Ser Tyr Glu Ala Leu Val Pro Leu Pro Glu Glu Ile Gln Val Ser
 195 200 205
 Pro Gly Asp Thr Glu Ile His Arg Val Glu Pro Glu Asp Val Ala Asn
 210 215 220
 His Leu Thr Ala Phe His Trp Glu Leu Phe Arg Cys Val His Glu Leu
 225 230 235 240
 Glu Phe Val Asp Tyr Val Phe His Gly Glu Arg Gly Arg Arg Glu Thr
 245 250 255
 Ala Asn Leu Glu Leu Leu Leu Gln Arg Cys Ser Glu Val Thr His Trp
 260 265 270
 Val Ala Thr Glu Val Leu Leu Cys Glu Ala Pro Gly Lys Arg Ala Gln
 275 280 285
 Leu Leu Lys Lys Phe Ile Lys Ile Ala Ala Leu Cys Lys Gln Asn Gln
 290 295 300
 Asp Leu Leu Ser Phe Tyr Ala Val Val Met Gly Leu Asp Asn Ala Ala
 305 310 315 320
 Val Ser Arg Leu Arg Leu Thr Trp Glu Lys Leu Pro Gly Lys Phe Lys
 325 330 335
 Asn Leu Phe Arg Lys Phe Glu Asn Leu Thr Asp Pro Cys Arg Asn His
 340 345 350
 Lys Ser Tyr Arg Glu Val Ile Ser Lys Met Lys Pro Pro Val Ile Pro
 355 360 365
 Phe Val Pro Leu Ile Leu Lys Asp Leu Thr Phe Leu His Glu Gly Ser
 370 375 380
 Lys Thr Leu Val Asp Gly Leu Val Asn Ile Glu Lys Leu His Ser Val
 385 390 395 400
 Ala Glu Lys Val Arg Thr Ile Arg Lys Tyr Arg Ser Arg Pro Leu Cys
 405 410 415
 Leu Asp Met Glu Ala Ser Pro Asn His Leu Gln Thr Lys Ala Tyr Val
 420 425 430
 Arg Gln Phe Gln Val Ile Asp Asn Gln Asn Leu Leu Phe Glu Leu Ser
 435 440 445
 Tyr Lys Leu Glu Ala Asn Ser Gln
 450 455

<210> 98

<211> 715

<212> PRT

<213> Homo sapiens

<400> 98

5 Met Ser Gln Val Met Ser Ser Pro Leu Leu Ala Gly Gly His Ala Val
 1 5 10 15
 Ser Leu Ala Pro Cys Asp Glu Pro Arg Arg Thr Leu His Pro Ala Pro
 20 25 30
 Ser Pro Ser Leu Pro Pro Gln Cys Ser Tyr Tyr Thr Thr Glu Gly Trp
 35 40 45
 10 Gly Ala Gln Ala Leu Met Ala Pro Val Pro Cys Met Gly Pro Pro Gly
 50 55 60
 Arg Leu Gln Gln Ala Pro Gln Val Glu Ala Lys Ala Thr Cys Phe Leu
 65 70 75 80
 Pro Ser Pro Gly Glu Lys Ala Leu Gly Thr Pro Glu Asp Leu Asp Ser
 85 90 95
 15 Tyr Ile Asp Phe Ser Leu Glu Ser Leu Asn Gln Met Ile Leu Glu Leu
 100 105 110
 Asp Pro Thr Phe Gln Leu Leu Pro Gly Thr Gly Gly Ser Gln Ala
 115 120 125
 Glu Leu Ala Gln Ser Thr Met Ser Met Arg Lys Lys Glu Glu Ser Glu
 130 135 140
 20 Ala Leu Asp Ile Lys Tyr Ile Glu Val Thr Ser Ala Arg Ser Arg Cys
 145 150 155 160
 His Asp Trp Pro Gln His Cys Ser Ser Pro Ser Val Thr Pro Pro Phe
 165 170 175
 25 Gly Ser Pro Arg Ser Gly Gly Leu Leu Leu Ser Arg Asp Val Pro Arg
 180 185 190
 Glu Thr Arg Ser Ser Ser Glu Ser Leu Ile Phe Ser Gly Asn Gln Gly
 195 200 205
 Arg Gly His Gln Arg Pro Leu Pro Pro Ser Glu Gly Leu Ser Pro Arg
 210 215 220
 30 Pro Pro Asn Ser Pro Ser Ile Ser Ile Pro Cys Met Gly Ser Lys Ala
 225 230 235 240
 Ser Ser Pro His Gly Leu Gly Ser Pro Leu Val Ala Ser Pro Arg Leu
 245 250 255
 Glu Lys Arg Leu Gly Gly Leu Ala Pro Gln Arg Gly Ser Arg Ile Ser
 260 265 270
 35 Val Leu Ser Ala Ser Pro Val Ser Asp Val Ser Tyr Met Phe Gly Ser
 275 280 285
 Ser Gln Ser Leu Leu His Ser Ser Asn Ser Ser His Gln Ser Ser Ser
 290 295 300
 Arg Ser Leu Glu Ser Pro Ala Asn Ser Ser Ser Leu His Ser Leu
 305 310 315 320
 Gly Ser Val Ser Leu Cys Thr Arg Pro Ser Asp Phe Gln Ala Pro Arg
 325 330 335
 Asn Pro Thr Leu Thr Met Gly Gln Pro Arg Thr Pro His Ser Pro Pro
 340 345 350
 40 Leu Ala Lys Glu His Ala Ser Ile Cys Pro Pro Ser Ile Thr Asn Ser
 355 360 365
 Mat Val Asp Ile Pro Ile Val Leu Ile Asn Gly Cys Pro Glu Pro Gly
 370 375 380
 Ser Ser Pro Pro Gln Arg Thr Pro Gly His Gln Asn Ser Val Gln Pro
 385 390 395 400
 50 Gly Ala Ala Ser Pro Ser Asn Pro Cys Pro Ala Thr Arg Ser Asn Ser
 405 410 415
 Gln Thr Leu Ser Asp Ala Pro Phe Thr Thr Cys Pro Glu Gly Pro Ala
 420 425 430
 Arg Asp Met Gln Pro Thr Met Lys Phe Val Met Asp Thr Ser Lys Tyr
 435 440 445

Trp Phe Lys Pro Asn Ile Thr Arg Glu Gln Ala Ile Glu Leu Leu Arg
 450 455 460
 Lys Glu Glu Pro Gly Ala Phe Val Ile Arg Asp Ser Ser Ser Tyr Arg
 465 470 475 480
 Gly Ser Phe Gly Leu Ala Leu Lys Val Gln Glu Val Pro Ala Ser Ala
 485 490 495
 Gln Asn Arg Pro Gly Glu Asp Ser Asn Asp Leu Ile Arg His Phe Leu
 500 505 510
 Ile Glu Ser Ser Ala Lys Gly Val His Leu Lys Gly Ala Asp Glu Glu
 515 520 525
 Pro Tyr Phe Gly Ser Leu Ser Ala Phe Val Cys Gln His Ser Ile Met
 530 535 540
 Ala Leu Ala Leu Pro Cys Lys Leu Thr Ile Pro Gln Arg Glu Leu Gly
 545 550 555 560
 Gly Ala Asp Gly Ala Ser Asp Ser Thr Asp Ser Pro Ala Ser Cys Gln
 565 570 575
 Lys Lys Ser Ala Gly Cys His Thr Leu Tyr Leu Ser Ser Val Ser Val
 580 585 590
 Glu Thr Leu Thr Gly Ala Leu Ala Val Gln Lys Ala Ile Ser Thr Thr
 595 600 605
 Phe Glu Arg Asp Ile Leu Pro Thr Pro Thr Val Val His Phe Glu Val
 610 615 620
 Thr Glu Gln Gly Ile Thr Leu Thr Asp Val Gln Arg Lys Val Phe Phe
 625 630 635 640
 Arg Arg His Tyr Pro Leu Thr Thr Leu Arg Phe Cys Gly Met Asp Pro
 645 650 655
 Glu Gln Arg Lys Trp Gln Lys Tyr Cys Lys Pro Ser Trp Ile Phe Gly
 660 665 670
 Phe Val Ala Lys Ser Gln Thr Glu Pro Gln Glu Asn Val Cys His Leu
 675 680 685
 Phe Ala Glu Tyr Asp Met Val Gln Pro Ala Ser Gln Val Ile Gly Leu
 690 695 700
 Val Thr Ala Leu Leu Gln Asp Ala Glu Arg Met
 705 710 715

35 <210> 99

<211> 35

<212> DNA

40 <213> Artificial sequence

45 <220>

<223> PCR primer

<400> 99

ccatatataa aaccactgtc ctgtcctttg tggct

35

50 <210> 100

<211> 26

<212> DNA

55 <213> Artificial sequence

5	<220>		
	<223>	PCR primer	
	<400>	100	
		cccccatotg tctgtctata ttgtc	26
10	<210>	101	
	<211>	22	
15	<212>	DNA	
	<213>	Artificial sequence	
20	<220>		
	<223>	PCR primer	
	<400>	101	
		tgccctacgt gacgactatg tg	22
25	<210>	102	
	<211>	25	
30	<212>	DNA	
	<213>	Artificial sequence	
35	<220>		
	<223>	PCR primer	
	<400>	102	
		tttggttttc tacaactggt gctat	25
40	<210>	103	
	<211>	19	
45	<212>	DNA	
	<213>	Artificial sequence	
50	<220>		
	<223>	PCR primer	
	<400>	103	
		gggtccaca caccagatg	19
55			

5
10
15
20
25
30
35
40
45
50
55

<210> 104
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> PCR primer
<400> 104
acgctctgag caccctctac a 21

<210> 105
<211> 31
<212> DNA
<213> Artificial sequence

<220>
<223> PCR primer
<400> 105
tgtcacaggg actgaaaacc tctcctcatg t 31

<210> 106
<211> 17
<212> DNA
<213> Artificial sequence

<220>
<223> PCR primer
<400> 106
cccaaggcca cgagctt 17

<210> 107
<211> 24
<212> DNA
<213> Artificial sequence

<220>

<223> PCR primer

<400> 107

tgttgctctc ttaacgaatc gaaa

24

<210> 108

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 108

ctgggtcaaac aaactctctg aacccctcc

29

<210> 109

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 109

tggtgaggaa aagcggacat

20

<210> 110

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 110

ctggcttgga ggacagtga g

21

<210> 111

<211> 24

<212> DNA

<213> Artificial sequence

5

<220>

<223> PCR primer

<400> 111

ccaagccctc cccatcccat gtat

24

<210> 112

15

<211> 21

<212> DNA

<213> Artificial sequence

20

<220>

<223> PCR primer

<400> 112

gaggtgtcgt accgcgttct a

21

<210> 113

30

<211> 21

<212> DNA

<213> Artificial sequence

35

<220>

<223> PCR primer

<400> 113

cggttctgct cttccctgtc t

21

<210> 114

45

<211> 23

<212> DNA

<213> Artificial sequence

50

<220>

<223> PCR primer

<400> 114

ccagaccgcg ttcactgacc tgc

23

55

5 <210> 115
 <211> 20
 <212> DNA
 <213> Artificial sequence

10 <220>
 <223> PCR primer
 15 <400> 115
 cgcctgtact tcagcatgga 20

<210> 116
 20 <211> 18
 <212> DNA
 <213> Artificial sequence

25 <220>
 <223> PCR primer
 30 <400> 116
 gcgggttcagc tgggtgaa 18

<210> 117
 <211> 25
 35 <212> DNA
 <213> Artificial sequence

40 <220>
 <223> PCR primer
 45 <400> 117
 accccgaggc atcaccacaa atcat 25

<210> 118
 <211> 23
 50 <212> DNA
 <213> Artificial sequence

55

<220>

<223> PCR primer

<400>	118
-------	-----

agttctgcct ctctgacaac cat

<210> 119

<211> 23

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 119

taggctcaga gtcagaccca aac

<210>. 120

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

$\langle 400 \rangle$	120
-----------------------	-----

ccctcgtggg cttgtgctcg g

<210> 121

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 121

aagccgccag ttcattctttt t

<210> 122

<211> 25

<212> DNA

<213> Artificial sequence

5

<220>

10 <223> PCR primer
<400> 122
ottgtggttc aagtcaaag ttcag 25

<210> 123

15 <211> 21

<212> DNA

<213> Artificial sequence

20

<220>

25 <223> PCR primer
<400> 123
tctgcctgcg ctctcgtagg t 21

<210> 124

30 <211> 18

<212> DNA

<213> Artificial sequence

35

<220>

40 <223> PCR primer
<400> 124
gggctgggca cctgactt 18

<210> 125

45 <211> 20

<212> DNA

<213> Artificial sequence

50

<220>

55 <223> PCR primer
<400> 125
cccaacaagg gtcccagact 20

5 <210> 126
<211> 17
<212> DNA
<213> Artificial sequence

10

<220>

15 <223> PCR primer
<400> 126
cggcgcattg agcggcg

17

<210> 127

20

<211> 20

<212> DNA

<213> Artificial sequence

25

<220>

30 <223> PCR primer
<400> 127
cccaaggac ttcgtgaatg

20

<210> 128

<211> 21

35

<212> DNA

<213> Artificial sequence

40

<220>

45 <223> PCR primer
<400> 128
ggcgatccot gatgacaagt a

21

<210> 129

<211> 29

50

<212> DNA

<213> Artificial sequence

55

<220>

<223> PCR primer#

<400> 129

agcaccaact gtgaaccagg tacaatggc

29

<210> 130

<211> 19

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 130

gagggaggct ctgcttttg

19

<210> 131

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 131

tcacaactag cgggtgagga g

21

<210> 132

<211> 21

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 132

tgcagaggaa cggcgtgagc g

21

<210> 133

<211> 22

<212> DNA
 <213> Artificial sequence
 5
 <220>
 10 <223> PCR primer
 <400> 133
 tgaggtttcc tcccaaatac ta 22
 <210> 134
 15 <211> 22
 <212> DNA
 <213> Artificial sequence
 20
 <220>
 25 <223> PCR primer
 <400> 134
 cagctcaagg gaagctgtca tc 22
 <210> 135
 30 <211> 24
 <212> DNA
 <213> Artificial sequence
 35
 <220>
 40 <223> PCR primer
 <400> 135
 cccccacatg ttccccaaga tgct 24
 <210> 136
 45 <211> 21
 <212> DNA
 <213> Artificial sequence
 50
 <220>
 55 <223> PCR primer
 <400> 136
 ggaggcgcta aaggtctacg t 21

5 <210> 137
 <211> 21
 <212> DNA
 <213> Artificial sequence

10 <220>
 <223> PCR primer
 15 <400> 137
 tgatgcttcg caggtcagta a

21

<210> 138
 20 <211> 26
 <212> DNA
 <213> Artificial sequence

25 <220>
 <223> PCR primer
 30 <400> 138
 ctctgcgcc tcctaaagct gaagcc

26

<210> 139
 35 <211> 17
 <212> DNA
 <213> Artificial sequence

40 <220>
 <223> PCR primer
 45 <400> 139
 ggacgcgtgg gcttttc

17

<210> 140
 <211> 20
 50 <212> DNA
 <213> Artificial sequence

55

<220>

<223> PCR primer

<400> 140

tgtggctgtg gacacctttc

20

<210> 141

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 141

ccacaagctg aaggcagaca aggcc

25

<210> 142

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 142

gcggtatttc atggaacaca

20

<210> 143

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 143

ggtcagccag gagcttcttg

20

<210> 144

<211> 23

<212> DNA
 <213> Artificial sequence
 5
 <220>
 <223> PCR primer
 10 <400> 144
 accaccttgc gcaggttgtc cag 23
 <210> 145
 15 <211> 18
 <212> DNA
 <213> Artificial sequence
 20
 <220>
 <223> PCR primer
 25 <400> 145
 cgcattgcaag acctgaac 18
 <210> 146
 30 <211> 23
 <212> DNA
 <213> Artificial sequence
 35
 <220>
 <223> PCR primer
 40 <400> 146
 gtctcgatct tggacagctt ctg 23
 <210> 147
 45 <211> 22
 <212> DNA
 <213> Artificial sequence
 50
 <220>
 <223> PCR primer
 55 <400> 147
 acactgtcca cacggcccga gg 22

5 <210> 148
<211> 21
<212> DNA
<213> Artificial sequence

10 <220>
<223> PCR primer
15 <400> 148
ctgggcagaa tggaaggatc t 21

<210> 149
20 <211> 22
<212> DNA
<213> Artificial sequence

25 <220>
<223> PCR primer
30 <400> 149
gggactctag cagacccaca ct 22

<210> 150
35 <211> 22
<212> DNA
<213> Artificial sequence

40 <220>
<223> PCR primer
45 <400> 150
caccacactg gattccctgt tc 22

<210> 151
50 <211> 23
<212> DNA
<213> Artificial sequence

55

<220>

<223> PCR primer

<400> 151

ccttcagaca ggcgtagatg atg

23

<210> 152

<211> 29

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 152

gggtattatt tctttattag gtgocactt

29

<210> 153

<211> 30

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 153

ttccctaagg ctttcagtac ccaggatctg

30

<210> 154

<211> 18

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 154

ccagcttggc cctttcct

18

<210> 155

<211> 23

<212> DNA

<213> Artificial sequence

5

<220>

10

<223> PCR primer

<400> 155

gaatgggtcg cttttgttct tag

23

<210> 156

15

<211> 22

<212> DNA

<213> Artificial sequence

20

<220>

25

<223> PCR primer

<400> 156

tcacggacct cagcctgccc ct

22

<210> 157

30

<211> 21

<212> DNA

<213> Artificial sequence

35

<220>

40

<223> PCR primer

<400> 157

tggtgaaggt gtcagccatg t

21

<210> 158

45

<211> 21

<212> DNA

<213> Artificial sequence

50

55

<220>

<223> PCR primer

<400> 158

tcagagtgc gcaatggctt t

21

<210> 159

<211> 20

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 159

acctccttcc ccagotcccc

20

<210> 160

<211> 24

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 160

ggcaacatct tacttgcct ttga

24

<210> 161

<211> 25

<212> DNA

<213> Artificial sequence

<220>

<223> PCR primer

<400> 161

ccaaggaagc acagacaact atttc

25

<210> 162

<211> 30

<212> DNA

<213> Artificial sequence

5

<220>

<223> PCR primer

<400> 162

tcctccctat ccatggcact aaaccacttc

30

<210> 163

15

<211> 19

<212> DNA

<213> Artificial sequence

20

<220>

<223> PCR primer

<400> 163

tgggcaaggg ctccctatct

19

<210> 164

30

<211> 21

<212> DNA

<213> Artificial sequence

35

<220>

<223> PCR primer

<400> 164

gttacccttg gcagacgtat g

21

<210> 165

45

<211> 31

<212> DNA

<213> Artificial sequence

50

<220>

<223> PCR primer

<400> 165

tgcctctgag tctgaatctc ccaaagagag a

31

55

<210> 166
5 <211> 31
<212> DNA
<213> Artificial sequence
10

<220>
15 <223> PCR primer
<400> 166
gagtagttat gtgattattt cagctcttga c 31

<210> 167
20 <211> 21
<212> DNA
<213> Artificial sequence
25

<220>
30 <223> PCR primer
<400> 167
tcaaatgttg tccccgagtc t 21

<210> 168
35 <211> 34
<212> DNA
<213> Artificial sequence
40

<220>
45 <223> PCR primer
<400> 168
cagaaattcg gaagacagaa ctattgtcat gcct 34

<210> 169
50 <211> 27
<212> DNA
<213> Artificial sequence
55

<220>
 <223> PCR primer
 5 <400> 169
 gattagtaac ccatagcagt tgaaggt 27
 <210> 170
 10 <211> 26
 <212> DNA
 <213> Artificial sequence
 15
 <220>
 <223> PCR primer
 20 <400> 170
 atttactgac ggtggtctga acatac 26
 <210> 171
 25 <211> 31
 <212> DNA
 <213> Artificial sequence
 30
 <220>
 <223> PCR primer
 35 <400> 171
 tgacagactc caaatcacao gcacagtcaa c 31
 <210> 172
 <211> 25
 40 <212> DNA
 <213> Artificial sequence
 45
 <220>
 <223> PCR primer
 50 <400> 172
 tgatggtttg gaggaagtt tattt 25
 <210> 173
 <211> 24
 55

<212> DNA

<213> Artificial sequence

5

<220>

10

<223> PCR primer

<400> 173

tttggttggg tctttagagg aatc

24

<210> 174

15

<211> 24

<212> DNA

<213> Artificial sequence

20

<220>

25

<223> PCR primer

<400> 174

tgccaaccat gcatcaggta gccc

24

<210> 175

30

<211> 20

<212> DNA

<213> Artificial sequence

35

<220>

40

<223> PCR primer

<400> 175

cagctcacct ggcaacttca

20

<210> 176

45

<211> 20

<212> DNA

<213> Artificial sequence

50

<220>

55

<223> PCR primer

<400> 176

cctgattttc ccagcgatgt

20

5 <210> 177
<211> 19
<212> DNA
<213> Artificial sequence

10 <220>
<223> PCR primer
15 <400> 177
cgccgctccc gggtctgct

19

<210> 178
20 <211> 20
<212> DNA
<213> Artificial sequence

25 <220>
<223> PCR primer
30 <400> 178
tggccaagcg taagctgatt

20

<210> 179
35 <211> 21
<212> DNA
<213> Artificial sequence

40 <220>
<223> PCR primer
45 <400> 179
gctgcagtga tcggatcatt

21

<210> 180
50 <211> 22
<212> DNA
<213> Artificial Sequence

55

<220>

<223> MLLT6

<400> 180

caccatggag cccatcgtgc tg

22

<210> 181

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> MLLT6 for

<400> 181

atccccgagg tgcaatttg

19

<210> 182

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> MLLT6 rev

<400> 182

agcgatcatg aggcacgtac t

21

<210> 183

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> ZNF144

<400> 183

cctgccagag ataggagacc cagacagct

29

<210> 184

<211> 19

<212> DNA
 <213> Artificial Sequence
 5
 <220>
 10 <223> ZNF144 for
 <400> 184
 atccccctga gccttttca 19
 <210> 185
 15 <211> 19
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 25 <223> ZNF144 rev
 <400> 185
 cagcctctgg tcccacat 19
 <210> 186
 30 <211> 28
 <212> DNA
 <213> Artificial Sequence
 35
 <220>
 40 <223> PIP5K2B
 <400> 186
 tgatcatcaa ttccaaacct ctcccgaa 28
 <210> 187
 45 <211> 19
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 55 <223> PIP5K2B for
 <400> 187
 ccccatggtg ttccgaaac 19

<210> 188

5 <211> 19

<212> DNA

<213> Artificial Sequence

10

<220>

<223> PIP5K2B rev

15 <400> 188

tgccaggagc ctccatacc

19

<210> 189

20 <211> 29

<212> DNA

<213> Artificial Sequence

25

<220>

<223> TEM7

30 <400> 189

cagccttcta aaacacaatg tattcatgt

29

<210> 190

<211> 29

35

<212> DNA

<213> Artificial Sequence

40

<220>

<223> TEM7 for

<400> 190

45 cctgaactta atggtagaat tcaaagatc

29

<210> 191

<211> 27

50

<212> DNA

<213> Artificial Sequence

55

<220>

<223> TEM7 rev

<400> 191

tattaacact gagaatccat gcagaga

27

<210> 192

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> ZNFN1A3

<400> 192

tatctggctc cagggattgc tcctatgtat tcagc

35

<210> 193

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> ZNFN1A3 for

<400> 193

cacagagccc tgetgaagtg

20

<210> 194

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> ZNFN1A3 rev

<400> 194

gcgaggtcat tggtttttag aaa

23

<210> 195

<211> 22

<212> DNA
 <213> Artificial Sequence
 5
 <220>
 10 <223> WIRE
 <400> 195
 ctgtgatccg aaatggtgcc ag 22
 <210> 196
 15 <211> 20
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 25 <223> WIRE for
 <400> 196
 ccgtctccac atccaaacct 20
 <210> 197
 30 <211> 20
 <212> DNA
 <213> Artificial Sequence
 35
 <220>
 40 <223> WIRE rev
 <400> 197
 acccatgcat tcggtatggt 20
 <210> 198
 45 <211> 21
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 55 <223> PSMB3
 <400> 198
 agtggcacct gcgccgaaca a 21

<210> 199

5 <211> 21

<212> DNA

<213> Artificial Sequence

10

<220>

<223> PSMB3 for

15 <400> 199

ccccatgggtg actgatgact t

21

<210> 200

20 <211> 21

<212> DNA

<213> Artificial Sequence

25

<220>

<223> PSMB3 rev

30 <400> 200

ccagagggac tcacacattc c

21

<210> 201

<211> 29

35

<212> DNA

<213> Artificial Sequence

40

<220>

<223> MGC9753

<400> 201

45 ccagaaactt tccatcccaa aggcagtct

29

<210> 202

<211> 21

50

<212> DNA

<213> Artificial Sequence

55

<220>

<223> MGC9753 for

<400> 202

ctgccccaca ggaatagaat g

21

<210> 203

<211> 23

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> MGC9753 rev

<400> 203

aaaaatccag totgettcaa cca

23

<210> 204

<211> 20

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> ORMDL3

<400> 204

agctgccccca gctccacgga

20

<210> 205

<211> 21

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> ORMDL3 for

<400> 205

tccctgatga gcgtgcttat c

21

<210> 206

<211> 28

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> ORMDL3 rev

<400> 206

tctcagtact tattgattcc aaaaatcc

28

<210> 207

<211> 25

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> MGC15482

<400> 207

tccagtggaa gcaaccccag tgttc

25

<210> 208

<211> 25

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> MGC15482 for

<400> 208

cacttctaga gctaccgtgg agtct

25

<210> 209

<211> 22

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> MGC15482 rev

<400> 209

ccctcacttt gtaacccttg ct

22

<210> 210

5 <211> 20

<212> DNA

<213> ARTIFICIAL SEQUENCE

10

<220>

<223> PPP1R1B

15 <400> 210

cagcgtggcg caacaaccca

20

<210> 211

20 <211> 21

<212> DNA

<213> ARTIFICIAL SEQUENCE

25

<220>

<223> PPP1R1B for

30 <400> 211

gggattgttt cgccacacat a

21

<210> 212

<211> 20

35

<212> DNA

<213> ARTIFICIAL SEQUENCE

40

<220>

<223> PPP1R1B rev

45 <400> 212

ccgatgttaa ggcccatagc

20

<210> 213

<211> 27

50

<212> DNA

<213> ARTIFICIAL SEQUENCE

55

<220>

<223> MGC14832

<400> 213

taaaatgtcc ggccaacatg agttccc

27

<210> 214

<211> 17

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> MGC14832 for

<400> 214

cgcagtgcct ggcacat

17

<210> 215

<211> 20

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> MGC14832 rev

<400> 215

gacacccct gacctatgga

20

<210> 216

<211> 25

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> LOC51242

<400> 216

cagtgcctc tccggtccc ttgga

25

<210> 217

<211> 20

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> LOC51242 for

<400> 217

tgggtccctg tgcctcttc

20

<210> 218

<211> 20

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> LOC51242 for

<400> 218

agggtcagga gggagaaaac

20

<210> 219

<211> 26

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> FLJ20291

<400> 219

ccagtgccca cccgttaaag agtcaa

26

<210> 220

<211> 24

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> FLJ20291 for

<400> 220

ttgtgggaca ctcagtaact ttgg

24

<210> 221

5 <211> 20

<212> DNA

10 <213> ARTIFICIAL SEQUENCE

<220>

15 <223> FLJ20291 rev
<400> 221
acaagcactc ccaccgagat

20

<210> 222

20 <211> 24

<212> DNA

25 <213> ARTIFICIAL SEQUENCE

<220>

30 <223> PRO2521
<400> 222
agtctgtcct cactgccatc gccca

24

<210> 223

35 <211> 21

<212> DNA

<213> ARTIFICIAL SEQUENCE

40 <220>

45 <223> PRO2521 for
<400> 223
aagcctctgg gttttccatt t

21

<210> 224

50 <211> 20

<212> DNA

<213> ARTIFICIAL SEQUENCE

55

<220>

<223> PRO2521 rev

<400> 224

cccactggtg acaggatggt

20

<210> 225

<211> 23

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> LINK-GEFII

<400> 225

catctgacat ctttcccgtg gag

23

<210> 226

<211> 21

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> LINK-GEFII for

<400> 226

ctttgcacga tgtctcaacc a

21

<210> 227

<211> 18

<212> DNA

<213> ARTIFICIAL SEQUENCE

<220>

<223> LINK-GEFII rev

<400> 227

tttcccgtgg agcaggaa

18

<210> 228

<211> 26

<212> DNA

<213> ARTIFICIAL SEQUENCE

5

<220>

<223> CTEN

<400> 228

10 ccgcgccta atatgcaaca ttaggg

26

<210> 229

<211> 23

15

<212> DNA

<213> ARTIFICIAL SEQUENCE

20

<220>

<223> CTEN for

<400> 229

25 cgagtattcc aaagctggta tog

23

<210> 230

<211> 24

30

<212> DNA

<213> ARTIFICIAL SEQUENCE

35

<220>

<223> CTEN rev

<400> 230

40 atcacagaga gatggccctt atct

24

<210> 231

<211> 25

45

<212> DNA

<213> Artificial Sequence

50

<220>

<223> D17S946 forward primer

<400> 231

55 acagtctatc aagcagaaaa atcct

25

<210> 232

5 **<211>** 16

<212> DNA

<213> Artificial Sequence

10

<220>.

<223> D17S946 reverse primer

15 <400> 232

tgccgtgcca gagaga

16

<210> 233

20 <211> 20

<212> DNA

<213> Artificial Sequence

25

<220>

<223> D17S1181 forward primer

<400> 233

gacaacagag cgagactccc

20

<210> 234

<21i> 20

35

<212> DNA

<213> Artificial Sequence

40

<220>

<223> D17S1181 reverse primer

<400> 234

gccagcctg tcacttattc

20

<210> 235

<211> 18

50

<212> DNA

<213> Artificial Sequence

55

<220>

<223> D17S2026 forward primer

<400> 235

tggtcattcg acaacgaa

18

<210> 236

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S2026 reverse primer

<400> 236

cagcattgga tgcaatcc

18

<210> 237

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S838 forward primer

<400> 237

ctocagaatc cagaccatga

20

<210> 238

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S838 reverse primer

<400> 238

aggacagtgt gtagcccttc

20

<210> 239

<211> 20

<212> DNA
 <213> Artificial Sequence
 5
 <220>
 <223> D17S250 forward primer
 10 <400> 239
 ggaagaatca aatagacaat 20
 <210> 240
 15 <211> 24
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 <223> D17S250 reverse primer
 25 <400> 240
 gctggccata tatatattta aacc 24
 <210> 241
 30 <211> 23
 <212> DNA
 <213> Artificial Sequence
 35
 <220>
 <223> D17S1818 forward primer
 40 <400> 241
 cataggtatg ttcagaaatg tga 23
 <210> 242
 45 <211> 18
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 <223> D17S1818 reverse primer
 55 <400> 242
 tgcctactgg aaaccaga 18

<210> 243
5 <211> 23
<212> DNA
<213> Artificial Sequence
10
<220>
<223> D17S614 forward primer
15 <400> 243
aaggggaagg ggctttcaaa gct 23
<210> 244
20 <211> 23
<212> DNA
<213> Artificial Sequence
25
<220>
<223> D17S614 reverse primer
30 <220>
<221> misc_feature
<222> (1) .. (1)
35 <223> n=a, c, g or t
<400> 244
nggaggttgc agtgagccaa gat 23
40 <210> 245
<211> 23
<212> DNA
45 <213> Artificial Sequence
<220>
50 <223> D17S2019 forward primer
<400> 245
caaaagctta tgatgctcaa acc 23
55

5
 <210> 246
 <211> 22
 <212> DNA
 <213> Artificial Sequence

10
 <220>
 <223> D17S2019 reverse primer
 15 <400> 246
 ttgtttccct ttgaatttct ga

22

20
 <210> 247
 <211> 25
 <212> DNA
 <213> Artificial Sequence

25
 <220>
 <223> D17S608 forward primer
 30 <400> 247
 taggttcacc totcattttc ttcag

25

35
 <210> 248
 <211> 24
 <212> DNA
 <213> Artificial Sequence

40
 <220>
 <223> D17S608 reverse primer
 <220>

45
 <221> misc_feature
 <222> (17)..(17)
 50 <223> n=a, c, g or t

<400> 248
 atataaatet ttataaact tata

24

55

<211> 20
5 <212> DNA
<213> Artificial Sequence

10 <220>
<223> D17S1655 forward primer
<400> 249
cggaccagag tgttccatgg
15 <210> 250
<211> 20
<212> DNA
20 <213> Artificial Sequence

25 <220>
<223> D17S1655 reverse primer
<400> 250
gcatacagca ccctctacct
30 <210> 251
<211> 25
<212> DNA
35 <213> Artificial Sequence

40 <220>
<223> D17S2147 forward primer
<400> 251
aggggagaat aaataaaatc tgtgg
45 <210> 252
<211> 22
<212> DNA
50 <213> Artificial Sequence

55

20

20

25

<220>

<223> D17S2147 reverse primer

<400> 252

caggagtgag acactctcca tg

22

<210> 253

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S754 forward primer

<400> 253

tggattcaact gactcagcct gc

22

<210> 254

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S754 reverse primer

<400> 254

gcgtgtctgt ctccatgtgt gc

22

<210> 255

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S1814 forward primer

<400> 255

tccccaatga cggtgatg

18

<210> 256

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S1814 reverse primer

<400> 256

ctggagggttg gcttgtggat

20

<210> 257

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S2007 forward primer

<400> 257

ggtcccacga atttgctg

18

<210> 258

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S2007 reverse primer

<400> 258

ccaccacaga aaacaggaga

20

<210> 259

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S1246 forward primer

<400> 259

tcatctctct gaccttgtga

20

<210> 260
5 <211> 20
<212> DNA
<213> Artificial Sequence
10
<220>
<223> D17S1246 reverse primer
15 <400> 260 20
ttgtcaccac attgcctttc
<210> 261
20 <211> 21
<212> DNA
<213> Artificial Sequence
25
<220>
<223> D17S1979 forward primer
30 <400> 261 21
ccttgatag attcagctcc c
<210> 262
35 <211> 21
<212> DNA
<213> Artificial Sequence
40
<220>
<223> D17S1979 reverse primer
45 <400> 262 21
cttgtccctt ctcaatcctc c
<210> 263
50 <211> 25
<212> DNA
<213> Artificial Sequence
55

<220>

<223> D17S1984 forward primer

<400> 263

ttaagcaagg ttttaattaa gctgc

25

<210> 264

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S1984 reverse primer

<400> 264

gattacagtg ctccctctcc c

21

<210> 265

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> G11580 forward primer

<400> 265

ggttttaatt aagctgcatg gc

22

<210> 266

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> G11580 reverse primer

<400> 266

gattacagtg ctccctctcc c

21

<210> 267

<211> 20

<212> DNA
 <213> Artificial Sequence
 5
 <220>
 10 <223> D17S1867 forward primer
 <400> 267
 agtttgacac tgaggctttg 20
 <210> 268
 15 <211> 20
 <212> DNA
 <213> Artificial Sequence
 20
 <220>
 25 <223> D17S1867 reverse primer
 <400> 268
 tttagacttg gtaactgccg 20
 <210> 269
 30 <211> 24
 <212> DNA
 <213> Artificial Sequence
 35
 <220>
 40 <223> D17S1788 forward primer
 <400> 269
 tgcagatgcc taagaacttt tcag 24
 <210> 270
 45 <211> 19
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 55 <223> D17S1788 reverse primer
 <400> 270
 gccatgatct cccaaagcc 19

5 <210> 271
 <211> 18
 <212> DNA
 <213> Artificial Sequence
 10
 <220>
 <223> D17S1836 forward primer
 15 <400> 271
 tcgaggttat ggtgagcc 18
 <210> 272
 20 <211> 24
 <212> DNA
 <213> Artificial Sequence
 25
 <220>
 <223> D17S1836 reverse primer
 30 <400> 272
 aaactgtgtg tgtcaaagga tact 24
 <210> 273
 35 <211> 19
 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> D17S1787 forward primer
 45 <400> 273
 gctgatctga agccaatga 19
 <210> 274
 50 <211> 19
 <212> DNA
 <213> Artificial Sequence
 55

<220>

<223> D17S1787 reverse primer

<400> 274

tacatgaagg catggtctg

19

<210> 275

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S1660 forward primer

<400> 275

ctaataataat cctgggcaca tgg

23

<210> 276

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S1660 reverse primer

<400> 276

gctgcggacc agacagat

18

<210> 277

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S2154 forward primer

<400> 277

gataaaaaca agcactggct cc

22

<210> 278

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S2154 reverse primer

<400> 278

cccacggctt tcttgatcta

20

<210> 279

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S1955 forward primer

<400> 279

tgtaatgtaa gccccatgag g

21

<210> 280

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S1955 reverse primer

<400> 280

cactcaactc aacagtctaa aggtg

25

<210> 281

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S2098 forward primer

<400> 281

gtgagttcaa gcatagtaat tatcc

25

<210> 282
5 <211> 23
<212> DNA
<213> Artificial Sequence
10
<220>
<223> D17S2098 reverse primer
15 <400> 282
attcagcctc agttcactgc ttc 23
<210> 283
20 <211> 20
<212> DNA
<213> Artificial Sequence
25
<220>
<223> D17S518 forward primer
30 <400> 283
gatocagtgg agactcagag 20
<210> 284
35 <211> 20
<212> DNA
<213> Artificial Sequence
40
<220>
<223> D17S518 reverse primer
45 <400> 284
tagtctctgg gacacccaga 20
<210> 285
50 <211> 25
<212> DNA
<213> Artificial Sequence
55

<220>

<223> D17S518 forward primer

<400> 285

attcctgagt gtctaccctg ttgag

25

<210> 286

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S518 reverse primer

<400> 286

actgactgcg ccactgc

17

<210> 287

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> D11S4358 forward primer

<400> 287

tcgagaagga caaaatcacc

20

<210> 288

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> D11S4358 reverse primer

<400> 288

gaacagggtt agtccattcg

20

<210> 289

<211> 19

<212> DNA

<213> Artificial Sequence

5

<220>

10

<223> D17S964 forward primer

<400> 289

gttcttttct cttgtgggg

19

<210> 290

15

<211> 19

<212> DNA

<213> Artificial Sequence

20

<220>

25

<223> D17S964 reverse primer

<400> 290

agtcagctga gattgtgcc

19

<210> 291

30

<211> 20

<212> DNA

<213> Artificial Sequence

35

<220>

40

<223> D19S1091 forward primer

<400> 291

caagccaaga catcccagtt

20

<210> 292

45

<211> 20

<212> DNA

<213> Artificial Sequence

50

<220>

55

<223> D19S1091 reverse primer

<400> 292

ccccacacac agtcatatg

20

<210> 293

5 . <211> 22

<212> DNA

<213> Artificial Sequence

10

<220>

<223> D17S1179 forward primer

15

<400> 293

ttttctctct cattccattg gg

22

<210> 294

30

<211> 20

<212> DNA

<213> Artificial Sequence

25

<220>

<223> D17S1179 reverse primer

30

<400> 294

gcaacagagg gagactccaa

20

<210> 295

35

<211> 19

<212> DNA

<213> Artificial Sequence

40

<220>

<223> D10S2160 forward primer

45

<400> 295

tcccatcccg taagacctc

19

<210> 296

50

<211> 25

<212> DNA

<213> Artificial Sequence

55

<220>

5 <223> D10S2160 reverse primer
<400> 296
tatggagtac ctactctatg ccagg 25

<210> 297

10 <211> 20

<212> DNA

<213> Artificial Sequence

15

<220>

20 <223> D17S1230 forward primer
<400> 297
attcaaagct ggatcccttt 20

<210> 298

25 <211> 20

<212> DNA

<213> Artificial Sequence

30

<220>

35 <223> D17S1230 reverse primer
<400> 298
agctgtgaca aatgcctgta 20

<210> 299

40 <211> 20

<212> DNA

<213> Artificial Sequence

45

<220>

50 <223> D17S1338 forward primer
<400> 299
tcacctgaga ttgggagacc 20

<210> 300

55 <211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S1338 reverse primer

<400> 300

aagatggggc aggaatgg

18

<210> 301

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S2011 forward primer

<400> 301

tcactgtcct ccaagccag

19

<210> 302

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S2011 reverse primer

<400> 302

aaacaccaca ctctcccctg

20

<210> 303

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S2011 forward primer

<400> 303

ttcttgggct tcccgtagcc

20

5 <210> 304
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 10
 <220>
 <223> D17S2011 reverse primer
 15 <400> 304
 ggggcagacg acttctcctt 20
 <210> 305
 20 <211> 23
 <212> DNA
 <213> Artificial Sequence
 25
 <220>
 <223> D17S2038 forward primer
 30 <400> 305
 ggggatacaa cctttaaagt tcc 23
 <210> 306
 <211> 25
 35 <212> DNA
 <213> Artificial Sequence
 40
 <220>
 <223> D17S2038 reverse primer
 45 <400> 306
 attcacctaa tgaggattct tcttt 25
 <210> 307
 <211> 24
 50 <212> DNA
 <213> Artificial Sequence
 55

<220>

<223> D17S2091 forward primer

<400> 307

gctgaaatag ccatcttgag ctac

24

<210> 308

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S2091 reverse primer

<400> 308

tccgcaccc ttttaagagg cac

23

<210> 309

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S649 forward primer

<400> 309

ctttcactct ttcagctgaa gagg

24

<210> 310

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> D17S649 reverse primer

<400> 310

tgacgtgcta tttcctgttt tgtct

25

<210> 311

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

No.	Doccode	Number of pages
1	1001	6
2	1002	1
3	DESC	4
4	CLMS	1
5	DRAW	1
6	ABST	1
7	PRIODOC	8

<220>

<223> D17S1190 reverse primer

<400> 312

caacacacta ccccaaga

Claims

1. A method for the prediction, diagnosis or prognosis of malignant neoplasia by the detection of at least 2 markers characterized in that the markers are genes and fragments thereof or genomic nucleic acid sequences that are located on one chromosomal region which is altered in malignant neoplasia.
2. A method for the prediction, diagnosis or prognosis of malignant neoplasia by the detection of at least 2 markers characterized in that the markers are:
 - a) genes that are located on one or more chromosomal region(s) which is/are altered in malignant neoplasia; and
 - b)
 - i) receptor and ligand; or
 - ii) members of the same signal transduction pathway; or
 - iii) members of synergistic signal transduction pathways; or
 - iv) members of antagonistic signal transduction pathways; or
 - v) transcription factor and transcription factor binding site.
3. The method of claim 1 or 2 wherein the malignant neoplasia is breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer.
4. The method of claim 1 or 2 wherein at least one chromosomal region is defined as the cytogenetic region: 1p13, 1q32, 3p21-p24, 5p13-p14, 8q23-q²⁴, 11q13, 12q13, 17q12-q24 or 20q13.

5. The method of claim 1 or 2 wherein at least chromosomal region is defined as the cytogenetic region 17q1 1.2-21.3 and the malignant neoplasia is breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer.

6. The method of claim 1 or 2 wherein at least one chromosomal region is defined as the cytogenetic region 3p21-24 and the malignant neoplasia is breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer.

7. The method of claim 1 or 2 wherein at least one chromosomal region is defined as the cytogenetic region 12q13 and the malignant neoplasia is breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer.

8. A method for the prediction, diagnosis or prognosis of malignant neoplasia by the detection of at least one marker whereby the marker is a VNTR, SNP, RFLP or STS **characterized in that** the marker is located on one chromosomal region which is altered in malignant neoplasia due to amplification and the marker is detected in a cancerous and a non-cancerous tissue or biological sample of the same individual.

9. The method of claim 8 wherein the marker is selected from the group consisting of the VNTRs:

D17S946, D17S1181, D17S2026, D17S838, D17S250, D17S1818, D17S614, D17S2019, D17S608, D17S1655, D17S2147, D17S754, D17S1814, D17S2007, D17S1246, D17S1979, D17S1984, D17S1984, D17S1867, D17S1788, D17S1836, D17S1787, D17S1660, D17S2154, D17S1955, D17S2098, D17S518, D17S1851, D11S4358, D17S964, D19S1091, D17S1179, D10S2160, D17S1230, D17S1338, D17S2011, D17S1237, D17S2038, D17S2091, D17S649, D17S1190 and M87506.

10. The method of claim 8 wherein the marker is selected from the group consisting of the SNPs:

rs2230698, rs2230700, rs1058808, rs1801200, rs903506, rs2313170, rs1136201, rs2934968, rs2172826, rs1810132, rs1801201, rs2230702, rs2230701, rs1126503, rs3471, rs13695, rs471692, rs558068, rs1064288, rs1061692, rs520630, rs782774, rs565121, rs2586112, rs532299, rs2732786, rs1804539, rs1804538, rs1804537, rs1141364 rs12231, rs1132259 rs1132257, rs113225 rs113225 rs1132254, rs113225 rs1132268 and rs11322

11. A method for the prediction, diagnosis or prognosis of malignant neoplasia by the detection of at least one marker **characterized in that** the marker is selected from:

a) a polynucleotide or polynucleotide analog comprising at least one of the sequences of SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19, 21 to 26 or 53 to 75;

b) a polynucleotide or polynucleotide analog which hybridizes under stringent conditions to a polynucleotide specified in (a) and encodes a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

c) a polynucleotide or polynucleotide analog the sequence of which deviates from the polynucleotide specified in (a) and (c) due to the generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

d) a polynucleotide or polynucleotide analog which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (d)

e) a purified polypeptide encoded by a polynucleotide or polynucleotide analog sequence specified in (a) to (e)

f) a purified polypeptide comprising at least one of the sequences of SEQ ID NO: 28 to 32, 34, 35, 37 to 42, 44, 45, 47 to 52 or 76 to 98;

are detected.

12. A method for the prediction, diagnosis or prognosis of malignant neoplasia by the detection of at least 2 markers

characterized in that at least 2 markers are selected from:

a) a polynucleotide or polynucleotide analog comprising at least one of the sequences of SEQ ID NO: 1 to 26 or 53 to 75;

b) a polynucleotide or polynucleotide analog which hybridizes under stringent conditions to a polynucleotide specified in (a) and encodes a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

c) a polynucleotide or polynucleotide analog the sequence of which deviates from the polynucleotide specified in (a) and (b) due to the generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

d) a polynucleotide or polynucleotide analog which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (c)

e) a purified polypeptide encoded by a polynucleotide sequence or polynucleotide analog specified in (a) to (d)

f) a purified polypeptide comprising at least one of the sequences of SEQ ID NO: 27 to 52 or 76 to 98

are detected.

13. The method of any of the claims 1 or 12 wherein the detection method comprises the use of PCR, arrays or beads.

14. A diagnostic kit comprising instructions for conducting the method of any of claims 1 to 13.

15. A composition for the prediction, diagnosis or prognosis of malignant neoplasia comprising:

a) a detection agent for:

i) any polynucleotide or polynucleotide analog comprising at least one of the sequences of SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19, 21 to 26 or 53 to 75;

ii) any polynucleotide or polynucleotide analog which hybridizes under stringent conditions to a polynucleotide specified in (a) encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

iii) a polynucleotide or polynucleotide analog the sequence of which deviates from the polynucleotide specified in (a) and (b) due to the generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

iv) a polynucleotide or polynucleotide analog which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (c)

v) a polypeptide encoded by a polynucleotide or polynucleotide analog sequence specified in (a) to (d);

vi) a polypeptide comprising at least one of the sequences of SEQ ID NO: 28 to 32, 34, 35, 37 to 42, 44, 45, 47 to 52 or 76 to 98.

or

b) at least 2 detection agents for at least 2 markers selected from:

i) any polynucleotide comprising at least one of the sequences of SEQ ID NO: 1 to 26 or 53 to 75;

ii) any polynucleotide which hybridizes under stringent conditions to a polynucleotide specified in (a) encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

iii) a polynucleotide the sequence of which deviates from the polynucleotide specified in (a) and (b) due to the generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

iv) a polynucleotide which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (c)

v) a polypeptide encoded by a polynucleotide sequence specified in (a) to (d);

vi) a polypeptide comprising at least one of the sequences of SEQ ID NO: 27 to 52 or 76 to 98.

16. An array comprising a plurality of polynucleotides or polynucleotide analogs wherein each of the polynucleotides is selected from:

a) a polynucleotide or polynucleotide analog comprising at least one of the sequences of SEQ ID NO: 1 to 26 or 53 to 75;

b) a polynucleotide or polynucleotide analog which hybridizes under stringent conditions to a polynucleotide specified in (a) encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

c) a polynucleotide or polynucleotide analog the sequence of which deviates from the polynucleotide specified in (a) and (b) due to the generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

d) a polynucleotide or polynucleotide analog which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (c)

attached to a solid support.

17. A method of screening for agents which regulate the activity of a polypeptide encoded by a polynucleotide or polynucleotide analog selected from the group consisting of:

a) a polynucleotide or polynucleotide analog comprising at least one of the sequences of SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19, 21 to 26 or 53 to 75;

b) a polynucleotide or polynucleotide analog which hybridizes under stringent conditions to a polynucleotide specified in (a) encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

c) a polynucleotide or polynucleotide analog the sequence of which deviates from the polynucleotide specified in (a) and (b) due to the generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

d) a polynucleotide or polynucleotide analog which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (c);

comprising the steps of:

i) contacting a test compound with at least one polypeptide encoded by a polynucleotide specified in (a) to (d); and

ii) detecting binding of the test compound to the polypeptide, wherein a test compound which binds to the polypeptide is identified as a potential therapeutic agent for modulating the activity of the polypeptide in order to prevent or treat malignant neoplasia.

18. A method of screening for agents which regulate the activity of a polypeptide encoded by a polynucleotide or polynucleotide analog selected from the group consisting of:

a) a polynucleotide or polynucleotide analog comprising at least one of the sequences of SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19, 21 to 26 or 53 to 75;

b) a polynucleotide or polynucleotide analog which hybridizes under stringent conditions to a polynucleotide specified in (a) encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

c) a polynucleotide or polynucleotide analog the sequence of which deviates from the polynucleotide specified in (a) and (b) due to the generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

d) a polynucleotide or polynucleotide analog which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (c)

comprising the steps of:

i) contacting a test compound with at least one polypeptide encoded by a polynucleotide specified in (a) to (d); and

ii) detecting the activity of the polypeptide as specified for the respective sequence in Table 2 or 3, wherein a test compound which increases the activity is identified as a potential preventive or therapeutic agent for increasing the polypeptide activity in malignant neoplasia, and wherein a test compound which decreases the activity of the polypeptide is identified as a potential therapeutic agent for decreasing the polypeptide activity in malignant neoplasia.

19. A method of screening for agents which regulate the activity of a polynucleotide or polynucleotide analog selected from group consisting of;

a) a polynucleotide or polynucleotide analog comprising at least one of the sequences of SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19, 21 to 26 or 53 to 75;

b) a polynucleotide or polynucleotide analog which hybridizes under stringent conditions to a polynucleotide specified in (a) encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

c) a polynucleotide or polynucleotide analog the sequence of which deviates from the polynucleotide specified in (a) and (b) due to the generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

d) a polynucleotide or polynucleotide analog which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (c)

comprising the steps of:

i) contacting a test compound with at least one polynucleotide or polynucleotide analog specified in (a) to (d), and

ii) detecting binding of the test compound to the polynucleotide, wherein a test compound which binds to the polynucleotide is identified as a potential preventive or therapeutic agent for regulating the activity of the polynucleotide in malignant neoplasia.

20. Use of

a) a polynucleotide or polynucleotide analog comprising at least one of the sequences of SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19, 21 to 26 or 53 to 75;

b) a polynucleotide which hybridizes under stringent conditions to a polynucleotide or polynucleotide analog specified in (a) encoding a polypeptide exhibiting the same biological function as specified for the respective

sequence in Table 2 or 3;

c) a polynucleotide or polynucleotide analog the sequence of which deviates from the polynucleotide specified in (a) and (b) due to the generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3;

d) a polynucleotide or polynucleotide analog which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (c);

e) an antisense molecule targeting specifically one of the polynucleotide sequences specified in (a) to (d);

f) a purified polypeptide encoded by a polynucleotide or polynucleotide analog sequence specified in (a) to (d)

g) a purified polypeptide comprising at least one of the sequences of SEQ ID NO: 28 to 32, 34, 35, 37 to 42, 44, 45, 47 to 52 or 76 to 98;

h) an antibody capable of binding to one of the polynucleotide specified in (a) to (d) or a polypeptide specified in (f) and (g);

i) a reagent identified by any of the methods of claim 17 to 19 that modulates the amount or activity of a polynucleotide sequence specified in (a) to (d) or a polypeptide specified in (f) and (g);

in the preparation of a composition for the prevention, prediction, diagnosis, prognosis or a medicament for the treatment of malignant neoplasia.

21. Use of claim 20 wherein the disease is breast cancer.

22. A reagent that regulates the activity of a polypeptide selected from the group consisting of:

a) a polypeptide encoded by any polynucleotide or polynucleotide analog comprising at least one of the sequences of SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19, 21 to 26 or 53 to 75;

b) a polypeptide encoded by any polynucleotide or polynucleotide analog which hybridizes under stringent conditions to any polynucleotide comprising at least one of the sequences of SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19, 21 to 26 or 53 to 75 encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

c) a polypeptide encoded by any polynucleotide or polynucleotide analog the sequence of which deviates from the polynucleotide specified in (a) and (b) due to the generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

d) a polypeptide encoded by any polynucleotide or polynucleotide analog which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (c) encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

e) or a polypeptide comprising at least one of the sequences of SEQ ID NO: 28 to 32, 34, 35, 37 to 42, 44, 45, 47 to 52 or 76 to 98;

wherein said reagent is identified by the method of any of the claims 17 to 19.

23. A reagent that regulates the activity of a polynucleotide or polynucleotide analog selected from the group consisting of:

a) a polynucleotide or polynucleotide analog comprising at least one of the sequences SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19, 21 to 26 or 53 to 75;

b) a polynucleotide or polynucleotide analog which hybridizes under stringent conditions to a polynucleotide specified in (a) encoding a polypeptide exhibiting the same biological function as specified for the respective

sequence in Table 2 or 3

c) a polynucleotide or polynucleotide analog the sequence of which deviates from the polynucleotide specified in (a) and (b) due to the generation of the genetic code encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

d) a polynucleotide or polynucleotide analog which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (c)_encoding a polypeptideexhibiting the same biological function as specified for the respective sequence in Table 2 or 3

wherein said reagent is identified by the method of any of the claims 17 to 19.

24. A pharmaceutical composition, comprising:

a) an expression vector containing at least one polynucleotide or polynucleotide analog selected from the group consisting of:

i) a polynucleotide or polynucleotide analog comprising at least one of the sequences of SEQ ID NO: 2 to 6, 8, 9, 11 to 16, 18, 19,21 to 26 or 53 to 75;

ii) a polynucleotide or polynucleotide analog which hybridizes under stringent conditions to a polynucleotide specified in (a) encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

iii) a polynucleotide or polynucleotide analog the sequence of which deviates from the polynucleotide specified in (a) and (b) due to the generation of the genetic code_encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3

iv) a polynucleotide or polynucleotide analog which represents a specific fragment, derivative or allelic variation of a polynucleotide sequence specified in (a) to (c)_encoding a polypeptide exhibiting the same biological function as specified for the respective sequence in Table 2 or 3;

or the reagent of claim 22 or 23 and a pharmaceutically acceptable carrier.

25. A computer-readable medium comprising:

a) at least one digitally encoded value representing a level of expression of at least one polynucleotide sequence of SEQ ID NO: 2 to 6, 8, 9, 11 to 16,18,19,21 to 26 or 53 to 75

b) at least 2 digitally encoded values representing the levels of expression of at least 2 polynucleotide sequences selected from SEQ ID NO: 1 to 26 or 53 to 75

in a cell from the a subject at risk for or having malignant neoplasia.

26. A method for the detection of chromosomal alterations **characterized in that** the relative abundance of individual mRNAs, encoded by genes, located in altered chromosomal regions is detected.

27. A method for the detection of chromosomal alterations **characterized in that** the copy number of one or more chromosomal region(s) is detected by quantitative PCR.

p	13	12	11.2	cen	11.2	12	21.1 - 21.3	22	23	24	25	q
p	13	12	11.2	cen	11.2	12	21.1 - 21.3	22	23	24	25	q




Figure 1




Figure 2



Figure 3






Figure 4





Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 365 034 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
18.02.2004 Bulletin 2004/08

(51) Int Cl.7: **C12Q 1/68**, B01L 3/00,
A61K 48/00, G06F 17/00

(43) Date of publication A2:
26.11.2003 Bulletin 2003/48

(21) Application number: **03010447.5**

(22) Date of filing: **09.05.2003**

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**
Designated Extension States:
AL LT LV MK

(71) Applicant: **Bayer HealthCare AG**
51368 Leverkusen (DE)

(30) Priority: **21.05.2002 EP 02010291**
13.02.2003 EP 03003112

(72) Inventors:
• **Wirtz, Ralph, Dr.**
50677 Köln (DE)
• **Munnes, Marc, Dr.**
40699 Erkrath (DE)
• **Kallabis, Harald, Dr.**
50161 Köln (DE)

(54) **Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia**

(57) The invention provides compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and breast cancer in particular. Genes that are differentially

expressed in breast tissue of breast cancer patients versus those of normal people are disclosed.

EP 1 365 034 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 03 01 0447 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	KAURANIEMI PAIVIKKI ET AL: "New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays" CANCER RESEARCH, vol. 61, no. 22, 15 November 2001 (2001-11-15), pages 8235-8240, XP002264781 ISSN: 0008-5472 Introduction * abstract * * page 8235, column 2, paragraph 4; table 1 * --- -/--	1-5,8, 10-13, 15-24	C12Q1/68 B01L3/00 A61K48/00 G06F17/00
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12Q
INCOMPLETE SEARCH The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims. Claims searched completely : Claims searched incompletely : Claims not searched : Reason for the limitation of the search: see sheet C			
Place of search		Date of completion of the search	Examiner
MUNICH		18 December 2003	Bradbrook, D
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.02 (P04007)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 03 01 0447

Claim(s) searched completely:
1-24,26-27

Claim(s) not searched:
25

Reason for the limitation of the search (non-patentable invention(s)):

Article 52 (2)(d) EPC - Presentation of information (claim 25)

Further limitation of the search

Claim(s) searched completely:
26,27

Claim(s) searched incompletely:
1-5,8,10-13,15-24

Claim(s) not searched:
6,7,9,14

Reason for the limitation of the search:

The present set of claims is unclear (Art.84 EPC), the reasons being as follows:

Claims 1 and 2 relate to the detection of at least two neoplasia markers which are defined such that they include a huge number of possible markers and combinations thereof. Claims 4-7 relate to markers on specific chromosomal regions, which still give rise to many possible combinations: the 17q12-q24 region alone appears to encompass about 50 known genes (cf Table 1), many VNTRs (cf claim 9), SNPs (cf claim 10) and possibly other markers.

The markers of claim 1 are defined only such that they are located on "one chromosomal region which is altered in malignant neoplasia", which renders it impossible for the skilled reader to determine what markers fall under the scope of said claim: the definition of "altered chromosomal region" given in the description (p.17, l.26-31), does not clearly define how a region is delimited, and the limits of such regions appear to vary according to cell type (cf Fig.4). The same applies also to independent claims 2 (part a) and 8. Claim 2, part b, further refers to five conditions which the two or more markers should fulfil, yet these are not clearly delimited, so that it is impossible for a meaningful search to be conducted.

The claims as a whole are neither clear nor concise. Claim 1 requires that the two or more markers are located on one altered chromosomal region, whereas in claim 2 the markers may be on more than one region, but must interact in some way. Claim 8 requires neither colocalisation nor interaction. Claims 11 and 12 appear to relate simply to detection of one or more marker genes located on the 17q12-q24 locus. Thus, it is not possible to determine the essential features of the present application. Thus, for the reasons given above, the claims are unclear and inconcise (Art.84 EPC), to the extent that no meaningful search could be carried



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 03 01 0447

out across the entire scope of the claims. The search was restricted initially to the 43 human genes (cf Tables 2 and 3) which are co-amplified from chromosomal region 17q12-q24 in neoplastic lesions from breast cancer tissue (cf p.3, 1.7-14). Due to the enormous number of possible combinations of two or more of said marker genes, the search has been further restricted to the groups of genes which have been clearly identified as interacting (cf p.21, 1.1-4), namely HER-2/neu, GRB7, CrkRS and CDC6 (SEQ ID NOs 10, 11, 5, 18; being part of identical pathways); HER-2/neu, THRA and RARA (SEQ ID NOs 10, 15, 19; influencing the expression of each other); PPARGBP, THRA, RARA, NR1D1 (SEQ ID NOs 4, 15, 19, 16; interacting with each other); HER-2/neu and GRB7 (SEQ ID NOs 10, 11; interacting with each other) (see also p.60, 1.18 - p.62, 1.5). Further limitations to the search due to lack of clarity (Art.84 EPC) are as follows:

Claim 11, part b, relates to a polynucleotide encoding a polypeptide exhibiting "the same biological function" as the sequences in Table 2 or 3. This definition does not enable the claimed polynucleotide to be identified, so that part b has not been searched. Part c is clear only insofar as it relates to a degenerate polynucleotide of part a encoding the same polypeptide, and has only been searched in this respect. Part d relates to fragments and derivatives or variations of the foregoing polynucleotide sequences but is only clear and has been searched only insofar as it refers to the sequences in part a. The polypeptides of part e are only clear and have been searched only in that they relate to the specific sequences encoded by the polynucleotides given in part a, i.e. the polypeptide sequences listed in part f. The same applies to independent claims 12, 15-20 and 22-24.

Additionally, claim 15 is defined only in terms of the polynucleotides or polypeptides which are to be detected, and not in terms of the features of the detection agents themselves. Therefore, said claim has been searched only insofar as the claim is clear, i.e. wherein the detection agents are antibodies or polynucleotide probes (cf description p.9, 1.10-16).

Additionally, claim 20 refers (step h) to an antibody "capable of binding to" the specified target; this is, and has been searched only insofar as it relates to an antibody specific for the specified target. Said claim also refers (step i) to a reagent identified by screening methods of claims 17-19, yet provides no features of such reagents per se; therefore, this feature is unclear and has been searched only insofar as such reagents have been identified, namely antibodies and antisense oligonucleotides (cf p.140, 1.9-15). This same objection applies equally to claims 22 and 23, directed to reagents identified by the methods of claims 17-19, as well as to claim 24 insofar as it refers to the reagents of claims 22 and 23.

Claim 14 is directed to a diagnostic kit, the only feature of which is instructions for carrying out a method. Said feature is not a limiting technical feature. In the absence of any indication of the specific composition of the kit, no meaningful search can be carried out for claim 14.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 03 01 0447

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	STEIN D ET AL: "THE SH2 DOMAIN PROTEIN GRB-7 IS CO-AMPLIFIED, OVEREXPRESSED AND IN A TIGHT COMPLEX WITH HER2 IN BREAST CANCER" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 13, no. 6, 15 March 1994 (1994-03-15), pages 1331-1340, XP001095119 ISSN: 0261-4189 * abstract *	1-5,8, 10-13, 15-24	
X	VAN DE VIJVER M ET AL: "Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erba oncogene." MOLECULAR AND CELLULAR BIOLOGY, UNITED STATES MAY 1987, vol. 7, no. 5, May 1987 (1987-05), pages 2019-2023, XP009022435 ISSN: 0270-7306 * abstract *	1-5,8, 10-13, 15-24	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	KEITH W N ET AL: "Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20." EUROPEAN JOURNAL OF CANCER (OXFORD, ENGLAND: 1990) ENGLAND 1993, vol. 29A, no. 10, 1993, pages 1469-1475, XP009022483 ISSN: 0959-8049 * abstract *	1-5,8, 10-13, 15-24	

	-/--		



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 03 01 0447

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	MONNI OUTI ET AL: "Comprehensive copy number and gene expression profiling of the 17q23 amplicon in human breast cancer" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 10, 8 May 2001 (2001-05-08), pages 5711-5716, XP002264782 May 8, 2001 ISSN: 0027-8424 * abstract * * page 5712, column 1, paragraph 5; table 1 *	15,16, 22,23	
X	AFFYMETRIX: "Product Catalogue 2001", AFFYMETRIX INC., SANTA CLARA, CA, USA XP002264784 * the whole document *	15,16, 22,23	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	AN H X ET AL: "int-2 and c-erbB-2 gene amplification detected in 70 frozen human breast carcinomas by quantitative polymerase chain reaction." ANTICANCER RESEARCH. GREECE 1997 JUL-AUG, vol. 17, no. 4B, July 1997 (1997-07), pages 3133-3136, XP009022507 ISSN: 0250-7005 * abstract *	27	
X	DATABASE GENBANK [Online] Human RB18A (i.e. PPARGBP), 23 January 1998 (1998-01-23) retrieved from WWW.NCBI.NLM.NIH.GOV Database accession no. Y13467 XP002264786 * abstract *	15,22,23	

	-/--		



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 03 01 0447

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	DATABASE GENBANK [Online] Human CrkRS mRNA, 5 September 2000 (2000-09-05) retrieved from WWW.NCBI.NLM.NIH.GOV Database accession no. AF227198 XP002264787 * abstract *	15,22,23	
X	--- DATABASE GENBANK [Online] Human Grb7V, 13 February 1999 (1999-02-13) retrieved from WWW.NCBI.NLM.NIH.GOV Database accession no. AB008790 XP002264788 * abstract *	15,22,23	
X	--- DATABASE GENBANK [Online] Human THRA1 mRNA, 8 October 1999 (1999-10-08) retrieved from WWW.NCBI.NLM.NIH.GOV Database accession no. X55005 XP002264789 * abstract *	15,22,23	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	--- DATABASE GENBANK [Online] Human Rev-ErbAalpha mRNA (i.e. NR1D1), 27 August 1999 (1999-08-27) retrieved from WWW.NCBI.NLM.NIH.GOV Database accession no. X72631,X53327,X72632 XP002264790 * abstract *	15,22,23	
X	--- DATABASE GENBANK [Online] Human CDC6, 21 December 1999 (1999-12-21) retrieved from WWW.NCBI.NLM.NIH.GOV Database accession no. U77949 XP002264791 * abstract *	15,22,23	
	--- -/--		



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 03 01 0447

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	DATABASE GENBANK [Online] Human RARA gene, 2 November 1999 (1999-11-02) retrieved from WWW.NCBI.NLM.NIH.GOV Database accession no. AH007261 XP002264792 * abstract *	15,22,23	
A	DATABASE GENBANK [Online] Human c-erb-B-2 mRNA, 30 March 1995 (1995-03-30) retrieved from WWW.NCBI.NLM.NIH.GOV Database accession no. X03363 XP002264793 * abstract *	15,22,23	
A	US 5 776 683 A (CHEN LING-CHUN ET AL) 7 July 1998 (1998-07-07) * the whole document *	1-5, 11-13, 15-26	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
T	DATABASE GENEANNOT [Online] Probe sets on Affymetrix HG-U95A-E microarrays, 3 December 2003 (2003-12-03) retrieved from HTTP://GENECARDS.WEIZMANN.AC.IL/CGI-BIN/GE NEANNOT/GA_SEARCH XP002264785 * abstract *	15,16, 22,23	

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 03 01 0447

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-12-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5776683 A	07-07-1998	AU 2452197 A	29-10-1997
		EP 0944651 A2	29-09-1999
		JP 2000509256 T	25-07-2000
		WO 9738085 A2	16-10-1997

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82